Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl2p_wp050

Request ID: cder_mpl2p_wp050

Request Description: In this report we described counts of new users of paliperidone palmitate, risperidone microspheres, and haloperidol decanoate in the Sentinel Distributed Database (SDD). We estimated the two-week and four-week risk of all-cause death comparing (1) paliperidone palmate users to risperidone microspheres users and (2) paliperidone palmitate users to haloperidol decanoate users.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 12.0.0, with Propensity Score Analysis module and custom programming.

Data Source: We distributed this request to one Sentinel Data Partner, the Center for Medicare and Medicaid Services - Medicare Data, on September 7, 2023. This Data Partner is a subset of the SDD. Data from Medicare patients having both fee-for-service medical coverage and Part D drug coverage are included. The study period included data from January 1, 2010 through July 1, 2022. Please see Appendix A for a list of dates of available data for this Data Partner.

Study Design: We identified individuals with incident use of paliperidone palmitate, risperidone microspheres, and haloperidol decanoate and evaluated the occurrence of death within two weeks or four weeks among a cohort who were at least 18 years of age. We then conducted a Propensity Score Analysis (PSA) comparing paliperidone palmitate users to (1) risperidone microspheres users and (2) haloperidol decanoate users using inverse probability of treatment weighting (IPTW) and including continuous age in the outcome regression model to adjust for confounding. Please see Appendices B through Q for the inverse probability of treatment weights estimated in this analysis. We evaluated the occurrence of death during the exposure episodes among these cohorts and estimated hazards ratios and 95% confidence intervals. This study used a retrospective active comparator new-user cohort design. This is a Type 2 analysis using the Propensity Score Analysis module in the Query Request Package (QRP) documentation.

Exposures: We defined the exposure of interest, paliperidone palmate, and the comparators, risperidone microspheres and haloperidol decanoate, using National Drug Codes (NDCs), Healthcare Common Procedure Coding System (HCPCS) codes and Current Procedural Terminology (CPT) codes. Only the first qualifying dispensing of paliperidone palmate, risperidone microspheres or haloperidol decanoate (index) in any care setting was included; cohort re-entry was not allowed. We defined new use as no prior use of any long-acting injectable antipsychotics (LAIAs) in the 183 days prior to the index dispensing or procedure.

Please see Appendix R for a list of generic and brand names and Appendix S for a list of procedure codes used to define the exposure and comparator medical products in this request.

Please see Appendix T for a list of generic and brand names of medical products and Appendix U for a list of procedure codes used to define the washout criteria in this request.

Outcomes of Interest: We defined the outcomes of interest as death within 14 days or 28 days, respectively.

Cohort Eligibility Criteria: We required patients included in the cohorts to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to the index exposure, during which gaps in coverage of up to 45 days were allowed and treated as continuous enrollment. The following age groups were included in the cohort: 18-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85+ years. We excluded index episodes with both the exposure and comparator dispensed on the same day.

Overview for Request: cder_mpl2p_wp050

Follow-up: We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data and assessed outcomes during these "as treated" episodes or the 14-day or 28-day outcome evaluation window, whichever was shortest. Follow-up began on the day of the index dispensing and continued until the first occurrence of any of the following: 1) disenrollment; 2) the end of the data provided by the Data Partner; 3) the end of the query period; 4) dispensing of a different LAIA other than the index medication; or 5) occurrence of the outcome (death).

Baseline Covariates: We assessed the following characteristics in the 183 days prior to and including the index date: age, year, sex, combined comorbidity score,[i] substance abuse, atrial fibrillation/flutter, ischemic heart disease, heart failure, stroke, diabetes, hypertension, rheumatic disease, chronic kidney disease, seizure disorder, dementia diagnosis, anti-dementia drug (memantine, galantamine, rivastigmine, donepezil, tacrine), dementia diagnosis and treatment, Parkinson's disease, chronic obstructive pulmonary disease, malignancy, asthma, hyperlipidemia, depression, schizophrenia, bipolar disorder, angiotensin-converting enzyme (ACE) inhibitor use, angiotensin ii receptor blocker (ARB) use, β-blocker use, oral anticoagulant use, antiplatelet agent use, opioid use, statin use, wheelchair or walker use, anti-arrhythmic use, antidiabetic use, calcium channel blocker use, diuretic use, antidepressant use, gastric acid suppressant use, nonsteroidal anti-inflammatory drugs, benzodiazepine-hypnotics use, chronic liver disease, pneumonia, cardiac arrhythmia, paliperidone palmitate use, risperidone microspheres use, haloperidol decanoate use, LAIA administered during an institutional stay (IS), number of ambulatory encounters, number of institutional stays, and number of inpatient encounters.

Please see Appendix V for a list of ICD-9-CM and ICD-10-CM diagnosis codes, Appendix W for a list of procedure codes, and Appendix X for a list of generic and brand names of medical products used to define baseline covariates in this request.

Propensity Score Estimation: We fit a logistic regression model to estimate the propensity score (PS) based on the potential confounders outlined in Appendices V, W, and X. After PS estimation and exclusion (i.e., trimming) of patients in non-overlapping regions of the PS distributions, the PS was used to create a stabilized average treatment effect (ATEs) weight for each patient.

We initially applied three candidate weight truncation percentile thresholds to deal with potential extreme inverse probability of treatment (IPT) weights: 0% (no truncation), 1%, and 2.5%. Truncation was operationalized symmetrically, in that weights smaller than the weight at the specified percentile of the weight distribution (1% or 2.5%) were re-assigned the value of the weight at the specified percentile (1^{st} or 2.5^{th}), while weights larger than the weight at the specified percentile of the weight distribution (99% or 97.5%) were re-assigned the value of the weight at the specified percentile (99^{th} or 97.5^{th}). After review of the distribution of IPT weights for the three truncation thresholds that was blinded to effect estimates, we selected the 0% truncation threshold and applied it to all analyses, as this threshold avoided extreme weights.

Subgroup analyses for effect estimation included age (18-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85+ years), dementia (dementia diagnosis and treatment, no dementia diagnosis and treatment), and LAIA administered during an institutional stay (during stay, not during stay). Subgroups were formed out of the post-trimming overall population to ensure only those patients contributing to the overall analysis contributed to a subgroup analysis.

See Appendix B through Appendix Q for inverse probability of treatment weights for each analysis.

See Appendix Y.1 through Y.3 for the specifications of parameters and Appendix Y.4 for a design diagram for this request.

Overview for Request: cder_mpl2p_wp050
Limitations: As with all observational studies, this evaluation was limited in its ability to control for all sources of potential bias. Algorithms used to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind. **Notes:** Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).
[i]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

Sentinel

Table of Contents

Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Glossary (PSA) List of Terms to Define the Propensity Score Analysis (PSA) Found in this Report

Table 1a Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1b Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1c Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1d Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1e Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1f Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1g Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1h Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1i Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1j Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1k Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1l Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1m Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1n Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1o Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1p Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1q Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1r Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1s Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Sentinel

Table of Contents

Table 1t Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1u Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1v Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1w Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1x Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1y Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1z Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1aa Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1ab Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1ac Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1ad Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1ae Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1af Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1ag Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1ah Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1ai Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1aj Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table of Contents

Table 1ak Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1al Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1am Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1an Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1ao Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1ap Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1aq Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1ar Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1as Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1at Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1au Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1av Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1aw Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1ax Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1ay Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1az Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1ba Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1bb Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1bc Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Sentinel

Table of Contents

Table 1bd Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1be Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1bf Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1bg Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1bh Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1bi Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1bj Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1bk Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1bl Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1bm Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1bn Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1bo Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1bp Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1bq Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1br Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1bs Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1bt Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table of Contents

Table 1bu Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1bv Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1bw Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1bx Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1by Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1bz Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1ca Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1cb Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1cc Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1cd Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1ce Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1cf Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1cg Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1ch Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1ci Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1cj Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1ck Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1cl Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1cm Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Sentinel

Table of Contents

Table 1cn Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1co Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1cp Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1cq Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1cr Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1cs Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1ct Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1cu Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1cv Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1cw Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1cx Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1cy Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1cz Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1da Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1db Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1dc Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1dd Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table of Contents

Table 1de Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1df Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1dg Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Table 1dh Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1di Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1dj Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Table 1dk Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1dl Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1dm Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table 1dn Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1do Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1dp Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table 1dq Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1dr Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1ds Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table 1dt Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1du Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1dv Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Table 1dw Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table of Contents

Table 1dx Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1dy Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table 1dz Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1ea Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1eb Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Table 1ec Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1ed Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1ee Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table 1ef Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1eg Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1eh Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table 1ei Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1ej Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1ek Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Table 1el Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1em Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Table 1en Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Sentinel

Table of Contents

Table 2a Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Table 2b Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Table 2c Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Table 2d Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Table 3a Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Table 3b Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Table 3c Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Table 3d Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Table 4a Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Table 4b Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Table 4c Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Table 4d Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Table 5a Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Table 5b Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Table 5c Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Table 5d Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Table 6 Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 1a Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 1b Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 1c Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Table of Contents

Figure 1d Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 1e Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 1f Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 1g Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 1h Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 1i Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 1j Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 1k Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 1l Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 2a Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 2b Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 2c Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 2d Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 2e Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Table of Contents

Figure 2f Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 2g Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 2h Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 2i Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 2j Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 2k Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 2l Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 3a Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 3b Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 3c Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 3d Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 3e Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 3f Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 3g Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Table of Contents

Figure 3h Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 3i Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 3j Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 3k Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 3l Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 4a Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 4b Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 4c Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 4d Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 4e Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 4f Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 4g Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 4h Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 4i Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Table of Contents

Figure 4j Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 4k Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 4l Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 5a Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 5b Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 6a Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 6b Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 6c Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 6d Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 6e Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 6f Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 6g Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 6h Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table of Contents

Figure 6i Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 6j Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 6k Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 6l Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 6m Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 6n Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 6o Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 6p Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 6q Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 6r Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 6s Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 6t Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table of Contents

Figure 6u Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 6v Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 6w Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 6x Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 7a Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 7b Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 7c Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 7d Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 7e Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 7f Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 7g Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 7h Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table of Contents

Figure 7i Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 7j Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 7k Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 7l Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 7m Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 7n Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 7o Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 7p Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 7q Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 7r Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 7s Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 7t Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table of Contents

Figure 7u Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 7v Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 7w Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 7x Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 8a Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 8b Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 8c Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 8d Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 8e Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 8f Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 8g Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 8h Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table of Contents

Figure 8i Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 8j Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 8k Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 8l Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 8m Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 8n Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 8o Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 8p Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 8q Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 8r Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 8s Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 8t Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table of Contents

Figure 8u Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 8v Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 8w Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 8x Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 9a Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 9b Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Figure 9c Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 9d Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Figure 9e Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 9f Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Figure 9g Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Figure 9h Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Table of Contents

Figure 9i Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 9j Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Figure 9k Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 9l Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Figure 9m Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 9n Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Figure 9o Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 9p Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Figure 9q Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 9r Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Figure 9s Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Figure 9t Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Table of Contents

Figure 9u Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 9v Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Figure 9w Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Figure 9x Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 7, 2023)

Appendix B Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Appendix C Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)

Appendix D Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)

Appendix E Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)

Appendix F Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Appendix G Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)

Appendix H Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)

Appendix I Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)

Table of Contents	
Appendix J	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix K	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix L	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix M	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix N	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix O	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix P	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix Q	Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix R	List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
Appendix S	List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request
Appendix T	List of Generic and Brand Names of Medical Products Used to Define Exposure Incidence Criteria in this Request
Appendix U	List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposure Incidence Criteria in this Request
Appendix V	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request
Appendix W	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Table of Contents	
Appendix X	List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request
Appendix Y.1	Specifications Defining Parameters for this Request
Appendix Y.2	Specifications for Propensity Score (PS) Models for this Request
Appendix Y.3	Specifications Defining Baseline Characteristics for this Request
Appendix Y.4	Design Diagram for this Request

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.
Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.
Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.
Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.
Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.
Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.
Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.
Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).
Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.
Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.
Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.
Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.
Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Glossary of Terms for Analyses Using Propensity Score Analysis (PSA) Module*

Covariate - requester defined binary variable to include in the propensity score estimation model (e.g., diabetes, heart failure, etc.) during requester-defined lookback period. Requester may also choose to add any of the following categorical, continuous, or count metrics to the propensity score estimation model:

1. Age (continuous)
2. Sex
3. Time period (i.e., monitoring period for sequential analyses)
4. Year of exposure
5. Comorbidity score
6. Medical utilization – number of inpatient stays
7. Medical utilization – number of institutional stays
8. Medical utilization – number of emergency department visits
9. Medical utilization – number of outpatient visits
10. Health care utilization – number of other ambulatory encounters (e.g., telemedicine, email consults)
11. Drug utilization – number of dispensings
12. Drug utilization – number of unique generics dispensed
13. Drug Utilization – number of unique drug classes dispensed

Covariate Evaluation Window - specified number of days relative to index date to evaluate the occurrence of covariates of interest. Note: members are required to have continuous enrollment during the covariate evaluation window, regardless of the value included in the "Continuous enrollment before exposure" field.

Individual Level Data Return - program may return individual-level, de-identified datasets to the Sentinel Operations Center (SOC). While the datasets contain a single row per patient for each specified analysis, patient identifiers such as a patient ID are not included in the output. Individual-level datasets are returned to the SOC, aggregated, and used to calculate effect estimates via Cox (proportional hazards) regression.

Mahalanobis Distance - provides a measure of balance across all variables while accounting for their correlation.

Matching Caliper - maximum allowed difference in propensity scores between treatment and control patients. Requester may select any caliper (e.g., 0.01, 0.025, and 0.05).

Matching Ratio - patients in exposed and comparator groups are nearest neighbor matched by a 1:1 or 1:n (up to 10) matching ratio.

Matched Conditional and Unconditional Analysis - in a conditional matched analysis, a Cox model, stratified by Data Partner site and matched set, is run on the matched population. This can be done for both the both 1:1 and 1:n matched cohorts. In an unconditional analysis, a Cox model, stratified by Data Partner site only, is run on the matched population. This can be done for the 1:1 matched cohort only.

Propensity Score Stratification - option to stratify propensity scores based on requester-defined percentiles in the unmatched population. In a stratified analysis, a Cox model, stratified by Data Partner site, is run on the stratified population. Note that all patients identified in exposure and comparator cohorts are used in the analysis.

PSM Tool - performs effect estimation by comparing exposure propensity-score matched parallel new user cohorts. Propensity score estimation and matching are conducted within each Sentinel Data Partner site via distributed programming code; data are returned to the SOC, aggregated, and used to calculate effect estimates.

Risk-set Level Data Return - alternative to the patient-level data return approach. In this approach, the PSM tool will produce de-identified, risk-set level datasets instead of or in addition to individual-level output. Whereas each observation in the patient-level datasets represents one patient in the cohort, each observation in the risk set dataset represents one event. Risk sets are created at the Data Partner site, returned to the SOC, aggregated, and used to calculate effect estimates via case-centered logistic regression.

Subgroup Analysis - may be conducted using any requester-defined covariates. Subgroup analyses may be performed in the unmatched and the matched population.
Zero Cell Correction - indicator for whether to screen variables with a zero correction added to each cell in the confounder/outcome 2x2 table. Recommended when the number of exposed outcomes is fewer than 150.

*all terms may not be used in this report

Table 1a. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,865	100.0%	44,674	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	55.9	18.9	-9.998	-0.602
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,517	26.5%	7,599	17.0%	9.523	0.232
35-44 years	19,747	23.3%	6,755	15.1%	8.148	0.208
45-54 years	19,449	22.9%	8,005	17.9%	4.999	0.124
55-64 years	14,759	17.4%	7,196	16.1%	1.283	0.034
65-74 years	6,525	7.7%	6,780	15.2%	-7.488	-0.237
75-84 years	1,496	1.8%	4,973	11.1%	-9.369	-0.389
≥ 85 years	372	0.4%	3,366	7.5%	-7.096	-0.369
Sex						
Female	34,509	40.7%	22,065	49.4%	-8.728	-0.176
Male	50,356	59.3%	22,609	50.6%	8.728	0.176
Race[2]						
American Indian or Alaska Native	1,010	1.2%	467	1.0%	0.145	0.014
Asian	1,920	2.3%	769	1.7%	0.541	0.039
Black or African American	22,132	26.1%	10,983	24.6%	1.494	0.034
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,025	8.3%	2,841	6.4%	1.918	0.074
White	52,778	62.2%	29,614	66.3%	-4.099	-0.086
Hispanic origin						
Yes	4,374	5.2%	2,000	4.5%	0.677	0.032
No	77,840	91.7%	41,833	93.6%	-1.918	-0.074
Unknown	2,651	3.1%	841	1.9%	1.241	0.080

Table 1a. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,471	2.9%	3,640	8.1%	-5.236	-0.231
2011	6,111	7.2%	7,260	16.3%	-9.050	-0.284
2012	7,365	8.7%	6,462	14.5%	-5.786	-0.182
2013	7,590	8.9%	5,876	13.2%	-4.209	-0.135
2014	7,267	8.6%	4,632	10.4%	-1.805	-0.062
2015	7,782	9.2%	3,701	8.3%	0.885	0.031
2016	8,038	9.5%	3,108	7.0%	2.514	0.092
2017	8,262	9.7%	2,641	5.9%	3.824	0.143
2018	8,275	9.8%	2,266	5.1%	4.678	0.179
2019	7,664	9.0%	1,823	4.1%	4.950	0.201
2020	5,913	7.0%	1,429	3.2%	3.769	0.172
2021	5,564	6.6%	1,268	2.8%	3.718	0.176
2022	2,563	3.0%	568	1.3%	1.749	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	3.0	2.7	-0.815	-0.343
Substance abuse	29,804	35.1%	11,289	25.3%	9.850	0.216
Atrial fibrilation/flutter	1,601	1.9%	2,738	6.1%	-4.242	-0.218
Ischemic heart disease	6,383	7.5%	6,942	15.5%	-8.018	-0.253
Heart failure	3,544	4.2%	4,724	10.6%	-6.398	-0.247
Stroke	2,111	2.5%	3,216	7.2%	-4.711	-0.221
Diabetes	20,555	24.2%	13,832	31.0%	-6.741	-0.151
Hypertension	38,596	45.5%	25,709	57.5%	-12.069	-0.243
Rheumatic disease	431	0.5%	385	0.9%	-0.354	-0.043
Chronic kidney disease	9,669	11.4%	7,119	15.9%	-4.542	-0.133
Seizure disorder	9,686	11.4%	5,867	13.1%	-1.719	-0.052

Table 1a. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,309	2.7%	6,166	13.8%	-11.081	-0.411
Dementia Diagnosis	7,737	9.1%	13,383	30.0%	-20.840	-0.545
Dementia Diagnosis and Treatment	1,677	2.0%	5,598	12.5%	-10.555	-0.416
Parkinsons disease	1,485	1.7%	1,713	3.8%	-2.085	-0.127
COPD	13,423	15.8%	8,792	19.7%	-3.863	-0.101
Malignancy	2,713	3.2%	1,851	4.1%	-0.947	-0.050
Asthma	11,506	13.6%	5,002	11.2%	2.361	0.072
Hyperlipidemia	29,046	34.2%	17,510	39.2%	-4.969	-0.103
Depression	38,798	45.7%	21,791	48.8%	-3.060	-0.061
Schizophrenia	68,268	80.4%	29,634	66.3%	14.109	0.323
Bipolar disorder	39,626	46.7%	18,556	41.5%	5.157	0.104
ACE inhibitor use	14,111	16.6%	9,403	21.0%	-4.420	-0.113
ARB use	3,738	4.4%	2,710	6.1%	-1.662	-0.075
Beta-blocker use	16,520	19.5%	11,143	24.9%	-5.477	-0.132
Oral anticoagulant use	1,769	2.1%	1,986	4.4%	-2.361	-0.133
Antiplatelet agent use	1,316	1.6%	2,026	4.5%	-2.984	-0.174
Opioid use	16,123	19.0%	10,417	23.3%	-4.319	-0.106
Statin use	18,723	22.1%	12,124	27.1%	-5.077	-0.118
Wheelchair or walker use	257	0.3%	926	2.1%	-1.770	-0.164
Anti-arrhythmic use	314	0.4%	438	1.0%	-0.610	-0.075
Antidiabetic use	14,202	16.7%	8,749	19.6%	-2.849	-0.074
Calcium channel blocker use	9,259	10.9%	7,065	15.8%	-4.904	-0.145
Diuretic use	12,378	14.6%	9,860	22.1%	-7.485	-0.194
Antidepressant use	49,434	58.3%	25,906	58.0%	0.261	0.005
Gastric acid suppressant use	22,788	26.9%	13,690	30.6%	-3.792	-0.084
NSAIDs	18,439	21.7%	8,604	19.3%	2.468	0.061

Table 1a. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,306	33.4%	13,928	31.2%	2.177	0.047
Chronic liver disease	5,352	6.3%	2,578	5.8%	0.536	0.022
Pneumonia	3,665	4.3%	3,430	7.7%	-3.359	-0.142
Cardiac arrhythmia	11,749	13.8%	5,706	12.8%	1.072	0.032
Paliperidone palmitate	84,865	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	44,674	100.0%	NaN	NaN
Haloperidol decanoate	84	0.1%	77	0.2%	-0.073	-0.020
IS Stay	8,702	10.3%	6,012	13.5%	-3.204	-0.099
Medical Product Use						
Mean number of filled prescriptions	29.1	27.2	33.6	30.5	-4.548	-0.158
Mean number of generics dispensed	9.5	6.3	10.3	6.5	-0.843	-0.131
Mean number of unique drug classes dispensed	8.5	5.5	9.4	5.7	-0.900	-0.161
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	14.7	18.0	1.810	0.098
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.060	-0.065
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.090	-0.073

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1b. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,864	100.0%	44,665	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	55.9	18.9	-9.992	-0.602
Age	**Number**	**Percent**[1]	**Number**	**Percent**[1]		
18-34 years	22,516	26.5%	7,599	17.0%	9.519	0.232
35-44 years	19,747	23.3%	6,755	15.1%	8.145	0.208
45-54 years	19,449	22.9%	8,005	17.9%	4.996	0.124
55-64 years	14,759	17.4%	7,196	16.1%	1.280	0.034
65-74 years	6,525	7.7%	6,779	15.2%	-7.489	-0.237
75-84 years	1,496	1.8%	4,969	11.1%	-9.362	-0.388
≥ 85 years	372	0.4%	3,362	7.5%	-7.089	-0.369
Sex						
Female	34,509	40.7%	22,060	49.4%	-8.726	-0.176
Male	50,355	59.3%	22,605	50.6%	8.726	0.176
Race[2]						
American Indian or Alaska Native	1,010	1.2%	467	1.0%	0.145	0.014
Asian	1,920	2.3%	769	1.7%	0.541	0.039
Black or African American	22,132	26.1%	10,981	24.6%	1.494	0.034
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,025	8.3%	2,840	6.4%	1.920	0.074
White	52,777	62.2%	29,608	66.3%	-4.099	-0.086
Hispanic origin						
Yes	4,374	5.2%	1,999	4.5%	0.679	0.032
No	77,839	91.7%	41,825	93.6%	-1.920	-0.074
Unknown	2,651	3.1%	841	1.9%	1.241	0.079

Table 1b. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,471	2.9%	3,639	8.1%	-5.236	-0.231
2011	6,111	7.2%	7,258	16.2%	-9.049	-0.284
2012	7,365	8.7%	6,461	14.5%	-5.787	-0.182
2013	7,590	8.9%	5,875	13.2%	-4.210	-0.135
2014	7,267	8.6%	4,631	10.4%	-1.805	-0.062
2015	7,782	9.2%	3,700	8.3%	0.886	0.031
2016	8,038	9.5%	3,106	7.0%	2.518	0.092
2017	8,262	9.7%	2,641	5.9%	3.823	0.143
2018	8,275	9.8%	2,266	5.1%	4.678	0.179
2019	7,664	9.0%	1,823	4.1%	4.949	0.201
2020	5,913	7.0%	1,429	3.2%	3.768	0.172
2021	5,564	6.6%	1,268	2.8%	3.717	0.176
2022	2,562	3.0%	568	1.3%	1.747	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	3.0	2.7	-0.814	-0.343
Substance abuse	29,803	35.1%	11,289	25.3%	9.844	0.216
Atrial fibrilation/flutter	1,601	1.9%	2,733	6.1%	-4.232	-0.217
Ischemic heart disease	6,383	7.5%	6,933	15.5%	-8.001	-0.253
Heart failure	3,544	4.2%	4,717	10.6%	-6.385	-0.246
Stroke	2,111	2.5%	3,208	7.2%	-4.695	-0.220
Diabetes	20,555	24.2%	13,827	31.0%	-6.736	-0.151
Hypertension	38,596	45.5%	25,700	57.5%	-12.060	-0.243
Rheumatic disease	431	0.5%	383	0.9%	-0.350	-0.042
Chronic kidney disease	9,668	11.4%	7,118	15.9%	-4.544	-0.133
Seizure disorder	9,685	11.4%	5,863	13.1%	-1.714	-0.052

Table 1b. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,309	2.7%	6,157	13.8%	-11.064	-0.410
Dementia Diagnosis	7,737	9.1%	13,374	29.9%	-20.826	-0.544
Dementia Diagnosis and Treatment	1,677	2.0%	5,589	12.5%	-10.537	-0.415
Parkinsons disease	1,485	1.7%	1,712	3.8%	-2.083	-0.127
COPD	13,423	15.8%	8,786	19.7%	-3.854	-0.101
Malignancy	2,713	3.2%	1,850	4.1%	-0.945	-0.050
Asthma	11,506	13.6%	5,002	11.2%	2.359	0.072
Hyperlipidemia	29,045	34.2%	17,505	39.2%	-4.966	-0.103
Depression	38,798	45.7%	21,785	48.8%	-3.056	-0.061
Schizophrenia	68,267	80.4%	29,634	66.3%	14.096	0.323
Bipolar disorder	39,625	46.7%	18,554	41.5%	5.152	0.104
ACE inhibitor use	14,111	16.6%	9,400	21.0%	-4.418	-0.113
ARB use	3,738	4.4%	2,708	6.1%	-1.658	-0.075
Beta-blocker use	16,520	19.5%	11,137	24.9%	-5.468	-0.132
Oral anticoagulant use	1,769	2.1%	1,982	4.4%	-2.353	-0.133
Antiplatelet agent use	1,316	1.6%	2,020	4.5%	-2.972	-0.174
Opioid use	16,123	19.0%	10,412	23.3%	-4.313	-0.106
Statin use	18,722	22.1%	12,119	27.1%	-5.072	-0.118
Wheelchair or walker use	257	0.3%	918	2.1%	-1.752	-0.163
Anti-arrhythmic use	314	0.4%	437	1.0%	-0.608	-0.074
Antidiabetic use	14,202	16.7%	8,747	19.6%	-2.849	-0.074
Calcium channel blocker use	9,259	10.9%	7,062	15.8%	-4.901	-0.144
Diuretic use	12,378	14.6%	9,852	22.1%	-7.472	-0.194
Antidepressant use	49,433	58.2%	25,900	58.0%	0.262	0.005
Gastric acid suppressant use	22,788	26.9%	13,684	30.6%	-3.785	-0.084
NSAIDs	18,439	21.7%	8,603	19.3%	2.467	0.061

Table 1b. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,305	33.4%	13,928	31.2%	2.170	0.046
Chronic liver disease	5,351	6.3%	2,578	5.8%	0.534	0.022
Pneumonia	3,664	4.3%	3,426	7.7%	-3.353	-0.142
Cardiac arrhythmia	11,748	13.8%	5,705	12.8%	1.070	0.032
Paliperidone palmitate	84,864	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	44,665	100.0%	NaN	NaN
Haloperidol decanoate	84	0.1%	77	0.2%	-0.073	-0.020
IS Stay	8,702	10.3%	6,012	13.5%	-3.206	-0.099
Medical Product Use						
Mean number of filled prescriptions	29.1	27.2	33.6	30.5	-4.547	-0.158
Mean number of generics dispensed	9.5	6.3	10.3	6.5	-0.842	-0.131
Mean number of unique drug classes dispensed	8.5	5.5	9.4	5.7	-0.899	-0.160
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	14.7	18.0	1.809	0.098
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.059	-0.065
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.090	-0.072

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1c. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	83,961	N/A	45,384	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.7	15.4	48.6	17.2	0.064	0.004
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	18,977	22.6%	12,096	26.7%	-4.051	-0.094
35-44 years	17,531	20.9%	9,153	20.2%	0.713	0.018
45-54 years	18,529	22.1%	9,093	20.0%	2.033	0.050
55-64 years	15,691	18.7%	6,583	14.5%	4.183	0.113
65-74 years	8,872	10.6%	4,488	9.9%	0.678	0.022
75-84 years	3,146	3.7%	2,493	5.5%	-1.746	-0.083
≥ 85 years	1,215	1.4%	1,478	3.3%	-1.810	-0.120
Sex						
Female	36,058	42.9%	19,432	42.8%	0.128	0.003
Male	47,904	57.1%	25,952	57.2%	-0.128	-0.003
Race[3]						
American Indian or Alaska Native	981	1.2%	554	1.2%	-0.054	-0.005
Asian	1,843	2.2%	913	2.0%	0.184	0.013
Black or African American	21,635	25.8%	11,940	26.3%	-0.541	-0.012
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,462	7.7%	3,498	7.7%	-0.010	-0.000
White	53,041	63.2%	28,479	62.8%	0.421	0.009
Hispanic origin						
Yes	4,077	4.9%	2,429	5.4%	-0.498	-0.023
No	77,499	92.3%	41,886	92.3%	0.010	0.000
Unknown	2,386	2.8%	1,068	2.4%	0.488	0.031

Table 1c. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,444	2.9%	3,871	8.5%	-5.618	-0.244
2011	5,937	7.1%	7,692	16.9%	-9.878	-0.307
2012	7,283	8.7%	6,735	14.8%	-6.167	-0.192
2013	7,461	8.9%	6,305	13.9%	-5.006	-0.158
2014	7,140	8.5%	4,803	10.6%	-2.079	-0.071
2015	7,687	9.2%	3,719	8.2%	0.960	0.034
2016	7,934	9.4%	3,055	6.7%	2.717	0.100
2017	8,235	9.8%	2,481	5.5%	4.343	0.164
2018	8,109	9.7%	2,079	4.6%	5.077	0.198
2019	7,643	9.1%	1,696	3.7%	5.365	0.220
2020	5,939	7.1%	1,284	2.8%	4.244	0.197
2021	5,540	6.6%	1,152	2.5%	4.059	0.195
2022	2,610	3.1%	511	1.1%	1.983	0.138
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.4	2.3	2.4	2.3	-0.000	-0.000
Substance abuse	27,156	32.3%	14,840	32.7%	-0.355	-0.008
Atrial fibrilation/flutter	2,683	3.2%	1,470	3.2%	-0.043	-0.002
Ischemic heart disease	8,399	10.0%	4,555	10.0%	-0.033	-0.001
Heart failure	5,267	6.3%	2,835	6.2%	0.026	0.001
Stroke	3,304	3.9%	1,801	4.0%	-0.033	-0.002
Diabetes	22,139	26.4%	11,859	26.1%	0.237	0.005
Hypertension	41,246	49.1%	22,215	48.9%	0.176	0.004
Rheumatic disease	512	0.6%	292	0.6%	-0.032	-0.004
Chronic kidney disease	10,656	12.7%	5,698	12.6%	0.137	0.004
Seizure disorder	10,169	12.1%	5,423	11.9%	0.163	0.005

Table 1c. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	5,126	6.1%	2,870	6.3%	-0.219	-0.009
Dementia Diagnosis	12,776	15.2%	7,037	15.5%	-0.288	-0.008
Dementia Diagnosis and Treatment	4,382	5.2%	2,473	5.4%	-0.230	-0.010
Parkinsons disease	2,105	2.5%	1,095	2.4%	0.095	0.006
COPD	14,400	17.2%	7,723	17.0%	0.134	0.004
Malignancy	2,958	3.5%	1,573	3.5%	0.056	0.003
Asthma	10,862	12.9%	5,871	12.9%	0.001	0.000
Hyperlipidemia	30,182	35.9%	16,253	35.8%	0.136	0.003
Depression	39,373	46.9%	21,282	46.9%	-0.000	-0.000
Schizophrenia	64,722	77.1%	34,857	76.8%	0.280	0.007
Bipolar disorder	38,340	45.7%	20,831	45.9%	-0.236	-0.005
ACE inhibitor use	15,111	18.0%	8,136	17.9%	0.070	0.002
ARB use	4,098	4.9%	2,206	4.9%	0.019	0.001
Beta-blocker use	17,674	21.1%	9,498	20.9%	0.122	0.003
Oral anticoagulant use	2,309	2.8%	1,257	2.8%	-0.019	-0.001
Antiplatelet agent use	2,141	2.6%	1,122	2.5%	0.079	0.005
Opioid use	16,950	20.2%	9,189	20.2%	-0.059	-0.001
Statin use	19,946	23.8%	10,675	23.5%	0.236	0.006
Wheelchair or walker use	767	0.9%	404	0.9%	0.023	0.002
Anti-arrhythmic use	468	0.6%	251	0.6%	0.004	0.001
Antidiabetic use	14,746	17.6%	7,876	17.4%	0.208	0.005
Calcium channel blocker use	10,352	12.3%	5,561	12.3%	0.077	0.002
Diuretic use	14,161	16.9%	7,621	16.8%	0.074	0.002
Antidepressant use	48,511	57.8%	26,240	57.8%	-0.041	-0.001
Gastric acid suppressant use	23,427	27.9%	12,582	27.7%	0.178	0.004
NSAIDs	17,669	21.0%	9,540	21.0%	0.023	0.001

Table 1c. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,187	32.4%	14,680	32.3%	0.034	0.001
Chronic liver disease	5,194	6.2%	2,824	6.2%	-0.036	-0.001
Pneumonia	4,571	5.4%	2,452	5.4%	0.041	0.002
Cardiac arrhythmia	11,366	13.5%	6,180	13.6%	-0.080	-0.002
Paliperidone palmitate	83,961	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	45,384	100.0%	NaN	NaN
Haloperidol decanoate	82	0.1%	87	0.2%	-0.094	-0.025
IS Stay	9,793	11.7%	5,239	11.5%	0.121	0.004
Medical Product Use						
Mean number of filled prescriptions	30.0	28.0	30.5	28.6	-0.468	-0.017
Mean number of generics dispensed	9.7	6.4	9.7	6.3	0.065	0.010
Mean number of unique drug classes dispensed	8.7	5.6	8.8	5.5	-0.026	-0.005
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.2	18.4	16.4	19.9	-0.166	-0.009
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.000	-0.001
Mean number of non-acute institutional encounters	0.9	1.3	0.9	1.2	-0.000	-0.000

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1d. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,516	100.0%	7,599	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.3	3.7	-0.075	-0.020
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,516	100.0%	7,599	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,756	30.0%	2,209	29.1%	0.936	0.021
Male	15,760	70.0%	5,390	70.9%	-0.936	-0.021
Race[2]						
American Indian or Alaska Native	325	1.4%	136	1.8%	-0.346	-0.027
Asian	522	2.3%	197	2.6%	-0.274	-0.018
Black or African American	6,707	29.8%	2,505	33.0%	-3.177	-0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,605	16.0%	1,004	13.2%	2.799	0.079
White	11,357	50.4%	3,757	49.4%	0.999	0.020
Hispanic origin						
Yes	1,849	8.2%	646	8.5%	-0.289	-0.010
No	18,911	84.0%	6,595	86.8%	-2.799	-0.079
Unknown	1,756	7.8%	358	4.7%	3.088	0.128

Table 1d. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	705	3.1%	773	10.2%	-7.041	-0.285
2011	1,747	7.8%	1,492	19.6%	-11.875	-0.351
2012	2,067	9.2%	1,229	16.2%	-6.993	-0.211
2013	2,066	9.2%	1,105	14.5%	-5.366	-0.167
2014	1,955	8.7%	792	10.4%	-1.740	-0.059
2015	1,982	8.8%	551	7.3%	1.552	0.057
2016	2,031	9.0%	453	6.0%	3.059	0.116
2017	2,108	9.4%	334	4.4%	4.967	0.197
2018	2,110	9.4%	249	3.3%	6.094	0.252
2019	1,898	8.4%	246	3.2%	5.192	0.223
2020	1,565	7.0%	159	2.1%	4.858	0.235
2021	1,551	6.9%	141	1.9%	5.033	0.248
2022	731	3.2%	75	1.0%	2.260	0.157
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.5	1.3	0.077	0.061
Substance abuse	9,666	42.9%	3,153	41.5%	1.437	0.029
Atrial fibrilation/flutter	57	0.3%	33	0.4%	-0.181	-0.031
Ischemic heart disease	310	1.4%	126	1.7%	-0.281	-0.023
Heart failure	159	0.7%	62	0.8%	-0.110	-0.013
Stroke	125	0.6%	45	0.6%	-0.037	-0.005
Diabetes	2,275	10.1%	752	9.9%	0.208	0.007
Hypertension	5,103	22.7%	1,665	21.9%	0.753	0.018
Rheumatic disease	39	0.2%	19	0.3%	-0.077	-0.017
Chronic kidney disease	895	4.0%	239	3.1%	0.830	0.045
Seizure disorder	2,064	9.2%	687	9.0%	0.126	0.004

Table 1d. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	49	0.2%	11	0.1%	0.073	0.017
Dementia Diagnosis	700	3.1%	165	2.2%	0.938	0.059
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.014	0.008
Parkinsons disease	58	0.3%	13	0.2%	0.087	0.019
COPD	1,124	5.0%	373	4.9%	0.083	0.004
Malignancy	473	2.1%	133	1.8%	0.350	0.026
Asthma	3,342	14.8%	1,055	13.9%	0.959	0.027
Hyperlipidemia	3,717	16.5%	1,203	15.8%	0.677	0.018
Depression	9,751	43.3%	3,257	42.9%	0.446	0.009
Schizophrenia	17,764	78.9%	5,720	75.3%	3.622	0.086
Bipolar disorder	10,802	48.0%	3,677	48.4%	-0.413	-0.008
ACE inhibitor use	1,273	5.7%	440	5.8%	-0.136	-0.006
ARB use	214	1.0%	62	0.8%	0.135	0.014
Beta-blocker use	2,705	12.0%	801	10.5%	1.473	0.047
Oral anticoagulant use	146	0.6%	36	0.5%	0.175	0.023
Antiplatelet agent use	22	0.1%	*****	*****	-0.008	-0.002
Opioid use	3,117	13.8%	1,199	15.8%	-1.935	-0.054
Statin use	1,420	6.3%	470	6.2%	0.122	0.005
Wheelchair or walker use	*****	*****	*****	*****	-0.061	-0.028
Anti-arrhythmic use	19	0.1%	*****	*****	0.019	0.007
Antidiabetic use	1,673	7.4%	476	6.3%	1.166	0.046
Calcium channel blocker use	711	3.2%	218	2.9%	0.289	0.017
Diuretic use	1,048	4.7%	335	4.4%	0.246	0.012
Antidepressant use	12,197	54.2%	3,688	48.5%	5.638	0.113
Gastric acid suppressant use	3,927	17.4%	1,230	16.2%	1.255	0.034
NSAIDs	3,973	17.6%	1,314	17.3%	0.353	0.009

Table 1d. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,159	27.4%	1,686	22.2%	5.167	0.120
Chronic liver disease	863	3.8%	300	3.9%	-0.115	-0.006
Pneumonia	398	1.8%	131	1.7%	0.044	0.003
Cardiac arrhythmia	3,047	13.5%	759	10.0%	3.544	0.110
Paliperidone palmitate	22,516	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,599	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	13	0.2%	-0.064	-0.017
IS Stay	2,079	9.2%	869	11.4%	-2.202	-0.072
Medical Product Use						
Mean number of filled prescriptions	20.6	21.3	19.1	20.2	1.507	0.073
Mean number of generics dispensed	7.5	5.5	7.1	5.1	0.445	0.083
Mean number of unique drug classes dispensed	6.7	4.8	6.4	4.5	0.291	0.063
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.8	17.4	14.5	17.6	0.317	0.018
Mean number of inpatient hospital encounters	0.4	0.8	0.4	1.0	-0.027	-0.030
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.042	-0.034

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1e. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,514	100.0%	7,594	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.3	3.7	-0.074	-0.020
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,514	100.0%	7,594	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,755	30.0%	2,207	29.1%	0.941	0.021
Male	15,759	70.0%	5,387	70.9%	-0.941	-0.021
Race[2]						
American Indian or Alaska Native	325	1.4%	136	1.8%	-0.347	-0.028
Asian	522	2.3%	197	2.6%	-0.276	-0.018
Black or African American	6,706	29.8%	2,504	33.0%	-3.187	-0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,604	16.0%	1,004	13.2%	2.787	0.079
White	11,357	50.4%	3,753	49.4%	1.024	0.020
Hispanic origin						
Yes	1,849	8.2%	646	8.5%	-0.294	-0.011
No	18,910	84.0%	6,590	86.8%	-2.787	-0.079
Unknown	1,755	7.8%	358	4.7%	3.081	0.127

Table 1e. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	705	3.1%	773	10.2%	-7.048	-0.286
2011	1,747	7.8%	1,490	19.6%	-11.861	-0.350
2012	2,067	9.2%	1,229	16.2%	-7.003	-0.212
2013	2,066	9.2%	1,104	14.5%	-5.361	-0.166
2014	1,955	8.7%	791	10.4%	-1.733	-0.059
2015	1,981	8.8%	551	7.3%	1.543	0.057
2016	2,031	9.0%	453	6.0%	3.056	0.116
2017	2,108	9.4%	333	4.4%	4.978	0.198
2018	2,110	9.4%	249	3.3%	6.093	0.252
2019	1,898	8.4%	246	3.2%	5.191	0.223
2020	1,565	7.0%	159	2.1%	4.857	0.235
2021	1,551	6.9%	141	1.9%	5.032	0.248
2022	730	3.2%	75	1.0%	2.255	0.157
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.5	1.3	0.078	0.061
Substance abuse	9,665	42.9%	3,150	41.5%	1.449	0.029
Atrial fibrilation/flutter	57	0.3%	33	0.4%	-0.181	-0.031
Ischemic heart disease	310	1.4%	126	1.7%	-0.282	-0.023
Heart failure	159	0.7%	61	0.8%	-0.097	-0.011
Stroke	125	0.6%	45	0.6%	-0.037	-0.005
Diabetes	2,274	10.1%	751	9.9%	0.211	0.007
Hypertension	5,101	22.7%	1,663	21.9%	0.758	0.018
Rheumatic disease	39	0.2%	19	0.3%	-0.077	-0.017
Chronic kidney disease	893	4.0%	238	3.1%	0.832	0.045
Seizure disorder	2,063	9.2%	686	9.0%	0.130	0.005

Table 1e. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	49	0.2%	11	0.1%	0.073	0.017
Dementia Diagnosis	698	3.1%	164	2.2%	0.941	0.059
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.014	0.007
Parkinsons disease	58	0.3%	13	0.2%	0.086	0.019
COPD	1,124	5.0%	372	4.9%	0.094	0.004
Malignancy	472	2.1%	132	1.7%	0.358	0.026
Asthma	3,342	14.8%	1,052	13.9%	0.991	0.028
Hyperlipidemia	3,716	16.5%	1,202	15.8%	0.677	0.018
Depression	9,750	43.3%	3,254	42.8%	0.457	0.009
Schizophrenia	17,763	78.9%	5,715	75.3%	3.641	0.087
Bipolar disorder	10,801	48.0%	3,672	48.4%	-0.379	-0.008
ACE inhibitor use	1,272	5.6%	440	5.8%	-0.144	-0.006
ARB use	214	1.0%	61	0.8%	0.147	0.016
Beta-blocker use	2,704	12.0%	801	10.5%	1.463	0.046
Oral anticoagulant use	145	0.6%	36	0.5%	0.170	0.023
Antiplatelet agent use	22	0.1%	*****	*****	-0.008	-0.002
Opioid use	3,117	13.8%	1,197	15.8%	-1.918	-0.054
Statin use	1,419	6.3%	469	6.2%	0.127	0.005
Wheelchair or walker use	*****	*****	*****	*****	-0.022	-0.013
Anti-arrhythmic use	19	0.1%	*****	*****	0.019	0.007
Antidiabetic use	1,672	7.4%	475	6.3%	1.172	0.046
Calcium channel blocker use	711	3.2%	217	2.9%	0.301	0.018
Diuretic use	1,048	4.7%	333	4.4%	0.270	0.013
Antidepressant use	12,195	54.2%	3,686	48.5%	5.628	0.113
Gastric acid suppressant use	3,927	17.4%	1,227	16.2%	1.285	0.034
NSAIDs	3,972	17.6%	1,312	17.3%	0.366	0.010

Table 1e. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,157	27.3%	1,685	22.2%	5.159	0.120
Chronic liver disease	862	3.8%	300	4.0%	-0.122	-0.006
Pneumonia	398	1.8%	131	1.7%	0.043	0.003
Cardiac arrhythmia	3,045	13.5%	757	10.0%	3.557	0.111
Paliperidone palmitate	22,514	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,594	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	13	0.2%	-0.065	-0.017
IS Stay	2,079	9.2%	866	11.4%	-2.169	-0.071
Medical Product Use						
Mean number of filled prescriptions	20.6	21.3	19.0	20.2	1.519	0.073
Mean number of generics dispensed	7.5	5.5	7.1	5.1	0.449	0.084
Mean number of unique drug classes dispensed	6.7	4.8	6.4	4.5	0.295	0.064
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.8	17.4	14.4	17.6	0.328	0.019
Mean number of inpatient hospital encounters	0.4	0.8	0.4	1.0	-0.025	-0.028
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.039	-0.032

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1f. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	22,516	N/A	7,596	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.2	3.7	-0.004	-0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	22,516	100.0%	7,596	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,700	29.8%	2,253	29.7%	0.102	0.002
Male	15,815	70.2%	5,343	70.3%	-0.102	-0.002
Race[3]						
American Indian or Alaska Native	324	1.4%	140	1.8%	-0.398	-0.031
Asian	522	2.3%	198	2.6%	-0.293	-0.019
Black or African American	6,772	30.1%	2,454	32.3%	-2.233	-0.048
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,573	15.9%	1,035	13.6%	2.249	0.063
White	11,325	50.3%	3,769	49.6%	0.676	0.014
Hispanic origin						
Yes	1,839	8.2%	662	8.7%	-0.541	-0.019
No	18,942	84.1%	6,562	86.4%	-2.249	-0.063
Unknown	1,734	7.7%	373	4.9%	2.789	0.115

Table 1f. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	716	3.2%	735	9.7%	-6.503	-0.267
2011	1,775	7.9%	1,444	19.0%	-11.123	-0.330
2012	2,108	9.4%	1,181	15.5%	-6.184	-0.188
2013	2,081	9.2%	1,111	14.6%	-5.383	-0.167
2014	1,961	8.7%	802	10.6%	-1.853	-0.063
2015	1,985	8.8%	565	7.4%	1.379	0.050
2016	2,014	8.9%	480	6.3%	2.625	0.099
2017	2,083	9.2%	349	4.6%	4.650	0.184
2018	2,098	9.3%	266	3.5%	5.811	0.239
2019	1,887	8.4%	257	3.4%	4.993	0.213
2020	1,554	6.9%	170	2.2%	4.657	0.224
2021	1,532	6.8%	154	2.0%	4.779	0.234
2022	723	3.2%	81	1.1%	2.152	0.149
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.6	1.3	1.6	1.3	0.002	0.001
Substance abuse	9,585	42.6%	3,241	42.7%	-0.099	-0.002
Atrial fibrilation/flutter	68	0.3%	23	0.3%	-0.005	-0.001
Ischemic heart disease	327	1.5%	111	1.5%	-0.011	-0.001
Heart failure	166	0.7%	57	0.8%	-0.014	-0.002
Stroke	128	0.6%	44	0.6%	-0.011	-0.001
Diabetes	2,263	10.1%	756	10.0%	0.099	0.003
Hypertension	5,066	22.5%	1,716	22.6%	-0.086	-0.002
Rheumatic disease	44	0.2%	16	0.2%	-0.009	-0.002
Chronic kidney disease	845	3.8%	276	3.6%	0.121	0.006
Seizure disorder	2,059	9.1%	697	9.2%	-0.031	-0.001

Table 1f. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	45	0.2%	16	0.2%	-0.010	-0.002
Dementia Diagnosis	645	2.9%	218	2.9%	-0.004	-0.000
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.006	0.003
Parkinsons disease	53	0.2%	17	0.2%	0.013	0.003
COPD	1,121	5.0%	378	5.0%	-0.001	-0.000
Malignancy	452	2.0%	149	2.0%	0.044	0.003
Asthma	3,288	14.6%	1,101	14.5%	0.113	0.003
Hyperlipidemia	3,682	16.4%	1,249	16.4%	-0.084	-0.002
Depression	9,728	43.2%	3,281	43.2%	0.010	0.000
Schizophrenia	17,557	78.0%	5,919	77.9%	0.053	0.001
Bipolar disorder	10,825	48.1%	3,655	48.1%	-0.042	-0.001
ACE inhibitor use	1,282	5.7%	436	5.7%	-0.045	-0.002
ARB use	207	0.9%	70	0.9%	-0.003	-0.000
Beta-blocker use	2,620	11.6%	878	11.6%	0.085	0.003
Oral anticoagulant use	135	0.6%	45	0.6%	0.007	0.001
Antiplatelet agent use	23	0.1%	*****	*****	-0.009	-0.003
Opioid use	3,226	14.3%	1,086	14.3%	0.028	0.001
Statin use	1,414	6.3%	475	6.3%	0.023	0.001
Wheelchair or walker use	*****	*****	*****	*****	0.012	0.008
Anti-arrhythmic use	18	0.1%	*****	*****	0.001	0.000
Antidiabetic use	1,607	7.1%	538	7.1%	0.055	0.002
Calcium channel blocker use	696	3.1%	234	3.1%	0.005	0.000
Diuretic use	1,035	4.6%	348	4.6%	0.016	0.001
Antidepressant use	11,884	52.8%	4,024	53.0%	-0.198	-0.004
Gastric acid suppressant use	3,856	17.1%	1,297	17.1%	0.045	0.001
NSAIDs	3,954	17.6%	1,338	17.6%	-0.051	-0.001

Table 1f. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,872	26.1%	2,005	26.4%	-0.311	-0.007
Chronic liver disease	868	3.9%	290	3.8%	0.040	0.002
Pneumonia	395	1.8%	131	1.7%	0.033	0.003
Cardiac arrhythmia	2,845	12.6%	963	12.7%	-0.041	-0.001
Paliperidone palmitate	22,516	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,596	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	12	0.2%	-0.054	-0.015
IS Stay	2,202	9.8%	736	9.7%	0.095	0.003
Medical Product Use						
Mean number of filled prescriptions	20.2	21.1	20.1	21.0	0.078	0.004
Mean number of generics dispensed	7.4	5.5	7.3	5.2	0.092	0.017
Mean number of unique drug classes dispensed	6.6	4.8	6.7	4.5	-0.026	-0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.7	17.8	-0.007	-0.000
Mean number of inpatient hospital encounters	0.4	0.8	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	0.000	0.000

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1g. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,747	100.0%	6,755	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.166	-0.057
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,747	100.0%	6,755	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,266	36.8%	2,494	36.9%	-0.125	-0.003
Male	12,481	63.2%	4,261	63.1%	0.125	0.003
Race[2]						
American Indian or Alaska Native	275	1.4%	91	1.3%	0.045	0.004
Asian	501	2.5%	182	2.7%	-0.157	-0.010
Black or African American	5,089	25.8%	1,868	27.7%	-1.883	-0.043
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,435	7.3%	501	7.4%	-0.150	-0.006
White	12,447	63.0%	4,113	60.9%	2.144	0.044
Hispanic origin						
Yes	1,047	5.3%	372	5.5%	-0.205	-0.009
No	18,312	92.7%	6,254	92.6%	0.150	0.006
Unknown	388	2.0%	129	1.9%	0.055	0.004

Table 1g. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	567	2.9%	606	9.0%	-6.100	-0.261
2011	1,412	7.2%	1,246	18.4%	-11.295	-0.343
2012	1,733	8.8%	1,142	16.9%	-8.130	-0.245
2013	1,802	9.1%	937	13.9%	-4.746	-0.149
2014	1,690	8.6%	702	10.4%	-1.834	-0.063
2015	1,768	9.0%	527	7.8%	1.152	0.042
2016	1,858	9.4%	393	5.8%	3.591	0.136
2017	1,886	9.6%	350	5.2%	4.369	0.168
2018	1,945	9.8%	258	3.8%	6.030	0.241
2019	1,842	9.3%	218	3.2%	6.101	0.254
2020	1,378	7.0%	176	2.6%	4.373	0.206
2021	1,285	6.5%	146	2.2%	4.346	0.215
2022	581	2.9%	54	0.8%	2.143	0.159
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.5	0.042	0.027
Substance abuse	7,990	40.5%	2,587	38.3%	2.164	0.044
Atrial fibrilation/flutter	123	0.6%	42	0.6%	0.001	0.000
Ischemic heart disease	659	3.3%	281	4.2%	-0.823	-0.043
Heart failure	333	1.7%	140	2.1%	-0.386	-0.028
Stroke	231	1.2%	103	1.5%	-0.355	-0.031
Diabetes	3,844	19.5%	1,363	20.2%	-0.711	-0.018
Hypertension	7,366	37.3%	2,477	36.7%	0.633	0.013
Rheumatic disease	57	0.3%	27	0.4%	-0.111	-0.019
Chronic kidney disease	1,512	7.7%	387	5.7%	1.928	0.077
Seizure disorder	2,134	10.8%	740	11.0%	-0.148	-0.005

Table 1g. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	25	0.4%	0.101	0.016
Dementia Diagnosis	735	3.7%	220	3.3%	0.465	0.025
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.012	-0.004
Parkinsons disease	94	0.5%	28	0.4%	0.062	0.009
COPD	2,001	10.1%	675	10.0%	0.141	0.005
Malignancy	480	2.4%	156	2.3%	0.121	0.008
Asthma	2,855	14.5%	989	14.6%	-0.183	-0.005
Hyperlipidemia	5,752	29.1%	1,876	27.8%	1.356	0.030
Depression	8,975	45.4%	3,025	44.8%	0.668	0.013
Schizophrenia	15,859	80.3%	5,259	77.9%	2.457	0.060
Bipolar disorder	9,614	48.7%	3,204	47.4%	1.254	0.025
ACE inhibitor use	2,565	13.0%	855	12.7%	0.332	0.010
ARB use	497	2.5%	172	2.5%	-0.029	-0.002
Beta-blocker use	3,237	16.4%	1,003	14.8%	1.544	0.043
Oral anticoagulant use	238	1.2%	80	1.2%	0.021	0.002
Antiplatelet agent use	81	0.4%	*****	*****	-0.182	-0.026
Opioid use	3,863	19.6%	1,347	19.9%	-0.378	-0.010
Statin use	3,162	16.0%	1,088	16.1%	-0.094	-0.003
Wheelchair or walker use	*****	*****	*****	*****	-0.083	-0.027
Anti-arrhythmic use	35	0.2%	*****	*****	-0.074	-0.016
Antidiabetic use	2,679	13.6%	931	13.8%	-0.216	-0.006
Calcium channel blocker use	1,312	6.6%	416	6.2%	0.486	0.020
Diuretic use	2,029	10.3%	706	10.5%	-0.177	-0.006
Antidepressant use	11,609	58.8%	3,671	54.3%	4.444	0.090
Gastric acid suppressant use	4,876	24.7%	1,583	23.4%	1.258	0.029
NSAIDs	4,405	22.3%	1,455	21.5%	0.768	0.019

Table 1g. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,667	33.8%	1,897	28.1%	5.679	0.123
Chronic liver disease	1,169	5.9%	349	5.2%	0.753	0.033
Pneumonia	590	3.0%	200	3.0%	0.027	0.002
Cardiac arrhythmia	2,554	12.9%	752	11.1%	1.801	0.055
Paliperidone palmitate	19,747	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,755	100.0%	NaN	NaN
Haloperidol decanoate	16	0.1%	12	0.2%	-0.097	-0.027
IS Stay	1,841	9.3%	798	11.8%	-2.491	-0.081
Medical Product Use						
Mean number of filled prescriptions	26.9	25.6	25.1	25.0	1.827	0.072
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.555	0.090
Mean number of unique drug classes dispensed	8.1	5.5	7.7	5.1	0.387	0.073
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.3	18.5	15.6	18.0	0.639	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.052	-0.056
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.075	-0.063

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1h. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,742	100.0%	6,754	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.165	-0.057
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,742	100.0%	6,754	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,264	36.8%	2,493	36.9%	-0.117	-0.002
Male	12,478	63.2%	4,261	63.1%	0.117	0.002
Race[2]						
American Indian or Alaska Native	275	1.4%	91	1.3%	0.046	0.004
Asian	501	2.5%	182	2.7%	-0.157	-0.010
Black or African American	5,089	25.8%	1,868	27.7%	-1.880	-0.043
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,435	7.3%	501	7.4%	-0.149	-0.006
White	12,442	63.0%	4,112	60.9%	2.141	0.044
Hispanic origin						
Yes	1,047	5.3%	372	5.5%	-0.204	-0.009
No	18,307	92.7%	6,253	92.6%	0.149	0.006
Unknown	388	2.0%	129	1.9%	0.055	0.004

Table 1h. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	567	2.9%	606	9.0%	-6.100	-0.261
2011	1,412	7.2%	1,246	18.4%	-11.296	-0.343
2012	1,733	8.8%	1,142	16.9%	-8.130	-0.245
2013	1,802	9.1%	937	13.9%	-4.746	-0.149
2014	1,690	8.6%	702	10.4%	-1.833	-0.063
2015	1,768	9.0%	527	7.8%	1.153	0.042
2016	1,858	9.4%	393	5.8%	3.593	0.136
2017	1,885	9.5%	349	5.2%	4.381	0.168
2018	1,943	9.8%	258	3.8%	6.022	0.240
2019	1,841	9.3%	218	3.2%	6.098	0.253
2020	1,378	7.0%	176	2.6%	4.374	0.206
2021	1,285	6.5%	146	2.2%	4.347	0.215
2022	580	2.9%	54	0.8%	2.138	0.158
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.5	0.042	0.028
Substance abuse	7,988	40.5%	2,586	38.3%	2.174	0.044
Atrial fibrilation/flutter	123	0.6%	42	0.6%	0.001	0.000
Ischemic heart disease	658	3.3%	280	4.1%	-0.813	-0.043
Heart failure	332	1.7%	139	2.1%	-0.376	-0.028
Stroke	230	1.2%	103	1.5%	-0.360	-0.031
Diabetes	3,841	19.5%	1,362	20.2%	-0.710	-0.018
Hypertension	7,362	37.3%	2,476	36.7%	0.631	0.013
Rheumatic disease	57	0.3%	26	0.4%	-0.096	-0.017
Chronic kidney disease	1,507	7.6%	386	5.7%	1.918	0.077
Seizure disorder	2,134	10.8%	739	10.9%	-0.132	-0.004

Table 1h. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	92	0.5%	25	0.4%	0.096	0.015
Dementia Diagnosis	734	3.7%	220	3.3%	0.461	0.025
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.012	-0.004
Parkinsons disease	94	0.5%	28	0.4%	0.062	0.009
COPD	1,999	10.1%	675	10.0%	0.132	0.004
Malignancy	480	2.4%	156	2.3%	0.122	0.008
Asthma	2,853	14.5%	988	14.6%	-0.177	-0.005
Hyperlipidemia	5,747	29.1%	1,875	27.8%	1.349	0.030
Depression	8,972	45.4%	3,024	44.8%	0.673	0.014
Schizophrenia	15,855	80.3%	5,259	77.9%	2.446	0.060
Bipolar disorder	9,610	48.7%	3,204	47.4%	1.239	0.025
ACE inhibitor use	2,563	13.0%	854	12.6%	0.338	0.010
ARB use	496	2.5%	171	2.5%	-0.019	-0.001
Beta-blocker use	3,233	16.4%	1,002	14.8%	1.541	0.042
Oral anticoagulant use	237	1.2%	80	1.2%	0.016	0.001
Antiplatelet agent use	80	0.4%	*****	*****	-0.187	-0.027
Opioid use	3,860	19.6%	1,346	19.9%	-0.377	-0.009
Statin use	3,160	16.0%	1,088	16.1%	-0.102	-0.003
Wheelchair or walker use	*****	*****	*****	*****	-0.083	-0.027
Anti-arrhythmic use	35	0.2%	*****	*****	-0.074	-0.016
Antidiabetic use	2,677	13.6%	931	13.8%	-0.225	-0.007
Calcium channel blocker use	1,312	6.6%	415	6.1%	0.501	0.020
Diuretic use	2,027	10.3%	706	10.5%	-0.186	-0.006
Antidepressant use	11,604	58.8%	3,670	54.3%	4.440	0.090
Gastric acid suppressant use	4,872	24.7%	1,582	23.4%	1.255	0.029
NSAIDs	4,403	22.3%	1,455	21.5%	0.760	0.018

Table 1h. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,663	33.8%	1,897	28.1%	5.663	0.123
Chronic liver disease	1,166	5.9%	348	5.2%	0.754	0.033
Pneumonia	587	3.0%	199	2.9%	0.027	0.002
Cardiac arrhythmia	2,551	12.9%	751	11.1%	1.802	0.055
Paliperidone palmitate	19,742	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,754	100.0%	NaN	NaN
Haloperidol decanoate	16	0.1%	12	0.2%	-0.097	-0.027
IS Stay	1,840	9.3%	798	11.8%	-2.495	-0.081
Medical Product Use						
Mean number of filled prescriptions	26.9	25.6	25.1	25.0	1.817	0.072
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.553	0.090
Mean number of unique drug classes dispensed	8.1	5.5	7.7	5.1	0.385	0.073
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.3	18.5	15.6	18.0	0.643	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.050	-0.054
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.075	-0.064

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1i. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,740	N/A	6,759	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.9	2.9	39.9	2.9	0.004	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,740	100.0%	6,759	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,264	36.8%	2,480	36.7%	0.113	0.002
Male	12,476	63.2%	4,279	63.3%	-0.113	-0.002
Race[3]						
American Indian or Alaska Native	274	1.4%	95	1.4%	-0.015	-0.001
Asian	502	2.5%	182	2.7%	-0.149	-0.009
Black or African American	5,150	26.1%	1,819	26.9%	-0.825	-0.019
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,428	7.2%	515	7.6%	-0.379	-0.014
White	12,386	62.7%	4,148	61.4%	1.368	0.028
Hispanic origin						
Yes	1,041	5.3%	385	5.7%	-0.423	-0.019
No	18,312	92.8%	6,244	92.4%	0.379	0.014
Unknown	388	2.0%	130	1.9%	0.043	0.003

Table 1i. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	578	2.9%	586	8.7%	-5.736	-0.247
2011	1,439	7.3%	1,205	17.8%	-10.541	-0.322
2012	1,773	9.0%	1,102	16.3%	-7.329	-0.222
2013	1,813	9.2%	954	14.1%	-4.925	-0.154
2014	1,690	8.6%	707	10.5%	-1.894	-0.065
2015	1,761	8.9%	528	7.8%	1.108	0.040
2016	1,834	9.3%	415	6.1%	3.149	0.118
2017	1,872	9.5%	364	5.4%	4.088	0.156
2018	1,925	9.8%	267	4.0%	5.799	0.231
2019	1,829	9.3%	233	3.4%	5.822	0.240
2020	1,374	7.0%	187	2.8%	4.188	0.196
2021	1,275	6.5%	153	2.3%	4.196	0.207
2022	578	2.9%	58	0.9%	2.076	0.153
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.8	1.5	1.8	1.5	-0.005	-0.003
Substance abuse	7,886	39.9%	2,709	40.1%	-0.126	-0.003
Atrial fibrilation/flutter	124	0.6%	43	0.6%	-0.007	-0.001
Ischemic heart disease	698	3.5%	239	3.5%	-0.005	-0.000
Heart failure	349	1.8%	119	1.8%	0.009	0.001
Stroke	247	1.3%	86	1.3%	-0.022	-0.002
Diabetes	3,875	19.6%	1,326	19.6%	0.016	0.000
Hypertension	7,330	37.1%	2,511	37.2%	-0.025	-0.001
Rheumatic disease	63	0.3%	21	0.3%	0.000	0.000
Chronic kidney disease	1,411	7.1%	491	7.3%	-0.119	-0.005
Seizure disorder	2,138	10.8%	733	10.8%	-0.012	-0.000

Table 1i. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	87	0.4%	31	0.5%	-0.015	-0.002
Dementia Diagnosis	710	3.6%	239	3.5%	0.065	0.004
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.004	0.001
Parkinsons disease	90	0.5%	30	0.4%	0.014	0.002
COPD	1,992	10.1%	677	10.0%	0.083	0.003
Malignancy	475	2.4%	166	2.5%	-0.053	-0.003
Asthma	2,865	14.5%	991	14.7%	-0.150	-0.004
Hyperlipidemia	5,676	28.8%	1,938	28.7%	0.077	0.002
Depression	8,938	45.3%	3,062	45.3%	-0.032	-0.001
Schizophrenia	15,733	79.7%	5,384	79.7%	0.046	0.001
Bipolar disorder	9,550	48.4%	3,270	48.4%	0.001	0.000
ACE inhibitor use	2,543	12.9%	867	12.8%	0.054	0.002
ARB use	498	2.5%	173	2.6%	-0.039	-0.003
Beta-blocker use	3,154	16.0%	1,077	15.9%	0.040	0.001
Oral anticoagulant use	234	1.2%	80	1.2%	-0.002	-0.000
Antiplatelet agent use	90	0.5%	*****	*****	-0.029	-0.004
Opioid use	3,873	19.6%	1,319	19.5%	0.102	0.003
Statin use	3,160	16.0%	1,075	15.9%	0.097	0.003
Wheelchair or walker use	*****	*****	*****	*****	-0.001	-0.000
Anti-arrhythmic use	39	0.2%	*****	*****	0.006	0.001
Antidiabetic use	2,684	13.6%	914	13.5%	0.072	0.002
Calcium channel blocker use	1,286	6.5%	444	6.6%	-0.046	-0.002
Diuretic use	2,037	10.3%	702	10.4%	-0.073	-0.002
Antidepressant use	11,381	57.7%	3,899	57.7%	-0.037	-0.001
Gastric acid suppressant use	4,809	24.4%	1,650	24.4%	-0.051	-0.001
NSAIDs	4,362	22.1%	1,494	22.1%	-0.008	-0.000

Table 1i. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,382	32.3%	2,193	32.5%	-0.121	-0.003
Chronic liver disease	1,129	5.7%	394	5.8%	-0.109	-0.005
Pneumonia	584	3.0%	199	3.0%	0.005	0.000
Cardiac arrhythmia	2,463	12.5%	854	12.6%	-0.159	-0.005
Paliperidone palmitate	19,740	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,759	100.0%	NaN	NaN
Haloperidol decanoate	17	0.1%	12	0.2%	-0.100	-0.027
IS Stay	1,965	10.0%	668	9.9%	0.076	0.003
Medical Product Use						
Mean number of filled prescriptions	26.5	25.5	26.2	25.3	0.354	0.014
Mean number of generics dispensed	9.0	6.3	8.8	6.0	0.211	0.034
Mean number of unique drug classes dispensed	8.0	5.4	7.9	5.2	0.077	0.015
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.1	18.3	16.3	19.0	-0.148	-0.008
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.004	-0.005
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.1	-0.001	-0.001

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1j. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,449	100.0%	8,005	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.8	-0.130	-0.045
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,449	100.0%	8,005	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,340	42.9%	3,420	42.7%	0.158	0.003
Male	11,109	57.1%	4,585	57.3%	-0.158	-0.003
Race[2]						
American Indian or Alaska Native	199	1.0%	108	1.3%	-0.326	-0.030
Asian	451	2.3%	153	1.9%	0.408	0.028
Black or African American	4,647	23.9%	2,106	26.3%	-2.415	-0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	981	5.0%	412	5.1%	-0.103	-0.005
White	13,171	67.7%	5,226	65.3%	2.437	0.052
Hispanic origin						
Yes	779	4.0%	328	4.1%	-0.092	-0.005
No	18,468	95.0%	7,593	94.9%	0.103	0.005
Unknown	202	1.0%	84	1.0%	-0.011	-0.001

Table 1j. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	677	3.5%	801	10.0%	-6.525	-0.262
2011	1,673	8.6%	1,583	19.8%	-11.173	-0.324
2012	1,948	10.0%	1,299	16.2%	-6.211	-0.185
2013	1,885	9.7%	1,174	14.7%	-4.974	-0.153
2014	1,767	9.1%	836	10.4%	-1.358	-0.046
2015	1,870	9.6%	648	8.1%	1.520	0.054
2016	1,897	9.8%	516	6.4%	3.308	0.121
2017	1,882	9.7%	356	4.4%	5.229	0.205
2018	1,848	9.5%	282	3.5%	5.979	0.244
2019	1,530	7.9%	201	2.5%	5.356	0.243
2020	1,064	5.5%	145	1.8%	3.659	0.196
2021	987	5.1%	117	1.5%	3.613	0.204
2022	421	2.2%	47	0.6%	1.578	0.136
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.1	2.0	-0.018	-0.009
Substance abuse	6,773	34.8%	2,548	31.8%	2.994	0.064
Atrial fibrilation/flutter	286	1.5%	126	1.6%	-0.104	-0.008
Ischemic heart disease	1,538	7.9%	679	8.5%	-0.574	-0.021
Heart failure	760	3.9%	389	4.9%	-0.952	-0.047
Stroke	446	2.3%	264	3.3%	-1.005	-0.061
Diabetes	5,716	29.4%	2,413	30.1%	-0.754	-0.016
Hypertension	10,275	52.8%	4,146	51.8%	1.038	0.021
Rheumatic disease	105	0.5%	47	0.6%	-0.047	-0.006
Chronic kidney disease	2,322	11.9%	816	10.2%	1.745	0.056
Seizure disorder	2,404	12.4%	1,080	13.5%	-1.131	-0.034

Table 1j. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	227	1.2%	162	2.0%	-0.857	-0.068
Dementia Diagnosis	1,045	5.4%	557	7.0%	-1.585	-0.066
Dementia Diagnosis and Treatment	95	0.5%	86	1.1%	-0.586	-0.067
Parkinsons disease	257	1.3%	96	1.2%	0.122	0.011
COPD	3,874	19.9%	1,523	19.0%	0.893	0.023
Malignancy	585	3.0%	260	3.2%	-0.240	-0.014
Asthma	2,751	14.1%	1,056	13.2%	0.953	0.028
Hyperlipidemia	7,917	40.7%	3,144	39.3%	1.431	0.029
Depression	9,078	46.7%	3,694	46.1%	0.530	0.011
Schizophrenia	15,798	81.2%	6,350	79.3%	1.902	0.048
Bipolar disorder	9,074	46.7%	3,666	45.8%	0.859	0.017
ACE inhibitor use	4,122	21.2%	1,718	21.5%	-0.268	-0.007
ARB use	1,024	5.3%	370	4.6%	0.643	0.030
Beta-blocker use	4,084	21.0%	1,556	19.4%	1.561	0.039
Oral anticoagulant use	391	2.0%	168	2.1%	-0.088	-0.006
Antiplatelet agent use	302	1.6%	175	2.2%	-0.633	-0.047
Opioid use	4,365	22.4%	1,853	23.1%	-0.705	-0.017
Statin use	5,397	27.7%	2,114	26.4%	1.341	0.030
Wheelchair or walker use	24	0.1%	41	0.5%	-0.389	-0.069
Anti-arrhythmic use	74	0.4%	29	0.4%	0.018	0.003
Antidiabetic use	4,090	21.0%	1,661	20.7%	0.280	0.007
Calcium channel blocker use	2,280	11.7%	940	11.7%	-0.020	-0.001
Diuretic use	3,379	17.4%	1,417	17.7%	-0.328	-0.009
Antidepressant use	12,041	61.9%	4,589	57.3%	4.584	0.094
Gastric acid suppressant use	6,105	31.4%	2,423	30.3%	1.121	0.024
NSAIDs	4,947	25.4%	1,850	23.1%	2.325	0.054

Table 1j. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,066	36.3%	2,387	29.8%	6.512	0.139
Chronic liver disease	1,517	7.8%	580	7.2%	0.554	0.021
Pneumonia	875	4.5%	406	5.1%	-0.573	-0.027
Cardiac arrhythmia	2,526	13.0%	893	11.2%	1.832	0.056
Paliperidone palmitate	19,449	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	8,005	100.0%	NaN	NaN
Haloperidol decanoate	23	0.1%	23	0.3%	-0.169	-0.038
IS Stay	1,835	9.4%	964	12.0%	-2.608	-0.084
Medical Product Use						
Mean number of filled prescriptions	32.8	28.2	31.6	27.4	1.164	0.042
Mean number of generics dispensed	10.4	6.5	10.0	6.4	0.439	0.068
Mean number of unique drug classes dispensed	9.3	5.7	8.9	5.5	0.336	0.060
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	19.8	17.3	20.1	0.446	0.022
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.051	-0.052
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.091	-0.077

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1k. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,433	99.9%	8,004	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.8	-0.129	-0.045
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,433	100.0%	8,004	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,331	42.9%	3,419	42.7%	0.154	0.003
Male	11,102	57.1%	4,585	57.3%	-0.154	-0.003
Race[2]						
American Indian or Alaska Native	198	1.0%	108	1.3%	-0.330	-0.031
Asian	451	2.3%	153	1.9%	0.409	0.028
Black or African American	4,642	23.9%	2,106	26.3%	-2.425	-0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	980	5.0%	412	5.1%	-0.104	-0.005
White	13,162	67.7%	5,225	65.3%	2.450	0.052
Hispanic origin						
Yes	778	4.0%	328	4.1%	-0.094	-0.005
No	18,453	95.0%	7,592	94.9%	0.104	0.005
Unknown	202	1.0%	84	1.0%	-0.010	-0.001

Table 1k. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	677	3.5%	801	10.0%	-6.524	-0.262
2011	1,673	8.6%	1,583	19.8%	-11.169	-0.324
2012	1,948	10.0%	1,298	16.2%	-6.193	-0.184
2013	1,884	9.7%	1,174	14.7%	-4.973	-0.152
2014	1,767	9.1%	836	10.4%	-1.352	-0.046
2015	1,869	9.6%	648	8.1%	1.522	0.054
2016	1,892	9.7%	516	6.4%	3.289	0.121
2017	1,880	9.7%	356	4.4%	5.226	0.205
2018	1,847	9.5%	282	3.5%	5.981	0.244
2019	1,529	7.9%	201	2.5%	5.357	0.243
2020	1,061	5.5%	145	1.8%	3.648	0.196
2021	986	5.1%	117	1.5%	3.612	0.204
2022	420	2.2%	47	0.6%	1.574	0.136
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.1	2.0	-0.020	-0.010
Substance abuse	6,761	34.8%	2,547	31.8%	2.970	0.063
Atrial fibrilation/flutter	284	1.5%	126	1.6%	-0.113	-0.009
Ischemic heart disease	1,534	7.9%	678	8.5%	-0.577	-0.021
Heart failure	759	3.9%	388	4.8%	-0.942	-0.046
Stroke	445	2.3%	264	3.3%	-1.008	-0.061
Diabetes	5,707	29.4%	2,412	30.1%	-0.767	-0.017
Hypertension	10,259	52.8%	4,145	51.8%	1.005	0.020
Rheumatic disease	104	0.5%	47	0.6%	-0.052	-0.007
Chronic kidney disease	2,307	11.9%	816	10.2%	1.677	0.054
Seizure disorder	2,402	12.4%	1,079	13.5%	-1.120	-0.033

Table 1k. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	227	1.2%	162	2.0%	-0.856	-0.068
Dementia Diagnosis	1,044	5.4%	557	7.0%	-1.587	-0.066
Dementia Diagnosis and Treatment	95	0.5%	86	1.1%	-0.586	-0.067
Parkinsons disease	255	1.3%	96	1.2%	0.113	0.010
COPD	3,864	19.9%	1,522	19.0%	0.868	0.022
Malignancy	585	3.0%	260	3.2%	-0.238	-0.014
Asthma	2,743	14.1%	1,056	13.2%	0.922	0.027
Hyperlipidemia	7,907	40.7%	3,144	39.3%	1.408	0.029
Depression	9,067	46.7%	3,694	46.2%	0.506	0.010
Schizophrenia	15,782	81.2%	6,350	79.3%	1.877	0.047
Bipolar disorder	9,063	46.6%	3,666	45.8%	0.835	0.017
ACE inhibitor use	4,117	21.2%	1,717	21.5%	-0.266	-0.006
ARB use	1,021	5.3%	370	4.6%	0.631	0.029
Beta-blocker use	4,074	21.0%	1,555	19.4%	1.537	0.038
Oral anticoagulant use	390	2.0%	168	2.1%	-0.092	-0.006
Antiplatelet agent use	302	1.6%	174	2.2%	-0.620	-0.046
Opioid use	4,362	22.4%	1,852	23.1%	-0.692	-0.016
Statin use	5,389	27.7%	2,113	26.4%	1.332	0.030
Wheelchair or walker use	22	0.1%	40	0.5%	-0.387	-0.070
Anti-arrhythmic use	73	0.4%	29	0.4%	0.013	0.002
Antidiabetic use	4,080	21.0%	1,661	20.8%	0.243	0.006
Calcium channel blocker use	2,275	11.7%	940	11.7%	-0.037	-0.001
Diuretic use	3,374	17.4%	1,416	17.7%	-0.329	-0.009
Antidepressant use	12,028	61.9%	4,588	57.3%	4.573	0.093
Gastric acid suppressant use	6,098	31.4%	2,422	30.3%	1.120	0.024
NSAIDs	4,934	25.4%	1,850	23.1%	2.276	0.053

Table 1k. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,050	36.3%	2,387	29.8%	6.456	0.138
Chronic liver disease	1,511	7.8%	580	7.2%	0.529	0.020
Pneumonia	874	4.5%	405	5.1%	-0.562	-0.026
Cardiac arrhythmia	2,513	12.9%	893	11.2%	1.775	0.055
Paliperidone palmitate	19,433	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	8,004	100.0%	NaN	NaN
Haloperidol decanoate	23	0.1%	23	0.3%	-0.169	-0.038
IS Stay	1,835	9.4%	964	12.0%	-2.601	-0.084
Medical Product Use						
Mean number of filled prescriptions	32.8	28.1	31.6	27.4	1.145	0.041
Mean number of generics dispensed	10.4	6.5	10.0	6.4	0.432	0.067
Mean number of unique drug classes dispensed	9.3	5.7	8.9	5.5	0.331	0.059
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	19.8	17.3	20.1	0.438	0.022
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.051	-0.053
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.092	-0.078

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1l. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,428	N/A	8,011	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.1	2.8	0.007	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,428	100.0%	8,011	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,316	42.8%	3,424	42.7%	0.067	0.001
Male	11,112	57.2%	4,587	57.3%	-0.067	-0.001
Race[3]						
American Indian or Alaska Native	197	1.0%	110	1.4%	-0.357	-0.033
Asian	453	2.3%	147	1.8%	0.499	0.035
Black or African American	4,691	24.1%	2,060	25.7%	-1.572	-0.036
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	978	5.0%	422	5.3%	-0.234	-0.011
White	13,108	67.5%	5,272	65.8%	1.664	0.035
Hispanic origin						
Yes	776	4.0%	337	4.2%	-0.209	-0.011
No	18,450	95.0%	7,589	94.7%	0.234	0.011
Unknown	202	1.0%	85	1.1%	-0.025	-0.002

Table 1l. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	693	3.6%	770	9.6%	-6.052	-0.246
2011	1,706	8.8%	1,517	18.9%	-10.157	-0.297
2012	1,996	10.3%	1,245	15.5%	-5.260	-0.157
2013	1,880	9.7%	1,200	15.0%	-5.304	-0.162
2014	1,766	9.1%	859	10.7%	-1.634	-0.055
2015	1,862	9.6%	668	8.3%	1.246	0.044
2016	1,871	9.6%	541	6.8%	2.874	0.105
2017	1,862	9.6%	374	4.7%	4.914	0.192
2018	1,830	9.4%	297	3.7%	5.711	0.232
2019	1,513	7.8%	211	2.6%	5.154	0.233
2020	1,055	5.4%	151	1.9%	3.549	0.190
2021	978	5.0%	127	1.6%	3.452	0.194
2022	415	2.1%	50	0.6%	1.507	0.129
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.1	1.9	2.1	1.9	-0.008	-0.004
Substance abuse	6,603	34.0%	2,744	34.2%	-0.259	-0.005
Atrial fibrilation/flutter	290	1.5%	123	1.5%	-0.043	-0.004
Ischemic heart disease	1,571	8.1%	652	8.1%	-0.054	-0.002
Heart failure	817	4.2%	346	4.3%	-0.109	-0.005
Stroke	500	2.6%	206	2.6%	-0.002	-0.000
Diabetes	5,743	29.6%	2,367	29.5%	0.011	0.000
Hypertension	10,203	52.5%	4,213	52.6%	-0.077	-0.002
Rheumatic disease	107	0.6%	45	0.6%	-0.016	-0.002
Chronic kidney disease	2,209	11.4%	919	11.5%	-0.104	-0.003
Seizure disorder	2,461	12.7%	1,012	12.6%	0.031	0.001

Table 1l. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	277	1.4%	115	1.4%	-0.007	-0.001
Dementia Diagnosis	1,135	5.8%	467	5.8%	0.008	0.000
Dementia Diagnosis and Treatment	129	0.7%	53	0.7%	0.007	0.001
Parkinsons disease	251	1.3%	105	1.3%	-0.023	-0.002
COPD	3,817	19.6%	1,580	19.7%	-0.077	-0.002
Malignancy	601	3.1%	251	3.1%	-0.034	-0.002
Asthma	2,690	13.8%	1,114	13.9%	-0.056	-0.002
Hyperlipidemia	7,833	40.3%	3,235	40.4%	-0.059	-0.001
Depression	9,036	46.5%	3,722	46.5%	0.048	0.001
Schizophrenia	15,681	80.7%	6,470	80.8%	-0.051	-0.001
Bipolar disorder	9,027	46.5%	3,740	46.7%	-0.227	-0.005
ACE inhibitor use	4,133	21.3%	1,708	21.3%	-0.050	-0.001
ARB use	983	5.1%	404	5.0%	0.020	0.001
Beta-blocker use	3,991	20.5%	1,657	20.7%	-0.138	-0.003
Oral anticoagulant use	394	2.0%	166	2.1%	-0.048	-0.003
Antiplatelet agent use	333	1.7%	135	1.7%	0.024	0.002
Opioid use	4,395	22.6%	1,809	22.6%	0.041	0.001
Statin use	5,312	27.3%	2,181	27.2%	0.109	0.002
Wheelchair or walker use	40	0.2%	19	0.2%	-0.026	-0.005
Anti-arrhythmic use	71	0.4%	31	0.4%	-0.020	-0.003
Antidiabetic use	4,056	20.9%	1,667	20.8%	0.071	0.002
Calcium channel blocker use	2,267	11.7%	928	11.6%	0.080	0.003
Diuretic use	3,395	17.5%	1,404	17.5%	-0.044	-0.001
Antidepressant use	11,765	60.6%	4,853	60.6%	-0.023	-0.000
Gastric acid suppressant use	6,026	31.0%	2,479	30.9%	0.074	0.002
NSAIDs	4,803	24.7%	1,985	24.8%	-0.053	-0.001

Table 1l. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,683	34.4%	2,761	34.5%	-0.065	-0.001
Chronic liver disease	1,483	7.6%	612	7.6%	-0.001	-0.000
Pneumonia	906	4.7%	378	4.7%	-0.048	-0.002
Cardiac arrhythmia	2,422	12.5%	1,017	12.7%	-0.230	-0.007
Paliperidone palmitate	19,428	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	8,011	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	23	0.3%	-0.171	-0.038
IS Stay	1,988	10.2%	823	10.3%	-0.036	-0.001
Medical Product Use						
Mean number of filled prescriptions	32.3	28.0	32.7	27.8	-0.346	-0.012
Mean number of generics dispensed	10.3	6.5	10.2	6.4	0.100	0.016
Mean number of unique drug classes dispensed	9.2	5.7	9.1	5.5	0.033	0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.6	19.7	17.7	20.5	-0.083	-0.004
Mean number of inpatient hospital encounters	0.4	1.0	0.4	1.0	-0.004	-0.004
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.1	-0.003	-0.003

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1m. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,759	100.0%	7,196	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.6	2.9	-0.351	-0.124
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,759	100.0%	7,196	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,877	46.6%	3,486	48.4%	-1.848	-0.037
Male	7,882	53.4%	3,710	51.6%	1.848	0.037
Race[2]						
American Indian or Alaska Native	157	1.1%	52	0.7%	0.341	0.036
Asian	275	1.9%	107	1.5%	0.376	0.029
Black or African American	3,706	25.1%	1,784	24.8%	0.319	0.007
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	615	4.2%	337	4.7%	-0.516	-0.025
White	10,006	67.8%	4,916	68.3%	-0.520	-0.011
Hispanic origin						
Yes	452	3.1%	243	3.4%	-0.314	-0.018
No	14,144	95.8%	6,859	95.3%	0.516	0.025
Unknown	163	1.1%	94	1.3%	-0.202	-0.018

Table 1m. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	373	2.5%	526	7.3%	-4.782	-0.223
2011	889	6.0%	1,021	14.2%	-8.165	-0.273
2012	1,109	7.5%	1,021	14.2%	-6.674	-0.216
2013	1,222	8.3%	931	12.9%	-4.658	-0.152
2014	1,269	8.6%	753	10.5%	-1.866	-0.064
2015	1,424	9.6%	639	8.9%	0.768	0.027
2016	1,427	9.7%	557	7.7%	1.928	0.068
2017	1,552	10.5%	483	6.7%	3.804	0.136
2018	1,540	10.4%	403	5.6%	4.834	0.179
2019	1,463	9.9%	319	4.4%	5.480	0.214
2020	1,116	7.6%	229	3.2%	4.379	0.195
2021	949	6.4%	218	3.0%	3.401	0.161
2022	426	2.9%	96	1.3%	1.552	0.108
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	3.0	2.7	-0.386	-0.152
Substance abuse	4,087	27.7%	1,654	23.0%	4.707	0.108
Atrial fibrilation/flutter	488	3.3%	324	4.5%	-1.196	-0.062
Ischemic heart disease	2,057	13.9%	1,266	17.6%	-3.656	-0.100
Heart failure	1,095	7.4%	777	10.8%	-3.378	-0.118
Stroke	641	4.3%	549	7.6%	-3.286	-0.139
Diabetes	5,340	36.2%	2,867	39.8%	-3.660	-0.075
Hypertension	9,416	63.8%	4,857	67.5%	-3.697	-0.078
Rheumatic disease	132	0.9%	56	0.8%	0.116	0.013
Chronic kidney disease	2,749	18.6%	1,389	19.3%	-0.676	-0.017
Seizure disorder	2,041	13.8%	1,219	16.9%	-3.111	-0.086

Table 1m. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	588	4.0%	516	7.2%	-3.187	-0.139
Dementia Diagnosis	1,833	12.4%	1,573	21.9%	-9.440	-0.252
Dementia Diagnosis and Treatment	364	2.5%	398	5.5%	-3.065	-0.157
Parkinsons disease	447	3.0%	329	4.6%	-1.543	-0.081
COPD	4,084	27.7%	2,030	28.2%	-0.539	-0.012
Malignancy	657	4.5%	338	4.7%	-0.246	-0.012
Asthma	1,804	12.2%	845	11.7%	0.480	0.015
Hyperlipidemia	7,114	48.2%	3,466	48.2%	0.035	0.001
Depression	6,729	45.6%	3,463	48.1%	-2.531	-0.051
Schizophrenia	12,418	84.1%	5,667	78.8%	5.386	0.139
Bipolar disorder	6,592	44.7%	3,157	43.9%	0.793	0.016
ACE inhibitor use	3,816	25.9%	1,983	27.6%	-1.702	-0.038
ARB use	1,081	7.3%	488	6.8%	0.543	0.021
Beta-blocker use	3,836	26.0%	2,019	28.1%	-2.066	-0.047
Oral anticoagulant use	526	3.6%	295	4.1%	-0.536	-0.028
Antiplatelet agent use	469	3.2%	340	4.7%	-1.547	-0.079
Opioid use	3,135	21.2%	1,713	23.8%	-2.564	-0.061
Statin use	5,427	36.8%	2,612	36.3%	0.473	0.010
Wheelchair or walker use	82	0.6%	131	1.8%	-1.265	-0.117
Anti-arrhythmic use	98	0.7%	61	0.8%	-0.184	-0.021
Antidiabetic use	3,723	25.2%	1,858	25.8%	-0.595	-0.014
Calcium channel blocker use	2,718	18.4%	1,329	18.5%	-0.053	-0.001
Diuretic use	3,424	23.2%	1,847	25.7%	-2.468	-0.057
Antidepressant use	8,824	59.8%	4,201	58.4%	1.408	0.029
Gastric acid suppressant use	5,045	34.2%	2,563	35.6%	-1.434	-0.030
NSAIDs	3,529	23.9%	1,550	21.5%	2.371	0.057

Table 1m. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,565	37.7%	2,472	34.4%	3.353	0.070
Chronic liver disease	1,229	8.3%	620	8.6%	-0.289	-0.010
Pneumonia	980	6.6%	678	9.4%	-2.782	-0.102
Cardiac arrhythmia	2,163	14.7%	1,012	14.1%	0.592	0.017
Paliperidone palmitate	14,759	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,196	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	16	0.2%	-0.127	-0.032
IS Stay	1,695	11.5%	1,066	14.8%	-3.329	-0.099
Medical Product Use						
Mean number of filled prescriptions	36.4	30.0	38.6	32.6	-2.198	-0.070
Mean number of generics dispensed	11.0	6.5	11.4	6.7	-0.313	-0.048
Mean number of unique drug classes dispensed	9.9	5.7	10.3	5.8	-0.375	-0.065
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.2	20.2	16.7	19.6	1.497	0.075
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.074	-0.076
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.117	-0.092

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1n. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,756	100.0%	7,194	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.6	2.9	-0.351	-0.124
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,756	100.0%	7,194	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,876	46.6%	3,486	48.5%	-1.859	-0.037
Male	7,880	53.4%	3,708	51.5%	1.859	0.037
Race[2]						
American Indian or Alaska Native	157	1.1%	52	0.7%	0.341	0.036
Asian	275	1.9%	107	1.5%	0.376	0.029
Black or African American	3,705	25.1%	1,784	24.8%	0.310	0.007
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	614	4.2%	337	4.7%	-0.523	-0.025
White	10,005	67.8%	4,914	68.3%	-0.504	-0.011
Hispanic origin						
Yes	451	3.1%	243	3.4%	-0.321	-0.018
No	14,142	95.8%	6,857	95.3%	0.523	0.025
Unknown	163	1.1%	94	1.3%	-0.202	-0.019

Table 1n. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	373	2.5%	525	7.3%	-4.770	-0.222
2011	889	6.0%	1,021	14.2%	-8.168	-0.273
2012	1,108	7.5%	1,021	14.2%	-6.684	-0.216
2013	1,221	8.3%	931	12.9%	-4.667	-0.152
2014	1,269	8.6%	753	10.5%	-1.867	-0.064
2015	1,424	9.7%	639	8.9%	0.768	0.026
2016	1,427	9.7%	557	7.7%	1.928	0.068
2017	1,552	10.5%	483	6.7%	3.804	0.136
2018	1,540	10.4%	402	5.6%	4.848	0.179
2019	1,462	9.9%	319	4.4%	5.474	0.213
2020	1,116	7.6%	229	3.2%	4.380	0.195
2021	949	6.4%	218	3.0%	3.401	0.161
2022	426	2.9%	96	1.3%	1.553	0.108
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	3.0	2.7	-0.385	-0.152
Substance abuse	4,085	27.7%	1,654	23.0%	4.692	0.108
Atrial fibrilation/flutter	488	3.3%	324	4.5%	-1.197	-0.062
Ischemic heart disease	2,057	13.9%	1,266	17.6%	-3.658	-0.100
Heart failure	1,095	7.4%	776	10.8%	-3.366	-0.117
Stroke	640	4.3%	548	7.6%	-3.280	-0.139
Diabetes	5,340	36.2%	2,865	39.8%	-3.636	-0.075
Hypertension	9,414	63.8%	4,856	67.5%	-3.703	-0.078
Rheumatic disease	132	0.9%	56	0.8%	0.116	0.013
Chronic kidney disease	2,749	18.6%	1,388	19.3%	-0.664	-0.017
Seizure disorder	2,040	13.8%	1,218	16.9%	-3.106	-0.086

Table 1n. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	587	4.0%	516	7.2%	-3.195	-0.140
Dementia Diagnosis	1,832	12.4%	1,572	21.9%	-9.436	-0.252
Dementia Diagnosis and Treatment	363	2.5%	398	5.5%	-3.072	-0.157
Parkinsons disease	447	3.0%	329	4.6%	-1.544	-0.081
COPD	4,083	27.7%	2,029	28.2%	-0.534	-0.012
Malignancy	657	4.5%	338	4.7%	-0.246	-0.012
Asthma	1,804	12.2%	845	11.7%	0.480	0.015
Hyperlipidemia	7,114	48.2%	3,466	48.2%	0.032	0.001
Depression	6,726	45.6%	3,462	48.1%	-2.542	-0.051
Schizophrenia	12,416	84.1%	5,665	78.7%	5.396	0.139
Bipolar disorder	6,590	44.7%	3,156	43.9%	0.790	0.016
ACE inhibitor use	3,816	25.9%	1,983	27.6%	-1.704	-0.039
ARB use	1,081	7.3%	488	6.8%	0.542	0.021
Beta-blocker use	3,836	26.0%	2,019	28.1%	-2.069	-0.047
Oral anticoagulant use	526	3.6%	295	4.1%	-0.536	-0.028
Antiplatelet agent use	469	3.2%	340	4.7%	-1.548	-0.080
Opioid use	3,135	21.2%	1,712	23.8%	-2.552	-0.061
Statin use	5,427	36.8%	2,612	36.3%	0.470	0.010
Wheelchair or walker use	81	0.5%	131	1.8%	-1.272	-0.118
Anti-arrhythmic use	98	0.7%	61	0.8%	-0.184	-0.021
Antidiabetic use	3,723	25.2%	1,857	25.8%	-0.583	-0.013
Calcium channel blocker use	2,717	18.4%	1,329	18.5%	-0.061	-0.002
Diuretic use	3,424	23.2%	1,846	25.7%	-2.456	-0.057
Antidepressant use	8,821	59.8%	4,199	58.4%	1.411	0.029
Gastric acid suppressant use	5,044	34.2%	2,562	35.6%	-1.430	-0.030
NSAIDs	3,527	23.9%	1,550	21.5%	2.356	0.056

Table 1n. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,563	37.7%	2,471	34.3%	3.352	0.070
Chronic liver disease	1,229	8.3%	619	8.6%	-0.276	-0.010
Pneumonia	979	6.6%	678	9.4%	-2.790	-0.103
Cardiac arrhythmia	2,161	14.6%	1,012	14.1%	0.578	0.016
Paliperidone palmitate	14,756	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,194	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	16	0.2%	-0.128	-0.032
IS Stay	1,694	11.5%	1,065	14.8%	-3.324	-0.099
Medical Product Use						
Mean number of filled prescriptions	36.4	30.0	38.6	32.6	-2.202	-0.070
Mean number of generics dispensed	11.0	6.5	11.4	6.7	-0.314	-0.048
Mean number of unique drug classes dispensed	9.9	5.7	10.3	5.8	-0.376	-0.066
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.1	20.1	16.6	19.6	1.501	0.076
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.072	-0.075
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.116	-0.092

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1o. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	14,746	N/A	7,208	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.4	2.8	59.4	2.8	0.007	0.003
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,746	100.0%	7,208	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,974	47.3%	3,404	47.2%	0.063	0.001
Male	7,772	52.7%	3,803	52.8%	-0.063	-0.001
Race[3]						
American Indian or Alaska Native	159	1.1%	51	0.7%	0.375	0.040
Asian	274	1.9%	109	1.5%	0.346	0.027
Black or African American	3,727	25.3%	1,774	24.6%	0.660	0.015
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	615	4.2%	345	4.8%	-0.613	-0.030
White	9,971	67.6%	4,929	68.4%	-0.768	-0.016
Hispanic origin						
Yes	452	3.1%	251	3.5%	-0.423	-0.024
No	14,131	95.8%	6,863	95.2%	0.613	0.030
Unknown	164	1.1%	94	1.3%	-0.191	-0.017

Table 1o. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	382	2.6%	512	7.1%	-4.516	-0.211
2011	893	6.1%	1,013	14.1%	-8.006	-0.269
2012	1,130	7.7%	1,000	13.9%	-6.212	-0.201
2013	1,221	8.3%	953	13.2%	-4.946	-0.160
2014	1,264	8.6%	772	10.7%	-2.138	-0.072
2015	1,413	9.6%	646	9.0%	0.612	0.021
2016	1,426	9.7%	560	7.8%	1.904	0.068
2017	1,550	10.5%	479	6.6%	3.866	0.138
2018	1,517	10.3%	409	5.7%	4.613	0.171
2019	1,454	9.9%	327	4.5%	5.316	0.207
2020	1,119	7.6%	222	3.1%	4.509	0.202
2021	954	6.5%	222	3.1%	3.386	0.159
2022	425	2.9%	91	1.3%	1.612	0.113
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.7	2.5	2.7	2.5	0.003	0.001
Substance abuse	3,864	26.2%	1,896	26.3%	-0.100	-0.002
Atrial fibrilation/flutter	544	3.7%	267	3.7%	-0.019	-0.001
Ischemic heart disease	2,227	15.1%	1,098	15.2%	-0.126	-0.004
Heart failure	1,265	8.6%	616	8.5%	0.031	0.001
Stroke	793	5.4%	384	5.3%	0.053	0.002
Diabetes	5,504	37.3%	2,686	37.3%	0.061	0.001
Hypertension	9,598	65.1%	4,694	65.1%	-0.032	-0.001
Rheumatic disease	126	0.9%	61	0.8%	0.013	0.001
Chronic kidney disease	2,767	18.8%	1,346	18.7%	0.086	0.002
Seizure disorder	2,201	14.9%	1,074	14.9%	0.030	0.001

Table 1o. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	733	5.0%	359	5.0%	-0.004	-0.000
Dementia Diagnosis	2,277	15.4%	1,106	15.3%	0.095	0.003
Dementia Diagnosis and Treatment	503	3.4%	245	3.4%	0.017	0.001
Parkinsons disease	525	3.6%	254	3.5%	0.042	0.002
COPD	4,117	27.9%	2,025	28.1%	-0.174	-0.004
Malignancy	668	4.5%	329	4.6%	-0.033	-0.002
Asthma	1,782	12.1%	874	12.1%	-0.038	-0.001
Hyperlipidemia	7,117	48.3%	3,484	48.3%	-0.078	-0.002
Depression	6,839	46.4%	3,332	46.2%	0.154	0.003
Schizophrenia	12,190	82.7%	5,970	82.8%	-0.167	-0.004
Bipolar disorder	6,568	44.5%	3,227	44.8%	-0.233	-0.005
ACE inhibitor use	3,896	26.4%	1,903	26.4%	0.022	0.001
ARB use	1,058	7.2%	524	7.3%	-0.103	-0.004
Beta-blocker use	3,944	26.7%	1,927	26.7%	0.017	0.000
Oral anticoagulant use	550	3.7%	271	3.8%	-0.033	-0.002
Antiplatelet agent use	536	3.6%	258	3.6%	0.059	0.003
Opioid use	3,251	22.0%	1,587	22.0%	0.035	0.001
Statin use	5,403	36.6%	2,643	36.7%	-0.030	-0.001
Wheelchair or walker use	146	1.0%	70	1.0%	0.017	0.002
Anti-arrhythmic use	104	0.7%	51	0.7%	0.002	0.000
Antidiabetic use	3,741	25.4%	1,824	25.3%	0.066	0.002
Calcium channel blocker use	2,706	18.3%	1,318	18.3%	0.064	0.002
Diuretic use	3,570	24.2%	1,747	24.2%	-0.032	-0.001
Antidepressant use	8,735	59.2%	4,265	59.2%	0.058	0.001
Gastric acid suppressant use	5,101	34.6%	2,491	34.6%	0.037	0.001
NSAIDs	3,416	23.2%	1,669	23.2%	0.005	0.000

Table 1o. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,400	36.6%	2,629	36.5%	0.148	0.003
Chronic liver disease	1,238	8.4%	603	8.4%	0.028	0.001
Pneumonia	1,115	7.6%	549	7.6%	-0.051	-0.002
Cardiac arrhythmia	2,131	14.4%	1,036	14.4%	0.069	0.002
Paliperidone palmitate	14,746	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,208	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	17	0.2%	-0.145	-0.035
IS Stay	1,872	12.7%	913	12.7%	0.029	0.001
Medical Product Use						
Mean number of filled prescriptions	36.7	30.3	37.9	31.9	-1.222	-0.039
Mean number of generics dispensed	11.1	6.6	11.2	6.5	-0.046	-0.007
Mean number of unique drug classes dispensed	10.0	5.7	10.1	5.7	-0.125	-0.022
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	19.5	17.9	21.2	-0.197	-0.010
Mean number of inpatient hospital encounters	0.5	1.0	0.5	0.9	-0.005	-0.005
Mean number of non-acute institutional encounters	1.0	1.3	1.0	1.3	-0.003	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1p. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,525	100.0%	6,779	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.7	2.8	-0.847	-0.308
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,525	100.0%	6,779	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,921	60.1%	4,247	62.6%	-2.557	-0.053
Male	2,604	39.9%	2,532	37.4%	2.557	0.053
Race[2]						
American Indian or Alaska Native	41	0.6%	38	0.6%	0.068	0.009
Asian	138	2.1%	65	1.0%	1.156	0.094
Black or African American	1,619	24.8%	1,521	22.4%	2.375	0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	297	4.6%	289	4.3%	0.289	0.014
White	4,430	67.9%	4,866	71.8%	-3.888	-0.085
Hispanic origin						
Yes	184	2.8%	181	2.7%	0.150	0.009
No	6,228	95.4%	6,490	95.7%	-0.289	-0.014
Unknown	113	1.7%	108	1.6%	0.139	0.011

Table 1p. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	419	6.2%	-4.495	-0.233
2011	301	4.6%	853	12.6%	-7.970	-0.287
2012	388	5.9%	787	11.6%	-5.663	-0.201
2013	476	7.3%	775	11.4%	-4.137	-0.142
2014	443	6.8%	688	10.1%	-3.360	-0.121
2015	575	8.8%	607	9.0%	-0.142	-0.005
2016	654	10.0%	546	8.1%	1.969	0.069
2017	643	9.9%	525	7.7%	2.110	0.075
2018	660	10.1%	470	6.9%	3.182	0.114
2019	732	11.2%	350	5.2%	6.055	0.222
2020	592	9.1%	336	5.0%	4.116	0.162
2021	641	9.8%	276	4.1%	5.752	0.228
2022	310	4.8%	147	2.2%	2.582	0.142
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	4.2	3.1	-0.714	-0.241
Substance abuse	1,142	17.5%	919	13.6%	3.945	0.109
Atrial fibrilation/flutter	387	5.9%	677	10.0%	-4.056	-0.150
Ischemic heart disease	1,289	19.8%	1,849	27.3%	-7.521	-0.178
Heart failure	810	12.4%	1,231	18.2%	-5.745	-0.160
Stroke	476	7.3%	906	13.4%	-6.070	-0.200
Diabetes	2,620	40.2%	3,097	45.7%	-5.532	-0.112
Hypertension	4,882	74.8%	5,434	80.2%	-5.339	-0.128
Rheumatic disease	72	1.1%	87	1.3%	-0.180	-0.017
Chronic kidney disease	1,647	25.2%	1,769	26.1%	-0.854	-0.020
Seizure disorder	860	13.2%	1,173	17.3%	-4.123	-0.115

Table 1p. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	791	12.1%	1,621	23.9%	-11.789	-0.310
Dementia Diagnosis	2,189	33.5%	3,714	54.8%	-21.239	-0.438
Dementia Diagnosis and Treatment	664	10.2%	1,466	21.6%	-11.449	-0.317
Parkinsons disease	445	6.8%	556	8.2%	-1.382	-0.052
COPD	1,860	28.5%	2,054	30.3%	-1.794	-0.039
Malignancy	401	6.1%	438	6.5%	-0.316	-0.013
Asthma	622	9.5%	612	9.0%	0.505	0.017
Hyperlipidemia	3,525	54.0%	3,727	55.0%	-0.956	-0.019
Depression	3,216	49.3%	3,696	54.5%	-5.234	-0.105
Schizophrenia	5,293	81.1%	4,313	63.6%	17.496	0.399
Bipolar disorder	2,855	43.8%	2,760	40.7%	3.041	0.062
ACE inhibitor use	1,839	28.2%	2,077	30.6%	-2.455	-0.054
ARB use	683	10.5%	656	9.7%	0.790	0.026
Beta-blocker use	2,005	30.7%	2,330	34.4%	-3.643	-0.078
Oral anticoagulant use	318	4.9%	526	7.8%	-2.886	-0.119
Antiplatelet agent use	301	4.6%	537	7.9%	-3.308	-0.137
Opioid use	1,230	18.9%	1,717	25.3%	-6.478	-0.157
Statin use	2,587	39.6%	2,859	42.2%	-2.527	-0.051
Wheelchair or walker use	75	1.1%	250	3.7%	-2.538	-0.166
Anti-arrhythmic use	54	0.8%	126	1.9%	-1.031	-0.090
Antidiabetic use	1,647	25.2%	1,945	28.7%	-3.450	-0.078
Calcium channel blocker use	1,671	25.6%	1,757	25.9%	-0.309	-0.007
Diuretic use	1,863	28.6%	2,257	33.3%	-4.742	-0.103
Antidepressant use	3,675	56.3%	4,123	60.8%	-4.498	-0.091
Gastric acid suppressant use	2,167	33.2%	2,637	38.9%	-5.689	-0.119
NSAIDs	1,290	19.8%	1,237	18.2%	1.523	0.039

Table 1p. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,239	34.3%	2,419	35.7%	-1.370	-0.029
Chronic liver disease	488	7.5%	448	6.6%	0.870	0.034
Pneumonia	586	9.0%	879	13.0%	-3.986	-0.128
Cardiac arrhythmia	1,115	17.1%	1,060	15.6%	1.452	0.039
Paliperidone palmitate	6,525	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,779	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	0.019	0.006
IS Stay	946	14.5%	1,120	16.5%	-2.024	-0.056
Medical Product Use						
Mean number of filled prescriptions	34.9	30.3	42.4	33.9	-7.467	-0.232
Mean number of generics dispensed	10.9	6.3	12.3	6.6	-1.468	-0.227
Mean number of unique drug classes dispensed	9.8	5.5	11.2	5.7	-1.362	-0.242
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.9	19.3	14.5	18.0	2.316	0.124
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.073	-0.081
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.4	-0.053	-0.040

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1q. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,521	99.9%	6,768	99.8%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.7	2.8	-0.844	-0.307
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,521	100.0%	6,768	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,920	60.1%	4,238	62.6%	-2.505	-0.051
Male	2,601	39.9%	2,530	37.4%	2.505	0.051
Race[2]						
American Indian or Alaska Native	41	0.6%	38	0.6%	0.067	0.009
Asian	138	2.1%	65	1.0%	1.156	0.094
Black or African American	1,618	24.8%	1,517	22.4%	2.398	0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	297	4.6%	289	4.3%	0.284	0.014
White	4,427	67.9%	4,859	71.8%	-3.905	-0.085
Hispanic origin						
Yes	184	2.8%	181	2.7%	0.147	0.009
No	6,224	95.4%	6,479	95.7%	-0.284	-0.014
Unknown	113	1.7%	108	1.6%	0.137	0.011

Table 1q. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	419	6.2%	-4.504	-0.233
2011	301	4.6%	852	12.6%	-7.973	-0.287
2012	387	5.9%	786	11.6%	-5.679	-0.202
2013	476	7.3%	771	11.4%	-4.092	-0.141
2014	442	6.8%	686	10.1%	-3.358	-0.121
2015	575	8.8%	606	9.0%	-0.136	-0.005
2016	654	10.0%	546	8.1%	1.962	0.068
2017	643	9.9%	525	7.8%	2.103	0.074
2018	660	10.1%	470	6.9%	3.177	0.114
2019	731	11.2%	349	5.2%	6.053	0.222
2020	592	9.1%	335	4.9%	4.129	0.162
2021	640	9.8%	276	4.1%	5.736	0.227
2022	310	4.8%	147	2.2%	2.582	0.142
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	4.2	3.1	-0.710	-0.240
Substance abuse	1,141	17.5%	918	13.6%	3.933	0.109
Atrial fibrilation/flutter	387	5.9%	673	9.9%	-4.009	-0.149
Ischemic heart disease	1,289	19.8%	1,840	27.2%	-7.420	-0.176
Heart failure	809	12.4%	1,223	18.1%	-5.664	-0.158
Stroke	476	7.3%	900	13.3%	-5.998	-0.198
Diabetes	2,620	40.2%	3,088	45.6%	-5.449	-0.110
Hypertension	4,880	74.8%	5,423	80.1%	-5.292	-0.127
Rheumatic disease	72	1.1%	85	1.3%	-0.152	-0.014
Chronic kidney disease	1,645	25.2%	1,766	26.1%	-0.867	-0.020
Seizure disorder	859	13.2%	1,167	17.2%	-4.070	-0.114

Table 1q. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	790	12.1%	1,615	23.9%	-11.748	-0.309
Dementia Diagnosis	2,188	33.6%	3,704	54.7%	-21.175	-0.436
Dementia Diagnosis and Treatment	663	10.2%	1,460	21.6%	-11.405	-0.316
Parkinsons disease	445	6.8%	555	8.2%	-1.376	-0.052
COPD	1,859	28.5%	2,050	30.3%	-1.782	-0.039
Malignancy	401	6.1%	438	6.5%	-0.322	-0.013
Asthma	622	9.5%	612	9.0%	0.496	0.017
Hyperlipidemia	3,524	54.0%	3,718	54.9%	-0.894	-0.018
Depression	3,214	49.3%	3,687	54.5%	-5.190	-0.104
Schizophrenia	5,290	81.1%	4,312	63.7%	17.411	0.397
Bipolar disorder	2,851	43.7%	2,758	40.8%	2.970	0.060
ACE inhibitor use	1,837	28.2%	2,072	30.6%	-2.444	-0.054
ARB use	683	10.5%	655	9.7%	0.796	0.026
Beta-blocker use	2,003	30.7%	2,324	34.3%	-3.622	-0.077
Oral anticoagulant use	318	4.9%	523	7.7%	-2.851	-0.118
Antiplatelet agent use	301	4.6%	532	7.9%	-3.245	-0.134
Opioid use	1,229	18.8%	1,711	25.3%	-6.434	-0.156
Statin use	2,587	39.7%	2,853	42.2%	-2.482	-0.051
Wheelchair or walker use	74	1.1%	241	3.6%	-2.426	-0.161
Anti-arrhythmic use	54	0.8%	126	1.9%	-1.034	-0.090
Antidiabetic use	1,647	25.3%	1,939	28.6%	-3.393	-0.077
Calcium channel blocker use	1,670	25.6%	1,751	25.9%	-0.262	-0.006
Diuretic use	1,861	28.5%	2,251	33.3%	-4.721	-0.102
Antidepressant use	3,672	56.3%	4,113	60.8%	-4.461	-0.091
Gastric acid suppressant use	2,166	33.2%	2,632	38.9%	-5.673	-0.118
NSAIDs	1,288	19.8%	1,236	18.3%	1.489	0.038

Table 1q. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,238	34.3%	2,417	35.7%	-1.392	-0.029
Chronic liver disease	488	7.5%	448	6.6%	0.864	0.034
Pneumonia	585	9.0%	876	12.9%	-3.972	-0.127
Cardiac arrhythmia	1,113	17.1%	1,059	15.6%	1.421	0.038
Paliperidone palmitate	6,521	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,768	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	0.019	0.006
IS Stay	946	14.5%	1,118	16.5%	-2.012	-0.056
Medical Product Use						
Mean number of filled prescriptions	34.9	30.3	42.4	33.9	-7.448	-0.232
Mean number of generics dispensed	10.9	6.3	12.3	6.6	-1.462	-0.226
Mean number of unique drug classes dispensed	9.8	5.5	11.2	5.7	-1.356	-0.241
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.8	19.1	14.5	18.0	2.267	0.122
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.072	-0.080
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.4	-0.052	-0.039

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1r. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	6,483	N/A	6,797	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	69.3	2.8	69.3	2.8	0.006	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,483	100.0%	6,797	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,985	61.5%	4,180	61.5%	-0.017	-0.000
Male	2,497	38.5%	2,617	38.5%	0.017	0.000
Race[3]						
American Indian or Alaska Native	43	0.7%	33	0.5%	0.185	0.024
Asian	129	2.0%	75	1.1%	0.893	0.072
Black or African American	1,553	24.0%	1,590	23.4%	0.554	0.013
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	291	4.5%	293	4.3%	0.178	0.009
White	4,466	68.9%	4,806	70.7%	-1.809	-0.039
Hispanic origin						
Yes	180	2.8%	177	2.6%	0.176	0.011
No	6,192	95.5%	6,504	95.7%	-0.178	-0.009
Unknown	111	1.7%	116	1.7%	0.002	0.000

Table 1r. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	116	1.8%	413	6.1%	-4.290	-0.222
2011	304	4.7%	845	12.4%	-7.745	-0.279
2012	397	6.1%	783	11.5%	-5.389	-0.191
2013	487	7.5%	792	11.7%	-4.143	-0.141
2014	448	6.9%	688	10.1%	-3.219	-0.116
2015	585	9.0%	622	9.1%	-0.121	-0.004
2016	653	10.1%	538	7.9%	2.148	0.075
2017	642	9.9%	528	7.8%	2.132	0.075
2018	640	9.9%	473	7.0%	2.925	0.106
2019	705	10.9%	353	5.2%	5.677	0.210
2020	577	8.9%	331	4.9%	4.021	0.159
2021	608	9.4%	284	4.2%	5.199	0.208
2022	321	5.0%	146	2.2%	2.804	0.152
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	3.9	3.0	3.9	3.0	0.010	0.003
Substance abuse	1,021	15.7%	1,084	15.9%	-0.201	-0.006
Atrial fibrilation/flutter	515	8.0%	541	8.0%	-0.006	-0.000
Ischemic heart disease	1,530	23.6%	1,601	23.6%	0.036	0.001
Heart failure	1,008	15.5%	1,047	15.4%	0.145	0.004
Stroke	640	9.9%	695	10.2%	-0.359	-0.012
Diabetes	2,794	43.1%	2,930	43.1%	-0.010	-0.000
Hypertension	5,051	77.9%	5,279	77.7%	0.244	0.006
Rheumatic disease	75	1.2%	77	1.1%	0.021	0.002
Chronic kidney disease	1,672	25.8%	1,750	25.7%	0.046	0.001
Seizure disorder	994	15.3%	1,034	15.2%	0.129	0.004

Table 1r. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	1,124	17.3%	1,208	17.8%	-0.431	-0.011
Dementia Diagnosis	2,844	43.9%	2,992	44.0%	-0.152	-0.003
Dementia Diagnosis and Treatment	994	15.3%	1,069	15.7%	-0.394	-0.011
Parkinsons disease	511	7.9%	522	7.7%	0.211	0.008
COPD	1,910	29.5%	2,004	29.5%	-0.018	-0.000
Malignancy	422	6.5%	436	6.4%	0.086	0.004
Asthma	612	9.4%	638	9.4%	0.061	0.002
Hyperlipidemia	3,560	54.9%	3,724	54.8%	0.136	0.003
Depression	3,376	52.1%	3,536	52.0%	0.062	0.001
Schizophrenia	4,755	73.4%	4,942	72.7%	0.638	0.014
Bipolar disorder	2,791	43.0%	2,908	42.8%	0.264	0.005
ACE inhibitor use	1,921	29.6%	2,000	29.4%	0.206	0.005
ARB use	655	10.1%	676	10.0%	0.150	0.005
Beta-blocker use	2,119	32.7%	2,213	32.6%	0.126	0.003
Oral anticoagulant use	405	6.2%	430	6.3%	-0.080	-0.003
Antiplatelet agent use	405	6.2%	419	6.2%	0.069	0.003
Opioid use	1,423	22.0%	1,497	22.0%	-0.071	-0.002
Statin use	2,682	41.4%	2,794	41.1%	0.275	0.006
Wheelchair or walker use	161	2.5%	162	2.4%	0.097	0.006
Anti-arrhythmic use	97	1.5%	94	1.4%	0.110	0.009
Antidiabetic use	1,744	26.9%	1,825	26.8%	0.058	0.001
Calcium channel blocker use	1,651	25.5%	1,732	25.5%	-0.015	-0.000
Diuretic use	2,016	31.1%	2,107	31.0%	0.090	0.002
Antidepressant use	3,760	58.0%	3,956	58.2%	-0.211	-0.004
Gastric acid suppressant use	2,332	36.0%	2,445	36.0%	0.003	0.000
NSAIDs	1,236	19.1%	1,303	19.2%	-0.105	-0.003

Table 1r. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,266	35.0%	2,375	34.9%	0.020	0.000
Chronic liver disease	453	7.0%	477	7.0%	-0.033	-0.001
Pneumonia	714	11.0%	746	11.0%	0.046	0.001
Cardiac arrhythmia	1,057	16.3%	1,111	16.3%	-0.044	-0.001
Paliperidone palmitate	6,483	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,797	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	0.023	0.008
IS Stay	1,061	16.4%	1,085	16.0%	0.399	0.011
Medical Product Use						
Mean number of filled prescriptions	37.4	32.1	39.9	32.8	-2.427	-0.075
Mean number of generics dispensed	11.5	6.5	11.7	6.5	-0.242	-0.037
Mean number of unique drug classes dispensed	10.4	5.7	10.6	5.6	-0.243	-0.043
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	17.9	16.0	20.0	-0.029	-0.002
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.3	0.007	0.006

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1s. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,496	100.0%	4,969	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.7	2.7	79.8	2.9	-1.048	-0.375
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,496	100.0%	4,969	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,049	70.1%	3,462	69.7%	0.448	0.010
Male	447	29.9%	1,507	30.3%	-0.448	-0.010
Race[2]						
American Indian or Alaska Native	*****	*****	28	0.6%	0.038	0.005
Asian	*****	*****	46	0.9%	0.946	0.081
Black or African American	314	21.0%	805	16.2%	4.789	0.123
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	181	3.6%	0.970	0.049
White	1,076	71.9%	3,909	78.7%	-6.743	-0.157
Hispanic origin						
Yes	*****	*****	136	2.7%	0.472	0.028
No	1,427	95.4%	4,788	96.4%	-0.970	-0.049
Unknown	*****	*****	45	0.9%	0.498	0.047

Table 1s. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	28	1.9%	296	6.0%	-4.085	-0.212
2011	75	5.0%	609	12.3%	-7.243	-0.260
2012	101	6.8%	554	11.1%	-4.398	-0.155
2013	107	7.2%	559	11.2%	-4.097	-0.142
2014	106	7.1%	515	10.4%	-3.279	-0.116
2015	127	8.5%	441	8.9%	-0.386	-0.014
2016	143	9.6%	381	7.7%	1.891	0.067
2017	143	9.6%	356	7.2%	2.394	0.087
2018	141	9.4%	368	7.4%	2.019	0.073
2019	160	10.7%	289	5.8%	4.879	0.178
2020	162	10.8%	253	5.1%	5.737	0.213
2021	127	8.5%	244	4.9%	3.579	0.144
2022	76	5.1%	104	2.1%	2.987	0.161
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	5.0	3.0	-0.623	-0.204
Substance abuse	123	8.2%	311	6.3%	1.963	0.076
Atrial fibrilation/flutter	187	12.5%	816	16.4%	-3.922	-0.112
Ischemic heart disease	426	28.5%	1,642	33.0%	-4.569	-0.099
Heart failure	296	19.8%	1,176	23.7%	-3.881	-0.094
Stroke	165	11.0%	792	15.9%	-4.909	-0.144
Diabetes	634	42.4%	2,192	44.1%	-1.734	-0.035
Hypertension	1,240	82.9%	4,255	85.6%	-2.743	-0.075
Rheumatic disease	*****	*****	88	1.8%	-0.434	-0.035
Chronic kidney disease	429	28.7%	1,531	30.8%	-2.135	-0.047
Seizure disorder	154	10.3%	668	13.4%	-3.149	-0.097

Table 1s. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	398	26.6%	2,228	44.8%	-18.234	-0.388
Dementia Diagnosis	911	60.9%	4,076	82.0%	-21.133	-0.481
Dementia Diagnosis and Treatment	365	24.4%	2,101	42.3%	-17.884	-0.386
Parkinsons disease	150	10.0%	474	9.5%	0.488	0.016
COPD	403	26.9%	1,345	27.1%	-0.129	-0.003
Malignancy	95	6.4%	341	6.9%	-0.512	-0.021
Asthma	112	7.5%	297	6.0%	1.510	0.060
Hyperlipidemia	831	55.5%	2,668	53.7%	1.855	0.037
Depression	821	54.9%	2,829	56.9%	-2.053	-0.041
Schizophrenia	996	66.6%	1,820	36.6%	29.950	0.628
Bipolar disorder	578	38.6%	1,468	29.5%	9.093	0.193
ACE inhibitor use	402	26.9%	1,443	29.0%	-2.168	-0.048
ARB use	199	13.3%	586	11.8%	1.509	0.046
Beta-blocker use	512	34.2%	2,023	40.7%	-6.488	-0.134
Oral anticoagulant use	111	7.4%	514	10.3%	-2.924	-0.103
Antiplatelet agent use	106	7.1%	550	11.1%	-3.983	-0.139
Opioid use	323	21.6%	1,453	29.2%	-7.650	-0.176
Statin use	600	40.1%	1,999	40.2%	-0.122	-0.002
Wheelchair or walker use	44	2.9%	261	5.3%	-2.311	-0.117
Anti-arrhythmic use	27	1.8%	114	2.3%	-0.489	-0.035
Antidiabetic use	338	22.6%	1,319	26.5%	-3.951	-0.092
Calcium channel blocker use	457	30.5%	1,467	29.5%	1.025	0.022
Diuretic use	515	34.4%	1,861	37.5%	-3.027	-0.063
Antidepressant use	847	56.6%	3,292	66.3%	-9.633	-0.199
Gastric acid suppressant use	542	36.2%	1,996	40.2%	-3.939	-0.081
NSAIDs	240	16.0%	783	15.8%	0.285	0.008

Table 1s. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	472	31.6%	1,797	36.2%	-4.613	-0.098
Chronic liver disease	*****	*****	199	4.0%	1.009	0.049
Pneumonia	175	11.7%	653	13.1%	-1.444	-0.044
Cardiac arrhythmia	277	18.5%	763	15.4%	3.161	0.084
Paliperidone palmitate	1,496	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	4,969	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	248	16.6%	752	15.1%	1.444	0.040
Medical Product Use						
Mean number of filled prescriptions	35.4	30.5	44.5	34.2	-9.160	-0.283
Mean number of generics dispensed	11.0	6.2	12.8	6.4	-1.791	-0.283
Mean number of unique drug classes dispensed	10.2	5.5	11.8	5.6	-1.630	-0.293
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.9	16.9	11.5	14.9	3.398	0.214
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.012	-0.014
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.099	0.075

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1t. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,495	99.9%	4,955	99.7%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.7	2.7	79.8	2.9	-1.041	-0.373
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,495	100.0%	4,955	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,049	70.2%	3,451	69.6%	0.520	0.011
Male	446	29.8%	1,504	30.4%	-0.520	-0.011
Race[2]						
American Indian or Alaska Native	*****	*****	28	0.6%	0.037	0.005
Asian	*****	*****	46	0.9%	0.945	0.080
Black or African American	314	21.0%	805	16.2%	4.757	0.122
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	179	3.6%	1.003	0.051
White	1,075	71.9%	3,897	78.6%	-6.741	-0.157
Hispanic origin						
Yes	*****	*****	134	2.7%	0.506	0.030
No	1,426	95.4%	4,776	96.4%	-1.003	-0.051
Unknown	*****	*****	45	0.9%	0.497	0.046

Table 1t. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	28	1.9%	295	6.0%	-4.081	-0.212
2011	75	5.0%	609	12.3%	-7.274	-0.261
2012	100	6.7%	553	11.2%	-4.471	-0.157
2013	107	7.2%	556	11.2%	-4.064	-0.141
2014	106	7.1%	513	10.4%	-3.263	-0.116
2015	127	8.5%	441	8.9%	-0.405	-0.014
2016	143	9.6%	377	7.6%	1.957	0.070
2017	143	9.6%	356	7.2%	2.381	0.086
2018	141	9.4%	366	7.4%	2.045	0.074
2019	160	10.7%	288	5.8%	4.890	0.178
2020	162	10.8%	253	5.1%	5.730	0.213
2021	127	8.5%	244	4.9%	3.571	0.143
2022	76	5.1%	104	2.1%	2.985	0.161
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	5.0	3.0	-0.621	-0.204
Substance abuse	123	8.2%	310	6.3%	1.971	0.076
Atrial fibrilation/flutter	187	12.5%	813	16.4%	-3.899	-0.111
Ischemic heart disease	425	28.4%	1,635	33.0%	-4.569	-0.099
Heart failure	295	19.7%	1,171	23.6%	-3.900	-0.095
Stroke	164	11.0%	784	15.8%	-4.853	-0.143
Diabetes	633	42.3%	2,183	44.1%	-1.715	-0.035
Hypertension	1,239	82.9%	4,242	85.6%	-2.734	-0.075
Rheumatic disease	*****	*****	87	1.8%	-0.418	-0.034
Chronic kidney disease	428	28.6%	1,526	30.8%	-2.168	-0.047
Seizure disorder	153	10.2%	659	13.3%	-3.066	-0.095

Table 1t. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	397	26.6%	2,216	44.7%	-18.167	-0.386
Dementia Diagnosis	910	60.9%	4,062	82.0%	-21.108	-0.481
Dementia Diagnosis and Treatment	364	24.3%	2,089	42.2%	-17.812	-0.385
Parkinsons disease	150	10.0%	474	9.6%	0.467	0.016
COPD	402	26.9%	1,341	27.1%	-0.174	-0.004
Malignancy	95	6.4%	341	6.9%	-0.527	-0.021
Asthma	112	7.5%	297	6.0%	1.498	0.060
Hyperlipidemia	830	55.5%	2,660	53.7%	1.835	0.037
Depression	821	54.9%	2,821	56.9%	-2.016	-0.041
Schizophrenia	996	66.6%	1,819	36.7%	29.912	0.627
Bipolar disorder	578	38.7%	1,468	29.6%	9.036	0.191
ACE inhibitor use	401	26.8%	1,437	29.0%	-2.178	-0.049
ARB use	199	13.3%	586	11.8%	1.485	0.045
Beta-blocker use	511	34.2%	2,012	40.6%	-6.425	-0.133
Oral anticoagulant use	111	7.4%	513	10.4%	-2.928	-0.103
Antiplatelet agent use	105	7.0%	540	10.9%	-3.875	-0.136
Opioid use	322	21.5%	1,445	29.2%	-7.624	-0.176
Statin use	599	40.1%	1,991	40.2%	-0.115	-0.002
Wheelchair or walker use	44	2.9%	257	5.2%	-2.244	-0.114
Anti-arrhythmic use	27	1.8%	114	2.3%	-0.495	-0.035
Antidiabetic use	338	22.6%	1,310	26.4%	-3.829	-0.089
Calcium channel blocker use	457	30.6%	1,464	29.5%	1.023	0.022
Diuretic use	514	34.4%	1,854	37.4%	-3.035	-0.063
Antidepressant use	846	56.6%	3,280	66.2%	-9.607	-0.198
Gastric acid suppressant use	541	36.2%	1,987	40.1%	-3.914	-0.081
NSAIDs	240	16.1%	781	15.8%	0.292	0.008

Table 1t. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	472	31.6%	1,787	36.1%	-4.493	-0.095
Chronic liver disease	*****	*****	198	4.0%	1.021	0.049
Pneumonia	175	11.7%	649	13.1%	-1.392	-0.042
Cardiac arrhythmia	277	18.5%	763	15.4%	3.130	0.083
Paliperidone palmitate	1,495	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	4,955	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	248	16.6%	749	15.1%	1.473	0.040
Medical Product Use						
Mean number of filled prescriptions	35.4	30.5	44.5	34.1	-9.116	-0.282
Mean number of generics dispensed	11.0	6.2	12.8	6.4	-1.787	-0.283
Mean number of unique drug classes dispensed	10.1	5.5	11.8	5.6	-1.625	-0.292
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.9	16.9	11.5	14.7	3.422	0.216
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.013	-0.015
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.097	0.074

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1u. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,474	N/A	4,965	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	79.5	2.9	79.5	2.9	-0.018	-0.006
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,474	100.0%	4,965	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,032	70.0%	3,471	69.9%	0.117	0.003
Male	442	30.0%	1,495	30.1%	-0.117	-0.003
Race[3]						
American Indian or Alaska Native	*****	*****	26	0.5%	0.246	0.031
Asian	21	1.4%	50	1.0%	0.437	0.040
Black or African American	290	19.7%	845	17.0%	2.682	0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	175	3.5%	0.804	0.041
White	1,087	73.8%	3,870	77.9%	-4.168	-0.097
Hispanic origin						
Yes	*****	*****	129	2.6%	0.259	0.016
No	1,410	95.7%	4,790	96.5%	-0.804	-0.041
Unknown	*****	*****	45	0.9%	0.545	0.050

Table 1u. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	27	1.8%	302	6.1%	-4.259	-0.220
2011	79	5.3%	618	12.4%	-7.115	-0.252
2012	95	6.4%	546	11.0%	-4.594	-0.163
2013	130	8.8%	560	11.3%	-2.490	-0.083
2014	124	8.4%	519	10.5%	-2.063	-0.071
2015	126	8.5%	435	8.8%	-0.236	-0.008
2016	141	9.6%	372	7.5%	2.089	0.075
2017	149	10.1%	347	7.0%	3.107	0.111
2018	136	9.2%	363	7.3%	1.926	0.070
2019	153	10.4%	286	5.8%	4.627	0.170
2020	143	9.7%	254	5.1%	4.548	0.174
2021	108	7.3%	255	5.1%	2.195	0.091
2022	65	4.4%	107	2.2%	2.265	0.127
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	4.9	3.0	4.9	3.0	0.033	0.011
Substance abuse	100	6.8%	337	6.8%	-0.040	-0.002
Atrial fibrilation/flutter	233	15.8%	773	15.6%	0.226	0.006
Ischemic heart disease	488	33.1%	1,590	32.0%	1.060	0.023
Heart failure	327	22.2%	1,133	22.8%	-0.618	-0.015
Stroke	240	16.2%	734	14.8%	1.465	0.040
Diabetes	627	42.5%	2,166	43.6%	-1.113	-0.022
Hypertension	1,244	84.4%	4,218	85.0%	-0.580	-0.016
Rheumatic disease	*****	*****	82	1.6%	0.140	0.011
Chronic kidney disease	459	31.1%	1,505	30.3%	0.835	0.018
Seizure disorder	196	13.3%	626	12.6%	0.655	0.020

Table 1u. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	615	41.7%	2,009	40.5%	1.248	0.025
Dementia Diagnosis	1,133	76.9%	3,821	77.0%	-0.077	-0.002
Dementia Diagnosis and Treatment	582	39.5%	1,888	38.0%	1.455	0.030
Parkinsons disease	142	9.6%	479	9.7%	-0.017	-0.001
COPD	414	28.1%	1,355	27.3%	0.804	0.018
Malignancy	94	6.4%	334	6.7%	-0.325	-0.013
Asthma	97	6.6%	321	6.5%	0.095	0.004
Hyperlipidemia	798	54.1%	2,688	54.1%	-0.000	-0.000
Depression	853	57.9%	2,811	56.6%	1.238	0.025
Schizophrenia	661	44.8%	2,176	43.8%	0.986	0.020
Bipolar disorder	488	33.1%	1,586	31.9%	1.182	0.025
ACE inhibitor use	412	28.0%	1,416	28.5%	-0.553	-0.012
ARB use	164	11.1%	596	12.0%	-0.886	-0.028
Beta-blocker use	589	40.0%	1,945	39.2%	0.781	0.016
Oral anticoagulant use	128	8.7%	479	9.6%	-0.938	-0.032
Antiplatelet agent use	174	11.8%	499	10.1%	1.755	0.056
Opioid use	384	26.0%	1,360	27.4%	-1.354	-0.031
Statin use	603	40.9%	1,996	40.2%	0.726	0.015
Wheelchair or walker use	62	4.2%	230	4.6%	-0.405	-0.020
Anti-arrhythmic use	36	2.5%	110	2.2%	0.243	0.016
Antidiabetic use	364	24.7%	1,264	25.4%	-0.753	-0.017
Calcium channel blocker use	432	29.3%	1,477	29.8%	-0.460	-0.010
Diuretic use	560	38.0%	1,827	36.8%	1.203	0.025
Antidepressant use	929	63.1%	3,164	63.7%	-0.679	-0.014
Gastric acid suppressant use	582	39.5%	1,948	39.2%	0.254	0.005
NSAIDs	241	16.3%	787	15.9%	0.471	0.013

Table 1u. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	522	35.4%	1,735	34.9%	0.474	0.010
Chronic liver disease	*****	*****	209	4.2%	-0.130	-0.007
Pneumonia	187	12.7%	637	12.8%	-0.170	-0.005
Cardiac arrhythmia	237	16.1%	803	16.2%	-0.068	-0.002
Paliperidone palmitate	1,474	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	4,965	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	253	17.2%	777	15.7%	1.513	0.041
Medical Product Use						
Mean number of filled prescriptions	40.7	36.6	42.9	33.6	-2.195	-0.062
Mean number of generics dispensed	12.2	6.4	12.5	6.4	-0.304	-0.047
Mean number of unique drug classes dispensed	11.2	5.7	11.5	5.6	-0.269	-0.048
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	13.3	14.7	12.4	16.3	0.900	0.058
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	0.019	0.022
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.3	0.066	0.050

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1v. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	372	100.0%	3,362	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.7	3.2	89.9	3.6	-1.194	-0.353
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	372	100.0%	3,362	100.0%	0.000	NaN
Sex						
Female	300	80.6%	2,742	81.6%	-0.913	-0.023
Male	72	19.4%	620	18.4%	0.913	0.023
Race[2]						
American Indian or Alaska Native	*****	*****	14	0.4%	0.659	0.077
Asian	*****	*****	19	0.6%	0.779	0.080
Black or African American	50	13.4%	392	11.7%	1.781	0.054
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	116	3.5%	2.732	0.128
White	290	78.0%	2,821	83.9%	-5.951	-0.152
Hispanic origin						
Yes	*****	*****	93	2.8%	1.266	0.070
No	349	93.8%	3,246	96.5%	-2.732	-0.128
Unknown	*****	*****	23	0.7%	1.466	0.124

Table 1v. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	11	3.0%	218	6.5%	-3.527	-0.167
2011	14	3.8%	454	13.5%	-9.740	-0.352
2012	19	5.1%	429	12.8%	-7.653	-0.271
2013	32	8.6%	394	11.7%	-3.117	-0.103
2014	37	9.9%	345	10.3%	-0.316	-0.010
2015	36	9.7%	287	8.5%	1.141	0.040
2016	28	7.5%	260	7.7%	-0.207	-0.008
2017	48	12.9%	237	7.0%	5.854	0.196
2018	31	8.3%	236	7.0%	1.314	0.049
2019	39	10.5%	200	5.9%	4.535	0.166
2020	36	9.7%	131	3.9%	5.781	0.231
2021	24	6.5%	126	3.7%	2.704	0.123
2022	17	4.6%	45	1.3%	3.231	0.192
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	3.0	5.0	2.9	0.001	0.001
Substance abuse	22	5.9%	117	3.5%	2.434	0.115
Atrial fibrilation/flutter	73	19.6%	715	21.3%	-1.643	-0.041
Ischemic heart disease	104	28.0%	1,090	32.4%	-4.464	-0.097
Heart failure	91	24.5%	942	28.0%	-3.557	-0.081
Stroke	27	7.3%	549	16.3%	-9.072	-0.284
Diabetes	126	33.9%	1,143	34.0%	-0.127	-0.003
Hypertension	314	84.4%	2,866	85.2%	-0.838	-0.023
Rheumatic disease	*****	*****	59	1.8%	-0.142	-0.011
Chronic kidney disease	114	30.6%	987	29.4%	1.288	0.028
Seizure disorder	28	7.5%	296	8.8%	-1.277	-0.047

Table 1v. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.8%	1,594	47.4%	-3.595	-0.072
Dementia Diagnosis	324	87.1%	3,069	91.3%	-4.188	-0.135
Dementia Diagnosis and Treatment	159	42.7%	1,528	45.4%	-2.707	-0.055
Parkinsons disease	34	9.1%	216	6.4%	2.715	0.101
COPD	77	20.7%	786	23.4%	-2.680	-0.065
Malignancy	22	5.9%	184	5.5%	0.441	0.019
Asthma	20	5.4%	148	4.4%	0.974	0.045
Hyperlipidemia	189	50.8%	1,421	42.3%	8.540	0.172
Depression	228	61.3%	1,821	54.2%	7.126	0.145
Schizophrenia	139	37.4%	505	15.0%	22.345	0.525
Bipolar disorder	110	29.6%	622	18.5%	11.069	0.261
ACE inhibitor use	94	25.3%	884	26.3%	-1.025	-0.023
ARB use	40	10.8%	374	11.1%	-0.372	-0.012
Beta-blocker use	141	37.9%	1,405	41.8%	-3.887	-0.079
Oral anticoagulant use	39	10.5%	363	10.8%	-0.313	-0.010
Antiplatelet agent use	35	9.4%	370	11.0%	-1.597	-0.053
Opioid use	90	24.2%	1,130	33.6%	-9.417	-0.209
Statin use	129	34.7%	977	29.1%	5.617	0.121
Wheelchair or walker use	18	4.8%	220	6.5%	-1.705	-0.074
Anti-arrhythmic use	*****	*****	85	2.5%	-0.647	-0.044
Antidiabetic use	52	14.0%	557	16.6%	-2.589	-0.072
Calcium channel blocker use	110	29.6%	935	27.8%	1.759	0.039
Diuretic use	120	32.3%	1,429	42.5%	-10.246	-0.213
Antidepressant use	240	64.5%	2,336	69.5%	-4.966	-0.106
Gastric acid suppressant use	126	33.9%	1,252	37.2%	-3.369	-0.070
NSAIDs	55	14.8%	414	12.3%	2.471	0.072

Table 1v. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	137	36.8%	1,270	37.8%	-0.947	-0.020
Chronic liver disease	*****	*****	82	2.4%	0.249	0.016
Pneumonia	60	16.1%	479	14.2%	1.882	0.052
Cardiac arrhythmia	66	17.7%	466	13.9%	3.881	0.107
Paliperidone palmitate	372	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	3,362	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	58	15.6%	443	13.2%	2.415	0.069
Medical Product Use						
Mean number of filled prescriptions	37.3	28.1	43.5	30.7	-6.232	-0.212
Mean number of generics dispensed	11.3	5.6	12.3	5.6	-1.052	-0.187
Mean number of unique drug classes dispensed	10.4	5.0	11.5	5.0	-1.034	-0.206
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.4	12.2	8.4	10.6	2.936	0.257
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.7	0.077	0.100
Mean number of non-acute institutional encounters	1.0	1.3	0.8	1.2	0.268	0.217

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1w. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	371	99.7%	3,338	99.3%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.8	3.2	89.9	3.6	-1.169	-0.345
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	371	100.0%	3,338	100.0%	0.000	NaN
Sex						
Female	299	80.6%	2,722	81.5%	-0.953	-0.024
Male	72	19.4%	616	18.5%	0.953	0.024
Race[2]						
American Indian or Alaska Native	*****	*****	14	0.4%	0.659	0.076
Asian	*****	*****	19	0.6%	0.779	0.080
Black or African American	50	13.5%	390	11.7%	1.793	0.054
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	116	3.5%	2.724	0.127
White	289	77.9%	2,799	83.9%	-5.955	-0.152
Hispanic origin						
Yes	*****	*****	93	2.8%	1.257	0.069
No	348	93.8%	3,222	96.5%	-2.724	-0.127
Unknown	*****	*****	23	0.7%	1.467	0.124

Table 1w. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	11	3.0%	214	6.4%	-3.446	-0.164
2011	14	3.8%	450	13.5%	-9.708	-0.351
2012	19	5.1%	425	12.7%	-7.611	-0.269
2013	32	8.6%	391	11.7%	-3.088	-0.102
2014	37	10.0%	341	10.2%	-0.243	-0.008
2015	36	9.7%	286	8.6%	1.135	0.039
2016	28	7.5%	260	7.8%	-0.242	-0.009
2017	48	12.9%	237	7.1%	5.838	0.195
2018	31	8.4%	234	7.0%	1.346	0.051
2019	39	10.5%	200	6.0%	4.521	0.165
2020	36	9.7%	131	3.9%	5.779	0.231
2021	23	6.2%	125	3.7%	2.455	0.113
2022	17	4.6%	44	1.3%	3.264	0.194
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	2.9	5.0	2.9	-0.010	-0.003
Substance abuse	21	5.7%	117	3.5%	2.155	0.103
Atrial fibrilation/flutter	73	19.7%	710	21.3%	-1.594	-0.040
Ischemic heart disease	104	28.0%	1,073	32.1%	-4.113	-0.090
Heart failure	91	24.5%	934	28.0%	-3.453	-0.079
Stroke	27	7.3%	525	15.7%	-8.450	-0.267
Diabetes	125	33.7%	1,127	33.8%	-0.070	-0.001
Hypertension	313	84.4%	2,844	85.2%	-0.834	-0.023
Rheumatic disease	*****	*****	58	1.7%	-0.120	-0.009
Chronic kidney disease	113	30.5%	980	29.4%	1.099	0.024
Seizure disorder	28	7.5%	290	8.7%	-1.141	-0.042

Table 1w. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.9%	1,583	47.4%	-3.488	-0.070
Dementia Diagnosis	323	87.1%	3,046	91.3%	-4.190	-0.135
Dementia Diagnosis and Treatment	159	42.9%	1,518	45.5%	-2.619	-0.053
Parkinsons disease	34	9.2%	215	6.4%	2.723	0.102
COPD	77	20.8%	774	23.2%	-2.433	-0.059
Malignancy	22	5.9%	181	5.4%	0.508	0.022
Asthma	19	5.1%	148	4.4%	0.688	0.032
Hyperlipidemia	188	50.7%	1,414	42.4%	8.313	0.167
Depression	227	61.2%	1,810	54.2%	6.962	0.141
Schizophrenia	138	37.2%	505	15.1%	22.068	0.519
Bipolar disorder	109	29.4%	622	18.6%	10.746	0.254
ACE inhibitor use	94	25.3%	880	26.4%	-1.026	-0.023
ARB use	40	10.8%	369	11.1%	-0.273	-0.009
Beta-blocker use	141	38.0%	1,385	41.5%	-3.487	-0.071
Oral anticoagulant use	39	10.5%	361	10.8%	-0.303	-0.010
Antiplatelet agent use	35	9.4%	365	10.9%	-1.501	-0.050
Opioid use	90	24.3%	1,117	33.5%	-9.204	-0.204
Statin use	128	34.5%	971	29.1%	5.412	0.116
Wheelchair or walker use	18	4.9%	215	6.4%	-1.589	-0.069
Anti-arrhythmic use	*****	*****	83	2.5%	-0.600	-0.041
Antidiabetic use	52	14.0%	547	16.4%	-2.371	-0.066
Calcium channel blocker use	110	29.6%	928	27.8%	1.849	0.041
Diuretic use	120	32.3%	1,411	42.3%	-9.926	-0.206
Antidepressant use	239	64.4%	2,315	69.4%	-4.932	-0.105
Gastric acid suppressant use	125	33.7%	1,237	37.1%	-3.365	-0.070
NSAIDs	55	14.8%	412	12.3%	2.482	0.072

Table 1w. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	137	36.9%	1,260	37.7%	-0.820	-0.017
Chronic liver disease	*****	*****	81	2.4%	0.269	0.017
Pneumonia	60	16.2%	475	14.2%	1.942	0.054
Cardiac arrhythmia	66	17.8%	466	14.0%	3.829	0.105
Paliperidone palmitate	371	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	3,338	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	57	15.4%	441	13.2%	2.152	0.062
Medical Product Use						
Mean number of filled prescriptions	37.4	28.1	43.4	30.7	-6.074	-0.206
Mean number of generics dispensed	11.3	5.6	12.3	5.6	-1.009	-0.179
Mean number of unique drug classes dispensed	10.5	5.0	11.5	5.0	-0.993	-0.198
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.4	12.2	8.5	10.7	2.910	0.254
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.7	0.073	0.095
Mean number of non-acute institutional encounters	1.0	1.2	0.8	1.2	0.250	0.207

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1x. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	379	N/A	3,340	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	90.0	3.8	89.8	3.6	0.182	0.050
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	379	100.0%	3,340	100.0%	0.000	NaN
Sex						
Female	288	76.0%	2,717	81.3%	-5.326	-0.130
Male	91	24.0%	623	18.7%	5.326	0.130
Race[3]						
American Indian or Alaska Native	*****	*****	14	0.4%	0.516	0.063
Asian	*****	*****	19	0.6%	0.406	0.046
Black or African American	45	11.8%	395	11.8%	-0.030	-0.001
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	118	3.5%	1.704	0.083
White	307	81.0%	2,793	83.6%	-2.596	-0.068
Hispanic origin						
Yes	*****	*****	94	2.8%	0.335	0.020
No	359	94.8%	3,222	96.5%	-1.704	-0.083
Unknown	*****	*****	24	0.7%	1.369	0.116

Table 1x. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	18	4.7%	212	6.3%	-1.661	-0.073
2011	19	5.0%	442	13.2%	-8.182	-0.287
2012	19	4.9%	424	12.7%	-7.759	-0.276
2013	33	8.8%	390	11.7%	-2.897	-0.096
2014	30	7.8%	338	10.1%	-2.314	-0.081
2015	30	8.0%	288	8.6%	-0.644	-0.023
2016	31	8.1%	260	7.8%	0.287	0.011
2017	46	12.1%	239	7.2%	4.904	0.167
2018	32	8.5%	236	7.1%	1.394	0.052
2019	45	11.8%	205	6.2%	5.687	0.199
2020	35	9.3%	134	4.0%	5.283	0.213
2021	24	6.3%	127	3.8%	2.464	0.113
2022	18	4.8%	44	1.3%	3.439	0.201
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.5	3.1	5.0	2.9	0.481	0.161
Substance abuse	13	3.4%	125	3.7%	-0.382	-0.021
Atrial fibrilation/flutter	97	25.5%	707	21.2%	4.360	0.103
Ischemic heart disease	137	36.2%	1,061	31.8%	4.460	0.094
Heart failure	115	30.4%	924	27.6%	2.731	0.060
Stroke	72	19.1%	497	14.9%	4.240	0.113
Diabetes	139	36.8%	1,128	33.8%	3.035	0.063
Hypertension	323	85.2%	2,844	85.1%	0.027	0.001
Rheumatic disease	*****	*****	58	1.7%	0.091	0.007
Chronic kidney disease	125	32.9%	986	29.5%	3.439	0.074
Seizure disorder	36	9.4%	287	8.6%	0.847	0.030

Table 1x. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	171	45.1%	1,572	47.1%	-1.959	-0.039
Dementia Diagnosis	346	91.3%	3,031	90.7%	0.553	0.019
Dementia Diagnosis and Treatment	165	43.6%	1,510	45.2%	-1.598	-0.032
Parkinsons disease	32	8.4%	225	6.7%	1.710	0.064
COPD	98	25.9%	768	23.0%	2.959	0.069
Malignancy	22	5.9%	183	5.5%	0.420	0.018
Asthma	24	6.4%	152	4.5%	1.870	0.082
Hyperlipidemia	179	47.4%	1,447	43.3%	4.022	0.081
Depression	228	60.1%	1,838	55.0%	5.120	0.104
Schizophrenia	66	17.4%	582	17.4%	-0.060	-0.002
Bipolar disorder	67	17.8%	659	19.7%	-1.954	-0.050
ACE inhibitor use	93	24.6%	876	26.2%	-1.653	-0.038
ARB use	39	10.4%	369	11.0%	-0.650	-0.021
Beta-blocker use	160	42.1%	1,376	41.2%	0.947	0.019
Oral anticoagulant use	46	12.3%	361	10.8%	1.452	0.045
Antiplatelet agent use	57	15.1%	360	10.8%	4.273	0.127
Opioid use	137	36.1%	1,087	32.5%	3.569	0.075
Statin use	125	33.1%	994	29.8%	3.347	0.072
Wheelchair or walker use	27	7.1%	210	6.3%	0.797	0.032
Anti-arrhythmic use	*****	*****	81	2.4%	-0.358	-0.024
Antidiabetic use	76	20.2%	539	16.1%	4.023	0.104
Calcium channel blocker use	107	28.3%	938	28.1%	0.182	0.004
Diuretic use	151	39.8%	1,377	41.2%	-1.439	-0.029
Antidepressant use	272	71.7%	2,302	68.9%	2.823	0.062
Gastric acid suppressant use	147	38.9%	1,228	36.8%	2.099	0.043
NSAIDs	48	12.7%	422	12.6%	0.087	0.003

Table 1x. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	145	38.4%	1,258	37.7%	0.713	0.015
Chronic liver disease	*****	*****	81	2.4%	-1.145	-0.085
Pneumonia	61	16.1%	482	14.4%	1.663	0.046
Cardiac arrhythmia	60	15.9%	480	14.4%	1.527	0.043
Paliperidone palmitate	379	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	3,340	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	48	12.7%	450	13.5%	-0.713	-0.021
Medical Product Use						
Mean number of filled prescriptions	42.7	29.0	43.1	30.7	-0.411	-0.014
Mean number of generics dispensed	12.7	5.7	12.2	5.6	0.441	0.078
Mean number of unique drug classes dispensed	11.7	5.1	11.4	5.0	0.325	0.065
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	8.6	9.3	8.8	11.2	-0.144	-0.014
Mean number of inpatient hospital encounters	0.4	0.7	0.4	0.7	-0.006	-0.009
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	0.026	0.022

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1y. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	83,187	100.0%	39,076	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	52.6	17.6	-7.263	-0.461
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	7.614	0.181
35-44 years	*****	*****	*****	*****	6.446	0.160
45-54 years	19,354	23.3%	*****	*****	3.000	0.073
55-64 years	14,395	17.3%	6,798	17.4%	-0.092	-0.002
65-74 years	5,861	7.0%	5,313	13.6%	-6.551	-0.217
75-84 years	1,131	1.4%	2,868	7.3%	-5.980	-0.296
≥ 85 years	213	0.3%	1,834	4.7%	-4.437	-0.289
Sex						
Female	33,543	40.3%	18,304	46.8%	-6.520	-0.132
Male	49,644	59.7%	20,772	53.2%	6.520	0.132
Race[2]						
American Indian or Alaska Native	993	1.2%	433	1.1%	0.086	0.008
Asian	1,892	2.3%	738	1.9%	0.386	0.027
Black or African American	21,793	26.2%	10,071	25.8%	0.425	0.010
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,940	8.3%	2,638	6.8%	1.592	0.060
White	51,569	62.0%	25,196	64.5%	-2.488	-0.052
Hispanic origin						
Yes	4,311	5.2%	1,851	4.7%	0.445	0.021
No	76,247	91.7%	36,438	93.2%	-1.592	-0.060
Unknown	2,629	3.2%	787	2.0%	1.146	0.072

Table 1y. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,431	2.9%	3,291	8.4%	-5.500	-0.239
2011	6,041	7.3%	6,501	16.6%	-9.375	-0.292
2012	7,238	8.7%	5,750	14.7%	-6.014	-0.188
2013	7,450	9.0%	5,213	13.3%	-4.385	-0.140
2014	7,114	8.6%	4,109	10.5%	-1.964	-0.067
2015	7,609	9.1%	3,196	8.2%	0.968	0.034
2016	7,874	9.5%	2,657	6.8%	2.666	0.098
2017	8,071	9.7%	2,221	5.7%	4.018	0.151
2018	8,130	9.8%	1,879	4.8%	4.965	0.192
2019	7,501	9.0%	1,503	3.8%	5.171	0.212
2020	5,781	6.9%	1,181	3.0%	3.927	0.181
2021	5,440	6.5%	1,088	2.8%	3.755	0.179
2022	2,507	3.0%	487	1.2%	1.767	0.123
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.6	2.5	-0.547	-0.243
Substance abuse	29,539	35.5%	10,848	27.8%	7.748	0.167
Atrial fibrilation/flutter	1,416	1.7%	1,876	4.8%	-3.099	-0.175
Ischemic heart disease	5,941	7.1%	5,096	13.0%	-5.900	-0.197
Heart failure	3,226	3.9%	3,423	8.8%	-4.882	-0.202
Stroke	1,893	2.3%	2,272	5.8%	-3.539	-0.180
Diabetes	19,813	23.8%	11,467	29.3%	-5.528	-0.125
Hypertension	37,183	44.7%	20,909	53.5%	-8.810	-0.177
Rheumatic disease	415	0.5%	296	0.8%	-0.259	-0.033
Chronic kidney disease	9,150	11.0%	5,474	14.0%	-3.009	-0.091
Seizure disorder	9,328	11.2%	4,973	12.7%	-1.513	-0.047

Table 1y. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	632	0.8%	568	1.5%	-0.694	-0.066
Dementia Diagnosis	6,060	7.3%	7,785	19.9%	-12.638	-0.375
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,273	1.5%	1,194	3.1%	-1.525	-0.102
COPD	12,930	15.5%	7,320	18.7%	-3.189	-0.085
Malignancy	2,626	3.2%	1,562	4.0%	-0.841	-0.045
Asthma	11,348	13.6%	4,681	12.0%	1.662	0.050
Hyperlipidemia	28,032	33.7%	14,479	37.1%	-3.356	-0.070
Depression	37,671	45.3%	18,330	46.9%	-1.624	-0.033
Schizophrenia	67,148	80.7%	28,018	71.7%	9.018	0.213
Bipolar disorder	38,856	46.7%	16,921	43.3%	3.406	0.069
ACE inhibitor use	13,607	16.4%	7,646	19.6%	-3.210	-0.084
ARB use	3,556	4.3%	2,113	5.4%	-1.133	-0.053
Beta-blocker use	15,899	19.1%	8,900	22.8%	-3.664	-0.090
Oral anticoagulant use	1,636	2.0%	1,441	3.7%	-1.721	-0.104
Antiplatelet agent use	1,166	1.4%	1,395	3.6%	-2.168	-0.140
Opioid use	15,723	18.9%	8,678	22.2%	-3.307	-0.082
Statin use	17,961	21.6%	9,789	25.1%	-3.460	-0.082
Wheelchair or walker use	210	0.3%	602	1.5%	-1.288	-0.137
Anti-arrhythmic use	287	0.3%	315	0.8%	-0.461	-0.061
Antidiabetic use	13,751	16.5%	7,317	18.7%	-2.195	-0.058
Calcium channel blocker use	8,789	10.6%	5,440	13.9%	-3.356	-0.103
Diuretic use	11,795	14.2%	7,690	19.7%	-5.501	-0.147
Antidepressant use	48,156	57.9%	21,584	55.2%	2.653	0.054
Gastric acid suppressant use	22,126	26.6%	11,353	29.1%	-2.456	-0.055
NSAIDs	18,104	21.8%	7,734	19.8%	1.971	0.049

Table 1y. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,528	33.1%	11,639	29.8%	3.306	0.071
Chronic liver disease	5,238	6.3%	2,338	6.0%	0.313	0.013
Pneumonia	3,431	4.1%	2,642	6.8%	-2.637	-0.116
Cardiac arrhythmia	11,423	13.7%	4,862	12.4%	1.289	0.038
Paliperidone palmitate	83,187	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,076	100.0%	NaN	NaN
Haloperidol decanoate	83	0.1%	70	0.2%	-0.079	-0.021
IS Stay	8,403	10.1%	5,110	13.1%	-2.976	-0.093
Medical Product Use						
Mean number of filled prescriptions	28.6	26.8	31.0	28.8	-2.380	-0.086
Mean number of generics dispensed	9.4	6.3	9.8	6.4	-0.366	-0.058
Mean number of unique drug classes dispensed	8.4	5.5	8.8	5.5	-0.450	-0.082
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	15.2	18.5	1.263	0.068
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.062	-0.066
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.075	-0.062

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1z. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	83,186	100.0%	39,066	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	52.6	17.6	-7.256	-0.461
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	7.612	0.181
35-44 years	*****	*****	*****	*****	6.442	0.160
45-54 years	19,353	23.3%	*****	*****	2.994	0.073
55-64 years	14,395	17.3%	6,798	17.4%	-0.097	-0.003
65-74 years	5,861	7.0%	5,311	13.6%	-6.549	-0.217
75-84 years	1,131	1.4%	2,866	7.3%	-5.977	-0.296
≥ 85 years	213	0.3%	1,829	4.7%	-4.426	-0.288
Sex						
Female	33,542	40.3%	18,298	46.8%	-6.517	-0.132
Male	49,644	59.7%	20,768	53.2%	6.517	0.132
Race[2]						
American Indian or Alaska Native	993	1.2%	433	1.1%	0.085	0.008
Asian	1,892	2.3%	738	1.9%	0.385	0.027
Black or African American	21,792	26.2%	10,070	25.8%	0.420	0.010
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,940	8.3%	2,638	6.8%	1.590	0.060
White	51,569	62.0%	25,187	64.5%	-2.481	-0.051
Hispanic origin						
Yes	4,311	5.2%	1,851	4.7%	0.444	0.020
No	76,246	91.7%	36,428	93.2%	-1.590	-0.060
Unknown	2,629	3.2%	787	2.0%	1.146	0.072

Table 1z. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,431	2.9%	3,290	8.4%	-5.499	-0.239
2011	6,041	7.3%	6,500	16.6%	-9.376	-0.292
2012	7,238	8.7%	5,750	14.7%	-6.018	-0.188
2013	7,450	9.0%	5,212	13.3%	-4.386	-0.140
2014	7,114	8.6%	4,108	10.5%	-1.964	-0.067
2015	7,609	9.1%	3,195	8.2%	0.969	0.034
2016	7,874	9.5%	2,655	6.8%	2.669	0.098
2017	8,071	9.7%	2,220	5.7%	4.020	0.151
2018	8,130	9.8%	1,878	4.8%	4.966	0.192
2019	7,501	9.0%	1,503	3.8%	5.170	0.212
2020	5,781	6.9%	1,181	3.0%	3.926	0.181
2021	5,439	6.5%	1,088	2.8%	3.753	0.179
2022	2,507	3.0%	486	1.2%	1.770	0.123
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.6	2.5	-0.546	-0.243
Substance abuse	29,538	35.5%	10,847	27.8%	7.743	0.167
Atrial fibrilation/flutter	1,416	1.7%	1,869	4.8%	-3.082	-0.175
Ischemic heart disease	5,941	7.1%	5,089	13.0%	-5.885	-0.196
Heart failure	3,226	3.9%	3,415	8.7%	-4.864	-0.201
Stroke	1,893	2.3%	2,264	5.8%	-3.520	-0.180
Diabetes	19,812	23.8%	11,458	29.3%	-5.513	-0.125
Hypertension	37,182	44.7%	20,899	53.5%	-8.799	-0.177
Rheumatic disease	415	0.5%	294	0.8%	-0.254	-0.032
Chronic kidney disease	9,149	11.0%	5,469	14.0%	-3.001	-0.091
Seizure disorder	9,328	11.2%	4,969	12.7%	-1.506	-0.046

Table 1z. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	632	0.8%	568	1.5%	-0.694	-0.066
Dementia Diagnosis	6,060	7.3%	7,776	19.9%	-12.620	-0.375
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,273	1.5%	1,193	3.1%	-1.524	-0.102
COPD	12,930	15.5%	7,318	18.7%	-3.189	-0.085
Malignancy	2,626	3.2%	1,560	4.0%	-0.836	-0.045
Asthma	11,347	13.6%	4,680	12.0%	1.661	0.050
Hyperlipidemia	28,031	33.7%	14,474	37.1%	-3.353	-0.070
Depression	37,670	45.3%	18,321	46.9%	-1.613	-0.032
Schizophrenia	67,147	80.7%	28,016	71.7%	9.005	0.213
Bipolar disorder	38,855	46.7%	16,919	43.3%	3.400	0.068
ACE inhibitor use	13,606	16.4%	7,642	19.6%	-3.206	-0.084
ARB use	3,556	4.3%	2,112	5.4%	-1.131	-0.053
Beta-blocker use	15,899	19.1%	8,891	22.8%	-3.646	-0.090
Oral anticoagulant use	1,636	2.0%	1,439	3.7%	-1.717	-0.104
Antiplatelet agent use	1,166	1.4%	1,391	3.6%	-2.159	-0.139
Opioid use	15,723	18.9%	8,673	22.2%	-3.300	-0.082
Statin use	17,960	21.6%	9,785	25.0%	-3.457	-0.082
Wheelchair or walker use	210	0.3%	594	1.5%	-1.268	-0.136
Anti-arrhythmic use	287	0.3%	315	0.8%	-0.461	-0.061
Antidiabetic use	13,750	16.5%	7,309	18.7%	-2.180	-0.057
Calcium channel blocker use	8,789	10.6%	5,436	13.9%	-3.349	-0.102
Diuretic use	11,795	14.2%	7,685	19.7%	-5.493	-0.147
Antidepressant use	48,155	57.9%	21,577	55.2%	2.656	0.054
Gastric acid suppressant use	22,126	26.6%	11,350	29.1%	-2.455	-0.055
NSAIDs	18,103	21.8%	7,733	19.8%	1.967	0.049

Table 1z. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,527	33.1%	11,636	29.8%	3.305	0.071
Chronic liver disease	5,237	6.3%	2,338	6.0%	0.311	0.013
Pneumonia	3,431	4.1%	2,638	6.8%	-2.628	-0.116
Cardiac arrhythmia	11,422	13.7%	4,861	12.4%	1.288	0.038
Paliperidone palmitate	83,186	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,066	100.0%	NaN	NaN
Haloperidol decanoate	83	0.1%	70	0.2%	-0.079	-0.021
IS Stay	8,403	10.1%	5,108	13.1%	-2.974	-0.093
Medical Product Use						
Mean number of filled prescriptions	28.6	26.8	31.0	28.8	-2.376	-0.085
Mean number of generics dispensed	9.4	6.3	9.8	6.4	-0.365	-0.058
Mean number of unique drug classes dispensed	8.4	5.5	8.8	5.5	-0.449	-0.081
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	15.2	18.5	1.262	0.068
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.062	-0.066
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.075	-0.061

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1aa. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	82,633	N/A	39,555	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	47.3	14.4	47.1	16.0	0.160	0.011
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	*****	*****	*****	*****	-3.905	-0.089
35-44 years	*****	*****	*****	*****	0.772	0.019
45-54 years	19,069	23.1%	*****	*****	1.924	0.046
55-64 years	15,560	18.8%	5,926	15.0%	3.848	0.103
65-74 years	7,581	9.2%	3,552	9.0%	0.196	0.007
75-84 years	1,938	2.3%	1,489	3.8%	-1.417	-0.082
≥ 85 years	515	0.6%	807	2.0%	-1.417	-0.124
Sex						
Female	34,667	42.0%	16,476	41.7%	0.299	0.006
Male	47,966	58.0%	23,079	58.3%	-0.299	-0.006
Race[3]						
American Indian or Alaska Native	966	1.2%	498	1.3%	-0.090	-0.008
Asian	1,852	2.2%	826	2.1%	0.154	0.011
Black or African American	21,601	26.1%	10,603	26.8%	-0.664	-0.015
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,517	7.9%	3,126	7.9%	-0.016	-0.001
White	51,697	62.6%	24,502	61.9%	0.616	0.013
Hispanic origin						
Yes	4,089	4.9%	2,170	5.5%	-0.538	-0.024
No	76,116	92.1%	36,429	92.1%	0.016	0.001
Unknown	2,428	2.9%	956	2.4%	0.522	0.032

Table 1aa. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,409	2.9%	3,420	8.6%	-5.732	-0.247
2011	5,966	7.2%	6,776	17.1%	-9.910	-0.307
2012	7,219	8.7%	5,914	15.0%	-6.214	-0.193
2013	7,312	8.8%	5,533	14.0%	-5.139	-0.162
2014	6,989	8.5%	4,220	10.7%	-2.211	-0.075
2015	7,500	9.1%	3,228	8.2%	0.916	0.033
2016	7,816	9.5%	2,637	6.7%	2.790	0.103
2017	8,026	9.7%	2,120	5.4%	4.352	0.165
2018	8,053	9.7%	1,761	4.5%	5.293	0.207
2019	7,509	9.1%	1,434	3.6%	5.463	0.225
2020	5,828	7.1%	1,084	2.7%	4.313	0.201
2021	5,447	6.6%	991	2.5%	4.087	0.197
2022	2,559	3.1%	437	1.1%	1.991	0.139
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.2	2.1	2.2	2.1	-0.001	-0.001
Substance abuse	27,658	33.5%	13,416	33.9%	-0.448	-0.009
Atrial fibrilation/flutter	2,087	2.5%	1,024	2.6%	-0.063	-0.004
Ischemic heart disease	7,272	8.8%	3,495	8.8%	-0.037	-0.001
Heart failure	4,348	5.3%	2,101	5.3%	-0.049	-0.002
Stroke	2,663	3.2%	1,295	3.3%	-0.052	-0.003
Diabetes	21,021	25.4%	9,968	25.2%	0.239	0.005
Hypertension	38,936	47.1%	18,551	46.9%	0.221	0.004
Rheumatic disease	477	0.6%	238	0.6%	-0.025	-0.003
Chronic kidney disease	9,711	11.8%	4,585	11.6%	0.161	0.005
Seizure disorder	9,646	11.7%	4,591	11.6%	0.067	0.002

Table 1aa. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	775	0.9%	368	0.9%	0.009	0.001
Dementia Diagnosis	8,763	10.6%	4,228	10.7%	-0.085	-0.003
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,652	2.0%	770	1.9%	0.052	0.004
COPD	13,661	16.5%	6,507	16.5%	0.081	0.002
Malignancy	2,817	3.4%	1,331	3.4%	0.044	0.002
Asthma	10,917	13.2%	5,241	13.3%	-0.040	-0.001
Hyperlipidemia	28,731	34.8%	13,712	34.7%	0.103	0.002
Depression	37,853	45.8%	18,135	45.8%	-0.039	-0.001
Schizophrenia	65,086	78.8%	31,161	78.8%	-0.015	-0.000
Bipolar disorder	38,086	46.1%	18,365	46.4%	-0.340	-0.007
ACE inhibitor use	14,265	17.3%	6,797	17.2%	0.079	0.002
ARB use	3,762	4.6%	1,793	4.5%	0.018	0.001
Beta-blocker use	16,559	20.0%	7,872	19.9%	0.138	0.003
Oral anticoagulant use	1,981	2.4%	951	2.4%	-0.006	-0.000
Antiplatelet agent use	1,647	2.0%	787	2.0%	0.003	0.000
Opioid use	16,335	19.8%	7,815	19.8%	0.011	0.000
Statin use	18,723	22.7%	8,879	22.4%	0.212	0.005
Wheelchair or walker use	549	0.7%	256	0.6%	0.017	0.002
Anti-arrhythmic use	382	0.5%	185	0.5%	-0.005	-0.001
Antidiabetic use	14,144	17.1%	6,681	16.9%	0.225	0.006
Calcium channel blocker use	9,453	11.4%	4,481	11.3%	0.111	0.003
Diuretic use	12,960	15.7%	6,170	15.6%	0.086	0.002
Antidepressant use	46,940	56.8%	22,453	56.8%	0.041	0.001
Gastric acid suppressant use	22,478	27.2%	10,684	27.0%	0.190	0.004
NSAIDs	17,541	21.2%	8,398	21.2%	-0.004	-0.000

Table 1aa. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	26,363	31.9%	12,586	31.8%	0.085	0.002
Chronic liver disease	5,147	6.2%	2,486	6.3%	-0.057	-0.002
Pneumonia	4,063	4.9%	1,935	4.9%	0.026	0.001
Cardiac arrhythmia	11,027	13.3%	5,321	13.5%	-0.109	-0.003
Paliperidone palmitate	82,633	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,555	100.0%	NaN	NaN
Haloperidol decanoate	83	0.1%	77	0.2%	-0.094	-0.024
IS Stay	9,259	11.2%	4,427	11.2%	0.014	0.000
Medical Product Use						
Mean number of filled prescriptions	29.0	27.2	29.3	27.6	-0.336	-0.012
Mean number of generics dispensed	9.5	6.4	9.4	6.2	0.077	0.012
Mean number of unique drug classes dispensed	8.5	5.5	8.5	5.4	-0.016	-0.003
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.3	18.5	16.5	19.8	-0.196	-0.010
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.003	-0.004
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.006	-0.005

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ab. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,677	100.0%	5,589	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.1	10.9	78.4	9.8	-8.243	-0.794
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.501	0.094
35-44 years	*****	*****	*****	*****	1.109	0.134
45-54 years	95	5.7%	*****	*****	4.126	0.223
55-64 years	364	21.7%	398	7.1%	14.584	0.424
65-74 years	664	39.6%	1,466	26.2%	13.364	0.287
75-84 years	365	21.8%	2,101	37.6%	-15.827	-0.352
≥ 85 years	159	9.5%	1,528	27.3%	-17.858	-0.474
Sex						
Female	966	57.6%	3,756	67.2%	-9.601	-0.199
Male	711	42.4%	1,833	32.8%	9.601	0.199
Race[2]						
American Indian or Alaska Native	17	1.0%	34	0.6%	0.405	0.045
Asian	28	1.7%	31	0.6%	1.115	0.106
Black or African American	339	20.2%	910	16.3%	3.933	0.102
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	85	5.1%	202	3.6%	1.454	0.071
White	1,208	72.0%	4,412	78.9%	-6.907	-0.161
Hispanic origin						
Yes	63	3.8%	148	2.6%	1.109	0.063
No	1,592	94.9%	5,387	96.4%	-1.454	-0.071
Unknown	22	1.3%	54	1.0%	0.346	0.033

Table 1ab. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	348	6.2%	-3.841	-0.190
2011	70	4.2%	757	13.5%	-9.370	-0.334
2012	127	7.6%	711	12.7%	-5.148	-0.171
2013	140	8.3%	662	11.8%	-3.496	-0.116
2014	153	9.1%	522	9.3%	-0.216	-0.007
2015	173	10.3%	504	9.0%	1.298	0.044
2016	164	9.8%	449	8.0%	1.746	0.061
2017	191	11.4%	420	7.5%	3.875	0.133
2018	145	8.6%	387	6.9%	1.722	0.064
2019	163	9.7%	320	5.7%	3.994	0.150
2020	132	7.9%	248	4.4%	3.434	0.143
2021	124	7.4%	180	3.2%	4.174	0.187
2022	55	3.3%	81	1.4%	1.830	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.7	5.3	2.8	-0.070	-0.026
Substance abuse	264	15.7%	441	7.9%	7.852	0.245
Atrial fibrilation/flutter	185	11.0%	857	15.3%	-4.302	-0.127
Ischemic heart disease	442	26.4%	1,837	32.9%	-6.512	-0.143
Heart failure	318	19.0%	1,294	23.2%	-4.190	-0.103
Stroke	218	13.0%	936	16.7%	-3.748	-0.105
Diabetes	742	44.2%	2,360	42.2%	2.020	0.041
Hypertension	1,413	84.3%	4,791	85.7%	-1.464	-0.041
Rheumatic disease	16	1.0%	87	1.6%	-0.603	-0.054
Chronic kidney disease	518	30.9%	1,644	29.4%	1.474	0.032
Seizure disorder	357	21.3%	890	15.9%	5.364	0.138

Table 1ab. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,677	100.0%	5,589	100.0%	0.000	NaN
Dementia Diagnosis	1,677	100.0%	5,589	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,677	100.0%	5,589	100.0%	0.000	NaN
Parkinsons disease	212	12.6%	518	9.3%	3.373	0.108
COPD	493	29.4%	1,466	26.2%	3.168	0.071
Malignancy	87	5.2%	288	5.2%	0.035	0.002
Asthma	158	9.4%	321	5.7%	3.678	0.139
Hyperlipidemia	1,013	60.4%	3,026	54.1%	6.263	0.127
Depression	1,127	67.2%	3,455	61.8%	5.385	0.113
Schizophrenia	1,119	66.7%	1,616	28.9%	37.812	0.818
Bipolar disorder	769	45.9%	1,633	29.2%	16.638	0.349
ACE inhibitor use	504	30.1%	1,754	31.4%	-1.329	-0.029
ARB use	182	10.9%	595	10.6%	0.207	0.007
Beta-blocker use	621	37.0%	2,237	40.0%	-2.995	-0.062
Oral anticoagulant use	133	7.9%	541	9.7%	-1.749	-0.062
Antiplatelet agent use	150	8.9%	625	11.2%	-2.238	-0.074
Opioid use	400	23.9%	1,734	31.0%	-7.173	-0.161
Statin use	761	45.4%	2,330	41.7%	3.690	0.074
Wheelchair or walker use	47	2.8%	316	5.7%	-2.851	-0.142
Anti-arrhythmic use	27	1.6%	122	2.2%	-0.573	-0.042
Antidiabetic use	451	26.9%	1,430	25.6%	1.307	0.030
Calcium channel blocker use	470	28.0%	1,622	29.0%	-0.995	-0.022
Diuretic use	583	34.8%	2,162	38.7%	-3.919	-0.081
Antidepressant use	1,277	76.1%	4,316	77.2%	-1.075	-0.025
Gastric acid suppressant use	662	39.5%	2,331	41.7%	-2.232	-0.045
NSAIDs	335	20.0%	869	15.5%	4.428	0.116

Table 1ab. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	777	46.3%	2,289	41.0%	5.377	0.109
Chronic liver disease	113	6.7%	240	4.3%	2.444	0.107
Pneumonia	233	13.9%	784	14.0%	-0.134	-0.004
Cardiac arrhythmia	325	19.4%	843	15.1%	4.297	0.114
Paliperidone palmitate	1,677	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	5,589	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.066	-0.022
IS Stay	299	17.8%	902	16.1%	1.691	0.045
Medical Product Use						
Mean number of filled prescriptions	51.1	35.4	51.9	35.2	-0.725	-0.021
Mean number of generics dispensed	14.7	6.3	14.4	5.9	0.263	0.043
Mean number of unique drug classes dispensed	13.3	5.4	13.2	5.1	0.088	0.017
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.1	19.3	11.1	14.1	6.941	0.411
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.8	0.044	0.053
Mean number of non-acute institutional encounters	1.4	1.5	1.1	1.4	0.286	0.197

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ac. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,675	99.9%	5,570	99.7%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.1	10.9	78.3	9.8	-8.187	-0.790
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.501	0.094
35-44 years	*****	*****	*****	*****	1.110	0.134
45-54 years	94	5.6%	*****	*****	4.068	0.220
55-64 years	364	21.7%	398	7.1%	14.586	0.424
65-74 years	664	39.6%	1,466	26.3%	13.322	0.286
75-84 years	365	21.8%	2,101	37.7%	-15.929	-0.354
≥ 85 years	158	9.4%	1,509	27.1%	-17.659	-0.469
Sex						
Female	965	57.6%	3,737	67.1%	-9.480	-0.197
Male	710	42.4%	1,833	32.9%	9.480	0.197
Race[2]						
American Indian or Alaska Native	17	1.0%	34	0.6%	0.405	0.045
Asian	28	1.7%	31	0.6%	1.115	0.106
Black or African American	338	20.2%	908	16.3%	3.877	0.101
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	85	5.1%	201	3.6%	1.466	0.072
White	1,207	72.1%	4,396	78.9%	-6.863	-0.160
Hispanic origin						
Yes	63	3.8%	148	2.7%	1.104	0.063
No	1,590	94.9%	5,369	96.4%	-1.466	-0.072
Unknown	22	1.3%	53	1.0%	0.362	0.034

Table 1ac. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	347	6.2%	-3.842	-0.190
2011	70	4.2%	752	13.5%	-9.322	-0.333
2012	127	7.6%	706	12.7%	-5.093	-0.169
2013	140	8.4%	659	11.8%	-3.473	-0.115
2014	153	9.1%	522	9.4%	-0.237	-0.008
2015	173	10.3%	504	9.0%	1.280	0.043
2016	163	9.7%	447	8.0%	1.706	0.060
2017	190	11.3%	420	7.5%	3.803	0.130
2018	145	8.7%	387	6.9%	1.709	0.064
2019	163	9.7%	318	5.7%	4.022	0.151
2020	132	7.9%	247	4.4%	3.446	0.144
2021	124	7.4%	180	3.2%	4.171	0.187
2022	55	3.3%	81	1.5%	1.829	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.7	5.2	2.8	-0.065	-0.024
Substance abuse	264	15.8%	441	7.9%	7.844	0.245
Atrial fibrilation/flutter	185	11.0%	854	15.3%	-4.287	-0.127
Ischemic heart disease	441	26.3%	1,827	32.8%	-6.472	-0.142
Heart failure	318	19.0%	1,288	23.1%	-4.139	-0.102
Stroke	218	13.0%	930	16.7%	-3.682	-0.104
Diabetes	742	44.3%	2,350	42.2%	2.108	0.043
Hypertension	1,411	84.2%	4,773	85.7%	-1.452	-0.041
Rheumatic disease	16	1.0%	85	1.5%	-0.571	-0.052
Chronic kidney disease	518	30.9%	1,639	29.4%	1.500	0.033
Seizure disorder	356	21.3%	883	15.9%	5.401	0.139

Table 1ac. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,675	100.0%	5,570	100.0%	0.000	NaN
Dementia Diagnosis	1,675	100.0%	5,570	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,675	100.0%	5,570	100.0%	0.000	NaN
Parkinsons disease	212	12.7%	518	9.3%	3.357	0.108
COPD	493	29.4%	1,461	26.2%	3.203	0.072
Malignancy	87	5.2%	288	5.2%	0.023	0.001
Asthma	158	9.4%	320	5.7%	3.688	0.140
Hyperlipidemia	1,012	60.4%	3,022	54.3%	6.163	0.125
Depression	1,126	67.2%	3,448	61.9%	5.321	0.111
Schizophrenia	1,118	66.7%	1,616	29.0%	37.734	0.816
Bipolar disorder	768	45.9%	1,631	29.3%	16.569	0.347
ACE inhibitor use	502	30.0%	1,743	31.3%	-1.322	-0.029
ARB use	182	10.9%	592	10.6%	0.237	0.008
Beta-blocker use	620	37.0%	2,225	39.9%	-2.931	-0.060
Oral anticoagulant use	133	7.9%	540	9.7%	-1.754	-0.062
Antiplatelet agent use	150	9.0%	625	11.2%	-2.266	-0.075
Opioid use	399	23.8%	1,721	30.9%	-7.077	-0.159
Statin use	760	45.4%	2,328	41.8%	3.578	0.072
Wheelchair or walker use	47	2.8%	306	5.5%	-2.688	-0.135
Anti-arrhythmic use	27	1.6%	120	2.2%	-0.542	-0.040
Antidiabetic use	451	26.9%	1,427	25.6%	1.306	0.030
Calcium channel blocker use	468	27.9%	1,614	29.0%	-1.036	-0.023
Diuretic use	582	34.7%	2,152	38.6%	-3.889	-0.081
Antidepressant use	1,275	76.1%	4,298	77.2%	-1.044	-0.025
Gastric acid suppressant use	661	39.5%	2,319	41.6%	-2.171	-0.044
NSAIDs	334	19.9%	868	15.6%	4.357	0.114

Table 1ac. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	776	46.3%	2,281	41.0%	5.377	0.109
Chronic liver disease	113	6.7%	239	4.3%	2.455	0.108
Pneumonia	233	13.9%	782	14.0%	-0.129	-0.004
Cardiac arrhythmia	325	19.4%	841	15.1%	4.304	0.114
Paliperidone palmitate	1,675	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	5,570	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.066	-0.022
IS Stay	299	17.9%	897	16.1%	1.747	0.047
Medical Product Use						
Mean number of filled prescriptions	51.1	35.4	51.9	35.2	-0.715	-0.020
Mean number of generics dispensed	14.7	6.3	14.4	6.0	0.267	0.044
Mean number of unique drug classes dispensed	13.3	5.4	13.2	5.1	0.092	0.017
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.0	19.1	11.2	14.1	6.858	0.408
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.8	0.045	0.054
Mean number of non-acute institutional encounters	1.4	1.5	1.1	1.4	0.287	0.198

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ad. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,668	N/A	5,585	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	76.5	10.7	76.4	10.7	0.190	0.018
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	*****	*****	16	0.3%	-0.134	-0.028
35-44 years	*****	*****	17	0.3%	0.117	0.019
45-54 years	*****	*****	149	2.7%	-0.359	-0.023
55-64 years	177	10.6%	586	10.5%	0.143	0.005
65-74 years	489	29.3%	1,608	28.8%	0.498	0.011
75-84 years	538	32.2%	1,945	34.8%	-2.587	-0.055
≥ 85 years	416	25.0%	1,264	22.6%	2.322	0.055
Sex						
Female	1,058	63.4%	3,620	64.8%	-1.416	-0.030
Male	611	36.6%	1,965	35.2%	1.416	0.030
Race[3]						
American Indian or Alaska Native	19	1.1%	33	0.6%	0.534	0.058
Asian	16	1.0%	32	0.6%	0.417	0.047
Black or African American	293	17.6%	983	17.6%	-0.006	-0.000
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	78	4.7%	205	3.7%	1.025	0.051
White	1,261	75.6%	4,333	77.6%	-1.970	-0.047
Hispanic origin						
Yes	57	3.4%	150	2.7%	0.710	0.041
No	1,590	95.3%	5,380	96.3%	-1.025	-0.051
Unknown	22	1.3%	55	1.0%	0.316	0.030

Table 1ad. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	47	2.8%	344	6.2%	-3.332	-0.161
2011	80	4.8%	736	13.2%	-8.390	-0.297
2012	121	7.3%	713	12.8%	-5.489	-0.184
2013	177	10.6%	668	12.0%	-1.370	-0.043
2014	154	9.2%	516	9.2%	-0.007	-0.000
2015	188	11.2%	509	9.1%	2.132	0.071
2016	146	8.8%	454	8.1%	0.638	0.023
2017	194	11.6%	421	7.5%	4.060	0.138
2018	135	8.1%	384	6.9%	1.228	0.047
2019	148	8.9%	325	5.8%	3.041	0.117
2020	122	7.3%	250	4.5%	2.813	0.120
2021	106	6.3%	180	3.2%	3.098	0.146
2022	52	3.1%	85	1.5%	1.579	0.105
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.3	2.7	5.2	2.8	0.059	0.022
Substance abuse	171	10.2%	559	10.0%	0.241	0.008
Atrial fibrilation/flutter	250	15.0%	792	14.2%	0.777	0.022
Ischemic heart disease	539	32.3%	1,751	31.3%	0.978	0.021
Heart failure	382	22.9%	1,238	22.2%	0.751	0.018
Stroke	273	16.3%	887	15.9%	0.460	0.013
Diabetes	718	43.1%	2,390	42.8%	0.257	0.005
Hypertension	1,437	86.1%	4,783	85.6%	0.511	0.015
Rheumatic disease	26	1.5%	77	1.4%	0.155	0.013
Chronic kidney disease	507	30.4%	1,652	29.6%	0.804	0.018
Seizure disorder	308	18.5%	980	17.5%	0.936	0.024

Table 1ad. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	1,668	100.0%	5,585	100.0%	0.000	NaN
Dementia Diagnosis	1,668	100.0%	5,585	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,668	100.0%	5,585	100.0%	0.000	NaN
Parkinsons disease	162	9.7%	563	10.1%	-0.352	-0.012
COPD	459	27.5%	1,524	27.3%	0.233	0.005
Malignancy	87	5.2%	289	5.2%	0.019	0.001
Asthma	125	7.5%	388	6.9%	0.555	0.021
Hyperlipidemia	929	55.7%	3,114	55.7%	-0.042	-0.001
Depression	1,077	64.6%	3,534	63.3%	1.279	0.027
Schizophrenia	633	38.0%	2,115	37.9%	0.081	0.002
Bipolar disorder	562	33.7%	1,855	33.2%	0.499	0.011
ACE inhibitor use	531	31.8%	1,737	31.1%	0.721	0.016
ARB use	176	10.5%	592	10.6%	-0.081	-0.003
Beta-blocker use	671	40.2%	2,205	39.5%	0.711	0.015
Oral anticoagulant use	165	9.9%	516	9.2%	0.637	0.022
Antiplatelet agent use	210	12.6%	604	10.8%	1.784	0.055
Opioid use	474	28.4%	1,643	29.4%	-1.030	-0.023
Statin use	737	44.2%	2,392	42.8%	1.352	0.027
Wheelchair or walker use	74	4.4%	272	4.9%	-0.433	-0.021
Anti-arrhythmic use	41	2.5%	114	2.0%	0.406	0.027
Antidiabetic use	426	25.5%	1,456	26.1%	-0.530	-0.012
Calcium channel blocker use	500	30.0%	1,612	28.9%	1.126	0.025
Diuretic use	613	36.7%	2,102	37.6%	-0.911	-0.019
Antidepressant use	1,266	75.9%	4,293	76.9%	-0.999	-0.024
Gastric acid suppressant use	707	42.4%	2,304	41.3%	1.121	0.023
NSAIDs	268	16.1%	949	17.0%	-0.920	-0.025

Table 1ad. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	691	41.4%	2,351	42.1%	-0.690	-0.014
Chronic liver disease	79	4.7%	273	4.9%	-0.166	-0.008
Pneumonia	245	14.7%	786	14.1%	0.589	0.017
Cardiac arrhythmia	275	16.5%	896	16.0%	0.468	0.013
Paliperidone palmitate	1,668	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	5,585	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.128	-0.039
IS Stay	313	18.8%	954	17.1%	1.676	0.044
Medical Product Use						
Mean number of filled prescriptions	50.1	35.2	52.0	35.3	-1.880	-0.053
Mean number of generics dispensed	14.4	6.1	14.5	6.0	-0.139	-0.023
Mean number of unique drug classes dispensed	13.1	5.3	13.3	5.2	-0.155	-0.030
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	13.6	14.7	13.3	17.9	0.378	0.023
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.8	0.046	0.054
Mean number of non-acute institutional encounters	1.3	1.4	1.2	1.5	0.107	0.073

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1ae. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	76,162	100.0%	38,653	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.8	55.6	18.9	-9.928	-0.599
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	20,437	26.8%	6,730	17.4%	9.422	0.228
35-44 years	17,906	23.5%	5,957	15.4%	8.099	0.206
45-54 years	17,614	23.1%	7,041	18.2%	4.911	0.122
55-64 years	13,064	17.2%	6,130	15.9%	1.294	0.035
65-74 years	5,579	7.3%	5,659	14.6%	-7.315	-0.236
75-84 years	1,248	1.6%	4,217	10.9%	-9.271	-0.390
≥ 85 years	314	0.4%	2,919	7.6%	-7.140	-0.371
Sex						
Female	30,756	40.4%	18,989	49.1%	-8.745	-0.177
Male	45,406	59.6%	19,664	50.9%	8.745	0.177
Race[2]						
American Indian or Alaska Native	912	1.2%	426	1.1%	0.095	0.009
Asian	1,736	2.3%	661	1.7%	0.569	0.041
Black or African American	19,916	26.1%	9,663	25.0%	1.150	0.026
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,396	8.4%	2,525	6.5%	1.865	0.071
White	47,202	62.0%	25,378	65.7%	-3.680	-0.077
Hispanic origin						
Yes	3,978	5.2%	1,794	4.6%	0.582	0.027
No	69,766	91.6%	36,128	93.5%	-1.865	-0.071
Unknown	2,418	3.2%	731	1.9%	1.284	0.082

Table 1ae. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,270	3.0%	3,173	8.2%	-5.228	-0.229
2011	5,627	7.4%	6,367	16.5%	-9.084	-0.283
2012	6,664	8.7%	5,632	14.6%	-5.821	-0.182
2013	6,805	8.9%	5,062	13.1%	-4.161	-0.133
2014	6,478	8.5%	3,958	10.2%	-1.734	-0.060
2015	6,987	9.2%	3,166	8.2%	0.983	0.035
2016	7,223	9.5%	2,658	6.9%	2.607	0.095
2017	7,405	9.7%	2,232	5.8%	3.948	0.148
2018	7,380	9.7%	1,945	5.0%	4.658	0.179
2019	6,856	9.0%	1,579	4.1%	4.917	0.200
2020	5,236	6.9%	1,244	3.2%	3.656	0.168
2021	4,928	6.5%	1,131	2.9%	3.544	0.168
2022	2,303	3.0%	506	1.3%	1.715	0.118
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.9	2.7	-0.788	-0.339
Substance abuse	25,921	34.0%	9,498	24.6%	9.462	0.209
Atrial fibrilation/flutter	1,348	1.8%	2,282	5.9%	-4.134	-0.216
Ischemic heart disease	5,406	7.1%	5,724	14.8%	-7.711	-0.249
Heart failure	2,987	3.9%	3,939	10.2%	-6.269	-0.247
Stroke	1,804	2.4%	2,724	7.0%	-4.679	-0.222
Diabetes	18,108	23.8%	11,804	30.5%	-6.763	-0.152
Hypertension	33,555	44.1%	21,774	56.3%	-12.275	-0.247
Rheumatic disease	362	0.5%	309	0.8%	-0.324	-0.041
Chronic kidney disease	8,329	10.9%	5,908	15.3%	-4.349	-0.129
Seizure disorder	8,345	11.0%	5,001	12.9%	-1.981	-0.061

Table 1ae. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,929	2.5%	5,204	13.5%	-10.931	-0.411
Dementia Diagnosis	6,352	8.3%	11,200	29.0%	-20.636	-0.549
Dementia Diagnosis and Treatment	1,378	1.8%	4,687	12.1%	-10.317	-0.414
Parkinsons disease	1,228	1.6%	1,402	3.6%	-2.015	-0.126
COPD	11,599	15.2%	7,382	19.1%	-3.869	-0.103
Malignancy	2,382	3.1%	1,576	4.1%	-0.950	-0.051
Asthma	10,016	13.2%	4,237	11.0%	2.189	0.067
Hyperlipidemia	25,474	33.4%	14,813	38.3%	-4.876	-0.102
Depression	33,869	44.5%	18,387	47.6%	-3.100	-0.062
Schizophrenia	60,540	79.5%	25,167	65.1%	14.378	0.326
Bipolar disorder	34,557	45.4%	15,625	40.4%	4.949	0.100
ACE inhibitor use	12,487	16.4%	8,017	20.7%	-4.346	-0.112
ARB use	3,318	4.4%	2,345	6.1%	-1.710	-0.077
Beta-blocker use	14,503	19.0%	9,499	24.6%	-5.533	-0.134
Oral anticoagulant use	1,540	2.0%	1,665	4.3%	-2.286	-0.131
Antiplatelet agent use	1,147	1.5%	1,727	4.5%	-2.962	-0.175
Opioid use	14,494	19.0%	9,111	23.6%	-4.541	-0.111
Statin use	16,617	21.8%	10,369	26.8%	-5.008	-0.117
Wheelchair or walker use	218	0.3%	818	2.1%	-1.830	-0.169
Anti-arrhythmic use	274	0.4%	369	1.0%	-0.595	-0.074
Antidiabetic use	12,692	16.7%	7,540	19.5%	-2.842	-0.074
Calcium channel blocker use	8,088	10.6%	5,996	15.5%	-4.893	-0.146
Diuretic use	10,960	14.4%	8,411	21.8%	-7.370	-0.192
Antidepressant use	44,267	58.1%	22,371	57.9%	0.246	0.005
Gastric acid suppressant use	20,203	26.5%	11,718	30.3%	-3.790	-0.084
NSAIDs	16,475	21.6%	7,456	19.3%	2.342	0.058

Table 1ae. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,946	32.8%	11,835	30.6%	2.135	0.046
Chronic liver disease	4,681	6.1%	2,185	5.7%	0.493	0.021
Pneumonia	3,115	4.1%	2,794	7.2%	-3.138	-0.136
Cardiac arrhythmia	9,884	13.0%	4,673	12.1%	0.888	0.027
Paliperidone palmitate	76,162	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	38,653	100.0%	NaN	NaN
Haloperidol decanoate	71	0.1%	63	0.2%	-0.070	-0.020
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.9	27.1	33.6	30.7	-4.759	-0.164
Mean number of generics dispensed	9.4	6.3	10.2	6.5	-0.843	-0.132
Mean number of unique drug classes dispensed	8.4	5.5	9.3	5.7	-0.912	-0.163
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	18.3	14.2	17.6	1.783	0.099
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.060
Mean number of non-acute institutional encounters	0.8	1.1	0.8	1.2	-0.062	-0.054

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1af. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	76,160	100.0%	38,652	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.8	55.6	18.9	-9.929	-0.599
Age	**Number**	**Percent**[1]	**Number**	**Percent**[1]		
18-34 years	20,437	26.8%	6,729	17.4%	9.425	0.229
35-44 years	17,906	23.5%	5,957	15.4%	8.099	0.206
45-54 years	17,613	23.1%	7,041	18.2%	4.910	0.121
55-64 years	13,064	17.2%	6,130	15.9%	1.294	0.035
65-74 years	5,579	7.3%	5,659	14.6%	-7.316	-0.236
75-84 years	1,247	1.6%	4,217	10.9%	-9.273	-0.390
≥ 85 years	314	0.4%	2,919	7.6%	-7.140	-0.371
Sex						
Female	30,755	40.4%	18,989	49.1%	-8.746	-0.177
Male	45,405	59.6%	19,663	50.9%	8.746	0.177
Race[2]						
American Indian or Alaska Native	912	1.2%	426	1.1%	0.095	0.009
Asian	1,736	2.3%	661	1.7%	0.569	0.041
Black or African American	19,915	26.1%	9,663	25.0%	1.149	0.026
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,396	8.4%	2,525	6.5%	1.865	0.071
White	47,201	62.0%	25,377	65.7%	-3.679	-0.077
Hispanic origin						
Yes	3,978	5.2%	1,794	4.6%	0.582	0.027
No	69,764	91.6%	36,127	93.5%	-1.865	-0.071
Unknown	2,418	3.2%	731	1.9%	1.284	0.082

Table 1af. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,270	3.0%	3,173	8.2%	-5.229	-0.229
2011	5,627	7.4%	6,367	16.5%	-9.084	-0.283
2012	6,664	8.8%	5,632	14.6%	-5.821	-0.182
2013	6,805	8.9%	5,061	13.1%	-4.159	-0.133
2014	6,478	8.5%	3,958	10.2%	-1.734	-0.060
2015	6,986	9.2%	3,166	8.2%	0.982	0.035
2016	7,223	9.5%	2,658	6.9%	2.607	0.095
2017	7,405	9.7%	2,232	5.8%	3.948	0.148
2018	7,380	9.7%	1,945	5.0%	4.658	0.179
2019	6,856	9.0%	1,579	4.1%	4.917	0.200
2020	5,236	6.9%	1,244	3.2%	3.657	0.168
2021	4,927	6.5%	1,131	2.9%	3.543	0.168
2022	2,303	3.0%	506	1.3%	1.715	0.118
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.9	2.7	-0.788	-0.339
Substance abuse	25,920	34.0%	9,497	24.6%	9.463	0.209
Atrial fibrilation/flutter	1,348	1.8%	2,282	5.9%	-4.134	-0.216
Ischemic heart disease	5,405	7.1%	5,724	14.8%	-7.712	-0.249
Heart failure	2,986	3.9%	3,939	10.2%	-6.270	-0.247
Stroke	1,804	2.4%	2,724	7.0%	-4.679	-0.222
Diabetes	18,106	23.8%	11,804	30.5%	-6.766	-0.153
Hypertension	33,553	44.1%	21,773	56.3%	-12.275	-0.247
Rheumatic disease	362	0.5%	309	0.8%	-0.324	-0.041
Chronic kidney disease	8,327	10.9%	5,907	15.3%	-4.349	-0.129
Seizure disorder	8,345	11.0%	5,001	12.9%	-1.981	-0.061

Table 1af. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,928	2.5%	5,204	13.5%	-10.932	-0.411
Dementia Diagnosis	6,351	8.3%	11,200	29.0%	-20.637	-0.549
Dementia Diagnosis and Treatment	1,377	1.8%	4,687	12.1%	-10.318	-0.414
Parkinsons disease	1,228	1.6%	1,402	3.6%	-2.015	-0.126
COPD	11,598	15.2%	7,382	19.1%	-3.870	-0.103
Malignancy	2,382	3.1%	1,576	4.1%	-0.950	-0.051
Asthma	10,015	13.1%	4,236	11.0%	2.191	0.067
Hyperlipidemia	25,473	33.4%	14,813	38.3%	-4.877	-0.102
Depression	33,867	44.5%	18,386	47.6%	-3.100	-0.062
Schizophrenia	60,539	79.5%	25,166	65.1%	14.380	0.326
Bipolar disorder	34,556	45.4%	15,624	40.4%	4.951	0.100
ACE inhibitor use	12,486	16.4%	8,016	20.7%	-4.344	-0.112
ARB use	3,318	4.4%	2,345	6.1%	-1.710	-0.077
Beta-blocker use	14,503	19.0%	9,499	24.6%	-5.533	-0.134
Oral anticoagulant use	1,540	2.0%	1,665	4.3%	-2.286	-0.131
Antiplatelet agent use	1,146	1.5%	1,727	4.5%	-2.963	-0.175
Opioid use	14,494	19.0%	9,111	23.6%	-4.541	-0.111
Statin use	16,616	21.8%	10,369	26.8%	-5.009	-0.117
Wheelchair or walker use	217	0.3%	818	2.1%	-1.831	-0.169
Anti-arrhythmic use	274	0.4%	369	1.0%	-0.595	-0.074
Antidiabetic use	12,690	16.7%	7,540	19.5%	-2.845	-0.074
Calcium channel blocker use	8,088	10.6%	5,996	15.5%	-4.893	-0.146
Diuretic use	10,959	14.4%	8,411	21.8%	-7.371	-0.192
Antidepressant use	44,266	58.1%	22,370	57.9%	0.247	0.005
Gastric acid suppressant use	20,202	26.5%	11,717	30.3%	-3.788	-0.084
NSAIDs	16,474	21.6%	7,455	19.3%	2.343	0.058

Table 1af. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,945	32.8%	11,834	30.6%	2.137	0.046
Chronic liver disease	4,680	6.1%	2,185	5.7%	0.492	0.021
Pneumonia	3,114	4.1%	2,794	7.2%	-3.140	-0.136
Cardiac arrhythmia	9,882	13.0%	4,672	12.1%	0.888	0.027
Paliperidone palmitate	76,160	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	38,652	100.0%	NaN	NaN
Haloperidol decanoate	71	0.1%	63	0.2%	-0.070	-0.020
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.9	27.1	33.6	30.7	-4.760	-0.164
Mean number of generics dispensed	9.4	6.3	10.2	6.5	-0.843	-0.132
Mean number of unique drug classes dispensed	8.4	5.5	9.3	5.7	-0.912	-0.163
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	18.3	14.2	17.6	1.783	0.099
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.060
Mean number of non-acute institutional encounters	0.8	1.1	0.8	1.2	-0.062	-0.054

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ag. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	75,254	N/A	39,332	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.3	15.2	48.2	17.1	0.054	0.003
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	17,344	23.0%	10,690	27.2%	-4.132	-0.095
35-44 years	15,983	21.2%	8,066	20.5%	0.732	0.018
45-54 years	16,851	22.4%	7,968	20.3%	2.133	0.052
55-64 years	13,894	18.5%	5,587	14.2%	4.257	0.115
65-74 years	7,553	10.0%	3,700	9.4%	0.630	0.021
75-84 years	2,585	3.4%	2,069	5.3%	-1.826	-0.090
≥ 85 years	1,044	1.4%	1,252	3.2%	-1.795	-0.120
Sex						
Female	32,048	42.6%	16,694	42.4%	0.142	0.003
Male	43,207	57.4%	22,638	57.6%	-0.142	-0.003
Race[3]						
American Indian or Alaska Native	882	1.2%	505	1.3%	-0.113	-0.010
Asian	1,669	2.2%	797	2.0%	0.192	0.013
Black or African American	19,466	25.9%	10,512	26.7%	-0.860	-0.020
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	5,915	7.9%	3,106	7.9%	-0.036	-0.001
White	47,323	62.9%	24,412	62.1%	0.818	0.017
Hispanic origin						
Yes	3,728	5.0%	2,168	5.5%	-0.558	-0.025
No	69,340	92.1%	36,227	92.1%	0.036	0.001
Unknown	2,186	2.9%	937	2.4%	0.522	0.033

Table 1ag. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	2,241	3.0%	3,392	8.6%	-5.645	-0.243
2011	5,468	7.3%	6,769	17.2%	-9.944	-0.307
2012	6,583	8.7%	5,878	14.9%	-6.196	-0.193
2013	6,688	8.9%	5,459	13.9%	-4.992	-0.158
2014	6,334	8.4%	4,115	10.5%	-2.047	-0.070
2015	6,844	9.1%	3,187	8.1%	0.991	0.035
2016	7,102	9.4%	2,627	6.7%	2.759	0.101
2017	7,379	9.8%	2,106	5.4%	4.451	0.169
2018	7,253	9.6%	1,783	4.5%	5.105	0.200
2019	6,853	9.1%	1,450	3.7%	5.418	0.223
2020	5,251	7.0%	1,110	2.8%	4.156	0.193
2021	4,915	6.5%	1,012	2.6%	3.957	0.191
2022	2,343	3.1%	444	1.1%	1.985	0.138
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.3	2.2	2.3	2.2	-0.004	-0.002
Substance abuse	23,693	31.5%	12,526	31.8%	-0.364	-0.008
Atrial fibrilation/flutter	2,278	3.0%	1,202	3.1%	-0.029	-0.002
Ischemic heart disease	7,053	9.4%	3,720	9.5%	-0.085	-0.003
Heart failure	4,413	5.9%	2,313	5.9%	-0.016	-0.001
Stroke	2,816	3.7%	1,497	3.8%	-0.063	-0.003
Diabetes	19,418	25.8%	10,061	25.6%	0.222	0.005
Hypertension	35,813	47.6%	18,641	47.4%	0.195	0.004
Rheumatic disease	438	0.6%	238	0.6%	-0.022	-0.003
Chronic kidney disease	9,117	12.1%	4,713	12.0%	0.133	0.004
Seizure disorder	8,813	11.7%	4,551	11.6%	0.142	0.004

Table 1ag. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	4,286	5.7%	2,358	6.0%	-0.299	-0.013
Dementia Diagnosis	10,607	14.1%	5,695	14.5%	-0.385	-0.011
Dementia Diagnosis and Treatment	3,622	4.8%	2,013	5.1%	-0.306	-0.014
Parkinsons disease	1,728	2.3%	874	2.2%	0.074	0.005
COPD	12,435	16.5%	6,465	16.4%	0.087	0.002
Malignancy	2,589	3.4%	1,332	3.4%	0.054	0.003
Asthma	9,505	12.6%	4,967	12.6%	0.003	0.000
Hyperlipidemia	26,435	35.1%	13,754	35.0%	0.159	0.003
Depression	34,300	45.6%	17,939	45.6%	-0.030	-0.001
Schizophrenia	57,356	76.2%	29,870	75.9%	0.273	0.006
Bipolar disorder	33,501	44.5%	17,588	44.7%	-0.201	-0.004
ACE inhibitor use	13,309	17.7%	6,917	17.6%	0.100	0.003
ARB use	3,612	4.8%	1,889	4.8%	-0.003	-0.000
Beta-blocker use	15,476	20.6%	8,043	20.4%	0.116	0.003
Oral anticoagulant use	2,009	2.7%	1,048	2.7%	0.005	0.000
Antiplatelet agent use	1,840	2.4%	941	2.4%	0.053	0.003
Opioid use	15,241	20.3%	7,975	20.3%	-0.025	-0.001
Statin use	17,682	23.5%	9,138	23.2%	0.263	0.006
Wheelchair or walker use	674	0.9%	348	0.9%	0.011	0.001
Anti-arrhythmic use	404	0.5%	209	0.5%	0.004	0.001
Antidiabetic use	13,120	17.4%	6,777	17.2%	0.203	0.005
Calcium channel blocker use	9,000	12.0%	4,671	11.9%	0.085	0.003
Diuretic use	12,435	16.5%	6,479	16.5%	0.052	0.001
Antidepressant use	43,383	57.6%	22,690	57.7%	-0.041	-0.001
Gastric acid suppressant use	20,708	27.5%	10,746	27.3%	0.197	0.004
NSAIDs	15,846	21.1%	8,257	21.0%	0.064	0.002

Table 1ag. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	23,959	31.8%	12,499	31.8%	0.060	0.001
Chronic liver disease	4,555	6.1%	2,389	6.1%	-0.023	-0.001
Pneumonia	3,835	5.1%	1,999	5.1%	0.015	0.001
Cardiac arrhythmia	9,570	12.7%	5,032	12.8%	-0.078	-0.002
Paliperidone palmitate	75,254	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,332	100.0%	NaN	NaN
Haloperidol decanoate	67	0.1%	74	0.2%	-0.099	-0.027
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	29.9	28.0	30.4	28.7	-0.532	-0.019
Mean number of generics dispensed	9.6	6.4	9.6	6.3	0.070	0.011
Mean number of unique drug classes dispensed	8.6	5.6	8.7	5.5	-0.032	-0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.7	17.9	15.8	19.4	-0.165	-0.009
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.002
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.1	-0.003	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable
Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1ah. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,702	100.0%	6,012	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.0	14.8	57.8	18.4	-9.843	-0.589
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	2,079	23.9%	869	14.5%	9.437	0.241
35-44 years	1,841	21.2%	798	13.3%	7.883	0.210
45-54 years	1,835	21.1%	964	16.0%	5.053	0.130
55-64 years	1,695	19.5%	1,066	17.7%	1.747	0.045
65-74 years	946	10.9%	1,120	18.6%	-7.758	-0.220
75-84 years	248	2.8%	752	12.5%	-9.658	-0.369
≥ 85 years	58	0.7%	443	7.4%	-6.702	-0.346
Sex						
Female	3,753	43.1%	3,071	51.1%	-7.953	-0.160
Male	4,949	56.9%	2,941	48.9%	7.953	0.160
Race[2]						
American Indian or Alaska Native	98	1.1%	41	0.7%	0.444	0.047
Asian	184	2.1%	108	1.8%	0.318	0.023
Black or African American	2,216	25.5%	1,318	21.9%	3.543	0.083
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	629	7.2%	315	5.2%	1.989	0.082
White	5,575	64.1%	4,230	70.4%	-6.294	-0.134
Hispanic origin						
Yes	396	4.6%	205	3.4%	1.141	0.058
No	8,073	92.8%	5,697	94.8%	-1.989	-0.082
Unknown	233	2.7%	110	1.8%	0.848	0.057

Table 1ah. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	201	2.3%	466	7.8%	-5.441	-0.251
2011	484	5.6%	891	14.8%	-9.258	-0.310
2012	701	8.1%	829	13.8%	-5.733	-0.185
2013	785	9.0%	813	13.5%	-4.502	-0.143
2014	789	9.1%	673	11.2%	-2.127	-0.071
2015	795	9.1%	534	8.9%	0.254	0.009
2016	815	9.4%	448	7.5%	1.914	0.069
2017	857	9.8%	409	6.8%	3.045	0.110
2018	895	10.3%	321	5.3%	4.946	0.185
2019	808	9.3%	244	4.1%	5.227	0.211
2020	677	7.8%	185	3.1%	4.703	0.209
2021	636	7.3%	137	2.3%	5.030	0.237
2022	259	3.0%	62	1.0%	1.945	0.139
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.6	2.9	-0.817	-0.311
Substance abuse	3,882	44.6%	1,791	29.8%	14.820	0.310
Atrial fibrilation/flutter	253	2.9%	451	7.5%	-4.594	-0.208
Ischemic heart disease	977	11.2%	1,209	20.1%	-8.882	-0.246
Heart failure	557	6.4%	778	12.9%	-6.540	-0.223
Stroke	307	3.5%	484	8.1%	-4.523	-0.195
Diabetes	2,447	28.1%	2,023	33.6%	-5.529	-0.120
Hypertension	5,041	57.9%	3,926	65.3%	-7.374	-0.152
Rheumatic disease	69	0.8%	74	1.2%	-0.438	-0.044
Chronic kidney disease	1,339	15.4%	1,210	20.1%	-4.739	-0.124
Seizure disorder	1,340	15.4%	862	14.3%	1.061	0.030

Table 1ah. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	380	4.4%	953	15.9%	-11.485	-0.388
Dementia Diagnosis	1,385	15.9%	2,174	36.2%	-20.245	-0.474
Dementia Diagnosis and Treatment	299	3.4%	902	15.0%	-11.567	-0.408
Parkinsons disease	257	3.0%	310	5.2%	-2.203	-0.112
COPD	1,824	21.0%	1,404	23.4%	-2.393	-0.058
Malignancy	331	3.8%	274	4.6%	-0.754	-0.038
Asthma	1,490	17.1%	765	12.7%	4.398	0.124
Hyperlipidemia	3,571	41.0%	2,692	44.8%	-3.741	-0.076
Depression	4,929	56.6%	3,398	56.5%	0.122	0.002
Schizophrenia	7,727	88.8%	4,467	74.3%	14.494	0.380
Bipolar disorder	5,068	58.2%	2,929	48.7%	9.520	0.192
ACE inhibitor use	1,624	18.7%	1,383	23.0%	-4.342	-0.107
ARB use	420	4.8%	363	6.0%	-1.211	-0.053
Beta-blocker use	2,017	23.2%	1,638	27.2%	-4.067	-0.094
Oral anticoagulant use	229	2.6%	317	5.3%	-2.641	-0.136
Antiplatelet agent use	169	1.9%	293	4.9%	-2.932	-0.162
Opioid use	1,629	18.7%	1,301	21.6%	-2.920	-0.073
Statin use	2,105	24.2%	1,750	29.1%	-4.919	-0.111
Wheelchair or walker use	39	0.4%	100	1.7%	-1.215	-0.119
Anti-arrhythmic use	40	0.5%	68	1.1%	-0.671	-0.076
Antidiabetic use	1,510	17.4%	1,207	20.1%	-2.724	-0.070
Calcium channel blocker use	1,171	13.5%	1,066	17.7%	-4.275	-0.118
Diuretic use	1,418	16.3%	1,441	24.0%	-7.674	-0.192
Antidepressant use	5,166	59.4%	3,529	58.7%	0.666	0.014
Gastric acid suppressant use	2,585	29.7%	1,966	32.7%	-2.995	-0.065
NSAIDs	1,964	22.6%	1,147	19.1%	3.491	0.086

Table 1ah. Unadjusted Characteristics of Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,359	38.6%	2,093	34.8%	3.787	0.079
Chronic liver disease	670	7.7%	393	6.5%	1.162	0.045
Pneumonia	549	6.3%	632	10.5%	-4.203	-0.152
Cardiac arrhythmia	1,864	21.4%	1,032	17.2%	4.255	0.108
Paliperidone palmitate	8,702	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,012	100.0%	NaN	NaN
Haloperidol decanoate	13	0.1%	14	0.2%	-0.083	-0.019
IS Stay	8,702	100.0%	6,012	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.5	27.4	33.3	28.9	-2.799	-0.099
Mean number of generics dispensed	10.4	6.6	11.0	6.5	-0.592	-0.090
Mean number of unique drug classes dispensed	9.3	5.7	9.9	5.7	-0.601	-0.106
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.4	22.4	18.1	20.1	3.272	0.154
Mean number of inpatient hospital encounters	0.4	0.8	0.5	0.9	-0.085	-0.096
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.4	0.012	0.009

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ai. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,697	99.9%	6,011	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.0	14.8	57.8	18.4	-9.830	-0.588
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	2,075	23.9%	869	14.5%	9.402	0.241
35-44 years	1,841	21.2%	798	13.3%	7.893	0.210
45-54 years	1,835	21.1%	964	16.0%	5.062	0.130
55-64 years	1,695	19.5%	1,066	17.7%	1.755	0.045
65-74 years	946	10.9%	1,120	18.6%	-7.755	-0.220
75-84 years	247	2.8%	751	12.5%	-9.654	-0.369
≥ 85 years	58	0.7%	443	7.4%	-6.703	-0.346
Sex						
Female	3,751	43.1%	3,071	51.1%	-7.960	-0.160
Male	4,946	56.9%	2,940	48.9%	7.960	0.160
Race[2]						
American Indian or Alaska Native	98	1.1%	41	0.7%	0.445	0.047
Asian	184	2.1%	108	1.8%	0.319	0.023
Black or African American	2,215	25.5%	1,318	21.9%	3.542	0.083
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	629	7.2%	315	5.2%	1.992	0.082
White	5,571	64.1%	4,229	70.4%	-6.298	-0.134
Hispanic origin						
Yes	396	4.6%	205	3.4%	1.143	0.058
No	8,068	92.8%	5,696	94.8%	-1.992	-0.082
Unknown	233	2.7%	110	1.8%	0.849	0.057

Table 1ai. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	201	2.3%	466	7.8%	-5.441	-0.251
2011	484	5.6%	891	14.8%	-9.258	-0.310
2012	701	8.1%	828	13.8%	-5.714	-0.184
2013	785	9.0%	813	13.5%	-4.499	-0.143
2014	789	9.1%	673	11.2%	-2.124	-0.070
2015	795	9.1%	534	8.9%	0.257	0.009
2016	814	9.4%	448	7.5%	1.907	0.069
2017	857	9.9%	409	6.8%	3.050	0.111
2018	894	10.3%	321	5.3%	4.939	0.185
2019	807	9.3%	244	4.1%	5.220	0.210
2020	676	7.8%	185	3.1%	4.695	0.208
2021	635	7.3%	137	2.3%	5.022	0.237
2022	259	3.0%	62	1.0%	1.947	0.139
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.6	2.9	-0.816	-0.311
Substance abuse	3,878	44.6%	1,791	29.8%	14.795	0.310
Atrial fibrilation/flutter	252	2.9%	451	7.5%	-4.605	-0.209
Ischemic heart disease	976	11.2%	1,209	20.1%	-8.891	-0.246
Heart failure	556	6.4%	778	12.9%	-6.550	-0.223
Stroke	306	3.5%	483	8.0%	-4.517	-0.195
Diabetes	2,446	28.1%	2,022	33.6%	-5.514	-0.120
Hypertension	5,038	57.9%	3,925	65.3%	-7.369	-0.152
Rheumatic disease	69	0.8%	74	1.2%	-0.438	-0.044
Chronic kidney disease	1,338	15.4%	1,209	20.1%	-4.729	-0.124
Seizure disorder	1,336	15.4%	862	14.3%	1.021	0.029

Table 1ai. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	379	4.4%	952	15.8%	-11.480	-0.388
Dementia Diagnosis	1,384	15.9%	2,173	36.2%	-20.237	-0.474
Dementia Diagnosis and Treatment	298	3.4%	901	15.0%	-11.563	-0.408
Parkinsons disease	257	3.0%	310	5.2%	-2.202	-0.112
COPD	1,824	21.0%	1,404	23.4%	-2.384	-0.057
Malignancy	331	3.8%	274	4.6%	-0.752	-0.038
Asthma	1,486	17.1%	765	12.7%	4.360	0.123
Hyperlipidemia	3,568	41.0%	2,691	44.8%	-3.742	-0.076
Depression	4,926	56.6%	3,398	56.5%	0.111	0.002
Schizophrenia	7,723	88.8%	4,467	74.3%	14.487	0.380
Bipolar disorder	5,064	58.2%	2,929	48.7%	9.500	0.191
ACE inhibitor use	1,624	18.7%	1,382	23.0%	-4.318	-0.106
ARB use	420	4.8%	363	6.0%	-1.210	-0.053
Beta-blocker use	2,016	23.2%	1,638	27.3%	-4.070	-0.094
Oral anticoagulant use	229	2.6%	317	5.3%	-2.641	-0.136
Antiplatelet agent use	169	1.9%	292	4.9%	-2.915	-0.161
Opioid use	1,629	18.7%	1,300	21.6%	-2.896	-0.072
Statin use	2,105	24.2%	1,750	29.1%	-4.910	-0.111
Wheelchair or walker use	39	0.4%	100	1.7%	-1.215	-0.119
Anti-arrhythmic use	40	0.5%	68	1.1%	-0.671	-0.076
Antidiabetic use	1,509	17.4%	1,206	20.1%	-2.712	-0.070
Calcium channel blocker use	1,170	13.5%	1,066	17.7%	-4.281	-0.118
Diuretic use	1,418	16.3%	1,440	24.0%	-7.652	-0.192
Antidepressant use	5,162	59.4%	3,528	58.7%	0.661	0.013
Gastric acid suppressant use	2,582	29.7%	1,965	32.7%	-3.002	-0.065
NSAIDs	1,960	22.5%	1,147	19.1%	3.455	0.085

Table 1ai. Unweighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,355	38.6%	2,093	34.8%	3.757	0.078
Chronic liver disease	670	7.7%	393	6.5%	1.166	0.045
Pneumonia	549	6.3%	632	10.5%	-4.202	-0.152
Cardiac arrhythmia	1,860	21.4%	1,032	17.2%	4.218	0.107
Paliperidone palmitate	8,697	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,011	100.0%	NaN	NaN
Haloperidol decanoate	13	0.1%	14	0.2%	-0.083	-0.019
IS Stay	8,697	100.0%	6,011	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.5	27.4	33.3	28.9	-2.798	-0.099
Mean number of generics dispensed	10.4	6.6	11.0	6.5	-0.592	-0.090
Mean number of unique drug classes dispensed	9.3	5.7	9.9	5.7	-0.601	-0.106
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.4	22.4	18.1	20.1	3.244	0.152
Mean number of inpatient hospital encounters	0.4	0.8	0.5	0.9	-0.085	-0.096
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.4	0.012	0.009

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1aj. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	8,607	N/A	6,065	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	51.4	16.1	51.6	17.7	-0.183	-0.011
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	1,668	19.4%	1,354	22.3%	-2.945	-0.073
35-44 years	1,579	18.3%	1,063	17.5%	0.811	0.021
45-54 years	1,698	19.7%	1,118	18.4%	1.284	0.033
55-64 years	1,760	20.4%	1,026	16.9%	3.532	0.091
65-74 years	1,253	14.6%	835	13.8%	0.794	0.023
75-84 years	489	5.7%	440	7.3%	-1.572	-0.064
≥ 85 years	160	1.9%	229	3.8%	-1.904	-0.115
Sex						
Female	3,931	45.7%	2,778	45.8%	-0.139	-0.003
Male	4,676	54.3%	3,286	54.2%	0.139	0.003
Race[3]						
American Indian or Alaska Native	95	1.1%	45	0.7%	0.372	0.039
Asian	177	2.1%	117	1.9%	0.122	0.009
Black or African American	2,142	24.9%	1,406	23.2%	1.696	0.040
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	566	6.6%	382	6.3%	0.280	0.011
White	5,627	65.4%	4,115	67.8%	-2.469	-0.052
Hispanic origin						
Yes	360	4.2%	250	4.1%	0.068	0.003
No	8,041	93.4%	5,683	93.7%	-0.280	-0.011
Unknown	206	2.4%	132	2.2%	0.212	0.014

Table 1aj. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	204	2.4%	472	7.8%	-5.423	-0.249
2011	482	5.6%	908	15.0%	-9.381	-0.313
2012	701	8.1%	849	14.0%	-5.856	-0.187
2013	766	8.9%	847	14.0%	-5.062	-0.160
2014	786	9.1%	699	11.5%	-2.388	-0.079
2015	807	9.4%	542	8.9%	0.445	0.015
2016	805	9.4%	435	7.2%	2.178	0.079
2017	852	9.9%	387	6.4%	3.520	0.129
2018	854	9.9%	303	5.0%	4.922	0.188
2019	788	9.2%	250	4.1%	5.036	0.203
2020	675	7.8%	174	2.9%	4.978	0.222
2021	619	7.2%	135	2.2%	4.971	0.236
2022	268	3.1%	64	1.1%	2.062	0.145
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	3.0	2.5	3.1	2.6	-0.016	-0.006
Substance abuse	3,376	39.2%	2,372	39.1%	0.106	0.002
Atrial fibrilation/flutter	370	4.3%	281	4.6%	-0.328	-0.016
Ischemic heart disease	1,242	14.4%	882	14.5%	-0.100	-0.003
Heart failure	762	8.9%	546	9.0%	-0.143	-0.005
Stroke	441	5.1%	316	5.2%	-0.084	-0.004
Diabetes	2,612	30.3%	1,837	30.3%	0.053	0.001
Hypertension	5,205	60.5%	3,680	60.7%	-0.199	-0.004
Rheumatic disease	75	0.9%	57	0.9%	-0.070	-0.007
Chronic kidney disease	1,456	16.9%	1,027	16.9%	-0.014	-0.000
Seizure disorder	1,294	15.0%	888	14.6%	0.399	0.011

Table 1aj. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	737	8.6%	537	8.9%	-0.294	-0.010
Dementia Diagnosis	1,982	23.0%	1,423	23.5%	-0.429	-0.010
Dementia Diagnosis and Treatment	661	7.7%	487	8.0%	-0.344	-0.013
Parkinsons disease	343	4.0%	235	3.9%	0.110	0.006
COPD	1,870	21.7%	1,295	21.4%	0.373	0.009
Malignancy	353	4.1%	249	4.1%	0.002	0.000
Asthma	1,325	15.4%	920	15.2%	0.222	0.006
Hyperlipidemia	3,646	42.4%	2,567	42.3%	0.030	0.001
Depression	4,881	56.7%	3,438	56.7%	0.031	0.001
Schizophrenia	7,262	84.4%	5,070	83.6%	0.776	0.021
Bipolar disorder	4,716	54.8%	3,321	54.8%	0.038	0.001
ACE inhibitor use	1,752	20.4%	1,241	20.5%	-0.107	-0.003
ARB use	455	5.3%	319	5.3%	0.035	0.002
Beta-blocker use	2,116	24.6%	1,491	24.6%	0.004	0.000
Oral anticoagulant use	292	3.4%	217	3.6%	-0.186	-0.010
Antiplatelet agent use	269	3.1%	188	3.1%	0.031	0.002
Opioid use	1,684	19.6%	1,198	19.7%	-0.183	-0.005
Statin use	2,230	25.9%	1,569	25.9%	0.042	0.001
Wheelchair or walker use	79	0.9%	57	0.9%	-0.022	-0.002
Anti-arrhythmic use	59	0.7%	43	0.7%	-0.020	-0.002
Antidiabetic use	1,581	18.4%	1,112	18.3%	0.032	0.001
Calcium channel blocker use	1,290	15.0%	915	15.1%	-0.103	-0.003
Diuretic use	1,644	19.1%	1,165	19.2%	-0.117	-0.003
Antidepressant use	5,051	58.7%	3,555	58.6%	0.070	0.001
Gastric acid suppressant use	2,632	30.6%	1,863	30.7%	-0.131	-0.003
NSAIDs	1,820	21.1%	1,282	21.1%	0.001	0.000

Table 1aj. Weighted Characteristics of Paliperidone vs. Risperidone - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,153	36.6%	2,221	36.6%	0.004	0.000
Chronic liver disease	624	7.2%	447	7.4%	-0.120	-0.005
Pneumonia	679	7.9%	479	7.9%	-0.011	-0.000
Cardiac arrhythmia	1,694	19.7%	1,200	19.8%	-0.108	-0.003
Paliperidone palmitate	8,607	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,065	100.0%	NaN	NaN
Haloperidol decanoate	14	0.2%	15	0.2%	-0.083	-0.019
IS Stay	8,607	100.0%	6,065	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	31.3	28.1	31.3	27.6	0.058	0.002
Mean number of generics dispensed	10.6	6.7	10.5	6.4	0.035	0.005
Mean number of unique drug classes dispensed	9.5	5.8	9.4	5.5	0.018	0.003
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	20.3	21.3	20.4	22.5	-0.117	-0.005
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.002
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.3	0.002	0.001

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable
Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1ak. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,398	100.0%	62,488	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	52.3	16.8	-6.471	-0.419
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,437	26.6%	11,316	18.1%	8.476	0.205
35-44 years	19,608	23.2%	10,933	17.5%	5.737	0.143
45-54 years	19,386	23.0%	13,895	22.2%	0.733	0.018
55-64 years	14,574	17.3%	11,670	18.7%	-1.407	-0.037
65-74 years	6,512	7.7%	8,244	13.2%	-5.477	-0.180
75-84 years	1,509	1.8%	4,139	6.6%	-4.836	-0.243
≥ 85 years	372	0.4%	2,291	3.7%	-3.226	-0.229
Sex						
Female	34,434	40.8%	26,389	42.2%	-1.431	-0.029
Male	49,964	59.2%	36,099	57.8%	1.431	0.029
Race[2]						
American Indian or Alaska Native	1,017	1.2%	530	0.8%	0.357	0.035
Asian	1,914	2.3%	1,251	2.0%	0.266	0.018
Black or African American	21,668	25.7%	22,605	36.2%	-10.501	-0.229
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,012	8.3%	4,506	7.2%	1.097	0.041
White	52,787	62.5%	33,596	53.8%	8.781	0.179
Hispanic origin						
Yes	4,378	5.2%	3,074	4.9%	0.268	0.012
No	77,386	91.7%	57,982	92.8%	-1.097	-0.041
Unknown	2,634	3.1%	1,432	2.3%	0.829	0.051

Table 1ak. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,467	2.9%	5,269	8.4%	-5.509	-0.240
2011	6,113	7.2%	9,594	15.4%	-8.110	-0.258
2012	7,347	8.7%	7,725	12.4%	-3.657	-0.119
2013	7,572	9.0%	6,821	10.9%	-1.944	-0.065
2014	7,284	8.6%	5,684	9.1%	-0.466	-0.016
2015	7,807	9.3%	5,033	8.1%	1.196	0.043
2016	8,044	9.5%	4,628	7.4%	2.125	0.076
2017	8,224	9.7%	4,174	6.7%	3.065	0.112
2018	8,193	9.7%	3,672	5.9%	3.831	0.143
2019	7,580	9.0%	3,410	5.5%	3.524	0.136
2020	5,847	6.9%	2,697	4.3%	2.612	0.114
2021	5,411	6.4%	2,587	4.1%	2.271	0.102
2022	2,509	3.0%	1,194	1.9%	1.062	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	2.5	2.5	-0.374	-0.167
Substance abuse	29,539	35.0%	16,731	26.8%	8.225	0.179
Atrial fibrilation/flutter	1,611	1.9%	2,395	3.8%	-1.924	-0.115
Ischemic heart disease	6,332	7.5%	7,647	12.2%	-4.735	-0.159
Heart failure	3,486	4.1%	4,933	7.9%	-3.764	-0.159
Stroke	2,101	2.5%	2,939	4.7%	-2.214	-0.119
Diabetes	20,351	24.1%	18,434	29.5%	-5.387	-0.122
Hypertension	38,140	45.2%	33,706	53.9%	-8.749	-0.176
Rheumatic disease	426	0.5%	415	0.7%	-0.159	-0.021
Chronic kidney disease	9,514	11.3%	8,416	13.5%	-2.195	-0.067
Seizure disorder	9,531	11.3%	7,843	12.6%	-1.258	-0.039

Table 1ak. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,297	2.7%	4,492	7.2%	-4.467	-0.207
Dementia Diagnosis	7,677	9.1%	12,220	19.6%	-10.460	-0.302
Dementia Diagnosis and Treatment	1,675	2.0%	3,933	6.3%	-4.309	-0.218
Parkinsons disease	1,475	1.7%	1,800	2.9%	-1.133	-0.075
COPD	13,260	15.7%	11,259	18.0%	-2.307	-0.062
Malignancy	2,689	3.2%	2,409	3.9%	-0.669	-0.036
Asthma	11,449	13.6%	7,077	11.3%	2.240	0.068
Hyperlipidemia	28,843	34.2%	22,990	36.8%	-2.616	-0.055
Depression	38,633	45.8%	24,864	39.8%	5.985	0.121
Schizophrenia	67,706	80.2%	48,804	78.1%	2.121	0.052
Bipolar disorder	39,399	46.7%	22,944	36.7%	9.965	0.203
ACE inhibitor use	14,009	16.6%	12,650	20.2%	-3.645	-0.094
ARB use	3,686	4.4%	3,575	5.7%	-1.354	-0.062
Beta-blocker use	16,373	19.4%	13,939	22.3%	-2.907	-0.072
Oral anticoagulant use	1,765	2.1%	1,864	3.0%	-0.892	-0.057
Antiplatelet agent use	1,295	1.5%	1,832	2.9%	-1.397	-0.095
Opioid use	16,155	19.1%	11,206	17.9%	1.208	0.031
Statin use	18,639	22.1%	15,728	25.2%	-3.085	-0.073
Wheelchair or walker use	255	0.3%	599	1.0%	-0.656	-0.083
Anti-arrhythmic use	309	0.4%	385	0.6%	-0.250	-0.036
Antidiabetic use	14,118	16.7%	11,931	19.1%	-2.365	-0.062
Calcium channel blocker use	9,103	10.8%	9,845	15.8%	-4.969	-0.147
Diuretic use	12,345	14.6%	11,977	19.2%	-4.540	-0.121
Antidepressant use	49,189	58.3%	31,375	50.2%	8.073	0.163
Gastric acid suppressant use	22,641	26.8%	16,750	26.8%	0.021	0.000
NSAIDs	18,369	21.8%	11,453	18.3%	3.436	0.086

Table 1ak. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,079	33.3%	18,005	28.8%	4.456	0.096
Chronic liver disease	5,330	6.3%	3,484	5.6%	0.740	0.031
Pneumonia	3,618	4.3%	3,905	6.2%	-1.962	-0.088
Cardiac arrhythmia	11,574	13.7%	7,958	12.7%	0.978	0.029
Paliperidone palmitate	84,398	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	75	0.1%	-0.099	-0.037
Haloperidol decanoate	0	0.0%	62,488	100.0%	NaN	NaN
IS Stay	8,558	10.1%	6,963	11.1%	-1.003	-0.033
Medical Product Use						
Mean number of filled prescriptions	29.0	27.1	30.0	27.7	-1.033	-0.038
Mean number of generics dispensed	9.5	6.3	9.4	6.1	0.060	0.010
Mean number of unique drug classes dispensed	8.5	5.5	8.2	5.3	0.242	0.045
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.7	14.8	18.9	1.671	0.089
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.059
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	-0.035	-0.029

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1al. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,398	100.0%	62,484	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	52.3	16.8	-6.472	-0.419
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,437	26.6%	11,314	18.1%	8.478	0.205
35-44 years	19,608	23.2%	10,933	17.5%	5.735	0.143
45-54 years	19,386	23.0%	13,894	22.2%	0.734	0.018
55-64 years	14,574	17.3%	11,670	18.7%	-1.409	-0.037
65-74 years	6,512	7.7%	8,244	13.2%	-5.478	-0.180
75-84 years	1,509	1.8%	4,138	6.6%	-4.835	-0.243
≥ 85 years	372	0.4%	2,291	3.7%	-3.226	-0.229
Sex						
Female	34,434	40.8%	26,388	42.2%	-1.432	-0.029
Male	49,964	59.2%	36,096	57.8%	1.432	0.029
Race[2]						
American Indian or Alaska Native	1,017	1.2%	530	0.8%	0.357	0.035
Asian	1,914	2.3%	1,251	2.0%	0.266	0.018
Black or African American	21,668	25.7%	22,604	36.2%	-10.502	-0.229
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,012	8.3%	4,506	7.2%	1.097	0.041
White	52,787	62.5%	33,593	53.8%	8.783	0.179
Hispanic origin						
Yes	4,378	5.2%	3,074	4.9%	0.268	0.012
No	77,386	91.7%	57,978	92.8%	-1.097	-0.041
Unknown	2,634	3.1%	1,432	2.3%	0.829	0.051

Table 1al. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,467	2.9%	5,269	8.4%	-5.510	-0.240
2011	6,113	7.2%	9,592	15.4%	-8.108	-0.258
2012	7,347	8.7%	7,725	12.4%	-3.658	-0.119
2013	7,572	9.0%	6,821	10.9%	-1.945	-0.065
2014	7,284	8.6%	5,684	9.1%	-0.466	-0.016
2015	7,807	9.3%	5,033	8.1%	1.195	0.043
2016	8,044	9.5%	4,628	7.4%	2.124	0.076
2017	8,224	9.7%	4,173	6.7%	3.066	0.112
2018	8,193	9.7%	3,672	5.9%	3.831	0.143
2019	7,580	9.0%	3,410	5.5%	3.524	0.136
2020	5,847	6.9%	2,697	4.3%	2.612	0.114
2021	5,411	6.4%	2,587	4.1%	2.271	0.102
2022	2,509	3.0%	1,193	1.9%	1.064	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	2.5	2.5	-0.374	-0.167
Substance abuse	29,539	35.0%	16,728	26.8%	8.228	0.179
Atrial fibrilation/flutter	1,611	1.9%	2,394	3.8%	-1.923	-0.115
Ischemic heart disease	6,332	7.5%	7,644	12.2%	-4.731	-0.159
Heart failure	3,486	4.1%	4,931	7.9%	-3.761	-0.159
Stroke	2,101	2.5%	2,937	4.7%	-2.211	-0.119
Diabetes	20,351	24.1%	18,431	29.5%	-5.384	-0.122
Hypertension	38,140	45.2%	33,703	53.9%	-8.748	-0.176
Rheumatic disease	426	0.5%	414	0.7%	-0.158	-0.021
Chronic kidney disease	9,514	11.3%	8,414	13.5%	-2.193	-0.067
Seizure disorder	9,531	11.3%	7,841	12.5%	-1.256	-0.039

Table 1al. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,297	2.7%	4,491	7.2%	-4.466	-0.207
Dementia Diagnosis	7,677	9.1%	12,219	19.6%	-10.459	-0.302
Dementia Diagnosis and Treatment	1,675	2.0%	3,932	6.3%	-4.308	-0.218
Parkinsons disease	1,475	1.7%	1,800	2.9%	-1.133	-0.075
COPD	13,260	15.7%	11,257	18.0%	-2.305	-0.062
Malignancy	2,689	3.2%	2,408	3.9%	-0.668	-0.036
Asthma	11,449	13.6%	7,076	11.3%	2.241	0.068
Hyperlipidemia	28,843	34.2%	22,987	36.8%	-2.614	-0.055
Depression	38,633	45.8%	24,861	39.8%	5.987	0.121
Schizophrenia	67,706	80.2%	48,801	78.1%	2.121	0.052
Bipolar disorder	39,399	46.7%	22,941	36.7%	9.967	0.203
ACE inhibitor use	14,009	16.6%	12,649	20.2%	-3.645	-0.094
ARB use	3,686	4.4%	3,575	5.7%	-1.354	-0.062
Beta-blocker use	16,373	19.4%	13,938	22.3%	-2.907	-0.072
Oral anticoagulant use	1,765	2.1%	1,864	3.0%	-0.892	-0.057
Antiplatelet agent use	1,295	1.5%	1,831	2.9%	-1.396	-0.095
Opioid use	16,155	19.1%	11,203	17.9%	1.212	0.031
Statin use	18,639	22.1%	15,727	25.2%	-3.085	-0.073
Wheelchair or walker use	255	0.3%	599	1.0%	-0.657	-0.083
Anti-arrhythmic use	309	0.4%	385	0.6%	-0.250	-0.036
Antidiabetic use	14,118	16.7%	11,929	19.1%	-2.363	-0.062
Calcium channel blocker use	9,103	10.8%	9,844	15.8%	-4.969	-0.147
Diuretic use	12,345	14.6%	11,976	19.2%	-4.539	-0.121
Antidepressant use	49,189	58.3%	31,372	50.2%	8.074	0.163
Gastric acid suppressant use	22,641	26.8%	16,747	26.8%	0.024	0.001
NSAIDs	18,369	21.8%	11,450	18.3%	3.440	0.086

Table 1al. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,079	33.3%	18,003	28.8%	4.458	0.096
Chronic liver disease	5,330	6.3%	3,481	5.6%	0.744	0.031
Pneumonia	3,618	4.3%	3,903	6.2%	-1.960	-0.088
Cardiac arrhythmia	11,574	13.7%	7,955	12.7%	0.982	0.029
Paliperidone palmitate	84,398	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	75	0.1%	-0.099	-0.037
Haloperidol decanoate	0	0.0%	62,484	100.0%	NaN	NaN
IS Stay	8,558	10.1%	6,962	11.1%	-1.002	-0.032
Medical Product Use						
Mean number of filled prescriptions	29.0	27.1	30.0	27.7	-1.033	-0.038
Mean number of generics dispensed	9.5	6.3	9.4	6.1	0.060	0.010
Mean number of unique drug classes dispensed	8.5	5.5	8.2	5.3	0.243	0.045
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.7	14.8	18.9	1.675	0.089
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.055	-0.059
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	-0.035	-0.029

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1am. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	84,146	N/A	62,754	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.3	14.9	48.3	15.9	0.009	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	18,983	22.6%	15,366	24.5%	-1.927	-0.045
35-44 years	17,667	21.0%	12,943	20.6%	0.370	0.009
45-54 years	19,022	22.6%	14,137	22.5%	0.079	0.002
55-64 years	16,158	19.2%	10,234	16.3%	2.894	0.076
65-74 years	8,788	10.4%	6,127	9.8%	0.680	0.023
75-84 years	2,688	3.2%	2,622	4.2%	-0.984	-0.052
≥ 85 years	840	1.0%	1,325	2.1%	-1.113	-0.090
Sex						
Female	34,731	41.3%	25,931	41.3%	-0.046	-0.001
Male	49,415	58.7%	36,823	58.7%	0.046	0.001
Race[3]						
American Indian or Alaska Native	978	1.2%	594	0.9%	0.216	0.021
Asian	1,925	2.3%	1,289	2.1%	0.234	0.016
Black or African American	22,246	26.4%	22,243	35.4%	-9.007	-0.196
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,566	7.8%	5,001	8.0%	-0.166	-0.006
White	52,431	62.3%	33,628	53.6%	8.723	0.177
Hispanic origin						
Yes	4,166	5.0%	3,378	5.4%	-0.432	-0.020
No	77,580	92.2%	57,754	92.0%	0.166	0.006
Unknown	2,400	2.9%	1,623	2.6%	0.266	0.016

Table 1am. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	2,476	2.9%	5,149	8.2%	-5.263	-0.231
2011	6,064	7.2%	9,371	14.9%	-7.727	-0.248
2012	7,352	8.7%	7,626	12.2%	-3.415	-0.112
2013	7,485	8.9%	6,969	11.1%	-2.210	-0.074
2014	7,187	8.5%	5,848	9.3%	-0.778	-0.027
2015	7,723	9.2%	5,163	8.2%	0.951	0.034
2016	7,968	9.5%	4,733	7.5%	1.927	0.069
2017	8,235	9.8%	4,206	6.7%	3.084	0.112
2018	8,101	9.6%	3,725	5.9%	3.691	0.138
2019	7,609	9.0%	3,454	5.5%	3.538	0.137
2020	5,917	7.0%	2,737	4.4%	2.670	0.115
2021	5,457	6.5%	2,599	4.1%	2.344	0.105
2022	2,573	3.1%	1,175	1.9%	1.186	0.077
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.3	2.2	2.3	2.2	-0.005	-0.002
Substance abuse	26,808	31.9%	20,164	32.1%	-0.274	-0.006
Atrial fibrilation/flutter	2,241	2.7%	1,688	2.7%	-0.028	-0.002
Ischemic heart disease	7,928	9.4%	5,928	9.4%	-0.025	-0.001
Heart failure	4,806	5.7%	3,584	5.7%	0.001	0.000
Stroke	2,844	3.4%	2,125	3.4%	-0.007	-0.000
Diabetes	22,258	26.5%	16,570	26.4%	0.046	0.001
Hypertension	41,148	48.9%	30,712	48.9%	-0.039	-0.001
Rheumatic disease	470	0.6%	354	0.6%	-0.006	-0.001
Chronic kidney disease	10,257	12.2%	7,662	12.2%	-0.020	-0.001
Seizure disorder	9,992	11.9%	7,452	11.9%	-0.000	-0.000

Table 1am. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	3,822	4.5%	2,872	4.6%	-0.034	-0.002
Dementia Diagnosis	11,154	13.3%	8,387	13.4%	-0.110	-0.003
Dementia Diagnosis and Treatment	3,154	3.7%	2,371	3.8%	-0.031	-0.002
Parkinsons disease	1,889	2.2%	1,408	2.2%	0.001	0.000
COPD	14,085	16.7%	10,488	16.7%	0.026	0.001
Malignancy	2,904	3.5%	2,172	3.5%	-0.010	-0.001
Asthma	10,680	12.7%	8,020	12.8%	-0.089	-0.003
Hyperlipidemia	29,803	35.4%	22,229	35.4%	-0.004	-0.000
Depression	36,559	43.4%	27,325	43.5%	-0.096	-0.002
Schizophrenia	67,571	80.3%	50,416	80.3%	-0.038	-0.001
Bipolar disorder	36,053	42.8%	27,000	43.0%	-0.180	-0.004
ACE inhibitor use	15,246	18.1%	11,341	18.1%	0.046	0.001
ARB use	4,134	4.9%	3,072	4.9%	0.017	0.001
Beta-blocker use	17,271	20.5%	12,895	20.5%	-0.024	-0.001
Oral anticoagulant use	2,042	2.4%	1,534	2.4%	-0.018	-0.001
Antiplatelet agent use	1,774	2.1%	1,321	2.1%	0.002	0.000
Opioid use	15,517	18.4%	11,592	18.5%	-0.031	-0.001
Statin use	19,684	23.4%	14,630	23.3%	0.080	0.002
Wheelchair or walker use	513	0.6%	366	0.6%	0.025	0.003
Anti-arrhythmic use	378	0.4%	286	0.5%	-0.006	-0.001
Antidiabetic use	14,885	17.7%	11,073	17.6%	0.045	0.001
Calcium channel blocker use	10,843	12.9%	8,064	12.8%	0.036	0.001
Diuretic use	13,868	16.5%	10,301	16.4%	0.066	0.002
Antidepressant use	46,070	54.7%	34,463	54.9%	-0.167	-0.003
Gastric acid suppressant use	22,497	26.7%	16,796	26.8%	-0.030	-0.001
NSAIDs	17,140	20.4%	12,787	20.4%	-0.008	-0.000

Table 1am. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	26,366	31.3%	19,749	31.5%	-0.136	-0.003
Chronic liver disease	5,081	6.0%	3,823	6.1%	-0.054	-0.002
Pneumonia	4,294	5.1%	3,199	5.1%	0.005	0.000
Cardiac arrhythmia	11,290	13.4%	8,523	13.6%	-0.164	-0.005
Paliperidone palmitate	84,146	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	79	0.1%	-0.105	-0.039
Haloperidol decanoate	0	0.0%	62,754	100.0%	NaN	NaN
IS Stay	9,098	10.8%	6,768	10.8%	0.027	0.001
Medical Product Use						
Mean number of filled prescriptions	29.0	27.4	29.8	27.3	-0.749	-0.027
Mean number of generics dispensed	9.4	6.3	9.5	6.2	-0.081	-0.013
Mean number of unique drug classes dispensed	8.4	5.5	8.3	5.3	0.148	0.027
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.3	16.0	20.0	-0.069	-0.004
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.000	-0.000
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.003	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1an. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,437	100.0%	11,314	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.4	3.6	-0.265	-0.072
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,437	100.0%	11,314	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,698	29.9%	3,180	28.1%	1.746	0.038
Male	15,739	70.1%	8,134	71.9%	-1.746	-0.038
Race[2]						
American Indian or Alaska Native	324	1.4%	161	1.4%	0.021	0.002
Asian	535	2.4%	246	2.2%	0.210	0.014
Black or African American	6,610	29.5%	4,828	42.7%	-13.213	-0.278
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,591	16.0%	1,626	14.4%	1.633	0.046
White	11,377	50.7%	4,453	39.4%	11.348	0.230
Hispanic origin						
Yes	1,846	8.2%	954	8.4%	-0.205	-0.007
No	18,846	84.0%	9,688	85.6%	-1.633	-0.046
Unknown	1,745	7.8%	672	5.9%	1.838	0.073

Table 1an. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	703	3.1%	858	7.6%	-4.450	-0.199
2011	1,756	7.8%	1,627	14.4%	-6.554	-0.210
2012	2,080	9.3%	1,367	12.1%	-2.812	-0.091
2013	2,095	9.3%	1,286	11.4%	-2.029	-0.067
2014	1,964	8.8%	1,084	9.6%	-0.828	-0.029
2015	1,994	8.9%	929	8.2%	0.676	0.024
2016	2,031	9.1%	884	7.8%	1.239	0.045
2017	2,105	9.4%	745	6.6%	2.797	0.103
2018	2,080	9.3%	654	5.8%	3.490	0.133
2019	1,878	8.4%	633	5.6%	2.775	0.109
2020	1,524	6.8%	531	4.7%	2.099	0.090
2021	1,511	6.7%	491	4.3%	2.395	0.105
2022	716	3.2%	225	2.0%	1.202	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.6	1.3	0.013	0.010
Substance abuse	9,579	42.7%	4,926	43.5%	-0.846	-0.017
Atrial fibrilation/flutter	61	0.3%	36	0.3%	-0.046	-0.009
Ischemic heart disease	304	1.4%	204	1.8%	-0.448	-0.036
Heart failure	158	0.7%	119	1.1%	-0.348	-0.037
Stroke	121	0.5%	65	0.6%	-0.035	-0.005
Diabetes	2,227	9.9%	1,349	11.9%	-1.998	-0.064
Hypertension	5,022	22.4%	2,936	26.0%	-3.567	-0.083
Rheumatic disease	38	0.2%	19	0.2%	0.001	0.000
Chronic kidney disease	888	4.0%	468	4.1%	-0.179	-0.009
Seizure disorder	2,021	9.0%	1,068	9.4%	-0.432	-0.015

Table 1an. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	48	0.20%	21	0.2%	0.028	0.006
Dementia Diagnosis	688	3.1%	361	3.2%	-0.124	-0.007
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.004	-0.002
Parkinsons disease	58	0.3%	40	0.4%	-0.095	-0.017
COPD	1,108	4.9%	619	5.5%	-0.533	-0.024
Malignancy	462	2.1%	237	2.1%	-0.036	-0.002
Asthma	3,313	14.8%	1,588	14.0%	0.730	0.021
Hyperlipidemia	3,676	16.4%	1,907	16.9%	-0.472	-0.013
Depression	9,690	43.2%	4,366	38.6%	4.598	0.094
Schizophrenia	17,654	78.7%	9,426	83.3%	-4.630	-0.118
Bipolar disorder	10,731	47.8%	4,920	43.5%	4.341	0.087
ACE inhibitor use	1,263	5.6%	719	6.4%	-0.726	-0.031
ARB use	208	0.9%	107	0.9%	-0.019	-0.002
Beta-blocker use	2,690	12.0%	1,307	11.6%	0.437	0.014
Oral anticoagulant use	146	0.7%	51	0.5%	0.200	0.027
Antiplatelet agent use	22	0.1%	*****	*****	0.027	0.009
Opioid use	3,121	13.9%	1,380	12.2%	1.713	0.051
Statin use	1,428	6.4%	726	6.4%	-0.052	-0.002
Wheelchair or walker use	*****	*****	*****	*****	-0.031	-0.018
Anti-arrhythmic use	19	0.1%	*****	*****	0.040	0.016
Antidiabetic use	1,656	7.4%	826	7.3%	0.080	0.003
Calcium channel blocker use	706	3.1%	463	4.1%	-0.946	-0.051
Diuretic use	1,048	4.7%	541	4.8%	-0.111	-0.005
Antidepressant use	12,135	54.1%	5,378	47.5%	6.551	0.131
Gastric acid suppressant use	3,880	17.3%	1,822	16.1%	1.189	0.032
NSAIDs	3,971	17.7%	1,800	15.9%	1.789	0.048

Table 1an. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,084	27.1%	2,826	25.0%	2.138	0.049
Chronic liver disease	854	3.8%	429	3.8%	0.014	0.001
Pneumonia	396	1.8%	215	1.9%	-0.135	-0.010
Cardiac arrhythmia	3,012	13.4%	1,404	12.4%	1.015	0.030
Paliperidone palmitate	22,437	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.084	-0.031
Haloperidol decanoate	0	0.0%	11,314	100.0%	NaN	NaN
IS Stay	2,030	9.0%	1,243	11.0%	-1.939	-0.065
Medical Product Use						
Mean number of filled prescriptions	20.5	21.2	19.9	20.4	0.592	0.028
Mean number of generics dispensed	7.5	5.5	7.3	5.2	0.183	0.034
Mean number of unique drug classes dispensed	6.7	4.8	6.3	4.4	0.384	0.083
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.7	18.3	0.039	0.002
Mean number of inpatient hospital encounters	0.4	0.8	0.4	1.0	-0.052	-0.058
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.122	-0.098

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ao. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,429	100.0%	11,314	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.4	3.6	-0.265	-0.072
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,429	100.0%	11,314	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,692	29.8%	3,180	28.1%	1.730	0.038
Male	15,737	70.2%	8,134	71.9%	-1.730	-0.038
Race[2]						
American Indian or Alaska Native	324	1.4%	161	1.4%	0.022	0.002
Asian	535	2.4%	246	2.2%	0.211	0.014
Black or African American	6,607	29.5%	4,828	42.7%	-13.215	-0.278
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,591	16.0%	1,626	14.4%	1.639	0.046
White	11,372	50.7%	4,453	39.4%	11.344	0.230
Hispanic origin						
Yes	1,846	8.2%	954	8.4%	-0.202	-0.007
No	18,838	84.0%	9,688	85.6%	-1.639	-0.046
Unknown	1,745	7.8%	672	5.9%	1.841	0.073

Table 1ao. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	703	3.1%	858	7.6%	-4.449	-0.199
2011	1,754	7.8%	1,627	14.4%	-6.560	-0.210
2012	2,079	9.3%	1,367	12.1%	-2.813	-0.091
2013	2,095	9.3%	1,286	11.4%	-2.026	-0.067
2014	1,963	8.8%	1,084	9.6%	-0.829	-0.029
2015	1,994	8.9%	929	8.2%	0.679	0.024
2016	2,030	9.1%	884	7.8%	1.237	0.045
2017	2,104	9.4%	745	6.6%	2.796	0.103
2018	2,079	9.3%	654	5.8%	3.489	0.133
2019	1,878	8.4%	633	5.6%	2.778	0.109
2020	1,524	6.8%	531	4.7%	2.101	0.090
2021	1,511	6.7%	491	4.3%	2.397	0.105
2022	715	3.2%	225	2.0%	1.199	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.6	1.3	0.012	0.009
Substance abuse	9,576	42.7%	4,926	43.5%	-0.844	-0.017
Atrial fibrilation/flutter	61	0.3%	36	0.3%	-0.046	-0.009
Ischemic heart disease	303	1.4%	204	1.8%	-0.452	-0.036
Heart failure	156	0.7%	119	1.1%	-0.356	-0.038
Stroke	121	0.5%	65	0.6%	-0.035	-0.005
Diabetes	2,225	9.9%	1,349	11.9%	-2.003	-0.064
Hypertension	5,020	22.4%	2,936	26.0%	-3.568	-0.083
Rheumatic disease	38	0.2%	19	0.2%	0.001	0.000
Chronic kidney disease	887	4.0%	468	4.1%	-0.182	-0.009
Seizure disorder	2,019	9.0%	1,068	9.4%	-0.438	-0.015

Table 1ao. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	48	0.2%	21	0.2%	0.028	0.006
Dementia Diagnosis	688	3.1%	361	3.2%	-0.123	-0.007
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.004	-0.002
Parkinsons disease	58	0.3%	40	0.4%	-0.095	-0.017
COPD	1,107	4.9%	619	5.5%	-0.536	-0.024
Malignancy	461	2.1%	237	2.1%	-0.039	-0.003
Asthma	3,309	14.8%	1,588	14.0%	0.718	0.020
Hyperlipidemia	3,674	16.4%	1,907	16.9%	-0.475	-0.013
Depression	9,682	43.2%	4,366	38.6%	4.578	0.093
Schizophrenia	17,651	78.7%	9,426	83.3%	-4.615	-0.118
Bipolar disorder	10,723	47.8%	4,920	43.5%	4.323	0.087
ACE inhibitor use	1,262	5.6%	719	6.4%	-0.728	-0.031
ARB use	208	0.9%	107	0.9%	-0.018	-0.002
Beta-blocker use	2,688	12.0%	1,307	11.6%	0.432	0.013
Oral anticoagulant use	144	0.6%	51	0.5%	0.191	0.026
Antiplatelet agent use	21	0.1%	*****	*****	0.023	0.008
Opioid use	3,116	13.9%	1,380	12.2%	1.695	0.050
Statin use	1,428	6.4%	726	6.4%	-0.050	-0.002
Wheelchair or walker use	*****	*****	*****	*****	-0.031	-0.018
Anti-arrhythmic use	15	0.1%	*****	*****	0.023	0.010
Antidiabetic use	1,653	7.4%	826	7.3%	0.069	0.003
Calcium channel blocker use	703	3.1%	463	4.1%	-0.958	-0.051
Diuretic use	1,044	4.7%	541	4.8%	-0.127	-0.006
Antidepressant use	12,130	54.1%	5,378	47.5%	6.548	0.131
Gastric acid suppressant use	3,878	17.3%	1,822	16.1%	1.186	0.032
NSAIDs	3,966	17.7%	1,800	15.9%	1.773	0.047

Table 1ao. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,078	27.1%	2,826	25.0%	2.121	0.048
Chronic liver disease	853	3.8%	429	3.8%	0.011	0.001
Pneumonia	396	1.8%	215	1.9%	-0.135	-0.010
Cardiac arrhythmia	3,008	13.4%	1,404	12.4%	1.002	0.030
Paliperidone palmitate	22,429	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.084	-0.031
Haloperidol decanoate	0	0.0%	11,314	100.0%	NaN	NaN
IS Stay	2,029	9.0%	1,243	11.0%	-1.940	-0.065
Medical Product Use						
Mean number of filled prescriptions	20.5	21.2	19.9	20.4	0.580	0.028
Mean number of generics dispensed	7.5	5.5	7.3	5.2	0.178	0.033
Mean number of unique drug classes dispensed	6.7	4.8	6.3	4.4	0.380	0.082
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.7	18.3	0.031	0.002
Mean number of inpatient hospital encounters	0.3	0.8	0.4	1.0	-0.053	-0.059
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.123	-0.099

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ap. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	22,430	N/A	11,309	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.3	3.7	29.3	3.7	-0.002	-0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	22,430	100.0%	11,309	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,558	29.2%	3,301	29.2%	0.050	0.001
Male	15,873	70.8%	8,009	70.8%	-0.050	-0.001
Race[3]						
American Indian or Alaska Native	322	1.4%	166	1.5%	-0.031	-0.003
Asian	545	2.4%	238	2.1%	0.329	0.022
Black or African American	6,785	30.2%	4,657	41.2%	-10.931	-0.230
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,589	16.0%	1,624	14.4%	1.636	0.046
White	11,190	49.9%	4,624	40.9%	8.998	0.181
Hispanic origin						
Yes	1,862	8.3%	949	8.4%	-0.091	-0.003
No	18,842	84.0%	9,685	85.6%	-1.636	-0.046
Unknown	1,727	7.7%	675	6.0%	1.727	0.068

Table 1ap. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	709	3.2%	837	7.4%	-4.237	-0.190
2011	1,762	7.9%	1,597	14.1%	-6.270	-0.201
2012	2,097	9.3%	1,334	11.8%	-2.442	-0.079
2013	2,094	9.3%	1,285	11.4%	-2.028	-0.067
2014	1,969	8.8%	1,096	9.7%	-0.918	-0.032
2015	1,993	8.9%	932	8.2%	0.646	0.023
2016	2,018	9.0%	893	7.9%	1.103	0.040
2017	2,094	9.3%	751	6.6%	2.689	0.099
2018	2,082	9.3%	670	5.9%	3.356	0.127
2019	1,868	8.3%	642	5.7%	2.654	0.104
2020	1,526	6.8%	539	4.8%	2.037	0.087
2021	1,503	6.7%	507	4.5%	2.217	0.097
2022	717	3.2%	226	2.0%	1.193	0.075
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.6	1.3	1.6	1.3	-0.004	-0.003
Substance abuse	9,642	43.0%	4,871	43.1%	-0.086	-0.002
Atrial fibrilation/flutter	65	0.3%	34	0.3%	-0.011	-0.002
Ischemic heart disease	335	1.5%	172	1.5%	-0.025	-0.002
Heart failure	180	0.8%	92	0.8%	-0.009	-0.001
Stroke	124	0.6%	62	0.5%	0.005	0.001
Diabetes	2,370	10.6%	1,198	10.6%	-0.028	-0.001
Hypertension	5,291	23.6%	2,675	23.7%	-0.064	-0.002
Rheumatic disease	38	0.2%	18	0.2%	0.006	0.001
Chronic kidney disease	909	4.1%	466	4.1%	-0.073	-0.004
Seizure disorder	2,054	9.2%	1,041	9.2%	-0.044	-0.002

Table 1ap. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	47	0.2%	25	0.2%	-0.011	-0.002
Dementia Diagnosis	701	3.1%	358	3.2%	-0.045	-0.003
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.004	-0.002
Parkinsons disease	66	0.3%	34	0.3%	-0.002	-0.000
COPD	1,147	5.1%	580	5.1%	-0.016	-0.001
Malignancy	464	2.1%	236	2.1%	-0.016	-0.001
Asthma	3,260	14.5%	1,657	14.6%	-0.113	-0.003
Hyperlipidemia	3,709	16.5%	1,881	16.6%	-0.100	-0.003
Depression	9,347	41.7%	4,711	41.7%	0.015	0.000
Schizophrenia	18,006	80.3%	9,094	80.4%	-0.132	-0.003
Bipolar disorder	10,398	46.4%	5,236	46.3%	0.064	0.001
ACE inhibitor use	1,315	5.9%	667	5.9%	-0.032	-0.001
ARB use	210	0.9%	107	0.9%	-0.004	-0.000
Beta-blocker use	2,653	11.8%	1,336	11.8%	0.012	0.000
Oral anticoagulant use	129	0.6%	64	0.6%	0.004	0.001
Antiplatelet agent use	19	0.1%	11	0.1%	-0.011	-0.004
Opioid use	2,990	13.3%	1,506	13.3%	0.012	0.000
Statin use	1,431	6.4%	728	6.4%	-0.060	-0.002
Wheelchair or walker use	*****	*****	*****	*****	0.000	0.000
Anti-arrhythmic use	13	0.1%	*****	*****	-0.000	-0.000
Antidiabetic use	1,645	7.3%	833	7.4%	-0.031	-0.001
Calcium channel blocker use	774	3.4%	389	3.4%	0.006	0.000
Diuretic use	1,047	4.7%	523	4.6%	0.047	0.002
Antidepressant use	11,644	51.9%	5,873	51.9%	-0.018	-0.000
Gastric acid suppressant use	3,787	16.9%	1,904	16.8%	0.046	0.001
NSAIDs	3,829	17.1%	1,926	17.0%	0.039	0.001

Table 1ap. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,924	26.4%	2,998	26.5%	-0.101	-0.002
Chronic liver disease	852	3.8%	433	3.8%	-0.026	-0.001
Pneumonia	405	1.8%	206	1.8%	-0.020	-0.002
Cardiac arrhythmia	2,941	13.1%	1,494	13.2%	-0.103	-0.003
Paliperidone palmitate	22,430	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.081	-0.030
Haloperidol decanoate	0	0.0%	11,309	100.0%	NaN	NaN
IS Stay	2,175	9.7%	1,097	9.7%	-0.000	-0.000
Medical Product Use						
Mean number of filled prescriptions	20.0	21.0	20.8	21.1	-0.769	-0.037
Mean number of generics dispensed	7.4	5.5	7.6	5.3	-0.182	-0.034
Mean number of unique drug classes dispensed	6.6	4.8	6.5	4.5	0.046	0.010
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.8	18.5	-0.038	-0.002
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.9	1.3	0.9	1.2	-0.005	-0.004

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1aq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,608	100.0%	10,933	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.181	-0.063
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,608	100.0%	10,933	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,254	37.0%	3,819	34.9%	2.064	0.043
Male	12,354	63.0%	7,114	65.1%	-2.064	-0.043
Race[2]						
American Indian or Alaska Native	275	1.4%	107	1.0%	0.424	0.039
Asian	495	2.5%	339	3.1%	-0.576	-0.035
Black or African American	4,980	25.4%	4,250	38.9%	-13.475	-0.292
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,441	7.3%	885	8.1%	-0.746	-0.028
White	12,417	63.3%	5,352	49.0%	14.373	0.293
Hispanic origin						
Yes	1,049	5.3%	677	6.2%	-0.842	-0.036
No	18,167	92.7%	10,048	91.9%	0.746	0.028
Unknown	392	2.0%	208	1.9%	0.097	0.007

Table 1aq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	566	2.9%	988	9.0%	-6.150	-0.262
2011	1,411	7.2%	1,667	15.2%	-8.051	-0.257
2012	1,717	8.8%	1,351	12.4%	-3.600	-0.117
2013	1,768	9.0%	1,246	11.4%	-2.380	-0.079
2014	1,689	8.6%	984	9.0%	-0.386	-0.014
2015	1,780	9.1%	855	7.8%	1.258	0.045
2016	1,846	9.4%	793	7.3%	2.161	0.078
2017	1,895	9.7%	748	6.8%	2.823	0.103
2018	1,935	9.9%	660	6.0%	3.832	0.142
2019	1,803	9.2%	556	5.1%	4.110	0.160
2020	1,381	7.0%	452	4.1%	2.909	0.127
2021	1,248	6.4%	429	3.9%	2.441	0.111
2022	569	2.9%	204	1.9%	1.036	0.068
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.6	0.057	0.036
Substance abuse	7,902	40.3%	3,939	36.0%	4.271	0.088
Atrial fibrilation/flutter	117	0.6%	83	0.8%	-0.162	-0.020
Ischemic heart disease	661	3.4%	477	4.4%	-0.992	-0.051
Heart failure	333	1.7%	239	2.2%	-0.488	-0.035
Stroke	232	1.2%	148	1.4%	-0.171	-0.015
Diabetes	3,812	19.4%	2,353	21.5%	-2.081	-0.052
Hypertension	7,241	36.9%	4,265	39.0%	-2.082	-0.043
Rheumatic disease	57	0.3%	34	0.3%	-0.020	-0.004
Chronic kidney disease	1,490	7.6%	714	6.5%	1.068	0.042
Seizure disorder	2,123	10.8%	1,153	10.5%	0.281	0.009

Table 1aq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	52	0.5%	-0.001	-0.000
Dementia Diagnosis	725	3.7%	406	3.7%	-0.016	-0.001
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.053	-0.015
Parkinsons disease	96	0.5%	56	0.5%	-0.023	-0.003
COPD	1,969	10.0%	1,122	10.3%	-0.221	-0.007
Malignancy	468	2.4%	235	2.1%	0.237	0.016
Asthma	2,845	14.5%	1,430	13.1%	1.430	0.041
Hyperlipidemia	5,700	29.1%	3,095	28.3%	0.761	0.017
Depression	8,927	45.5%	4,260	39.0%	6.563	0.133
Schizophrenia	15,692	80.0%	9,245	84.6%	-4.532	-0.119
Bipolar disorder	9,532	48.6%	4,498	41.1%	7.471	0.151
ACE inhibitor use	2,541	13.0%	1,487	13.6%	-0.642	-0.019
ARB use	503	2.6%	292	2.7%	-0.106	-0.007
Beta-blocker use	3,212	16.4%	1,705	15.6%	0.786	0.021
Oral anticoagulant use	234	1.2%	121	1.1%	0.087	0.008
Antiplatelet agent use	80	0.4%	*****	*****	-0.196	-0.028
Opioid use	3,862	19.7%	1,811	16.6%	3.132	0.081
Statin use	3,154	16.1%	1,743	15.9%	0.143	0.004
Wheelchair or walker use	*****	*****	*****	*****	-0.046	-0.017
Anti-arrhythmic use	35	0.2%	*****	*****	0.050	0.013
Antidiabetic use	2,697	13.8%	1,570	14.4%	-0.606	-0.017
Calcium channel blocker use	1,300	6.6%	898	8.2%	-1.584	-0.060
Diuretic use	2,007	10.2%	1,251	11.4%	-1.207	-0.039
Antidepressant use	11,516	58.7%	5,458	49.9%	8.809	0.178
Gastric acid suppressant use	4,839	24.7%	2,450	22.4%	2.269	0.054
NSAIDs	4,379	22.3%	2,105	19.3%	3.079	0.076

Table 1aq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,609	33.7%	3,020	27.6%	6.083	0.132
Chronic liver disease	1,174	6.0%	565	5.2%	0.820	0.036
Pneumonia	581	3.0%	322	2.9%	0.018	0.001
Cardiac arrhythmia	2,508	12.8%	1,336	12.2%	0.571	0.017
Paliperidone palmitate	19,608	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	12	0.1%	-0.094	-0.038
Haloperidol decanoate	0	0.0%	10,933	100.0%	NaN	NaN
IS Stay	1,785	9.1%	1,116	10.2%	-1.104	-0.037
Medical Product Use						
Mean number of filled prescriptions	26.9	25.4	25.0	24.1	1.896	0.077
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.628	0.102
Mean number of unique drug classes dispensed	8.1	5.5	7.3	5.1	0.758	0.143
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.2	18.3	15.6	19.0	0.644	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.034	-0.036
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.3	-0.085	-0.070

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ar. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,607	100.0%	10,931	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.181	-0.063
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,607	100.0%	10,931	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,254	37.0%	3,818	34.9%	2.069	0.043
Male	12,353	63.0%	7,113	65.1%	-2.069	-0.043
Race[2]						
American Indian or Alaska Native	275	1.4%	107	1.0%	0.424	0.039
Asian	495	2.5%	339	3.1%	-0.577	-0.035
Black or African American	4,980	25.4%	4,249	38.9%	-13.472	-0.292
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,441	7.3%	885	8.1%	-0.747	-0.028
White	12,416	63.3%	5,351	49.0%	14.372	0.293
Hispanic origin						
Yes	1,049	5.4%	677	6.2%	-0.843	-0.036
No	18,166	92.7%	10,046	91.9%	0.747	0.028
Unknown	392	2.0%	208	1.9%	0.096	0.007

Table 1ar. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	566	2.9%	988	9.0%	-6.152	-0.262
2011	1,411	7.2%	1,667	15.3%	-8.054	-0.257
2012	1,717	8.8%	1,350	12.4%	-3.593	-0.117
2013	1,768	9.0%	1,246	11.4%	-2.382	-0.079
2014	1,689	8.6%	983	9.0%	-0.379	-0.013
2015	1,780	9.1%	855	7.8%	1.257	0.045
2016	1,846	9.4%	793	7.3%	2.160	0.078
2017	1,895	9.7%	748	6.8%	2.822	0.103
2018	1,935	9.9%	660	6.0%	3.831	0.142
2019	1,803	9.2%	556	5.1%	4.109	0.160
2020	1,381	7.0%	452	4.1%	2.908	0.127
2021	1,248	6.4%	429	3.9%	2.440	0.111
2022	568	2.9%	204	1.9%	1.031	0.068
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.6	0.057	0.037
Substance abuse	7,901	40.3%	3,937	36.0%	4.280	0.088
Atrial fibrilation/flutter	117	0.6%	83	0.8%	-0.163	-0.020
Ischemic heart disease	661	3.4%	476	4.4%	-0.983	-0.051
Heart failure	333	1.7%	238	2.2%	-0.479	-0.035
Stroke	232	1.2%	148	1.4%	-0.171	-0.015
Diabetes	3,812	19.4%	2,353	21.5%	-2.084	-0.052
Hypertension	7,240	36.9%	4,263	39.0%	-2.074	-0.043
Rheumatic disease	57	0.3%	34	0.3%	-0.020	-0.004
Chronic kidney disease	1,489	7.6%	713	6.5%	1.071	0.042
Seizure disorder	2,123	10.8%	1,152	10.5%	0.289	0.009

Table 1ar. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	52	0.5%	-0.001	-0.000
Dementia Diagnosis	725	3.7%	406	3.7%	-0.017	-0.001
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.054	-0.015
Parkinsons disease	96	0.5%	56	0.5%	-0.023	-0.003
COPD	1,969	10.0%	1,121	10.3%	-0.213	-0.007
Malignancy	468	2.4%	234	2.1%	0.246	0.017
Asthma	2,845	14.5%	1,429	13.1%	1.437	0.042
Hyperlipidemia	5,699	29.1%	3,093	28.3%	0.770	0.017
Depression	8,926	45.5%	4,258	39.0%	6.571	0.133
Schizophrenia	15,691	80.0%	9,244	84.6%	-4.539	-0.119
Bipolar disorder	9,531	48.6%	4,496	41.1%	7.479	0.151
ACE inhibitor use	2,540	13.0%	1,487	13.6%	-0.649	-0.019
ARB use	503	2.6%	292	2.7%	-0.106	-0.007
Beta-blocker use	3,211	16.4%	1,705	15.6%	0.779	0.021
Oral anticoagulant use	234	1.2%	121	1.1%	0.087	0.008
Antiplatelet agent use	80	0.4%	*****	*****	-0.196	-0.028
Opioid use	3,861	19.7%	1,809	16.5%	3.143	0.082
Statin use	3,154	16.1%	1,742	15.9%	0.150	0.004
Wheelchair or walker use	*****	*****	*****	*****	-0.046	-0.017
Anti-arrhythmic use	35	0.2%	*****	*****	0.050	0.013
Antidiabetic use	2,697	13.8%	1,570	14.4%	-0.608	-0.017
Calcium channel blocker use	1,300	6.6%	898	8.2%	-1.585	-0.060
Diuretic use	2,007	10.2%	1,250	11.4%	-1.199	-0.039
Antidepressant use	11,515	58.7%	5,456	49.9%	8.816	0.178
Gastric acid suppressant use	4,838	24.7%	2,449	22.4%	2.271	0.054
NSAIDs	4,378	22.3%	2,104	19.2%	3.081	0.076

Table 1ar. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,608	33.7%	3,019	27.6%	6.084	0.132
Chronic liver disease	1,174	6.0%	565	5.2%	0.819	0.036
Pneumonia	580	3.0%	321	2.9%	0.022	0.001
Cardiac arrhythmia	2,508	12.8%	1,335	12.2%	0.578	0.017
Paliperidone palmitate	19,607	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	12	0.1%	-0.094	-0.038
Haloperidol decanoate	0	0.0%	10,931	100.0%	NaN	NaN
IS Stay	1,785	9.1%	1,116	10.2%	-1.106	-0.037
Medical Product Use						
Mean number of filled prescriptions	26.9	25.4	25.0	24.1	1.897	0.077
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.628	0.102
Mean number of unique drug classes dispensed	8.1	5.5	7.3	5.1	0.759	0.143
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.2	18.3	15.6	19.0	0.647	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.033	-0.034
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.3	-0.084	-0.069

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1as. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,611	N/A	10,927	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.9	2.9	39.9	2.9	0.003	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,611	100.0%	10,927	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,106	36.2%	3,948	36.1%	0.103	0.002
Male	12,505	63.8%	6,979	63.9%	-0.103	-0.002
Race[3]						
American Indian or Alaska Native	271	1.4%	114	1.0%	0.342	0.031
Asian	510	2.6%	325	3.0%	-0.369	-0.022
Black or African American	5,212	26.6%	3,967	36.3%	-9.726	-0.211
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,448	7.4%	890	8.1%	-0.765	-0.029
White	12,169	62.1%	5,632	51.5%	10.517	0.214
Hispanic origin						
Yes	1,052	5.4%	686	6.3%	-0.914	-0.039
No	18,163	92.6%	10,037	91.9%	0.765	0.029
Unknown	396	2.0%	204	1.9%	0.149	0.011

Table 1as. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	583	3.0%	941	8.6%	-5.634	-0.243
2011	1,446	7.4%	1,586	14.5%	-7.140	-0.230
2012	1,763	9.0%	1,297	11.9%	-2.880	-0.094
2013	1,775	9.1%	1,242	11.4%	-2.314	-0.076
2014	1,675	8.5%	1,006	9.2%	-0.664	-0.023
2015	1,761	9.0%	886	8.1%	0.874	0.031
2016	1,823	9.3%	828	7.6%	1.713	0.062
2017	1,877	9.6%	769	7.0%	2.534	0.092
2018	1,926	9.8%	676	6.2%	3.628	0.134
2019	1,781	9.1%	581	5.3%	3.763	0.146
2020	1,384	7.1%	466	4.3%	2.795	0.121
2021	1,249	6.4%	443	4.1%	2.314	0.104
2022	567	2.9%	205	1.9%	1.012	0.066
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.8	1.5	1.8	1.6	-0.007	-0.004
Substance abuse	7,611	38.8%	4,257	39.0%	-0.150	-0.003
Atrial fibrilation/flutter	129	0.7%	73	0.7%	-0.008	-0.001
Ischemic heart disease	729	3.7%	404	3.7%	0.017	0.001
Heart failure	370	1.9%	207	1.9%	-0.009	-0.001
Stroke	244	1.2%	136	1.2%	0.004	0.000
Diabetes	3,954	20.2%	2,193	20.1%	0.099	0.002
Hypertension	7,383	37.7%	4,110	37.6%	0.036	0.001
Rheumatic disease	58	0.3%	32	0.3%	0.005	0.001
Chronic kidney disease	1,416	7.2%	785	7.2%	0.039	0.002
Seizure disorder	2,102	10.7%	1,170	10.7%	0.013	0.000

Table 1as. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	51	0.5%	0.003	0.000
Dementia Diagnosis	731	3.7%	415	3.8%	-0.073	-0.004
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.000	0.000
Parkinsons disease	98	0.5%	55	0.5%	-0.005	-0.001
COPD	1,983	10.1%	1,101	10.1%	0.032	0.001
Malignancy	449	2.3%	251	2.3%	-0.011	-0.001
Asthma	2,745	14.0%	1,532	14.0%	-0.026	-0.001
Hyperlipidemia	5,645	28.8%	3,140	28.7%	0.044	0.001
Depression	8,463	43.2%	4,711	43.1%	0.041	0.001
Schizophrenia	16,025	81.7%	8,959	82.0%	-0.269	-0.007
Bipolar disorder	9,011	46.0%	5,021	46.0%	-0.001	-0.000
ACE inhibitor use	2,577	13.1%	1,429	13.1%	0.067	0.002
ARB use	508	2.6%	279	2.5%	0.039	0.002
Beta-blocker use	3,157	16.1%	1,764	16.1%	-0.045	-0.001
Oral anticoagulant use	231	1.2%	133	1.2%	-0.036	-0.003
Antiplatelet agent use	95	0.5%	*****	*****	0.003	0.000
Opioid use	3,638	18.6%	2,026	18.5%	0.012	0.000
Statin use	3,139	16.0%	1,742	15.9%	0.064	0.002
Wheelchair or walker use	12	0.1%	*****	*****	0.001	0.000
Anti-arrhythmic use	32	0.2%	*****	*****	-0.006	-0.001
Antidiabetic use	2,733	13.9%	1,515	13.9%	0.070	0.002
Calcium channel blocker use	1,409	7.2%	781	7.1%	0.039	0.002
Diuretic use	2,094	10.7%	1,168	10.7%	-0.011	-0.000
Antidepressant use	10,899	55.6%	6,074	55.6%	-0.008	-0.000
Gastric acid suppressant use	4,678	23.9%	2,602	23.8%	0.047	0.001
NSAIDs	4,156	21.2%	2,308	21.1%	0.068	0.002

Table 1as. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,186	31.5%	3,461	31.7%	-0.124	-0.003
Chronic liver disease	1,122	5.7%	628	5.8%	-0.029	-0.001
Pneumonia	582	3.0%	325	3.0%	-0.009	-0.001
Cardiac arrhythmia	2,476	12.6%	1,398	12.8%	-0.167	-0.005
Paliperidone palmitate	19,611	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.107	-0.041
Haloperidol decanoate	0	0.0%	10,927	100.0%	NaN	NaN
IS Stay	1,867	9.5%	1,041	9.5%	-0.006	-0.000
Medical Product Use						
Mean number of filled prescriptions	26.1	25.2	26.4	24.6	-0.255	-0.010
Mean number of generics dispensed	8.8	6.3	8.9	6.1	-0.038	-0.006
Mean number of unique drug classes dispensed	7.8	5.4	7.7	5.2	0.157	0.030
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	18.2	16.0	19.3	-0.024	-0.001
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.002	-0.002
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.002	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1at. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,386	100.0%	13,894	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.9	-0.166	-0.058
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,386	100.0%	13,894	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,346	43.1%	5,356	38.5%	4.503	0.092
Male	11,040	56.9%	8,538	61.5%	-4.503	-0.092
Race[2]						
American Indian or Alaska Native	211	1.1%	119	0.9%	0.232	0.024
Asian	443	2.3%	280	2.0%	0.270	0.019
Black or African American	4,555	23.5%	5,191	37.4%	-13.865	-0.305
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	976	5.0%	793	5.7%	-0.673	-0.030
White	13,201	68.1%	7,511	54.1%	14.036	0.291
Hispanic origin						
Yes	775	4.0%	633	4.6%	-0.558	-0.028
No	18,410	95.0%	13,101	94.3%	0.673	0.030
Unknown	201	1.0%	160	1.2%	-0.115	-0.011

Table 1at. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	676	3.5%	1,512	10.9%	-7.395	-0.289
2011	1,672	8.6%	2,595	18.7%	-10.052	-0.296
2012	1,934	10.0%	1,968	14.2%	-4.188	-0.129
2013	1,875	9.7%	1,532	11.0%	-1.354	-0.044
2014	1,785	9.2%	1,282	9.2%	-0.019	-0.001
2015	1,869	9.6%	1,108	8.0%	1.666	0.059
2016	1,911	9.9%	893	6.4%	3.430	0.126
2017	1,850	9.5%	768	5.5%	4.015	0.153
2018	1,846	9.5%	675	4.9%	4.664	0.181
2019	1,531	7.9%	566	4.1%	3.824	0.162
2020	1,063	5.5%	439	3.2%	2.324	0.114
2021	954	4.9%	388	2.8%	2.129	0.111
2022	420	2.2%	168	1.2%	0.957	0.074
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.0	2.0	0.046	0.024
Substance abuse	6,778	35.0%	3,976	28.6%	6.347	0.137
Atrial fibrilation/flutter	287	1.5%	202	1.5%	0.027	0.002
Ischemic heart disease	1,518	7.8%	1,158	8.3%	-0.504	-0.018
Heart failure	748	3.9%	670	4.8%	-0.964	-0.047
Stroke	441	2.3%	382	2.7%	-0.475	-0.030
Diabetes	5,681	29.3%	4,237	30.5%	-1.191	-0.026
Hypertension	10,195	52.6%	7,295	52.5%	0.085	0.002
Rheumatic disease	100	0.5%	75	0.5%	-0.024	-0.003
Chronic kidney disease	2,271	11.7%	1,462	10.5%	1.192	0.038
Seizure disorder	2,366	12.2%	1,790	12.9%	-0.679	-0.020

Table 1at. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	225	1.2%	176	1.3%	-0.106	-0.010
Dementia Diagnosis	1,033	5.3%	876	6.3%	-0.976	-0.042
Dementia Diagnosis and Treatment	94	0.5%	85	0.6%	-0.127	-0.017
Parkinsons disease	258	1.3%	172	1.2%	0.093	0.008
COPD	3,854	19.9%	2,510	18.1%	1.815	0.046
Malignancy	586	3.0%	403	2.9%	0.122	0.007
Asthma	2,749	14.2%	1,679	12.1%	2.096	0.062
Hyperlipidemia	7,901	40.8%	5,265	37.9%	2.862	0.059
Depression	9,080	46.8%	5,175	37.2%	9.592	0.195
Schizophrenia	15,723	81.1%	11,763	84.7%	-3.558	-0.095
Bipolar disorder	9,065	46.8%	5,187	37.3%	9.428	0.192
ACE inhibitor use	4,101	21.2%	3,089	22.2%	-1.078	-0.026
ARB use	1,007	5.2%	719	5.2%	0.020	0.001
Beta-blocker use	4,030	20.8%	2,829	20.4%	0.427	0.011
Oral anticoagulant use	388	2.0%	264	1.9%	0.101	0.007
Antiplatelet agent use	298	1.5%	214	1.5%	-0.003	-0.000
Opioid use	4,382	22.6%	2,479	17.8%	4.762	0.119
Statin use	5,379	27.7%	3,620	26.1%	1.692	0.038
Wheelchair or walker use	25	0.1%	28	0.2%	-0.073	-0.018
Anti-arrhythmic use	71	0.4%	50	0.4%	0.006	0.001
Antidiabetic use	4,063	21.0%	2,958	21.3%	-0.331	-0.008
Calcium channel blocker use	2,235	11.5%	1,917	13.8%	-2.268	-0.068
Diuretic use	3,378	17.4%	2,519	18.1%	-0.705	-0.018
Antidepressant use	12,031	62.1%	6,870	49.4%	12.614	0.256
Gastric acid suppressant use	6,085	31.4%	3,755	27.0%	4.363	0.096
NSAIDs	4,938	25.5%	2,964	21.3%	4.139	0.098

Table 1at. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,056	36.4%	3,901	28.1%	8.321	0.179
Chronic liver disease	1,509	7.8%	905	6.5%	1.270	0.049
Pneumonia	864	4.5%	632	4.5%	-0.092	-0.004
Cardiac arrhythmia	2,488	12.8%	1,519	10.9%	1.901	0.059
Paliperidone palmitate	19,386	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	22	0.2%	-0.138	-0.046
Haloperidol decanoate	0	0.0%	13,894	100.0%	NaN	NaN
IS Stay	1,809	9.3%	1,415	10.2%	-0.853	-0.029
Medical Product Use						
Mean number of filled prescriptions	32.7	28.1	30.1	26.9	2.667	0.097
Mean number of generics dispensed	10.4	6.5	9.4	6.2	1.010	0.159
Mean number of unique drug classes dispensed	9.3	5.7	8.2	5.3	1.102	0.201
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.6	19.6	16.1	19.9	1.583	0.080
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.1	-0.031	-0.032
Mean number of non-acute institutional encounters	0.8	1.1	0.8	1.2	-0.023	-0.020

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1au. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,376	99.9%	13,892	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.9	-0.164	-0.057
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,376	100.0%	13,892	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,337	43.0%	5,355	38.5%	4.480	0.091
Male	11,039	57.0%	8,537	61.5%	-4.480	-0.091
Race[2]						
American Indian or Alaska Native	211	1.1%	119	0.9%	0.232	0.024
Asian	443	2.3%	280	2.0%	0.271	0.019
Black or African American	4,553	23.5%	5,189	37.4%	-13.854	-0.305
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	976	5.0%	793	5.7%	-0.671	-0.030
White	13,193	68.1%	7,511	54.1%	14.022	0.291
Hispanic origin						
Yes	775	4.0%	633	4.6%	-0.557	-0.028
No	18,400	95.0%	13,099	94.3%	0.671	0.030
Unknown	201	1.0%	160	1.2%	-0.114	-0.011

Table 1au. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	675	3.5%	1,510	10.9%	-7.386	-0.289
2011	1,672	8.6%	2,595	18.7%	-10.051	-0.296
2012	1,933	10.0%	1,968	14.2%	-4.190	-0.129
2013	1,875	9.7%	1,532	11.0%	-1.351	-0.044
2014	1,784	9.2%	1,282	9.2%	-0.021	-0.001
2015	1,868	9.6%	1,108	8.0%	1.665	0.059
2016	1,910	9.9%	893	6.4%	3.429	0.126
2017	1,849	9.5%	768	5.5%	4.014	0.153
2018	1,846	9.5%	675	4.9%	4.668	0.181
2019	1,531	7.9%	566	4.1%	3.827	0.162
2020	1,062	5.5%	439	3.2%	2.321	0.114
2021	952	4.9%	388	2.8%	2.120	0.110
2022	419	2.2%	168	1.2%	0.953	0.074
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.0	2.0	0.045	0.023
Substance abuse	6,769	34.9%	3,974	28.6%	6.329	0.136
Atrial fibrilation/flutter	284	1.5%	202	1.5%	0.012	0.001
Ischemic heart disease	1,518	7.8%	1,157	8.3%	-0.494	-0.018
Heart failure	748	3.9%	669	4.8%	-0.955	-0.047
Stroke	441	2.3%	381	2.7%	-0.467	-0.030
Diabetes	5,679	29.3%	4,236	30.5%	-1.183	-0.026
Hypertension	10,190	52.6%	7,294	52.5%	0.086	0.002
Rheumatic disease	100	0.5%	75	0.5%	-0.024	-0.003
Chronic kidney disease	2,268	11.7%	1,461	10.5%	1.188	0.038
Seizure disorder	2,366	12.2%	1,789	12.9%	-0.667	-0.020

Table 1au. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	225	1.2%	176	1.3%	-0.106	-0.010
Dementia Diagnosis	1,033	5.3%	876	6.3%	-0.974	-0.042
Dementia Diagnosis and Treatment	94	0.5%	85	0.6%	-0.127	-0.017
Parkinsons disease	258	1.3%	172	1.2%	0.093	0.008
COPD	3,850	19.9%	2,509	18.1%	1.809	0.046
Malignancy	586	3.0%	402	2.9%	0.131	0.008
Asthma	2,744	14.2%	1,677	12.1%	2.090	0.062
Hyperlipidemia	7,897	40.8%	5,263	37.9%	2.871	0.059
Depression	9,070	46.8%	5,173	37.2%	9.573	0.195
Schizophrenia	15,720	81.1%	11,762	84.7%	-3.536	-0.094
Bipolar disorder	9,055	46.7%	5,185	37.3%	9.409	0.191
ACE inhibitor use	4,100	21.2%	3,089	22.2%	-1.076	-0.026
ARB use	1,006	5.2%	719	5.2%	0.016	0.001
Beta-blocker use	4,026	20.8%	2,827	20.3%	0.428	0.011
Oral anticoagulant use	387	2.0%	264	1.9%	0.097	0.007
Antiplatelet agent use	298	1.5%	214	1.5%	-0.002	-0.000
Opioid use	4,376	22.6%	2,478	17.8%	4.747	0.118
Statin use	5,375	27.7%	3,618	26.0%	1.697	0.038
Wheelchair or walker use	25	0.1%	28	0.2%	-0.073	-0.018
Anti-arrhythmic use	70	0.4%	50	0.4%	0.001	0.000
Antidiabetic use	4,061	21.0%	2,958	21.3%	-0.334	-0.008
Calcium channel blocker use	2,235	11.5%	1,917	13.8%	-2.264	-0.068
Diuretic use	3,375	17.4%	2,518	18.1%	-0.707	-0.018
Antidepressant use	12,021	62.0%	6,868	49.4%	12.602	0.256
Gastric acid suppressant use	6,078	31.4%	3,753	27.0%	4.353	0.096
NSAIDs	4,931	25.4%	2,962	21.3%	4.127	0.098

Table 1au. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,046	36.4%	3,900	28.1%	8.291	0.178
Chronic liver disease	1,503	7.8%	905	6.5%	1.242	0.048
Pneumonia	863	4.5%	632	4.5%	-0.095	-0.005
Cardiac arrhythmia	2,482	12.8%	1,519	10.9%	1.875	0.058
Paliperidone palmitate	19,376	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	22	0.2%	-0.138	-0.046
Haloperidol decanoate	0	0.0%	13,892	100.0%	NaN	NaN
IS Stay	1,809	9.3%	1,415	10.2%	-0.849	-0.029
Medical Product Use						
Mean number of filled prescriptions	32.7	28.1	30.1	26.9	2.655	0.097
Mean number of generics dispensed	10.4	6.5	9.4	6.2	1.006	0.158
Mean number of unique drug classes dispensed	9.3	5.6	8.2	5.3	1.098	0.201
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.6	19.5	16.1	19.9	1.568	0.079
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.1	-0.030	-0.031
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.022	-0.019

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1av. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,380	N/A	13,893	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.1	2.9	0.006	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,380	100.0%	13,893	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,974	41.1%	5,710	41.1%	0.044	0.001
Male	11,406	58.9%	8,183	58.9%	-0.044	-0.001
Race[3]						
American Indian or Alaska Native	205	1.1%	122	0.9%	0.177	0.018
Asian	469	2.4%	267	1.9%	0.503	0.034
Black or African American	4,805	24.8%	4,798	34.5%	-9.737	-0.214
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	987	5.1%	786	5.7%	-0.570	-0.025
White	12,914	66.6%	7,920	57.0%	9.627	0.199
Hispanic origin						
Yes	783	4.0%	633	4.6%	-0.519	-0.026
No	18,393	94.9%	13,107	94.3%	0.570	0.025
Unknown	204	1.1%	153	1.1%	-0.051	-0.005

Table 1av. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	706	3.6%	1,431	10.3%	-6.659	-0.264
2011	1,736	9.0%	2,446	17.6%	-8.646	-0.257
2012	1,979	10.2%	1,903	13.7%	-3.484	-0.108
2013	1,872	9.7%	1,541	11.1%	-1.434	-0.047
2014	1,778	9.2%	1,318	9.5%	-0.315	-0.011
2015	1,837	9.5%	1,147	8.3%	1.220	0.043
2016	1,880	9.7%	937	6.7%	2.955	0.108
2017	1,824	9.4%	800	5.8%	3.652	0.138
2018	1,828	9.4%	709	5.1%	4.333	0.168
2019	1,507	7.8%	606	4.4%	3.414	0.143
2020	1,064	5.5%	471	3.4%	2.103	0.102
2021	952	4.9%	409	2.9%	1.967	0.101
2022	417	2.2%	175	1.3%	0.893	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.1	1.9	2.1	1.9	-0.006	-0.003
Substance abuse	6,285	32.4%	4,537	32.7%	-0.223	-0.005
Atrial fibrilation/flutter	288	1.5%	208	1.5%	-0.010	-0.001
Ischemic heart disease	1,562	8.1%	1,121	8.1%	-0.009	-0.000
Heart failure	832	4.3%	597	4.3%	-0.003	-0.000
Stroke	488	2.5%	349	2.5%	0.002	0.000
Diabetes	5,777	29.8%	4,149	29.9%	-0.054	-0.001
Hypertension	10,205	52.7%	7,331	52.8%	-0.110	-0.002
Rheumatic disease	100	0.5%	73	0.5%	-0.012	-0.002
Chronic kidney disease	2,183	11.3%	1,579	11.4%	-0.101	-0.003
Seizure disorder	2,427	12.5%	1,739	12.5%	0.006	0.000

Table 1av. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	236	1.2%	172	1.2%	-0.018	-0.002
Dementia Diagnosis	1,129	5.8%	811	5.8%	-0.007	-0.000
Dementia Diagnosis and Treatment	105	0.5%	75	0.5%	0.004	0.001
Parkinsons disease	256	1.3%	187	1.3%	-0.023	-0.002
COPD	3,714	19.2%	2,669	19.2%	-0.048	-0.001
Malignancy	581	3.0%	420	3.0%	-0.025	-0.001
Asthma	2,575	13.3%	1,843	13.3%	0.017	0.000
Hyperlipidemia	7,682	39.6%	5,514	39.7%	-0.051	-0.001
Depression	8,308	42.9%	5,960	42.9%	-0.034	-0.001
Schizophrenia	16,040	82.8%	11,528	83.0%	-0.207	-0.006
Bipolar disorder	8,309	42.9%	5,961	42.9%	-0.032	-0.001
ACE inhibitor use	4,178	21.6%	2,999	21.6%	-0.029	-0.001
ARB use	1,010	5.2%	722	5.2%	0.012	0.001
Beta-blocker use	4,000	20.6%	2,876	20.7%	-0.063	-0.002
Oral anticoagulant use	390	2.0%	285	2.1%	-0.040	-0.003
Antiplatelet agent use	299	1.5%	218	1.6%	-0.026	-0.002
Opioid use	3,993	20.6%	2,865	20.6%	-0.020	-0.000
Statin use	5,239	27.0%	3,750	27.0%	0.040	0.001
Wheelchair or walker use	35	0.2%	24	0.2%	0.010	0.002
Anti-arrhythmic use	71	0.4%	51	0.4%	0.001	0.000
Antidiabetic use	4,086	21.1%	2,940	21.2%	-0.075	-0.002
Calcium channel blocker use	2,416	12.5%	1,730	12.5%	0.015	0.000
Diuretic use	3,420	17.6%	2,436	17.5%	0.110	0.003
Antidepressant use	11,007	56.8%	7,893	56.8%	-0.018	-0.000
Gastric acid suppressant use	5,731	29.6%	4,112	29.6%	-0.027	-0.001
NSAIDs	4,608	23.8%	3,313	23.8%	-0.072	-0.002

Table 1av. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,371	32.9%	4,559	32.8%	0.054	0.001
Chronic liver disease	1,401	7.2%	1,011	7.3%	-0.047	-0.002
Pneumonia	876	4.5%	623	4.5%	0.037	0.002
Cardiac arrhythmia	2,354	12.1%	1,707	12.3%	-0.141	-0.004
Paliperidone palmitate	19,380	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	24	0.2%	-0.151	-0.049
Haloperidol decanoate	0	0.0%	13,893	100.0%	NaN	NaN
IS Stay	1,889	9.7%	1,361	9.8%	-0.051	-0.002
Medical Product Use						
Mean number of filled prescriptions	31.4	27.7	32.0	27.8	-0.644	-0.023
Mean number of generics dispensed	10.0	6.4	10.0	6.4	-0.019	-0.003
Mean number of unique drug classes dispensed	8.9	5.6	8.7	5.5	0.182	0.033
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.0	19.2	17.1	20.7	-0.084	-0.004
Mean number of inpatient hospital encounters	0.4	1.0	0.4	1.0	-0.001	-0.001
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.002	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1aw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,574	100.0%	11,670	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.5	2.8	-0.185	-0.066
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,574	100.0%	11,670	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,831	46.9%	4,906	42.0%	4.832	0.097
Male	7,743	53.1%	6,764	58.0%	-4.832	-0.097
Race[2]						
American Indian or Alaska Native	154	1.1%	73	0.6%	0.431	0.047
Asian	269	1.8%	166	1.4%	0.423	0.033
Black or African American	3,601	24.7%	4,295	36.8%	-12.095	-0.264
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	612	4.2%	561	4.8%	-0.608	-0.029
White	9,938	68.2%	6,575	56.3%	11.849	0.246
Hispanic origin						
Yes	455	3.1%	409	3.5%	-0.383	-0.021
No	13,962	95.8%	11,109	95.2%	0.608	0.029
Unknown	157	1.1%	152	1.3%	-0.225	-0.021

Table 1aw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	373	2.6%	906	7.8%	-5.204	-0.237
2011	883	6.1%	1,812	15.5%	-9.468	-0.309
2012	1,106	7.6%	1,499	12.8%	-5.256	-0.174
2013	1,224	8.4%	1,319	11.3%	-2.904	-0.098
2014	1,253	8.6%	1,034	8.9%	-0.263	-0.009
2015	1,420	9.7%	942	8.1%	1.671	0.059
2016	1,428	9.8%	881	7.5%	2.249	0.080
2017	1,540	10.6%	806	6.9%	3.660	0.130
2018	1,504	10.3%	662	5.7%	4.647	0.172
2019	1,431	9.8%	661	5.7%	4.155	0.156
2020	1,092	7.5%	493	4.2%	3.268	0.140
2021	913	6.3%	460	3.9%	2.323	0.106
2022	407	2.8%	195	1.7%	1.122	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	2.7	2.6	-0.050	-0.020
Substance abuse	3,998	27.4%	2,470	21.2%	6.267	0.147
Atrial fibrilation/flutter	489	3.4%	364	3.1%	0.236	0.013
Ischemic heart disease	2,020	13.9%	1,747	15.0%	-1.110	-0.032
Heart failure	1,067	7.3%	1,072	9.2%	-1.865	-0.068
Stroke	636	4.4%	652	5.6%	-1.223	-0.056
Diabetes	5,268	36.1%	4,410	37.8%	-1.643	-0.034
Hypertension	9,251	63.5%	7,609	65.2%	-1.725	-0.036
Rheumatic disease	127	0.9%	84	0.7%	0.152	0.017
Chronic kidney disease	2,689	18.5%	2,002	17.2%	1.296	0.034
Seizure disorder	1,984	13.6%	1,788	15.3%	-1.708	-0.049

Table 1aw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	573	3.9%	575	4.9%	-0.996	-0.048
Dementia Diagnosis	1,790	12.3%	1,907	16.3%	-4.059	-0.116
Dementia Diagnosis and Treatment	356	2.4%	419	3.6%	-1.148	-0.067
Parkinsons disease	425	2.9%	380	3.3%	-0.340	-0.020
COPD	3,989	27.4%	2,990	25.6%	1.749	0.040
Malignancy	650	4.5%	510	4.4%	0.090	0.004
Asthma	1,781	12.2%	1,233	10.6%	1.655	0.052
Hyperlipidemia	7,002	48.0%	5,333	45.7%	2.346	0.047
Depression	6,620	45.4%	4,411	37.8%	7.626	0.155
Schizophrenia	12,221	83.9%	9,905	84.9%	-1.021	-0.028
Bipolar disorder	6,502	44.6%	4,108	35.2%	9.412	0.193
ACE inhibitor use	3,762	25.8%	3,194	27.4%	-1.556	-0.035
ARB use	1,064	7.3%	878	7.5%	-0.223	-0.009
Beta-blocker use	3,779	25.9%	3,069	26.3%	-0.368	-0.008
Oral anticoagulant use	522	3.6%	352	3.0%	0.565	0.032
Antiplatelet agent use	453	3.1%	432	3.7%	-0.594	-0.033
Opioid use	3,123	21.4%	2,093	17.9%	3.494	0.088
Statin use	5,370	36.8%	4,046	34.7%	2.176	0.045
Wheelchair or walker use	81	0.6%	101	0.9%	-0.310	-0.037
Anti-arrhythmic use	97	0.7%	61	0.5%	0.143	0.019
Antidiabetic use	3,670	25.2%	2,933	25.1%	0.049	0.001
Calcium channel blocker use	2,654	18.2%	2,435	20.9%	-2.655	-0.067
Diuretic use	3,402	23.3%	2,862	24.5%	-1.181	-0.028
Antidepressant use	8,741	60.0%	5,660	48.5%	11.476	0.232
Gastric acid suppressant use	4,981	34.2%	3,611	30.9%	3.235	0.069
NSAIDs	3,484	23.9%	2,294	19.7%	4.248	0.103

Table 1aw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,465	37.5%	3,528	30.2%	7.267	0.154
Chronic liver disease	1,214	8.3%	825	7.1%	1.260	0.047
Pneumonia	957	6.6%	911	7.8%	-1.240	-0.048
Cardiac arrhythmia	2,121	14.6%	1,448	12.4%	2.145	0.063
Paliperidone palmitate	14,574	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	15	0.1%	-0.122	-0.047
Haloperidol decanoate	0	0.0%	11,670	100.0%	NaN	NaN
IS Stay	1,676	11.5%	1,372	11.8%	-0.257	-0.008
Medical Product Use						
Mean number of filled prescriptions	36.3	29.9	34.5	29.8	1.890	0.063
Mean number of generics dispensed	11.0	6.5	10.2	6.3	0.827	0.130
Mean number of unique drug classes dispensed	9.9	5.7	8.9	5.4	0.969	0.175
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.1	20.0	15.8	20.6	2.227	0.110
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.058
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	0.009	0.007

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ax. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,569	100.0%	11,665	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.5	2.8	-0.184	-0.065
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,569	100.0%	11,665	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,827	46.9%	4,904	42.0%	4.819	0.097
Male	7,742	53.1%	6,761	58.0%	-4.819	-0.097
Race[2]						
American Indian or Alaska Native	154	1.1%	73	0.6%	0.431	0.047
Asian	269	1.8%	166	1.4%	0.423	0.033
Black or African American	3,601	24.7%	4,291	36.8%	-12.068	-0.264
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	611	4.2%	561	4.8%	-0.615	-0.030
White	9,934	68.2%	6,574	56.4%	11.829	0.246
Hispanic origin						
Yes	454	3.1%	409	3.5%	-0.390	-0.022
No	13,958	95.8%	11,104	95.2%	0.615	0.030
Unknown	157	1.1%	152	1.3%	-0.225	-0.021

Table 1ax. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	373	2.6%	906	7.8%	-5.207	-0.237
2011	882	6.1%	1,812	15.5%	-9.480	-0.309
2012	1,106	7.6%	1,499	12.9%	-5.259	-0.174
2013	1,224	8.4%	1,318	11.3%	-2.897	-0.097
2014	1,253	8.6%	1,033	8.9%	-0.255	-0.009
2015	1,420	9.7%	942	8.1%	1.671	0.059
2016	1,427	9.8%	881	7.6%	2.242	0.080
2017	1,539	10.6%	805	6.9%	3.663	0.130
2018	1,504	10.3%	661	5.7%	4.657	0.172
2019	1,430	9.8%	661	5.7%	4.149	0.156
2020	1,092	7.5%	493	4.2%	3.269	0.140
2021	912	6.3%	459	3.9%	2.325	0.106
2022	407	2.8%	195	1.7%	1.122	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	2.7	2.6	-0.047	-0.019
Substance abuse	3,993	27.4%	2,468	21.2%	6.250	0.146
Atrial fibrilation/flutter	486	3.3%	363	3.1%	0.224	0.013
Ischemic heart disease	2,019	13.9%	1,743	14.9%	-1.084	-0.031
Heart failure	1,067	7.3%	1,070	9.2%	-1.849	-0.067
Stroke	635	4.4%	650	5.6%	-1.214	-0.056
Diabetes	5,266	36.1%	4,406	37.8%	-1.626	-0.034
Hypertension	9,248	63.5%	7,604	65.2%	-1.709	-0.036
Rheumatic disease	127	0.9%	83	0.7%	0.160	0.018
Chronic kidney disease	2,687	18.4%	1,999	17.1%	1.307	0.034
Seizure disorder	1,984	13.6%	1,785	15.3%	-1.684	-0.048

Table 1ax. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	573	3.9%	575	4.9%	-0.996	-0.048
Dementia Diagnosis	1,790	12.3%	1,904	16.3%	-4.036	-0.115
Dementia Diagnosis and Treatment	356	2.4%	419	3.6%	-1.148	-0.067
Parkinsons disease	425	2.9%	380	3.3%	-0.340	-0.020
COPD	3,987	27.4%	2,987	25.6%	1.760	0.040
Malignancy	650	4.5%	509	4.4%	0.098	0.005
Asthma	1,781	12.2%	1,233	10.6%	1.655	0.052
Hyperlipidemia	6,998	48.0%	5,330	45.7%	2.341	0.047
Depression	6,617	45.4%	4,408	37.8%	7.630	0.155
Schizophrenia	12,217	83.9%	9,900	84.9%	-1.013	-0.028
Bipolar disorder	6,498	44.6%	4,107	35.2%	9.394	0.193
ACE inhibitor use	3,761	25.8%	3,193	27.4%	-1.557	-0.035
ARB use	1,064	7.3%	878	7.5%	-0.224	-0.009
Beta-blocker use	3,775	25.9%	3,066	26.3%	-0.373	-0.008
Oral anticoagulant use	520	3.6%	351	3.0%	0.560	0.031
Antiplatelet agent use	453	3.1%	432	3.7%	-0.594	-0.033
Opioid use	3,121	21.4%	2,091	17.9%	3.497	0.088
Statin use	5,367	36.8%	4,043	34.7%	2.179	0.045
Wheelchair or walker use	81	0.6%	101	0.9%	-0.310	-0.037
Anti-arrhythmic use	95	0.7%	61	0.5%	0.129	0.017
Antidiabetic use	3,668	25.2%	2,931	25.1%	0.050	0.001
Calcium channel blocker use	2,654	18.2%	2,432	20.8%	-2.632	-0.066
Diuretic use	3,400	23.3%	2,859	24.5%	-1.172	-0.027
Antidepressant use	8,736	60.0%	5,659	48.5%	11.450	0.231
Gastric acid suppressant use	4,976	34.2%	3,609	30.9%	3.216	0.069
NSAIDs	3,481	23.9%	2,293	19.7%	4.236	0.103

Table 1ax. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,460	37.5%	3,526	30.2%	7.250	0.154
Chronic liver disease	1,212	8.3%	824	7.1%	1.255	0.047
Pneumonia	957	6.6%	908	7.8%	-1.215	-0.047
Cardiac arrhythmia	2,116	14.5%	1,445	12.4%	2.137	0.063
Paliperidone palmitate	14,569	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	15	0.1%	-0.122	-0.047
Haloperidol decanoate	0	0.0%	11,665	100.0%	NaN	NaN
IS Stay	1,676	11.5%	1,370	11.7%	-0.241	-0.008
Medical Product Use						
Mean number of filled prescriptions	36.3	29.9	34.5	29.8	1.891	0.063
Mean number of generics dispensed	11.0	6.5	10.2	6.3	0.828	0.130
Mean number of unique drug classes dispensed	9.9	5.7	8.9	5.4	0.969	0.175
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.0	20.0	15.8	20.6	2.225	0.110
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.054	-0.056
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	0.011	0.009

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ay. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	14,582	N/A	11,657	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.4	2.8	59.4	2.8	0.006	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,582	100.0%	11,657	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,524	44.7%	5,214	44.7%	0.010	0.000
Male	8,058	55.3%	6,443	55.3%	-0.010	-0.000
Race[3]						
American Indian or Alaska Native	157	1.1%	72	0.6%	0.458	0.050
Asian	277	1.9%	164	1.4%	0.489	0.038
Black or African American	3,808	26.1%	4,047	34.7%	-8.601	-0.188
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	616	4.2%	557	4.8%	-0.552	-0.027
White	9,724	66.7%	6,817	58.5%	8.207	0.170
Hispanic origin						
Yes	455	3.1%	409	3.5%	-0.387	-0.022
No	13,965	95.8%	11,100	95.2%	0.552	0.027
Unknown	161	1.1%	148	1.3%	-0.165	-0.015

Table 1ay. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	387	2.7%	860	7.4%	-4.726	-0.218
2011	912	6.3%	1,732	14.9%	-8.606	-0.283
2012	1,152	7.9%	1,449	12.4%	-4.535	-0.150
2013	1,233	8.5%	1,324	11.4%	-2.903	-0.097
2014	1,260	8.6%	1,049	9.0%	-0.361	-0.013
2015	1,399	9.6%	965	8.3%	1.318	0.046
2016	1,413	9.7%	903	7.7%	1.947	0.069
2017	1,548	10.6%	827	7.1%	3.520	0.124
2018	1,464	10.0%	682	5.9%	4.193	0.155
2019	1,413	9.7%	685	5.9%	3.808	0.143
2020	1,081	7.4%	514	4.4%	3.005	0.128
2021	914	6.3%	466	4.0%	2.266	0.103
2022	406	2.8%	200	1.7%	1.074	0.072
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.6	2.4	2.6	2.5	0.001	0.000
Substance abuse	3,600	24.7%	2,877	24.7%	0.009	0.000
Atrial fibrilation/flutter	473	3.2%	379	3.3%	-0.012	-0.001
Ischemic heart disease	2,098	14.4%	1,676	14.4%	0.006	0.000
Heart failure	1,198	8.2%	960	8.2%	-0.024	-0.001
Stroke	721	4.9%	572	4.9%	0.037	0.002
Diabetes	5,377	36.9%	4,297	36.9%	0.010	0.000
Hypertension	9,385	64.4%	7,503	64.4%	-0.003	-0.000
Rheumatic disease	116	0.8%	92	0.8%	0.009	0.001
Chronic kidney disease	2,602	17.8%	2,075	17.8%	0.042	0.001
Seizure disorder	2,098	14.4%	1,678	14.4%	-0.007	-0.000

Table 1ay. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	642	4.4%	513	4.4%	0.004	0.000
Dementia Diagnosis	2,076	14.2%	1,656	14.2%	0.028	0.001
Dementia Diagnosis and Treatment	435	3.0%	346	3.0%	0.012	0.001
Parkinsons disease	458	3.1%	366	3.1%	0.007	0.000
COPD	3,883	26.6%	3,101	26.6%	0.022	0.000
Malignancy	643	4.4%	513	4.4%	0.006	0.000
Asthma	1,674	11.5%	1,344	11.5%	-0.048	-0.002
Hyperlipidemia	6,872	47.1%	5,508	47.3%	-0.127	-0.003
Depression	6,128	42.0%	4,899	42.0%	0.004	0.000
Schizophrenia	12,328	84.5%	9,867	84.6%	-0.100	-0.003
Bipolar disorder	5,899	40.5%	4,723	40.5%	-0.059	-0.001
ACE inhibitor use	3,880	26.6%	3,108	26.7%	-0.053	-0.001
ARB use	1,072	7.3%	859	7.4%	-0.018	-0.001
Beta-blocker use	3,784	26.0%	3,019	25.9%	0.052	0.001
Oral anticoagulant use	483	3.3%	390	3.3%	-0.032	-0.002
Antiplatelet agent use	492	3.4%	397	3.4%	-0.034	-0.002
Opioid use	2,896	19.9%	2,309	19.8%	0.049	0.001
Statin use	5,231	35.9%	4,192	36.0%	-0.081	-0.002
Wheelchair or walker use	106	0.7%	82	0.7%	0.017	0.002
Anti-arrhythmic use	85	0.6%	68	0.6%	0.001	0.000
Antidiabetic use	3,655	25.1%	2,915	25.0%	0.057	0.001
Calcium channel blocker use	2,822	19.4%	2,253	19.3%	0.019	0.000
Diuretic use	3,486	23.9%	2,783	23.9%	0.034	0.001
Antidepressant use	7,996	54.8%	6,396	54.9%	-0.033	-0.001
Gastric acid suppressant use	4,764	32.7%	3,810	32.7%	-0.016	-0.000
NSAIDs	3,207	22.0%	2,557	21.9%	0.054	0.001

Table 1ay. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	4,990	34.2%	3,992	34.2%	-0.029	-0.001
Chronic liver disease	1,130	7.7%	903	7.7%	0.001	0.000
Pneumonia	1,048	7.2%	837	7.2%	0.012	0.000
Cardiac arrhythmia	1,985	13.6%	1,593	13.7%	-0.057	-0.002
Paliperidone palmitate	14,582	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	15	0.1%	-0.122	-0.046
Haloperidol decanoate	0	0.0%	11,657	100.0%	NaN	NaN
IS Stay	1,707	11.7%	1,369	11.7%	-0.039	-0.001
Medical Product Use						
Mean number of filled prescriptions	35.3	29.8	35.7	30.1	-0.411	-0.014
Mean number of generics dispensed	10.7	6.4	10.6	6.4	0.043	0.007
Mean number of unique drug classes dispensed	9.6	5.6	9.3	5.5	0.275	0.050
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.1	19.3	17.2	21.9	-0.061	-0.003
Mean number of inpatient hospital encounters	0.5	1.0	0.5	1.0	0.001	0.001
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	-0.002	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1az. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,512	100.0%	8,244	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.4	2.8	-0.508	-0.185
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,512	100.0%	8,244	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,943	60.5%	4,662	56.6%	4.000	0.081
Male	2,569	39.5%	3,582	43.4%	-4.000	-0.081
Race[2]						
American Indian or Alaska Native	39	0.6%	47	0.6%	0.029	0.004
Asian	139	2.1%	131	1.6%	0.545	0.040
Black or African American	1,573	24.2%	2,768	33.6%	-9.421	-0.209
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	294	4.5%	382	4.6%	-0.119	-0.006
White	4,467	68.6%	4,916	59.6%	8.965	0.188
Hispanic origin						
Yes	185	2.8%	220	2.7%	0.172	0.011
No	6,218	95.5%	7,862	95.4%	0.119	0.006
Unknown	109	1.7%	162	2.0%	-0.291	-0.022

Table 1az. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	548	6.6%	-4.958	-0.250
2011	302	4.6%	1,032	12.5%	-7.881	-0.284
2012	389	6.0%	877	10.6%	-4.664	-0.170
2013	469	7.2%	768	9.3%	-2.114	-0.077
2014	448	6.9%	714	8.7%	-1.781	-0.067
2015	583	9.0%	661	8.0%	0.935	0.034
2016	659	10.1%	681	8.3%	1.859	0.064
2017	642	9.9%	629	7.6%	2.229	0.079
2018	655	10.1%	583	7.1%	2.987	0.107
2019	729	11.2%	585	7.1%	4.099	0.143
2020	585	9.0%	429	5.2%	3.780	0.148
2021	636	9.8%	489	5.9%	3.835	0.143
2022	305	4.7%	248	3.0%	1.675	0.087
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	3.7	3.1	-0.256	-0.087
Substance abuse	1,134	17.4%	1,120	13.6%	3.828	0.106
Atrial fibrilation/flutter	392	6.0%	637	7.7%	-1.707	-0.068
Ischemic heart disease	1,293	19.9%	1,928	23.4%	-3.531	-0.086
Heart failure	794	12.2%	1,307	15.9%	-3.661	-0.106
Stroke	476	7.3%	801	9.7%	-2.407	-0.086
Diabetes	2,604	40.0%	3,615	43.9%	-3.862	-0.078
Hypertension	4,866	74.7%	6,325	76.7%	-1.999	-0.047
Rheumatic disease	77	1.2%	94	1.1%	0.042	0.004
Chronic kidney disease	1,633	25.1%	1,998	24.2%	0.841	0.020
Seizure disorder	852	13.1%	1,317	16.0%	-2.892	-0.082

Table 1az. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	787	12.1%	1,300	15.8%	-3.684	-0.107
Dementia Diagnosis	2,193	33.7%	3,554	43.1%	-9.434	-0.195
Dementia Diagnosis and Treatment	666	10.2%	1,145	13.9%	-3.662	-0.113
Parkinsons disease	461	7.1%	600	7.3%	-0.199	-0.008
COPD	1,851	28.4%	2,377	28.8%	-0.409	-0.009
Malignancy	406	6.2%	540	6.6%	-0.316	-0.013
Asthma	630	9.7%	756	9.2%	0.504	0.017
Hyperlipidemia	3,532	54.2%	4,260	51.7%	2.564	0.051
Depression	3,250	49.9%	3,594	43.6%	6.313	0.127
Schizophrenia	5,268	80.9%	6,114	74.2%	6.734	0.162
Bipolar disorder	2,875	44.1%	2,798	33.9%	10.209	0.210
ACE inhibitor use	1,843	28.3%	2,392	29.0%	-0.713	-0.016
ARB use	671	10.3%	825	10.0%	0.297	0.010
Beta-blocker use	2,003	30.8%	2,582	31.3%	-0.561	-0.012
Oral anticoagulant use	322	4.9%	433	5.3%	-0.308	-0.014
Antiplatelet agent use	303	4.7%	505	6.1%	-1.473	-0.065
Opioid use	1,244	19.1%	1,652	20.0%	-0.936	-0.024
Statin use	2,588	39.7%	3,286	39.9%	-0.117	-0.002
Wheelchair or walker use	74	1.1%	191	2.3%	-1.180	-0.091
Anti-arrhythmic use	54	0.8%	91	1.1%	-0.275	-0.028
Antidiabetic use	1,644	25.2%	2,285	27.7%	-2.471	-0.056
Calcium channel blocker use	1,647	25.3%	2,294	27.8%	-2.535	-0.057
Diuretic use	1,863	28.6%	2,472	30.0%	-1.377	-0.030
Antidepressant use	3,677	56.5%	4,177	50.7%	5.798	0.116
Gastric acid suppressant use	2,188	33.6%	2,795	33.9%	-0.304	-0.006
NSAIDs	1,298	19.9%	1,396	16.9%	2.999	0.077

Table 1az. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,251	34.6%	2,604	31.6%	2.980	0.063
Chronic liver disease	488	7.5%	518	6.3%	1.210	0.048
Pneumonia	585	9.0%	919	11.1%	-2.164	-0.072
Cardiac arrhythmia	1,102	16.9%	1,290	15.6%	1.275	0.035
Paliperidone palmitate	6,512	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	-0.042	-0.018
Haloperidol decanoate	0	0.0%	8,244	100.0%	NaN	NaN
IS Stay	940	14.4%	1,088	13.2%	1.237	0.036
Medical Product Use						
Mean number of filled prescriptions	35.1	30.4	36.8	30.6	-1.700	-0.056
Mean number of generics dispensed	10.9	6.3	10.9	6.2	0.012	0.002
Mean number of unique drug classes dispensed	9.9	5.6	9.6	5.3	0.270	0.050
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.6	18.9	14.0	18.6	2.603	0.139
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.062	-0.069
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.087	0.066

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ba. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,510	100.0%	8,241	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.4	2.8	-0.507	-0.184
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,510	100.0%	8,241	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,941	60.5%	4,660	56.5%	3.991	0.081
Male	2,569	39.5%	3,581	43.5%	-3.991	-0.081
Race[2]						
American Indian or Alaska Native	39	0.6%	47	0.6%	0.029	0.004
Asian	139	2.1%	131	1.6%	0.546	0.040
Black or African American	1,572	24.1%	2,767	33.6%	-9.429	-0.209
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	294	4.5%	382	4.6%	-0.119	-0.006
White	4,466	68.6%	4,914	59.6%	8.973	0.188
Hispanic origin						
Yes	185	2.8%	220	2.7%	0.172	0.011
No	6,216	95.5%	7,859	95.4%	0.119	0.006
Unknown	109	1.7%	162	2.0%	-0.291	-0.022

Table 1ba. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	548	6.6%	-4.960	-0.250
2011	302	4.6%	1,031	12.5%	-7.872	-0.284
2012	389	6.0%	876	10.6%	-4.654	-0.169
2013	469	7.2%	768	9.3%	-2.115	-0.077
2014	448	6.9%	714	8.7%	-1.782	-0.067
2015	583	9.0%	661	8.0%	0.935	0.034
2016	659	10.1%	680	8.3%	1.871	0.065
2017	642	9.9%	629	7.6%	2.229	0.079
2018	654	10.0%	583	7.1%	2.972	0.106
2019	729	11.2%	585	7.1%	4.100	0.143
2020	585	9.0%	429	5.2%	3.780	0.148
2021	636	9.8%	489	5.9%	3.836	0.143
2022	304	4.7%	248	3.0%	1.660	0.086
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	3.7	3.1	-0.257	-0.087
Substance abuse	1,133	17.4%	1,119	13.6%	3.826	0.106
Atrial fibrilation/flutter	391	6.0%	636	7.7%	-1.711	-0.068
Ischemic heart disease	1,292	19.8%	1,927	23.4%	-3.537	-0.086
Heart failure	794	12.2%	1,305	15.8%	-3.639	-0.105
Stroke	475	7.3%	801	9.7%	-2.423	-0.087
Diabetes	2,603	40.0%	3,613	43.8%	-3.857	-0.078
Hypertension	4,864	74.7%	6,322	76.7%	-1.998	-0.047
Rheumatic disease	77	1.2%	94	1.1%	0.042	0.004
Chronic kidney disease	1,631	25.1%	1,997	24.2%	0.821	0.019
Seizure disorder	852	13.1%	1,315	16.0%	-2.869	-0.082

Table 1ba. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	787	12.1%	1,300	15.8%	-3.686	-0.107
Dementia Diagnosis	2,192	33.7%	3,552	43.1%	-9.430	-0.195
Dementia Diagnosis and Treatment	666	10.2%	1,145	13.9%	-3.664	-0.113
Parkinsons disease	461	7.1%	600	7.3%	-0.199	-0.008
COPD	1,851	28.4%	2,375	28.8%	-0.386	-0.009
Malignancy	406	6.2%	540	6.6%	-0.316	-0.013
Asthma	630	9.7%	755	9.2%	0.516	0.018
Hyperlipidemia	3,530	54.2%	4,259	51.7%	2.544	0.051
Depression	3,249	49.9%	3,592	43.6%	6.321	0.127
Schizophrenia	5,267	80.9%	6,113	74.2%	6.728	0.162
Bipolar disorder	2,874	44.1%	2,797	33.9%	10.207	0.210
ACE inhibitor use	1,842	28.3%	2,391	29.0%	-0.719	-0.016
ARB use	670	10.3%	825	10.0%	0.281	0.009
Beta-blocker use	2,001	30.7%	2,581	31.3%	-0.582	-0.013
Oral anticoagulant use	322	4.9%	433	5.3%	-0.308	-0.014
Antiplatelet agent use	302	4.6%	504	6.1%	-1.477	-0.066
Opioid use	1,244	19.1%	1,651	20.0%	-0.925	-0.023
Statin use	2,586	39.7%	3,286	39.9%	-0.150	-0.003
Wheelchair or walker use	73	1.1%	190	2.3%	-1.184	-0.091
Anti-arrhythmic use	54	0.8%	91	1.1%	-0.275	-0.028
Antidiabetic use	1,643	25.2%	2,284	27.7%	-2.477	-0.056
Calcium channel blocker use	1,645	25.3%	2,293	27.8%	-2.555	-0.058
Diuretic use	1,862	28.6%	2,470	30.0%	-1.370	-0.030
Antidepressant use	3,676	56.5%	4,175	50.7%	5.806	0.117
Gastric acid suppressant use	2,187	33.6%	2,794	33.9%	-0.309	-0.007
NSAIDs	1,297	19.9%	1,395	16.9%	2.996	0.077

Table 1ba. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,250	34.6%	2,603	31.6%	2.976	0.063
Chronic liver disease	487	7.5%	518	6.3%	1.195	0.047
Pneumonia	584	9.0%	918	11.1%	-2.169	-0.072
Cardiac arrhythmia	1,101	16.9%	1,288	15.6%	1.283	0.035
Paliperidone palmitate	6,510	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	-0.042	-0.019
Haloperidol decanoate	0	0.0%	8,241	100.0%	NaN	NaN
IS Stay	940	14.4%	1,088	13.2%	1.237	0.036
Medical Product Use						
Mean number of filled prescriptions	35.1	30.4	36.8	30.6	-1.708	-0.056
Mean number of generics dispensed	10.9	6.3	10.9	6.2	0.011	0.002
Mean number of unique drug classes dispensed	9.9	5.6	9.6	5.3	0.271	0.050
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.6	18.9	14.0	18.6	2.605	0.139
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.061	-0.068
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.088	0.067

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bb. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	6,490	N/A	8,256	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	69.2	2.8	69.2	2.8	-0.007	-0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,490	100.0%	8,256	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,780	58.2%	4,808	58.2%	0.008	0.000
Male	2,710	41.8%	3,448	41.8%	-0.008	-0.000
Race[3]						
American Indian or Alaska Native	38	0.6%	47	0.6%	0.018	0.002
Asian	142	2.2%	135	1.6%	0.559	0.041
Black or African American	1,628	25.1%	2,731	33.1%	-7.994	-0.177
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	294	4.5%	387	4.7%	-0.161	-0.008
White	4,388	67.6%	4,957	60.0%	7.578	0.158
Hispanic origin						
Yes	182	2.8%	223	2.7%	0.092	0.006
No	6,196	95.5%	7,869	95.3%	0.161	0.008
Unknown	112	1.7%	163	2.0%	-0.253	-0.019

Table 1bb. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	116	1.8%	535	6.5%	-4.695	-0.238
2011	306	4.7%	987	12.0%	-7.239	-0.264
2012	399	6.1%	860	10.4%	-4.269	-0.155
2013	480	7.4%	781	9.5%	-2.070	-0.075
2014	439	6.8%	712	8.6%	-1.866	-0.070
2015	586	9.0%	678	8.2%	0.819	0.029
2016	659	10.2%	694	8.4%	1.754	0.060
2017	644	9.9%	637	7.7%	2.206	0.078
2018	637	9.8%	588	7.1%	2.696	0.097
2019	718	11.1%	602	7.3%	3.771	0.131
2020	574	8.8%	440	5.3%	3.509	0.137
2021	623	9.6%	492	6.0%	3.649	0.136
2022	309	4.8%	250	3.0%	1.735	0.090
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	3.6	2.9	3.6	3.0	0.004	0.001
Substance abuse	993	15.3%	1,266	15.3%	-0.042	-0.001
Atrial fibrilation/flutter	449	6.9%	574	7.0%	-0.042	-0.002
Ischemic heart disease	1,414	21.8%	1,796	21.8%	0.031	0.001
Heart failure	925	14.3%	1,171	14.2%	0.071	0.002
Stroke	549	8.5%	708	8.6%	-0.118	-0.004
Diabetes	2,745	42.3%	3,493	42.3%	-0.013	-0.000
Hypertension	4,932	76.0%	6,267	75.9%	0.085	0.002
Rheumatic disease	72	1.1%	93	1.1%	-0.019	-0.002
Chronic kidney disease	1,613	24.9%	2,037	24.7%	0.182	0.004
Seizure disorder	950	14.6%	1,210	14.7%	-0.013	-0.000

Table 1bb. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	906	14.0%	1,163	14.1%	-0.123	-0.004
Dementia Diagnosis	2,522	38.9%	3,216	39.0%	-0.096	-0.002
Dementia Diagnosis and Treatment	787	12.1%	1,009	12.2%	-0.100	-0.003
Parkinsons disease	471	7.3%	595	7.2%	0.049	0.002
COPD	1,867	28.8%	2,366	28.7%	0.109	0.002
Malignancy	413	6.4%	528	6.4%	-0.034	-0.001
Asthma	614	9.5%	778	9.4%	0.026	0.001
Hyperlipidemia	3,450	53.2%	4,374	53.0%	0.187	0.004
Depression	3,024	46.6%	3,844	46.6%	0.035	0.001
Schizophrenia	5,054	77.9%	6,399	77.5%	0.377	0.009
Bipolar disorder	2,514	38.7%	3,192	38.7%	0.073	0.001
ACE inhibitor use	1,864	28.7%	2,372	28.7%	-0.013	-0.000
ARB use	661	10.2%	840	10.2%	0.009	0.000
Beta-blocker use	2,012	31.0%	2,557	31.0%	0.034	0.001
Oral anticoagulant use	330	5.1%	421	5.1%	-0.011	-0.001
Antiplatelet agent use	349	5.4%	448	5.4%	-0.045	-0.002
Opioid use	1,260	19.4%	1,615	19.6%	-0.154	-0.004
Statin use	2,604	40.1%	3,294	39.9%	0.224	0.005
Wheelchair or walker use	120	1.8%	149	1.8%	0.039	0.003
Anti-arrhythmic use	65	1.0%	82	1.0%	0.005	0.001
Antidiabetic use	1,728	26.6%	2,199	26.6%	-0.012	-0.000
Calcium channel blocker use	1,731	26.7%	2,206	26.7%	-0.048	-0.001
Diuretic use	1,917	29.5%	2,429	29.4%	0.109	0.002
Antidepressant use	3,449	53.1%	4,396	53.3%	-0.107	-0.002
Gastric acid suppressant use	2,191	33.8%	2,788	33.8%	0.001	0.000
NSAIDs	1,189	18.3%	1,505	18.2%	0.102	0.003

Table 1bb. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,138	33.0%	2,718	32.9%	0.031	0.001
Chronic liver disease	440	6.8%	569	6.9%	-0.107	-0.004
Pneumonia	658	10.1%	837	10.1%	-0.006	-0.000
Cardiac arrhythmia	1,049	16.2%	1,333	16.1%	0.020	0.001
Paliperidone palmitate	6,490	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	-0.052	-0.024
Haloperidol decanoate	0	0.0%	8,256	100.0%	NaN	NaN
IS Stay	917	14.1%	1,151	13.9%	0.181	0.005
Medical Product Use						
Mean number of filled prescriptions	35.5	31.0	36.4	30.1	-0.920	-0.030
Mean number of generics dispensed	10.9	6.4	10.9	6.1	-0.010	-0.002
Mean number of unique drug classes dispensed	9.9	5.6	9.6	5.3	0.263	0.048
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.4	17.6	15.4	20.3	-0.010	-0.001
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	1.0	1.3	1.0	1.3	0.003	0.003

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1bc. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,509	100.0%	4,138	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.8	2.7	79.5	2.9	-0.764	-0.274
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,509	100.0%	4,138	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,061	70.3%	2,703	65.3%	4.990	0.107
Male	448	29.7%	1,435	34.7%	-4.990	-0.107
Race[2]						
American Indian or Alaska Native	*****	*****	*****	*****	0.204	0.027
Asian	*****	*****	*****	*****	0.502	0.040
Black or African American	303	20.1%	946	22.9%	-2.782	-0.068
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	161	3.9%	1.013	0.049
White	1,094	72.5%	2,956	71.4%	1.063	0.024
Hispanic origin						
Yes	*****	*****	107	2.6%	0.860	0.050
No	1,435	95.1%	3,977	96.1%	-1.013	-0.049
Unknown	*****	*****	54	1.3%	0.153	0.013

Table 1bc. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	28	1.9%	312	7.5%	-5.684	-0.271
2011	75	5.0%	571	13.8%	-8.829	-0.306
2012	101	6.7%	404	9.8%	-3.070	-0.112
2013	108	7.2%	427	10.3%	-3.162	-0.112
2014	106	7.0%	357	8.6%	-1.603	-0.060
2015	126	8.3%	330	8.0%	0.375	0.014
2016	143	9.5%	308	7.4%	2.033	0.073
2017	145	9.6%	308	7.4%	2.166	0.078
2018	142	9.4%	281	6.8%	2.619	0.096
2019	168	11.1%	280	6.8%	4.367	0.153
2020	166	11.0%	233	5.6%	5.370	0.195
2021	126	8.3%	223	5.4%	2.961	0.117
2022	75	5.0%	104	2.5%	2.457	0.130
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	4.6	3.1	-0.213	-0.069
Substance abuse	127	8.4%	230	5.6%	2.858	0.112
Atrial fibrilation/flutter	191	12.7%	610	14.7%	-2.084	-0.061
Ischemic heart disease	433	28.7%	1,359	32.8%	-4.147	-0.090
Heart failure	296	19.6%	895	21.6%	-2.013	-0.050
Stroke	167	11.1%	556	13.4%	-2.370	-0.072
Diabetes	635	42.1%	1,770	42.8%	-0.693	-0.014
Hypertension	1,251	82.9%	3,411	82.4%	0.471	0.012
Rheumatic disease	*****	*****	*****	*****	-0.082	-0.007
Chronic kidney disease	428	28.4%	1,111	26.8%	1.514	0.034
Seizure disorder	158	10.5%	554	13.4%	-2.918	-0.090

Table 1bc. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	408	27.0%	1,460	35.3%	-8.245	-0.179
Dementia Diagnosis	924	61.2%	3,102	75.0%	-13.731	-0.298
Dementia Diagnosis and Treatment	371	24.6%	1,393	33.7%	-9.078	-0.201
Parkinsons disease	144	9.5%	405	9.8%	-0.245	-0.008
COPD	411	27.2%	1,117	27.0%	0.243	0.005
Malignancy	95	6.3%	350	8.5%	-2.163	-0.083
Asthma	111	7.4%	280	6.8%	0.589	0.023
Hyperlipidemia	845	56.0%	2,159	52.2%	3.822	0.077
Depression	837	55.5%	1,979	47.8%	7.642	0.153
Schizophrenia	1,010	66.9%	1,912	46.2%	20.726	0.428
Bipolar disorder	582	38.6%	1,099	26.6%	12.010	0.258
ACE inhibitor use	404	26.8%	1,190	28.8%	-1.985	-0.044
ARB use	195	12.9%	460	11.1%	1.806	0.056
Beta-blocker use	517	34.3%	1,535	37.1%	-2.834	-0.059
Oral anticoagulant use	113	7.5%	400	9.7%	-2.178	-0.078
Antiplatelet agent use	104	6.9%	379	9.2%	-2.267	-0.084
Opioid use	331	21.9%	1,090	26.3%	-4.406	-0.103
Statin use	594	39.4%	1,644	39.7%	-0.366	-0.007
Wheelchair or walker use	44	2.9%	140	3.4%	-0.467	-0.027
Anti-arrhythmic use	26	1.7%	96	2.3%	-0.597	-0.042
Antidiabetic use	337	22.3%	1,027	24.8%	-2.486	-0.059
Calcium channel blocker use	452	30.0%	1,186	28.7%	1.292	0.028
Diuretic use	526	34.9%	1,445	34.9%	-0.063	-0.001
Antidepressant use	849	56.3%	2,399	58.0%	-1.712	-0.035
Gastric acid suppressant use	542	35.9%	1,474	35.6%	0.297	0.006
NSAIDs	242	16.0%	591	14.3%	1.755	0.049

Table 1bc. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	478	31.7%	1,362	32.9%	-1.238	-0.026
Chronic liver disease	*****	*****	173	4.2%	1.187	0.056
Pneumonia	174	11.5%	559	13.5%	-1.978	-0.060
Cardiac arrhythmia	278	18.4%	620	15.0%	3.440	0.092
Paliperidone palmitate	1,509	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	4,138	100.0%	NaN	NaN
IS Stay	258	17.1%	494	11.9%	5.159	0.147
Medical Product Use						
Mean number of filled prescriptions	35.3	30.5	39.6	31.7	-4.293	-0.138
Mean number of generics dispensed	11.0	6.3	11.6	6.1	-0.561	-0.091
Mean number of unique drug classes dispensed	10.2	5.6	10.4	5.3	-0.193	-0.035
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.0	17.0	11.1	14.7	3.961	0.250
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.022	-0.026
Mean number of non-acute institutional encounters	1.1	1.3	0.9	1.3	0.239	0.186

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bd. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,506	99.8%	4,132	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.8	2.7	79.5	2.9	-0.763	-0.274
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,506	100.0%	4,132	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,059	70.3%	2,701	65.4%	4.951	0.106
Male	447	29.7%	1,431	34.6%	-4.951	-0.106
Race[2]						
American Indian or Alaska Native	*****	*****	*****	*****	0.204	0.027
Asian	*****	*****	*****	*****	0.504	0.040
Black or African American	302	20.1%	946	22.9%	-2.841	-0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	160	3.9%	1.041	0.051
White	1,092	72.5%	2,951	71.4%	1.092	0.024
Hispanic origin						
Yes	*****	*****	107	2.6%	0.863	0.050
No	1,432	95.1%	3,972	96.1%	-1.041	-0.051
Unknown	*****	*****	53	1.3%	0.178	0.015

Table 1bd. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	28	1.9%	311	7.5%	-5.667	-0.270
2011	75	5.0%	571	13.8%	-8.839	-0.306
2012	100	6.6%	404	9.8%	-3.137	-0.114
2013	108	7.2%	426	10.3%	-3.138	-0.111
2014	106	7.0%	355	8.6%	-1.553	-0.058
2015	126	8.4%	330	8.0%	0.380	0.014
2016	142	9.4%	308	7.5%	1.975	0.071
2017	145	9.6%	307	7.4%	2.198	0.079
2018	141	9.4%	280	6.8%	2.586	0.095
2019	168	11.2%	280	6.8%	4.379	0.154
2020	166	11.0%	233	5.6%	5.384	0.196
2021	126	8.4%	223	5.4%	2.970	0.118
2022	75	5.0%	104	2.5%	2.463	0.130
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	4.6	3.1	-0.207	-0.067
Substance abuse	126	8.4%	230	5.6%	2.800	0.110
Atrial fibrilation/flutter	190	12.6%	606	14.7%	-2.050	-0.060
Ischemic heart disease	432	28.7%	1,354	32.8%	-4.083	-0.089
Heart failure	295	19.6%	890	21.5%	-1.951	-0.048
Stroke	166	11.0%	555	13.4%	-2.409	-0.074
Diabetes	632	42.0%	1,766	42.7%	-0.774	-0.016
Hypertension	1,248	82.9%	3,406	82.4%	0.439	0.012
Rheumatic disease	*****	*****	*****	*****	-0.058	-0.005
Chronic kidney disease	426	28.3%	1,108	26.8%	1.472	0.033
Seizure disorder	157	10.4%	552	13.4%	-2.934	-0.091

Table 1bd. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	405	26.9%	1,457	35.3%	-8.369	-0.182
Dementia Diagnosis	923	61.3%	3,097	75.0%	-13.663	-0.296
Dementia Diagnosis and Treatment	370	24.6%	1,391	33.7%	-9.096	-0.201
Parkinsons disease	144	9.6%	403	9.8%	-0.191	-0.006
COPD	410	27.2%	1,116	27.0%	0.216	0.005
Malignancy	95	6.3%	347	8.4%	-2.090	-0.080
Asthma	111	7.4%	280	6.8%	0.594	0.023
Hyperlipidemia	842	55.9%	2,155	52.2%	3.756	0.075
Depression	835	55.4%	1,976	47.8%	7.623	0.153
Schizophrenia	1,008	66.9%	1,911	46.2%	20.683	0.427
Bipolar disorder	580	38.5%	1,098	26.6%	11.940	0.257
ACE inhibitor use	401	26.6%	1,187	28.7%	-2.100	-0.047
ARB use	195	12.9%	460	11.1%	1.816	0.056
Beta-blocker use	516	34.3%	1,530	37.0%	-2.765	-0.058
Oral anticoagulant use	113	7.5%	397	9.6%	-2.105	-0.075
Antiplatelet agent use	103	6.8%	379	9.2%	-2.333	-0.086
Opioid use	330	21.9%	1,085	26.3%	-4.346	-0.102
Statin use	592	39.3%	1,641	39.7%	-0.405	-0.008
Wheelchair or walker use	44	2.9%	140	3.4%	-0.467	-0.027
Anti-arrhythmic use	26	1.7%	96	2.3%	-0.597	-0.042
Antidiabetic use	337	22.4%	1,023	24.8%	-2.381	-0.056
Calcium channel blocker use	450	29.9%	1,184	28.7%	1.226	0.027
Diuretic use	524	34.8%	1,440	34.8%	-0.056	-0.001
Antidepressant use	846	56.2%	2,395	58.0%	-1.787	-0.036
Gastric acid suppressant use	541	35.9%	1,473	35.6%	0.274	0.006
NSAIDs	241	16.0%	589	14.3%	1.748	0.049

Table 1bd. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	478	31.7%	1,358	32.9%	-1.126	-0.024
Chronic liver disease	*****	*****	172	4.2%	1.216	0.057
Pneumonia	174	11.6%	556	13.5%	-1.902	-0.058
Cardiac arrhythmia	277	18.4%	619	15.0%	3.412	0.092
Paliperidone palmitate	1,506	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	4,132	100.0%	NaN	NaN
IS Stay	258	17.1%	494	12.0%	5.176	0.147
Medical Product Use						
Mean number of filled prescriptions	35.3	30.5	39.6	31.7	-4.289	-0.138
Mean number of generics dispensed	11.0	6.3	11.6	6.1	-0.563	-0.091
Mean number of unique drug classes dispensed	10.2	5.6	10.4	5.3	-0.195	-0.036
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.0	16.8	11.1	14.7	3.879	0.246
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.022	-0.025
Mean number of non-acute institutional encounters	1.1	1.3	0.9	1.3	0.238	0.185

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1be. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,479	N/A	4,144	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	79.2	2.8	79.3	2.8	-0.071	-0.025
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,479	100.0%	4,144	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	987	66.7%	2,764	66.7%	0.040	0.001
Male	492	33.3%	1,380	33.3%	-0.040	-0.001
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	0.256	0.034
Asian	*****	*****	*****	*****	0.202	0.017
Black or African American	296	20.0%	975	23.5%	-3.516	-0.085
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	160	3.8%	0.963	0.047
White	1,079	72.9%	2,934	70.8%	2.096	0.047
Hispanic origin						
Yes	*****	*****	107	2.6%	0.739	0.044
No	1,408	95.2%	3,984	96.2%	-0.963	-0.047
Unknown	*****	*****	53	1.3%	0.224	0.019

Table 1be. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	27	1.8%	308	7.4%	-5.635	-0.271
2011	82	5.5%	569	13.7%	-8.199	-0.281
2012	96	6.5%	399	9.6%	-3.119	-0.115
2013	124	8.4%	421	10.1%	-1.758	-0.061
2014	112	7.6%	356	8.6%	-1.051	-0.039
2015	125	8.5%	336	8.1%	0.369	0.013
2016	134	9.1%	317	7.6%	1.411	0.051
2017	151	10.2%	304	7.3%	2.851	0.101
2018	130	8.8%	280	6.8%	2.054	0.077
2019	162	10.9%	289	7.0%	3.944	0.138
2020	152	10.3%	234	5.7%	4.615	0.171
2021	115	7.7%	223	5.4%	2.362	0.095
2022	70	4.7%	107	2.6%	2.156	0.115
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	4.6	3.0	4.6	3.1	-0.007	-0.002
Substance abuse	92	6.2%	261	6.3%	-0.083	-0.003
Atrial fibrilation/flutter	204	13.8%	585	14.1%	-0.343	-0.010
Ischemic heart disease	479	32.4%	1,317	31.8%	0.581	0.012
Heart failure	300	20.3%	870	21.0%	-0.705	-0.017
Stroke	193	13.1%	533	12.9%	0.209	0.006
Diabetes	624	42.2%	1,764	42.6%	-0.362	-0.007
Hypertension	1,218	82.4%	3,423	82.6%	-0.252	-0.007
Rheumatic disease	*****	*****	*****	*****	-0.125	-0.011
Chronic kidney disease	415	28.1%	1,135	27.4%	0.682	0.015
Seizure disorder	189	12.8%	521	12.6%	0.245	0.007

Table 1be. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	500	33.8%	1,369	33.0%	0.767	0.016
Dementia Diagnosis	1,046	70.7%	2,955	71.3%	-0.590	-0.013
Dementia Diagnosis and Treatment	475	32.1%	1,297	31.3%	0.790	0.017
Parkinsons disease	138	9.3%	400	9.7%	-0.338	-0.012
COPD	412	27.8%	1,128	27.2%	0.602	0.013
Malignancy	115	7.8%	324	7.8%	-0.013	-0.000
Asthma	113	7.7%	292	7.0%	0.614	0.024
Hyperlipidemia	789	53.3%	2,206	53.2%	0.071	0.001
Depression	745	50.4%	2,068	49.9%	0.453	0.009
Schizophrenia	793	53.6%	2,159	52.1%	1.543	0.031
Bipolar disorder	453	30.6%	1,235	29.8%	0.833	0.018
ACE inhibitor use	419	28.3%	1,173	28.3%	0.047	0.001
ARB use	168	11.3%	483	11.7%	-0.319	-0.010
Beta-blocker use	543	36.7%	1,507	36.4%	0.324	0.007
Oral anticoagulant use	126	8.5%	373	9.0%	-0.461	-0.016
Antiplatelet agent use	133	9.0%	356	8.6%	0.417	0.015
Opioid use	362	24.5%	1,034	24.9%	-0.471	-0.011
Statin use	596	40.3%	1,646	39.7%	0.594	0.012
Wheelchair or walker use	45	3.0%	133	3.2%	-0.197	-0.011
Anti-arrhythmic use	33	2.2%	91	2.2%	0.026	0.002
Antidiabetic use	354	23.9%	1,000	24.1%	-0.191	-0.004
Calcium channel blocker use	428	28.9%	1,205	29.1%	-0.158	-0.003
Diuretic use	515	34.8%	1,442	34.8%	0.022	0.000
Antidepressant use	841	56.9%	2,385	57.6%	-0.699	-0.014
Gastric acid suppressant use	521	35.2%	1,475	35.6%	-0.371	-0.008
NSAIDs	217	14.6%	609	14.7%	-0.049	-0.001

Table 1be. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Benzodiazepine-Hypnotics use	474	32.0%	1,344	32.4%	-0.416	-0.009
Chronic liver disease	*****	*****	186	4.5%	0.193	0.009
Pneumonia	188	12.7%	537	13.0%	-0.253	-0.008
Cardiac arrhythmia	226	15.3%	659	15.9%	-0.598	-0.016
Paliperidone palmitate	1,479	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	4,144	100.0%	NaN	NaN
IS Stay	217	14.7%	567	13.7%	1.015	0.029
Medical Product Use						
Mean number of filled prescriptions	37.3	32.3	38.9	31.5	-1.622	-0.051
Mean number of generics dispensed	11.4	6.3	11.5	6.1	-0.129	-0.021
Mean number of unique drug classes dispensed	10.5	5.6	10.2	5.3	0.220	0.040
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	12.8	14.4	12.4	17.1	0.377	0.024
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	0.004	0.005
Mean number of non-acute institutional encounters	1.0	1.3	1.0	1.3	0.046	0.035

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bf. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	372	100.0%	2,291	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.8	3.2	90.0	3.7	-1.272	-0.366
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	372	100.0%	2,291	100.0%	0.000	NaN
Sex						
Female	301	80.9%	1,762	76.9%	4.004	0.098
Male	71	19.1%	529	23.1%	-4.004	-0.098
Race[2]						
American Indian or Alaska Native	*****	*****	*****	*****	0.901	0.114
Asian	*****	*****	*****	*****	-0.096	-0.008
Black or African American	46	12.4%	326	14.2%	-1.864	-0.055
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	98	4.3%	2.174	0.097
White	293	78.8%	1,830	79.9%	-1.114	-0.028
Hispanic origin						
Yes	*****	*****	74	3.2%	1.071	0.056
No	348	93.5%	2,193	95.7%	-2.174	-0.097
Unknown	*****	*****	24	1.0%	1.103	0.088

Table 1bf. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	11	3.0%	145	6.3%	-3.372	-0.161
2011	14	3.8%	288	12.6%	-8.807	-0.326
2012	20	5.4%	259	11.3%	-5.929	-0.216
2013	33	8.9%	243	10.6%	-1.736	-0.059
2014	39	10.5%	229	10.0%	0.488	0.016
2015	35	9.4%	208	9.1%	0.330	0.011
2016	26	7.0%	188	8.2%	-1.217	-0.046
2017	47	12.6%	169	7.4%	5.258	0.176
2018	31	8.3%	157	6.9%	1.480	0.056
2019	40	10.8%	129	5.6%	5.122	0.188
2020	36	9.7%	120	5.2%	4.440	0.170
2021	23	6.2%	107	4.7%	1.512	0.067
2022	17	4.6%	49	2.1%	2.431	0.135
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	3.0	4.8	3.0	0.212	0.071
Substance abuse	21	5.6%	67	2.9%	2.721	0.135
Atrial fibrilation/flutter	74	19.9%	462	20.2%	-0.273	-0.007
Ischemic heart disease	103	27.7%	771	33.7%	-5.965	-0.130
Heart failure	90	24.2%	629	27.5%	-3.262	-0.075
Stroke	28	7.5%	333	14.5%	-7.008	-0.225
Diabetes	124	33.3%	697	30.4%	2.910	0.062
Hypertension	314	84.4%	1,862	81.3%	3.134	0.083
Rheumatic disease	*****	*****	47	2.1%	-0.439	-0.033
Chronic kidney disease	115	30.9%	659	28.8%	2.149	0.047
Seizure disorder	27	7.3%	171	7.5%	-0.206	-0.008

Table 1bf. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.8%	907	39.6%	4.228	0.086
Dementia Diagnosis	324	87.1%	2,013	87.9%	-0.769	-0.023
Dementia Diagnosis and Treatment	159	42.7%	868	37.9%	4.855	0.099
Parkinsons disease	33	8.9%	147	6.4%	2.455	0.092
COPD	78	21.0%	522	22.8%	-1.817	-0.044
Malignancy	22	5.9%	133	5.8%	0.109	0.005
Asthma	20	5.4%	110	4.8%	0.575	0.026
Hyperlipidemia	187	50.3%	968	42.3%	8.017	0.161
Depression	229	61.6%	1,076	47.0%	14.593	0.296
Schizophrenia	138	37.1%	436	19.0%	18.066	0.410
Bipolar disorder	112	30.1%	331	14.4%	15.660	0.383
ACE inhibitor use	95	25.5%	578	25.2%	0.308	0.007
ARB use	38	10.2%	294	12.8%	-2.618	-0.082
Beta-blocker use	142	38.2%	911	39.8%	-1.592	-0.033
Oral anticoagulant use	40	10.8%	243	10.6%	0.146	0.005
Antiplatelet agent use	35	9.4%	227	9.9%	-0.500	-0.017
Opioid use	92	24.7%	698	30.5%	-5.736	-0.129
Statin use	126	33.9%	662	28.9%	4.975	0.107
Wheelchair or walker use	19	5.1%	124	5.4%	-0.305	-0.014
Anti-arrhythmic use	*****	*****	68	3.0%	-1.086	-0.071
Antidiabetic use	51	13.7%	330	14.4%	-0.695	-0.020
Calcium channel blocker use	109	29.3%	651	28.4%	0.886	0.020
Diuretic use	121	32.5%	886	38.7%	-6.146	-0.129
Antidepressant use	240	64.5%	1,430	62.4%	2.098	0.044
Gastric acid suppressant use	126	33.9%	840	36.7%	-2.794	-0.059
NSAIDs	57	15.3%	300	13.1%	2.228	0.064

Table 1bf. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	136	36.6%	762	33.3%	3.299	0.069
Chronic liver disease	*****	*****	66	2.9%	-0.193	-0.012
Pneumonia	61	16.4%	345	15.1%	1.339	0.037
Cardiac arrhythmia	65	17.5%	338	14.8%	2.720	0.074
Paliperidone palmitate	372	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	0.182	0.043
Haloperidol decanoate	0	0.0%	2,291	100.0%	NaN	NaN
IS Stay	60	16.1%	234	10.2%	5.915	0.176
Medical Product Use						
Mean number of filled prescriptions	37.3	28.2	39.5	28.5	-2.248	-0.079
Mean number of generics dispensed	11.3	5.6	11.5	5.6	-0.231	-0.041
Mean number of unique drug classes dispensed	10.4	5.1	10.4	4.9	0.066	0.013
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.3	12.2	7.7	9.7	3.631	0.330
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.8	0.031	0.041
Mean number of non-acute institutional encounters	1.1	1.3	0.7	1.1	0.386	0.320

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)f

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	371	99.7%	2,275	99.3%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.8	3.2	90.0	3.7	-1.235	-0.357
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	371	100.0%	2,275	100.0%	0.000	NaN
Sex						
Female	300	80.9%	1,751	77.0%	3.896	0.096
Male	71	19.1%	524	23.0%	-3.896	-0.096
Race[2]						
American Indian or Alaska Native	*****	*****	*****	*****	0.902	0.115
Asian	*****	*****	*****	*****	-0.059	-0.005
Black or African American	46	12.4%	323	14.2%	-1.799	-0.053
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	96	4.2%	2.249	0.100
White	292	78.7%	1,820	80.0%	-1.294	-0.032
Hispanic origin						
Yes	*****	*****	72	3.2%	1.148	0.061
No	347	93.5%	2,179	95.8%	-2.249	-0.100
Unknown	*****	*****	24	1.1%	1.101	0.088

Table 1bg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	11	3.0%	143	6.3%	-3.321	-0.159
2011	14	3.8%	284	12.5%	-8.710	-0.323
2012	20	5.4%	257	11.3%	-5.906	-0.215
2013	33	8.9%	241	10.6%	-1.699	-0.057
2014	39	10.5%	228	10.0%	0.490	0.016
2015	35	9.4%	208	9.1%	0.291	0.010
2016	26	7.0%	188	8.3%	-1.256	-0.047
2017	47	12.7%	168	7.4%	5.284	0.177
2018	31	8.4%	156	6.9%	1.499	0.057
2019	40	10.8%	128	5.6%	5.155	0.189
2020	36	9.7%	118	5.2%	4.517	0.173
2021	22	5.9%	107	4.7%	1.227	0.055
2022	17	4.6%	49	2.2%	2.428	0.135
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	2.9	4.7	3.0	0.211	0.071
Substance abuse	20	5.4%	67	2.9%	2.446	0.123
Atrial fibrilation/flutter	74	19.9%	456	20.0%	-0.098	-0.002
Ischemic heart disease	103	27.8%	759	33.4%	-5.600	-0.122
Heart failure	90	24.3%	619	27.2%	-2.950	-0.068
Stroke	28	7.5%	321	14.1%	-6.563	-0.212
Diabetes	123	33.2%	692	30.4%	2.736	0.059
Hypertension	313	84.4%	1,847	81.2%	3.180	0.084
Rheumatic disease	*****	*****	47	2.1%	-0.449	-0.033
Chronic kidney disease	114	30.7%	651	28.6%	2.112	0.046
Seizure disorder	27	7.3%	169	7.4%	-0.151	-0.006

Table 1bg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.9%	905	39.8%	4.155	0.084
Dementia Diagnosis	323	87.1%	1,998	87.8%	-0.762	-0.023
Dementia Diagnosis and Treatment	159	42.9%	867	38.1%	4.747	0.097
Parkinsons disease	33	8.9%	147	6.5%	2.433	0.091
COPD	78	21.0%	516	22.7%	-1.657	-0.040
Malignancy	22	5.9%	129	5.7%	0.260	0.011
Asthma	19	5.1%	107	4.7%	0.418	0.019
Hyperlipidemia	186	50.1%	962	42.3%	7.849	0.158
Depression	228	61.5%	1,074	47.2%	14.247	0.289
Schizophrenia	137	36.9%	435	19.1%	17.806	0.405
Bipolar disorder	111	29.9%	331	14.5%	15.370	0.376
ACE inhibitor use	95	25.6%	567	24.9%	0.683	0.016
ARB use	38	10.2%	288	12.7%	-2.417	-0.076
Beta-blocker use	142	38.3%	900	39.6%	-1.286	-0.026
Oral anticoagulant use	40	10.8%	242	10.6%	0.144	0.005
Antiplatelet agent use	35	9.4%	225	9.9%	-0.456	-0.015
Opioid use	92	24.8%	689	30.3%	-5.488	-0.123
Statin use	125	33.7%	658	28.9%	4.770	0.103
Wheelchair or walker use	19	5.1%	123	5.4%	-0.285	-0.013
Anti-arrhythmic use	*****	*****	66	2.9%	-1.014	-0.066
Antidiabetic use	51	13.7%	327	14.4%	-0.627	-0.018
Calcium channel blocker use	109	29.4%	647	28.4%	0.940	0.021
Diuretic use	121	32.6%	876	38.5%	-5.891	-0.123
Antidepressant use	239	64.4%	1,420	62.4%	2.003	0.042
Gastric acid suppressant use	125	33.7%	833	36.6%	-2.923	-0.061
NSAIDs	57	15.4%	297	13.1%	2.309	0.066

Table 1bg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	136	36.7%	756	33.2%	3.427	0.072
Chronic liver disease	*****	*****	63	2.8%	-0.074	-0.005
Pneumonia	61	16.4%	342	15.0%	1.409	0.039
Cardiac arrhythmia	65	17.5%	336	14.8%	2.751	0.075
Paliperidone palmitate	371	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	0.182	0.043
Haloperidol decanoate	0	0.0%	2,275	100.0%	NaN	NaN
IS Stay	59	15.9%	233	10.2%	5.661	0.169
Medical Product Use						
Mean number of filled prescriptions	37.4	28.1	39.5	28.5	-2.122	-0.075
Mean number of generics dispensed	11.3	5.6	11.5	5.6	-0.180	-0.032
Mean number of unique drug classes dispensed	10.5	5.1	10.4	4.9	0.108	0.022
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.3	12.2	7.7	9.5	3.662	0.335
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.8	0.030	0.040
Mean number of non-acute institutional encounters	1.1	1.2	0.7	1.1	0.367	0.311

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bh. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	365	N/A	2,279	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	89.8	3.7	89.8	3.7	-0.037	-0.010
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	365	100.0%	2,279	100.0%	0.000	NaN
Sex						
Female	271	74.1%	1,764	77.4%	-3.324	-0.078
Male	95	25.9%	515	22.6%	3.324	0.078
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	0.737	0.101
Asian	*****	*****	*****	*****	-0.030	-0.003
Black or African American	47	13.0%	328	14.4%	-1.405	-0.041
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	96	4.2%	1.876	0.085
White	287	78.7%	1,819	79.8%	-1.178	-0.029
Hispanic origin						
Yes	*****	*****	71	3.1%	0.668	0.037
No	343	93.9%	2,182	95.8%	-1.876	-0.085
Unknown	*****	*****	25	1.1%	1.208	0.094

Table 1bh. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	15	4.0%	141	6.2%	-2.193	-0.100
2011	18	5.0%	277	12.2%	-7.190	-0.259
2012	20	5.5%	253	11.1%	-5.548	-0.202
2013	31	8.6%	239	10.5%	-1.901	-0.065
2014	31	8.4%	228	10.0%	-1.647	-0.057
2015	29	7.9%	212	9.3%	-1.465	-0.052
2016	25	6.9%	195	8.5%	-1.617	-0.060
2017	43	11.9%	171	7.5%	4.383	0.148
2018	31	8.5%	156	6.8%	1.677	0.063
2019	49	13.3%	129	5.7%	7.637	0.263
2020	34	9.3%	120	5.3%	3.967	0.153
2021	21	5.7%	107	4.7%	0.978	0.044
2022	19	5.1%	50	2.2%	2.919	0.156
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.1	3.0	4.8	3.0	0.353	0.117
Substance abuse	12	3.2%	76	3.3%	-0.118	-0.007
Atrial fibrilation/flutter	85	23.2%	460	20.2%	3.040	0.074
Ischemic heart disease	127	34.7%	744	32.6%	2.085	0.044
Heart failure	104	28.5%	612	26.9%	1.658	0.037
Stroke	58	16.0%	301	13.2%	2.751	0.078
Diabetes	118	32.3%	705	30.9%	1.373	0.030
Hypertension	299	81.8%	1,862	81.7%	0.117	0.003
Rheumatic disease	*****	*****	45	2.0%	-0.152	-0.011
Chronic kidney disease	108	29.6%	660	29.0%	0.680	0.015
Seizure disorder	30	8.2%	170	7.5%	0.740	0.028

Table 1bh. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	150	41.1%	923	40.5%	0.577	0.012
Dementia Diagnosis	321	87.8%	1,998	87.7%	0.147	0.004
Dementia Diagnosis and Treatment	145	39.6%	887	38.9%	0.711	0.015
Parkinsons disease	25	6.9%	156	6.8%	0.069	0.003
COPD	88	24.0%	516	22.6%	1.386	0.033
Malignancy	20	5.6%	129	5.6%	-0.058	-0.003
Asthma	25	6.7%	111	4.9%	1.851	0.079
Hyperlipidemia	167	45.7%	993	43.6%	2.144	0.043
Depression	199	54.4%	1,126	49.4%	4.952	0.099
Schizophrenia	79	21.7%	495	21.7%	0.028	0.001
Bipolar disorder	61	16.7%	386	16.9%	-0.222	-0.006
ACE inhibitor use	87	23.8%	567	24.9%	-1.088	-0.025
ARB use	37	10.2%	279	12.3%	-2.050	-0.065
Beta-blocker use	148	40.5%	899	39.4%	1.027	0.021
Oral anticoagulant use	47	12.9%	247	10.8%	2.082	0.064
Antiplatelet agent use	44	12.2%	224	9.8%	2.350	0.075
Opioid use	118	32.2%	674	29.6%	2.664	0.058
Statin use	122	33.5%	678	29.8%	3.677	0.079
Wheelchair or walker use	22	6.0%	122	5.4%	0.648	0.028
Anti-arrhythmic use	*****	*****	63	2.7%	-0.254	-0.016
Antidiabetic use	59	16.1%	327	14.3%	1.808	0.050
Calcium channel blocker use	104	28.5%	657	28.8%	-0.360	-0.008
Diuretic use	136	37.1%	858	37.6%	-0.554	-0.011
Antidepressant use	240	65.7%	1,432	62.9%	2.841	0.059
Gastric acid suppressant use	141	38.6%	830	36.4%	2.192	0.045
NSAIDs	55	15.1%	308	13.5%	1.567	0.045

Table 1bh. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	128	35.0%	772	33.9%	1.133	0.024
Chronic liver disease	*****	*****	63	2.8%	-0.413	-0.026
Pneumonia	56	15.3%	345	15.2%	0.120	0.003
Cardiac arrhythmia	65	17.9%	346	15.2%	2.677	0.072
Paliperidone palmitate	365	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	0.528	0.090
Haloperidol decanoate	0	0.0%	2,279	100.0%	NaN	NaN
IS Stay	40	10.9%	254	11.2%	-0.262	-0.008
Medical Product Use						
Mean number of filled prescriptions	40.3	28.8	39.5	28.6	0.866	0.030
Mean number of generics dispensed	12.1	5.7	11.5	5.6	0.577	0.102
Mean number of unique drug classes dispensed	11.2	5.1	10.4	4.9	0.844	0.168
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	8.6	9.3	8.2	10.4	0.402	0.041
Mean number of inpatient hospital encounters	0.4	0.7	0.4	0.8	-0.023	-0.030
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	0.038	0.032

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bi. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	82,723	100.0%	58,552	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	50.7	15.8	-5.348	-0.362
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	7.798	0.185
35-44 years	*****	*****	*****	*****	5.036	0.124
45-54 years	19,292	23.3%	13,809	23.6%	-0.263	-0.006
55-64 years	14,218	17.2%	11,251	19.2%	-2.028	-0.053
65-74 years	5,846	7.1%	7,099	12.1%	-5.057	-0.172
75-84 years	1,138	1.4%	2,745	4.7%	-3.312	-0.194
≥ 85 years	213	0.3%	1,423	2.4%	-2.173	-0.190
Sex						
Female	33,461	40.4%	24,083	41.1%	-0.682	-0.014
Male	49,262	59.6%	34,469	58.9%	0.682	0.014
Race[2]						
American Indian or Alaska Native	1,001	1.2%	518	0.9%	0.325	0.032
Asian	1,885	2.3%	1,202	2.1%	0.226	0.016
Black or African American	21,339	25.8%	21,702	37.1%	-11.269	-0.245
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,924	8.4%	4,347	7.4%	0.946	0.035
White	51,574	62.3%	30,783	52.6%	9.772	0.199
Hispanic origin						
Yes	4,311	5.2%	2,955	5.0%	0.165	0.007
No	75,799	91.6%	54,205	92.6%	-0.946	-0.035
Unknown	2,613	3.2%	1,392	2.4%	0.781	0.048

Table 1bi. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,427	2.9%	5,050	8.6%	-5.691	-0.246
2011	6,044	7.3%	9,136	15.6%	-8.297	-0.263
2012	7,221	8.7%	7,322	12.5%	-3.776	-0.123
2013	7,434	9.0%	6,407	10.9%	-1.956	-0.065
2014	7,131	8.6%	5,290	9.0%	-0.414	-0.015
2015	7,635	9.2%	4,695	8.0%	1.211	0.043
2016	7,881	9.5%	4,279	7.3%	2.219	0.080
2017	8,039	9.7%	3,857	6.6%	3.131	0.115
2018	8,040	9.7%	3,386	5.8%	3.936	0.148
2019	7,412	9.0%	3,147	5.4%	3.585	0.139
2020	5,717	6.9%	2,508	4.3%	2.628	0.114
2021	5,288	6.4%	2,373	4.1%	2.340	0.105
2022	2,454	3.0%	1,102	1.9%	1.084	0.071
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.3	2.3	-0.253	-0.118
Substance abuse	29,275	35.4%	16,327	27.9%	7.505	0.162
Atrial fibrilation/flutter	1,424	1.7%	1,854	3.2%	-1.445	-0.094
Ischemic heart disease	5,891	7.1%	6,372	10.9%	-3.761	-0.132
Heart failure	3,171	3.8%	4,050	6.9%	-3.084	-0.137
Stroke	1,877	2.3%	2,306	3.9%	-1.669	-0.096
Diabetes	19,611	23.7%	16,781	28.7%	-4.953	-0.113
Hypertension	36,728	44.4%	30,367	51.9%	-7.465	-0.150
Rheumatic disease	409	0.5%	349	0.6%	-0.102	-0.014
Chronic kidney disease	8,997	10.9%	7,238	12.4%	-1.486	-0.046
Seizure disorder	9,170	11.1%	7,088	12.1%	-1.020	-0.032

Table 1bi. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	622	0.8%	559	1.0%	-0.203	-0.022
Dementia Diagnosis	6,002	7.3%	8,287	14.2%	-6.898	-0.225
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,262	1.5%	1,408	2.4%	-0.879	-0.063
COPD	12,764	15.4%	10,169	17.4%	-1.938	-0.052
Malignancy	2,603	3.1%	2,178	3.7%	-0.573	-0.031
Asthma	11,295	13.7%	6,811	11.6%	2.022	0.061
Hyperlipidemia	27,826	33.6%	20,810	35.5%	-1.903	-0.040
Depression	37,504	45.3%	22,555	38.5%	6.816	0.138
Schizophrenia	66,587	80.5%	47,252	80.7%	-0.207	-0.005
Bipolar disorder	38,633	46.7%	21,733	37.1%	9.584	0.195
ACE inhibitor use	13,498	16.3%	11,462	19.6%	-3.259	-0.085
ARB use	3,505	4.2%	3,121	5.3%	-1.093	-0.051
Beta-blocker use	15,754	19.0%	12,442	21.2%	-2.205	-0.055
Oral anticoagulant use	1,631	2.0%	1,528	2.6%	-0.638	-0.043
Antiplatelet agent use	1,145	1.4%	1,434	2.4%	-1.065	-0.078
Opioid use	15,752	19.0%	10,135	17.3%	1.732	0.045
Statin use	17,882	21.6%	14,085	24.1%	-2.439	-0.058
Wheelchair or walker use	207	0.3%	436	0.7%	-0.494	-0.070
Anti-arrhythmic use	281	0.3%	287	0.5%	-0.150	-0.023
Antidiabetic use	13,670	16.5%	10,958	18.7%	-2.190	-0.058
Calcium channel blocker use	8,637	10.4%	8,674	14.8%	-4.373	-0.132
Diuretic use	11,760	14.2%	10,628	18.2%	-3.935	-0.107
Antidepressant use	47,917	57.9%	28,524	48.7%	9.209	0.185
Gastric acid suppressant use	21,984	26.6%	15,204	26.0%	0.609	0.014
NSAIDs	18,024	21.8%	10,843	18.5%	3.270	0.082

Table 1bi. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,300	33.0%	16,377	28.0%	5.032	0.109
Chronic liver disease	5,218	6.3%	3,248	5.5%	0.761	0.032
Pneumonia	3,385	4.1%	3,340	5.7%	-1.612	-0.075
Cardiac arrhythmia	11,248	13.6%	7,281	12.4%	1.162	0.035
Paliperidone palmitate	82,723	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	*****	*****	-0.094	-0.036
Haloperidol decanoate	0	0.0%	58,552	100.0%	NaN	NaN
IS Stay	8,255	10.0%	6,389	10.9%	-0.933	-0.030
Medical Product Use						
Mean number of filled prescriptions	28.6	26.7	28.8	26.9	-0.240	-0.009
Mean number of generics dispensed	9.4	6.3	9.1	6.0	0.253	0.041
Mean number of unique drug classes dispensed	8.4	5.5	8.0	5.2	0.423	0.079
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.4	18.7	14.9	19.1	1.474	0.078
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.048	-0.051
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.029	-0.024

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bj. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	82,721	100.0%	58,551	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	50.7	15.8	-5.349	-0.362
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,427	27.1%	11,308	19.3%	7.799	0.186
35-44 years	19,588	23.7%	10,916	18.6%	5.036	0.124
45-54 years	19,292	23.3%	13,809	23.6%	-0.263	-0.006
55-64 years	14,218	17.2%	11,251	19.2%	-2.028	-0.053
65-74 years	5,846	7.1%	7,099	12.1%	-5.057	-0.172
75-84 years	1,137	1.4%	2,745	4.7%	-3.314	-0.194
≥ 85 years	213	0.3%	1,423	2.4%	-2.173	-0.190
Sex						
Female	33,459	40.4%	24,082	41.1%	-0.682	-0.014
Male	49,262	59.6%	34,469	58.9%	0.682	0.014
Race[2]						
American Indian or Alaska Native	1,001	1.2%	518	0.9%	0.325	0.032
Asian	1,885	2.3%	1,202	2.1%	0.226	0.016
Black or African American	21,339	25.8%	21,702	37.1%	-11.269	-0.245
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,924	8.4%	4,347	7.4%	0.946	0.035
White	51,572	62.3%	30,782	52.6%	9.772	0.199
Hispanic origin						
Yes	4,311	5.2%	2,955	5.0%	0.165	0.007
No	75,797	91.6%	54,204	92.6%	-0.946	-0.035
Unknown	2,613	3.2%	1,392	2.4%	0.781	0.048

Table 1bj. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,427	2.9%	5,050	8.6%	-5.691	-0.246
2011	6,044	7.3%	9,136	15.6%	-8.297	-0.263
2012	7,221	8.7%	7,322	12.5%	-3.776	-0.123
2013	7,434	9.0%	6,407	10.9%	-1.956	-0.065
2014	7,131	8.6%	5,290	9.0%	-0.414	-0.015
2015	7,635	9.2%	4,694	8.0%	1.213	0.043
2016	7,881	9.5%	4,279	7.3%	2.219	0.080
2017	8,039	9.7%	3,857	6.6%	3.131	0.115
2018	8,039	9.7%	3,386	5.8%	3.935	0.148
2019	7,411	9.0%	3,147	5.4%	3.584	0.139
2020	5,717	6.9%	2,508	4.3%	2.628	0.115
2021	5,288	6.4%	2,373	4.1%	2.340	0.105
2022	2,454	3.0%	1,102	1.9%	1.084	0.071
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.3	2.3	-0.253	-0.119
Substance abuse	29,274	35.4%	16,326	27.9%	7.505	0.162
Atrial fibrilation/flutter	1,423	1.7%	1,854	3.2%	-1.446	-0.094
Ischemic heart disease	5,891	7.1%	6,372	10.9%	-3.761	-0.132
Heart failure	3,170	3.8%	4,050	6.9%	-3.085	-0.137
Stroke	1,876	2.3%	2,306	3.9%	-1.671	-0.096
Diabetes	19,609	23.7%	16,781	28.7%	-4.955	-0.113
Hypertension	36,727	44.4%	30,366	51.9%	-7.464	-0.150
Rheumatic disease	408	0.5%	349	0.6%	-0.103	-0.014
Chronic kidney disease	8,995	10.9%	7,237	12.4%	-1.486	-0.046
Seizure disorder	9,170	11.1%	7,088	12.1%	-1.020	-0.032

Table 1bj. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	622	0.8%	559	1.0%	-0.203	-0.022
Dementia Diagnosis	6,001	7.3%	8,287	14.2%	-6.899	-0.225
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,262	1.5%	1,408	2.4%	-0.879	-0.063
COPD	12,763	15.4%	10,169	17.4%	-1.939	-0.052
Malignancy	2,603	3.1%	2,178	3.7%	-0.573	-0.031
Asthma	11,294	13.7%	6,810	11.6%	2.022	0.061
Hyperlipidemia	27,825	33.6%	20,810	35.5%	-1.904	-0.040
Depression	37,503	45.3%	22,554	38.5%	6.816	0.138
Schizophrenia	66,586	80.5%	47,251	80.7%	-0.206	-0.005
Bipolar disorder	38,632	46.7%	21,732	37.1%	9.585	0.195
ACE inhibitor use	13,498	16.3%	11,462	19.6%	-3.259	-0.085
ARB use	3,505	4.2%	3,121	5.3%	-1.093	-0.051
Beta-blocker use	15,752	19.0%	12,441	21.2%	-2.206	-0.055
Oral anticoagulant use	1,630	2.0%	1,528	2.6%	-0.639	-0.043
Antiplatelet agent use	1,145	1.4%	1,434	2.4%	-1.065	-0.078
Opioid use	15,751	19.0%	10,134	17.3%	1.733	0.045
Statin use	17,881	21.6%	14,085	24.1%	-2.440	-0.058
Wheelchair or walker use	206	0.2%	436	0.7%	-0.496	-0.071
Anti-arrhythmic use	281	0.3%	287	0.5%	-0.150	-0.023
Antidiabetic use	13,669	16.5%	10,958	18.7%	-2.191	-0.058
Calcium channel blocker use	8,637	10.4%	8,674	14.8%	-4.373	-0.132
Diuretic use	11,759	14.2%	10,628	18.2%	-3.936	-0.107
Antidepressant use	47,916	57.9%	28,523	48.7%	9.210	0.185
Gastric acid suppressant use	21,982	26.6%	15,203	26.0%	0.608	0.014
NSAIDs	18,023	21.8%	10,842	18.5%	3.271	0.082

Table 1bj. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,299	33.0%	16,376	28.0%	5.033	0.109
Chronic liver disease	5,217	6.3%	3,248	5.5%	0.759	0.032
Pneumonia	3,385	4.1%	3,340	5.7%	-1.612	-0.075
Cardiac arrhythmia	11,247	13.6%	7,281	12.4%	1.161	0.035
Paliperidone palmitate	82,721	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	*****	*****	-0.094	-0.036
Haloperidol decanoate	0	0.0%	58,551	100.0%	NaN	NaN
IS Stay	8,255	10.0%	6,389	10.9%	-0.933	-0.030
Medical Product Use						
Mean number of filled prescriptions	28.6	26.7	28.8	26.9	-0.239	-0.009
Mean number of generics dispensed	9.4	6.3	9.1	6.0	0.253	0.041
Mean number of unique drug classes dispensed	8.4	5.5	8.0	5.2	0.423	0.079
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.4	18.7	14.9	19.1	1.475	0.078
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.048	-0.052
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.029	-0.024

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bk. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	82,540	N/A	58,757	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	47.4	14.2	47.3	15.1	0.033	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	19,387	23.5%	14,852	25.3%	-1.788	-0.042
35-44 years	18,000	21.8%	12,559	21.4%	0.433	0.011
45-54 years	19,249	23.3%	13,718	23.3%	-0.026	-0.001
55-64 years	15,895	19.3%	9,712	16.5%	2.728	0.071
65-74 years	7,724	9.4%	5,298	9.0%	0.340	0.012
75-84 years	1,864	2.3%	1,781	3.0%	-0.773	-0.048
≥ 85 years	420	0.5%	836	1.4%	-0.914	-0.094
Sex						
Female	33,533	40.6%	23,883	40.6%	-0.021	-0.000
Male	49,007	59.4%	34,874	59.4%	0.021	0.000
Race[3]						
American Indian or Alaska Native	966	1.2%	571	1.0%	0.199	0.019
Asian	1,909	2.3%	1,223	2.1%	0.231	0.016
Black or African American	22,039	26.7%	21,088	35.9%	-9.189	-0.199
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,541	7.9%	4,760	8.1%	-0.178	-0.007
White	51,085	61.9%	31,115	53.0%	8.936	0.181
Hispanic origin						
Yes	4,130	5.0%	3,211	5.5%	-0.462	-0.021
No	75,999	92.1%	53,996	91.9%	0.178	0.007
Unknown	2,411	2.9%	1,549	2.6%	0.284	0.017

Table 1bk. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,441	3.0%	4,888	8.3%	-5.361	-0.234
2011	6,041	7.3%	8,858	15.1%	-7.757	-0.248
2012	7,256	8.8%	7,184	12.2%	-3.435	-0.112
2013	7,338	8.9%	6,534	11.1%	-2.230	-0.074
2014	7,025	8.5%	5,460	9.3%	-0.782	-0.027
2015	7,534	9.1%	4,824	8.2%	0.917	0.033
2016	7,823	9.5%	4,398	7.5%	1.992	0.072
2017	8,033	9.7%	3,906	6.6%	3.086	0.113
2018	7,968	9.7%	3,455	5.9%	3.773	0.141
2019	7,439	9.0%	3,204	5.5%	3.561	0.138
2020	5,783	7.0%	2,555	4.3%	2.658	0.115
2021	5,340	6.5%	2,402	4.1%	2.382	0.107
2022	2,517	3.0%	1,088	1.9%	1.197	0.077
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.2	2.1	2.2	2.1	-0.007	-0.003
Substance abuse	26,904	32.6%	19,322	32.9%	-0.289	-0.006
Atrial fibrilation/flutter	1,855	2.2%	1,344	2.3%	-0.040	-0.003
Ischemic heart disease	7,103	8.6%	5,072	8.6%	-0.026	-0.001
Heart failure	4,181	5.1%	2,993	5.1%	-0.029	-0.001
Stroke	2,395	2.9%	1,717	2.9%	-0.020	-0.001
Diabetes	21,287	25.8%	15,134	25.8%	0.033	0.001
Hypertension	39,196	47.5%	27,925	47.5%	-0.038	-0.001
Rheumatic disease	430	0.5%	313	0.5%	-0.012	-0.002
Chronic kidney disease	9,489	11.5%	6,765	11.5%	-0.018	-0.001
Seizure disorder	9,510	11.5%	6,784	11.5%	-0.024	-0.001

Table 1bk. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	683	0.8%	488	0.8%	-0.003	-0.000
Dementia Diagnosis	8,177	9.9%	5,865	10.0%	-0.075	-0.003
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,563	1.9%	1,115	1.9%	-0.004	-0.000
COPD	13,424	16.3%	9,550	16.3%	0.010	0.000
Malignancy	2,776	3.4%	1,984	3.4%	-0.013	-0.001
Asthma	10,618	12.9%	7,618	13.0%	-0.101	-0.003
Hyperlipidemia	28,518	34.6%	20,309	34.6%	-0.014	-0.000
Depression	35,241	42.7%	25,149	42.8%	-0.106	-0.002
Schizophrenia	67,099	81.3%	47,860	81.5%	-0.161	-0.004
Bipolar disorder	35,541	43.1%	25,412	43.3%	-0.191	-0.004
ACE inhibitor use	14,549	17.6%	10,333	17.6%	0.041	0.001
ARB use	3,848	4.7%	2,729	4.6%	0.017	0.001
Beta-blocker use	16,387	19.9%	11,676	19.9%	-0.017	-0.000
Oral anticoagulant use	1,807	2.2%	1,304	2.2%	-0.030	-0.002
Antiplatelet agent use	1,475	1.8%	1,059	1.8%	-0.015	-0.001
Opioid use	15,015	18.2%	10,690	18.2%	-0.003	-0.000
Statin use	18,677	22.6%	13,253	22.6%	0.073	0.002
Wheelchair or walker use	394	0.5%	270	0.5%	0.018	0.003
Anti-arrhythmic use	319	0.4%	228	0.4%	-0.001	-0.000
Antidiabetic use	14,341	17.4%	10,190	17.3%	0.032	0.001
Calcium channel blocker use	10,096	12.2%	7,168	12.2%	0.032	0.001
Diuretic use	12,990	15.7%	9,218	15.7%	0.049	0.001
Antidepressant use	44,623	54.1%	31,849	54.2%	-0.143	-0.003
Gastric acid suppressant use	21,678	26.3%	15,445	26.3%	-0.023	-0.001
NSAIDs	16,893	20.5%	12,034	20.5%	-0.014	-0.000

Table 1bk. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	25,508	30.9%	18,236	31.0%	-0.132	-0.003
Chronic liver disease	4,985	6.0%	3,584	6.1%	-0.060	-0.003
Pneumonia	3,914	4.7%	2,783	4.7%	0.006	0.000
Cardiac arrhythmia	10,912	13.2%	7,878	13.4%	-0.188	-0.006
Paliperidone palmitate	82,540	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	*****	*****	-0.102	-0.038
Haloperidol decanoate	0	0.0%	58,757	100.0%	NaN	NaN
IS Stay	8,707	10.5%	6,205	10.6%	-0.012	-0.000
Medical Product Use						
Mean number of filled prescriptions	28.3	26.8	29.0	26.8	-0.750	-0.028
Mean number of generics dispensed	9.2	6.3	9.3	6.1	-0.086	-0.014
Mean number of unique drug classes dispensed	8.3	5.5	8.1	5.3	0.141	0.026
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.4	16.0	20.0	-0.084	-0.004
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.006	-0.005

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1bl. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,675	100.0%	3,932	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.3	10.9	76.4	10.6	-6.167	-0.575
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.410	0.071
35-44 years	*****	*****	*****	*****	0.762	0.085
45-54 years	94	5.6%	85	2.2%	3.450	0.179
55-64 years	356	21.3%	419	10.7%	10.598	0.292
65-74 years	666	39.8%	1,145	29.1%	10.641	0.225
75-84 years	371	22.1%	1,393	35.4%	-13.278	-0.296
≥ 85 years	159	9.5%	868	22.1%	-12.583	-0.350
Sex						
Female	973	58.1%	2,305	58.6%	-0.532	-0.011
Male	702	41.9%	1,627	41.4%	0.532	0.011
Race[2]						
American Indian or Alaska Native	16	1.0%	12	0.3%	0.650	0.082
Asian	29	1.7%	49	1.2%	0.485	0.040
Black or African American	329	19.6%	902	22.9%	-3.298	-0.081
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	88	5.3%	159	4.0%	1.210	0.057
White	1,213	72.4%	2,810	71.5%	0.953	0.021
Hispanic origin						
Yes	67	4.0%	119	3.0%	0.974	0.053
No	1,587	94.7%	3,773	96.0%	-1.210	-0.057
Unknown	21	1.3%	40	1.0%	0.236	0.022

Table 1bl. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	219	5.6%	-3.182	-0.163
2011	69	4.1%	456	11.6%	-7.478	-0.281
2012	126	7.5%	403	10.2%	-2.727	-0.096
2013	138	8.2%	414	10.5%	-2.290	-0.079
2014	153	9.1%	394	10.0%	-0.886	-0.030
2015	172	10.3%	338	8.6%	1.673	0.057
2016	163	9.7%	349	8.9%	0.855	0.029
2017	185	11.0%	316	8.0%	3.008	0.103
2018	153	9.1%	286	7.3%	1.861	0.068
2019	168	10.0%	263	6.7%	3.341	0.121
2020	130	7.8%	189	4.8%	2.954	0.122
2021	123	7.3%	214	5.4%	1.901	0.078
2022	55	3.3%	91	2.3%	0.969	0.059
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.6	5.2	2.9	-0.037	-0.013
Substance abuse	264	15.8%	401	10.2%	5.563	0.166
Atrial fibrilation/flutter	187	11.2%	540	13.7%	-2.569	-0.078
Ischemic heart disease	441	26.3%	1,272	32.3%	-6.022	-0.133
Heart failure	315	18.8%	881	22.4%	-3.600	-0.089
Stroke	224	13.4%	631	16.0%	-2.675	-0.076
Diabetes	740	44.2%	1,650	42.0%	2.216	0.045
Hypertension	1,412	84.3%	3,336	84.8%	-0.544	-0.015
Rheumatic disease	17	1.0%	65	1.7%	-0.638	-0.056
Chronic kidney disease	517	30.9%	1,176	29.9%	0.957	0.021
Seizure disorder	361	21.6%	753	19.2%	2.402	0.060

Table 1bl. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,675	100.0%	3,932	100.0%	0.000	NaN
Dementia Diagnosis	1,675	100.0%	3,932	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,675	100.0%	3,932	100.0%	0.000	NaN
Parkinsons disease	213	12.7%	392	10.0%	2.747	0.087
COPD	496	29.6%	1,088	27.7%	1.942	0.043
Malignancy	86	5.1%	230	5.8%	-0.715	-0.031
Asthma	154	9.2%	265	6.7%	2.454	0.091
Hyperlipidemia	1,017	60.7%	2,177	55.4%	5.350	0.109
Depression	1,129	67.4%	2,306	58.6%	8.756	0.182
Schizophrenia	1,119	66.8%	1,549	39.4%	27.411	0.571
Bipolar disorder	766	45.7%	1,208	30.7%	15.009	0.313
ACE inhibitor use	511	30.5%	1,187	30.2%	0.319	0.007
ARB use	181	10.8%	454	11.5%	-0.740	-0.023
Beta-blocker use	619	37.0%	1,496	38.0%	-1.092	-0.023
Oral anticoagulant use	134	8.0%	336	8.5%	-0.545	-0.020
Antiplatelet agent use	150	9.0%	397	10.1%	-1.141	-0.039
Opioid use	403	24.1%	1,068	27.2%	-3.102	-0.071
Statin use	757	45.2%	1,642	41.8%	3.434	0.069
Wheelchair or walker use	48	2.9%	163	4.1%	-1.280	-0.070
Anti-arrhythmic use	28	1.7%	98	2.5%	-0.821	-0.058
Antidiabetic use	448	26.7%	971	24.7%	2.051	0.047
Calcium channel blocker use	466	27.8%	1,170	29.8%	-1.935	-0.043
Diuretic use	585	34.9%	1,348	34.3%	0.643	0.014
Antidepressant use	1,272	75.9%	2,848	72.4%	3.509	0.080
Gastric acid suppressant use	657	39.2%	1,543	39.2%	-0.018	-0.000
NSAIDs	345	20.6%	607	15.4%	5.160	0.135

Table 1bl. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	779	46.5%	1,626	41.4%	5.154	0.104
Chronic liver disease	112	6.7%	233	5.9%	0.761	0.031
Pneumonia	233	13.9%	563	14.3%	-0.408	-0.012
Cardiac arrhythmia	326	19.5%	674	17.1%	2.321	0.060
Paliperidone palmitate	1,675	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	3,932	100.0%	NaN	NaN
IS Stay	303	18.1%	573	14.6%	3.517	0.095
Medical Product Use						
Mean number of filled prescriptions	51.2	35.4	48.5	32.3	2.643	0.078
Mean number of generics dispensed	14.7	6.2	13.9	5.7	0.805	0.135
Mean number of unique drug classes dispensed	13.3	5.4	12.4	4.9	0.940	0.182
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.0	19.0	12.2	15.4	5.725	0.331
Mean number of inpatient hospital encounters	0.5	0.9	0.6	1.0	-0.084	-0.090
Mean number of non-acute institutional encounters	1.4	1.5	1.2	1.5	0.278	0.190

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bm. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,670	99.7%	3,929	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.3	10.9	76.4	10.5	-6.131	-0.572
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.412	0.071
35-44 years	*****	*****	*****	*****	0.765	0.085
45-54 years	91	5.4%	85	2.2%	3.286	0.172
55-64 years	355	21.3%	419	10.7%	10.593	0.292
65-74 years	666	39.9%	1,144	29.1%	10.763	0.228
75-84 years	370	22.2%	1,392	35.4%	-13.273	-0.296
≥ 85 years	159	9.5%	867	22.1%	-12.546	-0.349
Sex						
Female	972	58.2%	2,303	58.6%	-0.412	-0.008
Male	698	41.8%	1,626	41.4%	0.412	0.008
Race[2]						
American Indian or Alaska Native	16	1.0%	12	0.3%	0.653	0.082
Asian	29	1.7%	49	1.2%	0.489	0.040
Black or African American	327	19.6%	900	22.9%	-3.326	-0.081
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	88	5.3%	159	4.0%	1.223	0.058
White	1,210	72.5%	2,809	71.5%	0.961	0.021
Hispanic origin						
Yes	67	4.0%	119	3.0%	0.983	0.053
No	1,582	94.7%	3,770	96.0%	-1.223	-0.058
Unknown	21	1.3%	40	1.0%	0.239	0.023

Table 1bm. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	219	5.6%	-3.179	-0.163
2011	69	4.1%	456	11.6%	-7.474	-0.280
2012	126	7.5%	403	10.3%	-2.712	-0.095
2013	138	8.3%	414	10.5%	-2.274	-0.078
2014	152	9.1%	391	10.0%	-0.850	-0.029
2015	172	10.3%	338	8.6%	1.697	0.058
2016	162	9.7%	349	8.9%	0.818	0.028
2017	184	11.0%	316	8.0%	2.975	0.101
2018	153	9.2%	286	7.3%	1.882	0.069
2019	167	10.0%	263	6.7%	3.306	0.120
2020	130	7.8%	189	4.8%	2.974	0.123
2021	123	7.4%	214	5.4%	1.919	0.078
2022	54	3.2%	91	2.3%	0.917	0.056
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.6	5.2	2.9	-0.033	-0.012
Substance abuse	262	15.7%	400	10.2%	5.508	0.165
Atrial fibrilation/flutter	186	11.1%	540	13.7%	-2.606	-0.079
Ischemic heart disease	440	26.3%	1,270	32.3%	-5.976	-0.132
Heart failure	314	18.8%	880	22.4%	-3.595	-0.089
Stroke	222	13.3%	629	16.0%	-2.716	-0.077
Diabetes	737	44.1%	1,649	42.0%	2.162	0.044
Hypertension	1,408	84.3%	3,333	84.8%	-0.519	-0.014
Rheumatic disease	16	1.0%	64	1.6%	-0.671	-0.059
Chronic kidney disease	514	30.8%	1,173	29.9%	0.924	0.020
Seizure disorder	361	21.6%	752	19.1%	2.477	0.062

Table 1bm. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,670	100.0%	3,929	100.0%	0.000	NaN
Dementia Diagnosis	1,670	100.0%	3,929	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,670	100.0%	3,929	100.0%	0.000	NaN
Parkinsons disease	213	12.8%	392	10.0%	2.777	0.088
COPD	494	29.6%	1,086	27.6%	1.940	0.043
Malignancy	86	5.1%	230	5.9%	-0.704	-0.031
Asthma	153	9.2%	265	6.7%	2.417	0.089
Hyperlipidemia	1,012	60.6%	2,175	55.4%	5.241	0.106
Depression	1,126	67.4%	2,305	58.7%	8.759	0.182
Schizophrenia	1,115	66.8%	1,548	39.4%	27.367	0.570
Bipolar disorder	762	45.6%	1,207	30.7%	14.908	0.311
ACE inhibitor use	508	30.4%	1,185	30.2%	0.259	0.006
ARB use	180	10.8%	454	11.6%	-0.777	-0.025
Beta-blocker use	616	36.9%	1,494	38.0%	-1.139	-0.024
Oral anticoagulant use	133	8.0%	335	8.5%	-0.562	-0.020
Antiplatelet agent use	150	9.0%	397	10.1%	-1.122	-0.038
Opioid use	403	24.1%	1,067	27.2%	-3.025	-0.069
Statin use	754	45.1%	1,642	41.8%	3.358	0.068
Wheelchair or walker use	48	2.9%	163	4.1%	-1.274	-0.069
Anti-arrhythmic use	28	1.7%	98	2.5%	-0.818	-0.057
Antidiabetic use	446	26.7%	971	24.7%	1.993	0.046
Calcium channel blocker use	464	27.8%	1,169	29.8%	-1.969	-0.043
Diuretic use	583	34.9%	1,348	34.3%	0.601	0.013
Antidepressant use	1,268	75.9%	2,846	72.4%	3.492	0.080
Gastric acid suppressant use	655	39.2%	1,541	39.2%	0.000	0.000
NSAIDs	341	20.4%	607	15.4%	4.970	0.130

Table 1bm. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	776	46.5%	1,624	41.3%	5.133	0.104
Chronic liver disease	110	6.6%	232	5.9%	0.682	0.028
Pneumonia	232	13.9%	561	14.3%	-0.386	-0.011
Cardiac arrhythmia	323	19.3%	672	17.1%	2.238	0.058
Paliperidone palmitate	1,670	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	3,929	100.0%	NaN	NaN
IS Stay	301	18.0%	572	14.6%	3.466	0.094
Medical Product Use						
Mean number of filled prescriptions	51.1	35.4	48.5	32.3	2.564	0.076
Mean number of generics dispensed	14.7	6.2	13.9	5.7	0.794	0.133
Mean number of unique drug classes dispensed	13.3	5.4	12.4	4.9	0.935	0.181
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	18.5	12.2	15.4	5.527	0.325
Mean number of inpatient hospital encounters	0.5	0.9	0.6	1.0	-0.080	-0.087
Mean number of non-acute institutional encounters	1.4	1.5	1.2	1.5	0.279	0.190

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bn. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,662	N/A	3,947	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	74.5	11.0	74.5	11.2	0.027	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	*****	*****	16	0.4%	-0.186	-0.033
35-44 years	*****	*****	29	0.7%	-0.157	-0.019
45-54 years	54	3.3%	125	3.2%	0.093	0.005
55-64 years	231	13.9%	560	14.2%	-0.277	-0.008
65-74 years	560	33.7%	1,235	31.3%	2.438	0.052
75-84 years	487	29.3%	1,271	32.2%	-2.871	-0.062
≥ 85 years	316	19.0%	712	18.0%	0.961	0.025
Sex						
Female	950	57.2%	2,303	58.4%	-1.208	-0.024
Male	712	42.8%	1,644	41.6%	1.208	0.024
Race[3]						
American Indian or Alaska Native	16	1.0%	12	0.3%	0.667	0.084
Asian	21	1.2%	48	1.2%	0.018	0.002
Black or African American	310	18.6%	956	24.2%	-5.588	-0.136
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	86	5.2%	163	4.1%	1.062	0.050
White	1,229	74.0%	2,768	70.1%	3.841	0.086
Hispanic origin						
Yes	63	3.8%	121	3.1%	0.744	0.041
No	1,575	94.8%	3,784	95.9%	-1.062	-0.050
Unknown	23	1.4%	43	1.1%	0.318	0.029

Table 1bn. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	44	2.6%	212	5.4%	-2.725	-0.139
2011	75	4.5%	454	11.5%	-7.010	-0.261
2012	119	7.2%	395	10.0%	-2.846	-0.102
2013	160	9.6%	412	10.4%	-0.809	-0.027
2014	152	9.1%	385	9.8%	-0.601	-0.021
2015	184	11.1%	340	8.6%	2.480	0.083
2016	148	8.9%	358	9.1%	-0.136	-0.005
2017	191	11.5%	325	8.2%	3.262	0.110
2018	146	8.8%	290	7.4%	1.459	0.054
2019	155	9.3%	274	6.9%	2.365	0.087
2020	123	7.4%	188	4.8%	2.656	0.111
2021	112	6.8%	219	5.6%	1.207	0.050
2022	52	3.1%	97	2.4%	0.696	0.042
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.3	2.7	5.2	2.8	0.059	0.021
Substance abuse	206	12.4%	472	12.0%	0.445	0.014
Atrial fibrilation/flutter	223	13.4%	515	13.0%	0.349	0.010
Ischemic heart disease	523	31.4%	1,205	30.5%	0.919	0.020
Heart failure	371	22.4%	853	21.6%	0.744	0.018
Stroke	267	16.1%	604	15.3%	0.788	0.022
Diabetes	705	42.4%	1,685	42.7%	-0.288	-0.006
Hypertension	1,420	85.4%	3,352	84.9%	0.510	0.014
Rheumatic disease	22	1.3%	57	1.4%	-0.098	-0.008
Chronic kidney disease	500	30.1%	1,185	30.0%	0.070	0.002
Seizure disorder	358	21.5%	797	20.2%	1.348	0.033

Table 1bn. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	1,662	100.0%	3,947	100.0%	0.000	NaN
Dementia Diagnosis	1,662	100.0%	3,947	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,662	100.0%	3,947	100.0%	0.000	NaN
Parkinsons disease	178	10.7%	431	10.9%	-0.212	-0.007
COPD	475	28.6%	1,117	28.3%	0.303	0.007
Malignancy	94	5.7%	223	5.6%	0.014	0.001
Asthma	140	8.4%	304	7.7%	0.706	0.026
Hyperlipidemia	939	56.5%	2,247	56.9%	-0.420	-0.008
Depression	1,030	62.0%	2,434	61.7%	0.307	0.006
Schizophrenia	795	47.9%	1,888	47.8%	0.026	0.001
Bipolar disorder	606	36.4%	1,410	35.7%	0.706	0.015
ACE inhibitor use	516	31.1%	1,189	30.1%	0.947	0.021
ARB use	180	10.8%	446	11.3%	-0.452	-0.014
Beta-blocker use	645	38.8%	1,494	37.8%	0.971	0.020
Oral anticoagulant use	148	8.9%	334	8.5%	0.448	0.016
Antiplatelet agent use	179	10.8%	387	9.8%	0.997	0.033
Opioid use	432	26.0%	1,038	26.3%	-0.316	-0.007
Statin use	721	43.4%	1,697	43.0%	0.415	0.008
Wheelchair or walker use	62	3.7%	148	3.8%	-0.029	-0.002
Anti-arrhythmic use	41	2.5%	91	2.3%	0.170	0.011
Antidiabetic use	414	24.9%	998	25.3%	-0.354	-0.008
Calcium channel blocker use	499	30.1%	1,158	29.3%	0.719	0.016
Diuretic use	563	33.9%	1,363	34.5%	-0.676	-0.014
Antidepressant use	1,218	73.3%	2,898	73.4%	-0.134	-0.003
Gastric acid suppressant use	658	39.6%	1,557	39.5%	0.116	0.002
NSAIDs	272	16.4%	674	17.1%	-0.681	-0.018

Table 1bn. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	705	42.4%	1,690	42.8%	-0.369	-0.007
Chronic liver disease	98	5.9%	248	6.3%	-0.363	-0.015
Pneumonia	238	14.3%	559	14.2%	0.159	0.005
Cardiac arrhythmia	301	18.1%	711	18.0%	0.122	0.003
Paliperidone palmitate	1,662	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	3,947	100.0%	NaN	NaN
IS Stay	293	17.6%	637	16.1%	1.473	0.039
Medical Product Use						
Mean number of filled prescriptions	49.1	34.3	49.4	32.8	-0.245	-0.007
Mean number of generics dispensed	14.2	6.1	14.1	5.8	0.089	0.015
Mean number of unique drug classes dispensed	12.9	5.3	12.6	5.0	0.393	0.077
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.4	15.4	14.4	19.0	0.005	0.000
Mean number of inpatient hospital encounters	0.6	1.0	0.6	0.9	0.030	0.031
Mean number of non-acute institutional encounters	1.3	1.5	1.3	1.5	0.085	0.057

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1bo. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	75,840	100.0%	55,522	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.9	52.2	16.8	-6.623	-0.431
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	20,407	26.9%	10,071	18.1%	8.769	0.211
35-44 years	17,823	23.5%	9,817	17.7%	5.820	0.144
45-54 years	17,577	23.2%	12,479	22.5%	0.701	0.017
55-64 years	12,898	17.0%	10,298	18.5%	-1.541	-0.040
65-74 years	5,572	7.3%	7,156	12.9%	-5.542	-0.185
75-84 years	1,251	1.6%	3,644	6.6%	-4.914	-0.250
≥ 85 years	312	0.4%	2,057	3.7%	-3.293	-0.234
Sex						
Female	30,706	40.5%	23,389	42.1%	-1.638	-0.033
Male	45,134	59.5%	32,133	57.9%	1.638	0.033
Race[2]						
American Indian or Alaska Native	913	1.2%	475	0.9%	0.348	0.035
Asian	1,736	2.3%	1,104	2.0%	0.301	0.021
Black or African American	19,575	25.8%	20,465	36.9%	-11.048	-0.240
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,390	8.4%	4,003	7.2%	1.216	0.045
White	47,226	62.3%	29,475	53.1%	9.184	0.187
Hispanic origin						
Yes	3,991	5.3%	2,748	4.9%	0.313	0.014
No	69,450	91.6%	51,519	92.8%	-1.216	-0.045
Unknown	2,399	3.2%	1,255	2.3%	0.903	0.056

Table 1bo. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,266	3.0%	4,855	8.7%	-5.756	-0.247
2011	5,627	7.4%	8,648	15.6%	-8.156	-0.258
2012	6,646	8.8%	6,893	12.4%	-3.652	-0.119
2013	6,800	9.0%	6,072	10.9%	-1.970	-0.066
2014	6,510	8.6%	4,971	9.0%	-0.369	-0.013
2015	7,025	9.3%	4,426	8.0%	1.291	0.046
2016	7,255	9.6%	4,069	7.3%	2.238	0.081
2017	7,385	9.7%	3,671	6.6%	3.126	0.114
2018	7,320	9.7%	3,215	5.8%	3.861	0.145
2019	6,797	9.0%	3,000	5.4%	3.559	0.138
2020	5,177	6.8%	2,362	4.3%	2.572	0.113
2021	4,781	6.3%	2,282	4.1%	2.194	0.099
2022	2,251	3.0%	1,058	1.9%	1.063	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.4	2.4	-0.361	-0.164
Substance abuse	25,769	34.0%	14,286	25.7%	8.248	0.181
Atrial fibrilation/flutter	1,358	1.8%	2,061	3.7%	-1.921	-0.118
Ischemic heart disease	5,374	7.1%	6,484	11.7%	-4.592	-0.158
Heart failure	2,937	3.9%	4,214	7.6%	-3.717	-0.160
Stroke	1,791	2.4%	2,529	4.6%	-2.193	-0.120
Diabetes	17,973	23.7%	16,123	29.0%	-5.340	-0.121
Hypertension	33,218	43.8%	29,321	52.8%	-9.010	-0.181
Rheumatic disease	360	0.5%	350	0.6%	-0.156	-0.021
Chronic kidney disease	8,198	10.8%	7,137	12.9%	-2.045	-0.063
Seizure disorder	8,218	10.8%	6,702	12.1%	-1.235	-0.039

Table 1bo. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,920	2.5%	3,861	7.0%	-4.422	-0.209
Dementia Diagnosis	6,283	8.3%	10,344	18.6%	-10.346	-0.307
Dementia Diagnosis and Treatment	1,372	1.8%	3,359	6.0%	-4.241	-0.220
Parkinsons disease	1,213	1.6%	1,516	2.7%	-1.131	-0.078
COPD	11,501	15.2%	9,657	17.4%	-2.228	-0.060
Malignancy	2,350	3.1%	2,074	3.7%	-0.637	-0.035
Asthma	9,983	13.2%	6,061	10.9%	2.247	0.069
Hyperlipidemia	25,337	33.4%	19,976	36.0%	-2.570	-0.054
Depression	33,757	44.5%	21,348	38.4%	6.061	0.123
Schizophrenia	60,133	79.3%	42,820	77.1%	2.167	0.053
Bipolar disorder	34,418	45.4%	19,556	35.2%	10.160	0.208
ACE inhibitor use	12,395	16.3%	11,149	20.1%	-3.737	-0.097
ARB use	3,287	4.3%	3,141	5.7%	-1.323	-0.061
Beta-blocker use	14,374	19.0%	12,119	21.8%	-2.874	-0.071
Oral anticoagulant use	1,544	2.0%	1,645	3.0%	-0.927	-0.059
Antiplatelet agent use	1,126	1.5%	1,603	2.9%	-1.402	-0.096
Opioid use	14,547	19.2%	10,009	18.0%	1.154	0.030
Statin use	16,568	21.8%	13,769	24.8%	-2.953	-0.070
Wheelchair or walker use	215	0.3%	540	1.0%	-0.689	-0.087
Anti-arrhythmic use	272	0.4%	345	0.6%	-0.263	-0.038
Antidiabetic use	12,633	16.7%	10,460	18.8%	-2.182	-0.057
Calcium channel blocker use	7,971	10.5%	8,664	15.6%	-5.094	-0.152
Diuretic use	10,941	14.4%	10,514	18.9%	-4.510	-0.121
Antidepressant use	44,122	58.2%	27,615	49.7%	8.441	0.170
Gastric acid suppressant use	20,095	26.5%	14,606	26.3%	0.190	0.004
NSAIDs	16,438	21.7%	10,132	18.2%	3.426	0.086

Table 1bo. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,778	32.7%	15,513	27.9%	4.731	0.103
Chronic liver disease	4,678	6.2%	3,016	5.4%	0.736	0.031
Pneumonia	3,084	4.1%	3,306	6.0%	-1.888	-0.087
Cardiac arrhythmia	9,763	12.9%	6,693	12.1%	0.818	0.025
Paliperidone palmitate	75,840	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	62	0.1%	-0.089	-0.034
Haloperidol decanoate	0	0.0%	55,522	100.0%	NaN	NaN
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.8	27.0	29.8	27.7	-0.922	-0.034
Mean number of generics dispensed	9.4	6.3	9.2	6.1	0.141	0.023
Mean number of unique drug classes dispensed	8.4	5.5	8.1	5.3	0.288	0.054
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.2	14.2	18.3	1.743	0.096
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.047	-0.051
Mean number of non-acute institutional encounters	0.7	1.1	0.8	1.2	-0.021	-0.018

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bp. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	75,837	100.0%	55,521	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.9	52.2	16.8	-6.622	-0.431
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	20,405	26.9%	10,071	18.1%	8.767	0.211
35-44 years	17,823	23.5%	9,817	17.7%	5.820	0.144
45-54 years	17,577	23.2%	12,479	22.5%	0.701	0.017
55-64 years	12,898	17.0%	10,298	18.5%	-1.540	-0.040
65-74 years	5,572	7.3%	7,155	12.9%	-5.540	-0.184
75-84 years	1,250	1.6%	3,644	6.6%	-4.915	-0.250
≥ 85 years	312	0.4%	2,057	3.7%	-3.293	-0.234
Sex						
Female	30,704	40.5%	23,389	42.1%	-1.640	-0.033
Male	45,133	59.5%	32,132	57.9%	1.640	0.033
Race[2]						
American Indian or Alaska Native	913	1.2%	475	0.9%	0.348	0.035
Asian	1,736	2.3%	1,104	2.0%	0.301	0.021
Black or African American	19,575	25.8%	20,464	36.9%	-11.046	-0.240
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,390	8.4%	4,003	7.2%	1.216	0.045
White	47,223	62.3%	29,475	53.1%	9.181	0.187
Hispanic origin						
Yes	3,991	5.3%	2,748	4.9%	0.313	0.014
No	69,447	91.6%	51,518	92.8%	-1.216	-0.045
Unknown	2,399	3.2%	1,255	2.3%	0.903	0.056

Table 1bp. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,266	3.0%	4,855	8.7%	-5.756	-0.247
2011	5,627	7.4%	8,648	15.6%	-8.156	-0.258
2012	6,646	8.8%	6,893	12.4%	-3.652	-0.119
2013	6,799	9.0%	6,071	10.9%	-1.969	-0.066
2014	6,510	8.6%	4,971	9.0%	-0.369	-0.013
2015	7,024	9.3%	4,426	8.0%	1.290	0.046
2016	7,255	9.6%	4,069	7.3%	2.238	0.081
2017	7,385	9.7%	3,671	6.6%	3.126	0.114
2018	7,320	9.7%	3,215	5.8%	3.862	0.145
2019	6,796	9.0%	3,000	5.4%	3.558	0.138
2020	5,177	6.8%	2,362	4.3%	2.572	0.113
2021	4,781	6.3%	2,282	4.1%	2.194	0.099
2022	2,251	3.0%	1,058	1.9%	1.063	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.4	2.4	-0.361	-0.164
Substance abuse	25,767	34.0%	14,286	25.7%	8.246	0.181
Atrial fibrilation/flutter	1,358	1.8%	2,060	3.7%	-1.920	-0.118
Ischemic heart disease	5,373	7.1%	6,483	11.7%	-4.592	-0.158
Heart failure	2,936	3.9%	4,213	7.6%	-3.717	-0.160
Stroke	1,791	2.4%	2,529	4.6%	-2.193	-0.120
Diabetes	17,971	23.7%	16,122	29.0%	-5.341	-0.121
Hypertension	33,217	43.8%	29,320	52.8%	-9.008	-0.181
Rheumatic disease	360	0.5%	350	0.6%	-0.156	-0.021
Chronic kidney disease	8,196	10.8%	7,137	12.9%	-2.047	-0.063
Seizure disorder	8,217	10.8%	6,701	12.1%	-1.234	-0.039

Table 1bp. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,919	2.5%	3,860	7.0%	-4.422	-0.209
Dementia Diagnosis	6,282	8.3%	10,343	18.6%	-10.345	-0.307
Dementia Diagnosis and Treatment	1,371	1.8%	3,358	6.0%	-4.240	-0.220
Parkinsons disease	1,213	1.6%	1,516	2.7%	-1.131	-0.078
COPD	11,499	15.2%	9,656	17.4%	-2.229	-0.060
Malignancy	2,350	3.1%	2,074	3.7%	-0.637	-0.035
Asthma	9,982	13.2%	6,060	10.9%	2.248	0.069
Hyperlipidemia	25,335	33.4%	19,976	36.0%	-2.572	-0.054
Depression	33,754	44.5%	21,348	38.5%	6.058	0.123
Schizophrenia	60,131	79.3%	42,819	77.1%	2.168	0.053
Bipolar disorder	34,416	45.4%	19,556	35.2%	10.159	0.208
ACE inhibitor use	12,395	16.3%	11,149	20.1%	-3.736	-0.097
ARB use	3,287	4.3%	3,141	5.7%	-1.323	-0.061
Beta-blocker use	14,373	19.0%	12,118	21.8%	-2.873	-0.071
Oral anticoagulant use	1,544	2.0%	1,645	3.0%	-0.927	-0.059
Antiplatelet agent use	1,125	1.5%	1,603	2.9%	-1.404	-0.096
Opioid use	14,546	19.2%	10,009	18.0%	1.153	0.030
Statin use	16,566	21.8%	13,769	24.8%	-2.955	-0.070
Wheelchair or walker use	214	0.3%	540	1.0%	-0.690	-0.088
Anti-arrhythmic use	272	0.4%	344	0.6%	-0.261	-0.037
Antidiabetic use	12,630	16.7%	10,459	18.8%	-2.184	-0.057
Calcium channel blocker use	7,971	10.5%	8,663	15.6%	-5.092	-0.152
Diuretic use	10,939	14.4%	10,513	18.9%	-4.511	-0.121
Antidepressant use	44,120	58.2%	27,615	49.7%	8.439	0.170
Gastric acid suppressant use	20,092	26.5%	14,606	26.3%	0.187	0.004
NSAIDs	16,437	21.7%	10,132	18.2%	3.425	0.086

Table 1bp. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,776	32.7%	15,513	27.9%	4.729	0.103
Chronic liver disease	4,676	6.2%	3,016	5.4%	0.734	0.031
Pneumonia	3,082	4.1%	3,305	6.0%	-1.889	-0.087
Cardiac arrhythmia	9,762	12.9%	6,692	12.1%	0.819	0.025
Paliperidone palmitate	75,837	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	62	0.1%	-0.089	-0.034
Haloperidol decanoate	0	0.0%	55,521	100.0%	NaN	NaN
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.8	27.0	29.8	27.7	-0.924	-0.034
Mean number of generics dispensed	9.4	6.3	9.2	6.1	0.141	0.023
Mean number of unique drug classes dispensed	8.4	5.5	8.1	5.3	0.288	0.053
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.2	14.2	18.3	1.742	0.096
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.047	-0.050
Mean number of non-acute institutional encounters	0.7	1.1	0.8	1.2	-0.021	-0.018

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bq. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	75,556	N/A	55,806	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.1	14.8	48.1	15.9	-0.000	-0.000
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	17,235	22.8%	13,824	24.8%	-1.961	-0.046
35-44 years	16,054	21.2%	11,669	20.9%	0.339	0.008
45-54 years	17,280	22.9%	12,667	22.7%	0.172	0.004
55-64 years	14,375	19.0%	8,963	16.1%	2.964	0.078
65-74 years	7,608	10.1%	5,250	9.4%	0.662	0.022
75-84 years	2,264	3.0%	2,266	4.1%	-1.064	-0.058
≥ 85 years	739	1.0%	1,167	2.1%	-1.113	-0.091
Sex						
Female	30,997	41.0%	22,925	41.1%	-0.055	-0.001
Male	44,559	59.0%	32,881	58.9%	0.055	0.001
Race[3]						
American Indian or Alaska Native	874	1.2%	538	1.0%	0.194	0.019
Asian	1,750	2.3%	1,138	2.0%	0.277	0.019
Black or African American	20,127	26.6%	20,121	36.1%	-9.416	-0.204
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	5,980	7.9%	4,459	8.0%	-0.075	-0.003
White	46,824	62.0%	29,551	53.0%	9.020	0.183
Hispanic origin						
Yes	3,796	5.0%	3,030	5.4%	-0.405	-0.018
No	69,576	92.1%	51,347	92.0%	0.075	0.003
Unknown	2,184	2.9%	1,429	2.6%	0.330	0.020

Table 1bq. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	2,275	3.0%	4,737	8.5%	-5.478	-0.237
2011	5,579	7.4%	8,449	15.1%	-7.756	-0.247
2012	6,640	8.8%	6,817	12.2%	-3.427	-0.112
2013	6,724	8.9%	6,213	11.1%	-2.234	-0.074
2014	6,404	8.5%	5,140	9.2%	-0.733	-0.026
2015	6,918	9.2%	4,552	8.2%	1.000	0.036
2016	7,164	9.5%	4,171	7.5%	2.009	0.072
2017	7,395	9.8%	3,700	6.6%	3.157	0.115
2018	7,247	9.6%	3,281	5.9%	3.713	0.139
2019	6,824	9.0%	3,030	5.4%	3.602	0.139
2020	5,239	6.9%	2,391	4.3%	2.651	0.115
2021	4,836	6.4%	2,286	4.1%	2.305	0.103
2022	2,310	3.1%	1,041	1.9%	1.193	0.077
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.2	2.2	2.2	2.2	-0.008	-0.004
Substance abuse	23,328	30.9%	17,404	31.2%	-0.311	-0.007
Atrial fibrilation/flutter	1,923	2.5%	1,433	2.6%	-0.023	-0.001
Ischemic heart disease	6,733	8.9%	4,997	9.0%	-0.042	-0.001
Heart failure	4,079	5.4%	3,023	5.4%	-0.020	-0.001
Stroke	2,443	3.2%	1,815	3.3%	-0.019	-0.001
Diabetes	19,632	26.0%	14,485	26.0%	0.027	0.001
Hypertension	35,950	47.6%	26,585	47.6%	-0.058	-0.001
Rheumatic disease	399	0.5%	294	0.5%	0.001	0.000
Chronic kidney disease	8,799	11.6%	6,519	11.7%	-0.035	-0.001
Seizure disorder	8,615	11.4%	6,361	11.4%	0.004	0.000

Table 1bq. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	3,241	4.3%	2,429	4.4%	-0.063	-0.003
Dementia Diagnosis	9,302	12.3%	6,958	12.5%	-0.157	-0.005
Dementia Diagnosis and Treatment	2,644	3.5%	1,986	3.6%	-0.059	-0.003
Parkinsons disease	1,568	2.1%	1,162	2.1%	-0.007	-0.001
COPD	12,209	16.2%	9,014	16.2%	0.007	0.000
Malignancy	2,522	3.3%	1,873	3.4%	-0.018	-0.001
Asthma	9,312	12.3%	6,931	12.4%	-0.096	-0.003
Hyperlipidemia	26,159	34.6%	19,323	34.6%	-0.003	-0.000
Depression	31,854	42.2%	23,599	42.3%	-0.127	-0.003
Schizophrenia	60,024	79.4%	44,343	79.5%	-0.015	-0.000
Bipolar disorder	31,385	41.5%	23,290	41.7%	-0.196	-0.004
ACE inhibitor use	13,530	17.9%	9,963	17.9%	0.053	0.001
ARB use	3,662	4.8%	2,699	4.8%	0.011	0.000
Beta-blocker use	15,142	20.0%	11,195	20.1%	-0.020	-0.001
Oral anticoagulant use	1,806	2.4%	1,339	2.4%	-0.010	-0.001
Antiplatelet agent use	1,537	2.0%	1,145	2.1%	-0.019	-0.001
Opioid use	13,981	18.5%	10,348	18.5%	-0.038	-0.001
Statin use	17,460	23.1%	12,845	23.0%	0.091	0.002
Wheelchair or walker use	442	0.6%	321	0.6%	0.010	0.001
Anti-arrhythmic use	336	0.4%	252	0.5%	-0.007	-0.001
Antidiabetic use	13,245	17.5%	9,763	17.5%	0.035	0.001
Calcium channel blocker use	9,558	12.7%	7,037	12.6%	0.041	0.001
Diuretic use	12,263	16.2%	9,034	16.2%	0.042	0.001
Antidepressant use	41,180	54.5%	30,542	54.7%	-0.226	-0.005
Gastric acid suppressant use	19,906	26.3%	14,728	26.4%	-0.045	-0.001
NSAIDs	15,347	20.3%	11,339	20.3%	-0.007	-0.000

Table 1bq. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	23,140	30.6%	17,192	30.8%	-0.180	-0.004
Chronic liver disease	4,460	5.9%	3,327	6.0%	-0.058	-0.002
Pneumonia	3,640	4.8%	2,702	4.8%	-0.023	-0.001
Cardiac arrhythmia	9,561	12.7%	7,159	12.8%	-0.175	-0.005
Paliperidone palmitate	75,556	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	68	0.1%	-0.099	-0.037
Haloperidol decanoate	0	0.0%	55,806	100.0%	NaN	NaN
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.8	27.3	29.5	27.3	-0.734	-0.027
Mean number of generics dispensed	9.3	6.3	9.3	6.1	-0.038	-0.006
Mean number of unique drug classes dispensed	8.3	5.5	8.2	5.3	0.163	0.030
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.4	17.7	15.5	19.4	-0.089	-0.005
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.004	-0.003

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1br. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,558	100.0%	6,962	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.1	14.9	53.2	16.7	-5.042	-0.318
Age	**Number**	**Percent**[1]	**Number**	**Percent**[1]		
18-34 years	2,030	23.7%	1,243	17.9%	5.866	0.145
35-44 years	1,785	20.9%	1,116	16.0%	4.828	0.125
45-54 years	1,809	21.1%	1,415	20.3%	0.813	0.020
55-64 years	1,676	19.6%	1,372	19.7%	-0.123	-0.003
65-74 years	940	11.0%	1,088	15.6%	-4.644	-0.137
75-84 years	258	3.0%	494	7.1%	-4.081	-0.187
≥ 85 years	60	0.7%	234	3.4%	-2.660	-0.189
Sex						
Female	3,728	43.6%	2,999	43.1%	0.485	0.010
Male	4,830	56.4%	3,963	56.9%	-0.485	-0.010
Race[2]						
American Indian or Alaska Native	104	1.2%	55	0.8%	0.425	0.043
Asian	178	2.1%	147	2.1%	-0.032	-0.002
Black or African American	2,093	24.5%	2,139	30.7%	-6.267	-0.141
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	622	7.3%	503	7.2%	0.043	0.002
White	5,561	65.0%	4,118	59.1%	5.830	0.120
Hispanic origin						
Yes	387	4.5%	326	4.7%	-0.160	-0.008
No	7,936	92.7%	6,459	92.8%	-0.043	-0.002
Unknown	235	2.7%	177	2.5%	0.204	0.013

Table 1br. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	201	2.3%	414	5.9%	-3.598	-0.181
2011	486	5.7%	944	13.6%	-7.880	-0.270
2012	701	8.2%	832	12.0%	-3.759	-0.125
2013	772	9.0%	749	10.8%	-1.738	-0.058
2014	774	9.0%	713	10.2%	-1.197	-0.041
2015	782	9.1%	607	8.7%	0.419	0.015
2016	789	9.2%	559	8.0%	1.190	0.042
2017	839	9.8%	502	7.2%	2.593	0.093
2018	873	10.2%	457	6.6%	3.637	0.132
2019	783	9.1%	410	5.9%	3.260	0.124
2020	670	7.8%	335	4.8%	3.017	0.124
2021	630	7.4%	305	4.4%	2.981	0.127
2022	258	3.0%	135	1.9%	1.076	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.2	2.7	-0.411	-0.166
Substance abuse	3,770	44.1%	2,442	35.1%	8.976	0.184
Atrial fibrilation/flutter	253	3.0%	333	4.8%	-1.827	-0.095
Ischemic heart disease	958	11.2%	1,160	16.7%	-5.468	-0.158
Heart failure	549	6.4%	717	10.3%	-3.884	-0.141
Stroke	310	3.6%	408	5.9%	-2.238	-0.105
Diabetes	2,378	27.8%	2,308	33.2%	-5.365	-0.117
Hypertension	4,922	57.5%	4,382	62.9%	-5.428	-0.111
Rheumatic disease	66	0.8%	64	0.9%	-0.148	-0.016
Chronic kidney disease	1,316	15.4%	1,277	18.3%	-2.965	-0.079
Seizure disorder	1,313	15.3%	1,139	16.4%	-1.018	-0.028

Table 1br. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	377	4.4%	630	9.0%	-4.644	-0.186
Dementia Diagnosis	1,394	16.3%	1,875	26.9%	-10.643	-0.261
Dementia Diagnosis and Treatment	303	3.5%	573	8.2%	-4.690	-0.200
Parkinsons disease	262	3.1%	284	4.1%	-1.018	-0.055
COPD	1,759	20.6%	1,600	23.0%	-2.428	-0.059
Malignancy	339	4.0%	334	4.8%	-0.836	-0.041
Asthma	1,466	17.1%	1,015	14.6%	2.551	0.070
Hyperlipidemia	3,506	41.0%	3,011	43.2%	-2.282	-0.046
Depression	4,876	57.0%	3,513	50.5%	6.516	0.131
Schizophrenia	7,573	88.5%	5,981	85.9%	2.581	0.077
Bipolar disorder	4,981	58.2%	3,385	48.6%	9.582	0.193
ACE inhibitor use	1,614	18.9%	1,500	21.5%	-2.686	-0.067
ARB use	399	4.7%	434	6.2%	-1.572	-0.069
Beta-blocker use	1,999	23.4%	1,819	26.1%	-2.769	-0.064
Oral anticoagulant use	221	2.6%	219	3.1%	-0.563	-0.034
Antiplatelet agent use	169	2.0%	228	3.3%	-1.300	-0.081
Opioid use	1,608	18.8%	1,194	17.2%	1.639	0.043
Statin use	2,071	24.2%	1,958	28.1%	-3.925	-0.089
Wheelchair or walker use	40	0.5%	59	0.8%	-0.380	-0.047
Anti-arrhythmic use	37	0.4%	40	0.6%	-0.142	-0.020
Antidiabetic use	1,485	17.4%	1,469	21.1%	-3.748	-0.095
Calcium channel blocker use	1,132	13.2%	1,180	16.9%	-3.722	-0.104
Diuretic use	1,404	16.4%	1,462	21.0%	-4.594	-0.118
Antidepressant use	5,067	59.2%	3,757	54.0%	5.243	0.106
Gastric acid suppressant use	2,546	29.7%	2,141	30.8%	-1.003	-0.022
NSAIDs	1,931	22.6%	1,318	18.9%	3.632	0.090

Table 1br. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,301	38.6%	2,490	35.8%	2.807	0.058
Chronic liver disease	652	7.6%	465	6.7%	0.939	0.036
Pneumonia	534	6.2%	597	8.6%	-2.335	-0.089
Cardiac arrhythmia	1,811	21.2%	1,262	18.1%	3.035	0.076
Paliperidone palmitate	8,558	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.2%	-0.175	-0.056
Haloperidol decanoate	0	0.0%	6,962	100.0%	NaN	NaN
IS Stay	8,558	100.0%	6,962	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.6	27.5	32.3	27.7	-1.759	-0.064
Mean number of generics dispensed	10.4	6.6	10.9	6.2	-0.496	-0.077
Mean number of unique drug classes dispensed	9.3	5.7	9.3	5.4	-0.035	-0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.3	22.3	19.6	23.1	1.618	0.071
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.117	-0.123
Mean number of non-acute institutional encounters	1.9	1.4	2.0	1.4	-0.041	-0.029

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bs. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,556	100.0%	6,955	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.1	14.9	53.1	16.7	-5.024	-0.317
Age	**Number**	**Percent**[1]	**Number**	**Percent**[1]		
18-34 years	2,029	23.7%	1,242	17.9%	5.857	0.145
35-44 years	1,784	20.9%	1,116	16.0%	4.805	0.124
45-54 years	1,809	21.1%	1,414	20.3%	0.812	0.020
55-64 years	1,676	19.6%	1,372	19.7%	-0.138	-0.003
65-74 years	940	11.0%	1,087	15.6%	-4.643	-0.137
75-84 years	258	3.0%	490	7.0%	-4.030	-0.185
≥ 85 years	60	0.7%	234	3.4%	-2.663	-0.190
Sex						
Female	3,726	43.5%	2,995	43.1%	0.486	0.010
Male	4,830	56.5%	3,960	56.9%	-0.486	-0.010
Race[2]						
American Indian or Alaska Native	104	1.2%	54	0.8%	0.439	0.044
Asian	178	2.1%	147	2.1%	-0.033	-0.002
Black or African American	2,093	24.5%	2,136	30.7%	-6.249	-0.140
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	622	7.3%	503	7.2%	0.038	0.001
White	5,559	65.0%	4,115	59.2%	5.806	0.120
Hispanic origin						
Yes	387	4.5%	326	4.7%	-0.164	-0.008
No	7,934	92.7%	6,452	92.8%	-0.038	-0.001
Unknown	235	2.7%	177	2.5%	0.202	0.013

Table 1bs. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	201	2.3%	413	5.9%	-3.589	-0.181
2011	486	5.7%	944	13.6%	-7.893	-0.270
2012	701	8.2%	831	11.9%	-3.755	-0.125
2013	772	9.0%	749	10.8%	-1.746	-0.059
2014	774	9.0%	712	10.2%	-1.191	-0.040
2015	781	9.1%	606	8.7%	0.415	0.015
2016	789	9.2%	559	8.0%	1.184	0.042
2017	839	9.8%	502	7.2%	2.588	0.093
2018	873	10.2%	457	6.6%	3.633	0.131
2019	783	9.2%	408	5.9%	3.285	0.125
2020	670	7.8%	335	4.8%	3.014	0.124
2021	630	7.4%	304	4.4%	2.992	0.128
2022	257	3.0%	135	1.9%	1.063	0.068
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.2	2.7	-0.404	-0.163
Substance abuse	3,768	44.0%	2,439	35.1%	8.971	0.184
Atrial fibrilation/flutter	253	3.0%	331	4.8%	-1.802	-0.094
Ischemic heart disease	958	11.2%	1,155	16.6%	-5.410	-0.157
Heart failure	549	6.4%	713	10.3%	-3.835	-0.139
Stroke	310	3.6%	406	5.8%	-2.214	-0.104
Diabetes	2,378	27.8%	2,302	33.1%	-5.305	-0.115
Hypertension	4,921	57.5%	4,375	62.9%	-5.389	-0.110
Rheumatic disease	66	0.8%	64	0.9%	-0.149	-0.016
Chronic kidney disease	1,316	15.4%	1,270	18.3%	-2.879	-0.077
Seizure disorder	1,313	15.3%	1,137	16.3%	-1.002	-0.027

Table 1bs. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	377	4.4%	626	9.0%	-4.594	-0.184
Dementia Diagnosis	1,394	16.3%	1,869	26.9%	-10.580	-0.259
Dementia Diagnosis and Treatment	303	3.5%	569	8.2%	-4.640	-0.198
Parkinsons disease	262	3.1%	284	4.1%	-1.021	-0.055
COPD	1,759	20.6%	1,594	22.9%	-2.360	-0.057
Malignancy	338	4.0%	332	4.8%	-0.823	-0.040
Asthma	1,465	17.1%	1,013	14.6%	2.557	0.070
Hyperlipidemia	3,506	41.0%	3,005	43.2%	-2.229	-0.045
Depression	4,874	57.0%	3,509	50.5%	6.513	0.131
Schizophrenia	7,571	88.5%	5,978	86.0%	2.535	0.076
Bipolar disorder	4,979	58.2%	3,382	48.6%	9.566	0.193
ACE inhibitor use	1,614	18.9%	1,497	21.5%	-2.660	-0.066
ARB use	399	4.7%	434	6.2%	-1.577	-0.069
Beta-blocker use	1,998	23.4%	1,815	26.1%	-2.744	-0.064
Oral anticoagulant use	221	2.6%	217	3.1%	-0.537	-0.032
Antiplatelet agent use	169	2.0%	226	3.2%	-1.274	-0.080
Opioid use	1,606	18.8%	1,189	17.1%	1.675	0.044
Statin use	2,071	24.2%	1,955	28.1%	-3.904	-0.089
Wheelchair or walker use	40	0.5%	59	0.8%	-0.381	-0.047
Anti-arrhythmic use	37	0.4%	40	0.6%	-0.143	-0.020
Antidiabetic use	1,485	17.4%	1,465	21.1%	-3.708	-0.094
Calcium channel blocker use	1,132	13.2%	1,177	16.9%	-3.693	-0.103
Diuretic use	1,404	16.4%	1,458	21.0%	-4.554	-0.117
Antidepressant use	5,065	59.2%	3,752	53.9%	5.251	0.106
Gastric acid suppressant use	2,545	29.7%	2,136	30.7%	-0.967	-0.021
NSAIDs	1,929	22.5%	1,317	18.9%	3.610	0.089

Table 1bs. Unweighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,299	38.6%	2,487	35.8%	2.799	0.058
Chronic liver disease	651	7.6%	463	6.7%	0.952	0.037
Pneumonia	534	6.2%	592	8.5%	-2.271	-0.087
Cardiac arrhythmia	1,809	21.1%	1,258	18.1%	3.055	0.077
Paliperidone palmitate	8,556	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.2%	-0.175	-0.056
Haloperidol decanoate	0	0.0%	6,955	100.0%	NaN	NaN
IS Stay	8,556	100.0%	6,955	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.6	27.5	32.3	27.6	-1.746	-0.063
Mean number of generics dispensed	10.4	6.6	10.9	6.2	-0.490	-0.077
Mean number of unique drug classes dispensed	9.3	5.7	9.3	5.4	-0.030	-0.005
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.2	22.3	19.6	23.1	1.635	0.072
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.110	-0.119
Mean number of non-acute institutional encounters	1.9	1.4	2.0	1.4	-0.037	-0.027

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bt. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	8,550	N/A	6,964	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.2	15.5	50.2	16.3	0.024	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	1,762	20.6%	1,547	22.2%	-1.600	-0.039
35-44 years	1,620	18.9%	1,281	18.4%	0.554	0.014
45-54 years	1,752	20.5%	1,462	21.0%	-0.497	-0.012
55-64 years	1,777	20.8%	1,271	18.3%	2.530	0.064
65-74 years	1,151	13.5%	894	12.8%	0.631	0.019
75-84 years	389	4.5%	355	5.1%	-0.556	-0.026
≥ 85 years	99	1.2%	155	2.2%	-1.062	-0.082
Sex						
Female	3,703	43.3%	3,018	43.3%	-0.026	-0.001
Male	4,847	56.7%	3,946	56.7%	0.026	0.001
Race[3]						
American Indian or Alaska Native	101	1.2%	56	0.8%	0.378	0.038
Asian	176	2.1%	151	2.2%	-0.109	-0.008
Black or African American	2,133	24.9%	2,112	30.3%	-5.384	-0.121
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	589	6.9%	542	7.8%	-0.886	-0.034
White	5,551	64.9%	4,103	58.9%	6.001	0.124
Hispanic origin						
Yes	371	4.3%	347	5.0%	-0.640	-0.030
No	7,961	93.1%	6,423	92.2%	0.886	0.034
Unknown	218	2.6%	195	2.8%	-0.247	-0.015

Table 1bt. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	203	2.4%	405	5.8%	-3.448	-0.175
2011	489	5.7%	920	13.2%	-7.495	-0.258
2012	707	8.3%	812	11.7%	-3.386	-0.113
2013	760	8.9%	756	10.9%	-1.962	-0.066
2014	775	9.1%	717	10.3%	-1.233	-0.042
2015	785	9.2%	615	8.8%	0.341	0.012
2016	797	9.3%	570	8.2%	1.136	0.040
2017	839	9.8%	503	7.2%	2.582	0.093
2018	859	10.1%	447	6.4%	3.628	0.132
2019	781	9.1%	427	6.1%	3.008	0.113
2020	674	7.9%	345	5.0%	2.919	0.119
2021	619	7.2%	312	4.5%	2.763	0.118
2022	262	3.1%	134	1.9%	1.146	0.074
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.9	2.5	2.9	2.5	0.007	0.003
Substance abuse	3,433	40.2%	2,799	40.2%	-0.045	-0.001
Atrial fibrilation/flutter	313	3.7%	258	3.7%	-0.046	-0.002
Ischemic heart disease	1,154	13.5%	941	13.5%	-0.016	-0.000
Heart failure	699	8.2%	565	8.1%	0.057	0.002
Stroke	391	4.6%	314	4.5%	0.068	0.003
Diabetes	2,585	30.2%	2,101	30.2%	0.072	0.002
Hypertension	5,117	59.9%	4,164	59.8%	0.061	0.001
Rheumatic disease	69	0.8%	59	0.8%	-0.035	-0.004
Chronic kidney disease	1,425	16.7%	1,155	16.6%	0.073	0.002
Seizure disorder	1,350	15.8%	1,101	15.8%	-0.015	-0.000

Table 1bt. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	555	6.5%	449	6.4%	0.050	0.002
Dementia Diagnosis	1,789	20.9%	1,453	20.9%	0.050	0.001
Dementia Diagnosis and Treatment	484	5.7%	390	5.6%	0.050	0.002
Parkinsons disease	306	3.6%	249	3.6%	0.003	0.000
COPD	1,839	21.5%	1,490	21.4%	0.106	0.003
Malignancy	373	4.4%	301	4.3%	0.043	0.002
Asthma	1,356	15.9%	1,102	15.8%	0.040	0.001
Hyperlipidemia	3,598	42.1%	2,932	42.1%	-0.018	-0.000
Depression	4,625	54.1%	3,768	54.1%	-0.008	-0.000
Schizophrenia	7,502	87.7%	6,111	87.7%	-0.005	-0.000
Bipolar disorder	4,611	53.9%	3,759	54.0%	-0.059	-0.001
ACE inhibitor use	1,707	20.0%	1,386	19.9%	0.060	0.002
ARB use	461	5.4%	375	5.4%	0.004	0.000
Beta-blocker use	2,102	24.6%	1,715	24.6%	-0.044	-0.001
Oral anticoagulant use	237	2.8%	194	2.8%	-0.012	-0.001
Antiplatelet agent use	221	2.6%	177	2.5%	0.045	0.003
Opioid use	1,531	17.9%	1,244	17.9%	0.043	0.001
Statin use	2,208	25.8%	1,798	25.8%	0.009	0.000
Wheelchair or walker use	60	0.7%	46	0.7%	0.039	0.005
Anti-arrhythmic use	40	0.5%	34	0.5%	-0.009	-0.001
Antidiabetic use	1,626	19.0%	1,323	19.0%	0.018	0.000
Calcium channel blocker use	1,269	14.8%	1,031	14.8%	0.042	0.001
Diuretic use	1,580	18.5%	1,276	18.3%	0.156	0.004
Antidepressant use	4,865	56.9%	3,953	56.8%	0.134	0.003
Gastric acid suppressant use	2,561	29.9%	2,085	29.9%	0.015	0.000
NSAIDs	1,788	20.9%	1,454	20.9%	0.035	0.001

Table 1bt. Weighted Characteristics of Paliperidone vs. Haloperidol - 14 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 14 Day		Haloperidol Users - 14 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,185	37.2%	2,588	37.2%	0.080	0.002
Chronic liver disease	612	7.2%	503	7.2%	-0.067	-0.003
Pneumonia	620	7.3%	500	7.2%	0.066	0.003
Cardiac arrhythmia	1,689	19.8%	1,380	19.8%	-0.066	-0.002
Paliperidone palmitate	8,550	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	12	0.2%	-0.159	-0.053
Haloperidol decanoate	0	0.0%	6,964	100.0%	NaN	NaN
IS Stay	8,550	100.0%	6,964	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.9	27.9	31.7	27.0	-0.884	-0.032
Mean number of generics dispensed	10.4	6.6	10.9	6.2	-0.449	-0.070
Mean number of unique drug classes dispensed	9.3	5.7	9.3	5.3	0.018	0.003
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	20.7	21.9	20.7	23.9	-0.019	-0.001
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	0.002	0.002
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.4	-0.000	-0.000

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1bu. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,865	100.0%	44,674	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	55.9	18.9	-9.998	-0.602
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,517	26.5%	7,599	17.0%	9.523	0.232
35-44 years	19,747	23.3%	6,755	15.1%	8.148	0.208
45-54 years	19,449	22.9%	8,005	17.9%	4.999	0.124
55-64 years	14,759	17.4%	7,196	16.1%	1.283	0.034
65-74 years	6,525	7.7%	6,780	15.2%	-7.488	-0.237
75-84 years	1,496	1.8%	4,973	11.1%	-9.369	-0.389
≥ 85 years	372	0.4%	3,366	7.5%	-7.096	-0.369
Sex						
Female	34,509	40.7%	22,065	49.4%	-8.728	-0.176
Male	50,356	59.3%	22,609	50.6%	8.728	0.176
Race[2]						
American Indian or Alaska Native	1,010	1.2%	467	1.0%	0.145	0.014
Asian	1,920	2.3%	769	1.7%	0.541	0.039
Black or African American	22,132	26.1%	10,983	24.6%	1.494	0.034
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,025	8.3%	2,841	6.4%	1.918	0.074
White	52,778	62.2%	29,614	66.3%	-4.099	-0.086
Hispanic origin						
Yes	4,374	5.2%	2,000	4.5%	0.677	0.032
No	77,840	91.7%	41,833	93.6%	-1.918	-0.074
Unknown	2,651	3.1%	841	1.9%	1.241	0.080

Table 1bu. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,471	2.9%	3,640	8.1%	-5.236	-0.231
2011	6,111	7.2%	7,260	16.3%	-9.050	-0.284
2012	7,365	8.7%	6,462	14.5%	-5.786	-0.182
2013	7,590	8.9%	5,876	13.2%	-4.209	-0.135
2014	7,267	8.6%	4,632	10.4%	-1.805	-0.062
2015	7,782	9.2%	3,701	8.3%	0.885	0.031
2016	8,038	9.5%	3,108	7.0%	2.514	0.092
2017	8,262	9.7%	2,641	5.9%	3.824	0.143
2018	8,275	9.8%	2,266	5.1%	4.678	0.179
2019	7,664	9.0%	1,823	4.1%	4.950	0.201
2020	5,913	7.0%	1,429	3.2%	3.769	0.172
2021	5,564	6.6%	1,268	2.8%	3.718	0.176
2022	2,563	3.0%	568	1.3%	1.749	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	3.0	2.7	-0.815	-0.343
Substance abuse	29,804	35.1%	11,289	25.3%	9.850	0.216
Atrial fibrilation/flutter	1,601	1.9%	2,738	6.1%	-4.242	-0.218
Ischemic heart disease	6,383	7.5%	6,942	15.5%	-8.018	-0.253
Heart failure	3,544	4.2%	4,724	10.6%	-6.398	-0.247
Stroke	2,111	2.5%	3,216	7.2%	-4.711	-0.221
Diabetes	20,555	24.2%	13,832	31.0%	-6.741	-0.151
Hypertension	38,596	45.5%	25,709	57.5%	-12.069	-0.243
Rheumatic disease	431	0.5%	385	0.9%	-0.354	-0.043
Chronic kidney disease	9,669	11.4%	7,119	15.9%	-4.542	-0.133
Seizure disorder	9,686	11.4%	5,867	13.1%	-1.719	-0.052

Table 1bu. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,309	2.7%	6,166	13.8%	-11.081	-0.411
Dementia Diagnosis	7,737	9.1%	13,383	30.0%	-20.840	-0.545
Dementia Diagnosis and Treatment	1,677	2.0%	5,598	12.5%	-10.555	-0.416
Parkinsons disease	1,485	1.7%	1,713	3.8%	-2.085	-0.127
COPD	13,423	15.8%	8,792	19.7%	-3.863	-0.101
Malignancy	2,713	3.2%	1,851	4.1%	-0.947	-0.050
Asthma	11,506	13.6%	5,002	11.2%	2.361	0.072
Hyperlipidemia	29,046	34.2%	17,510	39.2%	-4.969	-0.103
Depression	38,798	45.7%	21,791	48.8%	-3.060	-0.061
Schizophrenia	68,268	80.4%	29,634	66.3%	14.109	0.323
Bipolar disorder	39,626	46.7%	18,556	41.5%	5.157	0.104
ACE inhibitor use	14,111	16.6%	9,403	21.0%	-4.420	-0.113
ARB use	3,738	4.4%	2,710	6.1%	-1.662	-0.075
Beta-blocker use	16,520	19.5%	11,143	24.9%	-5.477	-0.132
Oral anticoagulant use	1,769	2.1%	1,986	4.4%	-2.361	-0.133
Antiplatelet agent use	1,316	1.6%	2,026	4.5%	-2.984	-0.174
Opioid use	16,123	19.0%	10,417	23.3%	-4.319	-0.106
Statin use	18,723	22.1%	12,124	27.1%	-5.077	-0.118
Wheelchair or walker use	257	0.3%	926	2.1%	-1.770	-0.164
Anti-arrhythmic use	314	0.4%	438	1.0%	-0.610	-0.075
Antidiabetic use	14,202	16.7%	8,749	19.6%	-2.849	-0.074
Calcium channel blocker use	9,259	10.9%	7,065	15.8%	-4.904	-0.145
Diuretic use	12,378	14.6%	9,860	22.1%	-7.485	-0.194
Antidepressant use	49,434	58.3%	25,906	58.0%	0.261	0.005
Gastric acid suppressant use	22,788	26.9%	13,690	30.6%	-3.792	-0.084
NSAIDs	18,439	21.7%	8,604	19.3%	2.468	0.061

Table 1bu. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,306	33.4%	13,928	31.2%	2.177	0.047
Chronic liver disease	5,352	6.3%	2,578	5.8%	0.536	0.022
Pneumonia	3,665	4.3%	3,430	7.7%	-3.359	-0.142
Cardiac arrhythmia	11,749	13.8%	5,706	12.8%	1.072	0.032
Paliperidone palmitate	84,865	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	44,674	100.0%	NaN	NaN
Haloperidol decanoate	84	0.1%	77	0.2%	-0.073	-0.020
IS Stay	8,702	10.3%	6,012	13.5%	-3.204	-0.099
Medical Product Use						
Mean number of filled prescriptions	29.1	27.2	33.6	30.5	-4.548	-0.158
Mean number of generics dispensed	9.5	6.3	10.3	6.5	-0.843	-0.131
Mean number of unique drug classes dispensed	8.5	5.5	9.4	5.7	-0.900	-0.161
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	14.7	18.0	1.810	0.098
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.060	-0.065
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.090	-0.073

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bv. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,864	100.0%	44,665	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	55.9	18.9	-9.992	-0.602
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,516	26.5%	7,599	17.0%	9.519	0.232
35-44 years	19,747	23.3%	6,755	15.1%	8.145	0.208
45-54 years	19,449	22.9%	8,005	17.9%	4.996	0.124
55-64 years	14,759	17.4%	7,196	16.1%	1.280	0.034
65-74 years	6,525	7.7%	6,779	15.2%	-7.489	-0.237
75-84 years	1,496	1.8%	4,969	11.1%	-9.362	-0.388
≥ 85 years	372	0.4%	3,362	7.5%	-7.089	-0.369
Sex						
Female	34,509	40.7%	22,060	49.4%	-8.726	-0.176
Male	50,355	59.3%	22,605	50.6%	8.726	0.176
Race[2]						
American Indian or Alaska Native	1,010	1.2%	467	1.0%	0.145	0.014
Asian	1,920	2.3%	769	1.7%	0.541	0.039
Black or African American	22,132	26.1%	10,981	24.6%	1.494	0.034
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,025	8.3%	2,840	6.4%	1.920	0.074
White	52,777	62.2%	29,608	66.3%	-4.099	-0.086
Hispanic origin						
Yes	4,374	5.2%	1,999	4.5%	0.679	0.032
No	77,839	91.7%	41,825	93.6%	-1.920	-0.074
Unknown	2,651	3.1%	841	1.9%	1.241	0.079

Table 1bv. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,471	2.9%	3,639	8.1%	-5.236	-0.231
2011	6,111	7.2%	7,258	16.2%	-9.049	-0.284
2012	7,365	8.7%	6,461	14.5%	-5.787	-0.182
2013	7,590	8.9%	5,875	13.2%	-4.210	-0.135
2014	7,267	8.6%	4,631	10.4%	-1.805	-0.062
2015	7,782	9.2%	3,700	8.3%	0.886	0.031
2016	8,038	9.5%	3,106	7.0%	2.518	0.092
2017	8,262	9.7%	2,641	5.9%	3.823	0.143
2018	8,275	9.8%	2,266	5.1%	4.678	0.179
2019	7,664	9.0%	1,823	4.1%	4.949	0.201
2020	5,913	7.0%	1,429	3.2%	3.768	0.172
2021	5,564	6.6%	1,268	2.8%	3.717	0.176
2022	2,562	3.0%	568	1.3%	1.747	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	3.0	2.7	-0.814	-0.343
Substance abuse	29,803	35.1%	11,289	25.3%	9.844	0.216
Atrial fibrilation/flutter	1,601	1.9%	2,733	6.1%	-4.232	-0.217
Ischemic heart disease	6,383	7.5%	6,933	15.5%	-8.001	-0.253
Heart failure	3,544	4.2%	4,717	10.6%	-6.385	-0.246
Stroke	2,111	2.5%	3,208	7.2%	-4.695	-0.220
Diabetes	20,555	24.2%	13,827	31.0%	-6.736	-0.151
Hypertension	38,596	45.5%	25,700	57.5%	-12.060	-0.243
Rheumatic disease	431	0.5%	383	0.9%	-0.350	-0.042
Chronic kidney disease	9,668	11.4%	7,118	15.9%	-4.544	-0.133
Seizure disorder	9,685	11.4%	5,863	13.1%	-1.714	-0.052

Table 1bv. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,309	2.7%	6,157	13.8%	-11.064	-0.410
Dementia Diagnosis	7,737	9.1%	13,374	29.9%	-20.826	-0.544
Dementia Diagnosis and Treatment	1,677	2.0%	5,589	12.5%	-10.537	-0.415
Parkinsons disease	1,485	1.7%	1,712	3.8%	-2.083	-0.127
COPD	13,423	15.8%	8,786	19.7%	-3.854	-0.101
Malignancy	2,713	3.2%	1,850	4.1%	-0.945	-0.050
Asthma	11,506	13.6%	5,002	11.2%	2.359	0.072
Hyperlipidemia	29,045	34.2%	17,505	39.2%	-4.966	-0.103
Depression	38,798	45.7%	21,785	48.8%	-3.056	-0.061
Schizophrenia	68,267	80.4%	29,634	66.3%	14.096	0.323
Bipolar disorder	39,625	46.7%	18,554	41.5%	5.152	0.104
ACE inhibitor use	14,111	16.6%	9,400	21.0%	-4.418	-0.113
ARB use	3,738	4.4%	2,708	6.1%	-1.658	-0.075
Beta-blocker use	16,520	19.5%	11,137	24.9%	-5.468	-0.132
Oral anticoagulant use	1,769	2.1%	1,982	4.4%	-2.353	-0.133
Antiplatelet agent use	1,316	1.6%	2,020	4.5%	-2.972	-0.174
Opioid use	16,123	19.0%	10,412	23.3%	-4.313	-0.106
Statin use	18,722	22.1%	12,119	27.1%	-5.072	-0.118
Wheelchair or walker use	257	0.3%	918	2.1%	-1.752	-0.163
Anti-arrhythmic use	314	0.4%	437	1.0%	-0.608	-0.074
Antidiabetic use	14,202	16.7%	8,747	19.6%	-2.849	-0.074
Calcium channel blocker use	9,259	10.9%	7,062	15.8%	-4.901	-0.144
Diuretic use	12,378	14.6%	9,852	22.1%	-7.472	-0.194
Antidepressant use	49,433	58.2%	25,900	58.0%	0.262	0.005
Gastric acid suppressant use	22,788	26.9%	13,684	30.6%	-3.785	-0.084
NSAIDs	18,439	21.7%	8,603	19.3%	2.467	0.061

Table 1bv. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,305	33.4%	13,928	31.2%	2.170	0.046
Chronic liver disease	5,351	6.3%	2,578	5.8%	0.534	0.022
Pneumonia	3,664	4.3%	3,426	7.7%	-3.353	-0.142
Cardiac arrhythmia	11,748	13.8%	5,705	12.8%	1.070	0.032
Paliperidone palmitate	84,864	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	44,665	100.0%	NaN	NaN
Haloperidol decanoate	84	0.1%	77	0.2%	-0.073	-0.020
IS Stay	8,702	10.3%	6,012	13.5%	-3.206	-0.099
Medical Product Use						
Mean number of filled prescriptions	29.1	27.2	33.6	30.5	-4.547	-0.158
Mean number of generics dispensed	9.5	6.3	10.3	6.5	-0.842	-0.131
Mean number of unique drug classes dispensed	8.5	5.5	9.4	5.7	-0.899	-0.160
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	14.7	18.0	1.809	0.098
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.059	-0.065
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.090	-0.072

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bw. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	83,961	N/A	45,384	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.7	15.4	48.6	17.2	0.064	0.004
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	18,977	22.6%	12,096	26.7%	-4.051	-0.094
35-44 years	17,531	20.9%	9,153	20.2%	0.713	0.018
45-54 years	18,529	22.1%	9,093	20.0%	2.033	0.050
55-64 years	15,691	18.7%	6,583	14.5%	4.183	0.113
65-74 years	8,872	10.6%	4,488	9.9%	0.678	0.022
75-84 years	3,146	3.7%	2,493	5.5%	-1.746	-0.083
≥ 85 years	1,215	1.4%	1,478	3.3%	-1.810	-0.120
Sex						
Female	36,058	42.9%	19,432	42.8%	0.128	0.003
Male	47,904	57.1%	25,952	57.2%	-0.128	-0.003
Race[3]						
American Indian or Alaska Native	981	1.2%	554	1.2%	-0.054	-0.005
Asian	1,843	2.2%	913	2.0%	0.184	0.013
Black or African American	21,635	25.8%	11,940	26.3%	-0.541	-0.012
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,462	7.7%	3,498	7.7%	-0.010	-0.000
White	53,041	63.2%	28,479	62.8%	0.421	0.009
Hispanic origin						
Yes	4,077	4.9%	2,429	5.4%	-0.498	-0.023
No	77,499	92.3%	41,886	92.3%	0.010	0.000
Unknown	2,386	2.8%	1,068	2.4%	0.488	0.031

Table 1bw. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	2,444	2.9%	3,871	8.5%	-5.618	-0.244
2011	5,937	7.1%	7,692	16.9%	-9.878	-0.307
2012	7,283	8.7%	6,735	14.8%	-6.167	-0.192
2013	7,461	8.9%	6,305	13.9%	-5.006	-0.158
2014	7,140	8.5%	4,803	10.6%	-2.079	-0.071
2015	7,687	9.2%	3,719	8.2%	0.960	0.034
2016	7,934	9.4%	3,055	6.7%	2.717	0.100
2017	8,235	9.8%	2,481	5.5%	4.343	0.164
2018	8,109	9.7%	2,079	4.6%	5.077	0.198
2019	7,643	9.1%	1,696	3.7%	5.365	0.220
2020	5,939	7.1%	1,284	2.8%	4.244	0.197
2021	5,540	6.6%	1,152	2.5%	4.059	0.195
2022	2,610	3.1%	511	1.1%	1.983	0.138
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.4	2.3	2.4	2.3	-0.000	-0.000
Substance abuse	27,156	32.3%	14,840	32.7%	-0.355	-0.008
Atrial fibrilation/flutter	2,683	3.2%	1,470	3.2%	-0.043	-0.002
Ischemic heart disease	8,399	10.0%	4,555	10.0%	-0.033	-0.001
Heart failure	5,267	6.3%	2,835	6.2%	0.026	0.001
Stroke	3,304	3.9%	1,801	4.0%	-0.033	-0.002
Diabetes	22,139	26.4%	11,859	26.1%	0.237	0.005
Hypertension	41,246	49.1%	22,215	48.9%	0.176	0.004
Rheumatic disease	512	0.6%	292	0.6%	-0.032	-0.004
Chronic kidney disease	10,656	12.7%	5,698	12.6%	0.137	0.004
Seizure disorder	10,169	12.1%	5,423	11.9%	0.163	0.005

Table 1bw. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	5,126	6.1%	2,870	6.3%	-0.219	-0.009
Dementia Diagnosis	12,776	15.2%	7,037	15.5%	-0.288	-0.008
Dementia Diagnosis and Treatment	4,382	5.2%	2,473	5.4%	-0.230	-0.010
Parkinsons disease	2,105	2.5%	1,095	2.4%	0.095	0.006
COPD	14,400	17.2%	7,723	17.0%	0.134	0.004
Malignancy	2,958	3.5%	1,573	3.5%	0.056	0.003
Asthma	10,862	12.9%	5,871	12.9%	0.001	0.000
Hyperlipidemia	30,182	35.9%	16,253	35.8%	0.136	0.003
Depression	39,373	46.9%	21,282	46.9%	-0.000	-0.000
Schizophrenia	64,722	77.1%	34,857	76.8%	0.280	0.007
Bipolar disorder	38,340	45.7%	20,831	45.9%	-0.236	-0.005
ACE inhibitor use	15,111	18.0%	8,136	17.9%	0.070	0.002
ARB use	4,098	4.9%	2,206	4.9%	0.019	0.001
Beta-blocker use	17,674	21.1%	9,498	20.9%	0.122	0.003
Oral anticoagulant use	2,309	2.8%	1,257	2.8%	-0.019	-0.001
Antiplatelet agent use	2,141	2.6%	1,122	2.5%	0.079	0.005
Opioid use	16,950	20.2%	9,189	20.2%	-0.059	-0.001
Statin use	19,946	23.8%	10,675	23.5%	0.236	0.006
Wheelchair or walker use	767	0.9%	404	0.9%	0.023	0.002
Anti-arrhythmic use	468	0.6%	251	0.6%	0.004	0.001
Antidiabetic use	14,746	17.6%	7,876	17.4%	0.208	0.005
Calcium channel blocker use	10,352	12.3%	5,561	12.3%	0.077	0.002
Diuretic use	14,161	16.9%	7,621	16.8%	0.074	0.002
Antidepressant use	48,511	57.8%	26,240	57.8%	-0.041	-0.001
Gastric acid suppressant use	23,427	27.9%	12,582	27.7%	0.178	0.004
NSAIDs	17,669	21.0%	9,540	21.0%	0.023	0.001

Table 1bw. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,187	32.4%	14,680	32.3%	0.034	0.001
Chronic liver disease	5,194	6.2%	2,824	6.2%	-0.036	-0.001
Pneumonia	4,571	5.4%	2,452	5.4%	0.041	0.002
Cardiac arrhythmia	11,366	13.5%	6,180	13.6%	-0.080	-0.002
Paliperidone palmitate	83,961	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	45,384	100.0%	NaN	NaN
Haloperidol decanoate	82	0.1%	87	0.2%	-0.094	-0.025
IS Stay	9,793	11.7%	5,239	11.5%	0.121	0.004
Medical Product Use						
Mean number of filled prescriptions	30.0	28.0	30.5	28.6	-0.468	-0.017
Mean number of generics dispensed	9.7	6.4	9.7	6.3	0.065	0.010
Mean number of unique drug classes dispensed	8.7	5.6	8.8	5.5	-0.026	-0.005
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.2	18.4	16.4	19.9	-0.166	-0.009
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.000	-0.001
Mean number of non-acute institutional encounters	0.9	1.3	0.9	1.2	-0.000	-0.000

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1bx. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,516	100.0%	7,599	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.3	3.7	-0.075	-0.020
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,516	100.0%	7,599	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,756	30.0%	2,209	29.1%	0.936	0.021
Male	15,760	70.0%	5,390	70.9%	-0.936	-0.021
Race[2]						
American Indian or Alaska Native	325	1.4%	136	1.8%	-0.346	-0.027
Asian	522	2.3%	197	2.6%	-0.274	-0.018
Black or African American	6,707	29.8%	2,505	33.0%	-3.177	-0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,605	16.0%	1,004	13.2%	2.799	0.079
White	11,357	50.4%	3,757	49.4%	0.999	0.020
Hispanic origin						
Yes	1,849	8.2%	646	8.5%	-0.289	-0.010
No	18,911	84.0%	6,595	86.8%	-2.799	-0.079
Unknown	1,756	7.8%	358	4.7%	3.088	0.128

Table 1bx. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	705	3.1%	773	10.2%	-7.041	-0.285
2011	1,747	7.8%	1,492	19.6%	-11.875	-0.351
2012	2,067	9.2%	1,229	16.2%	-6.993	-0.211
2013	2,066	9.2%	1,105	14.5%	-5.366	-0.167
2014	1,955	8.7%	792	10.4%	-1.740	-0.059
2015	1,982	8.8%	551	7.3%	1.552	0.057
2016	2,031	9.0%	453	6.0%	3.059	0.116
2017	2,108	9.4%	334	4.4%	4.967	0.197
2018	2,110	9.4%	249	3.3%	6.094	0.252
2019	1,898	8.4%	246	3.2%	5.192	0.223
2020	1,565	7.0%	159	2.1%	4.858	0.235
2021	1,551	6.9%	141	1.9%	5.033	0.248
2022	731	3.2%	75	1.0%	2.260	0.157
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.5	1.3	0.077	0.061
Substance abuse	9,666	42.9%	3,153	41.5%	1.437	0.029
Atrial fibrilation/flutter	57	0.3%	33	0.4%	-0.181	-0.031
Ischemic heart disease	310	1.4%	126	1.7%	-0.281	-0.023
Heart failure	159	0.7%	62	0.8%	-0.110	-0.013
Stroke	125	0.6%	45	0.6%	-0.037	-0.005
Diabetes	2,275	10.1%	752	9.9%	0.208	0.007
Hypertension	5,103	22.7%	1,665	21.9%	0.753	0.018
Rheumatic disease	39	0.2%	19	0.3%	-0.077	-0.017
Chronic kidney disease	895	4.0%	239	3.1%	0.830	0.045
Seizure disorder	2,064	9.2%	687	9.0%	0.126	0.004

Table 1bx. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	49	0.2%	11	0.1%	0.073	0.017
Dementia Diagnosis	700	3.1%	165	2.2%	0.938	0.059
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.014	0.008
Parkinsons disease	58	0.3%	13	0.2%	0.087	0.019
COPD	1,124	5.0%	373	4.9%	0.083	0.004
Malignancy	473	2.1%	133	1.8%	0.350	0.026
Asthma	3,342	14.8%	1,055	13.9%	0.959	0.027
Hyperlipidemia	3,717	16.5%	1,203	15.8%	0.677	0.018
Depression	9,751	43.3%	3,257	42.9%	0.446	0.009
Schizophrenia	17,764	78.9%	5,720	75.3%	3.622	0.086
Bipolar disorder	10,802	48.0%	3,677	48.4%	-0.413	-0.008
ACE inhibitor use	1,273	5.7%	440	5.8%	-0.136	-0.006
ARB use	214	1.0%	62	0.8%	0.135	0.014
Beta-blocker use	2,705	12.0%	801	10.5%	1.473	0.047
Oral anticoagulant use	146	0.6%	36	0.5%	0.175	0.023
Antiplatelet agent use	22	0.1%	*****	*****	-0.008	-0.002
Opioid use	3,117	13.8%	1,199	15.8%	-1.935	-0.054
Statin use	1,420	6.3%	470	6.2%	0.122	0.005
Wheelchair or walker use	*****	*****	*****	*****	-0.061	-0.028
Anti-arrhythmic use	19	0.1%	*****	*****	0.019	0.007
Antidiabetic use	1,673	7.4%	476	6.3%	1.166	0.046
Calcium channel blocker use	711	3.2%	218	2.9%	0.289	0.017
Diuretic use	1,048	4.7%	335	4.4%	0.246	0.012
Antidepressant use	12,197	54.2%	3,688	48.5%	5.638	0.113
Gastric acid suppressant use	3,927	17.4%	1,230	16.2%	1.255	0.034
NSAIDs	3,973	17.6%	1,314	17.3%	0.353	0.009

Table 1bx. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,159	27.4%	1,686	22.2%	5.167	0.120
Chronic liver disease	863	3.8%	300	3.9%	-0.115	-0.006
Pneumonia	398	1.8%	131	1.7%	0.044	0.003
Cardiac arrhythmia	3,047	13.5%	759	10.0%	3.544	0.110
Paliperidone palmitate	22,516	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,599	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	13	0.2%	-0.064	-0.017
IS Stay	2,079	9.2%	869	11.4%	-2.202	-0.072
Medical Product Use						
Mean number of filled prescriptions	20.6	21.3	19.1	20.2	1.507	0.073
Mean number of generics dispensed	7.5	5.5	7.1	5.1	0.445	0.083
Mean number of unique drug classes dispensed	6.7	4.8	6.4	4.5	0.291	0.063
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.8	17.4	14.5	17.6	0.317	0.018
Mean number of inpatient hospital encounters	0.4	0.8	0.4	1.0	-0.027	-0.030
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.042	-0.034

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1by. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,514	100.0%	7,594	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.3	3.7	-0.074	-0.020
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,514	100.0%	7,594	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,755	30.0%	2,207	29.1%	0.941	0.021
Male	15,759	70.0%	5,387	70.9%	-0.941	-0.021
Race[2]						
American Indian or Alaska Native	325	1.4%	136	1.8%	-0.347	-0.028
Asian	522	2.3%	197	2.6%	-0.276	-0.018
Black or African American	6,706	29.8%	2,504	33.0%	-3.187	-0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,604	16.0%	1,004	13.2%	2.787	0.079
White	11,357	50.4%	3,753	49.4%	1.024	0.020
Hispanic origin						
Yes	1,849	8.2%	646	8.5%	-0.294	-0.011
No	18,910	84.0%	6,590	86.8%	-2.787	-0.079
Unknown	1,755	7.8%	358	4.7%	3.081	0.127

Table 1by. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	705	3.1%	773	10.2%	-7.048	-0.286
2011	1,747	7.8%	1,490	19.6%	-11.861	-0.350
2012	2,067	9.2%	1,229	16.2%	-7.003	-0.212
2013	2,066	9.2%	1,104	14.5%	-5.361	-0.166
2014	1,955	8.7%	791	10.4%	-1.733	-0.059
2015	1,981	8.8%	551	7.3%	1.543	0.057
2016	2,031	9.0%	453	6.0%	3.056	0.116
2017	2,108	9.4%	333	4.4%	4.978	0.198
2018	2,110	9.4%	249	3.3%	6.093	0.252
2019	1,898	8.4%	246	3.2%	5.191	0.223
2020	1,565	7.0%	159	2.1%	4.857	0.235
2021	1,551	6.9%	141	1.9%	5.032	0.248
2022	730	3.2%	75	1.0%	2.255	0.157
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.5	1.3	0.078	0.061
Substance abuse	9,665	42.9%	3,150	41.5%	1.449	0.029
Atrial fibrilation/flutter	57	0.3%	33	0.4%	-0.181	-0.031
Ischemic heart disease	310	1.4%	126	1.7%	-0.282	-0.023
Heart failure	159	0.7%	61	0.8%	-0.097	-0.011
Stroke	125	0.6%	45	0.6%	-0.037	-0.005
Diabetes	2,274	10.1%	751	9.9%	0.211	0.007
Hypertension	5,101	22.7%	1,663	21.9%	0.758	0.018
Rheumatic disease	39	0.2%	19	0.3%	-0.077	-0.017
Chronic kidney disease	893	4.0%	238	3.1%	0.832	0.045
Seizure disorder	2,063	9.2%	686	9.0%	0.130	0.005

Table 1by. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	49	0.2%	11	0.1%	0.073	0.017
Dementia Diagnosis	698	3.1%	164	2.2%	0.941	0.059
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.014	0.007
Parkinsons disease	58	0.3%	13	0.2%	0.086	0.019
COPD	1,124	5.0%	372	4.9%	0.094	0.004
Malignancy	472	2.1%	132	1.7%	0.358	0.026
Asthma	3,342	14.8%	1,052	13.9%	0.991	0.028
Hyperlipidemia	3,716	16.5%	1,202	15.8%	0.677	0.018
Depression	9,750	43.3%	3,254	42.8%	0.457	0.009
Schizophrenia	17,763	78.9%	5,715	75.3%	3.641	0.087
Bipolar disorder	10,801	48.0%	3,672	48.4%	-0.379	-0.008
ACE inhibitor use	1,272	5.6%	440	5.8%	-0.144	-0.006
ARB use	214	1.0%	61	0.8%	0.147	0.016
Beta-blocker use	2,704	12.0%	801	10.5%	1.463	0.046
Oral anticoagulant use	145	0.6%	36	0.5%	0.170	0.023
Antiplatelet agent use	22	0.1%	*****	*****	-0.008	-0.002
Opioid use	3,117	13.8%	1,197	15.8%	-1.918	-0.054
Statin use	1,419	6.3%	469	6.2%	0.127	0.005
Wheelchair or walker use	*****	*****	*****	*****	-0.022	-0.013
Anti-arrhythmic use	19	0.1%	*****	*****	0.019	0.007
Antidiabetic use	1,672	7.4%	475	6.3%	1.172	0.046
Calcium channel blocker use	711	3.2%	217	2.9%	0.301	0.018
Diuretic use	1,048	4.7%	333	4.4%	0.270	0.013
Antidepressant use	12,195	54.2%	3,686	48.5%	5.628	0.113
Gastric acid suppressant use	3,927	17.4%	1,227	16.2%	1.285	0.034
NSAIDs	3,972	17.6%	1,312	17.3%	0.366	0.010

Table 1by. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,157	27.3%	1,685	22.2%	5.159	0.120
Chronic liver disease	862	3.8%	300	4.0%	-0.122	-0.006
Pneumonia	398	1.8%	131	1.7%	0.043	0.003
Cardiac arrhythmia	3,045	13.5%	757	10.0%	3.557	0.111
Paliperidone palmitate	22,514	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,594	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	13	0.2%	-0.065	-0.017
IS Stay	2,079	9.2%	866	11.4%	-2.169	-0.071
Medical Product Use						
Mean number of filled prescriptions	20.6	21.3	19.0	20.2	1.519	0.073
Mean number of generics dispensed	7.5	5.5	7.1	5.1	0.449	0.084
Mean number of unique drug classes dispensed	6.7	4.8	6.4	4.5	0.295	0.064
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.8	17.4	14.4	17.6	0.328	0.019
Mean number of inpatient hospital encounters	0.4	0.8	0.4	1.0	-0.025	-0.028
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.039	-0.032

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1bz. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	22,516	N/A	7,596	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.2	3.7	-0.004	-0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	22,516	100.0%	7,596	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,700	29.8%	2,253	29.7%	0.102	0.002
Male	15,815	70.2%	5,343	70.3%	-0.102	-0.002
Race[3]						
American Indian or Alaska Native	324	1.4%	140	1.8%	-0.398	-0.031
Asian	522	2.3%	198	2.6%	-0.293	-0.019
Black or African American	6,772	30.1%	2,454	32.3%	-2.233	-0.048
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,573	15.9%	1,035	13.6%	2.249	0.063
White	11,325	50.3%	3,769	49.6%	0.676	0.014
Hispanic origin						
Yes	1,839	8.2%	662	8.7%	-0.541	-0.019
No	18,942	84.1%	6,562	86.4%	-2.249	-0.063
Unknown	1,734	7.7%	373	4.9%	2.789	0.115

Table 1bz. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	716	3.2%	735	9.7%	-6.503	-0.267
2011	1,775	7.9%	1,444	19.0%	-11.123	-0.330
2012	2,108	9.4%	1,181	15.5%	-6.184	-0.188
2013	2,081	9.2%	1,111	14.6%	-5.383	-0.167
2014	1,961	8.7%	802	10.6%	-1.853	-0.063
2015	1,985	8.8%	565	7.4%	1.379	0.050
2016	2,014	8.9%	480	6.3%	2.625	0.099
2017	2,083	9.2%	349	4.6%	4.650	0.184
2018	2,098	9.3%	266	3.5%	5.811	0.239
2019	1,887	8.4%	257	3.4%	4.993	0.213
2020	1,554	6.9%	170	2.2%	4.657	0.224
2021	1,532	6.8%	154	2.0%	4.779	0.234
2022	723	3.2%	81	1.1%	2.152	0.149
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.6	1.3	1.6	1.3	0.002	0.001
Substance abuse	9,585	42.6%	3,241	42.7%	-0.099	-0.002
Atrial fibrilation/flutter	68	0.3%	23	0.3%	-0.005	-0.001
Ischemic heart disease	327	1.5%	111	1.5%	-0.011	-0.001
Heart failure	166	0.7%	57	0.8%	-0.014	-0.002
Stroke	128	0.6%	44	0.6%	-0.011	-0.001
Diabetes	2,263	10.1%	756	10.0%	0.099	0.003
Hypertension	5,066	22.5%	1,716	22.6%	-0.086	-0.002
Rheumatic disease	44	0.2%	16	0.2%	-0.009	-0.002
Chronic kidney disease	845	3.8%	276	3.6%	0.121	0.006
Seizure disorder	2,059	9.1%	697	9.2%	-0.031	-0.001

Table 1bz. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	45	0.2%	16	0.2%	-0.010	-0.002
Dementia Diagnosis	645	2.9%	218	2.9%	-0.004	-0.000
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.006	0.003
Parkinsons disease	53	0.2%	17	0.2%	0.013	0.003
COPD	1,121	5.0%	378	5.0%	-0.001	-0.000
Malignancy	452	2.0%	149	2.0%	0.044	0.003
Asthma	3,288	14.6%	1,101	14.5%	0.113	0.003
Hyperlipidemia	3,682	16.4%	1,249	16.4%	-0.084	-0.002
Depression	9,728	43.2%	3,281	43.2%	0.010	0.000
Schizophrenia	17,557	78.0%	5,919	77.9%	0.053	0.001
Bipolar disorder	10,825	48.1%	3,655	48.1%	-0.042	-0.001
ACE inhibitor use	1,282	5.7%	436	5.7%	-0.045	-0.002
ARB use	207	0.9%	70	0.9%	-0.003	-0.000
Beta-blocker use	2,620	11.6%	878	11.6%	0.085	0.003
Oral anticoagulant use	135	0.6%	45	0.6%	0.007	0.001
Antiplatelet agent use	23	0.1%	*****	*****	-0.009	-0.003
Opioid use	3,226	14.3%	1,086	14.3%	0.028	0.001
Statin use	1,414	6.3%	475	6.3%	0.023	0.001
Wheelchair or walker use	*****	*****	*****	*****	0.012	0.008
Anti-arrhythmic use	18	0.1%	*****	*****	0.001	0.000
Antidiabetic use	1,607	7.1%	538	7.1%	0.055	0.002
Calcium channel blocker use	696	3.1%	234	3.1%	0.005	0.000
Diuretic use	1,035	4.6%	348	4.6%	0.016	0.001
Antidepressant use	11,884	52.8%	4,024	53.0%	-0.198	-0.004
Gastric acid suppressant use	3,856	17.1%	1,297	17.1%	0.045	0.001
NSAIDs	3,954	17.6%	1,338	17.6%	-0.051	-0.001

Table 1bz. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,872	26.1%	2,005	26.4%	-0.311	-0.007
Chronic liver disease	868	3.9%	290	3.8%	0.040	0.002
Pneumonia	395	1.8%	131	1.7%	0.033	0.003
Cardiac arrhythmia	2,845	12.6%	963	12.7%	-0.041	-0.001
Paliperidone palmitate	22,516	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,596	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	12	0.2%	-0.054	-0.015
IS Stay	2,202	9.8%	736	9.7%	0.095	0.003
Medical Product Use						
Mean number of filled prescriptions	20.2	21.1	20.1	21.0	0.078	0.004
Mean number of generics dispensed	7.4	5.5	7.3	5.2	0.092	0.017
Mean number of unique drug classes dispensed	6.6	4.8	6.7	4.5	-0.026	-0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.7	17.8	-0.007	-0.000
Mean number of inpatient hospital encounters	0.4	0.8	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	0.000	0.000

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1ca. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,747	100.0%	6,755	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.166	-0.057
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,747	100.0%	6,755	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,266	36.8%	2,494	36.9%	-0.125	-0.003
Male	12,481	63.2%	4,261	63.1%	0.125	0.003
Race[2]						
American Indian or Alaska Native	275	1.4%	91	1.3%	0.045	0.004
Asian	501	2.5%	182	2.7%	-0.157	-0.010
Black or African American	5,089	25.8%	1,868	27.7%	-1.883	-0.043
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,435	7.3%	501	7.4%	-0.150	-0.006
White	12,447	63.0%	4,113	60.9%	2.144	0.044
Hispanic origin						
Yes	1,047	5.3%	372	5.5%	-0.205	-0.009
No	18,312	92.7%	6,254	92.6%	0.150	0.006
Unknown	388	2.0%	129	1.9%	0.055	0.004

Table 1ca. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	567	2.9%	606	9.0%	-6.100	-0.261
2011	1,412	7.2%	1,246	18.4%	-11.295	-0.343
2012	1,733	8.8%	1,142	16.9%	-8.130	-0.245
2013	1,802	9.1%	937	13.9%	-4.746	-0.149
2014	1,690	8.6%	702	10.4%	-1.834	-0.063
2015	1,768	9.0%	527	7.8%	1.152	0.042
2016	1,858	9.4%	393	5.8%	3.591	0.136
2017	1,886	9.6%	350	5.2%	4.369	0.168
2018	1,945	9.8%	258	3.8%	6.030	0.241
2019	1,842	9.3%	218	3.2%	6.101	0.254
2020	1,378	7.0%	176	2.6%	4.373	0.206
2021	1,285	6.5%	146	2.2%	4.346	0.215
2022	581	2.9%	54	0.8%	2.143	0.159
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.5	0.042	0.027
Substance abuse	7,990	40.5%	2,587	38.3%	2.164	0.044
Atrial fibrilation/flutter	123	0.6%	42	0.6%	0.001	0.000
Ischemic heart disease	659	3.3%	281	4.2%	-0.823	-0.043
Heart failure	333	1.7%	140	2.1%	-0.386	-0.028
Stroke	231	1.2%	103	1.5%	-0.355	-0.031
Diabetes	3,844	19.5%	1,363	20.2%	-0.711	-0.018
Hypertension	7,366	37.3%	2,477	36.7%	0.633	0.013
Rheumatic disease	57	0.3%	27	0.4%	-0.111	-0.019
Chronic kidney disease	1,512	7.7%	387	5.7%	1.928	0.077
Seizure disorder	2,134	10.8%	740	11.0%	-0.148	-0.005

Table 1ca. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	25	0.4%	0.101	0.016
Dementia Diagnosis	735	3.7%	220	3.3%	0.465	0.025
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.012	-0.004
Parkinsons disease	94	0.5%	28	0.4%	0.062	0.009
COPD	2,001	10.1%	675	10.0%	0.141	0.005
Malignancy	480	2.4%	156	2.3%	0.121	0.008
Asthma	2,855	14.5%	989	14.6%	-0.183	-0.005
Hyperlipidemia	5,752	29.1%	1,876	27.8%	1.356	0.030
Depression	8,975	45.4%	3,025	44.8%	0.668	0.013
Schizophrenia	15,859	80.3%	5,259	77.9%	2.457	0.060
Bipolar disorder	9,614	48.7%	3,204	47.4%	1.254	0.025
ACE inhibitor use	2,565	13.0%	855	12.7%	0.332	0.010
ARB use	497	2.5%	172	2.5%	-0.029	-0.002
Beta-blocker use	3,237	16.4%	1,003	14.8%	1.544	0.043
Oral anticoagulant use	238	1.2%	80	1.2%	0.021	0.002
Antiplatelet agent use	81	0.4%	*****	*****	-0.182	-0.026
Opioid use	3,863	19.6%	1,347	19.9%	-0.378	-0.010
Statin use	3,162	16.0%	1,088	16.1%	-0.094	-0.003
Wheelchair or walker use	*****	*****	*****	*****	-0.083	-0.027
Anti-arrhythmic use	35	0.2%	*****	*****	-0.074	-0.016
Antidiabetic use	2,679	13.6%	931	13.8%	-0.216	-0.006
Calcium channel blocker use	1,312	6.6%	416	6.2%	0.486	0.020
Diuretic use	2,029	10.3%	706	10.5%	-0.177	-0.006
Antidepressant use	11,609	58.8%	3,671	54.3%	4.444	0.090
Gastric acid suppressant use	4,876	24.7%	1,583	23.4%	1.258	0.029
NSAIDs	4,405	22.3%	1,455	21.5%	0.768	0.019

Table 1ca. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,667	33.8%	1,897	28.1%	5.679	0.123
Chronic liver disease	1,169	5.9%	349	5.2%	0.753	0.033
Pneumonia	590	3.0%	200	3.0%	0.027	0.002
Cardiac arrhythmia	2,554	12.9%	752	11.1%	1.801	0.055
Paliperidone palmitate	19,747	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,755	100.0%	NaN	NaN
Haloperidol decanoate	16	0.1%	12	0.2%	-0.097	-0.027
IS Stay	1,841	9.3%	798	11.8%	-2.491	-0.081
Medical Product Use						
Mean number of filled prescriptions	26.9	25.6	25.1	25.0	1.827	0.072
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.555	0.090
Mean number of unique drug classes dispensed	8.1	5.5	7.7	5.1	0.387	0.073
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.3	18.5	15.6	18.0	0.639	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.052	-0.056
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.075	-0.063

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cb. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,742	100.0%	6,754	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.165	-0.057
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,742	100.0%	6,754	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,264	36.8%	2,493	36.9%	-0.117	-0.002
Male	12,478	63.2%	4,261	63.1%	0.117	0.002
Race[2]						
American Indian or Alaska Native	275	1.4%	91	1.3%	0.046	0.004
Asian	501	2.5%	182	2.7%	-0.157	-0.010
Black or African American	5,089	25.8%	1,868	27.7%	-1.880	-0.043
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,435	7.3%	501	7.4%	-0.149	-0.006
White	12,442	63.0%	4,112	60.9%	2.141	0.044
Hispanic origin						
Yes	1,047	5.3%	372	5.5%	-0.204	-0.009
No	18,307	92.7%	6,253	92.6%	0.149	0.006
Unknown	388	2.0%	129	1.9%	0.055	0.004

Table 1cb. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	567	2.9%	606	9.0%	-6.100	-0.261
2011	1,412	7.2%	1,246	18.4%	-11.296	-0.343
2012	1,733	8.8%	1,142	16.9%	-8.130	-0.245
2013	1,802	9.1%	937	13.9%	-4.746	-0.149
2014	1,690	8.6%	702	10.4%	-1.833	-0.063
2015	1,768	9.0%	527	7.8%	1.153	0.042
2016	1,858	9.4%	393	5.8%	3.593	0.136
2017	1,885	9.5%	349	5.2%	4.381	0.168
2018	1,943	9.8%	258	3.8%	6.022	0.240
2019	1,841	9.3%	218	3.2%	6.098	0.253
2020	1,378	7.0%	176	2.6%	4.374	0.206
2021	1,285	6.5%	146	2.2%	4.347	0.215
2022	580	2.9%	54	0.8%	2.138	0.158
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.5	0.042	0.028
Substance abuse	7,988	40.5%	2,586	38.3%	2.174	0.044
Atrial fibrilation/flutter	123	0.6%	42	0.6%	0.001	0.000
Ischemic heart disease	658	3.3%	280	4.1%	-0.813	-0.043
Heart failure	332	1.7%	139	2.1%	-0.376	-0.028
Stroke	230	1.2%	103	1.5%	-0.360	-0.031
Diabetes	3,841	19.5%	1,362	20.2%	-0.710	-0.018
Hypertension	7,362	37.3%	2,476	36.7%	0.631	0.013
Rheumatic disease	57	0.3%	26	0.4%	-0.096	-0.017
Chronic kidney disease	1,507	7.6%	386	5.7%	1.918	0.077
Seizure disorder	2,134	10.8%	739	10.9%	-0.132	-0.004

Table 1cb. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	92	0.5%	25	0.4%	0.096	0.015
Dementia Diagnosis	734	3.7%	220	3.3%	0.461	0.025
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.012	-0.004
Parkinsons disease	94	0.5%	28	0.4%	0.062	0.009
COPD	1,999	10.1%	675	10.0%	0.132	0.004
Malignancy	480	2.4%	156	2.3%	0.122	0.008
Asthma	2,853	14.5%	988	14.6%	-0.177	-0.005
Hyperlipidemia	5,747	29.1%	1,875	27.8%	1.349	0.030
Depression	8,972	45.4%	3,024	44.8%	0.673	0.014
Schizophrenia	15,855	80.3%	5,259	77.9%	2.446	0.060
Bipolar disorder	9,610	48.7%	3,204	47.4%	1.239	0.025
ACE inhibitor use	2,563	13.0%	854	12.6%	0.338	0.010
ARB use	496	2.5%	171	2.5%	-0.019	-0.001
Beta-blocker use	3,233	16.4%	1,002	14.8%	1.541	0.042
Oral anticoagulant use	237	1.2%	80	1.2%	0.016	0.001
Antiplatelet agent use	80	0.4%	*****	*****	-0.187	-0.027
Opioid use	3,860	19.6%	1,346	19.9%	-0.377	-0.009
Statin use	3,160	16.0%	1,088	16.1%	-0.102	-0.003
Wheelchair or walker use	*****	*****	*****	*****	-0.083	-0.027
Anti-arrhythmic use	35	0.2%	*****	*****	-0.074	-0.016
Antidiabetic use	2,677	13.6%	931	13.8%	-0.225	-0.007
Calcium channel blocker use	1,312	6.6%	415	6.1%	0.501	0.020
Diuretic use	2,027	10.3%	706	10.5%	-0.186	-0.006
Antidepressant use	11,604	58.8%	3,670	54.3%	4.440	0.090
Gastric acid suppressant use	4,872	24.7%	1,582	23.4%	1.255	0.029
NSAIDs	4,403	22.3%	1,455	21.5%	0.760	0.018

Table 1cb. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,663	33.8%	1,897	28.1%	5.663	0.123
Chronic liver disease	1,166	5.9%	348	5.2%	0.754	0.033
Pneumonia	587	3.0%	199	2.9%	0.027	0.002
Cardiac arrhythmia	2,551	12.9%	751	11.1%	1.802	0.055
Paliperidone palmitate	19,742	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,754	100.0%	NaN	NaN
Haloperidol decanoate	16	0.1%	12	0.2%	-0.097	-0.027
IS Stay	1,840	9.3%	798	11.8%	-2.495	-0.081
Medical Product Use						
Mean number of filled prescriptions	26.9	25.6	25.1	25.0	1.817	0.072
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.553	0.090
Mean number of unique drug classes dispensed	8.1	5.5	7.7	5.1	0.385	0.073
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.3	18.5	15.6	18.0	0.643	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.050	-0.054
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.075	-0.064

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cc. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,740	N/A	6,759	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.9	2.9	39.9	2.9	0.004	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,740	100.0%	6,759	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,264	36.8%	2,480	36.7%	0.113	0.002
Male	12,476	63.2%	4,279	63.3%	-0.113	-0.002
Race[3]						
American Indian or Alaska Native	274	1.4%	95	1.4%	-0.015	-0.001
Asian	502	2.5%	182	2.7%	-0.149	-0.009
Black or African American	5,150	26.1%	1,819	26.9%	-0.825	-0.019
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,428	7.2%	515	7.6%	-0.379	-0.014
White	12,386	62.7%	4,148	61.4%	1.368	0.028
Hispanic origin						
Yes	1,041	5.3%	385	5.7%	-0.423	-0.019
No	18,312	92.8%	6,244	92.4%	0.379	0.014
Unknown	388	2.0%	130	1.9%	0.043	0.003

Table 1cc. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	578	2.9%	586	8.7%	-5.736	-0.247
2011	1,439	7.3%	1,205	17.8%	-10.541	-0.322
2012	1,773	9.0%	1,102	16.3%	-7.329	-0.222
2013	1,813	9.2%	954	14.1%	-4.925	-0.154
2014	1,690	8.6%	707	10.5%	-1.894	-0.065
2015	1,761	8.9%	528	7.8%	1.108	0.040
2016	1,834	9.3%	415	6.1%	3.149	0.118
2017	1,872	9.5%	364	5.4%	4.088	0.156
2018	1,925	9.8%	267	4.0%	5.799	0.231
2019	1,829	9.3%	233	3.4%	5.822	0.240
2020	1,374	7.0%	187	2.8%	4.188	0.196
2021	1,275	6.5%	153	2.3%	4.196	0.207
2022	578	2.9%	58	0.9%	2.076	0.153
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.8	1.5	1.8	1.5	-0.005	-0.003
Substance abuse	7,886	39.9%	2,709	40.1%	-0.126	-0.003
Atrial fibrilation/flutter	124	0.6%	43	0.6%	-0.007	-0.001
Ischemic heart disease	698	3.5%	239	3.5%	-0.005	-0.000
Heart failure	349	1.8%	119	1.8%	0.009	0.001
Stroke	247	1.3%	86	1.3%	-0.022	-0.002
Diabetes	3,875	19.6%	1,326	19.6%	0.016	0.000
Hypertension	7,330	37.1%	2,511	37.2%	-0.025	-0.001
Rheumatic disease	63	0.3%	21	0.3%	0.000	0.000
Chronic kidney disease	1,411	7.1%	491	7.3%	-0.119	-0.005
Seizure disorder	2,138	10.8%	733	10.8%	-0.012	-0.000

Table 1cc. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	87	0.4%	31	0.5%	-0.015	-0.002
Dementia Diagnosis	710	3.6%	239	3.5%	0.065	0.004
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.004	0.001
Parkinsons disease	90	0.5%	30	0.4%	0.014	0.002
COPD	1,992	10.1%	677	10.0%	0.083	0.003
Malignancy	475	2.4%	166	2.5%	-0.053	-0.003
Asthma	2,865	14.5%	991	14.7%	-0.150	-0.004
Hyperlipidemia	5,676	28.8%	1,938	28.7%	0.077	0.002
Depression	8,938	45.3%	3,062	45.3%	-0.032	-0.001
Schizophrenia	15,733	79.7%	5,384	79.7%	0.046	0.001
Bipolar disorder	9,550	48.4%	3,270	48.4%	0.001	0.000
ACE inhibitor use	2,543	12.9%	867	12.8%	0.054	0.002
ARB use	498	2.5%	173	2.6%	-0.039	-0.003
Beta-blocker use	3,154	16.0%	1,077	15.9%	0.040	0.001
Oral anticoagulant use	234	1.2%	80	1.2%	-0.002	-0.000
Antiplatelet agent use	90	0.5%	*****	*****	-0.029	-0.004
Opioid use	3,873	19.6%	1,319	19.5%	0.102	0.003
Statin use	3,160	16.0%	1,075	15.9%	0.097	0.003
Wheelchair or walker use	14	0.1%	*****	*****	-0.001	-0.000
Anti-arrhythmic use	39	0.2%	*****	*****	0.006	0.001
Antidiabetic use	2,684	13.6%	914	13.5%	0.072	0.002
Calcium channel blocker use	1,286	6.5%	444	6.6%	-0.046	-0.002
Diuretic use	2,037	10.3%	702	10.4%	-0.073	-0.002
Antidepressant use	11,381	57.7%	3,899	57.7%	-0.037	-0.001
Gastric acid suppressant use	4,809	24.4%	1,650	24.4%	-0.051	-0.001
NSAIDs	4,362	22.1%	1,494	22.1%	-0.008	-0.000

Table 1cc. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,382	32.3%	2,193	32.5%	-0.121	-0.003
Chronic liver disease	1,129	5.7%	394	5.8%	-0.109	-0.005
Pneumonia	584	3.0%	199	3.0%	0.005	0.000
Cardiac arrhythmia	2,463	12.5%	854	12.6%	-0.159	-0.005
Paliperidone palmitate	19,740	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,759	100.0%	NaN	NaN
Haloperidol decanoate	17	0.1%	12	0.2%	-0.100	-0.027
IS Stay	1,965	10.0%	668	9.9%	0.076	0.003
Medical Product Use						
Mean number of filled prescriptions	26.5	25.5	26.2	25.3	0.354	0.014
Mean number of generics dispensed	9.0	6.3	8.8	6.0	0.211	0.034
Mean number of unique drug classes dispensed	8.0	5.4	7.9	5.2	0.077	0.015
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.1	18.3	16.3	19.0	-0.148	-0.008
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.004	-0.005
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.1	-0.001	-0.001

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1cd. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,449	100.0%	8,005	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.8	-0.130	-0.045
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,449	100.0%	8,005	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,340	42.9%	3,420	42.7%	0.158	0.003
Male	11,109	57.1%	4,585	57.3%	-0.158	-0.003
Race[2]						
American Indian or Alaska Native	199	1.0%	108	1.3%	-0.326	-0.030
Asian	451	2.3%	153	1.9%	0.408	0.028
Black or African American	4,647	23.9%	2,106	26.3%	-2.415	-0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	981	5.0%	412	5.1%	-0.103	-0.005
White	13,171	67.7%	5,226	65.3%	2.437	0.052
Hispanic origin						
Yes	779	4.0%	328	4.1%	-0.092	-0.005
No	18,468	95.0%	7,593	94.9%	0.103	0.005
Unknown	202	1.0%	84	1.0%	-0.011	-0.001

Table 1cd. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	677	3.5%	801	10.0%	-6.525	-0.262
2011	1,673	8.6%	1,583	19.8%	-11.173	-0.324
2012	1,948	10.0%	1,299	16.2%	-6.211	-0.185
2013	1,885	9.7%	1,174	14.7%	-4.974	-0.153
2014	1,767	9.1%	836	10.4%	-1.358	-0.046
2015	1,870	9.6%	648	8.1%	1.520	0.054
2016	1,897	9.8%	516	6.4%	3.308	0.121
2017	1,882	9.7%	356	4.4%	5.229	0.205
2018	1,848	9.5%	282	3.5%	5.979	0.244
2019	1,530	7.9%	201	2.5%	5.356	0.243
2020	1,064	5.5%	145	1.8%	3.659	0.196
2021	987	5.1%	117	1.5%	3.613	0.204
2022	421	2.2%	47	0.6%	1.578	0.136
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.1	2.0	-0.018	-0.009
Substance abuse	6,773	34.8%	2,548	31.8%	2.994	0.064
Atrial fibrilation/flutter	286	1.5%	126	1.6%	-0.104	-0.008
Ischemic heart disease	1,538	7.9%	679	8.5%	-0.574	-0.021
Heart failure	760	3.9%	389	4.9%	-0.952	-0.047
Stroke	446	2.3%	264	3.3%	-1.005	-0.061
Diabetes	5,716	29.4%	2,413	30.1%	-0.754	-0.016
Hypertension	10,275	52.8%	4,146	51.8%	1.038	0.021
Rheumatic disease	105	0.5%	47	0.6%	-0.047	-0.006
Chronic kidney disease	2,322	11.9%	816	10.2%	1.745	0.056
Seizure disorder	2,404	12.4%	1,080	13.5%	-1.131	-0.034

Table 1cd. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	227	1.2%	162	2.0%	-0.857	-0.068
Dementia Diagnosis	1,045	5.4%	557	7.0%	-1.585	-0.066
Dementia Diagnosis and Treatment	95	0.5%	86	1.1%	-0.586	-0.067
Parkinsons disease	257	1.3%	96	1.2%	0.122	0.011
COPD	3,874	19.9%	1,523	19.0%	0.893	0.023
Malignancy	585	3.0%	260	3.2%	-0.240	-0.014
Asthma	2,751	14.1%	1,056	13.2%	0.953	0.028
Hyperlipidemia	7,917	40.7%	3,144	39.3%	1.431	0.029
Depression	9,078	46.7%	3,694	46.1%	0.530	0.011
Schizophrenia	15,798	81.2%	6,350	79.3%	1.902	0.048
Bipolar disorder	9,074	46.7%	3,666	45.8%	0.859	0.017
ACE inhibitor use	4,122	21.2%	1,718	21.5%	-0.268	-0.007
ARB use	1,024	5.3%	370	4.6%	0.643	0.030
Beta-blocker use	4,084	21.0%	1,556	19.4%	1.561	0.039
Oral anticoagulant use	391	2.0%	168	2.1%	-0.088	-0.006
Antiplatelet agent use	302	1.6%	175	2.2%	-0.633	-0.047
Opioid use	4,365	22.4%	1,853	23.1%	-0.705	-0.017
Statin use	5,397	27.7%	2,114	26.4%	1.341	0.030
Wheelchair or walker use	24	0.1%	41	0.5%	-0.389	-0.069
Anti-arrhythmic use	74	0.4%	29	0.4%	0.018	0.003
Antidiabetic use	4,090	21.0%	1,661	20.7%	0.280	0.007
Calcium channel blocker use	2,280	11.7%	940	11.7%	-0.020	-0.001
Diuretic use	3,379	17.4%	1,417	17.7%	-0.328	-0.009
Antidepressant use	12,041	61.9%	4,589	57.3%	4.584	0.094
Gastric acid suppressant use	6,105	31.4%	2,423	30.3%	1.121	0.024
NSAIDs	4,947	25.4%	1,850	23.1%	2.325	0.054

Table 1cd. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,066	36.3%	2,387	29.8%	6.512	0.139
Chronic liver disease	1,517	7.8%	580	7.2%	0.554	0.021
Pneumonia	875	4.5%	406	5.1%	-0.573	-0.027
Cardiac arrhythmia	2,526	13.0%	893	11.2%	1.832	0.056
Paliperidone palmitate	19,449	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	8,005	100.0%	NaN	NaN
Haloperidol decanoate	23	0.1%	23	0.3%	-0.169	-0.038
IS Stay	1,835	9.4%	964	12.0%	-2.608	-0.084
Medical Product Use						
Mean number of filled prescriptions	32.8	28.2	31.6	27.4	1.164	0.042
Mean number of generics dispensed	10.4	6.5	10.0	6.4	0.439	0.068
Mean number of unique drug classes dispensed	9.3	5.7	8.9	5.5	0.336	0.060
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	19.8	17.3	20.1	0.446	0.022
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.051	-0.052
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.091	-0.077

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ce. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,433	99.9%	8,004	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.8	-0.129	-0.045
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,433	100.0%	8,004	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,331	42.9%	3,419	42.7%	0.154	0.003
Male	11,102	57.1%	4,585	57.3%	-0.154	-0.003
Race[2]						
American Indian or Alaska Native	198	1.0%	108	1.3%	-0.330	-0.031
Asian	451	2.3%	153	1.9%	0.409	0.028
Black or African American	4,642	23.9%	2,106	26.3%	-2.425	-0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	980	5.0%	412	5.1%	-0.104	-0.005
White	13,162	67.7%	5,225	65.3%	2.450	0.052
Hispanic origin						
Yes	778	4.0%	328	4.1%	-0.094	-0.005
No	18,453	95.0%	7,592	94.9%	0.104	0.005
Unknown	202	1.0%	84	1.0%	-0.010	-0.001

Table 1ce. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	677	3.5%	801	10.0%	-6.524	-0.262
2011	1,673	8.6%	1,583	19.8%	-11.169	-0.324
2012	1,948	10.0%	1,298	16.2%	-6.193	-0.184
2013	1,884	9.7%	1,174	14.7%	-4.973	-0.152
2014	1,767	9.1%	836	10.4%	-1.352	-0.046
2015	1,869	9.6%	648	8.1%	1.522	0.054
2016	1,892	9.7%	516	6.4%	3.289	0.121
2017	1,880	9.7%	356	4.4%	5.226	0.205
2018	1,847	9.5%	282	3.5%	5.981	0.244
2019	1,529	7.9%	201	2.5%	5.357	0.243
2020	1,061	5.5%	145	1.8%	3.648	0.196
2021	986	5.1%	117	1.5%	3.612	0.204
2022	420	2.2%	47	0.6%	1.574	0.136
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.1	2.0	-0.020	-0.010
Substance abuse	6,761	34.8%	2,547	31.8%	2.970	0.063
Atrial fibrilation/flutter	284	1.5%	126	1.6%	-0.113	-0.009
Ischemic heart disease	1,534	7.9%	678	8.5%	-0.577	-0.021
Heart failure	759	3.9%	388	4.8%	-0.942	-0.046
Stroke	445	2.3%	264	3.3%	-1.008	-0.061
Diabetes	5,707	29.4%	2,412	30.1%	-0.767	-0.017
Hypertension	10,259	52.8%	4,145	51.8%	1.005	0.020
Rheumatic disease	104	0.5%	47	0.6%	-0.052	-0.007
Chronic kidney disease	2,307	11.9%	816	10.2%	1.677	0.054
Seizure disorder	2,402	12.4%	1,079	13.5%	-1.120	-0.033

Table 1ce. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	227	1.2%	162	2.0%	-0.856	-0.068
Dementia Diagnosis	1,044	5.4%	557	7.0%	-1.587	-0.066
Dementia Diagnosis and Treatment	95	0.5%	86	1.1%	-0.586	-0.067
Parkinsons disease	255	1.3%	96	1.2%	0.113	0.010
COPD	3,864	19.9%	1,522	19.0%	0.868	0.022
Malignancy	585	3.0%	260	3.2%	-0.238	-0.014
Asthma	2,743	14.1%	1,056	13.2%	0.922	0.027
Hyperlipidemia	7,907	40.7%	3,144	39.3%	1.408	0.029
Depression	9,067	46.7%	3,694	46.2%	0.506	0.010
Schizophrenia	15,782	81.2%	6,350	79.3%	1.877	0.047
Bipolar disorder	9,063	46.6%	3,666	45.8%	0.835	0.017
ACE inhibitor use	4,117	21.2%	1,717	21.5%	-0.266	-0.006
ARB use	1,021	5.3%	370	4.6%	0.631	0.029
Beta-blocker use	4,074	21.0%	1,555	19.4%	1.537	0.038
Oral anticoagulant use	390	2.0%	168	2.1%	-0.092	-0.006
Antiplatelet agent use	302	1.6%	174	2.2%	-0.620	-0.046
Opioid use	4,362	22.4%	1,852	23.1%	-0.692	-0.016
Statin use	5,389	27.7%	2,113	26.4%	1.332	0.030
Wheelchair or walker use	22	0.1%	40	0.5%	-0.387	-0.070
Anti-arrhythmic use	73	0.4%	29	0.4%	0.013	0.002
Antidiabetic use	4,080	21.0%	1,661	20.8%	0.243	0.006
Calcium channel blocker use	2,275	11.7%	940	11.7%	-0.037	-0.001
Diuretic use	3,374	17.4%	1,416	17.7%	-0.329	-0.009
Antidepressant use	12,028	61.9%	4,588	57.3%	4.573	0.093
Gastric acid suppressant use	6,098	31.4%	2,422	30.3%	1.120	0.024
NSAIDs	4,934	25.4%	1,850	23.1%	2.276	0.053

Table 1ce. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,050	36.3%	2,387	29.8%	6.456	0.138
Chronic liver disease	1,511	7.8%	580	7.2%	0.529	0.020
Pneumonia	874	4.5%	405	5.1%	-0.562	-0.026
Cardiac arrhythmia	2,513	12.9%	893	11.2%	1.775	0.055
Paliperidone palmitate	19,433	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	8,004	100.0%	NaN	NaN
Haloperidol decanoate	23	0.1%	23	0.3%	-0.169	-0.038
IS Stay	1,835	9.4%	964	12.0%	-2.601	-0.084
Medical Product Use						
Mean number of filled prescriptions	32.8	28.1	31.6	27.4	1.145	0.041
Mean number of generics dispensed	10.4	6.5	10.0	6.4	0.432	0.067
Mean number of unique drug classes dispensed	9.3	5.7	8.9	5.5	0.331	0.059
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	19.8	17.3	20.1	0.438	0.022
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.051	-0.053
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.2	-0.092	-0.078

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cf. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,428	N/A	8,011	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.1	2.8	0.007	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,428	100.0%	8,011	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,316	42.8%	3,424	42.7%	0.067	0.001
Male	11,112	57.2%	4,587	57.3%	-0.067	-0.001
Race[3]						
American Indian or Alaska Native	197	1.0%	110	1.4%	-0.357	-0.033
Asian	453	2.3%	147	1.8%	0.499	0.035
Black or African American	4,691	24.1%	2,060	25.7%	-1.572	-0.036
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	978	5.0%	422	5.3%	-0.234	-0.011
White	13,108	67.5%	5,272	65.8%	1.664	0.035
Hispanic origin						
Yes	776	4.0%	337	4.2%	-0.209	-0.011
No	18,450	95.0%	7,589	94.7%	0.234	0.011
Unknown	202	1.0%	85	1.1%	-0.025	-0.002

Table 1cf. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	693	3.6%	770	9.6%	-6.052	-0.246
2011	1,706	8.8%	1,517	18.9%	-10.157	-0.297
2012	1,996	10.3%	1,245	15.5%	-5.260	-0.157
2013	1,880	9.7%	1,200	15.0%	-5.304	-0.162
2014	1,766	9.1%	859	10.7%	-1.634	-0.055
2015	1,862	9.6%	668	8.3%	1.246	0.044
2016	1,871	9.6%	541	6.8%	2.874	0.105
2017	1,862	9.6%	374	4.7%	4.914	0.192
2018	1,830	9.4%	297	3.7%	5.711	0.232
2019	1,513	7.8%	211	2.6%	5.154	0.233
2020	1,055	5.4%	151	1.9%	3.549	0.190
2021	978	5.0%	127	1.6%	3.452	0.194
2022	415	2.1%	50	0.6%	1.507	0.129
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.1	1.9	2.1	1.9	-0.008	-0.004
Substance abuse	6,603	34.0%	2,744	34.2%	-0.259	-0.005
Atrial fibrilation/flutter	290	1.5%	123	1.5%	-0.043	-0.004
Ischemic heart disease	1,571	8.1%	652	8.1%	-0.054	-0.002
Heart failure	817	4.2%	346	4.3%	-0.109	-0.005
Stroke	500	2.6%	206	2.6%	-0.002	-0.000
Diabetes	5,743	29.6%	2,367	29.5%	0.011	0.000
Hypertension	10,203	52.5%	4,213	52.6%	-0.077	-0.002
Rheumatic disease	107	0.6%	45	0.6%	-0.016	-0.002
Chronic kidney disease	2,209	11.4%	919	11.5%	-0.104	-0.003
Seizure disorder	2,461	12.7%	1,012	12.6%	0.031	0.001

Table 1cf. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	277	1.4%	115	1.4%	-0.007	-0.001
Dementia Diagnosis	1,135	5.8%	467	5.8%	0.008	0.000
Dementia Diagnosis and Treatment	129	0.7%	53	0.7%	0.007	0.001
Parkinsons disease	251	1.3%	105	1.3%	-0.023	-0.002
COPD	3,817	19.6%	1,580	19.7%	-0.077	-0.002
Malignancy	601	3.1%	251	3.1%	-0.034	-0.002
Asthma	2,690	13.8%	1,114	13.9%	-0.056	-0.002
Hyperlipidemia	7,833	40.3%	3,235	40.4%	-0.059	-0.001
Depression	9,036	46.5%	3,722	46.5%	0.048	0.001
Schizophrenia	15,681	80.7%	6,470	80.8%	-0.051	-0.001
Bipolar disorder	9,027	46.5%	3,740	46.7%	-0.227	-0.005
ACE inhibitor use	4,133	21.3%	1,708	21.3%	-0.050	-0.001
ARB use	983	5.1%	404	5.0%	0.020	0.001
Beta-blocker use	3,991	20.5%	1,657	20.7%	-0.138	-0.003
Oral anticoagulant use	394	2.0%	166	2.1%	-0.048	-0.003
Antiplatelet agent use	333	1.7%	135	1.7%	0.024	0.002
Opioid use	4,395	22.6%	1,809	22.6%	0.041	0.001
Statin use	5,312	27.3%	2,181	27.2%	0.109	0.002
Wheelchair or walker use	40	0.2%	19	0.2%	-0.026	-0.005
Anti-arrhythmic use	71	0.4%	31	0.4%	-0.020	-0.003
Antidiabetic use	4,056	20.9%	1,667	20.8%	0.071	0.002
Calcium channel blocker use	2,267	11.7%	928	11.6%	0.080	0.003
Diuretic use	3,395	17.5%	1,404	17.5%	-0.044	-0.001
Antidepressant use	11,765	60.6%	4,853	60.6%	-0.023	-0.000
Gastric acid suppressant use	6,026	31.0%	2,479	30.9%	0.074	0.002
NSAIDs	4,803	24.7%	1,985	24.8%	-0.053	-0.001

Table 1cf. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,683	34.4%	2,761	34.5%	-0.065	-0.001
Chronic liver disease	1,483	7.6%	612	7.6%	-0.001	-0.000
Pneumonia	906	4.7%	378	4.7%	-0.048	-0.002
Cardiac arrhythmia	2,422	12.5%	1,017	12.7%	-0.230	-0.007
Paliperidone palmitate	19,428	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	8,011	100.0%	NaN	NaN
Haloperidol decanoate	24	0.1%	23	0.3%	-0.171	-0.038
IS Stay	1,988	10.2%	823	10.3%	-0.036	-0.001
Medical Product Use						
Mean number of filled prescriptions	32.3	28.0	32.7	27.8	-0.346	-0.012
Mean number of generics dispensed	10.3	6.5	10.2	6.4	0.100	0.016
Mean number of unique drug classes dispensed	9.2	5.7	9.1	5.5	0.033	0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.6	19.7	17.7	20.5	-0.083	-0.004
Mean number of inpatient hospital encounters	0.4	1.0	0.4	1.0	-0.004	-0.004
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.1	-0.003	-0.003

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1cg. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,759	100.0%	7,196	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.6	2.9	-0.351	-0.124
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,759	100.0%	7,196	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,877	46.6%	3,486	48.4%	-1.848	-0.037
Male	7,882	53.4%	3,710	51.6%	1.848	0.037
Race[2]						
American Indian or Alaska Native	157	1.1%	52	0.7%	0.341	0.036
Asian	275	1.9%	107	1.5%	0.376	0.029
Black or African American	3,706	25.1%	1,784	24.8%	0.319	0.007
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	615	4.2%	337	4.7%	-0.516	-0.025
White	10,006	67.8%	4,916	68.3%	-0.520	-0.011
Hispanic origin						
Yes	452	3.1%	243	3.4%	-0.314	-0.018
No	14,144	95.8%	6,859	95.3%	0.516	0.025
Unknown	163	1.1%	94	1.3%	-0.202	-0.018

Table 1cg. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	373	2.5%	526	7.3%	-4.782	-0.223
2011	889	6.0%	1,021	14.2%	-8.165	-0.273
2012	1,109	7.5%	1,021	14.2%	-6.674	-0.216
2013	1,222	8.3%	931	12.9%	-4.658	-0.152
2014	1,269	8.6%	753	10.5%	-1.866	-0.064
2015	1,424	9.6%	639	8.9%	0.768	0.027
2016	1,427	9.7%	557	7.7%	1.928	0.068
2017	1,552	10.5%	483	6.7%	3.804	0.136
2018	1,540	10.4%	403	5.6%	4.834	0.179
2019	1,463	9.9%	319	4.4%	5.480	0.214
2020	1,116	7.6%	229	3.2%	4.379	0.195
2021	949	6.4%	218	3.0%	3.401	0.161
2022	426	2.9%	96	1.3%	1.552	0.108
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	3.0	2.7	-0.386	-0.152
Substance abuse	4,087	27.7%	1,654	23.0%	4.707	0.108
Atrial fibrilation/flutter	488	3.3%	324	4.5%	-1.196	-0.062
Ischemic heart disease	2,057	13.9%	1,266	17.6%	-3.656	-0.100
Heart failure	1,095	7.4%	777	10.8%	-3.378	-0.118
Stroke	641	4.3%	549	7.6%	-3.286	-0.139
Diabetes	5,340	36.2%	2,867	39.8%	-3.660	-0.075
Hypertension	9,416	63.8%	4,857	67.5%	-3.697	-0.078
Rheumatic disease	132	0.9%	56	0.8%	0.116	0.013
Chronic kidney disease	2,749	18.6%	1,389	19.3%	-0.676	-0.017
Seizure disorder	2,041	13.8%	1,219	16.9%	-3.111	-0.086

Table 1cg. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	588	4.0%	516	7.2%	-3.187	-0.139
Dementia Diagnosis	1,833	12.4%	1,573	21.9%	-9.440	-0.252
Dementia Diagnosis and Treatment	364	2.5%	398	5.5%	-3.065	-0.157
Parkinsons disease	447	3.0%	329	4.6%	-1.543	-0.081
COPD	4,084	27.7%	2,030	28.2%	-0.539	-0.012
Malignancy	657	4.5%	338	4.7%	-0.246	-0.012
Asthma	1,804	12.2%	845	11.7%	0.480	0.015
Hyperlipidemia	7,114	48.2%	3,466	48.2%	0.035	0.001
Depression	6,729	45.6%	3,463	48.1%	-2.531	-0.051
Schizophrenia	12,418	84.1%	5,667	78.8%	5.386	0.139
Bipolar disorder	6,592	44.7%	3,157	43.9%	0.793	0.016
ACE inhibitor use	3,816	25.9%	1,983	27.6%	-1.702	-0.038
ARB use	1,081	7.3%	488	6.8%	0.543	0.021
Beta-blocker use	3,836	26.0%	2,019	28.1%	-2.066	-0.047
Oral anticoagulant use	526	3.6%	295	4.1%	-0.536	-0.028
Antiplatelet agent use	469	3.2%	340	4.7%	-1.547	-0.079
Opioid use	3,135	21.2%	1,713	23.8%	-2.564	-0.061
Statin use	5,427	36.8%	2,612	36.3%	0.473	0.010
Wheelchair or walker use	82	0.6%	131	1.8%	-1.265	-0.117
Anti-arrhythmic use	98	0.7%	61	0.8%	-0.184	-0.021
Antidiabetic use	3,723	25.2%	1,858	25.8%	-0.595	-0.014
Calcium channel blocker use	2,718	18.4%	1,329	18.5%	-0.053	-0.001
Diuretic use	3,424	23.2%	1,847	25.7%	-2.468	-0.057
Antidepressant use	8,824	59.8%	4,201	58.4%	1.408	0.029
Gastric acid suppressant use	5,045	34.2%	2,563	35.6%	-1.434	-0.030
NSAIDs	3,529	23.9%	1,550	21.5%	2.371	0.057

Table 1cg. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,565	37.7%	2,472	34.4%	3.353	0.070
Chronic liver disease	1,229	8.3%	620	8.6%	-0.289	-0.010
Pneumonia	980	6.6%	678	9.4%	-2.782	-0.102
Cardiac arrhythmia	2,163	14.7%	1,012	14.1%	0.592	0.017
Paliperidone palmitate	14,759	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,196	100.0%	NaN	NaN
Haloperidol decanoate	14	0.1%	16	0.2%	-0.127	-0.032
IS Stay	1,695	11.5%	1,066	14.8%	-3.329	-0.099
Medical Product Use						
Mean number of filled prescriptions	36.4	30.0	38.6	32.6	-2.198	-0.070
Mean number of generics dispensed	11.0	6.5	11.4	6.7	-0.313	-0.048
Mean number of unique drug classes dispensed	9.9	5.7	10.3	5.8	-0.375	-0.065
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.2	20.2	16.7	19.6	1.497	0.075
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.074	-0.076
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.117	-0.092

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ch. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,756	100.0%	7,194	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.6	2.9	-0.351	-0.124
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,756	100.0%	7,194	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,876	46.6%	3,486	48.5%	-1.859	-0.037
Male	7,880	53.4%	3,708	51.5%	1.859	0.037
Race[2]						
American Indian or Alaska Native	157	1.1%	52	0.7%	0.341	0.036
Asian	275	1.9%	107	1.5%	0.376	0.029
Black or African American	3,705	25.1%	1,784	24.8%	0.310	0.007
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	614	4.2%	337	4.7%	-0.523	-0.025
White	10,005	67.8%	4,914	68.3%	-0.504	-0.011
Hispanic origin						
Yes	451	3.1%	243	3.4%	-0.321	-0.018
No	14,142	95.8%	6,857	95.3%	0.523	0.025
Unknown	163	1.1%	94	1.3%	-0.202	-0.019

Table 1ch. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	373	2.5%	525	7.3%	-4.770	-0.222
2011	889	6.0%	1,021	14.2%	-8.168	-0.273
2012	1,108	7.5%	1,021	14.2%	-6.684	-0.216
2013	1,221	8.3%	931	12.9%	-4.667	-0.152
2014	1,269	8.6%	753	10.5%	-1.867	-0.064
2015	1,424	9.7%	639	8.9%	0.768	0.026
2016	1,427	9.7%	557	7.7%	1.928	0.068
2017	1,552	10.5%	483	6.7%	3.804	0.136
2018	1,540	10.4%	402	5.6%	4.848	0.179
2019	1,462	9.9%	319	4.4%	5.474	0.213
2020	1,116	7.6%	229	3.2%	4.380	0.195
2021	949	6.4%	218	3.0%	3.401	0.161
2022	426	2.9%	96	1.3%	1.553	0.108
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	3.0	2.7	-0.385	-0.152
Substance abuse	4,085	27.7%	1,654	23.0%	4.692	0.108
Atrial fibrilation/flutter	488	3.3%	324	4.5%	-1.197	-0.062
Ischemic heart disease	2,057	13.9%	1,266	17.6%	-3.658	-0.100
Heart failure	1,095	7.4%	776	10.8%	-3.366	-0.117
Stroke	640	4.3%	548	7.6%	-3.280	-0.139
Diabetes	5,340	36.2%	2,865	39.8%	-3.636	-0.075
Hypertension	9,414	63.8%	4,856	67.5%	-3.703	-0.078
Rheumatic disease	132	0.9%	56	0.8%	0.116	0.013
Chronic kidney disease	2,749	18.6%	1,388	19.3%	-0.664	-0.017
Seizure disorder	2,040	13.8%	1,218	16.9%	-3.106	-0.086

Table 1ch. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	587	4.0%	516	7.2%	-3.195	-0.140
Dementia Diagnosis	1,832	12.4%	1,572	21.9%	-9.436	-0.252
Dementia Diagnosis and Treatment	363	2.5%	398	5.5%	-3.072	-0.157
Parkinsons disease	447	3.0%	329	4.6%	-1.544	-0.081
COPD	4,083	27.7%	2,029	28.2%	-0.534	-0.012
Malignancy	657	4.5%	338	4.7%	-0.246	-0.012
Asthma	1,804	12.2%	845	11.7%	0.480	0.015
Hyperlipidemia	7,114	48.2%	3,466	48.2%	0.032	0.001
Depression	6,726	45.6%	3,462	48.1%	-2.542	-0.051
Schizophrenia	12,416	84.1%	5,665	78.7%	5.396	0.139
Bipolar disorder	6,590	44.7%	3,156	43.9%	0.790	0.016
ACE inhibitor use	3,816	25.9%	1,983	27.6%	-1.704	-0.039
ARB use	1,081	7.3%	488	6.8%	0.542	0.021
Beta-blocker use	3,836	26.0%	2,019	28.1%	-2.069	-0.047
Oral anticoagulant use	526	3.6%	295	4.1%	-0.536	-0.028
Antiplatelet agent use	469	3.2%	340	4.7%	-1.548	-0.080
Opioid use	3,135	21.2%	1,712	23.8%	-2.552	-0.061
Statin use	5,427	36.8%	2,612	36.3%	0.470	0.010
Wheelchair or walker use	81	0.5%	131	1.8%	-1.272	-0.118
Anti-arrhythmic use	98	0.7%	61	0.8%	-0.184	-0.021
Antidiabetic use	3,723	25.2%	1,857	25.8%	-0.583	-0.013
Calcium channel blocker use	2,717	18.4%	1,329	18.5%	-0.061	-0.002
Diuretic use	3,424	23.2%	1,846	25.7%	-2.456	-0.057
Antidepressant use	8,821	59.8%	4,199	58.4%	1.411	0.029
Gastric acid suppressant use	5,044	34.2%	2,562	35.6%	-1.430	-0.030
NSAIDs	3,527	23.9%	1,550	21.5%	2.356	0.056

Table 1ch. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,563	37.7%	2,471	34.3%	3.352	0.070
Chronic liver disease	1,229	8.3%	619	8.6%	-0.276	-0.010
Pneumonia	979	6.6%	678	9.4%	-2.790	-0.103
Cardiac arrhythmia	2,161	14.6%	1,012	14.1%	0.578	0.016
Paliperidone palmitate	14,756	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,194	100.0%	NaN	NaN
Haloperidol decanoate	14	0.1%	16	0.2%	-0.128	-0.032
IS Stay	1,694	11.5%	1,065	14.8%	-3.324	-0.099
Medical Product Use						
Mean number of filled prescriptions	36.4	30.0	38.6	32.6	-2.202	-0.070
Mean number of generics dispensed	11.0	6.5	11.4	6.7	-0.314	-0.048
Mean number of unique drug classes dispensed	9.9	5.7	10.3	5.8	-0.376	-0.066
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.1	20.1	16.6	19.6	1.501	0.076
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.072	-0.075
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.116	-0.092

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ci. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	14,746	N/A	7,208	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.4	2.8	59.4	2.8	0.007	0.003
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,746	100.0%	7,208	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,974	47.3%	3,404	47.2%	0.063	0.001
Male	7,772	52.7%	3,803	52.8%	-0.063	-0.001
Race[3]						
American Indian or Alaska Native	159	1.1%	51	0.7%	0.375	0.040
Asian	274	1.9%	109	1.5%	0.346	0.027
Black or African American	3,727	25.3%	1,774	24.6%	0.660	0.015
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	615	4.2%	345	4.8%	-0.613	-0.030
White	9,971	67.6%	4,929	68.4%	-0.768	-0.016
Hispanic origin						
Yes	452	3.1%	251	3.5%	-0.423	-0.024
No	14,131	95.8%	6,863	95.2%	0.613	0.030
Unknown	164	1.1%	94	1.3%	-0.191	-0.017

Table 1ci. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	382	2.6%	512	7.1%	-4.516	-0.211
2011	893	6.1%	1,013	14.1%	-8.006	-0.269
2012	1,130	7.7%	1,000	13.9%	-6.212	-0.201
2013	1,221	8.3%	953	13.2%	-4.946	-0.160
2014	1,264	8.6%	772	10.7%	-2.138	-0.072
2015	1,413	9.6%	646	9.0%	0.612	0.021
2016	1,426	9.7%	560	7.8%	1.904	0.068
2017	1,550	10.5%	479	6.6%	3.866	0.138
2018	1,517	10.3%	409	5.7%	4.613	0.171
2019	1,454	9.9%	327	4.5%	5.316	0.207
2020	1,119	7.6%	222	3.1%	4.509	0.202
2021	954	6.5%	222	3.1%	3.386	0.159
2022	425	2.9%	91	1.3%	1.612	0.113
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.7	2.5	2.7	2.5	0.003	0.001
Substance abuse	3,864	26.2%	1,896	26.3%	-0.100	-0.002
Atrial fibrilation/flutter	544	3.7%	267	3.7%	-0.019	-0.001
Ischemic heart disease	2,227	15.1%	1,098	15.2%	-0.126	-0.004
Heart failure	1,265	8.6%	616	8.5%	0.031	0.001
Stroke	793	5.4%	384	5.3%	0.053	0.002
Diabetes	5,504	37.3%	2,686	37.3%	0.061	0.001
Hypertension	9,598	65.1%	4,694	65.1%	-0.032	-0.001
Rheumatic disease	126	0.9%	61	0.8%	0.013	0.001
Chronic kidney disease	2,767	18.8%	1,346	18.7%	0.086	0.002
Seizure disorder	2,201	14.9%	1,074	14.9%	0.030	0.001

Table 1ci. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	733	5.0%	359	5.0%	-0.004	-0.000
Dementia Diagnosis	2,277	15.4%	1,106	15.3%	0.095	0.003
Dementia Diagnosis and Treatment	503	3.4%	245	3.4%	0.017	0.001
Parkinsons disease	525	3.6%	254	3.5%	0.042	0.002
COPD	4,117	27.9%	2,025	28.1%	-0.174	-0.004
Malignancy	668	4.5%	329	4.6%	-0.033	-0.002
Asthma	1,782	12.1%	874	12.1%	-0.038	-0.001
Hyperlipidemia	7,117	48.3%	3,484	48.3%	-0.078	-0.002
Depression	6,839	46.4%	3,332	46.2%	0.154	0.003
Schizophrenia	12,190	82.7%	5,970	82.8%	-0.167	-0.004
Bipolar disorder	6,568	44.5%	3,227	44.8%	-0.233	-0.005
ACE inhibitor use	3,896	26.4%	1,903	26.4%	0.022	0.001
ARB use	1,058	7.2%	524	7.3%	-0.103	-0.004
Beta-blocker use	3,944	26.7%	1,927	26.7%	0.017	0.000
Oral anticoagulant use	550	3.7%	271	3.8%	-0.033	-0.002
Antiplatelet agent use	536	3.6%	258	3.6%	0.059	0.003
Opioid use	3,251	22.0%	1,587	22.0%	0.035	0.001
Statin use	5,403	36.6%	2,643	36.7%	-0.030	-0.001
Wheelchair or walker use	146	1.0%	70	1.0%	0.017	0.002
Anti-arrhythmic use	104	0.7%	51	0.7%	0.002	0.000
Antidiabetic use	3,741	25.4%	1,824	25.3%	0.066	0.002
Calcium channel blocker use	2,706	18.3%	1,318	18.3%	0.064	0.002
Diuretic use	3,570	24.2%	1,747	24.2%	-0.032	-0.001
Antidepressant use	8,735	59.2%	4,265	59.2%	0.058	0.001
Gastric acid suppressant use	5,101	34.6%	2,491	34.6%	0.037	0.001
NSAIDs	3,416	23.2%	1,669	23.2%	0.005	0.000

Table 1ci. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,400	36.6%	2,629	36.5%	0.148	0.003
Chronic liver disease	1,238	8.4%	603	8.4%	0.028	0.001
Pneumonia	1,115	7.6%	549	7.6%	-0.051	-0.002
Cardiac arrhythmia	2,131	14.4%	1,036	14.4%	0.069	0.002
Paliperidone palmitate	14,746	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	7,208	100.0%	NaN	NaN
Haloperidol decanoate	14	0.1%	17	0.2%	-0.145	-0.035
IS Stay	1,872	12.7%	913	12.7%	0.029	0.001
Medical Product Use						
Mean number of filled prescriptions	36.7	30.3	37.9	31.9	-1.222	-0.039
Mean number of generics dispensed	11.1	6.6	11.2	6.5	-0.046	-0.007
Mean number of unique drug classes dispensed	10.0	5.7	10.1	5.7	-0.125	-0.022
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	19.5	17.9	21.2	-0.197	-0.010
Mean number of inpatient hospital encounters	0.5	1.0	0.5	0.9	-0.005	-0.005
Mean number of non-acute institutional encounters	1.0	1.3	1.0	1.3	-0.003	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable
Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1cj. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,525	100.0%	6,779	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.7	2.8	-0.847	-0.308
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,525	100.0%	6,779	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,921	60.1%	4,247	62.6%	-2.557	-0.053
Male	2,604	39.9%	2,532	37.4%	2.557	0.053
Race[2]						
American Indian or Alaska Native	41	0.6%	38	0.6%	0.068	0.009
Asian	138	2.1%	65	1.0%	1.156	0.094
Black or African American	1,619	24.8%	1,521	22.4%	2.375	0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	297	4.6%	289	4.3%	0.289	0.014
White	4,430	67.9%	4,866	71.8%	-3.888	-0.085
Hispanic origin						
Yes	184	2.8%	181	2.7%	0.150	0.009
No	6,228	95.4%	6,490	95.7%	-0.289	-0.014
Unknown	113	1.7%	108	1.6%	0.139	0.011

Table 1cj. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	419	6.2%	-4.495	-0.233
2011	301	4.6%	853	12.6%	-7.970	-0.287
2012	388	5.9%	787	11.6%	-5.663	-0.201
2013	476	7.3%	775	11.4%	-4.137	-0.142
2014	443	6.8%	688	10.1%	-3.360	-0.121
2015	575	8.8%	607	9.0%	-0.142	-0.005
2016	654	10.0%	546	8.1%	1.969	0.069
2017	643	9.9%	525	7.7%	2.110	0.075
2018	660	10.1%	470	6.9%	3.182	0.114
2019	732	11.2%	350	5.2%	6.055	0.222
2020	592	9.1%	336	5.0%	4.116	0.162
2021	641	9.8%	276	4.1%	5.752	0.228
2022	310	4.8%	147	2.2%	2.582	0.142
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	4.2	3.1	-0.714	-0.241
Substance abuse	1,142	17.5%	919	13.6%	3.945	0.109
Atrial fibrilation/flutter	387	5.9%	677	10.0%	-4.056	-0.150
Ischemic heart disease	1,289	19.8%	1,849	27.3%	-7.521	-0.178
Heart failure	810	12.4%	1,231	18.2%	-5.745	-0.160
Stroke	476	7.3%	906	13.4%	-6.070	-0.200
Diabetes	2,620	40.2%	3,097	45.7%	-5.532	-0.112
Hypertension	4,882	74.8%	5,434	80.2%	-5.339	-0.128
Rheumatic disease	72	1.1%	87	1.3%	-0.180	-0.017
Chronic kidney disease	1,647	25.2%	1,769	26.1%	-0.854	-0.020
Seizure disorder	860	13.2%	1,173	17.3%	-4.123	-0.115

Table 1cj. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	791	12.1%	1,621	23.9%	-11.789	-0.310
Dementia Diagnosis	2,189	33.5%	3,714	54.8%	-21.239	-0.438
Dementia Diagnosis and Treatment	664	10.2%	1,466	21.6%	-11.449	-0.317
Parkinsons disease	445	6.8%	556	8.2%	-1.382	-0.052
COPD	1,860	28.5%	2,054	30.3%	-1.794	-0.039
Malignancy	401	6.1%	438	6.5%	-0.316	-0.013
Asthma	622	9.5%	612	9.0%	0.505	0.017
Hyperlipidemia	3,525	54.0%	3,727	55.0%	-0.956	-0.019
Depression	3,216	49.3%	3,696	54.5%	-5.234	-0.105
Schizophrenia	5,293	81.1%	4,313	63.6%	17.496	0.399
Bipolar disorder	2,855	43.8%	2,760	40.7%	3.041	0.062
ACE inhibitor use	1,839	28.2%	2,077	30.6%	-2.455	-0.054
ARB use	683	10.5%	656	9.7%	0.790	0.026
Beta-blocker use	2,005	30.7%	2,330	34.4%	-3.643	-0.078
Oral anticoagulant use	318	4.9%	526	7.8%	-2.886	-0.119
Antiplatelet agent use	301	4.6%	537	7.9%	-3.308	-0.137
Opioid use	1,230	18.9%	1,717	25.3%	-6.478	-0.157
Statin use	2,587	39.6%	2,859	42.2%	-2.527	-0.051
Wheelchair or walker use	75	1.1%	250	3.7%	-2.538	-0.166
Anti-arrhythmic use	54	0.8%	126	1.9%	-1.031	-0.090
Antidiabetic use	1,647	25.2%	1,945	28.7%	-3.450	-0.078
Calcium channel blocker use	1,671	25.6%	1,757	25.9%	-0.309	-0.007
Diuretic use	1,863	28.6%	2,257	33.3%	-4.742	-0.103
Antidepressant use	3,675	56.3%	4,123	60.8%	-4.498	-0.091
Gastric acid suppressant use	2,167	33.2%	2,637	38.9%	-5.689	-0.119
NSAIDs	1,290	19.8%	1,237	18.2%	1.523	0.039

Table 1cj. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,239	34.3%	2,419	35.7%	-1.370	-0.029
Chronic liver disease	488	7.5%	448	6.6%	0.870	0.034
Pneumonia	586	9.0%	879	13.0%	-3.986	-0.128
Cardiac arrhythmia	1,115	17.1%	1,060	15.6%	1.452	0.039
Paliperidone palmitate	6,525	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,779	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	0.019	0.006
IS Stay	946	14.5%	1,120	16.5%	-2.024	-0.056
Medical Product Use						
Mean number of filled prescriptions	34.9	30.3	42.4	33.9	-7.467	-0.232
Mean number of generics dispensed	10.9	6.3	12.3	6.6	-1.468	-0.227
Mean number of unique drug classes dispensed	9.8	5.5	11.2	5.7	-1.362	-0.242
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.9	19.3	14.5	18.0	2.316	0.124
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.073	-0.081
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.4	-0.053	-0.040

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ck. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,521	99.9%	6,768	99.8%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.7	2.8	-0.844	-0.307
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,521	100.0%	6,768	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,920	60.1%	4,238	62.6%	-2.505	-0.051
Male	2,601	39.9%	2,530	37.4%	2.505	0.051
Race[2]						
American Indian or Alaska Native	41	0.6%	38	0.6%	0.067	0.009
Asian	138	2.1%	65	1.0%	1.156	0.094
Black or African American	1,618	24.8%	1,517	22.4%	2.398	0.056
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	297	4.6%	289	4.3%	0.284	0.014
White	4,427	67.9%	4,859	71.8%	-3.905	-0.085
Hispanic origin						
Yes	184	2.8%	181	2.7%	0.147	0.009
No	6,224	95.4%	6,479	95.7%	-0.284	-0.014
Unknown	113	1.7%	108	1.6%	0.137	0.011

Table 1ck. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	419	6.2%	-4.504	-0.233
2011	301	4.6%	852	12.6%	-7.973	-0.287
2012	387	5.9%	786	11.6%	-5.679	-0.202
2013	476	7.3%	771	11.4%	-4.092	-0.141
2014	442	6.8%	686	10.1%	-3.358	-0.121
2015	575	8.8%	606	9.0%	-0.136	-0.005
2016	654	10.0%	546	8.1%	1.962	0.068
2017	643	9.9%	525	7.8%	2.103	0.074
2018	660	10.1%	470	6.9%	3.177	0.114
2019	731	11.2%	349	5.2%	6.053	0.222
2020	592	9.1%	335	4.9%	4.129	0.162
2021	640	9.8%	276	4.1%	5.736	0.227
2022	310	4.8%	147	2.2%	2.582	0.142
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	4.2	3.1	-0.710	-0.240
Substance abuse	1,141	17.5%	918	13.6%	3.933	0.109
Atrial fibrilation/flutter	387	5.9%	673	9.9%	-4.009	-0.149
Ischemic heart disease	1,289	19.8%	1,840	27.2%	-7.420	-0.176
Heart failure	809	12.4%	1,223	18.1%	-5.664	-0.158
Stroke	476	7.3%	900	13.3%	-5.998	-0.198
Diabetes	2,620	40.2%	3,088	45.6%	-5.449	-0.110
Hypertension	4,880	74.8%	5,423	80.1%	-5.292	-0.127
Rheumatic disease	72	1.1%	85	1.3%	-0.152	-0.014
Chronic kidney disease	1,645	25.2%	1,766	26.1%	-0.867	-0.020
Seizure disorder	859	13.2%	1,167	17.2%	-4.070	-0.114

Table 1ck. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	790	12.1%	1,615	23.9%	-11.748	-0.309
Dementia Diagnosis	2,188	33.6%	3,704	54.7%	-21.175	-0.436
Dementia Diagnosis and Treatment	663	10.2%	1,460	21.6%	-11.405	-0.316
Parkinsons disease	445	6.8%	555	8.2%	-1.376	-0.052
COPD	1,859	28.5%	2,050	30.3%	-1.782	-0.039
Malignancy	401	6.1%	438	6.5%	-0.322	-0.013
Asthma	622	9.5%	612	9.0%	0.496	0.017
Hyperlipidemia	3,524	54.0%	3,718	54.9%	-0.894	-0.018
Depression	3,214	49.3%	3,687	54.5%	-5.190	-0.104
Schizophrenia	5,290	81.1%	4,312	63.7%	17.411	0.397
Bipolar disorder	2,851	43.7%	2,758	40.8%	2.970	0.060
ACE inhibitor use	1,837	28.2%	2,072	30.6%	-2.444	-0.054
ARB use	683	10.5%	655	9.7%	0.796	0.026
Beta-blocker use	2,003	30.7%	2,324	34.3%	-3.622	-0.077
Oral anticoagulant use	318	4.9%	523	7.7%	-2.851	-0.118
Antiplatelet agent use	301	4.6%	532	7.9%	-3.245	-0.134
Opioid use	1,229	18.8%	1,711	25.3%	-6.434	-0.156
Statin use	2,587	39.7%	2,853	42.2%	-2.482	-0.051
Wheelchair or walker use	74	1.1%	241	3.6%	-2.426	-0.161
Anti-arrhythmic use	54	0.8%	126	1.9%	-1.034	-0.090
Antidiabetic use	1,647	25.3%	1,939	28.6%	-3.393	-0.077
Calcium channel blocker use	1,670	25.6%	1,751	25.9%	-0.262	-0.006
Diuretic use	1,861	28.5%	2,251	33.3%	-4.721	-0.102
Antidepressant use	3,672	56.3%	4,113	60.8%	-4.461	-0.091
Gastric acid suppressant use	2,166	33.2%	2,632	38.9%	-5.673	-0.118
NSAIDs	1,288	19.8%	1,236	18.3%	1.489	0.038

Table 1ck. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,238	34.3%	2,417	35.7%	-1.392	-0.029
Chronic liver disease	488	7.5%	448	6.6%	0.864	0.034
Pneumonia	585	9.0%	876	12.9%	-3.972	-0.127
Cardiac arrhythmia	1,113	17.1%	1,059	15.6%	1.421	0.038
Paliperidone palmitate	6,521	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,768	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	0.019	0.006
IS Stay	946	14.5%	1,118	16.5%	-2.012	-0.056
Medical Product Use						
Mean number of filled prescriptions	34.9	30.3	42.4	33.9	-7.448	-0.232
Mean number of generics dispensed	10.9	6.3	12.3	6.6	-1.462	-0.226
Mean number of unique drug classes dispensed	9.8	5.5	11.2	5.7	-1.356	-0.241
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.8	19.1	14.5	18.0	2.267	0.122
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.072	-0.080
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.4	-0.052	-0.039

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cl. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	6,483	N/A	6,797	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	69.3	2.8	69.3	2.8	0.006	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,483	100.0%	6,797	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,985	61.5%	4,180	61.5%	-0.017	-0.000
Male	2,497	38.5%	2,617	38.5%	0.017	0.000
Race[3]						
American Indian or Alaska Native	43	0.7%	33	0.5%	0.185	0.024
Asian	129	2.0%	75	1.1%	0.893	0.072
Black or African American	1,553	24.0%	1,590	23.4%	0.554	0.013
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	291	4.5%	293	4.3%	0.178	0.009
White	4,466	68.9%	4,806	70.7%	-1.809	-0.039
Hispanic origin						
Yes	180	2.8%	177	2.6%	0.176	0.011
No	6,192	95.5%	6,504	95.7%	-0.178	-0.009
Unknown	111	1.7%	116	1.7%	0.002	0.000

Table 1cl. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	116	1.8%	413	6.1%	-4.290	-0.222
2011	304	4.7%	845	12.4%	-7.745	-0.279
2012	397	6.1%	783	11.5%	-5.389	-0.191
2013	487	7.5%	792	11.7%	-4.143	-0.141
2014	448	6.9%	688	10.1%	-3.219	-0.116
2015	585	9.0%	622	9.1%	-0.121	-0.004
2016	653	10.1%	538	7.9%	2.148	0.075
2017	642	9.9%	528	7.8%	2.132	0.075
2018	640	9.9%	473	7.0%	2.925	0.106
2019	705	10.9%	353	5.2%	5.677	0.210
2020	577	8.9%	331	4.9%	4.021	0.159
2021	608	9.4%	284	4.2%	5.199	0.208
2022	321	5.0%	146	2.2%	2.804	0.152
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	3.9	3.0	3.9	3.0	0.010	0.003
Substance abuse	1,021	15.7%	1,084	15.9%	-0.201	-0.006
Atrial fibrilation/flutter	515	8.0%	541	8.0%	-0.006	-0.000
Ischemic heart disease	1,530	23.6%	1,601	23.6%	0.036	0.001
Heart failure	1,008	15.5%	1,047	15.4%	0.145	0.004
Stroke	640	9.9%	695	10.2%	-0.359	-0.012
Diabetes	2,794	43.1%	2,930	43.1%	-0.010	-0.000
Hypertension	5,051	77.9%	5,279	77.7%	0.244	0.006
Rheumatic disease	75	1.2%	77	1.1%	0.021	0.002
Chronic kidney disease	1,672	25.8%	1,750	25.7%	0.046	0.001
Seizure disorder	994	15.3%	1,034	15.2%	0.129	0.004

Table 1cl. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	1,124	17.3%	1,208	17.8%	-0.431	-0.011
Dementia Diagnosis	2,844	43.9%	2,992	44.0%	-0.152	-0.003
Dementia Diagnosis and Treatment	994	15.3%	1,069	15.7%	-0.394	-0.011
Parkinsons disease	511	7.9%	522	7.7%	0.211	0.008
COPD	1,910	29.5%	2,004	29.5%	-0.018	-0.000
Malignancy	422	6.5%	436	6.4%	0.086	0.004
Asthma	612	9.4%	638	9.4%	0.061	0.002
Hyperlipidemia	3,560	54.9%	3,724	54.8%	0.136	0.003
Depression	3,376	52.1%	3,536	52.0%	0.062	0.001
Schizophrenia	4,755	73.4%	4,942	72.7%	0.638	0.014
Bipolar disorder	2,791	43.0%	2,908	42.8%	0.264	0.005
ACE inhibitor use	1,921	29.6%	2,000	29.4%	0.206	0.005
ARB use	655	10.1%	676	10.0%	0.150	0.005
Beta-blocker use	2,119	32.7%	2,213	32.6%	0.126	0.003
Oral anticoagulant use	405	6.2%	430	6.3%	-0.080	-0.003
Antiplatelet agent use	405	6.2%	419	6.2%	0.069	0.003
Opioid use	1,423	22.0%	1,497	22.0%	-0.071	-0.002
Statin use	2,682	41.4%	2,794	41.1%	0.275	0.006
Wheelchair or walker use	161	2.5%	162	2.4%	0.097	0.006
Anti-arrhythmic use	97	1.5%	94	1.4%	0.110	0.009
Antidiabetic use	1,744	26.9%	1,825	26.8%	0.058	0.001
Calcium channel blocker use	1,651	25.5%	1,732	25.5%	-0.015	-0.000
Diuretic use	2,016	31.1%	2,107	31.0%	0.090	0.002
Antidepressant use	3,760	58.0%	3,956	58.2%	-0.211	-0.004
Gastric acid suppressant use	2,332	36.0%	2,445	36.0%	0.003	0.000
NSAIDs	1,236	19.1%	1,303	19.2%	-0.105	-0.003

Table 1cl. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,266	35.0%	2,375	34.9%	0.020	0.000
Chronic liver disease	453	7.0%	477	7.0%	-0.033	-0.001
Pneumonia	714	11.0%	746	11.0%	0.046	0.001
Cardiac arrhythmia	1,057	16.3%	1,111	16.3%	-0.044	-0.001
Paliperidone palmitate	6,483	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,797	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	0.023	0.008
IS Stay	1,061	16.4%	1,085	16.0%	0.399	0.011
Medical Product Use						
Mean number of filled prescriptions	37.4	32.1	39.9	32.8	-2.427	-0.075
Mean number of generics dispensed	11.5	6.5	11.7	6.5	-0.242	-0.037
Mean number of unique drug classes dispensed	10.4	5.7	10.6	5.6	-0.243	-0.043
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	17.9	16.0	20.0	-0.029	-0.002
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.3	0.007	0.006

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cm. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,496	100.0%	4,969	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.7	2.7	79.8	2.9	-1.048	-0.375
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,496	100.0%	4,969	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,049	70.1%	3,462	69.7%	0.448	0.010
Male	447	29.9%	1,507	30.3%	-0.448	-0.010
Race[2]						
American Indian or Alaska Native	*****	*****	28	0.6%	0.038	0.005
Asian	*****	*****	46	0.9%	0.946	0.081
Black or African American	314	21.0%	805	16.2%	4.789	0.123
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	181	3.6%	0.970	0.049
White	1,076	71.9%	3,909	78.7%	-6.743	-0.157
Hispanic origin						
Yes	48	3.2%	136	2.7%	0.472	0.028
No	1,427	95.4%	4,788	96.4%	-0.970	-0.049
Unknown	21	1.4%	45	0.9%	0.498	0.047

Table 1cm. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	28	1.9%	296	6.0%	-4.085	-0.212
2011	75	5.0%	609	12.3%	-7.243	-0.260
2012	101	6.8%	554	11.1%	-4.398	-0.155
2013	107	7.2%	559	11.2%	-4.097	-0.142
2014	106	7.1%	515	10.4%	-3.279	-0.116
2015	127	8.5%	441	8.9%	-0.386	-0.014
2016	143	9.6%	381	7.7%	1.891	0.067
2017	143	9.6%	356	7.2%	2.394	0.087
2018	141	9.4%	368	7.4%	2.019	0.073
2019	160	10.7%	289	5.8%	4.879	0.178
2020	162	10.8%	253	5.1%	5.737	0.213
2021	127	8.5%	244	4.9%	3.579	0.144
2022	76	5.1%	104	2.1%	2.987	0.161
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	5.0	3.0	-0.623	-0.204
Substance abuse	123	8.2%	311	6.3%	1.963	0.076
Atrial fibrilation/flutter	187	12.5%	816	16.4%	-3.922	-0.112
Ischemic heart disease	426	28.5%	1,642	33.0%	-4.569	-0.099
Heart failure	296	19.8%	1,176	23.7%	-3.881	-0.094
Stroke	165	11.0%	792	15.9%	-4.909	-0.144
Diabetes	634	42.4%	2,192	44.1%	-1.734	-0.035
Hypertension	1,240	82.9%	4,255	85.6%	-2.743	-0.075
Rheumatic disease	20	1.3%	88	1.8%	-0.434	-0.035
Chronic kidney disease	429	28.7%	1,531	30.8%	-2.135	-0.047
Seizure disorder	154	10.3%	668	13.4%	-3.149	-0.097

Table 1cm. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	398	26.6%	2,228	44.8%	-18.234	-0.388
Dementia Diagnosis	911	60.9%	4,076	82.0%	-21.133	-0.481
Dementia Diagnosis and Treatment	365	24.4%	2,101	42.3%	-17.884	-0.386
Parkinsons disease	150	10.0%	474	9.5%	0.488	0.016
COPD	403	26.9%	1,345	27.1%	-0.129	-0.003
Malignancy	95	6.4%	341	6.9%	-0.512	-0.021
Asthma	112	7.5%	297	6.0%	1.510	0.060
Hyperlipidemia	831	55.5%	2,668	53.7%	1.855	0.037
Depression	821	54.9%	2,829	56.9%	-2.053	-0.041
Schizophrenia	996	66.6%	1,820	36.6%	29.950	0.628
Bipolar disorder	578	38.6%	1,468	29.5%	9.093	0.193
ACE inhibitor use	402	26.9%	1,443	29.0%	-2.168	-0.048
ARB use	199	13.3%	586	11.8%	1.509	0.046
Beta-blocker use	512	34.2%	2,023	40.7%	-6.488	-0.134
Oral anticoagulant use	111	7.4%	514	10.3%	-2.924	-0.103
Antiplatelet agent use	106	7.1%	550	11.1%	-3.983	-0.139
Opioid use	323	21.6%	1,453	29.2%	-7.650	-0.176
Statin use	600	40.1%	1,999	40.2%	-0.122	-0.002
Wheelchair or walker use	44	2.9%	261	5.3%	-2.311	-0.117
Anti-arrhythmic use	27	1.8%	114	2.3%	-0.489	-0.035
Antidiabetic use	338	22.6%	1,319	26.5%	-3.951	-0.092
Calcium channel blocker use	457	30.5%	1,467	29.5%	1.025	0.022
Diuretic use	515	34.4%	1,861	37.5%	-3.027	-0.063
Antidepressant use	847	56.6%	3,292	66.3%	-9.633	-0.199
Gastric acid suppressant use	542	36.2%	1,996	40.2%	-3.939	-0.081
NSAIDs	240	16.0%	783	15.8%	0.285	0.008

Table 1cm. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	472	31.6%	1,797	36.2%	-4.613	-0.098
Chronic liver disease	75	5.0%	199	4.0%	1.009	0.049
Pneumonia	175	11.7%	653	13.1%	-1.444	-0.044
Cardiac arrhythmia	277	18.5%	763	15.4%	3.161	0.084
Paliperidone palmitate	1,496	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	4,969	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	NaN	NaN
IS Stay	248	16.6%	752	15.1%	1.444	0.040
Medical Product Use						
Mean number of filled prescriptions	35.4	30.5	44.5	34.2	-9.160	-0.283
Mean number of generics dispensed	11.0	6.2	12.8	6.4	-1.791	-0.283
Mean number of unique drug classes dispensed	10.2	5.5	11.8	5.6	-1.630	-0.293
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.9	16.9	11.5	14.9	3.398	0.214
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.012	-0.014
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.099	0.075

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cn. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,495	99.9%	4,955	99.7%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.7	2.7	79.8	2.9	-1.041	-0.373
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,495	100.0%	4,955	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,049	70.2%	3,451	69.6%	0.520	0.011
Male	446	29.8%	1,504	30.4%	-0.520	-0.011
Race[2]						
American Indian or Alaska Native	*****	*****	28	0.6%	0.037	0.005
Asian	*****	*****	46	0.9%	0.945	0.080
Black or African American	314	21.0%	805	16.2%	4.757	0.122
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	179	3.6%	1.003	0.051
White	1,075	71.9%	3,897	78.6%	-6.741	-0.157
Hispanic origin						
Yes	48	3.2%	134	2.7%	0.506	0.030
No	1,426	95.4%	4,776	96.4%	-1.003	-0.051
Unknown	21	1.4%	45	0.9%	0.497	0.046

Table 1cn. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	28	1.9%	295	6.0%	-4.081	-0.212
2011	75	5.0%	609	12.3%	-7.274	-0.261
2012	100	6.7%	553	11.2%	-4.471	-0.157
2013	107	7.2%	556	11.2%	-4.064	-0.141
2014	106	7.1%	513	10.4%	-3.263	-0.116
2015	127	8.5%	441	8.9%	-0.405	-0.014
2016	143	9.6%	377	7.6%	1.957	0.070
2017	143	9.6%	356	7.2%	2.381	0.086
2018	141	9.4%	366	7.4%	2.045	0.074
2019	160	10.7%	288	5.8%	4.890	0.178
2020	162	10.8%	253	5.1%	5.730	0.213
2021	127	8.5%	244	4.9%	3.571	0.143
2022	76	5.1%	104	2.1%	2.985	0.161
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	5.0	3.0	-0.621	-0.204
Substance abuse	123	8.2%	310	6.3%	1.971	0.076
Atrial fibrilation/flutter	187	12.5%	813	16.4%	-3.899	-0.111
Ischemic heart disease	425	28.4%	1,635	33.0%	-4.569	-0.099
Heart failure	295	19.7%	1,171	23.6%	-3.900	-0.095
Stroke	164	11.0%	784	15.8%	-4.853	-0.143
Diabetes	633	42.3%	2,183	44.1%	-1.715	-0.035
Hypertension	1,239	82.9%	4,242	85.6%	-2.734	-0.075
Rheumatic disease	20	1.3%	87	1.8%	-0.418	-0.034
Chronic kidney disease	428	28.6%	1,526	30.8%	-2.168	-0.047
Seizure disorder	153	10.2%	659	13.3%	-3.066	-0.095

Table 1cn. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	397	26.6%	2,216	44.7%	-18.167	-0.386
Dementia Diagnosis	910	60.9%	4,062	82.0%	-21.108	-0.481
Dementia Diagnosis and Treatment	364	24.3%	2,089	42.2%	-17.812	-0.385
Parkinsons disease	150	10.0%	474	9.6%	0.467	0.016
COPD	402	26.9%	1,341	27.1%	-0.174	-0.004
Malignancy	95	6.4%	341	6.9%	-0.527	-0.021
Asthma	112	7.5%	297	6.0%	1.498	0.060
Hyperlipidemia	830	55.5%	2,660	53.7%	1.835	0.037
Depression	821	54.9%	2,821	56.9%	-2.016	-0.041
Schizophrenia	996	66.6%	1,819	36.7%	29.912	0.627
Bipolar disorder	578	38.7%	1,468	29.6%	9.036	0.191
ACE inhibitor use	401	26.8%	1,437	29.0%	-2.178	-0.049
ARB use	199	13.3%	586	11.8%	1.485	0.045
Beta-blocker use	511	34.2%	2,012	40.6%	-6.425	-0.133
Oral anticoagulant use	111	7.4%	513	10.4%	-2.928	-0.103
Antiplatelet agent use	105	7.0%	540	10.9%	-3.875	-0.136
Opioid use	322	21.5%	1,445	29.2%	-7.624	-0.176
Statin use	599	40.1%	1,991	40.2%	-0.115	-0.002
Wheelchair or walker use	44	2.9%	257	5.2%	-2.244	-0.114
Anti-arrhythmic use	27	1.8%	114	2.3%	-0.495	-0.035
Antidiabetic use	338	22.6%	1,310	26.4%	-3.829	-0.089
Calcium channel blocker use	457	30.6%	1,464	29.5%	1.023	0.022
Diuretic use	514	34.4%	1,854	37.4%	-3.035	-0.063
Antidepressant use	846	56.6%	3,280	66.2%	-9.607	-0.198
Gastric acid suppressant use	541	36.2%	1,987	40.1%	-3.914	-0.081
NSAIDs	240	16.1%	781	15.8%	0.292	0.008

Table 1cn. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	472	31.6%	1,787	36.1%	-4.493	-0.095
Chronic liver disease	75	5.0%	198	4.0%	1.021	0.049
Pneumonia	175	11.7%	649	13.1%	-1.392	-0.042
Cardiac arrhythmia	277	18.5%	763	15.4%	3.130	0.083
Paliperidone palmitate	1,495	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	4,955	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	NaN	NaN
IS Stay	248	16.6%	749	15.1%	1.473	0.040
Medical Product Use						
Mean number of filled prescriptions	35.4	30.5	44.5	34.1	-9.116	-0.282
Mean number of generics dispensed	11.0	6.2	12.8	6.4	-1.787	-0.283
Mean number of unique drug classes dispensed	10.1	5.5	11.8	5.6	-1.625	-0.292
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.9	16.9	11.5	14.7	3.422	0.216
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.013	-0.015
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.097	0.074

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1co. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,474	N/A	4,965	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	79.5	2.9	79.5	2.9	-0.018	-0.006
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,474	100.0%	4,965	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,032	70.0%	3,471	69.9%	0.117	0.003
Male	442	30.0%	1,495	30.1%	-0.117	-0.003
Race[3]						
American Indian or Alaska Native	11	0.8%	26	0.5%	0.246	0.031
Asian	21	1.4%	50	1.0%	0.437	0.040
Black or African American	290	19.7%	845	17.0%	2.682	0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	175	3.5%	0.804	0.041
White	1,087	73.8%	3,870	77.9%	-4.168	-0.097
Hispanic origin						
Yes	42	2.9%	129	2.6%	0.259	0.016
No	1,410	95.7%	4,790	96.5%	-0.804	-0.041
Unknown	22	1.5%	45	0.9%	0.545	0.050

Table 1co. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	27	1.8%	302	6.1%	-4.259	-0.220
2011	79	5.3%	618	12.4%	-7.115	-0.252
2012	95	6.4%	546	11.0%	-4.594	-0.163
2013	130	8.8%	560	11.3%	-2.490	-0.083
2014	124	8.4%	519	10.5%	-2.063	-0.071
2015	126	8.5%	435	8.8%	-0.236	-0.008
2016	141	9.6%	372	7.5%	2.089	0.075
2017	149	10.1%	347	7.0%	3.107	0.111
2018	136	9.2%	363	7.3%	1.926	0.070
2019	153	10.4%	286	5.8%	4.627	0.170
2020	143	9.7%	254	5.1%	4.548	0.174
2021	108	7.3%	255	5.1%	2.195	0.091
2022	65	4.4%	107	2.2%	2.265	0.127
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	4.9	3.0	4.9	3.0	0.033	0.011
Substance abuse	100	6.8%	337	6.8%	-0.040	-0.002
Atrial fibrilation/flutter	233	15.8%	773	15.6%	0.226	0.006
Ischemic heart disease	488	33.1%	1,590	32.0%	1.060	0.023
Heart failure	327	22.2%	1,133	22.8%	-0.618	-0.015
Stroke	240	16.2%	734	14.8%	1.465	0.040
Diabetes	627	42.5%	2,166	43.6%	-1.113	-0.022
Hypertension	1,244	84.4%	4,218	85.0%	-0.580	-0.016
Rheumatic disease	26	1.8%	82	1.6%	0.140	0.011
Chronic kidney disease	459	31.1%	1,505	30.3%	0.835	0.018
Seizure disorder	196	13.3%	626	12.6%	0.655	0.020

Table 1co. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	615	41.7%	2,009	40.5%	1.248	0.025
Dementia Diagnosis	1,133	76.9%	3,821	77.0%	-0.077	-0.002
Dementia Diagnosis and Treatment	582	39.5%	1,888	38.0%	1.455	0.030
Parkinsons disease	142	9.6%	479	9.7%	-0.017	-0.001
COPD	414	28.1%	1,355	27.3%	0.804	0.018
Malignancy	94	6.4%	334	6.7%	-0.325	-0.013
Asthma	97	6.6%	321	6.5%	0.095	0.004
Hyperlipidemia	798	54.1%	2,688	54.1%	-0.000	-0.000
Depression	853	57.9%	2,811	56.6%	1.238	0.025
Schizophrenia	661	44.8%	2,176	43.8%	0.986	0.020
Bipolar disorder	488	33.1%	1,586	31.9%	1.182	0.025
ACE inhibitor use	412	28.0%	1,416	28.5%	-0.553	-0.012
ARB use	164	11.1%	596	12.0%	-0.886	-0.028
Beta-blocker use	589	40.0%	1,945	39.2%	0.781	0.016
Oral anticoagulant use	128	8.7%	479	9.6%	-0.938	-0.032
Antiplatelet agent use	174	11.8%	499	10.1%	1.755	0.056
Opioid use	384	26.0%	1,360	27.4%	-1.354	-0.031
Statin use	603	40.9%	1,996	40.2%	0.726	0.015
Wheelchair or walker use	62	4.2%	230	4.6%	-0.405	-0.020
Anti-arrhythmic use	36	2.5%	110	2.2%	0.243	0.016
Antidiabetic use	364	24.7%	1,264	25.4%	-0.753	-0.017
Calcium channel blocker use	432	29.3%	1,477	29.8%	-0.460	-0.010
Diuretic use	560	38.0%	1,827	36.8%	1.203	0.025
Antidepressant use	929	63.1%	3,164	63.7%	-0.679	-0.014
Gastric acid suppressant use	582	39.5%	1,948	39.2%	0.254	0.005
NSAIDs	241	16.3%	787	15.9%	0.471	0.013

Table 1co. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	522	35.4%	1,735	34.9%	0.474	0.010
Chronic liver disease	60	4.1%	209	4.2%	-0.130	-0.007
Pneumonia	187	12.7%	637	12.8%	-0.170	-0.005
Cardiac arrhythmia	237	16.1%	803	16.2%	-0.068	-0.002
Paliperidone palmitate	1,474	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	4,965	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	NaN	NaN
IS Stay	253	17.2%	777	15.7%	1.513	0.041
Medical Product Use						
Mean number of filled prescriptions	40.7	36.6	42.9	33.6	-2.195	-0.062
Mean number of generics dispensed	12.2	6.4	12.5	6.4	-0.304	-0.047
Mean number of unique drug classes dispensed	11.2	5.7	11.5	5.6	-0.269	-0.048
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	13.3	14.7	12.4	16.3	0.900	0.058
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	0.019	0.022
Mean number of non-acute institutional encounters	1.1	1.3	1.1	1.3	0.066	0.050

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1cp. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	372	100.0%	3,362	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.7	3.2	89.9	3.6	-1.194	-0.353
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	372	100.0%	3,362	100.0%	0.000	NaN
Sex						
Female	300	80.6%	2,742	81.6%	-0.913	-0.023
Male	72	19.4%	620	18.4%	0.913	0.023
Race[2]						
American Indian or Alaska Native	*****	*****	14	0.4%	0.659	0.077
Asian	*****	*****	19	0.6%	0.779	0.080
Black or African American	50	13.4%	392	11.7%	1.781	0.054
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	116	3.5%	2.732	0.128
White	290	78.0%	2,821	83.9%	-5.951	-0.152
Hispanic origin						
Yes	*****	*****	93	2.8%	1.266	0.070
No	349	93.8%	3,246	96.5%	-2.732	-0.128
Unknown	*****	*****	23	0.7%	1.466	0.124

Table 1cp. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	11	3.0%	218	6.5%	-3.527	-0.167
2011	14	3.8%	454	13.5%	-9.740	-0.352
2012	19	5.1%	429	12.8%	-7.653	-0.271
2013	32	8.6%	394	11.7%	-3.117	-0.103
2014	37	9.9%	345	10.3%	-0.316	-0.010
2015	36	9.7%	287	8.5%	1.141	0.040
2016	28	7.5%	260	7.7%	-0.207	-0.008
2017	48	12.9%	237	7.0%	5.854	0.196
2018	31	8.3%	236	7.0%	1.314	0.049
2019	39	10.5%	200	5.9%	4.535	0.166
2020	36	9.7%	131	3.9%	5.781	0.231
2021	24	6.5%	126	3.7%	2.704	0.123
2022	17	4.6%	45	1.3%	3.231	0.192
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	3.0	5.0	2.9	0.001	0.001
Substance abuse	22	5.9%	117	3.5%	2.434	0.115
Atrial fibrilation/flutter	73	19.6%	715	21.3%	-1.643	-0.041
Ischemic heart disease	104	28.0%	1,090	32.4%	-4.464	-0.097
Heart failure	91	24.5%	942	28.0%	-3.557	-0.081
Stroke	27	7.3%	549	16.3%	-9.072	-0.284
Diabetes	126	33.9%	1,143	34.0%	-0.127	-0.003
Hypertension	314	84.4%	2,866	85.2%	-0.838	-0.023
Rheumatic disease	*****	*****	59	1.8%	-0.142	-0.011
Chronic kidney disease	114	30.6%	987	29.4%	1.288	0.028
Seizure disorder	28	7.5%	296	8.8%	-1.277	-0.047

Table 1cp. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.8%	1,594	47.4%	-3.595	-0.072
Dementia Diagnosis	324	87.1%	3,069	91.3%	-4.188	-0.135
Dementia Diagnosis and Treatment	159	42.7%	1,528	45.4%	-2.707	-0.055
Parkinsons disease	34	9.1%	216	6.4%	2.715	0.101
COPD	77	20.7%	786	23.4%	-2.680	-0.065
Malignancy	22	5.9%	184	5.5%	0.441	0.019
Asthma	20	5.4%	148	4.4%	0.974	0.045
Hyperlipidemia	189	50.8%	1,421	42.3%	8.540	0.172
Depression	228	61.3%	1,821	54.2%	7.126	0.145
Schizophrenia	139	37.4%	505	15.0%	22.345	0.525
Bipolar disorder	110	29.6%	622	18.5%	11.069	0.261
ACE inhibitor use	94	25.3%	884	26.3%	-1.025	-0.023
ARB use	40	10.8%	374	11.1%	-0.372	-0.012
Beta-blocker use	141	37.9%	1,405	41.8%	-3.887	-0.079
Oral anticoagulant use	39	10.5%	363	10.8%	-0.313	-0.010
Antiplatelet agent use	35	9.4%	370	11.0%	-1.597	-0.053
Opioid use	90	24.2%	1,130	33.6%	-9.417	-0.209
Statin use	129	34.7%	977	29.1%	5.617	0.121
Wheelchair or walker use	18	4.8%	220	6.5%	-1.705	-0.074
Anti-arrhythmic use	*****	*****	85	2.5%	-0.647	-0.044
Antidiabetic use	52	14.0%	557	16.6%	-2.589	-0.072
Calcium channel blocker use	110	29.6%	935	27.8%	1.759	0.039
Diuretic use	120	32.3%	1,429	42.5%	-10.246	-0.213
Antidepressant use	240	64.5%	2,336	69.5%	-4.966	-0.106
Gastric acid suppressant use	126	33.9%	1,252	37.2%	-3.369	-0.070
NSAIDs	55	14.8%	414	12.3%	2.471	0.072

Table 1cp. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	137	36.8%	1,270	37.8%	-0.947	-0.020
Chronic liver disease	*****	*****	82	2.4%	0.249	0.016
Pneumonia	60	16.1%	479	14.2%	1.882	0.052
Cardiac arrhythmia	66	17.7%	466	13.9%	3.881	0.107
Paliperidone palmitate	372	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	3,362	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	58	15.6%	443	13.2%	2.415	0.069
Medical Product Use						
Mean number of filled prescriptions	37.3	28.1	43.5	30.7	-6.232	-0.212
Mean number of generics dispensed	11.3	5.6	12.3	5.6	-1.052	-0.187
Mean number of unique drug classes dispensed	10.4	5.0	11.5	5.0	-1.034	-0.206
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.4	12.2	8.4	10.6	2.936	0.257
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.7	0.077	0.100
Mean number of non-acute institutional encounters	1.0	1.3	0.8	1.2	0.268	0.217

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cq. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	371	99.7%	3,338	99.3%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.8	3.2	89.9	3.6	-1.169	-0.345
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	371	100.0%	3,338	100.0%	0.000	NaN
Sex						
Female	299	80.6%	2,722	81.5%	-0.953	-0.024
Male	72	19.4%	616	18.5%	0.953	0.024
Race[2]						
American Indian or Alaska Native	*****	*****	14	0.4%	0.659	0.076
Asian	*****	*****	19	0.6%	0.779	0.080
Black or African American	50	13.5%	390	11.7%	1.793	0.054
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	116	3.5%	2.724	0.127
White	289	77.9%	2,799	83.9%	-5.955	-0.152
Hispanic origin						
Yes	*****	*****	93	2.8%	1.257	0.069
No	348	93.8%	3,222	96.5%	-2.724	-0.127
Unknown	*****	*****	23	0.7%	1.467	0.124

Table 1cq. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	11	3.0%	214	6.4%	-3.446	-0.164
2011	14	3.8%	450	13.5%	-9.708	-0.351
2012	19	5.1%	425	12.7%	-7.611	-0.269
2013	32	8.6%	391	11.7%	-3.088	-0.102
2014	37	10.0%	341	10.2%	-0.243	-0.008
2015	36	9.7%	286	8.6%	1.135	0.039
2016	28	7.5%	260	7.8%	-0.242	-0.009
2017	48	12.9%	237	7.1%	5.838	0.195
2018	31	8.4%	234	7.0%	1.346	0.051
2019	39	10.5%	200	6.0%	4.521	0.165
2020	36	9.7%	131	3.9%	5.779	0.231
2021	23	6.2%	125	3.7%	2.455	0.113
2022	17	4.6%	44	1.3%	3.264	0.194
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	2.9	5.0	2.9	-0.010	-0.003
Substance abuse	21	5.7%	117	3.5%	2.155	0.103
Atrial fibrilation/flutter	73	19.7%	710	21.3%	-1.594	-0.040
Ischemic heart disease	104	28.0%	1,073	32.1%	-4.113	-0.090
Heart failure	91	24.5%	934	28.0%	-3.453	-0.079
Stroke	27	7.3%	525	15.7%	-8.450	-0.267
Diabetes	125	33.7%	1,127	33.8%	-0.070	-0.001
Hypertension	313	84.4%	2,844	85.2%	-0.834	-0.023
Rheumatic disease	*****	*****	58	1.7%	-0.120	-0.009
Chronic kidney disease	113	30.5%	980	29.4%	1.099	0.024
Seizure disorder	28	7.5%	290	8.7%	-1.141	-0.042

Table 1cq. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.9%	1,583	47.4%	-3.488	-0.070
Dementia Diagnosis	323	87.1%	3,046	91.3%	-4.190	-0.135
Dementia Diagnosis and Treatment	159	42.9%	1,518	45.5%	-2.619	-0.053
Parkinsons disease	34	9.2%	215	6.4%	2.723	0.102
COPD	77	20.8%	774	23.2%	-2.433	-0.059
Malignancy	22	5.9%	181	5.4%	0.508	0.022
Asthma	19	5.1%	148	4.4%	0.688	0.032
Hyperlipidemia	188	50.7%	1,414	42.4%	8.313	0.167
Depression	227	61.2%	1,810	54.2%	6.962	0.141
Schizophrenia	138	37.2%	505	15.1%	22.068	0.519
Bipolar disorder	109	29.4%	622	18.6%	10.746	0.254
ACE inhibitor use	94	25.3%	880	26.4%	-1.026	-0.023
ARB use	40	10.8%	369	11.1%	-0.273	-0.009
Beta-blocker use	141	38.0%	1,385	41.5%	-3.487	-0.071
Oral anticoagulant use	39	10.5%	361	10.8%	-0.303	-0.010
Antiplatelet agent use	35	9.4%	365	10.9%	-1.501	-0.050
Opioid use	90	24.3%	1,117	33.5%	-9.204	-0.204
Statin use	128	34.5%	971	29.1%	5.412	0.116
Wheelchair or walker use	18	4.9%	215	6.4%	-1.589	-0.069
Anti-arrhythmic use	*****	*****	83	2.5%	-0.600	-0.041
Antidiabetic use	52	14.0%	547	16.4%	-2.371	-0.066
Calcium channel blocker use	110	29.6%	928	27.8%	1.849	0.041
Diuretic use	120	32.3%	1,411	42.3%	-9.926	-0.206
Antidepressant use	239	64.4%	2,315	69.4%	-4.932	-0.105
Gastric acid suppressant use	125	33.7%	1,237	37.1%	-3.365	-0.070
NSAIDs	55	14.8%	412	12.3%	2.482	0.072

Table 1cq. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	137	36.9%	1,260	37.7%	-0.820	-0.017
Chronic liver disease	*****	*****	81	2.4%	0.269	0.017
Pneumonia	60	16.2%	475	14.2%	1.942	0.054
Cardiac arrhythmia	66	17.8%	466	14.0%	3.829	0.105
Paliperidone palmitate	371	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	3,338	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	57	15.4%	441	13.2%	2.152	0.062
Medical Product Use						
Mean number of filled prescriptions	37.4	28.1	43.4	30.7	-6.074	-0.206
Mean number of generics dispensed	11.3	5.6	12.3	5.6	-1.009	-0.179
Mean number of unique drug classes dispensed	10.5	5.0	11.5	5.0	-0.993	-0.198
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.4	12.2	8.5	10.7	2.910	0.254
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.7	0.073	0.095
Mean number of non-acute institutional encounters	1.0	1.2	0.8	1.2	0.250	0.207

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cr. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	379	N/A	3,340	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	90.0	3.8	89.8	3.6	0.182	0.050
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	379	100.0%	3,340	100.0%	0.000	NaN
Sex						
Female	288	76.0%	2,717	81.3%	-5.326	-0.130
Male	91	24.0%	623	18.7%	5.326	0.130
Race[3]						
American Indian or Alaska Native	*****	*****	14	0.4%	0.516	0.063
Asian	*****	*****	19	0.6%	0.406	0.046
Black or African American	45	11.8%	395	11.8%	-0.030	-0.001
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	118	3.5%	1.704	0.083
White	307	81.0%	2,793	83.6%	-2.596	-0.068
Hispanic origin						
Yes	*****	*****	94	2.8%	0.335	0.020
No	359	94.8%	3,222	96.5%	-1.704	-0.083
Unknown	*****	*****	24	0.7%	1.369	0.116

Table 1cr. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	18	4.7%	212	6.3%	-1.661	-0.073
2011	19	5.0%	442	13.2%	-8.182	-0.287
2012	19	4.9%	424	12.7%	-7.759	-0.276
2013	33	8.8%	390	11.7%	-2.897	-0.096
2014	30	7.8%	338	10.1%	-2.314	-0.081
2015	30	8.0%	288	8.6%	-0.644	-0.023
2016	31	8.1%	260	7.8%	0.287	0.011
2017	46	12.1%	239	7.2%	4.904	0.167
2018	32	8.5%	236	7.1%	1.394	0.052
2019	45	11.8%	205	6.2%	5.687	0.199
2020	35	9.3%	134	4.0%	5.283	0.213
2021	24	6.3%	127	3.8%	2.464	0.113
2022	18	4.8%	44	1.3%	3.439	0.201
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.5	3.1	5.0	2.9	0.481	0.161
Substance abuse	13	3.4%	125	3.7%	-0.382	-0.021
Atrial fibrilation/flutter	97	25.5%	707	21.2%	4.360	0.103
Ischemic heart disease	137	36.2%	1,061	31.8%	4.460	0.094
Heart failure	115	30.4%	924	27.6%	2.731	0.060
Stroke	72	19.1%	497	14.9%	4.240	0.113
Diabetes	139	36.8%	1,128	33.8%	3.035	0.063
Hypertension	323	85.2%	2,844	85.1%	0.027	0.001
Rheumatic disease	*****	*****	58	1.7%	0.091	0.007
Chronic kidney disease	125	32.9%	986	29.5%	3.439	0.074
Seizure disorder	36	9.4%	287	8.6%	0.847	0.030

Table 1cr. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	171	45.1%	1,572	47.1%	-1.959	-0.039
Dementia Diagnosis	346	91.3%	3,031	90.7%	0.553	0.019
Dementia Diagnosis and Treatment	165	43.6%	1,510	45.2%	-1.598	-0.032
Parkinsons disease	32	8.4%	225	6.7%	1.710	0.064
COPD	98	25.9%	768	23.0%	2.959	0.069
Malignancy	22	5.9%	183	5.5%	0.420	0.018
Asthma	24	6.4%	152	4.5%	1.870	0.082
Hyperlipidemia	179	47.4%	1,447	43.3%	4.022	0.081
Depression	228	60.1%	1,838	55.0%	5.120	0.104
Schizophrenia	66	17.4%	582	17.4%	-0.060	-0.002
Bipolar disorder	67	17.8%	659	19.7%	-1.954	-0.050
ACE inhibitor use	93	24.6%	876	26.2%	-1.653	-0.038
ARB use	39	10.4%	369	11.0%	-0.650	-0.021
Beta-blocker use	160	42.1%	1,376	41.2%	0.947	0.019
Oral anticoagulant use	46	12.3%	361	10.8%	1.452	0.045
Antiplatelet agent use	57	15.1%	360	10.8%	4.273	0.127
Opioid use	137	36.1%	1,087	32.5%	3.569	0.075
Statin use	125	33.1%	994	29.8%	3.347	0.072
Wheelchair or walker use	27	7.1%	210	6.3%	0.797	0.032
Anti-arrhythmic use	*****	*****	81	2.4%	-0.358	-0.024
Antidiabetic use	76	20.2%	539	16.1%	4.023	0.104
Calcium channel blocker use	107	28.3%	938	28.1%	0.182	0.004
Diuretic use	151	39.8%	1,377	41.2%	-1.439	-0.029
Antidepressant use	272	71.7%	2,302	68.9%	2.823	0.062
Gastric acid suppressant use	147	38.9%	1,228	36.8%	2.099	0.043
NSAIDs	48	12.7%	422	12.6%	0.087	0.003

Table 1cr. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	145	38.4%	1,258	37.7%	0.713	0.015
Chronic liver disease	*****	*****	81	2.4%	-1.145	-0.085
Pneumonia	61	16.1%	482	14.4%	1.663	0.046
Cardiac arrhythmia	60	15.9%	480	14.4%	1.527	0.043
Paliperidone palmitate	379	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	3,340	100.0%	NaN	NaN
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	48	12.7%	450	13.5%	-0.713	-0.021
Medical Product Use						
Mean number of filled prescriptions	42.7	29.0	43.1	30.7	-0.411	-0.014
Mean number of generics dispensed	12.7	5.7	12.2	5.6	0.441	0.078
Mean number of unique drug classes dispensed	11.7	5.1	11.4	5.0	0.325	0.065
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	8.6	9.3	8.8	11.2	-0.144	-0.014
Mean number of inpatient hospital encounters	0.4	0.7	0.4	0.7	-0.006	-0.009
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	0.026	0.022

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1cs. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	83,187	100.0%	39,076	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	52.6	17.6	-7.263	-0.461
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	7.614	0.181
35-44 years	*****	*****	*****	*****	6.446	0.160
45-54 years	19,354	23.3%	*****	*****	3.000	0.073
55-64 years	14,395	17.3%	6,798	17.4%	-0.092	-0.002
65-74 years	5,861	7.0%	5,313	13.6%	-6.551	-0.217
75-84 years	1,131	1.4%	2,868	7.3%	-5.980	-0.296
≥ 85 years	213	0.3%	1,834	4.7%	-4.437	-0.289
Sex						
Female	33,543	40.3%	18,304	46.8%	-6.520	-0.132
Male	49,644	59.7%	20,772	53.2%	6.520	0.132
Race[2]						
American Indian or Alaska Native	993	1.2%	433	1.1%	0.086	0.008
Asian	1,892	2.3%	738	1.9%	0.386	0.027
Black or African American	21,793	26.2%	10,071	25.8%	0.425	0.010
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,940	8.3%	2,638	6.8%	1.592	0.060
White	51,569	62.0%	25,196	64.5%	-2.488	-0.052
Hispanic origin						
Yes	4,311	5.2%	1,851	4.7%	0.445	0.021
No	76,247	91.7%	36,438	93.2%	-1.592	-0.060
Unknown	2,629	3.2%	787	2.0%	1.146	0.072

Table 1cs. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,431	2.9%	3,291	8.4%	-5.500	-0.239
2011	6,041	7.3%	6,501	16.6%	-9.375	-0.292
2012	7,238	8.7%	5,750	14.7%	-6.014	-0.188
2013	7,450	9.0%	5,213	13.3%	-4.385	-0.140
2014	7,114	8.6%	4,109	10.5%	-1.964	-0.067
2015	7,609	9.1%	3,196	8.2%	0.968	0.034
2016	7,874	9.5%	2,657	6.8%	2.666	0.098
2017	8,071	9.7%	2,221	5.7%	4.018	0.151
2018	8,130	9.8%	1,879	4.8%	4.965	0.192
2019	7,501	9.0%	1,503	3.8%	5.171	0.212
2020	5,781	6.9%	1,181	3.0%	3.927	0.181
2021	5,440	6.5%	1,088	2.8%	3.755	0.179
2022	2,507	3.0%	487	1.2%	1.767	0.123
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.6	2.5	-0.547	-0.243
Substance abuse	29,539	35.5%	10,848	27.8%	7.748	0.167
Atrial fibrilation/flutter	1,416	1.7%	1,876	4.8%	-3.099	-0.175
Ischemic heart disease	5,941	7.1%	5,096	13.0%	-5.900	-0.197
Heart failure	3,226	3.9%	3,423	8.8%	-4.882	-0.202
Stroke	1,893	2.3%	2,272	5.8%	-3.539	-0.180
Diabetes	19,813	23.8%	11,467	29.3%	-5.528	-0.125
Hypertension	37,183	44.7%	20,909	53.5%	-8.810	-0.177
Rheumatic disease	415	0.5%	296	0.8%	-0.259	-0.033
Chronic kidney disease	9,150	11.0%	5,474	14.0%	-3.009	-0.091
Seizure disorder	9,328	11.2%	4,973	12.7%	-1.513	-0.047

Table 1cs. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	632	0.8%	568	1.5%	-0.694	-0.066
Dementia Diagnosis	6,060	7.3%	7,785	19.9%	-12.638	-0.375
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,273	1.5%	1,194	3.1%	-1.525	-0.102
COPD	12,930	15.5%	7,320	18.7%	-3.189	-0.085
Malignancy	2,626	3.2%	1,562	4.0%	-0.841	-0.045
Asthma	11,348	13.6%	4,681	12.0%	1.662	0.050
Hyperlipidemia	28,032	33.7%	14,479	37.1%	-3.356	-0.070
Depression	37,671	45.3%	18,330	46.9%	-1.624	-0.033
Schizophrenia	67,148	80.7%	28,018	71.7%	9.018	0.213
Bipolar disorder	38,856	46.7%	16,921	43.3%	3.406	0.069
ACE inhibitor use	13,607	16.4%	7,646	19.6%	-3.210	-0.084
ARB use	3,556	4.3%	2,113	5.4%	-1.133	-0.053
Beta-blocker use	15,899	19.1%	8,900	22.8%	-3.664	-0.090
Oral anticoagulant use	1,636	2.0%	1,441	3.7%	-1.721	-0.104
Antiplatelet agent use	1,166	1.4%	1,395	3.6%	-2.168	-0.140
Opioid use	15,723	18.9%	8,678	22.2%	-3.307	-0.082
Statin use	17,961	21.6%	9,789	25.1%	-3.460	-0.082
Wheelchair or walker use	210	0.3%	602	1.5%	-1.288	-0.137
Anti-arrhythmic use	287	0.3%	315	0.8%	-0.461	-0.061
Antidiabetic use	13,751	16.5%	7,317	18.7%	-2.195	-0.058
Calcium channel blocker use	8,789	10.6%	5,440	13.9%	-3.356	-0.103
Diuretic use	11,795	14.2%	7,690	19.7%	-5.501	-0.147
Antidepressant use	48,156	57.9%	21,584	55.2%	2.653	0.054
Gastric acid suppressant use	22,126	26.6%	11,353	29.1%	-2.456	-0.055
NSAIDs	18,104	21.8%	7,734	19.8%	1.971	0.049

Table 1cs. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,528	33.1%	11,639	29.8%	3.306	0.071
Chronic liver disease	5,238	6.3%	2,338	6.0%	0.313	0.013
Pneumonia	3,431	4.1%	2,642	6.8%	-2.637	-0.116
Cardiac arrhythmia	11,423	13.7%	4,862	12.4%	1.289	0.038
Paliperidone palmitate	83,187	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,076	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.079	-0.021
IS Stay	8,403	10.1%	5,110	13.1%	-2.976	-0.093
Medical Product Use						
Mean number of filled prescriptions	28.6	26.8	31.0	28.8	-2.380	-0.086
Mean number of generics dispensed	9.4	6.3	9.8	6.4	-0.366	-0.058
Mean number of unique drug classes dispensed	8.4	5.5	8.8	5.5	-0.450	-0.082
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	15.2	18.5	1.263	0.068
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.062	-0.066
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.075	-0.062

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ct. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	83,186	100.0%	39,066	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	52.6	17.6	-7.256	-0.461
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	7.612	0.181
35-44 years	*****	*****	*****	*****	6.442	0.160
45-54 years	19,353	23.3%	*****	*****	2.994	0.073
55-64 years	14,395	17.3%	6,798	17.4%	-0.097	-0.003
65-74 years	5,861	7.0%	5,311	13.6%	-6.549	-0.217
75-84 years	1,131	1.4%	2,866	7.3%	-5.977	-0.296
≥ 85 years	213	0.3%	1,829	4.7%	-4.426	-0.288
Sex						
Female	33,542	40.3%	18,298	46.8%	-6.517	-0.132
Male	49,644	59.7%	20,768	53.2%	6.517	0.132
Race[2]						
American Indian or Alaska Native	993	1.2%	433	1.1%	0.085	0.008
Asian	1,892	2.3%	738	1.9%	0.385	0.027
Black or African American	21,792	26.2%	10,070	25.8%	0.420	0.010
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,940	8.3%	2,638	6.8%	1.590	0.060
White	51,569	62.0%	25,187	64.5%	-2.481	-0.051
Hispanic origin						
Yes	4,311	5.2%	1,851	4.7%	0.444	0.020
No	76,246	91.7%	36,428	93.2%	-1.590	-0.060
Unknown	2,629	3.2%	787	2.0%	1.146	0.072

Table 1ct. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,431	2.9%	3,290	8.4%	-5.499	-0.239
2011	6,041	7.3%	6,500	16.6%	-9.376	-0.292
2012	7,238	8.7%	5,750	14.7%	-6.018	-0.188
2013	7,450	9.0%	5,212	13.3%	-4.386	-0.140
2014	7,114	8.6%	4,108	10.5%	-1.964	-0.067
2015	7,609	9.1%	3,195	8.2%	0.969	0.034
2016	7,874	9.5%	2,655	6.8%	2.669	0.098
2017	8,071	9.7%	2,220	5.7%	4.020	0.151
2018	8,130	9.8%	1,878	4.8%	4.966	0.192
2019	7,501	9.0%	1,503	3.8%	5.170	0.212
2020	5,781	6.9%	1,181	3.0%	3.926	0.181
2021	5,439	6.5%	1,088	2.8%	3.753	0.179
2022	2,507	3.0%	486	1.2%	1.770	0.123
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.6	2.5	-0.546	-0.243
Substance abuse	29,538	35.5%	10,847	27.8%	7.743	0.167
Atrial fibrilation/flutter	1,416	1.7%	1,869	4.8%	-3.082	-0.175
Ischemic heart disease	5,941	7.1%	5,089	13.0%	-5.885	-0.196
Heart failure	3,226	3.9%	3,415	8.7%	-4.864	-0.201
Stroke	1,893	2.3%	2,264	5.8%	-3.520	-0.180
Diabetes	19,812	23.8%	11,458	29.3%	-5.513	-0.125
Hypertension	37,182	44.7%	20,899	53.5%	-8.799	-0.177
Rheumatic disease	415	0.5%	294	0.8%	-0.254	-0.032
Chronic kidney disease	9,149	11.0%	5,469	14.0%	-3.001	-0.091
Seizure disorder	9,328	11.2%	4,969	12.7%	-1.506	-0.046

Table 1ct. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	632	0.8%	568	1.5%	-0.694	-0.066
Dementia Diagnosis	6,060	7.3%	7,776	19.9%	-12.620	-0.375
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,273	1.5%	1,193	3.1%	-1.524	-0.102
COPD	12,930	15.5%	7,318	18.7%	-3.189	-0.085
Malignancy	2,626	3.2%	1,560	4.0%	-0.836	-0.045
Asthma	11,347	13.6%	4,680	12.0%	1.661	0.050
Hyperlipidemia	28,031	33.7%	14,474	37.1%	-3.353	-0.070
Depression	37,670	45.3%	18,321	46.9%	-1.613	-0.032
Schizophrenia	67,147	80.7%	28,016	71.7%	9.005	0.213
Bipolar disorder	38,855	46.7%	16,919	43.3%	3.400	0.068
ACE inhibitor use	13,606	16.4%	7,642	19.6%	-3.206	-0.084
ARB use	3,556	4.3%	2,112	5.4%	-1.131	-0.053
Beta-blocker use	15,899	19.1%	8,891	22.8%	-3.646	-0.090
Oral anticoagulant use	1,636	2.0%	1,439	3.7%	-1.717	-0.104
Antiplatelet agent use	1,166	1.4%	1,391	3.6%	-2.159	-0.139
Opioid use	15,723	18.9%	8,673	22.2%	-3.300	-0.082
Statin use	17,960	21.6%	9,785	25.0%	-3.457	-0.082
Wheelchair or walker use	210	0.3%	594	1.5%	-1.268	-0.136
Anti-arrhythmic use	287	0.3%	315	0.8%	-0.461	-0.061
Antidiabetic use	13,750	16.5%	7,309	18.7%	-2.180	-0.057
Calcium channel blocker use	8,789	10.6%	5,436	13.9%	-3.349	-0.102
Diuretic use	11,795	14.2%	7,685	19.7%	-5.493	-0.147
Antidepressant use	48,155	57.9%	21,577	55.2%	2.656	0.054
Gastric acid suppressant use	22,126	26.6%	11,350	29.1%	-2.455	-0.055
NSAIDs	18,103	21.8%	7,733	19.8%	1.967	0.049

Table 1ct. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,527	33.1%	11,636	29.8%	3.305	0.071
Chronic liver disease	5,237	6.3%	2,338	6.0%	0.311	0.013
Pneumonia	3,431	4.1%	2,638	6.8%	-2.628	-0.116
Cardiac arrhythmia	11,422	13.7%	4,861	12.4%	1.288	0.038
Paliperidone palmitate	83,186	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,066	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.079	-0.021
IS Stay	8,403	10.1%	5,108	13.1%	-2.974	-0.093
Medical Product Use						
Mean number of filled prescriptions	28.6	26.8	31.0	28.8	-2.376	-0.085
Mean number of generics dispensed	9.4	6.3	9.8	6.4	-0.365	-0.058
Mean number of unique drug classes dispensed	8.4	5.5	8.8	5.5	-0.449	-0.081
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.9	15.2	18.5	1.262	0.068
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.062	-0.066
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.075	-0.061

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cu. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	82,633	N/A	39,555	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	47.3	14.4	47.1	16.0	0.160	0.011
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	*****	*****	*****	*****	-3.905	-0.089
35-44 years	*****	*****	*****	*****	0.772	0.019
45-54 years	19,069	23.1%	*****	*****	1.924	0.046
55-64 years	15,560	18.8%	5,926	15.0%	3.848	0.103
65-74 years	7,581	9.2%	3,552	9.0%	0.196	0.007
75-84 years	1,938	2.3%	1,489	3.8%	-1.417	-0.082
≥ 85 years	515	0.6%	807	2.0%	-1.417	-0.124
Sex						
Female	34,667	42.0%	16,476	41.7%	0.299	0.006
Male	47,966	58.0%	23,079	58.3%	-0.299	-0.006
Race[3]						
American Indian or Alaska Native	966	1.2%	498	1.3%	-0.090	-0.008
Asian	1,852	2.2%	826	2.1%	0.154	0.011
Black or African American	21,601	26.1%	10,603	26.8%	-0.664	-0.015
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,517	7.9%	3,126	7.9%	-0.016	-0.001
White	51,697	62.6%	24,502	61.9%	0.616	0.013
Hispanic origin						
Yes	4,089	4.9%	2,170	5.5%	-0.538	-0.024
No	76,116	92.1%	36,429	92.1%	0.016	0.001
Unknown	2,428	2.9%	956	2.4%	0.522	0.032

Table 1cu. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,409	2.9%	3,420	8.6%	-5.732	-0.247
2011	5,966	7.2%	6,776	17.1%	-9.910	-0.307
2012	7,219	8.7%	5,914	15.0%	-6.214	-0.193
2013	7,312	8.8%	5,533	14.0%	-5.139	-0.162
2014	6,989	8.5%	4,220	10.7%	-2.211	-0.075
2015	7,500	9.1%	3,228	8.2%	0.916	0.033
2016	7,816	9.5%	2,637	6.7%	2.790	0.103
2017	8,026	9.7%	2,120	5.4%	4.352	0.165
2018	8,053	9.7%	1,761	4.5%	5.293	0.207
2019	7,509	9.1%	1,434	3.6%	5.463	0.225
2020	5,828	7.1%	1,084	2.7%	4.313	0.201
2021	5,447	6.6%	991	2.5%	4.087	0.197
2022	2,559	3.1%	437	1.1%	1.991	0.139
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.2	2.1	2.2	2.1	-0.001	-0.001
Substance abuse	27,658	33.5%	13,416	33.9%	-0.448	-0.009
Atrial fibrilation/flutter	2,087	2.5%	1,024	2.6%	-0.063	-0.004
Ischemic heart disease	7,272	8.8%	3,495	8.8%	-0.037	-0.001
Heart failure	4,348	5.3%	2,101	5.3%	-0.049	-0.002
Stroke	2,663	3.2%	1,295	3.3%	-0.052	-0.003
Diabetes	21,021	25.4%	9,968	25.2%	0.239	0.005
Hypertension	38,936	47.1%	18,551	46.9%	0.221	0.004
Rheumatic disease	477	0.6%	238	0.6%	-0.025	-0.003
Chronic kidney disease	9,711	11.8%	4,585	11.6%	0.161	0.005
Seizure disorder	9,646	11.7%	4,591	11.6%	0.067	0.002

Table 1cu. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	775	0.9%	368	0.9%	0.009	0.001
Dementia Diagnosis	8,763	10.6%	4,228	10.7%	-0.085	-0.003
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,652	2.0%	770	1.9%	0.052	0.004
COPD	13,661	16.5%	6,507	16.5%	0.081	0.002
Malignancy	2,817	3.4%	1,331	3.4%	0.044	0.002
Asthma	10,917	13.2%	5,241	13.3%	-0.040	-0.001
Hyperlipidemia	28,731	34.8%	13,712	34.7%	0.103	0.002
Depression	37,853	45.8%	18,135	45.8%	-0.039	-0.001
Schizophrenia	65,086	78.8%	31,161	78.8%	-0.015	-0.000
Bipolar disorder	38,086	46.1%	18,365	46.4%	-0.340	-0.007
ACE inhibitor use	14,265	17.3%	6,797	17.2%	0.079	0.002
ARB use	3,762	4.6%	1,793	4.5%	0.018	0.001
Beta-blocker use	16,559	20.0%	7,872	19.9%	0.138	0.003
Oral anticoagulant use	1,981	2.4%	951	2.4%	-0.006	-0.000
Antiplatelet agent use	1,647	2.0%	787	2.0%	0.003	0.000
Opioid use	16,335	19.8%	7,815	19.8%	0.011	0.000
Statin use	18,723	22.7%	8,879	22.4%	0.212	0.005
Wheelchair or walker use	549	0.7%	256	0.6%	0.017	0.002
Anti-arrhythmic use	382	0.5%	185	0.5%	-0.005	-0.001
Antidiabetic use	14,144	17.1%	6,681	16.9%	0.225	0.006
Calcium channel blocker use	9,453	11.4%	4,481	11.3%	0.111	0.003
Diuretic use	12,960	15.7%	6,170	15.6%	0.086	0.002
Antidepressant use	46,940	56.8%	22,453	56.8%	0.041	0.001
Gastric acid suppressant use	22,478	27.2%	10,684	27.0%	0.190	0.004
NSAIDs	17,541	21.2%	8,398	21.2%	-0.004	-0.000

Table 1cu. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	26,363	31.9%	12,586	31.8%	0.085	0.002
Chronic liver disease	5,147	6.2%	2,486	6.3%	-0.057	-0.002
Pneumonia	4,063	4.9%	1,935	4.9%	0.026	0.001
Cardiac arrhythmia	11,027	13.3%	5,321	13.5%	-0.109	-0.003
Paliperidone palmitate	82,633	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,555	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.094	-0.024
IS Stay	9,259	11.2%	4,427	11.2%	0.014	0.000
Medical Product Use						
Mean number of filled prescriptions	29.0	27.2	29.3	27.6	-0.336	-0.012
Mean number of generics dispensed	9.5	6.4	9.4	6.2	0.077	0.012
Mean number of unique drug classes dispensed	8.5	5.5	8.5	5.4	-0.016	-0.003
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.3	18.5	16.5	19.8	-0.196	-0.010
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.003	-0.004
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.006	-0.005

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1cv. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,677	100.0%	5,589	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.1	10.9	78.4	9.8	-8.243	-0.794
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.501	0.094
35-44 years	*****	*****	*****	*****	1.109	0.134
45-54 years	95	5.7%	*****	*****	4.126	0.223
55-64 years	364	21.7%	398	7.1%	14.584	0.424
65-74 years	664	39.6%	1,466	26.2%	13.364	0.287
75-84 years	365	21.8%	2,101	37.6%	-15.827	-0.352
≥ 85 years	159	9.5%	1,528	27.3%	-17.858	-0.474
Sex						
Female	966	57.6%	3,756	67.2%	-9.601	-0.199
Male	711	42.4%	1,833	32.8%	9.601	0.199
Race[2]						
American Indian or Alaska Native	17	1.0%	34	0.6%	0.405	0.045
Asian	28	1.7%	31	0.6%	1.115	0.106
Black or African American	339	20.2%	910	16.3%	3.933	0.102
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	85	5.1%	202	3.6%	1.454	0.071
White	1,208	72.0%	4,412	78.9%	-6.907	-0.161
Hispanic origin						
Yes	63	3.8%	148	2.6%	1.109	0.063
No	1,592	94.9%	5,387	96.4%	-1.454	-0.071
Unknown	22	1.3%	54	1.0%	0.346	0.033

Table 1cv. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	348	6.2%	-3.841	-0.190
2011	70	4.2%	757	13.5%	-9.370	-0.334
2012	127	7.6%	711	12.7%	-5.148	-0.171
2013	140	8.3%	662	11.8%	-3.496	-0.116
2014	153	9.1%	522	9.3%	-0.216	-0.007
2015	173	10.3%	504	9.0%	1.298	0.044
2016	164	9.8%	449	8.0%	1.746	0.061
2017	191	11.4%	420	7.5%	3.875	0.133
2018	145	8.6%	387	6.9%	1.722	0.064
2019	163	9.7%	320	5.7%	3.994	0.150
2020	132	7.9%	248	4.4%	3.434	0.143
2021	124	7.4%	180	3.2%	4.174	0.187
2022	55	3.3%	81	1.4%	1.830	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.7	5.3	2.8	-0.070	-0.026
Substance abuse	264	15.7%	441	7.9%	7.852	0.245
Atrial fibrilation/flutter	185	11.0%	857	15.3%	-4.302	-0.127
Ischemic heart disease	442	26.4%	1,837	32.9%	-6.512	-0.143
Heart failure	318	19.0%	1,294	23.2%	-4.190	-0.103
Stroke	218	13.0%	936	16.7%	-3.748	-0.105
Diabetes	742	44.2%	2,360	42.2%	2.020	0.041
Hypertension	1,413	84.3%	4,791	85.7%	-1.464	-0.041
Rheumatic disease	16	1.0%	87	1.6%	-0.603	-0.054
Chronic kidney disease	518	30.9%	1,644	29.4%	1.474	0.032
Seizure disorder	357	21.3%	890	15.9%	5.364	0.138

Table 1cv. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,677	100.0%	5,589	100.0%	0.000	NaN
Dementia Diagnosis	1,677	100.0%	5,589	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,677	100.0%	5,589	100.0%	0.000	NaN
Parkinsons disease	212	12.6%	518	9.3%	3.373	0.108
COPD	493	29.4%	1,466	26.2%	3.168	0.071
Malignancy	87	5.2%	288	5.2%	0.035	0.002
Asthma	158	9.4%	321	5.7%	3.678	0.139
Hyperlipidemia	1,013	60.4%	3,026	54.1%	6.263	0.127
Depression	1,127	67.2%	3,455	61.8%	5.385	0.113
Schizophrenia	1,119	66.7%	1,616	28.9%	37.812	0.818
Bipolar disorder	769	45.9%	1,633	29.2%	16.638	0.349
ACE inhibitor use	504	30.1%	1,754	31.4%	-1.329	-0.029
ARB use	182	10.9%	595	10.6%	0.207	0.007
Beta-blocker use	621	37.0%	2,237	40.0%	-2.995	-0.062
Oral anticoagulant use	133	7.9%	541	9.7%	-1.749	-0.062
Antiplatelet agent use	150	8.9%	625	11.2%	-2.238	-0.074
Opioid use	400	23.9%	1,734	31.0%	-7.173	-0.161
Statin use	761	45.4%	2,330	41.7%	3.690	0.074
Wheelchair or walker use	47	2.8%	316	5.7%	-2.851	-0.142
Anti-arrhythmic use	27	1.6%	122	2.2%	-0.573	-0.042
Antidiabetic use	451	26.9%	1,430	25.6%	1.307	0.030
Calcium channel blocker use	470	28.0%	1,622	29.0%	-0.995	-0.022
Diuretic use	583	34.8%	2,162	38.7%	-3.919	-0.081
Antidepressant use	1,277	76.1%	4,316	77.2%	-1.075	-0.025
Gastric acid suppressant use	662	39.5%	2,331	41.7%	-2.232	-0.045
NSAIDs	335	20.0%	869	15.5%	4.428	0.116

Table 1cv. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	777	46.3%	2,289	41.0%	5.377	0.109
Chronic liver disease	113	6.7%	240	4.3%	2.444	0.107
Pneumonia	233	13.9%	784	14.0%	-0.134	-0.004
Cardiac arrhythmia	325	19.4%	843	15.1%	4.297	0.114
Paliperidone palmitate	1,677	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	5,589	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.066	-0.022
IS Stay	299	17.8%	902	16.1%	1.691	0.045
Medical Product Use						
Mean number of filled prescriptions	51.1	35.4	51.9	35.2	-0.725	-0.021
Mean number of generics dispensed	14.7	6.3	14.4	5.9	0.263	0.043
Mean number of unique drug classes dispensed	13.3	5.4	13.2	5.1	0.088	0.017
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.1	19.3	11.1	14.1	6.941	0.411
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.8	0.044	0.053
Mean number of non-acute institutional encounters	1.4	1.5	1.1	1.4	0.286	0.197

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cw. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,675	99.9%	5,570	99.7%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.1	10.9	78.3	9.8	-8.187	-0.790
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.501	0.094
35-44 years	*****	*****	*****	*****	1.110	0.134
45-54 years	94	5.6%	*****	*****	4.068	0.220
55-64 years	364	21.7%	398	7.1%	14.586	0.424
65-74 years	664	39.6%	1,466	26.3%	13.322	0.286
75-84 years	365	21.8%	2,101	37.7%	-15.929	-0.354
≥ 85 years	158	9.4%	1,509	27.1%	-17.659	-0.469
Sex						
Female	965	57.6%	3,737	67.1%	-9.480	-0.197
Male	710	42.4%	1,833	32.9%	9.480	0.197
Race[2]						
American Indian or Alaska Native	17	1.0%	34	0.6%	0.405	0.045
Asian	28	1.7%	31	0.6%	1.115	0.106
Black or African American	338	20.2%	908	16.3%	3.877	0.101
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	85	5.1%	201	3.6%	1.466	0.072
White	1,207	72.1%	4,396	78.9%	-6.863	-0.160
Hispanic origin						
Yes	63	3.8%	148	2.7%	1.104	0.063
No	1,590	94.9%	5,369	96.4%	-1.466	-0.072
Unknown	22	1.3%	53	1.0%	0.362	0.034

Table 1cw. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	347	6.2%	-3.842	-0.190
2011	70	4.2%	752	13.5%	-9.322	-0.333
2012	127	7.6%	706	12.7%	-5.093	-0.169
2013	140	8.4%	659	11.8%	-3.473	-0.115
2014	153	9.1%	522	9.4%	-0.237	-0.008
2015	173	10.3%	504	9.0%	1.280	0.043
2016	163	9.7%	447	8.0%	1.706	0.060
2017	190	11.3%	420	7.5%	3.803	0.130
2018	145	8.7%	387	6.9%	1.709	0.064
2019	163	9.7%	318	5.7%	4.022	0.151
2020	132	7.9%	247	4.4%	3.446	0.144
2021	124	7.4%	180	3.2%	4.171	0.187
2022	55	3.3%	81	1.5%	1.829	0.121
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.7	5.2	2.8	-0.065	-0.024
Substance abuse	264	15.8%	441	7.9%	7.844	0.245
Atrial fibrilation/flutter	185	11.0%	854	15.3%	-4.287	-0.127
Ischemic heart disease	441	26.3%	1,827	32.8%	-6.472	-0.142
Heart failure	318	19.0%	1,288	23.1%	-4.139	-0.102
Stroke	218	13.0%	930	16.7%	-3.682	-0.104
Diabetes	742	44.3%	2,350	42.2%	2.108	0.043
Hypertension	1,411	84.2%	4,773	85.7%	-1.452	-0.041
Rheumatic disease	16	1.0%	85	1.5%	-0.571	-0.052
Chronic kidney disease	518	30.9%	1,639	29.4%	1.500	0.033
Seizure disorder	356	21.3%	883	15.9%	5.401	0.139

Table 1cw. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,675	100.0%	5,570	100.0%	0.000	NaN
Dementia Diagnosis	1,675	100.0%	5,570	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,675	100.0%	5,570	100.0%	0.000	NaN
Parkinsons disease	212	12.7%	518	9.3%	3.357	0.108
COPD	493	29.4%	1,461	26.2%	3.203	0.072
Malignancy	87	5.2%	288	5.2%	0.023	0.001
Asthma	158	9.4%	320	5.7%	3.688	0.140
Hyperlipidemia	1,012	60.4%	3,022	54.3%	6.163	0.125
Depression	1,126	67.2%	3,448	61.9%	5.321	0.111
Schizophrenia	1,118	66.7%	1,616	29.0%	37.734	0.816
Bipolar disorder	768	45.9%	1,631	29.3%	16.569	0.347
ACE inhibitor use	502	30.0%	1,743	31.3%	-1.322	-0.029
ARB use	182	10.9%	592	10.6%	0.237	0.008
Beta-blocker use	620	37.0%	2,225	39.9%	-2.931	-0.060
Oral anticoagulant use	133	7.9%	540	9.7%	-1.754	-0.062
Antiplatelet agent use	150	9.0%	625	11.2%	-2.266	-0.075
Opioid use	399	23.8%	1,721	30.9%	-7.077	-0.159
Statin use	760	45.4%	2,328	41.8%	3.578	0.072
Wheelchair or walker use	47	2.8%	306	5.5%	-2.688	-0.135
Anti-arrhythmic use	27	1.6%	120	2.2%	-0.542	-0.040
Antidiabetic use	451	26.9%	1,427	25.6%	1.306	0.030
Calcium channel blocker use	468	27.9%	1,614	29.0%	-1.036	-0.023
Diuretic use	582	34.7%	2,152	38.6%	-3.889	-0.081
Antidepressant use	1,275	76.1%	4,298	77.2%	-1.044	-0.025
Gastric acid suppressant use	661	39.5%	2,319	41.6%	-2.171	-0.044
NSAIDs	334	19.9%	868	15.6%	4.357	0.114

Table 1cw. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	776	46.3%	2,281	41.0%	5.377	0.109
Chronic liver disease	113	6.7%	239	4.3%	2.455	0.108
Pneumonia	233	13.9%	782	14.0%	-0.129	-0.004
Cardiac arrhythmia	325	19.4%	841	15.1%	4.304	0.114
Paliperidone palmitate	1,675	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	5,570	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.066	-0.022
IS Stay	299	17.9%	897	16.1%	1.747	0.047
Medical Product Use						
Mean number of filled prescriptions	51.1	35.4	51.9	35.2	-0.715	-0.020
Mean number of generics dispensed	14.7	6.3	14.4	6.0	0.267	0.044
Mean number of unique drug classes dispensed	13.3	5.4	13.2	5.1	0.092	0.017
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.0	19.1	11.2	14.1	6.858	0.408
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.8	0.045	0.054
Mean number of non-acute institutional encounters	1.4	1.5	1.1	1.4	0.287	0.198

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cx. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,668	N/A	5,585	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	76.5	10.7	76.4	10.7	0.190	0.018
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	*****	*****	16	0.3%	-0.134	-0.028
35-44 years	*****	*****	17	0.3%	0.117	0.019
45-54 years	*****	*****	149	2.7%	-0.359	-0.023
55-64 years	177	10.6%	586	10.5%	0.143	0.005
65-74 years	489	29.3%	1,608	28.8%	0.498	0.011
75-84 years	538	32.2%	1,945	34.8%	-2.587	-0.055
≥ 85 years	416	25.0%	1,264	22.6%	2.322	0.055
Sex						
Female	1,058	63.4%	3,620	64.8%	-1.416	-0.030
Male	611	36.6%	1,965	35.2%	1.416	0.030
Race[3]						
American Indian or Alaska Native	19	1.1%	33	0.6%	0.534	0.058
Asian	16	1.0%	32	0.6%	0.417	0.047
Black or African American	293	17.6%	983	17.6%	-0.006	-0.000
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	78	4.7%	205	3.7%	1.025	0.051
White	1,261	75.6%	4,333	77.6%	-1.970	-0.047
Hispanic origin						
Yes	57	3.4%	150	2.7%	0.710	0.041
No	1,590	95.3%	5,380	96.3%	-1.025	-0.051
Unknown	22	1.3%	55	1.0%	0.316	0.030

Table 1cx. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	47	2.8%	344	6.2%	-3.332	-0.161
2011	80	4.8%	736	13.2%	-8.390	-0.297
2012	121	7.3%	713	12.8%	-5.489	-0.184
2013	177	10.6%	668	12.0%	-1.370	-0.043
2014	154	9.2%	516	9.2%	-0.007	-0.000
2015	188	11.2%	509	9.1%	2.132	0.071
2016	146	8.8%	454	8.1%	0.638	0.023
2017	194	11.6%	421	7.5%	4.060	0.138
2018	135	8.1%	384	6.9%	1.228	0.047
2019	148	8.9%	325	5.8%	3.041	0.117
2020	122	7.3%	250	4.5%	2.813	0.120
2021	106	6.3%	180	3.2%	3.098	0.146
2022	52	3.1%	85	1.5%	1.579	0.105
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.3	2.7	5.2	2.8	0.059	0.022
Substance abuse	171	10.2%	559	10.0%	0.241	0.008
Atrial fibrilation/flutter	250	15.0%	792	14.2%	0.777	0.022
Ischemic heart disease	539	32.3%	1,751	31.3%	0.978	0.021
Heart failure	382	22.9%	1,238	22.2%	0.751	0.018
Stroke	273	16.3%	887	15.9%	0.460	0.013
Diabetes	718	43.1%	2,390	42.8%	0.257	0.005
Hypertension	1,437	86.1%	4,783	85.6%	0.511	0.015
Rheumatic disease	26	1.5%	77	1.4%	0.155	0.013
Chronic kidney disease	507	30.4%	1,652	29.6%	0.804	0.018
Seizure disorder	308	18.5%	980	17.5%	0.936	0.024

Table 1cx. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	1,668	100.0%	5,585	100.0%	0.000	NaN
Dementia Diagnosis	1,668	100.0%	5,585	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,668	100.0%	5,585	100.0%	0.000	NaN
Parkinsons disease	162	9.7%	563	10.1%	-0.352	-0.012
COPD	459	27.5%	1,524	27.3%	0.233	0.005
Malignancy	87	5.2%	289	5.2%	0.019	0.001
Asthma	125	7.5%	388	6.9%	0.555	0.021
Hyperlipidemia	929	55.7%	3,114	55.7%	-0.042	-0.001
Depression	1,077	64.6%	3,534	63.3%	1.279	0.027
Schizophrenia	633	38.0%	2,115	37.9%	0.081	0.002
Bipolar disorder	562	33.7%	1,855	33.2%	0.499	0.011
ACE inhibitor use	531	31.8%	1,737	31.1%	0.721	0.016
ARB use	176	10.5%	592	10.6%	-0.081	-0.003
Beta-blocker use	671	40.2%	2,205	39.5%	0.711	0.015
Oral anticoagulant use	165	9.9%	516	9.2%	0.637	0.022
Antiplatelet agent use	210	12.6%	604	10.8%	1.784	0.055
Opioid use	474	28.4%	1,643	29.4%	-1.030	-0.023
Statin use	737	44.2%	2,392	42.8%	1.352	0.027
Wheelchair or walker use	74	4.4%	272	4.9%	-0.433	-0.021
Anti-arrhythmic use	41	2.5%	114	2.0%	0.406	0.027
Antidiabetic use	426	25.5%	1,456	26.1%	-0.530	-0.012
Calcium channel blocker use	500	30.0%	1,612	28.9%	1.126	0.025
Diuretic use	613	36.7%	2,102	37.6%	-0.911	-0.019
Antidepressant use	1,266	75.9%	4,293	76.9%	-0.999	-0.024
Gastric acid suppressant use	707	42.4%	2,304	41.3%	1.121	0.023
NSAIDs	268	16.1%	949	17.0%	-0.920	-0.025

Table 1cx. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	691	41.4%	2,351	42.1%	-0.690	-0.014
Chronic liver disease	79	4.7%	273	4.9%	-0.166	-0.008
Pneumonia	245	14.7%	786	14.1%	0.589	0.017
Cardiac arrhythmia	275	16.5%	896	16.0%	0.468	0.013
Paliperidone palmitate	1,668	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	5,585	100.0%	NaN	NaN
Haloperidol decanoate	*****	*****	*****	*****	-0.128	-0.039
IS Stay	313	18.8%	954	17.1%	1.676	0.044
Medical Product Use						
Mean number of filled prescriptions	50.1	35.2	52.0	35.3	-1.880	-0.053
Mean number of generics dispensed	14.4	6.1	14.5	6.0	-0.139	-0.023
Mean number of unique drug classes dispensed	13.1	5.3	13.3	5.2	-0.155	-0.030
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	13.6	14.7	13.3	17.9	0.378	0.023
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.8	0.046	0.054
Mean number of non-acute institutional encounters	1.3	1.4	1.2	1.5	0.107	0.073

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1cy. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	76,162	100.0%	38,653	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.8	55.6	18.9	-9.928	-0.599
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	20,437	26.8%	6,730	17.4%	9.422	0.228
35-44 years	17,906	23.5%	5,957	15.4%	8.099	0.206
45-54 years	17,614	23.1%	7,041	18.2%	4.911	0.122
55-64 years	13,064	17.2%	6,130	15.9%	1.294	0.035
65-74 years	5,579	7.3%	5,659	14.6%	-7.315	-0.236
75-84 years	1,248	1.6%	4,217	10.9%	-9.271	-0.390
≥ 85 years	314	0.4%	2,919	7.6%	-7.140	-0.371
Sex						
Female	30,756	40.4%	18,989	49.1%	-8.745	-0.177
Male	45,406	59.6%	19,664	50.9%	8.745	0.177
Race[2]						
American Indian or Alaska Native	912	1.2%	426	1.1%	0.095	0.009
Asian	1,736	2.3%	661	1.7%	0.569	0.041
Black or African American	19,916	26.1%	9,663	25.0%	1.150	0.026
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,396	8.4%	2,525	6.5%	1.865	0.071
White	47,202	62.0%	25,378	65.7%	-3.680	-0.077
Hispanic origin						
Yes	3,978	5.2%	1,794	4.6%	0.582	0.027
No	69,766	91.6%	36,128	93.5%	-1.865	-0.071
Unknown	2,418	3.2%	731	1.9%	1.284	0.082

Table 1cy. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,270	3.0%	3,173	8.2%	-5.228	-0.229
2011	5,627	7.4%	6,367	16.5%	-9.084	-0.283
2012	6,664	8.7%	5,632	14.6%	-5.821	-0.182
2013	6,805	8.9%	5,062	13.1%	-4.161	-0.133
2014	6,478	8.5%	3,958	10.2%	-1.734	-0.060
2015	6,987	9.2%	3,166	8.2%	0.983	0.035
2016	7,223	9.5%	2,658	6.9%	2.607	0.095
2017	7,405	9.7%	2,232	5.8%	3.948	0.148
2018	7,380	9.7%	1,945	5.0%	4.658	0.179
2019	6,856	9.0%	1,579	4.1%	4.917	0.200
2020	5,236	6.9%	1,244	3.2%	3.656	0.168
2021	4,928	6.5%	1,131	2.9%	3.544	0.168
2022	2,303	3.0%	506	1.3%	1.715	0.118
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.9	2.7	-0.788	-0.339
Substance abuse	25,921	34.0%	9,498	24.6%	9.462	0.209
Atrial fibrilation/flutter	1,348	1.8%	2,282	5.9%	-4.134	-0.216
Ischemic heart disease	5,406	7.1%	5,724	14.8%	-7.711	-0.249
Heart failure	2,987	3.9%	3,939	10.2%	-6.269	-0.247
Stroke	1,804	2.4%	2,724	7.0%	-4.679	-0.222
Diabetes	18,108	23.8%	11,804	30.5%	-6.763	-0.152
Hypertension	33,555	44.1%	21,774	56.3%	-12.275	-0.247
Rheumatic disease	362	0.5%	309	0.8%	-0.324	-0.041
Chronic kidney disease	8,329	10.9%	5,908	15.3%	-4.349	-0.129
Seizure disorder	8,345	11.0%	5,001	12.9%	-1.981	-0.061

Table 1cy. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,929	2.5%	5,204	13.5%	-10.931	-0.411
Dementia Diagnosis	6,352	8.3%	11,200	29.0%	-20.636	-0.549
Dementia Diagnosis and Treatment	1,378	1.8%	4,687	12.1%	-10.317	-0.414
Parkinsons disease	1,228	1.6%	1,402	3.6%	-2.015	-0.126
COPD	11,599	15.2%	7,382	19.1%	-3.869	-0.103
Malignancy	2,382	3.1%	1,576	4.1%	-0.950	-0.051
Asthma	10,016	13.2%	4,237	11.0%	2.189	0.067
Hyperlipidemia	25,474	33.4%	14,813	38.3%	-4.876	-0.102
Depression	33,869	44.5%	18,387	47.6%	-3.100	-0.062
Schizophrenia	60,540	79.5%	25,167	65.1%	14.378	0.326
Bipolar disorder	34,557	45.4%	15,625	40.4%	4.949	0.100
ACE inhibitor use	12,487	16.4%	8,017	20.7%	-4.346	-0.112
ARB use	3,318	4.4%	2,345	6.1%	-1.710	-0.077
Beta-blocker use	14,503	19.0%	9,499	24.6%	-5.533	-0.134
Oral anticoagulant use	1,540	2.0%	1,665	4.3%	-2.286	-0.131
Antiplatelet agent use	1,147	1.5%	1,727	4.5%	-2.962	-0.175
Opioid use	14,494	19.0%	9,111	23.6%	-4.541	-0.111
Statin use	16,617	21.8%	10,369	26.8%	-5.008	-0.117
Wheelchair or walker use	218	0.3%	818	2.1%	-1.830	-0.169
Anti-arrhythmic use	274	0.4%	369	1.0%	-0.595	-0.074
Antidiabetic use	12,692	16.7%	7,540	19.5%	-2.842	-0.074
Calcium channel blocker use	8,088	10.6%	5,996	15.5%	-4.893	-0.146
Diuretic use	10,960	14.4%	8,411	21.8%	-7.370	-0.192
Antidepressant use	44,267	58.1%	22,371	57.9%	0.246	0.005
Gastric acid suppressant use	20,203	26.5%	11,718	30.3%	-3.790	-0.084
NSAIDs	16,475	21.6%	7,456	19.3%	2.342	0.058

Table 1cy. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,946	32.8%	11,835	30.6%	2.135	0.046
Chronic liver disease	4,681	6.1%	2,185	5.7%	0.493	0.021
Pneumonia	3,115	4.1%	2,794	7.2%	-3.138	-0.136
Cardiac arrhythmia	9,884	13.0%	4,673	12.1%	0.888	0.027
Paliperidone palmitate	76,162	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	38,653	100.0%	NaN	NaN
Haloperidol decanoate	71	0.1%	63	0.2%	-0.070	-0.020
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.9	27.1	33.6	30.7	-4.759	-0.164
Mean number of generics dispensed	9.4	6.3	10.2	6.5	-0.843	-0.132
Mean number of unique drug classes dispensed	8.4	5.5	9.3	5.7	-0.912	-0.163
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	18.3	14.2	17.6	1.783	0.099
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.060
Mean number of non-acute institutional encounters	0.8	1.1	0.8	1.2	-0.062	-0.054

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1cz. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	76,160	100.0%	38,652	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.8	55.6	18.9	-9.929	-0.599
Age	**Number**	**Percent**[1]	**Number**	**Percent**[1]		
18-34 years	20,437	26.8%	6,729	17.4%	9.425	0.229
35-44 years	17,906	23.5%	5,957	15.4%	8.099	0.206
45-54 years	17,613	23.1%	7,041	18.2%	4.910	0.121
55-64 years	13,064	17.2%	6,130	15.9%	1.294	0.035
65-74 years	5,579	7.3%	5,659	14.6%	-7.316	-0.236
75-84 years	1,247	1.6%	4,217	10.9%	-9.273	-0.390
≥ 85 years	314	0.4%	2,919	7.6%	-7.140	-0.371
Sex						
Female	30,755	40.4%	18,989	49.1%	-8.746	-0.177
Male	45,405	59.6%	19,663	50.9%	8.746	0.177
Race[2]						
American Indian or Alaska Native	912	1.2%	426	1.1%	0.095	0.009
Asian	1,736	2.3%	661	1.7%	0.569	0.041
Black or African American	19,915	26.1%	9,663	25.0%	1.149	0.026
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,396	8.4%	2,525	6.5%	1.865	0.071
White	47,201	62.0%	25,377	65.7%	-3.679	-0.077
Hispanic origin						
Yes	3,978	5.2%	1,794	4.6%	0.582	0.027
No	69,764	91.6%	36,127	93.5%	-1.865	-0.071
Unknown	2,418	3.2%	731	1.9%	1.284	0.082

Table 1cz. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,270	3.0%	3,173	8.2%	-5.229	-0.229
2011	5,627	7.4%	6,367	16.5%	-9.084	-0.283
2012	6,664	8.8%	5,632	14.6%	-5.821	-0.182
2013	6,805	8.9%	5,061	13.1%	-4.159	-0.133
2014	6,478	8.5%	3,958	10.2%	-1.734	-0.060
2015	6,986	9.2%	3,166	8.2%	0.982	0.035
2016	7,223	9.5%	2,658	6.9%	2.607	0.095
2017	7,405	9.7%	2,232	5.8%	3.948	0.148
2018	7,380	9.7%	1,945	5.0%	4.658	0.179
2019	6,856	9.0%	1,579	4.1%	4.917	0.200
2020	5,236	6.9%	1,244	3.2%	3.657	0.168
2021	4,927	6.5%	1,131	2.9%	3.543	0.168
2022	2,303	3.0%	506	1.3%	1.715	0.118
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.9	2.7	-0.788	-0.339
Substance abuse	25,920	34.0%	9,497	24.6%	9.463	0.209
Atrial fibrilation/flutter	1,348	1.8%	2,282	5.9%	-4.134	-0.216
Ischemic heart disease	5,405	7.1%	5,724	14.8%	-7.712	-0.249
Heart failure	2,986	3.9%	3,939	10.2%	-6.270	-0.247
Stroke	1,804	2.4%	2,724	7.0%	-4.679	-0.222
Diabetes	18,106	23.8%	11,804	30.5%	-6.766	-0.153
Hypertension	33,553	44.1%	21,773	56.3%	-12.275	-0.247
Rheumatic disease	362	0.5%	309	0.8%	-0.324	-0.041
Chronic kidney disease	8,327	10.9%	5,907	15.3%	-4.349	-0.129
Seizure disorder	8,345	11.0%	5,001	12.9%	-1.981	-0.061

Table 1cz. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,928	2.5%	5,204	13.5%	-10.932	-0.411
Dementia Diagnosis	6,351	8.3%	11,200	29.0%	-20.637	-0.549
Dementia Diagnosis and Treatment	1,377	1.8%	4,687	12.1%	-10.318	-0.414
Parkinsons disease	1,228	1.6%	1,402	3.6%	-2.015	-0.126
COPD	11,598	15.2%	7,382	19.1%	-3.870	-0.103
Malignancy	2,382	3.1%	1,576	4.1%	-0.950	-0.051
Asthma	10,015	13.1%	4,236	11.0%	2.191	0.067
Hyperlipidemia	25,473	33.4%	14,813	38.3%	-4.877	-0.102
Depression	33,867	44.5%	18,386	47.6%	-3.100	-0.062
Schizophrenia	60,539	79.5%	25,166	65.1%	14.380	0.326
Bipolar disorder	34,556	45.4%	15,624	40.4%	4.951	0.100
ACE inhibitor use	12,486	16.4%	8,016	20.7%	-4.344	-0.112
ARB use	3,318	4.4%	2,345	6.1%	-1.710	-0.077
Beta-blocker use	14,503	19.0%	9,499	24.6%	-5.533	-0.134
Oral anticoagulant use	1,540	2.0%	1,665	4.3%	-2.286	-0.131
Antiplatelet agent use	1,146	1.5%	1,727	4.5%	-2.963	-0.175
Opioid use	14,494	19.0%	9,111	23.6%	-4.541	-0.111
Statin use	16,616	21.8%	10,369	26.8%	-5.009	-0.117
Wheelchair or walker use	217	0.3%	818	2.1%	-1.831	-0.169
Anti-arrhythmic use	274	0.4%	369	1.0%	-0.595	-0.074
Antidiabetic use	12,690	16.7%	7,540	19.5%	-2.845	-0.074
Calcium channel blocker use	8,088	10.6%	5,996	15.5%	-4.893	-0.146
Diuretic use	10,959	14.4%	8,411	21.8%	-7.371	-0.192
Antidepressant use	44,266	58.1%	22,370	57.9%	0.247	0.005
Gastric acid suppressant use	20,202	26.5%	11,717	30.3%	-3.788	-0.084
NSAIDs	16,474	21.6%	7,455	19.3%	2.343	0.058

Table 1cz. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,945	32.8%	11,834	30.6%	2.137	0.046
Chronic liver disease	4,680	6.1%	2,185	5.7%	0.492	0.021
Pneumonia	3,114	4.1%	2,794	7.2%	-3.140	-0.136
Cardiac arrhythmia	9,882	13.0%	4,672	12.1%	0.888	0.027
Paliperidone palmitate	76,160	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	38,652	100.0%	NaN	NaN
Haloperidol decanoate	71	0.1%	63	0.2%	-0.070	-0.020
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.9	27.1	33.6	30.7	-4.760	-0.164
Mean number of generics dispensed	9.4	6.3	10.2	6.5	-0.843	-0.132
Mean number of unique drug classes dispensed	8.4	5.5	9.3	5.7	-0.912	-0.163
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	18.3	14.2	17.6	1.783	0.099
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.060
Mean number of non-acute institutional encounters	0.8	1.1	0.8	1.2	-0.062	-0.054

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1da. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	75,254	N/A	39,332	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.3	15.2	48.2	17.1	0.054	0.003
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	17,344	23.0%	10,690	27.2%	-4.132	-0.095
35-44 years	15,983	21.2%	8,066	20.5%	0.732	0.018
45-54 years	16,851	22.4%	7,968	20.3%	2.133	0.052
55-64 years	13,894	18.5%	5,587	14.2%	4.257	0.115
65-74 years	7,553	10.0%	3,700	9.4%	0.630	0.021
75-84 years	2,585	3.4%	2,069	5.3%	-1.826	-0.090
≥ 85 years	1,044	1.4%	1,252	3.2%	-1.795	-0.120
Sex						
Female	32,048	42.6%	16,694	42.4%	0.142	0.003
Male	43,207	57.4%	22,638	57.6%	-0.142	-0.003
Race[3]						
American Indian or Alaska Native	882	1.2%	505	1.3%	-0.113	-0.010
Asian	1,669	2.2%	797	2.0%	0.192	0.013
Black or African American	19,466	25.9%	10,512	26.7%	-0.860	-0.020
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	5,915	7.9%	3,106	7.9%	-0.036	-0.001
White	47,323	62.9%	24,412	62.1%	0.818	0.017
Hispanic origin						
Yes	3,728	5.0%	2,168	5.5%	-0.558	-0.025
No	69,340	92.1%	36,227	92.1%	0.036	0.001
Unknown	2,186	2.9%	937	2.4%	0.522	0.033

Table 1da. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	2,241	3.0%	3,392	8.6%	-5.645	-0.243
2011	5,468	7.3%	6,769	17.2%	-9.944	-0.307
2012	6,583	8.7%	5,878	14.9%	-6.196	-0.193
2013	6,688	8.9%	5,459	13.9%	-4.992	-0.158
2014	6,334	8.4%	4,115	10.5%	-2.047	-0.070
2015	6,844	9.1%	3,187	8.1%	0.991	0.035
2016	7,102	9.4%	2,627	6.7%	2.759	0.101
2017	7,379	9.8%	2,106	5.4%	4.451	0.169
2018	7,253	9.6%	1,783	4.5%	5.105	0.200
2019	6,853	9.1%	1,450	3.7%	5.418	0.223
2020	5,251	7.0%	1,110	2.8%	4.156	0.193
2021	4,915	6.5%	1,012	2.6%	3.957	0.191
2022	2,343	3.1%	444	1.1%	1.985	0.138
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.3	2.2	2.3	2.2	-0.004	-0.002
Substance abuse	23,693	31.5%	12,526	31.8%	-0.364	-0.008
Atrial fibrilation/flutter	2,278	3.0%	1,202	3.1%	-0.029	-0.002
Ischemic heart disease	7,053	9.4%	3,720	9.5%	-0.085	-0.003
Heart failure	4,413	5.9%	2,313	5.9%	-0.016	-0.001
Stroke	2,816	3.7%	1,497	3.8%	-0.063	-0.003
Diabetes	19,418	25.8%	10,061	25.6%	0.222	0.005
Hypertension	35,813	47.6%	18,641	47.4%	0.195	0.004
Rheumatic disease	438	0.6%	238	0.6%	-0.022	-0.003
Chronic kidney disease	9,117	12.1%	4,713	12.0%	0.133	0.004
Seizure disorder	8,813	11.7%	4,551	11.6%	0.142	0.004

Table 1da. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	4,286	5.7%	2,358	6.0%	-0.299	-0.013
Dementia Diagnosis	10,607	14.1%	5,695	14.5%	-0.385	-0.011
Dementia Diagnosis and Treatment	3,622	4.8%	2,013	5.1%	-0.306	-0.014
Parkinsons disease	1,728	2.3%	874	2.2%	0.074	0.005
COPD	12,435	16.5%	6,465	16.4%	0.087	0.002
Malignancy	2,589	3.4%	1,332	3.4%	0.054	0.003
Asthma	9,505	12.6%	4,967	12.6%	0.003	0.000
Hyperlipidemia	26,435	35.1%	13,754	35.0%	0.159	0.003
Depression	34,300	45.6%	17,939	45.6%	-0.030	-0.001
Schizophrenia	57,356	76.2%	29,870	75.9%	0.273	0.006
Bipolar disorder	33,501	44.5%	17,588	44.7%	-0.201	-0.004
ACE inhibitor use	13,309	17.7%	6,917	17.6%	0.100	0.003
ARB use	3,612	4.8%	1,889	4.8%	-0.003	-0.000
Beta-blocker use	15,476	20.6%	8,043	20.4%	0.116	0.003
Oral anticoagulant use	2,009	2.7%	1,048	2.7%	0.005	0.000
Antiplatelet agent use	1,840	2.4%	941	2.4%	0.053	0.003
Opioid use	15,241	20.3%	7,975	20.3%	-0.025	-0.001
Statin use	17,682	23.5%	9,138	23.2%	0.263	0.006
Wheelchair or walker use	674	0.9%	348	0.9%	0.011	0.001
Anti-arrhythmic use	404	0.5%	209	0.5%	0.004	0.001
Antidiabetic use	13,120	17.4%	6,777	17.2%	0.203	0.005
Calcium channel blocker use	9,000	12.0%	4,671	11.9%	0.085	0.003
Diuretic use	12,435	16.5%	6,479	16.5%	0.052	0.001
Antidepressant use	43,383	57.6%	22,690	57.7%	-0.041	-0.001
Gastric acid suppressant use	20,708	27.5%	10,746	27.3%	0.197	0.004
NSAIDs	15,846	21.1%	8,257	21.0%	0.064	0.002

Table 1da. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	23,959	31.8%	12,499	31.8%	0.060	0.001
Chronic liver disease	4,555	6.1%	2,389	6.1%	-0.023	-0.001
Pneumonia	3,835	5.1%	1,999	5.1%	0.015	0.001
Cardiac arrhythmia	9,570	12.7%	5,032	12.8%	-0.078	-0.002
Paliperidone palmitate	75,254	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	39,332	100.0%	NaN	NaN
Haloperidol decanoate	67	0.1%	74	0.2%	-0.099	-0.027
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	29.9	28.0	30.4	28.7	-0.532	-0.019
Mean number of generics dispensed	9.6	6.4	9.6	6.3	0.070	0.011
Mean number of unique drug classes dispensed	8.6	5.6	8.7	5.5	-0.032	-0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.7	17.9	15.8	19.4	-0.165	-0.009
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.002
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.1	-0.003	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1db. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,702	100.0%	6,012	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.0	14.8	57.8	18.4	-9.843	-0.589
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	2,079	23.9%	869	14.5%	9.437	0.241
35-44 years	1,841	21.2%	798	13.3%	7.883	0.210
45-54 years	1,835	21.1%	964	16.0%	5.053	0.130
55-64 years	1,695	19.5%	1,066	17.7%	1.747	0.045
65-74 years	946	10.9%	1,120	18.6%	-7.758	-0.220
75-84 years	248	2.8%	752	12.5%	-9.658	-0.369
≥ 85 years	58	0.7%	443	7.4%	-6.702	-0.346
Sex						
Female	3,753	43.1%	3,071	51.1%	-7.953	-0.160
Male	4,949	56.9%	2,941	48.9%	7.953	0.160
Race[2]						
American Indian or Alaska Native	98	1.1%	41	0.7%	0.444	0.047
Asian	184	2.1%	108	1.8%	0.318	0.023
Black or African American	2,216	25.5%	1,318	21.9%	3.543	0.083
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	629	7.2%	315	5.2%	1.989	0.082
White	5,575	64.1%	4,230	70.4%	-6.294	-0.134
Hispanic origin						
Yes	396	4.6%	205	3.4%	1.141	0.058
No	8,073	92.8%	5,697	94.8%	-1.989	-0.082
Unknown	233	2.7%	110	1.8%	0.848	0.057

Table 1db. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	201	2.3%	466	7.8%	-5.441	-0.251
2011	484	5.6%	891	14.8%	-9.258	-0.310
2012	701	8.1%	829	13.8%	-5.733	-0.185
2013	785	9.0%	813	13.5%	-4.502	-0.143
2014	789	9.1%	673	11.2%	-2.127	-0.071
2015	795	9.1%	534	8.9%	0.254	0.009
2016	815	9.4%	448	7.5%	1.914	0.069
2017	857	9.8%	409	6.8%	3.045	0.110
2018	895	10.3%	321	5.3%	4.946	0.185
2019	808	9.3%	244	4.1%	5.227	0.211
2020	677	7.8%	185	3.1%	4.703	0.209
2021	636	7.3%	137	2.3%	5.030	0.237
2022	259	3.0%	62	1.0%	1.945	0.139
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.6	2.9	-0.817	-0.311
Substance abuse	3,882	44.6%	1,791	29.8%	14.820	0.310
Atrial fibrilation/flutter	253	2.9%	451	7.5%	-4.594	-0.208
Ischemic heart disease	977	11.2%	1,209	20.1%	-8.882	-0.246
Heart failure	557	6.4%	778	12.9%	-6.540	-0.223
Stroke	307	3.5%	484	8.1%	-4.523	-0.195
Diabetes	2,447	28.1%	2,023	33.6%	-5.529	-0.120
Hypertension	5,041	57.9%	3,926	65.3%	-7.374	-0.152
Rheumatic disease	69	0.8%	74	1.2%	-0.438	-0.044
Chronic kidney disease	1,339	15.4%	1,210	20.1%	-4.739	-0.124
Seizure disorder	1,340	15.4%	862	14.3%	1.061	0.030

Table 1db. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	380	4.4%	953	15.9%	-11.485	-0.388
Dementia Diagnosis	1,385	15.9%	2,174	36.2%	-20.245	-0.474
Dementia Diagnosis and Treatment	299	3.4%	902	15.0%	-11.567	-0.408
Parkinsons disease	257	3.0%	310	5.2%	-2.203	-0.112
COPD	1,824	21.0%	1,404	23.4%	-2.393	-0.058
Malignancy	331	3.8%	274	4.6%	-0.754	-0.038
Asthma	1,490	17.1%	765	12.7%	4.398	0.124
Hyperlipidemia	3,571	41.0%	2,692	44.8%	-3.741	-0.076
Depression	4,929	56.6%	3,398	56.5%	0.122	0.002
Schizophrenia	7,727	88.8%	4,467	74.3%	14.494	0.380
Bipolar disorder	5,068	58.2%	2,929	48.7%	9.520	0.192
ACE inhibitor use	1,624	18.7%	1,383	23.0%	-4.342	-0.107
ARB use	420	4.8%	363	6.0%	-1.211	-0.053
Beta-blocker use	2,017	23.2%	1,638	27.2%	-4.067	-0.094
Oral anticoagulant use	229	2.6%	317	5.3%	-2.641	-0.136
Antiplatelet agent use	169	1.9%	293	4.9%	-2.932	-0.162
Opioid use	1,629	18.7%	1,301	21.6%	-2.920	-0.073
Statin use	2,105	24.2%	1,750	29.1%	-4.919	-0.111
Wheelchair or walker use	39	0.4%	100	1.7%	-1.215	-0.119
Anti-arrhythmic use	40	0.5%	68	1.1%	-0.671	-0.076
Antidiabetic use	1,510	17.4%	1,207	20.1%	-2.724	-0.070
Calcium channel blocker use	1,171	13.5%	1,066	17.7%	-4.275	-0.118
Diuretic use	1,418	16.3%	1,441	24.0%	-7.674	-0.192
Antidepressant use	5,166	59.4%	3,529	58.7%	0.666	0.014
Gastric acid suppressant use	2,585	29.7%	1,966	32.7%	-2.995	-0.065
NSAIDs	1,964	22.6%	1,147	19.1%	3.491	0.086

Table 1db. Unadjusted Characteristics of Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,359	38.6%	2,093	34.8%	3.787	0.079
Chronic liver disease	670	7.7%	393	6.5%	1.162	0.045
Pneumonia	549	6.3%	632	10.5%	-4.203	-0.152
Cardiac arrhythmia	1,864	21.4%	1,032	17.2%	4.255	0.108
Paliperidone palmitate	8,702	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,012	100.0%	NaN	NaN
Haloperidol decanoate	13	0.1%	14	0.2%	-0.083	-0.019
IS Stay	8,702	100.0%	6,012	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.5	27.4	33.3	28.9	-2.799	-0.099
Mean number of generics dispensed	10.4	6.6	11.0	6.5	-0.592	-0.090
Mean number of unique drug classes dispensed	9.3	5.7	9.9	5.7	-0.601	-0.106
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.4	22.4	18.1	20.1	3.272	0.154
Mean number of inpatient hospital encounters	0.4	0.8	0.5	0.9	-0.085	-0.096
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.4	0.012	0.009

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dc. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,697	99.9%	6,011	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.0	14.8	57.8	18.4	-9.830	-0.588
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	2,075	23.9%	869	14.5%	9.402	0.241
35-44 years	1,841	21.2%	798	13.3%	7.893	0.210
45-54 years	1,835	21.1%	964	16.0%	5.062	0.130
55-64 years	1,695	19.5%	1,066	17.7%	1.755	0.045
65-74 years	946	10.9%	1,120	18.6%	-7.755	-0.220
75-84 years	247	2.8%	751	12.5%	-9.654	-0.369
≥ 85 years	58	0.7%	443	7.4%	-6.703	-0.346
Sex						
Female	3,751	43.1%	3,071	51.1%	-7.960	-0.160
Male	4,946	56.9%	2,940	48.9%	7.960	0.160
Race[2]						
American Indian or Alaska Native	98	1.1%	41	0.7%	0.445	0.047
Asian	184	2.1%	108	1.8%	0.319	0.023
Black or African American	2,215	25.5%	1,318	21.9%	3.542	0.083
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	629	7.2%	315	5.2%	1.992	0.082
White	5,571	64.1%	4,229	70.4%	-6.298	-0.134
Hispanic origin						
Yes	396	4.6%	205	3.4%	1.143	0.058
No	8,068	92.8%	5,696	94.8%	-1.992	-0.082
Unknown	233	2.7%	110	1.8%	0.849	0.057

Table 1dc. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	201	2.3%	466	7.8%	-5.441	-0.251
2011	484	5.6%	891	14.8%	-9.258	-0.310
2012	701	8.1%	828	13.8%	-5.714	-0.184
2013	785	9.0%	813	13.5%	-4.499	-0.143
2014	789	9.1%	673	11.2%	-2.124	-0.070
2015	795	9.1%	534	8.9%	0.257	0.009
2016	814	9.4%	448	7.5%	1.907	0.069
2017	857	9.9%	409	6.8%	3.050	0.111
2018	894	10.3%	321	5.3%	4.939	0.185
2019	807	9.3%	244	4.1%	5.220	0.210
2020	676	7.8%	185	3.1%	4.695	0.208
2021	635	7.3%	137	2.3%	5.022	0.237
2022	259	3.0%	62	1.0%	1.947	0.139
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.6	2.9	-0.816	-0.311
Substance abuse	3,878	44.6%	1,791	29.8%	14.795	0.310
Atrial fibrilation/flutter	252	2.9%	451	7.5%	-4.605	-0.209
Ischemic heart disease	976	11.2%	1,209	20.1%	-8.891	-0.246
Heart failure	556	6.4%	778	12.9%	-6.550	-0.223
Stroke	306	3.5%	483	8.0%	-4.517	-0.195
Diabetes	2,446	28.1%	2,022	33.6%	-5.514	-0.120
Hypertension	5,038	57.9%	3,925	65.3%	-7.369	-0.152
Rheumatic disease	69	0.8%	74	1.2%	-0.438	-0.044
Chronic kidney disease	1,338	15.4%	1,209	20.1%	-4.729	-0.124
Seizure disorder	1,336	15.4%	862	14.3%	1.021	0.029

Table 1dc. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	379	4.4%	952	15.8%	-11.480	-0.388
Dementia Diagnosis	1,384	15.9%	2,173	36.2%	-20.237	-0.474
Dementia Diagnosis and Treatment	298	3.4%	901	15.0%	-11.563	-0.408
Parkinsons disease	257	3.0%	310	5.2%	-2.202	-0.112
COPD	1,824	21.0%	1,404	23.4%	-2.384	-0.057
Malignancy	331	3.8%	274	4.6%	-0.752	-0.038
Asthma	1,486	17.1%	765	12.7%	4.360	0.123
Hyperlipidemia	3,568	41.0%	2,691	44.8%	-3.742	-0.076
Depression	4,926	56.6%	3,398	56.5%	0.111	0.002
Schizophrenia	7,723	88.8%	4,467	74.3%	14.487	0.380
Bipolar disorder	5,064	58.2%	2,929	48.7%	9.500	0.191
ACE inhibitor use	1,624	18.7%	1,382	23.0%	-4.318	-0.106
ARB use	420	4.8%	363	6.0%	-1.210	-0.053
Beta-blocker use	2,016	23.2%	1,638	27.3%	-4.070	-0.094
Oral anticoagulant use	229	2.6%	317	5.3%	-2.641	-0.136
Antiplatelet agent use	169	1.9%	292	4.9%	-2.915	-0.161
Opioid use	1,629	18.7%	1,300	21.6%	-2.896	-0.072
Statin use	2,105	24.2%	1,750	29.1%	-4.910	-0.111
Wheelchair or walker use	39	0.4%	100	1.7%	-1.215	-0.119
Anti-arrhythmic use	40	0.5%	68	1.1%	-0.671	-0.076
Antidiabetic use	1,509	17.4%	1,206	20.1%	-2.712	-0.070
Calcium channel blocker use	1,170	13.5%	1,066	17.7%	-4.281	-0.118
Diuretic use	1,418	16.3%	1,440	24.0%	-7.652	-0.192
Antidepressant use	5,162	59.4%	3,528	58.7%	0.661	0.013
Gastric acid suppressant use	2,582	29.7%	1,965	32.7%	-3.002	-0.065
NSAIDs	1,960	22.5%	1,147	19.1%	3.455	0.085

Table 1dc. Unweighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,355	38.6%	2,093	34.8%	3.757	0.078
Chronic liver disease	670	7.7%	393	6.5%	1.166	0.045
Pneumonia	549	6.3%	632	10.5%	-4.202	-0.152
Cardiac arrhythmia	1,860	21.4%	1,032	17.2%	4.218	0.107
Paliperidone palmitate	8,697	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,011	100.0%	NaN	NaN
Haloperidol decanoate	13	0.1%	14	0.2%	-0.083	-0.019
IS Stay	8,697	100.0%	6,011	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.5	27.4	33.3	28.9	-2.798	-0.099
Mean number of generics dispensed	10.4	6.6	11.0	6.5	-0.592	-0.090
Mean number of unique drug classes dispensed	9.3	5.7	9.9	5.7	-0.601	-0.106
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.4	22.4	18.1	20.1	3.244	0.152
Mean number of inpatient hospital encounters	0.4	0.8	0.5	0.9	-0.085	-0.096
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.4	0.012	0.009

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dd. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	8,607	N/A	6,065	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	51.4	16.1	51.6	17.7	-0.183	-0.011
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	1,668	19.4%	1,354	22.3%	-2.945	-0.073
35-44 years	1,579	18.3%	1,063	17.5%	0.811	0.021
45-54 years	1,698	19.7%	1,118	18.4%	1.284	0.033
55-64 years	1,760	20.4%	1,026	16.9%	3.532	0.091
65-74 years	1,253	14.6%	835	13.8%	0.794	0.023
75-84 years	489	5.7%	440	7.3%	-1.572	-0.064
≥ 85 years	160	1.9%	229	3.8%	-1.904	-0.115
Sex						
Female	3,931	45.7%	2,778	45.8%	-0.139	-0.003
Male	4,676	54.3%	3,286	54.2%	0.139	0.003
Race[3]						
American Indian or Alaska Native	95	1.1%	45	0.7%	0.372	0.039
Asian	177	2.1%	117	1.9%	0.122	0.009
Black or African American	2,142	24.9%	1,406	23.2%	1.696	0.040
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	566	6.6%	382	6.3%	0.280	0.011
White	5,627	65.4%	4,115	67.8%	-2.469	-0.052
Hispanic origin						
Yes	360	4.2%	250	4.1%	0.068	0.003
No	8,041	93.4%	5,683	93.7%	-0.280	-0.011
Unknown	206	2.4%	132	2.2%	0.212	0.014

Table 1dd. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	204	2.4%	472	7.8%	-5.423	-0.249
2011	482	5.6%	908	15.0%	-9.381	-0.313
2012	701	8.1%	849	14.0%	-5.856	-0.187
2013	766	8.9%	847	14.0%	-5.062	-0.160
2014	786	9.1%	699	11.5%	-2.388	-0.079
2015	807	9.4%	542	8.9%	0.445	0.015
2016	805	9.4%	435	7.2%	2.178	0.079
2017	852	9.9%	387	6.4%	3.520	0.129
2018	854	9.9%	303	5.0%	4.922	0.188
2019	788	9.2%	250	4.1%	5.036	0.203
2020	675	7.8%	174	2.9%	4.978	0.222
2021	619	7.2%	135	2.2%	4.971	0.236
2022	268	3.1%	64	1.1%	2.062	0.145
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	3.0	2.5	3.1	2.6	-0.016	-0.006
Substance abuse	3,376	39.2%	2,372	39.1%	0.106	0.002
Atrial fibrilation/flutter	370	4.3%	281	4.6%	-0.328	-0.016
Ischemic heart disease	1,242	14.4%	882	14.5%	-0.100	-0.003
Heart failure	762	8.9%	546	9.0%	-0.143	-0.005
Stroke	441	5.1%	316	5.2%	-0.084	-0.004
Diabetes	2,612	30.3%	1,837	30.3%	0.053	0.001
Hypertension	5,205	60.5%	3,680	60.7%	-0.199	-0.004
Rheumatic disease	75	0.9%	57	0.9%	-0.070	-0.007
Chronic kidney disease	1,456	16.9%	1,027	16.9%	-0.014	-0.000
Seizure disorder	1,294	15.0%	888	14.6%	0.399	0.011

Table 1dd. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	737	8.6%	537	8.9%	-0.294	-0.010
Dementia Diagnosis	1,982	23.0%	1,423	23.5%	-0.429	-0.010
Dementia Diagnosis and Treatment	661	7.7%	487	8.0%	-0.344	-0.013
Parkinsons disease	343	4.0%	235	3.9%	0.110	0.006
COPD	1,870	21.7%	1,295	21.4%	0.373	0.009
Malignancy	353	4.1%	249	4.1%	0.002	0.000
Asthma	1,325	15.4%	920	15.2%	0.222	0.006
Hyperlipidemia	3,646	42.4%	2,567	42.3%	0.030	0.001
Depression	4,881	56.7%	3,438	56.7%	0.031	0.001
Schizophrenia	7,262	84.4%	5,070	83.6%	0.776	0.021
Bipolar disorder	4,716	54.8%	3,321	54.8%	0.038	0.001
ACE inhibitor use	1,752	20.4%	1,241	20.5%	-0.107	-0.003
ARB use	455	5.3%	319	5.3%	0.035	0.002
Beta-blocker use	2,116	24.6%	1,491	24.6%	0.004	0.000
Oral anticoagulant use	292	3.4%	217	3.6%	-0.186	-0.010
Antiplatelet agent use	269	3.1%	188	3.1%	0.031	0.002
Opioid use	1,684	19.6%	1,198	19.7%	-0.183	-0.005
Statin use	2,230	25.9%	1,569	25.9%	0.042	0.001
Wheelchair or walker use	79	0.9%	57	0.9%	-0.022	-0.002
Anti-arrhythmic use	59	0.7%	43	0.7%	-0.020	-0.002
Antidiabetic use	1,581	18.4%	1,112	18.3%	0.032	0.001
Calcium channel blocker use	1,290	15.0%	915	15.1%	-0.103	-0.003
Diuretic use	1,644	19.1%	1,165	19.2%	-0.117	-0.003
Antidepressant use	5,051	58.7%	3,555	58.6%	0.070	0.001
Gastric acid suppressant use	2,632	30.6%	1,863	30.7%	-0.131	-0.003
NSAIDs	1,820	21.1%	1,282	21.1%	0.001	0.000

Table 1dd. Weighted Characteristics of Paliperidone vs. Risperidone - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,153	36.6%	2,221	36.6%	0.004	0.000
Chronic liver disease	624	7.2%	447	7.4%	-0.120	-0.005
Pneumonia	679	7.9%	479	7.9%	-0.011	-0.000
Cardiac arrhythmia	1,694	19.7%	1,200	19.8%	-0.108	-0.003
Paliperidone palmitate	8,607	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	6,065	100.0%	NaN	NaN
Haloperidol decanoate	14	0.2%	15	0.2%	-0.083	-0.019
IS Stay	8,607	100.0%	6,065	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	31.3	28.1	31.3	27.6	0.058	0.002
Mean number of generics dispensed	10.6	6.7	10.5	6.4	0.035	0.005
Mean number of unique drug classes dispensed	9.5	5.8	9.4	5.5	0.018	0.003
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	20.3	21.3	20.4	22.5	-0.117	-0.005
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.002
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.3	0.002	0.001

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable
Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1de. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,398	100.0%	62,488	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	52.3	16.8	-6.471	-0.419
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,437	26.6%	11,316	18.1%	8.476	0.205
35-44 years	19,608	23.2%	10,933	17.5%	5.737	0.143
45-54 years	19,386	23.0%	13,895	22.2%	0.733	0.018
55-64 years	14,574	17.3%	11,670	18.7%	-1.407	-0.037
65-74 years	6,512	7.7%	8,244	13.2%	-5.477	-0.180
75-84 years	1,509	1.8%	4,139	6.6%	-4.836	-0.243
≥ 85 years	372	0.4%	2,291	3.7%	-3.226	-0.229
Sex						
Female	34,434	40.8%	26,389	42.2%	-1.431	-0.029
Male	49,964	59.2%	36,099	57.8%	1.431	0.029
Race[2]						
American Indian or Alaska Native	1,017	1.2%	530	0.8%	0.357	0.035
Asian	1,914	2.3%	1,251	2.0%	0.266	0.018
Black or African American	21,668	25.7%	22,605	36.2%	-10.501	-0.229
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,012	8.3%	4,506	7.2%	1.097	0.041
White	52,787	62.5%	33,596	53.8%	8.781	0.179
Hispanic origin						
Yes	4,378	5.2%	3,074	4.9%	0.268	0.012
No	77,386	91.7%	57,982	92.8%	-1.097	-0.041
Unknown	2,634	3.1%	1,432	2.3%	0.829	0.051

Table 1de. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,467	2.9%	5,269	8.4%	-5.509	-0.240
2011	6,113	7.2%	9,594	15.4%	-8.110	-0.258
2012	7,347	8.7%	7,725	12.4%	-3.657	-0.119
2013	7,572	9.0%	6,821	10.9%	-1.944	-0.065
2014	7,284	8.6%	5,684	9.1%	-0.466	-0.016
2015	7,807	9.3%	5,033	8.1%	1.196	0.043
2016	8,044	9.5%	4,628	7.4%	2.125	0.076
2017	8,224	9.7%	4,174	6.7%	3.065	0.112
2018	8,193	9.7%	3,672	5.9%	3.831	0.143
2019	7,580	9.0%	3,410	5.5%	3.524	0.136
2020	5,847	6.9%	2,697	4.3%	2.612	0.114
2021	5,411	6.4%	2,587	4.1%	2.271	0.102
2022	2,509	3.0%	1,194	1.9%	1.062	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	2.5	2.5	-0.374	-0.167
Substance abuse	29,539	35.0%	16,731	26.8%	8.225	0.179
Atrial fibrilation/flutter	1,611	1.9%	2,395	3.8%	-1.924	-0.115
Ischemic heart disease	6,332	7.5%	7,647	12.2%	-4.735	-0.159
Heart failure	3,486	4.1%	4,933	7.9%	-3.764	-0.159
Stroke	2,101	2.5%	2,939	4.7%	-2.214	-0.119
Diabetes	20,351	24.1%	18,434	29.5%	-5.387	-0.122
Hypertension	38,140	45.2%	33,706	53.9%	-8.749	-0.176
Rheumatic disease	426	0.5%	415	0.7%	-0.159	-0.021
Chronic kidney disease	9,514	11.3%	8,416	13.5%	-2.195	-0.067
Seizure disorder	9,531	11.3%	7,843	12.6%	-1.258	-0.039

Table 1de. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,297	2.7%	4,492	7.2%	-4.467	-0.207
Dementia Diagnosis	7,677	9.1%	12,220	19.6%	-10.460	-0.302
Dementia Diagnosis and Treatment	1,675	2.0%	3,933	6.3%	-4.309	-0.218
Parkinsons disease	1,475	1.7%	1,800	2.9%	-1.133	-0.075
COPD	13,260	15.7%	11,259	18.0%	-2.307	-0.062
Malignancy	2,689	3.2%	2,409	3.9%	-0.669	-0.036
Asthma	11,449	13.6%	7,077	11.3%	2.240	0.068
Hyperlipidemia	28,843	34.2%	22,990	36.8%	-2.616	-0.055
Depression	38,633	45.8%	24,864	39.8%	5.985	0.121
Schizophrenia	67,706	80.2%	48,804	78.1%	2.121	0.052
Bipolar disorder	39,399	46.7%	22,944	36.7%	9.965	0.203
ACE inhibitor use	14,009	16.6%	12,650	20.2%	-3.645	-0.094
ARB use	3,686	4.4%	3,575	5.7%	-1.354	-0.062
Beta-blocker use	16,373	19.4%	13,939	22.3%	-2.907	-0.072
Oral anticoagulant use	1,765	2.1%	1,864	3.0%	-0.892	-0.057
Antiplatelet agent use	1,295	1.5%	1,832	2.9%	-1.397	-0.095
Opioid use	16,155	19.1%	11,206	17.9%	1.208	0.031
Statin use	18,639	22.1%	15,728	25.2%	-3.085	-0.073
Wheelchair or walker use	255	0.3%	599	1.0%	-0.656	-0.083
Anti-arrhythmic use	309	0.4%	385	0.6%	-0.250	-0.036
Antidiabetic use	14,118	16.7%	11,931	19.1%	-2.365	-0.062
Calcium channel blocker use	9,103	10.8%	9,845	15.8%	-4.969	-0.147
Diuretic use	12,345	14.6%	11,977	19.2%	-4.540	-0.121
Antidepressant use	49,189	58.3%	31,375	50.2%	8.073	0.163
Gastric acid suppressant use	22,641	26.8%	16,750	26.8%	0.021	0.000
NSAIDs	18,369	21.8%	11,453	18.3%	3.436	0.086

Table 1de. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,079	33.3%	18,005	28.8%	4.456	0.096
Chronic liver disease	5,330	6.3%	3,484	5.6%	0.740	0.031
Pneumonia	3,618	4.3%	3,905	6.2%	-1.962	-0.088
Cardiac arrhythmia	11,574	13.7%	7,958	12.7%	0.978	0.029
Paliperidone palmitate	84,398	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	75	0.1%	-0.099	-0.037
Haloperidol decanoate	0	0.0%	62,488	100.0%	NaN	NaN
IS Stay	8,558	10.1%	6,963	11.1%	-1.003	-0.033
Medical Product Use						
Mean number of filled prescriptions	29.0	27.1	30.0	27.7	-1.033	-0.038
Mean number of generics dispensed	9.5	6.3	9.4	6.1	0.060	0.010
Mean number of unique drug classes dispensed	8.5	5.5	8.2	5.3	0.242	0.045
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.7	14.8	18.9	1.671	0.089
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.059
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	-0.035	-0.029

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1df. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	84,398	100.0%	62,484	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.9	14.0	52.3	16.8	-6.472	-0.419
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,437	26.6%	11,314	18.1%	8.478	0.205
35-44 years	19,608	23.2%	10,933	17.5%	5.735	0.143
45-54 years	19,386	23.0%	13,894	22.2%	0.734	0.018
55-64 years	14,574	17.3%	11,670	18.7%	-1.409	-0.037
65-74 years	6,512	7.7%	8,244	13.2%	-5.478	-0.180
75-84 years	1,509	1.8%	4,138	6.6%	-4.835	-0.243
≥ 85 years	372	0.4%	2,291	3.7%	-3.226	-0.229
Sex						
Female	34,434	40.8%	26,388	42.2%	-1.432	-0.029
Male	49,964	59.2%	36,096	57.8%	1.432	0.029
Race[2]						
American Indian or Alaska Native	1,017	1.2%	530	0.8%	0.357	0.035
Asian	1,914	2.3%	1,251	2.0%	0.266	0.018
Black or African American	21,668	25.7%	22,604	36.2%	-10.502	-0.229
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	7,012	8.3%	4,506	7.2%	1.097	0.041
White	52,787	62.5%	33,593	53.8%	8.783	0.179
Hispanic origin						
Yes	4,378	5.2%	3,074	4.9%	0.268	0.012
No	77,386	91.7%	57,978	92.8%	-1.097	-0.041
Unknown	2,634	3.1%	1,432	2.3%	0.829	0.051

Table 1df. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,467	2.9%	5,269	8.4%	-5.510	-0.240
2011	6,113	7.2%	9,592	15.4%	-8.108	-0.258
2012	7,347	8.7%	7,725	12.4%	-3.658	-0.119
2013	7,572	9.0%	6,821	10.9%	-1.945	-0.065
2014	7,284	8.6%	5,684	9.1%	-0.466	-0.016
2015	7,807	9.3%	5,033	8.1%	1.195	0.043
2016	8,044	9.5%	4,628	7.4%	2.124	0.076
2017	8,224	9.7%	4,173	6.7%	3.066	0.112
2018	8,193	9.7%	3,672	5.9%	3.831	0.143
2019	7,580	9.0%	3,410	5.5%	3.524	0.136
2020	5,847	6.9%	2,697	4.3%	2.612	0.114
2021	5,411	6.4%	2,587	4.1%	2.271	0.102
2022	2,509	3.0%	1,193	1.9%	1.064	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	2.0	2.5	2.5	-0.374	-0.167
Substance abuse	29,539	35.0%	16,728	26.8%	8.228	0.179
Atrial fibrilation/flutter	1,611	1.9%	2,394	3.8%	-1.923	-0.115
Ischemic heart disease	6,332	7.5%	7,644	12.2%	-4.731	-0.159
Heart failure	3,486	4.1%	4,931	7.9%	-3.761	-0.159
Stroke	2,101	2.5%	2,937	4.7%	-2.211	-0.119
Diabetes	20,351	24.1%	18,431	29.5%	-5.384	-0.122
Hypertension	38,140	45.2%	33,703	53.9%	-8.748	-0.176
Rheumatic disease	426	0.5%	414	0.7%	-0.158	-0.021
Chronic kidney disease	9,514	11.3%	8,414	13.5%	-2.193	-0.067
Seizure disorder	9,531	11.3%	7,841	12.5%	-1.256	-0.039

Table 1df. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	2,297	2.7%	4,491	7.2%	-4.466	-0.207
Dementia Diagnosis	7,677	9.1%	12,219	19.6%	-10.459	-0.302
Dementia Diagnosis and Treatment	1,675	2.0%	3,932	6.3%	-4.308	-0.218
Parkinsons disease	1,475	1.7%	1,800	2.9%	-1.133	-0.075
COPD	13,260	15.7%	11,257	18.0%	-2.305	-0.062
Malignancy	2,689	3.2%	2,408	3.9%	-0.668	-0.036
Asthma	11,449	13.6%	7,076	11.3%	2.241	0.068
Hyperlipidemia	28,843	34.2%	22,987	36.8%	-2.614	-0.055
Depression	38,633	45.8%	24,861	39.8%	5.987	0.121
Schizophrenia	67,706	80.2%	48,801	78.1%	2.121	0.052
Bipolar disorder	39,399	46.7%	22,941	36.7%	9.967	0.203
ACE inhibitor use	14,009	16.6%	12,649	20.2%	-3.645	-0.094
ARB use	3,686	4.4%	3,575	5.7%	-1.354	-0.062
Beta-blocker use	16,373	19.4%	13,938	22.3%	-2.907	-0.072
Oral anticoagulant use	1,765	2.1%	1,864	3.0%	-0.892	-0.057
Antiplatelet agent use	1,295	1.5%	1,831	2.9%	-1.396	-0.095
Opioid use	16,155	19.1%	11,203	17.9%	1.212	0.031
Statin use	18,639	22.1%	15,727	25.2%	-3.085	-0.073
Wheelchair or walker use	255	0.3%	599	1.0%	-0.657	-0.083
Anti-arrhythmic use	309	0.4%	385	0.6%	-0.250	-0.036
Antidiabetic use	14,118	16.7%	11,929	19.1%	-2.363	-0.062
Calcium channel blocker use	9,103	10.8%	9,844	15.8%	-4.969	-0.147
Diuretic use	12,345	14.6%	11,976	19.2%	-4.539	-0.121
Antidepressant use	49,189	58.3%	31,372	50.2%	8.074	0.163
Gastric acid suppressant use	22,641	26.8%	16,747	26.8%	0.024	0.001
NSAIDs	18,369	21.8%	11,450	18.3%	3.440	0.086

Table 1df. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	28,079	33.3%	18,003	28.8%	4.458	0.096
Chronic liver disease	5,330	6.3%	3,481	5.6%	0.744	0.031
Pneumonia	3,618	4.3%	3,903	6.2%	-1.960	-0.088
Cardiac arrhythmia	11,574	13.7%	7,955	12.7%	0.982	0.029
Paliperidone palmitate	84,398	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	75	0.1%	-0.099	-0.037
Haloperidol decanoate	0	0.0%	62,484	100.0%	NaN	NaN
IS Stay	8,558	10.1%	6,962	11.1%	-1.002	-0.032
Medical Product Use						
Mean number of filled prescriptions	29.0	27.1	30.0	27.7	-1.033	-0.038
Mean number of generics dispensed	9.5	6.3	9.4	6.1	0.060	0.010
Mean number of unique drug classes dispensed	8.5	5.5	8.2	5.3	0.243	0.045
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.5	18.7	14.8	18.9	1.675	0.089
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.055	-0.059
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	-0.035	-0.029

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dg. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	84,146	N/A	62,754	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.3	14.9	48.3	15.9	0.009	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	18,983	22.6%	15,366	24.5%	-1.927	-0.045
35-44 years	17,667	21.0%	12,943	20.6%	0.370	0.009
45-54 years	19,022	22.6%	14,137	22.5%	0.079	0.002
55-64 years	16,158	19.2%	10,234	16.3%	2.894	0.076
65-74 years	8,788	10.4%	6,127	9.8%	0.680	0.023
75-84 years	2,688	3.2%	2,622	4.2%	-0.984	-0.052
≥ 85 years	840	1.0%	1,325	2.1%	-1.113	-0.090
Sex						
Female	34,731	41.3%	25,931	41.3%	-0.046	-0.001
Male	49,415	58.7%	36,823	58.7%	0.046	0.001
Race[3]						
American Indian or Alaska Native	978	1.2%	594	0.9%	0.216	0.021
Asian	1,925	2.3%	1,289	2.1%	0.234	0.016
Black or African American	22,246	26.4%	22,243	35.4%	-9.007	-0.196
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,566	7.8%	5,001	8.0%	-0.166	-0.006
White	52,431	62.3%	33,628	53.6%	8.723	0.177
Hispanic origin						
Yes	4,166	5.0%	3,378	5.4%	-0.432	-0.020
No	77,580	92.2%	57,754	92.0%	0.166	0.006
Unknown	2,400	2.9%	1,623	2.6%	0.266	0.016

Table 1dg. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	2,476	2.9%	5,149	8.2%	-5.263	-0.231
2011	6,064	7.2%	9,371	14.9%	-7.727	-0.248
2012	7,352	8.7%	7,626	12.2%	-3.415	-0.112
2013	7,485	8.9%	6,969	11.1%	-2.210	-0.074
2014	7,187	8.5%	5,848	9.3%	-0.778	-0.027
2015	7,723	9.2%	5,163	8.2%	0.951	0.034
2016	7,968	9.5%	4,733	7.5%	1.927	0.069
2017	8,235	9.8%	4,206	6.7%	3.084	0.112
2018	8,101	9.6%	3,725	5.9%	3.691	0.138
2019	7,609	9.0%	3,454	5.5%	3.538	0.137
2020	5,917	7.0%	2,737	4.4%	2.670	0.115
2021	5,457	6.5%	2,599	4.1%	2.344	0.105
2022	2,573	3.1%	1,175	1.9%	1.186	0.077
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.3	2.2	2.3	2.2	-0.005	-0.002
Substance abuse	26,808	31.9%	20,164	32.1%	-0.274	-0.006
Atrial fibrilation/flutter	2,241	2.7%	1,688	2.7%	-0.028	-0.002
Ischemic heart disease	7,928	9.4%	5,928	9.4%	-0.025	-0.001
Heart failure	4,806	5.7%	3,584	5.7%	0.001	0.000
Stroke	2,844	3.4%	2,125	3.4%	-0.007	-0.000
Diabetes	22,258	26.5%	16,570	26.4%	0.046	0.001
Hypertension	41,148	48.9%	30,712	48.9%	-0.039	-0.001
Rheumatic disease	470	0.6%	354	0.6%	-0.006	-0.001
Chronic kidney disease	10,257	12.2%	7,662	12.2%	-0.020	-0.001
Seizure disorder	9,992	11.9%	7,452	11.9%	-0.000	-0.000

Table 1dg. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	3,822	4.5%	2,872	4.6%	-0.034	-0.002
Dementia Diagnosis	11,154	13.3%	8,387	13.4%	-0.110	-0.003
Dementia Diagnosis and Treatment	3,154	3.7%	2,371	3.8%	-0.031	-0.002
Parkinsons disease	1,889	2.2%	1,408	2.2%	0.001	0.000
COPD	14,085	16.7%	10,488	16.7%	0.026	0.001
Malignancy	2,904	3.5%	2,172	3.5%	-0.010	-0.001
Asthma	10,680	12.7%	8,020	12.8%	-0.089	-0.003
Hyperlipidemia	29,803	35.4%	22,229	35.4%	-0.004	-0.000
Depression	36,559	43.4%	27,325	43.5%	-0.096	-0.002
Schizophrenia	67,571	80.3%	50,416	80.3%	-0.038	-0.001
Bipolar disorder	36,053	42.8%	27,000	43.0%	-0.180	-0.004
ACE inhibitor use	15,246	18.1%	11,341	18.1%	0.046	0.001
ARB use	4,134	4.9%	3,072	4.9%	0.017	0.001
Beta-blocker use	17,271	20.5%	12,895	20.5%	-0.024	-0.001
Oral anticoagulant use	2,042	2.4%	1,534	2.4%	-0.018	-0.001
Antiplatelet agent use	1,774	2.1%	1,321	2.1%	0.002	0.000
Opioid use	15,517	18.4%	11,592	18.5%	-0.031	-0.001
Statin use	19,684	23.4%	14,630	23.3%	0.080	0.002
Wheelchair or walker use	513	0.6%	366	0.6%	0.025	0.003
Anti-arrhythmic use	378	0.4%	286	0.5%	-0.006	-0.001
Antidiabetic use	14,885	17.7%	11,073	17.6%	0.045	0.001
Calcium channel blocker use	10,843	12.9%	8,064	12.8%	0.036	0.001
Diuretic use	13,868	16.5%	10,301	16.4%	0.066	0.002
Antidepressant use	46,070	54.7%	34,463	54.9%	-0.167	-0.003
Gastric acid suppressant use	22,497	26.7%	16,796	26.8%	-0.030	-0.001
NSAIDs	17,140	20.4%	12,787	20.4%	-0.008	-0.000

Table 1dg. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	26,366	31.3%	19,749	31.5%	-0.136	-0.003
Chronic liver disease	5,081	6.0%	3,823	6.1%	-0.054	-0.002
Pneumonia	4,294	5.1%	3,199	5.1%	0.005	0.000
Cardiac arrhythmia	11,290	13.4%	8,523	13.6%	-0.164	-0.005
Paliperidone palmitate	84,146	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	79	0.1%	-0.105	-0.039
Haloperidol decanoate	0	0.0%	62,754	100.0%	NaN	NaN
IS Stay	9,098	10.8%	6,768	10.8%	0.027	0.001
Medical Product Use						
Mean number of filled prescriptions	29.0	27.4	29.8	27.3	-0.749	-0.027
Mean number of generics dispensed	9.4	6.3	9.5	6.2	-0.081	-0.013
Mean number of unique drug classes dispensed	8.4	5.5	8.3	5.3	0.148	0.027
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.3	16.0	20.0	-0.069	-0.004
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.000	-0.000
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.003	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1dh. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,437	100.0%	11,314	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.4	3.6	-0.265	-0.072
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,437	100.0%	11,314	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,698	29.9%	3,180	28.1%	1.746	0.038
Male	15,739	70.1%	8,134	71.9%	-1.746	-0.038
Race[2]						
American Indian or Alaska Native	324	1.4%	161	1.4%	0.021	0.002
Asian	535	2.4%	246	2.2%	0.210	0.014
Black or African American	6,610	29.5%	4,828	42.7%	-13.213	-0.278
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,591	16.0%	1,626	14.4%	1.633	0.046
White	11,377	50.7%	4,453	39.4%	11.348	0.230
Hispanic origin						
Yes	1,846	8.2%	954	8.4%	-0.205	-0.007
No	18,846	84.0%	9,688	85.6%	-1.633	-0.046
Unknown	1,745	7.8%	672	5.9%	1.838	0.073

Table 1dh. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	703	3.1%	858	7.6%	-4.450	-0.199
2011	1,756	7.8%	1,627	14.4%	-6.554	-0.210
2012	2,080	9.3%	1,367	12.1%	-2.812	-0.091
2013	2,095	9.3%	1,286	11.4%	-2.029	-0.067
2014	1,964	8.8%	1,084	9.6%	-0.828	-0.029
2015	1,994	8.9%	929	8.2%	0.676	0.024
2016	2,031	9.1%	884	7.8%	1.239	0.045
2017	2,105	9.4%	745	6.6%	2.797	0.103
2018	2,080	9.3%	654	5.8%	3.490	0.133
2019	1,878	8.4%	633	5.6%	2.775	0.109
2020	1,524	6.8%	531	4.7%	2.099	0.090
2021	1,511	6.7%	491	4.3%	2.395	0.105
2022	716	3.2%	225	2.0%	1.202	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.6	1.3	0.013	0.010
Substance abuse	9,579	42.7%	4,926	43.5%	-0.846	-0.017
Atrial fibrilation/flutter	61	0.3%	36	0.3%	-0.046	-0.009
Ischemic heart disease	304	1.4%	204	1.8%	-0.448	-0.036
Heart failure	158	0.7%	119	1.1%	-0.348	-0.037
Stroke	121	0.5%	65	0.6%	-0.035	-0.005
Diabetes	2,227	9.9%	1,349	11.9%	-1.998	-0.064
Hypertension	5,022	22.4%	2,936	26.0%	-3.567	-0.083
Rheumatic disease	38	0.2%	19	0.2%	0.001	0.000
Chronic kidney disease	888	4.0%	468	4.1%	-0.179	-0.009
Seizure disorder	2,021	9.0%	1,068	9.4%	-0.432	-0.015

Table 1dh. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	48	0.2%	21	0.2%	0.028	0.006
Dementia Diagnosis	688	3.1%	361	3.2%	-0.124	-0.007
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.004	-0.002
Parkinsons disease	58	0.3%	40	0.4%	-0.095	-0.017
COPD	1,108	4.9%	619	5.5%	-0.533	-0.024
Malignancy	462	2.1%	237	2.1%	-0.036	-0.002
Asthma	3,313	14.8%	1,588	14.0%	0.730	0.021
Hyperlipidemia	3,676	16.4%	1,907	16.9%	-0.472	-0.013
Depression	9,690	43.2%	4,366	38.6%	4.598	0.094
Schizophrenia	17,654	78.7%	9,426	83.3%	-4.630	-0.118
Bipolar disorder	10,731	47.8%	4,920	43.5%	4.341	0.087
ACE inhibitor use	1,263	5.6%	719	6.4%	-0.726	-0.031
ARB use	208	0.9%	107	0.9%	-0.019	-0.002
Beta-blocker use	2,690	12.0%	1,307	11.6%	0.437	0.014
Oral anticoagulant use	146	0.7%	51	0.5%	0.200	0.027
Antiplatelet agent use	22	0.1%	*****	*****	0.027	0.009
Opioid use	3,121	13.9%	1,380	12.2%	1.713	0.051
Statin use	1,428	6.4%	726	6.4%	-0.052	-0.002
Wheelchair or walker use	*****	*****	*****	*****	-0.031	-0.018
Anti-arrhythmic use	19	0.1%	*****	*****	0.040	0.016
Antidiabetic use	1,656	7.4%	826	7.3%	0.080	0.003
Calcium channel blocker use	706	3.1%	463	4.1%	-0.946	-0.051
Diuretic use	1,048	4.7%	541	4.8%	-0.111	-0.005
Antidepressant use	12,135	54.1%	5,378	47.5%	6.551	0.131
Gastric acid suppressant use	3,880	17.3%	1,822	16.1%	1.189	0.032
NSAIDs	3,971	17.7%	1,800	15.9%	1.789	0.048

Table 1dh. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,084	27.1%	2,826	25.0%	2.138	0.049
Chronic liver disease	854	3.8%	429	3.8%	0.014	0.001
Pneumonia	396	1.8%	215	1.9%	-0.135	-0.010
Cardiac arrhythmia	3,012	13.4%	1,404	12.4%	1.015	0.030
Paliperidone palmitate	22,437	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.084	-0.031
Haloperidol decanoate	0	0.0%	11,314	100.0%	NaN	NaN
IS Stay	2,030	9.0%	1,243	11.0%	-1.939	-0.065
Medical Product Use						
Mean number of filled prescriptions	20.5	21.2	19.9	20.4	0.592	0.028
Mean number of generics dispensed	7.5	5.5	7.3	5.2	0.183	0.034
Mean number of unique drug classes dispensed	6.7	4.8	6.3	4.4	0.384	0.083
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.7	18.3	0.039	0.002
Mean number of inpatient hospital encounters	0.4	0.8	0.4	1.0	-0.052	-0.058
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.122	-0.098

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1di. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	22,429	100.0%	11,314	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.2	3.7	29.4	3.6	-0.265	-0.072
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	22,429	100.0%	11,314	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,692	29.8%	3,180	28.1%	1.730	0.038
Male	15,737	70.2%	8,134	71.9%	-1.730	-0.038
Race[2]						
American Indian or Alaska Native	324	1.4%	161	1.4%	0.022	0.002
Asian	535	2.4%	246	2.2%	0.211	0.014
Black or African American	6,607	29.5%	4,828	42.7%	-13.215	-0.278
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,591	16.0%	1,626	14.4%	1.639	0.046
White	11,372	50.7%	4,453	39.4%	11.344	0.230
Hispanic origin						
Yes	1,846	8.2%	954	8.4%	-0.202	-0.007
No	18,838	84.0%	9,688	85.6%	-1.639	-0.046
Unknown	1,745	7.8%	672	5.9%	1.841	0.073

Table 1di. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	703	3.1%	858	7.6%	-4.449	-0.199
2011	1,754	7.8%	1,627	14.4%	-6.560	-0.210
2012	2,079	9.3%	1,367	12.1%	-2.813	-0.091
2013	2,095	9.3%	1,286	11.4%	-2.026	-0.067
2014	1,963	8.8%	1,084	9.6%	-0.829	-0.029
2015	1,994	8.9%	929	8.2%	0.679	0.024
2016	2,030	9.1%	884	7.8%	1.237	0.045
2017	2,104	9.4%	745	6.6%	2.796	0.103
2018	2,079	9.3%	654	5.8%	3.489	0.133
2019	1,878	8.4%	633	5.6%	2.778	0.109
2020	1,524	6.8%	531	4.7%	2.101	0.090
2021	1,511	6.7%	491	4.3%	2.397	0.105
2022	715	3.2%	225	2.0%	1.199	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.6	1.3	1.6	1.3	0.012	0.009
Substance abuse	9,576	42.7%	4,926	43.5%	-0.844	-0.017
Atrial fibrilation/flutter	61	0.3%	36	0.3%	-0.046	-0.009
Ischemic heart disease	303	1.4%	204	1.8%	-0.452	-0.036
Heart failure	156	0.7%	119	1.1%	-0.356	-0.038
Stroke	121	0.5%	65	0.6%	-0.035	-0.005
Diabetes	2,225	9.9%	1,349	11.9%	-2.003	-0.064
Hypertension	5,020	22.4%	2,936	26.0%	-3.568	-0.083
Rheumatic disease	38	0.2%	19	0.2%	0.001	0.000
Chronic kidney disease	887	4.0%	468	4.1%	-0.182	-0.009
Seizure disorder	2,019	9.0%	1,068	9.4%	-0.438	-0.015

Table 1di. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	48	0.2%	21	0.2%	0.028	0.006
Dementia Diagnosis	688	3.1%	361	3.2%	-0.123	-0.007
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.004	-0.002
Parkinsons disease	58	0.3%	40	0.4%	-0.095	-0.017
COPD	1,107	4.9%	619	5.5%	-0.536	-0.024
Malignancy	461	2.1%	237	2.1%	-0.039	-0.003
Asthma	3,309	14.8%	1,588	14.0%	0.718	0.020
Hyperlipidemia	3,674	16.4%	1,907	16.9%	-0.475	-0.013
Depression	9,682	43.2%	4,366	38.6%	4.578	0.093
Schizophrenia	17,651	78.7%	9,426	83.3%	-4.615	-0.118
Bipolar disorder	10,723	47.8%	4,920	43.5%	4.323	0.087
ACE inhibitor use	1,262	5.6%	719	6.4%	-0.728	-0.031
ARB use	208	0.9%	107	0.9%	-0.018	-0.002
Beta-blocker use	2,688	12.0%	1,307	11.6%	0.432	0.013
Oral anticoagulant use	144	0.6%	51	0.5%	0.191	0.026
Antiplatelet agent use	21	0.1%	*****	*****	0.023	0.008
Opioid use	3,116	13.9%	1,380	12.2%	1.695	0.050
Statin use	1,428	6.4%	726	6.4%	-0.050	-0.002
Wheelchair or walker use	*****	*****	*****	*****	-0.031	-0.018
Anti-arrhythmic use	15	0.1%	*****	*****	0.023	0.010
Antidiabetic use	1,653	7.4%	826	7.3%	0.069	0.003
Calcium channel blocker use	703	3.1%	463	4.1%	-0.958	-0.051
Diuretic use	1,044	4.7%	541	4.8%	-0.127	-0.006
Antidepressant use	12,130	54.1%	5,378	47.5%	6.548	0.131
Gastric acid suppressant use	3,878	17.3%	1,822	16.1%	1.186	0.032
NSAIDs	3,966	17.7%	1,800	15.9%	1.773	0.047

Table 1di. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,078	27.1%	2,826	25.0%	2.121	0.048
Chronic liver disease	853	3.8%	429	3.8%	0.011	0.001
Pneumonia	396	1.8%	215	1.9%	-0.135	-0.010
Cardiac arrhythmia	3,008	13.4%	1,404	12.4%	1.002	0.030
Paliperidone palmitate	22,429	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.084	-0.031
Haloperidol decanoate	0	0.0%	11,314	100.0%	NaN	NaN
IS Stay	2,029	9.0%	1,243	11.0%	-1.940	-0.065
Medical Product Use						
Mean number of filled prescriptions	20.5	21.2	19.9	20.4	0.580	0.028
Mean number of generics dispensed	7.5	5.5	7.3	5.2	0.178	0.033
Mean number of unique drug classes dispensed	6.7	4.8	6.3	4.4	0.380	0.082
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.7	18.3	0.031	0.002
Mean number of inpatient hospital encounters	0.3	0.8	0.4	1.0	-0.053	-0.059
Mean number of non-acute institutional encounters	0.9	1.2	1.0	1.3	-0.123	-0.099

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dj. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	22,430	N/A	11,309	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	29.3	3.7	29.3	3.7	-0.002	-0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	22,430	100.0%	11,309	100.0%	0.000	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,558	29.2%	3,301	29.2%	0.050	0.001
Male	15,873	70.8%	8,009	70.8%	-0.050	-0.001
Race[3]						
American Indian or Alaska Native	322	1.4%	166	1.5%	-0.031	-0.003
Asian	545	2.4%	238	2.1%	0.329	0.022
Black or African American	6,785	30.2%	4,657	41.2%	-10.931	-0.230
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	3,589	16.0%	1,624	14.4%	1.636	0.046
White	11,190	49.9%	4,624	40.9%	8.998	0.181
Hispanic origin						
Yes	1,862	8.3%	949	8.4%	-0.091	-0.003
No	18,842	84.0%	9,685	85.6%	-1.636	-0.046
Unknown	1,727	7.7%	675	6.0%	1.727	0.068

Table 1dj. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	709	3.2%	837	7.4%	-4.237	-0.190
2011	1,762	7.9%	1,597	14.1%	-6.270	-0.201
2012	2,097	9.3%	1,334	11.8%	-2.442	-0.079
2013	2,094	9.3%	1,285	11.4%	-2.028	-0.067
2014	1,969	8.8%	1,096	9.7%	-0.918	-0.032
2015	1,993	8.9%	932	8.2%	0.646	0.023
2016	2,018	9.0%	893	7.9%	1.103	0.040
2017	2,094	9.3%	751	6.6%	2.689	0.099
2018	2,082	9.3%	670	5.9%	3.356	0.127
2019	1,868	8.3%	642	5.7%	2.654	0.104
2020	1,526	6.8%	539	4.8%	2.037	0.087
2021	1,503	6.7%	507	4.5%	2.217	0.097
2022	717	3.2%	226	2.0%	1.193	0.075
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.6	1.3	1.6	1.3	-0.004	-0.003
Substance abuse	9,642	43.0%	4,871	43.1%	-0.086	-0.002
Atrial fibrilation/flutter	65	0.3%	34	0.3%	-0.011	-0.002
Ischemic heart disease	335	1.5%	172	1.5%	-0.025	-0.002
Heart failure	180	0.8%	92	0.8%	-0.009	-0.001
Stroke	124	0.6%	62	0.5%	0.005	0.001
Diabetes	2,370	10.6%	1,198	10.6%	-0.028	-0.001
Hypertension	5,291	23.6%	2,675	23.7%	-0.064	-0.002
Rheumatic disease	38	0.2%	18	0.2%	0.006	0.001
Chronic kidney disease	909	4.1%	466	4.1%	-0.073	-0.004
Seizure disorder	2,054	9.2%	1,041	9.2%	-0.044	-0.002

Table 1dj. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	47	0.2%	25	0.2%	-0.011	-0.002
Dementia Diagnosis	701	3.1%	358	3.2%	-0.045	-0.003
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.004	-0.002
Parkinsons disease	66	0.3%	34	0.3%	-0.002	-0.000
COPD	1,147	5.1%	580	5.1%	-0.016	-0.001
Malignancy	464	2.1%	236	2.1%	-0.016	-0.001
Asthma	3,260	14.5%	1,657	14.6%	-0.113	-0.003
Hyperlipidemia	3,709	16.5%	1,881	16.6%	-0.100	-0.003
Depression	9,347	41.7%	4,711	41.7%	0.015	0.000
Schizophrenia	18,006	80.3%	9,094	80.4%	-0.132	-0.003
Bipolar disorder	10,398	46.4%	5,236	46.3%	0.064	0.001
ACE inhibitor use	1,315	5.9%	667	5.9%	-0.032	-0.001
ARB use	210	0.9%	107	0.9%	-0.004	-0.000
Beta-blocker use	2,653	11.8%	1,336	11.8%	0.012	0.000
Oral anticoagulant use	129	0.6%	64	0.6%	0.004	0.001
Antiplatelet agent use	19	0.1%	11	0.1%	-0.011	-0.004
Opioid use	2,990	13.3%	1,506	13.3%	0.012	0.000
Statin use	1,431	6.4%	728	6.4%	-0.060	-0.002
Wheelchair or walker use	*****	*****	*****	*****	0.000	0.000
Anti-arrhythmic use	13	0.1%	*****	*****	-0.000	-0.000
Antidiabetic use	1,645	7.3%	833	7.4%	-0.031	-0.001
Calcium channel blocker use	774	3.4%	389	3.4%	0.006	0.000
Diuretic use	1,047	4.7%	523	4.6%	0.047	0.002
Antidepressant use	11,644	51.9%	5,873	51.9%	-0.018	-0.000
Gastric acid suppressant use	3,787	16.9%	1,904	16.8%	0.046	0.001
NSAIDs	3,829	17.1%	1,926	17.0%	0.039	0.001

Table 1dj. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,924	26.4%	2,998	26.5%	-0.101	-0.002
Chronic liver disease	852	3.8%	433	3.8%	-0.026	-0.001
Pneumonia	405	1.8%	206	1.8%	-0.020	-0.002
Cardiac arrhythmia	2,941	13.1%	1,494	13.2%	-0.103	-0.003
Paliperidone palmitate	22,430	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.081	-0.030
Haloperidol decanoate	0	0.0%	11,309	100.0%	NaN	NaN
IS Stay	2,175	9.7%	1,097	9.7%	-0.000	-0.000
Medical Product Use						
Mean number of filled prescriptions	20.0	21.0	20.8	21.1	-0.769	-0.037
Mean number of generics dispensed	7.4	5.5	7.6	5.3	-0.182	-0.034
Mean number of unique drug classes dispensed	6.6	4.8	6.5	4.5	0.046	0.010
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.7	17.4	14.8	18.5	-0.038	-0.002
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.9	1.3	0.9	1.2	-0.005	-0.004

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1dk. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,608	100.0%	10,933	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.181	-0.063
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,608	100.0%	10,933	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,254	37.0%	3,819	34.9%	2.064	0.043
Male	12,354	63.0%	7,114	65.1%	-2.064	-0.043
Race[2]						
American Indian or Alaska Native	275	1.4%	107	1.0%	0.424	0.039
Asian	495	2.5%	339	3.1%	-0.576	-0.035
Black or African American	4,980	25.4%	4,250	38.9%	-13.475	-0.292
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,441	7.3%	885	8.1%	-0.746	-0.028
White	12,417	63.3%	5,352	49.0%	14.373	0.293
Hispanic origin						
Yes	1,049	5.3%	677	6.2%	-0.842	-0.036
No	18,167	92.7%	10,048	91.9%	0.746	0.028
Unknown	392	2.0%	208	1.9%	0.097	0.007

Table 1dk. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	566	2.9%	988	9.0%	-6.150	-0.262
2011	1,411	7.2%	1,667	15.2%	-8.051	-0.257
2012	1,717	8.8%	1,351	12.4%	-3.600	-0.117
2013	1,768	9.0%	1,246	11.4%	-2.380	-0.079
2014	1,689	8.6%	984	9.0%	-0.386	-0.014
2015	1,780	9.1%	855	7.8%	1.258	0.045
2016	1,846	9.4%	793	7.3%	2.161	0.078
2017	1,895	9.7%	748	6.8%	2.823	0.103
2018	1,935	9.9%	660	6.0%	3.832	0.142
2019	1,803	9.2%	556	5.1%	4.110	0.160
2020	1,381	7.0%	452	4.1%	2.909	0.127
2021	1,248	6.4%	429	3.9%	2.441	0.111
2022	569	2.9%	204	1.9%	1.036	0.068
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.6	0.057	0.036
Substance abuse	7,902	40.3%	3,939	36.0%	4.271	0.088
Atrial fibrilation/flutter	117	0.6%	83	0.8%	-0.162	-0.020
Ischemic heart disease	661	3.4%	477	4.4%	-0.992	-0.051
Heart failure	333	1.7%	239	2.2%	-0.488	-0.035
Stroke	232	1.2%	148	1.4%	-0.171	-0.015
Diabetes	3,812	19.4%	2,353	21.5%	-2.081	-0.052
Hypertension	7,241	36.9%	4,265	39.0%	-2.082	-0.043
Rheumatic disease	57	0.3%	34	0.3%	-0.020	-0.004
Chronic kidney disease	1,490	7.6%	714	6.5%	1.068	0.042
Seizure disorder	2,123	10.8%	1,153	10.5%	0.281	0.009

Table 1dk. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	52	0.5%	-0.001	-0.000
Dementia Diagnosis	725	3.7%	406	3.7%	-0.016	-0.001
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.053	-0.015
Parkinsons disease	96	0.5%	56	0.5%	-0.023	-0.003
COPD	1,969	10.0%	1,122	10.3%	-0.221	-0.007
Malignancy	468	2.4%	235	2.1%	0.237	0.016
Asthma	2,845	14.5%	1,430	13.1%	1.430	0.041
Hyperlipidemia	5,700	29.1%	3,095	28.3%	0.761	0.017
Depression	8,927	45.5%	4,260	39.0%	6.563	0.133
Schizophrenia	15,692	80.0%	9,245	84.6%	-4.532	-0.119
Bipolar disorder	9,532	48.6%	4,498	41.1%	7.471	0.151
ACE inhibitor use	2,541	13.0%	1,487	13.6%	-0.642	-0.019
ARB use	503	2.6%	292	2.7%	-0.106	-0.007
Beta-blocker use	3,212	16.4%	1,705	15.6%	0.786	0.021
Oral anticoagulant use	234	1.2%	121	1.1%	0.087	0.008
Antiplatelet agent use	80	0.4%	*****	*****	-0.196	-0.028
Opioid use	3,862	19.7%	1,811	16.6%	3.132	0.081
Statin use	3,154	16.1%	1,743	15.9%	0.143	0.004
Wheelchair or walker use	*****	*****	*****	*****	-0.046	-0.017
Anti-arrhythmic use	35	0.2%	*****	*****	0.050	0.013
Antidiabetic use	2,697	13.8%	1,570	14.4%	-0.606	-0.017
Calcium channel blocker use	1,300	6.6%	898	8.2%	-1.584	-0.060
Diuretic use	2,007	10.2%	1,251	11.4%	-1.207	-0.039
Antidepressant use	11,516	58.7%	5,458	49.9%	8.809	0.178
Gastric acid suppressant use	4,839	24.7%	2,450	22.4%	2.269	0.054
NSAIDs	4,379	22.3%	2,105	19.3%	3.079	0.076

Table 1dk. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,609	33.7%	3,020	27.6%	6.083	0.132
Chronic liver disease	1,174	6.0%	565	5.2%	0.820	0.036
Pneumonia	581	3.0%	322	2.9%	0.018	0.001
Cardiac arrhythmia	2,508	12.8%	1,336	12.2%	0.571	0.017
Paliperidone palmitate	19,608	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	12	0.1%	-0.094	-0.038
Haloperidol decanoate	0	0.0%	10,933	100.0%	NaN	NaN
IS Stay	1,785	9.1%	1,116	10.2%	-1.104	-0.037
Medical Product Use						
Mean number of filled prescriptions	26.9	25.4	25.0	24.1	1.896	0.077
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.628	0.102
Mean number of unique drug classes dispensed	8.1	5.5	7.3	5.1	0.758	0.143
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.2	18.3	15.6	19.0	0.644	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.034	-0.036
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.3	-0.085	-0.070

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dl. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,607	100.0%	10,931	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.8	2.9	40.0	2.9	-0.181	-0.063
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,607	100.0%	10,931	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,254	37.0%	3,818	34.9%	2.069	0.043
Male	12,353	63.0%	7,113	65.1%	-2.069	-0.043
Race[2]						
American Indian or Alaska Native	275	1.4%	107	1.0%	0.424	0.039
Asian	495	2.5%	339	3.1%	-0.577	-0.035
Black or African American	4,980	25.4%	4,249	38.9%	-13.472	-0.292
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,441	7.3%	885	8.1%	-0.747	-0.028
White	12,416	63.3%	5,351	49.0%	14.372	0.293
Hispanic origin						
Yes	1,049	5.4%	677	6.2%	-0.843	-0.036
No	18,166	92.7%	10,046	91.9%	0.747	0.028
Unknown	392	2.0%	208	1.9%	0.096	0.007

Table 1dl. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	566	2.9%	988	9.0%	-6.152	-0.262
2011	1,411	7.2%	1,667	15.3%	-8.054	-0.257
2012	1,717	8.8%	1,350	12.4%	-3.593	-0.117
2013	1,768	9.0%	1,246	11.4%	-2.382	-0.079
2014	1,689	8.6%	983	9.0%	-0.379	-0.013
2015	1,780	9.1%	855	7.8%	1.257	0.045
2016	1,846	9.4%	793	7.3%	2.160	0.078
2017	1,895	9.7%	748	6.8%	2.822	0.103
2018	1,935	9.9%	660	6.0%	3.831	0.142
2019	1,803	9.2%	556	5.1%	4.109	0.160
2020	1,381	7.0%	452	4.1%	2.908	0.127
2021	1,248	6.4%	429	3.9%	2.440	0.111
2022	568	2.9%	204	1.9%	1.031	0.068
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	1.8	1.5	1.7	1.6	0.057	0.037
Substance abuse	7,901	40.3%	3,937	36.0%	4.280	0.088
Atrial fibrilation/flutter	117	0.6%	83	0.8%	-0.163	-0.020
Ischemic heart disease	661	3.4%	476	4.4%	-0.983	-0.051
Heart failure	333	1.7%	238	2.2%	-0.479	-0.035
Stroke	232	1.2%	148	1.4%	-0.171	-0.015
Diabetes	3,812	19.4%	2,353	21.5%	-2.084	-0.052
Hypertension	7,240	36.9%	4,263	39.0%	-2.074	-0.043
Rheumatic disease	57	0.3%	34	0.3%	-0.020	-0.004
Chronic kidney disease	1,489	7.6%	713	6.5%	1.071	0.042
Seizure disorder	2,123	10.8%	1,152	10.5%	0.289	0.009

Table 1dl. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	52	0.5%	-0.001	-0.000
Dementia Diagnosis	725	3.7%	406	3.7%	-0.017	-0.001
Dementia Diagnosis and Treatment	*****	*****	*****	*****	-0.054	-0.015
Parkinsons disease	96	0.5%	56	0.5%	-0.023	-0.003
COPD	1,969	10.0%	1,121	10.3%	-0.213	-0.007
Malignancy	468	2.4%	234	2.1%	0.246	0.017
Asthma	2,845	14.5%	1,429	13.1%	1.437	0.042
Hyperlipidemia	5,699	29.1%	3,093	28.3%	0.770	0.017
Depression	8,926	45.5%	4,258	39.0%	6.571	0.133
Schizophrenia	15,691	80.0%	9,244	84.6%	-4.539	-0.119
Bipolar disorder	9,531	48.6%	4,496	41.1%	7.479	0.151
ACE inhibitor use	2,540	13.0%	1,487	13.6%	-0.649	-0.019
ARB use	503	2.6%	292	2.7%	-0.106	-0.007
Beta-blocker use	3,211	16.4%	1,705	15.6%	0.779	0.021
Oral anticoagulant use	234	1.2%	121	1.1%	0.087	0.008
Antiplatelet agent use	80	0.4%	*****	*****	-0.196	-0.028
Opioid use	3,861	19.7%	1,809	16.5%	3.143	0.082
Statin use	3,154	16.1%	1,742	15.9%	0.150	0.004
Wheelchair or walker use	*****	*****	*****	*****	-0.046	-0.017
Anti-arrhythmic use	35	0.2%	*****	*****	0.050	0.013
Antidiabetic use	2,697	13.8%	1,570	14.4%	-0.608	-0.017
Calcium channel blocker use	1,300	6.6%	898	8.2%	-1.585	-0.060
Diuretic use	2,007	10.2%	1,250	11.4%	-1.199	-0.039
Antidepressant use	11,515	58.7%	5,456	49.9%	8.816	0.178
Gastric acid suppressant use	4,838	24.7%	2,449	22.4%	2.271	0.054
NSAIDs	4,378	22.3%	2,104	19.2%	3.081	0.076

Table 1dl. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,608	33.7%	3,019	27.6%	6.084	0.132
Chronic liver disease	1,174	6.0%	565	5.2%	0.819	0.036
Pneumonia	580	3.0%	321	2.9%	0.022	0.001
Cardiac arrhythmia	2,508	12.8%	1,335	12.2%	0.578	0.017
Paliperidone palmitate	19,607	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	12	0.1%	-0.094	-0.038
Haloperidol decanoate	0	0.0%	10,931	100.0%	NaN	NaN
IS Stay	1,785	9.1%	1,116	10.2%	-1.106	-0.037
Medical Product Use						
Mean number of filled prescriptions	26.9	25.4	25.0	24.1	1.897	0.077
Mean number of generics dispensed	9.1	6.3	8.5	6.0	0.628	0.102
Mean number of unique drug classes dispensed	8.1	5.5	7.3	5.1	0.759	0.143
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.2	18.3	15.6	19.0	0.647	0.035
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.033	-0.034
Mean number of non-acute institutional encounters	0.8	1.2	0.9	1.3	-0.084	-0.069

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dm. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,611	N/A	10,927	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	39.9	2.9	39.9	2.9	0.003	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	19,611	100.0%	10,927	100.0%	0.000	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,106	36.2%	3,948	36.1%	0.103	0.002
Male	12,505	63.8%	6,979	63.9%	-0.103	-0.002
Race[3]						
American Indian or Alaska Native	271	1.4%	114	1.0%	0.342	0.031
Asian	510	2.6%	325	3.0%	-0.369	-0.022
Black or African American	5,212	26.6%	3,967	36.3%	-9.726	-0.211
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	1,448	7.4%	890	8.1%	-0.765	-0.029
White	12,169	62.1%	5,632	51.5%	10.517	0.214
Hispanic origin						
Yes	1,052	5.4%	686	6.3%	-0.914	-0.039
No	18,163	92.6%	10,037	91.9%	0.765	0.029
Unknown	396	2.0%	204	1.9%	0.149	0.011

Table 1dm. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	583	3.0%	941	8.6%	-5.634	-0.243
2011	1,446	7.4%	1,586	14.5%	-7.140	-0.230
2012	1,763	9.0%	1,297	11.9%	-2.880	-0.094
2013	1,775	9.1%	1,242	11.4%	-2.314	-0.076
2014	1,675	8.5%	1,006	9.2%	-0.664	-0.023
2015	1,761	9.0%	886	8.1%	0.874	0.031
2016	1,823	9.3%	828	7.6%	1.713	0.062
2017	1,877	9.6%	769	7.0%	2.534	0.092
2018	1,926	9.8%	676	6.2%	3.628	0.134
2019	1,781	9.1%	581	5.3%	3.763	0.146
2020	1,384	7.1%	466	4.3%	2.795	0.121
2021	1,249	6.4%	443	4.1%	2.314	0.104
2022	567	2.9%	205	1.9%	1.012	0.066
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	1.8	1.5	1.8	1.6	-0.007	-0.004
Substance abuse	7,611	38.8%	4,257	39.0%	-0.150	-0.003
Atrial fibrilation/flutter	129	0.7%	73	0.7%	-0.008	-0.001
Ischemic heart disease	729	3.7%	404	3.7%	0.017	0.001
Heart failure	370	1.9%	207	1.9%	-0.009	-0.001
Stroke	244	1.2%	136	1.2%	0.004	0.000
Diabetes	3,954	20.2%	2,193	20.1%	0.099	0.002
Hypertension	7,383	37.7%	4,110	37.6%	0.036	0.001
Rheumatic disease	58	0.3%	32	0.3%	0.005	0.001
Chronic kidney disease	1,416	7.2%	785	7.2%	0.039	0.002
Seizure disorder	2,102	10.7%	1,170	10.7%	0.013	0.000

Table 1dm. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	93	0.5%	51	0.5%	0.003	0.000
Dementia Diagnosis	731	3.7%	415	3.8%	-0.073	-0.004
Dementia Diagnosis and Treatment	*****	*****	*****	*****	0.000	0.000
Parkinsons disease	98	0.5%	55	0.5%	-0.005	-0.001
COPD	1,983	10.1%	1,101	10.1%	0.032	0.001
Malignancy	449	2.3%	251	2.3%	-0.011	-0.001
Asthma	2,745	14.0%	1,532	14.0%	-0.026	-0.001
Hyperlipidemia	5,645	28.8%	3,140	28.7%	0.044	0.001
Depression	8,463	43.2%	4,711	43.1%	0.041	0.001
Schizophrenia	16,025	81.7%	8,959	82.0%	-0.269	-0.007
Bipolar disorder	9,011	46.0%	5,021	46.0%	-0.001	-0.000
ACE inhibitor use	2,577	13.1%	1,429	13.1%	0.067	0.002
ARB use	508	2.6%	279	2.5%	0.039	0.002
Beta-blocker use	3,157	16.1%	1,764	16.1%	-0.045	-0.001
Oral anticoagulant use	231	1.2%	133	1.2%	-0.036	-0.003
Antiplatelet agent use	95	0.5%	*****	*****	0.003	0.000
Opioid use	3,638	18.6%	2,026	18.5%	0.012	0.000
Statin use	3,139	16.0%	1,742	15.9%	0.064	0.002
Wheelchair or walker use	12	0.1%	*****	*****	0.001	0.000
Anti-arrhythmic use	32	0.2%	*****	*****	-0.006	-0.001
Antidiabetic use	2,733	13.9%	1,515	13.9%	0.070	0.002
Calcium channel blocker use	1,409	7.2%	781	7.1%	0.039	0.002
Diuretic use	2,094	10.7%	1,168	10.7%	-0.011	-0.000
Antidepressant use	10,899	55.6%	6,074	55.6%	-0.008	-0.000
Gastric acid suppressant use	4,678	23.9%	2,602	23.8%	0.047	0.001
NSAIDs	4,156	21.2%	2,308	21.1%	0.068	0.002

Table 1dm. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,186	31.5%	3,461	31.7%	-0.124	-0.003
Chronic liver disease	1,122	5.7%	628	5.8%	-0.029	-0.001
Pneumonia	582	3.0%	325	3.0%	-0.009	-0.001
Cardiac arrhythmia	2,476	12.6%	1,398	12.8%	-0.167	-0.005
Paliperidone palmitate	19,611	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.1%	-0.107	-0.041
Haloperidol decanoate	0	0.0%	10,927	100.0%	NaN	NaN
IS Stay	1,867	9.5%	1,041	9.5%	-0.006	-0.000
Medical Product Use						
Mean number of filled prescriptions	26.1	25.2	26.4	24.6	-0.255	-0.010
Mean number of generics dispensed	8.8	6.3	8.9	6.1	-0.038	-0.006
Mean number of unique drug classes dispensed	7.8	5.4	7.7	5.2	0.157	0.030
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.0	18.2	16.0	19.3	-0.024	-0.001
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.002	-0.002
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.002	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1dn. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,386	100.0%	13,894	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.9	-0.166	-0.058
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,386	100.0%	13,894	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,346	43.1%	5,356	38.5%	4.503	0.092
Male	11,040	56.9%	8,538	61.5%	-4.503	-0.092
Race[2]						
American Indian or Alaska Native	211	1.1%	119	0.9%	0.232	0.024
Asian	443	2.3%	280	2.0%	0.270	0.019
Black or African American	4,555	23.5%	5,191	37.4%	-13.865	-0.305
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	976	5.0%	793	5.7%	-0.673	-0.030
White	13,201	68.1%	7,511	54.1%	14.036	0.291
Hispanic origin						
Yes	775	4.0%	633	4.6%	-0.558	-0.028
No	18,410	95.0%	13,101	94.3%	0.673	0.030
Unknown	201	1.0%	160	1.2%	-0.115	-0.011

Table 1dn. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	676	3.5%	1,512	10.9%	-7.395	-0.289
2011	1,672	8.6%	2,595	18.7%	-10.052	-0.296
2012	1,934	10.0%	1,968	14.2%	-4.188	-0.129
2013	1,875	9.7%	1,532	11.0%	-1.354	-0.044
2014	1,785	9.2%	1,282	9.2%	-0.019	-0.001
2015	1,869	9.6%	1,108	8.0%	1.666	0.059
2016	1,911	9.9%	893	6.4%	3.430	0.126
2017	1,850	9.5%	768	5.5%	4.015	0.153
2018	1,846	9.5%	675	4.9%	4.664	0.181
2019	1,531	7.9%	566	4.1%	3.824	0.162
2020	1,063	5.5%	439	3.2%	2.324	0.114
2021	954	4.9%	388	2.8%	2.129	0.111
2022	420	2.2%	168	1.2%	0.957	0.074
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.0	2.0	0.046	0.024
Substance abuse	6,778	35.0%	3,976	28.6%	6.347	0.137
Atrial fibrilation/flutter	287	1.5%	202	1.5%	0.027	0.002
Ischemic heart disease	1,518	7.8%	1,158	8.3%	-0.504	-0.018
Heart failure	748	3.9%	670	4.8%	-0.964	-0.047
Stroke	441	2.3%	382	2.7%	-0.475	-0.030
Diabetes	5,681	29.3%	4,237	30.5%	-1.191	-0.026
Hypertension	10,195	52.6%	7,295	52.5%	0.085	0.002
Rheumatic disease	100	0.5%	75	0.5%	-0.024	-0.003
Chronic kidney disease	2,271	11.7%	1,462	10.5%	1.192	0.038
Seizure disorder	2,366	12.2%	1,790	12.9%	-0.679	-0.020

Table 1dn. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	225	1.2%	176	1.3%	-0.106	-0.010
Dementia Diagnosis	1,033	5.3%	876	6.3%	-0.976	-0.042
Dementia Diagnosis and Treatment	94	0.5%	85	0.6%	-0.127	-0.017
Parkinsons disease	258	1.3%	172	1.2%	0.093	0.008
COPD	3,854	19.9%	2,510	18.1%	1.815	0.046
Malignancy	586	3.0%	403	2.9%	0.122	0.007
Asthma	2,749	14.2%	1,679	12.1%	2.096	0.062
Hyperlipidemia	7,901	40.8%	5,265	37.9%	2.862	0.059
Depression	9,080	46.8%	5,175	37.2%	9.592	0.195
Schizophrenia	15,723	81.1%	11,763	84.7%	-3.558	-0.095
Bipolar disorder	9,065	46.8%	5,187	37.3%	9.428	0.192
ACE inhibitor use	4,101	21.2%	3,089	22.2%	-1.078	-0.026
ARB use	1,007	5.2%	719	5.2%	0.020	0.001
Beta-blocker use	4,030	20.8%	2,829	20.4%	0.427	0.011
Oral anticoagulant use	388	2.0%	264	1.9%	0.101	0.007
Antiplatelet agent use	298	1.5%	214	1.5%	-0.003	-0.000
Opioid use	4,382	22.6%	2,479	17.8%	4.762	0.119
Statin use	5,379	27.7%	3,620	26.1%	1.692	0.038
Wheelchair or walker use	25	0.1%	28	0.2%	-0.073	-0.018
Anti-arrhythmic use	71	0.4%	50	0.4%	0.006	0.001
Antidiabetic use	4,063	21.0%	2,958	21.3%	-0.331	-0.008
Calcium channel blocker use	2,235	11.5%	1,917	13.8%	-2.268	-0.068
Diuretic use	3,378	17.4%	2,519	18.1%	-0.705	-0.018
Antidepressant use	12,031	62.1%	6,870	49.4%	12.614	0.256
Gastric acid suppressant use	6,085	31.4%	3,755	27.0%	4.363	0.096
NSAIDs	4,938	25.5%	2,964	21.3%	4.139	0.098

Table 1dn. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,056	36.4%	3,901	28.1%	8.321	0.179
Chronic liver disease	1,509	7.8%	905	6.5%	1.270	0.049
Pneumonia	864	4.5%	632	4.5%	-0.092	-0.004
Cardiac arrhythmia	2,488	12.8%	1,519	10.9%	1.901	0.059
Paliperidone palmitate	19,386	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	22	0.2%	-0.138	-0.046
Haloperidol decanoate	0	0.0%	13,894	100.0%	NaN	NaN
IS Stay	1,809	9.3%	1,415	10.2%	-0.853	-0.029
Medical Product Use						
Mean number of filled prescriptions	32.7	28.1	30.1	26.9	2.667	0.097
Mean number of generics dispensed	10.4	6.5	9.4	6.2	1.010	0.159
Mean number of unique drug classes dispensed	9.3	5.7	8.2	5.3	1.102	0.201
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.6	19.6	16.1	19.9	1.583	0.080
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.1	-0.031	-0.032
Mean number of non-acute institutional encounters	0.8	1.1	0.8	1.2	-0.023	-0.020

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1do. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	19,376	99.9%	13,892	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.2	2.9	-0.164	-0.057
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,376	100.0%	13,892	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	8,337	43.0%	5,355	38.5%	4.480	0.091
Male	11,039	57.0%	8,537	61.5%	-4.480	-0.091
Race[2]						
American Indian or Alaska Native	211	1.1%	119	0.9%	0.232	0.024
Asian	443	2.3%	280	2.0%	0.271	0.019
Black or African American	4,553	23.5%	5,189	37.4%	-13.854	-0.305
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	976	5.0%	793	5.7%	-0.671	-0.030
White	13,193	68.1%	7,511	54.1%	14.022	0.291
Hispanic origin						
Yes	775	4.0%	633	4.6%	-0.557	-0.028
No	18,400	95.0%	13,099	94.3%	0.671	0.030
Unknown	201	1.0%	160	1.2%	-0.114	-0.011

Table 1do. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	675	3.5%	1,510	10.9%	-7.386	-0.289
2011	1,672	8.6%	2,595	18.7%	-10.051	-0.296
2012	1,933	10.0%	1,968	14.2%	-4.190	-0.129
2013	1,875	9.7%	1,532	11.0%	-1.351	-0.044
2014	1,784	9.2%	1,282	9.2%	-0.021	-0.001
2015	1,868	9.6%	1,108	8.0%	1.665	0.059
2016	1,910	9.9%	893	6.4%	3.429	0.126
2017	1,849	9.5%	768	5.5%	4.014	0.153
2018	1,846	9.5%	675	4.9%	4.668	0.181
2019	1,531	7.9%	566	4.1%	3.827	0.162
2020	1,062	5.5%	439	3.2%	2.321	0.114
2021	952	4.9%	388	2.8%	2.120	0.110
2022	419	2.2%	168	1.2%	0.953	0.074
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.0	2.0	0.045	0.023
Substance abuse	6,769	34.9%	3,974	28.6%	6.329	0.136
Atrial fibrilation/flutter	284	1.5%	202	1.5%	0.012	0.001
Ischemic heart disease	1,518	7.8%	1,157	8.3%	-0.494	-0.018
Heart failure	748	3.9%	669	4.8%	-0.955	-0.047
Stroke	441	2.3%	381	2.7%	-0.467	-0.030
Diabetes	5,679	29.3%	4,236	30.5%	-1.183	-0.026
Hypertension	10,190	52.6%	7,294	52.5%	0.086	0.002
Rheumatic disease	100	0.5%	75	0.5%	-0.024	-0.003
Chronic kidney disease	2,268	11.7%	1,461	10.5%	1.188	0.038
Seizure disorder	2,366	12.2%	1,789	12.9%	-0.667	-0.020

Table 1do. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	225	1.2%	176	1.3%	-0.106	-0.010
Dementia Diagnosis	1,033	5.3%	876	6.3%	-0.974	-0.042
Dementia Diagnosis and Treatment	94	0.5%	85	0.6%	-0.127	-0.017
Parkinsons disease	258	1.3%	172	1.2%	0.093	0.008
COPD	3,850	19.9%	2,509	18.1%	1.809	0.046
Malignancy	586	3.0%	402	2.9%	0.131	0.008
Asthma	2,744	14.2%	1,677	12.1%	2.090	0.062
Hyperlipidemia	7,897	40.8%	5,263	37.9%	2.871	0.059
Depression	9,070	46.8%	5,173	37.2%	9.573	0.195
Schizophrenia	15,720	81.1%	11,762	84.7%	-3.536	-0.094
Bipolar disorder	9,055	46.7%	5,185	37.3%	9.409	0.191
ACE inhibitor use	4,100	21.2%	3,089	22.2%	-1.076	-0.026
ARB use	1,006	5.2%	719	5.2%	0.016	0.001
Beta-blocker use	4,026	20.8%	2,827	20.3%	0.428	0.011
Oral anticoagulant use	387	2.0%	264	1.9%	0.097	0.007
Antiplatelet agent use	298	1.5%	214	1.5%	-0.002	-0.000
Opioid use	4,376	22.6%	2,478	17.8%	4.747	0.118
Statin use	5,375	27.7%	3,618	26.0%	1.697	0.038
Wheelchair or walker use	25	0.1%	28	0.2%	-0.073	-0.018
Anti-arrhythmic use	70	0.4%	50	0.4%	0.001	0.000
Antidiabetic use	4,061	21.0%	2,958	21.3%	-0.334	-0.008
Calcium channel blocker use	2,235	11.5%	1,917	13.8%	-2.264	-0.068
Diuretic use	3,375	17.4%	2,518	18.1%	-0.707	-0.018
Antidepressant use	12,021	62.0%	6,868	49.4%	12.602	0.256
Gastric acid suppressant use	6,078	31.4%	3,753	27.0%	4.353	0.096
NSAIDs	4,931	25.4%	2,962	21.3%	4.127	0.098

Table 1do. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	7,046	36.4%	3,900	28.1%	8.291	0.178
Chronic liver disease	1,503	7.8%	905	6.5%	1.242	0.048
Pneumonia	863	4.5%	632	4.5%	-0.095	-0.005
Cardiac arrhythmia	2,482	12.8%	1,519	10.9%	1.875	0.058
Paliperidone palmitate	19,376	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	22	0.2%	-0.138	-0.046
Haloperidol decanoate	0	0.0%	13,892	100.0%	NaN	NaN
IS Stay	1,809	9.3%	1,415	10.2%	-0.849	-0.029
Medical Product Use						
Mean number of filled prescriptions	32.7	28.1	30.1	26.9	2.655	0.097
Mean number of generics dispensed	10.4	6.5	9.4	6.2	1.006	0.158
Mean number of unique drug classes dispensed	9.3	5.6	8.2	5.3	1.098	0.201
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.6	19.5	16.1	19.9	1.568	0.079
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.1	-0.030	-0.031
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.022	-0.019

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dp. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	19,380	N/A	13,893	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.1	2.9	50.1	2.9	0.006	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	19,380	100.0%	13,893	100.0%	0.000	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	7,974	41.1%	5,710	41.1%	0.044	0.001
Male	11,406	58.9%	8,183	58.9%	-0.044	-0.001
Race[3]						
American Indian or Alaska Native	205	1.1%	122	0.9%	0.177	0.018
Asian	469	2.4%	267	1.9%	0.503	0.034
Black or African American	4,805	24.8%	4,798	34.5%	-9.737	-0.214
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	987	5.1%	786	5.7%	-0.570	-0.025
White	12,914	66.6%	7,920	57.0%	9.627	0.199
Hispanic origin						
Yes	783	4.0%	633	4.6%	-0.519	-0.026
No	18,393	94.9%	13,107	94.3%	0.570	0.025
Unknown	204	1.1%	153	1.1%	-0.051	-0.005

Table 1dp. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	706	3.6%	1,431	10.3%	-6.659	-0.264
2011	1,736	9.0%	2,446	17.6%	-8.646	-0.257
2012	1,979	10.2%	1,903	13.7%	-3.484	-0.108
2013	1,872	9.7%	1,541	11.1%	-1.434	-0.047
2014	1,778	9.2%	1,318	9.5%	-0.315	-0.011
2015	1,837	9.5%	1,147	8.3%	1.220	0.043
2016	1,880	9.7%	937	6.7%	2.955	0.108
2017	1,824	9.4%	800	5.8%	3.652	0.138
2018	1,828	9.4%	709	5.1%	4.333	0.168
2019	1,507	7.8%	606	4.4%	3.414	0.143
2020	1,064	5.5%	471	3.4%	2.103	0.102
2021	952	4.9%	409	2.9%	1.967	0.101
2022	417	2.2%	175	1.3%	0.893	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.1	1.9	2.1	1.9	-0.006	-0.003
Substance abuse	6,285	32.4%	4,537	32.7%	-0.223	-0.005
Atrial fibrilation/flutter	288	1.5%	208	1.5%	-0.010	-0.001
Ischemic heart disease	1,562	8.1%	1,121	8.1%	-0.009	-0.000
Heart failure	832	4.3%	597	4.3%	-0.003	-0.000
Stroke	488	2.5%	349	2.5%	0.002	0.000
Diabetes	5,777	29.8%	4,149	29.9%	-0.054	-0.001
Hypertension	10,205	52.7%	7,331	52.8%	-0.110	-0.002
Rheumatic disease	100	0.5%	73	0.5%	-0.012	-0.002
Chronic kidney disease	2,183	11.3%	1,579	11.4%	-0.101	-0.003
Seizure disorder	2,427	12.5%	1,739	12.5%	0.006	0.000

Table 1dp. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	236	1.2%	172	1.2%	-0.018	-0.002
Dementia Diagnosis	1,129	5.8%	811	5.8%	-0.007	-0.000
Dementia Diagnosis and Treatment	105	0.5%	75	0.5%	0.004	0.001
Parkinsons disease	256	1.3%	187	1.3%	-0.023	-0.002
COPD	3,714	19.2%	2,669	19.2%	-0.048	-0.001
Malignancy	581	3.0%	420	3.0%	-0.025	-0.001
Asthma	2,575	13.3%	1,843	13.3%	0.017	0.000
Hyperlipidemia	7,682	39.6%	5,514	39.7%	-0.051	-0.001
Depression	8,308	42.9%	5,960	42.9%	-0.034	-0.001
Schizophrenia	16,040	82.8%	11,528	83.0%	-0.207	-0.006
Bipolar disorder	8,309	42.9%	5,961	42.9%	-0.032	-0.001
ACE inhibitor use	4,178	21.6%	2,999	21.6%	-0.029	-0.001
ARB use	1,010	5.2%	722	5.2%	0.012	0.001
Beta-blocker use	4,000	20.6%	2,876	20.7%	-0.063	-0.002
Oral anticoagulant use	390	2.0%	285	2.1%	-0.040	-0.003
Antiplatelet agent use	299	1.5%	218	1.6%	-0.026	-0.002
Opioid use	3,993	20.6%	2,865	20.6%	-0.020	-0.000
Statin use	5,239	27.0%	3,750	27.0%	0.040	0.001
Wheelchair or walker use	35	0.2%	24	0.2%	0.010	0.002
Anti-arrhythmic use	71	0.4%	51	0.4%	0.001	0.000
Antidiabetic use	4,086	21.1%	2,940	21.2%	-0.075	-0.002
Calcium channel blocker use	2,416	12.5%	1,730	12.5%	0.015	0.000
Diuretic use	3,420	17.6%	2,436	17.5%	0.110	0.003
Antidepressant use	11,007	56.8%	7,893	56.8%	-0.018	-0.000
Gastric acid suppressant use	5,731	29.6%	4,112	29.6%	-0.027	-0.001
NSAIDs	4,608	23.8%	3,313	23.8%	-0.072	-0.002

Table 1dp. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	6,371	32.9%	4,559	32.8%	0.054	0.001
Chronic liver disease	1,401	7.2%	1,011	7.3%	-0.047	-0.002
Pneumonia	876	4.5%	623	4.5%	0.037	0.002
Cardiac arrhythmia	2,354	12.1%	1,707	12.3%	-0.141	-0.004
Paliperidone palmitate	19,380	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	24	0.2%	-0.151	-0.049
Haloperidol decanoate	0	0.0%	13,893	100.0%	NaN	NaN
IS Stay	1,889	9.7%	1,361	9.8%	-0.051	-0.002
Medical Product Use						
Mean number of filled prescriptions	31.4	27.7	32.0	27.8	-0.644	-0.023
Mean number of generics dispensed	10.0	6.4	10.0	6.4	-0.019	-0.003
Mean number of unique drug classes dispensed	8.9	5.6	8.7	5.5	0.182	0.033
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.0	19.2	17.1	20.7	-0.084	-0.004
Mean number of inpatient hospital encounters	0.4	1.0	0.4	1.0	-0.001	-0.001
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.002	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1dq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,574	100.0%	11,670	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.5	2.8	-0.185	-0.066
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,574	100.0%	11,670	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,831	46.9%	4,906	42.0%	4.832	0.097
Male	7,743	53.1%	6,764	58.0%	-4.832	-0.097
Race[2]						
American Indian or Alaska Native	154	1.1%	73	0.6%	0.431	0.047
Asian	269	1.8%	166	1.4%	0.423	0.033
Black or African American	3,601	24.7%	4,295	36.8%	-12.095	-0.264
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	612	4.2%	561	4.8%	-0.608	-0.029
White	9,938	68.2%	6,575	56.3%	11.849	0.246
Hispanic origin						
Yes	455	3.1%	409	3.5%	-0.383	-0.021
No	13,962	95.8%	11,109	95.2%	0.608	0.029
Unknown	157	1.1%	152	1.3%	-0.225	-0.021

Table 1dq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	373	2.6%	906	7.8%	-5.204	-0.237
2011	883	6.1%	1,812	15.5%	-9.468	-0.309
2012	1,106	7.6%	1,499	12.8%	-5.256	-0.174
2013	1,224	8.4%	1,319	11.3%	-2.904	-0.098
2014	1,253	8.6%	1,034	8.9%	-0.263	-0.009
2015	1,420	9.7%	942	8.1%	1.671	0.059
2016	1,428	9.8%	881	7.5%	2.249	0.080
2017	1,540	10.6%	806	6.9%	3.660	0.130
2018	1,504	10.3%	662	5.7%	4.647	0.172
2019	1,431	9.8%	661	5.7%	4.155	0.156
2020	1,092	7.5%	493	4.2%	3.268	0.140
2021	913	6.3%	460	3.9%	2.323	0.106
2022	407	2.8%	195	1.7%	1.122	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	2.7	2.6	-0.050	-0.020
Substance abuse	3,998	27.4%	2,470	21.2%	6.267	0.147
Atrial fibrilation/flutter	489	3.4%	364	3.1%	0.236	0.013
Ischemic heart disease	2,020	13.9%	1,747	15.0%	-1.110	-0.032
Heart failure	1,067	7.3%	1,072	9.2%	-1.865	-0.068
Stroke	636	4.4%	652	5.6%	-1.223	-0.056
Diabetes	5,268	36.1%	4,410	37.8%	-1.643	-0.034
Hypertension	9,251	63.5%	7,609	65.2%	-1.725	-0.036
Rheumatic disease	127	0.9%	84	0.7%	0.152	0.017
Chronic kidney disease	2,689	18.5%	2,002	17.2%	1.296	0.034
Seizure disorder	1,984	13.6%	1,788	15.3%	-1.708	-0.049

Table 1dq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	573	3.9%	575	4.9%	-0.996	-0.048
Dementia Diagnosis	1,790	12.3%	1,907	16.3%	-4.059	-0.116
Dementia Diagnosis and Treatment	356	2.4%	419	3.6%	-1.148	-0.067
Parkinsons disease	425	2.9%	380	3.3%	-0.340	-0.020
COPD	3,989	27.4%	2,990	25.6%	1.749	0.040
Malignancy	650	4.5%	510	4.4%	0.090	0.004
Asthma	1,781	12.2%	1,233	10.6%	1.655	0.052
Hyperlipidemia	7,002	48.0%	5,333	45.7%	2.346	0.047
Depression	6,620	45.4%	4,411	37.8%	7.626	0.155
Schizophrenia	12,221	83.9%	9,905	84.9%	-1.021	-0.028
Bipolar disorder	6,502	44.6%	4,108	35.2%	9.412	0.193
ACE inhibitor use	3,762	25.8%	3,194	27.4%	-1.556	-0.035
ARB use	1,064	7.3%	878	7.5%	-0.223	-0.009
Beta-blocker use	3,779	25.9%	3,069	26.3%	-0.368	-0.008
Oral anticoagulant use	522	3.6%	352	3.0%	0.565	0.032
Antiplatelet agent use	453	3.1%	432	3.7%	-0.594	-0.033
Opioid use	3,123	21.4%	2,093	17.9%	3.494	0.088
Statin use	5,370	36.8%	4,046	34.7%	2.176	0.045
Wheelchair or walker use	81	0.6%	101	0.9%	-0.310	-0.037
Anti-arrhythmic use	97	0.7%	61	0.5%	0.143	0.019
Antidiabetic use	3,670	25.2%	2,933	25.1%	0.049	0.001
Calcium channel blocker use	2,654	18.2%	2,435	20.9%	-2.655	-0.067
Diuretic use	3,402	23.3%	2,862	24.5%	-1.181	-0.028
Antidepressant use	8,741	60.0%	5,660	48.5%	11.476	0.232
Gastric acid suppressant use	4,981	34.2%	3,611	30.9%	3.235	0.069
NSAIDs	3,484	23.9%	2,294	19.7%	4.248	0.103

Table 1dq. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,465	37.5%	3,528	30.2%	7.267	0.154
Chronic liver disease	1,214	8.3%	825	7.1%	1.260	0.047
Pneumonia	957	6.6%	911	7.8%	-1.240	-0.048
Cardiac arrhythmia	2,121	14.6%	1,448	12.4%	2.145	0.063
Paliperidone palmitate	14,574	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	15	0.1%	-0.122	-0.047
Haloperidol decanoate	0	0.0%	11,670	100.0%	NaN	NaN
IS Stay	1,676	11.5%	1,372	11.8%	-0.257	-0.008
Medical Product Use						
Mean number of filled prescriptions	36.3	29.9	34.5	29.8	1.890	0.063
Mean number of generics dispensed	11.0	6.5	10.2	6.3	0.827	0.130
Mean number of unique drug classes dispensed	9.9	5.7	8.9	5.4	0.969	0.175
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.1	20.0	15.8	20.6	2.227	0.110
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.056	-0.058
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	0.009	0.007

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dr. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	14,569	100.0%	11,665	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.3	2.8	59.5	2.8	-0.184	-0.065
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,569	100.0%	11,665	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,827	46.9%	4,904	42.0%	4.819	0.097
Male	7,742	53.1%	6,761	58.0%	-4.819	-0.097
Race[2]						
American Indian or Alaska Native	154	1.1%	73	0.6%	0.431	0.047
Asian	269	1.8%	166	1.4%	0.423	0.033
Black or African American	3,601	24.7%	4,291	36.8%	-12.068	-0.264
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	611	4.2%	561	4.8%	-0.615	-0.030
White	9,934	68.2%	6,574	56.4%	11.829	0.246
Hispanic origin						
Yes	454	3.1%	409	3.5%	-0.390	-0.022
No	13,958	95.8%	11,104	95.2%	0.615	0.030
Unknown	157	1.1%	152	1.3%	-0.225	-0.021

Table 1dr. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	373	2.6%	906	7.8%	-5.207	-0.237
2011	882	6.1%	1,812	15.5%	-9.480	-0.309
2012	1,106	7.6%	1,499	12.9%	-5.259	-0.174
2013	1,224	8.4%	1,318	11.3%	-2.897	-0.097
2014	1,253	8.6%	1,033	8.9%	-0.255	-0.009
2015	1,420	9.7%	942	8.1%	1.671	0.059
2016	1,427	9.8%	881	7.6%	2.242	0.080
2017	1,539	10.6%	805	6.9%	3.663	0.130
2018	1,504	10.3%	661	5.7%	4.657	0.172
2019	1,430	9.8%	661	5.7%	4.149	0.156
2020	1,092	7.5%	493	4.2%	3.269	0.140
2021	912	6.3%	459	3.9%	2.325	0.106
2022	407	2.8%	195	1.7%	1.122	0.076
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.6	2.4	2.7	2.6	-0.047	-0.019
Substance abuse	3,993	27.4%	2,468	21.2%	6.250	0.146
Atrial fibrilation/flutter	486	3.3%	363	3.1%	0.224	0.013
Ischemic heart disease	2,019	13.9%	1,743	14.9%	-1.084	-0.031
Heart failure	1,067	7.3%	1,070	9.2%	-1.849	-0.067
Stroke	635	4.4%	650	5.6%	-1.214	-0.056
Diabetes	5,266	36.1%	4,406	37.8%	-1.626	-0.034
Hypertension	9,248	63.5%	7,604	65.2%	-1.709	-0.036
Rheumatic disease	127	0.9%	83	0.7%	0.160	0.018
Chronic kidney disease	2,687	18.4%	1,999	17.1%	1.307	0.034
Seizure disorder	1,984	13.6%	1,785	15.3%	-1.684	-0.048

Table 1dr. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	573	3.9%	575	4.9%	-0.996	-0.048
Dementia Diagnosis	1,790	12.3%	1,904	16.3%	-4.036	-0.115
Dementia Diagnosis and Treatment	356	2.4%	419	3.6%	-1.148	-0.067
Parkinsons disease	425	2.9%	380	3.3%	-0.340	-0.020
COPD	3,987	27.4%	2,987	25.6%	1.760	0.040
Malignancy	650	4.5%	509	4.4%	0.098	0.005
Asthma	1,781	12.2%	1,233	10.6%	1.655	0.052
Hyperlipidemia	6,998	48.0%	5,330	45.7%	2.341	0.047
Depression	6,617	45.4%	4,408	37.8%	7.630	0.155
Schizophrenia	12,217	83.9%	9,900	84.9%	-1.013	-0.028
Bipolar disorder	6,498	44.6%	4,107	35.2%	9.394	0.193
ACE inhibitor use	3,761	25.8%	3,193	27.4%	-1.557	-0.035
ARB use	1,064	7.3%	878	7.5%	-0.224	-0.009
Beta-blocker use	3,775	25.9%	3,066	26.3%	-0.373	-0.008
Oral anticoagulant use	520	3.6%	351	3.0%	0.560	0.031
Antiplatelet agent use	453	3.1%	432	3.7%	-0.594	-0.033
Opioid use	3,121	21.4%	2,091	17.9%	3.497	0.088
Statin use	5,367	36.8%	4,043	34.7%	2.179	0.045
Wheelchair or walker use	81	0.6%	101	0.9%	-0.310	-0.037
Anti-arrhythmic use	95	0.7%	61	0.5%	0.129	0.017
Antidiabetic use	3,668	25.2%	2,931	25.1%	0.050	0.001
Calcium channel blocker use	2,654	18.2%	2,432	20.8%	-2.632	-0.066
Diuretic use	3,400	23.3%	2,859	24.5%	-1.172	-0.027
Antidepressant use	8,736	60.0%	5,659	48.5%	11.450	0.231
Gastric acid suppressant use	4,976	34.2%	3,609	30.9%	3.216	0.069
NSAIDs	3,481	23.9%	2,293	19.7%	4.236	0.103

Table 1dr. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	5,460	37.5%	3,526	30.2%	7.250	0.154
Chronic liver disease	1,212	8.3%	824	7.1%	1.255	0.047
Pneumonia	957	6.6%	908	7.8%	-1.215	-0.047
Cardiac arrhythmia	2,116	14.5%	1,445	12.4%	2.137	0.063
Paliperidone palmitate	14,569	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	15	0.1%	-0.122	-0.047
Haloperidol decanoate	0	0.0%	11,665	100.0%	NaN	NaN
IS Stay	1,676	11.5%	1,370	11.7%	-0.241	-0.008
Medical Product Use						
Mean number of filled prescriptions	36.3	29.9	34.5	29.8	1.891	0.063
Mean number of generics dispensed	11.0	6.5	10.2	6.3	0.828	0.130
Mean number of unique drug classes dispensed	9.9	5.7	8.9	5.4	0.969	0.175
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.0	20.0	15.8	20.6	2.225	0.110
Mean number of inpatient hospital encounters	0.4	0.9	0.5	1.0	-0.054	-0.056
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	0.011	0.009

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ds. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	14,582	N/A	11,657	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	59.4	2.8	59.4	2.8	0.006	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	14,582	100.0%	11,657	100.0%	0.000	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	6,524	44.7%	5,214	44.7%	0.010	0.000
Male	8,058	55.3%	6,443	55.3%	-0.010	-0.000
Race[3]						
American Indian or Alaska Native	157	1.1%	72	0.6%	0.458	0.050
Asian	277	1.9%	164	1.4%	0.489	0.038
Black or African American	3,808	26.1%	4,047	34.7%	-8.601	-0.188
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	616	4.2%	557	4.8%	-0.552	-0.027
White	9,724	66.7%	6,817	58.5%	8.207	0.170
Hispanic origin						
Yes	455	3.1%	409	3.5%	-0.387	-0.022
No	13,965	95.8%	11,100	95.2%	0.552	0.027
Unknown	161	1.1%	148	1.3%	-0.165	-0.015

Table 1ds. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	387	2.7%	860	7.4%	-4.726	-0.218
2011	912	6.3%	1,732	14.9%	-8.606	-0.283
2012	1,152	7.9%	1,449	12.4%	-4.535	-0.150
2013	1,233	8.5%	1,324	11.4%	-2.903	-0.097
2014	1,260	8.6%	1,049	9.0%	-0.361	-0.013
2015	1,399	9.6%	965	8.3%	1.318	0.046
2016	1,413	9.7%	903	7.7%	1.947	0.069
2017	1,548	10.6%	827	7.1%	3.520	0.124
2018	1,464	10.0%	682	5.9%	4.193	0.155
2019	1,413	9.7%	685	5.9%	3.808	0.143
2020	1,081	7.4%	514	4.4%	3.005	0.128
2021	914	6.3%	466	4.0%	2.266	0.103
2022	406	2.8%	200	1.7%	1.074	0.072
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.6	2.4	2.6	2.5	0.001	0.000
Substance abuse	3,600	24.7%	2,877	24.7%	0.009	0.000
Atrial fibrilation/flutter	473	3.2%	379	3.3%	-0.012	-0.001
Ischemic heart disease	2,098	14.4%	1,676	14.4%	0.006	0.000
Heart failure	1,198	8.2%	960	8.2%	-0.024	-0.001
Stroke	721	4.9%	572	4.9%	0.037	0.002
Diabetes	5,377	36.9%	4,297	36.9%	0.010	0.000
Hypertension	9,385	64.4%	7,503	64.4%	-0.003	-0.000
Rheumatic disease	116	0.8%	92	0.8%	0.009	0.001
Chronic kidney disease	2,602	17.8%	2,075	17.8%	0.042	0.001
Seizure disorder	2,098	14.4%	1,678	14.4%	-0.007	-0.000

Table 1ds. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	642	4.4%	513	4.4%	0.004	0.000
Dementia Diagnosis	2,076	14.2%	1,656	14.2%	0.028	0.001
Dementia Diagnosis and Treatment	435	3.0%	346	3.0%	0.012	0.001
Parkinsons disease	458	3.1%	366	3.1%	0.007	0.000
COPD	3,883	26.6%	3,101	26.6%	0.022	0.000
Malignancy	643	4.4%	513	4.4%	0.006	0.000
Asthma	1,674	11.5%	1,344	11.5%	-0.048	-0.002
Hyperlipidemia	6,872	47.1%	5,508	47.3%	-0.127	-0.003
Depression	6,128	42.0%	4,899	42.0%	0.004	0.000
Schizophrenia	12,328	84.5%	9,867	84.6%	-0.100	-0.003
Bipolar disorder	5,899	40.5%	4,723	40.5%	-0.059	-0.001
ACE inhibitor use	3,880	26.6%	3,108	26.7%	-0.053	-0.001
ARB use	1,072	7.3%	859	7.4%	-0.018	-0.001
Beta-blocker use	3,784	26.0%	3,019	25.9%	0.052	0.001
Oral anticoagulant use	483	3.3%	390	3.3%	-0.032	-0.002
Antiplatelet agent use	492	3.4%	397	3.4%	-0.034	-0.002
Opioid use	2,896	19.9%	2,309	19.8%	0.049	0.001
Statin use	5,231	35.9%	4,192	36.0%	-0.081	-0.002
Wheelchair or walker use	106	0.7%	82	0.7%	0.017	0.002
Anti-arrhythmic use	85	0.6%	68	0.6%	0.001	0.000
Antidiabetic use	3,655	25.1%	2,915	25.0%	0.057	0.001
Calcium channel blocker use	2,822	19.4%	2,253	19.3%	0.019	0.000
Diuretic use	3,486	23.9%	2,783	23.9%	0.034	0.001
Antidepressant use	7,996	54.8%	6,396	54.9%	-0.033	-0.001
Gastric acid suppressant use	4,764	32.7%	3,810	32.7%	-0.016	-0.000
NSAIDs	3,207	22.0%	2,557	21.9%	0.054	0.001

Table 1ds. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	4,990	34.2%	3,992	34.2%	-0.029	-0.001
Chronic liver disease	1,130	7.7%	903	7.7%	0.001	0.000
Pneumonia	1,048	7.2%	837	7.2%	0.012	0.000
Cardiac arrhythmia	1,985	13.6%	1,593	13.7%	-0.057	-0.002
Paliperidone palmitate	14,582	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	15	0.1%	-0.122	-0.046
Haloperidol decanoate	0	0.0%	11,657	100.0%	NaN	NaN
IS Stay	1,707	11.7%	1,369	11.7%	-0.039	-0.001
Medical Product Use						
Mean number of filled prescriptions	35.3	29.8	35.7	30.1	-0.411	-0.014
Mean number of generics dispensed	10.7	6.4	10.6	6.4	0.043	0.007
Mean number of unique drug classes dispensed	9.6	5.6	9.3	5.5	0.275	0.050
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.1	19.3	17.2	21.9	-0.061	-0.003
Mean number of inpatient hospital encounters	0.5	1.0	0.5	1.0	0.001	0.001
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.3	-0.002	-0.002

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1dt. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,512	100.0%	8,244	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.4	2.8	-0.508	-0.185
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,512	100.0%	8,244	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,943	60.5%	4,662	56.6%	4.000	0.081
Male	2,569	39.5%	3,582	43.4%	-4.000	-0.081
Race[2]						
American Indian or Alaska Native	39	0.6%	47	0.6%	0.029	0.004
Asian	139	2.1%	131	1.6%	0.545	0.040
Black or African American	1,573	24.2%	2,768	33.6%	-9.421	-0.209
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	294	4.5%	382	4.6%	-0.119	-0.006
White	4,467	68.6%	4,916	59.6%	8.965	0.188
Hispanic origin						
Yes	185	2.8%	220	2.7%	0.172	0.011
No	6,218	95.5%	7,862	95.4%	0.119	0.006
Unknown	109	1.7%	162	2.0%	-0.291	-0.022

Table 1dt. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	548	6.6%	-4.958	-0.250
2011	302	4.6%	1,032	12.5%	-7.881	-0.284
2012	389	6.0%	877	10.6%	-4.664	-0.170
2013	469	7.2%	768	9.3%	-2.114	-0.077
2014	448	6.9%	714	8.7%	-1.781	-0.067
2015	583	9.0%	661	8.0%	0.935	0.034
2016	659	10.1%	681	8.3%	1.859	0.064
2017	642	9.9%	629	7.6%	2.229	0.079
2018	655	10.1%	583	7.1%	2.987	0.107
2019	729	11.2%	585	7.1%	4.099	0.143
2020	585	9.0%	429	5.2%	3.780	0.148
2021	636	9.8%	489	5.9%	3.835	0.143
2022	305	4.7%	248	3.0%	1.675	0.087
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	3.7	3.1	-0.256	-0.087
Substance abuse	1,134	17.4%	1,120	13.6%	3.828	0.106
Atrial fibrilation/flutter	392	6.0%	637	7.7%	-1.707	-0.068
Ischemic heart disease	1,293	19.9%	1,928	23.4%	-3.531	-0.086
Heart failure	794	12.2%	1,307	15.9%	-3.661	-0.106
Stroke	476	7.3%	801	9.7%	-2.407	-0.086
Diabetes	2,604	40.0%	3,615	43.9%	-3.862	-0.078
Hypertension	4,866	74.7%	6,325	76.7%	-1.999	-0.047
Rheumatic disease	77	1.2%	94	1.1%	0.042	0.004
Chronic kidney disease	1,633	25.1%	1,998	24.2%	0.841	0.020
Seizure disorder	852	13.1%	1,317	16.0%	-2.892	-0.082

Table 1dt. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	787	12.1%	1,300	15.8%	-3.684	-0.107
Dementia Diagnosis	2,193	33.7%	3,554	43.1%	-9.434	-0.195
Dementia Diagnosis and Treatment	666	10.2%	1,145	13.9%	-3.662	-0.113
Parkinsons disease	461	7.1%	600	7.3%	-0.199	-0.008
COPD	1,851	28.4%	2,377	28.8%	-0.409	-0.009
Malignancy	406	6.2%	540	6.6%	-0.316	-0.013
Asthma	630	9.7%	756	9.2%	0.504	0.017
Hyperlipidemia	3,532	54.2%	4,260	51.7%	2.564	0.051
Depression	3,250	49.9%	3,594	43.6%	6.313	0.127
Schizophrenia	5,268	80.9%	6,114	74.2%	6.734	0.162
Bipolar disorder	2,875	44.1%	2,798	33.9%	10.209	0.210
ACE inhibitor use	1,843	28.3%	2,392	29.0%	-0.713	-0.016
ARB use	671	10.3%	825	10.0%	0.297	0.010
Beta-blocker use	2,003	30.8%	2,582	31.3%	-0.561	-0.012
Oral anticoagulant use	322	4.9%	433	5.3%	-0.308	-0.014
Antiplatelet agent use	303	4.7%	505	6.1%	-1.473	-0.065
Opioid use	1,244	19.1%	1,652	20.0%	-0.936	-0.024
Statin use	2,588	39.7%	3,286	39.9%	-0.117	-0.002
Wheelchair or walker use	74	1.1%	191	2.3%	-1.180	-0.091
Anti-arrhythmic use	54	0.8%	91	1.1%	-0.275	-0.028
Antidiabetic use	1,644	25.2%	2,285	27.7%	-2.471	-0.056
Calcium channel blocker use	1,647	25.3%	2,294	27.8%	-2.535	-0.057
Diuretic use	1,863	28.6%	2,472	30.0%	-1.377	-0.030
Antidepressant use	3,677	56.5%	4,177	50.7%	5.798	0.116
Gastric acid suppressant use	2,188	33.6%	2,795	33.9%	-0.304	-0.006
NSAIDs	1,298	19.9%	1,396	16.9%	2.999	0.077

Table 1dt. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,251	34.6%	2,604	31.6%	2.980	0.063
Chronic liver disease	488	7.5%	518	6.3%	1.210	0.048
Pneumonia	585	9.0%	919	11.1%	-2.164	-0.072
Cardiac arrhythmia	1,102	16.9%	1,290	15.6%	1.275	0.035
Paliperidone palmitate	6,512	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	-0.042	-0.018
Haloperidol decanoate	0	0.0%	8,244	100.0%	NaN	NaN
IS Stay	940	14.4%	1,088	13.2%	1.237	0.036
Medical Product Use						
Mean number of filled prescriptions	35.1	30.4	36.8	30.6	-1.700	-0.056
Mean number of generics dispensed	10.9	6.3	10.9	6.2	0.012	0.002
Mean number of unique drug classes dispensed	9.9	5.6	9.6	5.3	0.270	0.050
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.6	18.9	14.0	18.6	2.603	0.139
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.062	-0.069
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.087	0.066

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1du. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	6,510	100.0%	8,241	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	68.9	2.7	69.4	2.8	-0.507	-0.184
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,510	100.0%	8,241	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,941	60.5%	4,660	56.5%	3.991	0.081
Male	2,569	39.5%	3,581	43.5%	-3.991	-0.081
Race[2]						
American Indian or Alaska Native	39	0.6%	47	0.6%	0.029	0.004
Asian	139	2.1%	131	1.6%	0.546	0.040
Black or African American	1,572	24.1%	2,767	33.6%	-9.429	-0.209
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	294	4.5%	382	4.6%	-0.119	-0.006
White	4,466	68.6%	4,914	59.6%	8.973	0.188
Hispanic origin						
Yes	185	2.8%	220	2.7%	0.172	0.011
No	6,216	95.5%	7,859	95.4%	0.119	0.006
Unknown	109	1.7%	162	2.0%	-0.291	-0.022

Table 1du. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	110	1.7%	548	6.6%	-4.960	-0.250
2011	302	4.6%	1,031	12.5%	-7.872	-0.284
2012	389	6.0%	876	10.6%	-4.654	-0.169
2013	469	7.2%	768	9.3%	-2.115	-0.077
2014	448	6.9%	714	8.7%	-1.782	-0.067
2015	583	9.0%	661	8.0%	0.935	0.034
2016	659	10.1%	680	8.3%	1.871	0.065
2017	642	9.9%	629	7.6%	2.229	0.079
2018	654	10.0%	583	7.1%	2.972	0.106
2019	729	11.2%	585	7.1%	4.100	0.143
2020	585	9.0%	429	5.2%	3.780	0.148
2021	636	9.8%	489	5.9%	3.836	0.143
2022	304	4.7%	248	3.0%	1.660	0.086
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	3.5	2.8	3.7	3.1	-0.257	-0.087
Substance abuse	1,133	17.4%	1,119	13.6%	3.826	0.106
Atrial fibrilation/flutter	391	6.0%	636	7.7%	-1.711	-0.068
Ischemic heart disease	1,292	19.8%	1,927	23.4%	-3.537	-0.086
Heart failure	794	12.2%	1,305	15.8%	-3.639	-0.105
Stroke	475	7.3%	801	9.7%	-2.423	-0.087
Diabetes	2,603	40.0%	3,613	43.8%	-3.857	-0.078
Hypertension	4,864	74.7%	6,322	76.7%	-1.998	-0.047
Rheumatic disease	77	1.2%	94	1.1%	0.042	0.004
Chronic kidney disease	1,631	25.1%	1,997	24.2%	0.821	0.019
Seizure disorder	852	13.1%	1,315	16.0%	-2.869	-0.082

Table 1du. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	787	12.1%	1,300	15.8%	-3.686	-0.107
Dementia Diagnosis	2,192	33.7%	3,552	43.1%	-9.430	-0.195
Dementia Diagnosis and Treatment	666	10.2%	1,145	13.9%	-3.664	-0.113
Parkinsons disease	461	7.1%	600	7.3%	-0.199	-0.008
COPD	1,851	28.4%	2,375	28.8%	-0.386	-0.009
Malignancy	406	6.2%	540	6.6%	-0.316	-0.013
Asthma	630	9.7%	755	9.2%	0.516	0.018
Hyperlipidemia	3,530	54.2%	4,259	51.7%	2.544	0.051
Depression	3,249	49.9%	3,592	43.6%	6.321	0.127
Schizophrenia	5,267	80.9%	6,113	74.2%	6.728	0.162
Bipolar disorder	2,874	44.1%	2,797	33.9%	10.207	0.210
ACE inhibitor use	1,842	28.3%	2,391	29.0%	-0.719	-0.016
ARB use	670	10.3%	825	10.0%	0.281	0.009
Beta-blocker use	2,001	30.7%	2,581	31.3%	-0.582	-0.013
Oral anticoagulant use	322	4.9%	433	5.3%	-0.308	-0.014
Antiplatelet agent use	302	4.6%	504	6.1%	-1.477	-0.066
Opioid use	1,244	19.1%	1,651	20.0%	-0.925	-0.023
Statin use	2,586	39.7%	3,286	39.9%	-0.150	-0.003
Wheelchair or walker use	73	1.1%	190	2.3%	-1.184	-0.091
Anti-arrhythmic use	54	0.8%	91	1.1%	-0.275	-0.028
Antidiabetic use	1,643	25.2%	2,284	27.7%	-2.477	-0.056
Calcium channel blocker use	1,645	25.3%	2,293	27.8%	-2.555	-0.058
Diuretic use	1,862	28.6%	2,470	30.0%	-1.370	-0.030
Antidepressant use	3,676	56.5%	4,175	50.7%	5.806	0.117
Gastric acid suppressant use	2,187	33.6%	2,794	33.9%	-0.309	-0.007
NSAIDs	1,297	19.9%	1,395	16.9%	2.996	0.077

Table 1du. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,250	34.6%	2,603	31.6%	2.976	0.063
Chronic liver disease	487	7.5%	518	6.3%	1.195	0.047
Pneumonia	584	9.0%	918	11.1%	-2.169	-0.072
Cardiac arrhythmia	1,101	16.9%	1,288	15.6%	1.283	0.035
Paliperidone palmitate	6,510	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	-0.042	-0.019
Haloperidol decanoate	0	0.0%	8,241	100.0%	NaN	NaN
IS Stay	940	14.4%	1,088	13.2%	1.237	0.036
Medical Product Use						
Mean number of filled prescriptions	35.1	30.4	36.8	30.6	-1.708	-0.056
Mean number of generics dispensed	10.9	6.3	10.9	6.2	0.011	0.002
Mean number of unique drug classes dispensed	9.9	5.6	9.6	5.3	0.271	0.050
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.6	18.9	14.0	18.6	2.605	0.139
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.061	-0.068
Mean number of non-acute institutional encounters	1.1	1.3	1.0	1.3	0.088	0.067

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dv. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	6,490	N/A	8,256	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	69.2	2.8	69.2	2.8	-0.007	-0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	6,490	100.0%	8,256	100.0%	0.000	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	3,780	58.2%	4,808	58.2%	0.008	0.000
Male	2,710	41.8%	3,448	41.8%	-0.008	-0.000
Race[3]						
American Indian or Alaska Native	38	0.6%	47	0.6%	0.018	0.002
Asian	142	2.2%	135	1.6%	0.559	0.041
Black or African American	1,628	25.1%	2,731	33.1%	-7.994	-0.177
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	294	4.5%	387	4.7%	-0.161	-0.008
White	4,388	67.6%	4,957	60.0%	7.578	0.158
Hispanic origin						
Yes	182	2.8%	223	2.7%	0.092	0.006
No	6,196	95.5%	7,869	95.3%	0.161	0.008
Unknown	112	1.7%	163	2.0%	-0.253	-0.019

Table 1dv. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	116	1.8%	535	6.5%	-4.695	-0.238
2011	306	4.7%	987	12.0%	-7.239	-0.264
2012	399	6.1%	860	10.4%	-4.269	-0.155
2013	480	7.4%	781	9.5%	-2.070	-0.075
2014	439	6.8%	712	8.6%	-1.866	-0.070
2015	586	9.0%	678	8.2%	0.819	0.029
2016	659	10.2%	694	8.4%	1.754	0.060
2017	644	9.9%	637	7.7%	2.206	0.078
2018	637	9.8%	588	7.1%	2.696	0.097
2019	718	11.1%	602	7.3%	3.771	0.131
2020	574	8.8%	440	5.3%	3.509	0.137
2021	623	9.6%	492	6.0%	3.649	0.136
2022	309	4.8%	250	3.0%	1.735	0.090
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	3.6	2.9	3.6	3.0	0.004	0.001
Substance abuse	993	15.3%	1,266	15.3%	-0.042	-0.001
Atrial fibrilation/flutter	449	6.9%	574	7.0%	-0.042	-0.002
Ischemic heart disease	1,414	21.8%	1,796	21.8%	0.031	0.001
Heart failure	925	14.3%	1,171	14.2%	0.071	0.002
Stroke	549	8.5%	708	8.6%	-0.118	-0.004
Diabetes	2,745	42.3%	3,493	42.3%	-0.013	-0.000
Hypertension	4,932	76.0%	6,267	75.9%	0.085	0.002
Rheumatic disease	72	1.1%	93	1.1%	-0.019	-0.002
Chronic kidney disease	1,613	24.9%	2,037	24.7%	0.182	0.004
Seizure disorder	950	14.6%	1,210	14.7%	-0.013	-0.000

Table 1dv. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	906	14.0%	1,163	14.1%	-0.123	-0.004
Dementia Diagnosis	2,522	38.9%	3,216	39.0%	-0.096	-0.002
Dementia Diagnosis and Treatment	787	12.1%	1,009	12.2%	-0.100	-0.003
Parkinsons disease	471	7.3%	595	7.2%	0.049	0.002
COPD	1,867	28.8%	2,366	28.7%	0.109	0.002
Malignancy	413	6.4%	528	6.4%	-0.034	-0.001
Asthma	614	9.5%	778	9.4%	0.026	0.001
Hyperlipidemia	3,450	53.2%	4,374	53.0%	0.187	0.004
Depression	3,024	46.6%	3,844	46.6%	0.035	0.001
Schizophrenia	5,054	77.9%	6,399	77.5%	0.377	0.009
Bipolar disorder	2,514	38.7%	3,192	38.7%	0.073	0.001
ACE inhibitor use	1,864	28.7%	2,372	28.7%	-0.013	-0.000
ARB use	661	10.2%	840	10.2%	0.009	0.000
Beta-blocker use	2,012	31.0%	2,557	31.0%	0.034	0.001
Oral anticoagulant use	330	5.1%	421	5.1%	-0.011	-0.001
Antiplatelet agent use	349	5.4%	448	5.4%	-0.045	-0.002
Opioid use	1,260	19.4%	1,615	19.6%	-0.154	-0.004
Statin use	2,604	40.1%	3,294	39.9%	0.224	0.005
Wheelchair or walker use	120	1.8%	149	1.8%	0.039	0.003
Anti-arrhythmic use	65	1.0%	82	1.0%	0.005	0.001
Antidiabetic use	1,728	26.6%	2,199	26.6%	-0.012	-0.000
Calcium channel blocker use	1,731	26.7%	2,206	26.7%	-0.048	-0.001
Diuretic use	1,917	29.5%	2,429	29.4%	0.109	0.002
Antidepressant use	3,449	53.1%	4,396	53.3%	-0.107	-0.002
Gastric acid suppressant use	2,191	33.8%	2,788	33.8%	0.001	0.000
NSAIDs	1,189	18.3%	1,505	18.2%	0.102	0.003

Table 1dv. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	2,138	33.0%	2,718	32.9%	0.031	0.001
Chronic liver disease	440	6.8%	569	6.9%	-0.107	-0.004
Pneumonia	658	10.1%	837	10.1%	-0.006	-0.000
Cardiac arrhythmia	1,049	16.2%	1,333	16.1%	0.020	0.001
Paliperidone palmitate	6,490	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	-0.052	-0.024
Haloperidol decanoate	0	0.0%	8,256	100.0%	NaN	NaN
IS Stay	917	14.1%	1,151	13.9%	0.181	0.005
Medical Product Use						
Mean number of filled prescriptions	35.5	31.0	36.4	30.1	-0.920	-0.030
Mean number of generics dispensed	10.9	6.4	10.9	6.1	-0.010	-0.002
Mean number of unique drug classes dispensed	9.9	5.6	9.6	5.3	0.263	0.048
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.4	17.6	15.4	20.3	-0.010	-0.001
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	1.0	1.3	1.0	1.3	0.003	0.003

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1dw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,509	100.0%	4,138	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.8	2.7	79.5	2.9	-0.764	-0.274
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,509	100.0%	4,138	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,061	70.3%	2,703	65.3%	4.990	0.107
Male	448	29.7%	1,435	34.7%	-4.990	-0.107
Race[2]						
American Indian or Alaska Native	*****	*****	19	0.5%	0.204	0.027
Asian	*****	*****	56	1.4%	0.502	0.040
Black or African American	303	20.1%	946	22.9%	-2.782	-0.068
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	161	3.9%	1.013	0.049
White	1,094	72.5%	2,956	71.4%	1.063	0.024
Hispanic origin						
Yes	*****	*****	107	2.6%	0.860	0.050
No	1,435	95.1%	3,977	96.1%	-1.013	-0.049
Unknown	*****	*****	54	1.3%	0.153	0.013

Table 1dw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	28	1.9%	312	7.5%	-5.684	-0.271
2011	75	5.0%	571	13.8%	-8.829	-0.306
2012	101	6.7%	404	9.8%	-3.070	-0.112
2013	108	7.2%	427	10.3%	-3.162	-0.112
2014	106	7.0%	357	8.6%	-1.603	-0.060
2015	126	8.3%	330	8.0%	0.375	0.014
2016	143	9.5%	308	7.4%	2.033	0.073
2017	145	9.6%	308	7.4%	2.166	0.078
2018	142	9.4%	281	6.8%	2.619	0.096
2019	168	11.1%	280	6.8%	4.367	0.153
2020	166	11.0%	233	5.6%	5.370	0.195
2021	126	8.3%	223	5.4%	2.961	0.117
2022	75	5.0%	104	2.5%	2.457	0.130
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	4.6	3.1	-0.213	-0.069
Substance abuse	127	8.4%	230	5.6%	2.858	0.112
Atrial fibrilation/flutter	191	12.7%	610	14.7%	-2.084	-0.061
Ischemic heart disease	433	28.7%	1,359	32.8%	-4.147	-0.090
Heart failure	296	19.6%	895	21.6%	-2.013	-0.050
Stroke	167	11.1%	556	13.4%	-2.370	-0.072
Diabetes	635	42.1%	1,770	42.8%	-0.693	-0.014
Hypertension	1,251	82.9%	3,411	82.4%	0.471	0.012
Rheumatic disease	*****	*****	61	1.5%	-0.082	-0.007
Chronic kidney disease	428	28.4%	1,111	26.8%	1.514	0.034
Seizure disorder	158	10.5%	554	13.4%	-2.918	-0.090

Table 1dw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	408	27.0%	1,460	35.3%	-8.245	-0.179
Dementia Diagnosis	924	61.2%	3,102	75.0%	-13.731	-0.298
Dementia Diagnosis and Treatment	371	24.6%	1,393	33.7%	-9.078	-0.201
Parkinsons disease	144	9.5%	405	9.8%	-0.245	-0.008
COPD	411	27.2%	1,117	27.0%	0.243	0.005
Malignancy	95	6.3%	350	8.5%	-2.163	-0.083
Asthma	111	7.4%	280	6.8%	0.589	0.023
Hyperlipidemia	845	56.0%	2,159	52.2%	3.822	0.077
Depression	837	55.5%	1,979	47.8%	7.642	0.153
Schizophrenia	1,010	66.9%	1,912	46.2%	20.726	0.428
Bipolar disorder	582	38.6%	1,099	26.6%	12.010	0.258
ACE inhibitor use	404	26.8%	1,190	28.8%	-1.985	-0.044
ARB use	195	12.9%	460	11.1%	1.806	0.056
Beta-blocker use	517	34.3%	1,535	37.1%	-2.834	-0.059
Oral anticoagulant use	113	7.5%	400	9.7%	-2.178	-0.078
Antiplatelet agent use	104	6.9%	379	9.2%	-2.267	-0.084
Opioid use	331	21.9%	1,090	26.3%	-4.406	-0.103
Statin use	594	39.4%	1,644	39.7%	-0.366	-0.007
Wheelchair or walker use	44	2.9%	140	3.4%	-0.467	-0.027
Anti-arrhythmic use	*****	*****	96	2.3%	-0.597	-0.042
Antidiabetic use	337	22.3%	1,027	24.8%	-2.486	-0.059
Calcium channel blocker use	452	30.0%	1,186	28.7%	1.292	0.028
Diuretic use	526	34.9%	1,445	34.9%	-0.063	-0.001
Antidepressant use	849	56.3%	2,399	58.0%	-1.712	-0.035
Gastric acid suppressant use	542	35.9%	1,474	35.6%	0.297	0.006
NSAIDs	242	16.0%	591	14.3%	1.755	0.049

Table 1dw. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	478	31.7%	1,362	32.9%	-1.238	-0.026
Chronic liver disease	81	5.4%	173	4.2%	1.187	0.056
Pneumonia	174	11.5%	559	13.5%	-1.978	-0.060
Cardiac arrhythmia	278	18.4%	620	15.0%	3.440	0.092
Paliperidone palmitate	1,509	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	4,138	100.0%	NaN	NaN
IS Stay	258	17.1%	494	11.9%	5.159	0.147
Medical Product Use						
Mean number of filled prescriptions	35.3	30.5	39.6	31.7	-4.293	-0.138
Mean number of generics dispensed	11.0	6.3	11.6	6.1	-0.561	-0.091
Mean number of unique drug classes dispensed	10.2	5.6	10.4	5.3	-0.193	-0.035
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.0	17.0	11.1	14.7	3.961	0.250
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.022	-0.026
Mean number of non-acute institutional encounters	1.1	1.3	0.9	1.3	0.239	0.186

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dx. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,506	99.8%	4,132	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	78.8	2.7	79.5	2.9	-0.763	-0.274
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,506	100.0%	4,132	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	1,059	70.3%	2,701	65.4%	4.951	0.106
Male	447	29.7%	1,431	34.6%	-4.951	-0.106
Race[2]						
American Indian or Alaska Native	*****	*****	19	0.5%	0.204	0.027
Asian	*****	*****	56	1.4%	0.504	0.040
Black or African American	302	20.1%	946	22.9%	-2.841	-0.069
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	160	3.9%	1.041	0.051
White	1,092	72.5%	2,951	71.4%	1.092	0.024
Hispanic origin						
Yes	*****	*****	107	2.6%	0.863	0.050
No	1,432	95.1%	3,972	96.1%	-1.041	-0.051
Unknown	*****	*****	53	1.3%	0.178	0.015

Table 1dx. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	28	1.9%	311	7.5%	-5.667	-0.270
2011	75	5.0%	571	13.8%	-8.839	-0.306
2012	100	6.6%	404	9.8%	-3.137	-0.114
2013	108	7.2%	426	10.3%	-3.138	-0.111
2014	106	7.0%	355	8.6%	-1.553	-0.058
2015	126	8.4%	330	8.0%	0.380	0.014
2016	142	9.4%	308	7.5%	1.975	0.071
2017	145	9.6%	307	7.4%	2.198	0.079
2018	141	9.4%	280	6.8%	2.586	0.095
2019	168	11.2%	280	6.8%	4.379	0.154
2020	166	11.0%	233	5.6%	5.384	0.196
2021	126	8.4%	223	5.4%	2.970	0.118
2022	75	5.0%	104	2.5%	2.463	0.130
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	4.4	3.1	4.6	3.1	-0.207	-0.067
Substance abuse	126	8.4%	230	5.6%	2.800	0.110
Atrial fibrilation/flutter	190	12.6%	606	14.7%	-2.050	-0.060
Ischemic heart disease	432	28.7%	1,354	32.8%	-4.083	-0.089
Heart failure	295	19.6%	890	21.5%	-1.951	-0.048
Stroke	166	11.0%	555	13.4%	-2.409	-0.074
Diabetes	632	42.0%	1,766	42.7%	-0.774	-0.016
Hypertension	1,248	82.9%	3,406	82.4%	0.439	0.012
Rheumatic disease	*****	*****	60	1.5%	-0.058	-0.005
Chronic kidney disease	426	28.3%	1,108	26.8%	1.472	0.033
Seizure disorder	157	10.4%	552	13.4%	-2.934	-0.091

Table 1dx. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	405	26.9%	1,457	35.3%	-8.369	-0.182
Dementia Diagnosis	923	61.3%	3,097	75.0%	-13.663	-0.296
Dementia Diagnosis and Treatment	370	24.6%	1,391	33.7%	-9.096	-0.201
Parkinsons disease	144	9.6%	403	9.8%	-0.191	-0.006
COPD	410	27.2%	1,116	27.0%	0.216	0.005
Malignancy	95	6.3%	347	8.4%	-2.090	-0.080
Asthma	111	7.4%	280	6.8%	0.594	0.023
Hyperlipidemia	842	55.9%	2,155	52.2%	3.756	0.075
Depression	835	55.4%	1,976	47.8%	7.623	0.153
Schizophrenia	1,008	66.9%	1,911	46.2%	20.683	0.427
Bipolar disorder	580	38.5%	1,098	26.6%	11.940	0.257
ACE inhibitor use	401	26.6%	1,187	28.7%	-2.100	-0.047
ARB use	195	12.9%	460	11.1%	1.816	0.056
Beta-blocker use	516	34.3%	1,530	37.0%	-2.765	-0.058
Oral anticoagulant use	113	7.5%	397	9.6%	-2.105	-0.075
Antiplatelet agent use	103	6.8%	379	9.2%	-2.333	-0.086
Opioid use	330	21.9%	1,085	26.3%	-4.346	-0.102
Statin use	592	39.3%	1,641	39.7%	-0.405	-0.008
Wheelchair or walker use	44	2.9%	140	3.4%	-0.467	-0.027
Anti-arrhythmic use	*****	*****	96	2.3%	-0.597	-0.042
Antidiabetic use	337	22.4%	1,023	24.8%	-2.381	-0.056
Calcium channel blocker use	450	29.9%	1,184	28.7%	1.226	0.027
Diuretic use	524	34.8%	1,440	34.8%	-0.056	-0.001
Antidepressant use	846	56.2%	2,395	58.0%	-1.787	-0.036
Gastric acid suppressant use	541	35.9%	1,473	35.6%	0.274	0.006
NSAIDs	241	16.0%	589	14.3%	1.748	0.049

Table 1dx. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	478	31.7%	1,358	32.9%	-1.126	-0.024
Chronic liver disease	81	5.4%	172	4.2%	1.216	0.057
Pneumonia	174	11.6%	556	13.5%	-1.902	-0.058
Cardiac arrhythmia	277	18.4%	619	15.0%	3.412	0.092
Paliperidone palmitate	1,506	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	4,132	100.0%	NaN	NaN
IS Stay	258	17.1%	494	12.0%	5.176	0.147
Medical Product Use						
Mean number of filled prescriptions	35.3	30.5	39.6	31.7	-4.289	-0.138
Mean number of generics dispensed	11.0	6.3	11.6	6.1	-0.563	-0.091
Mean number of unique drug classes dispensed	10.2	5.6	10.4	5.3	-0.195	-0.036
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.0	16.8	11.1	14.7	3.879	0.246
Mean number of inpatient hospital encounters	0.5	0.8	0.5	0.9	-0.022	-0.025
Mean number of non-acute institutional encounters	1.1	1.3	0.9	1.3	0.238	0.185

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1dy. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,479	N/A	4,144	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	79.2	2.8	79.3	2.8	-0.071	-0.025
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	1,479	100.0%	4,144	100.0%	0.000	NaN
≥ 85 years	0	0.0%	0	0.0%	NaN	NaN
Sex						
Female	987	66.7%	2,764	66.7%	0.040	0.001
Male	492	33.3%	1,380	33.3%	-0.040	-0.001
Race[3]						
American Indian or Alaska Native	*****	*****	18	0.4%	0.256	0.034
Asian	*****	*****	57	1.4%	0.202	0.017
Black or African American	296	20.0%	975	23.5%	-3.516	-0.085
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	160	3.8%	0.963	0.047
White	1,079	72.9%	2,934	70.8%	2.096	0.047
Hispanic origin						
Yes	*****	*****	107	2.6%	0.739	0.044
No	1,408	95.2%	3,984	96.2%	-0.963	-0.047
Unknown	*****	*****	53	1.3%	0.224	0.019

Table 1dy. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	27	1.8%	308	7.4%	-5.635	-0.271
2011	82	5.5%	569	13.7%	-8.199	-0.281
2012	96	6.5%	399	9.6%	-3.119	-0.115
2013	124	8.4%	421	10.1%	-1.758	-0.061
2014	112	7.6%	356	8.6%	-1.051	-0.039
2015	125	8.5%	336	8.1%	0.369	0.013
2016	134	9.1%	317	7.6%	1.411	0.051
2017	151	10.2%	304	7.3%	2.851	0.101
2018	130	8.8%	280	6.8%	2.054	0.077
2019	162	10.9%	289	7.0%	3.944	0.138
2020	152	10.3%	234	5.7%	4.615	0.171
2021	115	7.7%	223	5.4%	2.362	0.095
2022	70	4.7%	107	2.6%	2.156	0.115
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	4.6	3.0	4.6	3.1	-0.007	-0.002
Substance abuse	92	6.2%	261	6.3%	-0.083	-0.003
Atrial fibrilation/flutter	204	13.8%	585	14.1%	-0.343	-0.010
Ischemic heart disease	479	32.4%	1,317	31.8%	0.581	0.012
Heart failure	300	20.3%	870	21.0%	-0.705	-0.017
Stroke	193	13.1%	533	12.9%	0.209	0.006
Diabetes	624	42.2%	1,764	42.6%	-0.362	-0.007
Hypertension	1,218	82.4%	3,423	82.6%	-0.252	-0.007
Rheumatic disease	*****	*****	57	1.4%	-0.125	-0.011
Chronic kidney disease	415	28.1%	1,135	27.4%	0.682	0.015
Seizure disorder	189	12.8%	521	12.6%	0.245	0.007

Table 1dy. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	500	33.8%	1,369	33.0%	0.767	0.016
Dementia Diagnosis	1,046	70.7%	2,955	71.3%	-0.590	-0.013
Dementia Diagnosis and Treatment	475	32.1%	1,297	31.3%	0.790	0.017
Parkinsons disease	138	9.3%	400	9.7%	-0.338	-0.012
COPD	412	27.8%	1,128	27.2%	0.602	0.013
Malignancy	115	7.8%	324	7.8%	-0.013	-0.000
Asthma	113	7.7%	292	7.0%	0.614	0.024
Hyperlipidemia	789	53.3%	2,206	53.2%	0.071	0.001
Depression	745	50.4%	2,068	49.9%	0.453	0.009
Schizophrenia	793	53.6%	2,159	52.1%	1.543	0.031
Bipolar disorder	453	30.6%	1,235	29.8%	0.833	0.018
ACE inhibitor use	419	28.3%	1,173	28.3%	0.047	0.001
ARB use	168	11.3%	483	11.7%	-0.319	-0.010
Beta-blocker use	543	36.7%	1,507	36.4%	0.324	0.007
Oral anticoagulant use	126	8.5%	373	9.0%	-0.461	-0.016
Antiplatelet agent use	133	9.0%	356	8.6%	0.417	0.015
Opioid use	362	24.5%	1,034	24.9%	-0.471	-0.011
Statin use	596	40.3%	1,646	39.7%	0.594	0.012
Wheelchair or walker use	45	3.0%	133	3.2%	-0.197	-0.011
Anti-arrhythmic use	*****	*****	91	2.2%	0.026	0.002
Antidiabetic use	354	23.9%	1,000	24.1%	-0.191	-0.004
Calcium channel blocker use	428	28.9%	1,205	29.1%	-0.158	-0.003
Diuretic use	515	34.8%	1,442	34.8%	0.022	0.000
Antidepressant use	841	56.9%	2,385	57.6%	-0.699	-0.014
Gastric acid suppressant use	521	35.2%	1,475	35.6%	-0.371	-0.008
NSAIDs	217	14.6%	609	14.7%	-0.049	-0.001

Table 1dy. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	474	32.0%	1,344	32.4%	-0.416	-0.009
Chronic liver disease	69	4.7%	186	4.5%	0.193	0.009
Pneumonia	188	12.7%	537	13.0%	-0.253	-0.008
Cardiac arrhythmia	226	15.3%	659	15.9%	-0.598	-0.016
Paliperidone palmitate	1,479	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	4,144	100.0%	NaN	NaN
IS Stay	217	14.7%	567	13.7%	1.015	0.029
Medical Product Use						
Mean number of filled prescriptions	37.3	32.3	38.9	31.5	-1.622	-0.051
Mean number of generics dispensed	11.4	6.3	11.5	6.1	-0.129	-0.021
Mean number of unique drug classes dispensed	10.5	5.6	10.2	5.3	0.220	0.040
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	12.8	14.4	12.4	17.1	0.377	0.024
Mean number of inpatient hospital encounters	0.5	0.9	0.5	0.9	0.004	0.005
Mean number of non-acute institutional encounters	1.0	1.3	1.0	1.3	0.046	0.035

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1dz. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	372	100.0%	2,291	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.8	3.2	90.0	3.7	-1.272	-0.366
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	372	100.0%	2,291	100.0%	0.000	NaN
Sex						
Female	301	80.9%	1,762	76.9%	4.004	0.098
Male	71	19.1%	529	23.1%	-4.004	-0.098
Race[2]						
American Indian or Alaska Native	*****	*****	*****	*****	0.901	0.114
Asian	*****	*****	*****	*****	-0.096	-0.008
Black or African American	46	12.4%	326	14.2%	-1.864	-0.055
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	98	4.3%	2.174	0.097
White	293	78.8%	1,830	79.9%	-1.114	-0.028
Hispanic origin						
Yes	*****	*****	74	3.2%	1.071	0.056
No	348	93.5%	2,193	95.7%	-2.174	-0.097
Unknown	*****	*****	24	1.0%	1.103	0.088

Table 1dz. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	11	3.0%	145	6.3%	-3.372	-0.161
2011	14	3.8%	288	12.6%	-8.807	-0.326
2012	20	5.4%	259	11.3%	-5.929	-0.216
2013	33	8.9%	243	10.6%	-1.736	-0.059
2014	39	10.5%	229	10.0%	0.488	0.016
2015	35	9.4%	208	9.1%	0.330	0.011
2016	26	7.0%	188	8.2%	-1.217	-0.046
2017	47	12.6%	169	7.4%	5.258	0.176
2018	31	8.3%	157	6.9%	1.480	0.056
2019	40	10.8%	129	5.6%	5.122	0.188
2020	36	9.7%	120	5.2%	4.440	0.170
2021	23	6.2%	107	4.7%	1.512	0.067
2022	17	4.6%	49	2.1%	2.431	0.135
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	3.0	4.8	3.0	0.212	0.071
Substance abuse	21	5.6%	67	2.9%	2.721	0.135
Atrial fibrilation/flutter	74	19.9%	462	20.2%	-0.273	-0.007
Ischemic heart disease	103	27.7%	771	33.7%	-5.965	-0.130
Heart failure	90	24.2%	629	27.5%	-3.262	-0.075
Stroke	28	7.5%	333	14.5%	-7.008	-0.225
Diabetes	124	33.3%	697	30.4%	2.910	0.062
Hypertension	314	84.4%	1,862	81.3%	3.134	0.083
Rheumatic disease	*****	*****	47	2.1%	-0.439	-0.033
Chronic kidney disease	115	30.9%	659	28.8%	2.149	0.047
Seizure disorder	27	7.3%	171	7.5%	-0.206	-0.008

Table 1dz. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.8%	907	39.6%	4.228	0.086
Dementia Diagnosis	324	87.1%	2,013	87.9%	-0.769	-0.023
Dementia Diagnosis and Treatment	159	42.7%	868	37.9%	4.855	0.099
Parkinsons disease	33	8.9%	147	6.4%	2.455	0.092
COPD	78	21.0%	522	22.8%	-1.817	-0.044
Malignancy	22	5.9%	133	5.8%	0.109	0.005
Asthma	20	5.4%	110	4.8%	0.575	0.026
Hyperlipidemia	187	50.3%	968	42.3%	8.017	0.161
Depression	229	61.6%	1,076	47.0%	14.593	0.296
Schizophrenia	138	37.1%	436	19.0%	18.066	0.410
Bipolar disorder	112	30.1%	331	14.4%	15.660	0.383
ACE inhibitor use	95	25.5%	578	25.2%	0.308	0.007
ARB use	38	10.2%	294	12.8%	-2.618	-0.082
Beta-blocker use	142	38.2%	911	39.8%	-1.592	-0.033
Oral anticoagulant use	40	10.8%	243	10.6%	0.146	0.005
Antiplatelet agent use	35	9.4%	227	9.9%	-0.500	-0.017
Opioid use	92	24.7%	698	30.5%	-5.736	-0.129
Statin use	126	33.9%	662	28.9%	4.975	0.107
Wheelchair or walker use	19	5.1%	124	5.4%	-0.305	-0.014
Anti-arrhythmic use	*****	*****	68	3.0%	-1.086	-0.071
Antidiabetic use	51	13.7%	330	14.4%	-0.695	-0.020
Calcium channel blocker use	109	29.3%	651	28.4%	0.886	0.020
Diuretic use	121	32.5%	886	38.7%	-6.146	-0.129
Antidepressant use	240	64.5%	1,430	62.4%	2.098	0.044
Gastric acid suppressant use	126	33.9%	840	36.7%	-2.794	-0.059
NSAIDs	57	15.3%	300	13.1%	2.228	0.064

Table 1dz. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	136	36.6%	762	33.3%	3.299	0.069
Chronic liver disease	*****	*****	66	2.9%	-0.193	-0.012
Pneumonia	61	16.4%	345	15.1%	1.339	0.037
Cardiac arrhythmia	65	17.5%	338	14.8%	2.720	0.074
Paliperidone palmitate	372	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	0.182	0.043
Haloperidol decanoate	0	0.0%	2,291	100.0%	NaN	NaN
IS Stay	60	16.1%	234	10.2%	5.915	0.176
Medical Product Use						
Mean number of filled prescriptions	37.3	28.2	39.5	28.5	-2.248	-0.079
Mean number of generics dispensed	11.3	5.6	11.5	5.6	-0.231	-0.041
Mean number of unique drug classes dispensed	10.4	5.1	10.4	4.9	0.066	0.013
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.3	12.2	7.7	9.7	3.631	0.330
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.8	0.031	0.041
Mean number of non-acute institutional encounters	1.1	1.3	0.7	1.1	0.386	0.320

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ea. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	371	99.7%	2,275	99.3%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	88.8	3.2	90.0	3.7	-1.235	-0.357
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	371	100.0%	2,275	100.0%	0.000	NaN
Sex						
Female	300	80.9%	1,751	77.0%	3.896	0.096
Male	71	19.1%	524	23.0%	-3.896	-0.096
Race[2]						
American Indian or Alaska Native	*****	*****	*****	*****	0.902	0.115
Asian	*****	*****	*****	*****	-0.059	-0.005
Black or African American	46	12.4%	323	14.2%	-1.799	-0.053
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	96	4.2%	2.249	0.100
White	292	78.7%	1,820	80.0%	-1.294	-0.032
Hispanic origin						
Yes	*****	*****	72	3.2%	1.148	0.061
No	347	93.5%	2,179	95.8%	-2.249	-0.100
Unknown	*****	*****	24	1.1%	1.101	0.088

Table 1ea. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	11	3.0%	143	6.3%	-3.321	-0.159
2011	14	3.8%	284	12.5%	-8.710	-0.323
2012	20	5.4%	257	11.3%	-5.906	-0.215
2013	33	8.9%	241	10.6%	-1.699	-0.057
2014	39	10.5%	228	10.0%	0.490	0.016
2015	35	9.4%	208	9.1%	0.291	0.010
2016	26	7.0%	188	8.3%	-1.256	-0.047
2017	47	12.7%	168	7.4%	5.284	0.177
2018	31	8.4%	156	6.9%	1.499	0.057
2019	40	10.8%	128	5.6%	5.155	0.189
2020	36	9.7%	118	5.2%	4.517	0.173
2021	22	5.9%	107	4.7%	1.227	0.055
2022	17	4.6%	49	2.2%	2.428	0.135
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.0	2.9	4.7	3.0	0.211	0.071
Substance abuse	20	5.4%	67	2.9%	2.446	0.123
Atrial fibrilation/flutter	74	19.9%	456	20.0%	-0.098	-0.002
Ischemic heart disease	103	27.8%	759	33.4%	-5.600	-0.122
Heart failure	90	24.3%	619	27.2%	-2.950	-0.068
Stroke	28	7.5%	321	14.1%	-6.563	-0.212
Diabetes	123	33.2%	692	30.4%	2.736	0.059
Hypertension	313	84.4%	1,847	81.2%	3.180	0.084
Rheumatic disease	*****	*****	47	2.1%	-0.449	-0.033
Chronic kidney disease	114	30.7%	651	28.6%	2.112	0.046
Seizure disorder	27	7.3%	169	7.4%	-0.151	-0.006

Table 1ea. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	163	43.9%	905	39.8%	4.155	0.084
Dementia Diagnosis	323	87.1%	1,998	87.8%	-0.762	-0.023
Dementia Diagnosis and Treatment	159	42.9%	867	38.1%	4.747	0.097
Parkinsons disease	33	8.9%	147	6.5%	2.433	0.091
COPD	78	21.0%	516	22.7%	-1.657	-0.040
Malignancy	22	5.9%	129	5.7%	0.260	0.011
Asthma	19	5.1%	107	4.7%	0.418	0.019
Hyperlipidemia	186	50.1%	962	42.3%	7.849	0.158
Depression	228	61.5%	1,074	47.2%	14.247	0.289
Schizophrenia	137	36.9%	435	19.1%	17.806	0.405
Bipolar disorder	111	29.9%	331	14.5%	15.370	0.376
ACE inhibitor use	95	25.6%	567	24.9%	0.683	0.016
ARB use	38	10.2%	288	12.7%	-2.417	-0.076
Beta-blocker use	142	38.3%	900	39.6%	-1.286	-0.026
Oral anticoagulant use	40	10.8%	242	10.6%	0.144	0.005
Antiplatelet agent use	35	9.4%	225	9.9%	-0.456	-0.015
Opioid use	92	24.8%	689	30.3%	-5.488	-0.123
Statin use	125	33.7%	658	28.9%	4.770	0.103
Wheelchair or walker use	19	5.1%	123	5.4%	-0.285	-0.013
Anti-arrhythmic use	*****	*****	66	2.9%	-1.014	-0.066
Antidiabetic use	51	13.7%	327	14.4%	-0.627	-0.018
Calcium channel blocker use	109	29.4%	647	28.4%	0.940	0.021
Diuretic use	121	32.6%	876	38.5%	-5.891	-0.123
Antidepressant use	239	64.4%	1,420	62.4%	2.003	0.042
Gastric acid suppressant use	125	33.7%	833	36.6%	-2.923	-0.061
NSAIDs	57	15.4%	297	13.1%	2.309	0.066

Table 1ea. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	136	36.7%	756	33.2%	3.427	0.072
Chronic liver disease	*****	*****	63	2.8%	-0.074	-0.005
Pneumonia	61	16.4%	342	15.0%	1.409	0.039
Cardiac arrhythmia	65	17.5%	336	14.8%	2.751	0.075
Paliperidone palmitate	371	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	0.182	0.043
Haloperidol decanoate	0	0.0%	2,275	100.0%	NaN	NaN
IS Stay	59	15.9%	233	10.2%	5.661	0.169
Medical Product Use						
Mean number of filled prescriptions	37.4	28.1	39.5	28.5	-2.122	-0.075
Mean number of generics dispensed	11.3	5.6	11.5	5.6	-0.180	-0.032
Mean number of unique drug classes dispensed	10.5	5.1	10.4	4.9	0.108	0.022
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.3	12.2	7.7	9.5	3.662	0.335
Mean number of inpatient hospital encounters	0.5	0.8	0.4	0.8	0.030	0.040
Mean number of non-acute institutional encounters	1.1	1.2	0.7	1.1	0.367	0.311

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1eb. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	365	N/A	2,279	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	89.8	3.7	89.8	3.7	-0.037	-0.010
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	0	0.0%	0	0.0%	NaN	NaN
35-44 years	0	0.0%	0	0.0%	NaN	NaN
45-54 years	0	0.0%	0	0.0%	NaN	NaN
55-64 years	0	0.0%	0	0.0%	NaN	NaN
65-74 years	0	0.0%	0	0.0%	NaN	NaN
75-84 years	0	0.0%	0	0.0%	NaN	NaN
≥ 85 years	365	100.0%	2,279	100.0%	0.000	NaN
Sex						
Female	271	74.1%	1,764	77.4%	-3.324	-0.078
Male	95	25.9%	515	22.6%	3.324	0.078
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	0.737	0.101
Asian	*****	*****	*****	*****	-0.030	-0.003
Black or African American	47	13.0%	328	14.4%	-1.405	-0.041
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	*****	*****	96	4.2%	1.876	0.085
White	287	78.7%	1,819	79.8%	-1.178	-0.029
Hispanic origin						
Yes	*****	*****	71	3.1%	0.668	0.037
No	343	93.9%	2,182	95.8%	-1.876	-0.085
Unknown	*****	*****	25	1.1%	1.208	0.094

Table 1eb. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	15	4.0%	141	6.2%	-2.193	-0.100
2011	18	5.0%	277	12.2%	-7.190	-0.259
2012	20	5.5%	253	11.1%	-5.548	-0.202
2013	31	8.6%	239	10.5%	-1.901	-0.065
2014	31	8.4%	228	10.0%	-1.647	-0.057
2015	29	7.9%	212	9.3%	-1.465	-0.052
2016	25	6.9%	195	8.5%	-1.617	-0.060
2017	43	11.9%	171	7.5%	4.383	0.148
2018	31	8.5%	156	6.8%	1.677	0.063
2019	49	13.3%	129	5.7%	7.637	0.263
2020	34	9.3%	120	5.3%	3.967	0.153
2021	21	5.7%	107	4.7%	0.978	0.044
2022	19	5.1%	50	2.2%	2.919	0.156
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.1	3.0	4.8	3.0	0.353	0.117
Substance abuse	12	3.2%	76	3.3%	-0.118	-0.007
Atrial fibrilation/flutter	85	23.2%	460	20.2%	3.040	0.074
Ischemic heart disease	127	34.7%	744	32.6%	2.085	0.044
Heart failure	104	28.5%	612	26.9%	1.658	0.037
Stroke	58	16.0%	301	13.2%	2.751	0.078
Diabetes	118	32.3%	705	30.9%	1.373	0.030
Hypertension	299	81.8%	1,862	81.7%	0.117	0.003
Rheumatic disease	*****	*****	45	2.0%	-0.152	-0.011
Chronic kidney disease	108	29.6%	660	29.0%	0.680	0.015
Seizure disorder	30	8.2%	170	7.5%	0.740	0.028

Table 1eb. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	150	41.1%	923	40.5%	0.577	0.012
Dementia Diagnosis	321	87.8%	1,998	87.7%	0.147	0.004
Dementia Diagnosis and Treatment	145	39.6%	887	38.9%	0.711	0.015
Parkinsons disease	25	6.9%	156	6.8%	0.069	0.003
COPD	88	24.0%	516	22.6%	1.386	0.033
Malignancy	20	5.6%	129	5.6%	-0.058	-0.003
Asthma	25	6.7%	111	4.9%	1.851	0.079
Hyperlipidemia	167	45.7%	993	43.6%	2.144	0.043
Depression	199	54.4%	1,126	49.4%	4.952	0.099
Schizophrenia	79	21.7%	495	21.7%	0.028	0.001
Bipolar disorder	61	16.7%	386	16.9%	-0.222	-0.006
ACE inhibitor use	87	23.8%	567	24.9%	-1.088	-0.025
ARB use	37	10.2%	279	12.3%	-2.050	-0.065
Beta-blocker use	148	40.5%	899	39.4%	1.027	0.021
Oral anticoagulant use	47	12.9%	247	10.8%	2.082	0.064
Antiplatelet agent use	44	12.2%	224	9.8%	2.350	0.075
Opioid use	118	32.2%	674	29.6%	2.664	0.058
Statin use	122	33.5%	678	29.8%	3.677	0.079
Wheelchair or walker use	22	6.0%	122	5.4%	0.648	0.028
Anti-arrhythmic use	*****	*****	63	2.7%	-0.254	-0.016
Antidiabetic use	59	16.1%	327	14.3%	1.808	0.050
Calcium channel blocker use	104	28.5%	657	28.8%	-0.360	-0.008
Diuretic use	136	37.1%	858	37.6%	-0.554	-0.011
Antidepressant use	240	65.7%	1,432	62.9%	2.841	0.059
Gastric acid suppressant use	141	38.6%	830	36.4%	2.192	0.045
NSAIDs	55	15.1%	308	13.5%	1.567	0.045

Table 1eb. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	128	35.0%	772	33.9%	1.133	0.024
Chronic liver disease	*****	*****	63	2.8%	-0.413	-0.026
Pneumonia	56	15.3%	345	15.2%	0.120	0.003
Cardiac arrhythmia	65	17.9%	346	15.2%	2.677	0.072
Paliperidone palmitate	365	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	*****	*****	0.528	0.090
Haloperidol decanoate	0	0.0%	2,279	100.0%	NaN	NaN
IS Stay	40	10.9%	254	11.2%	-0.262	-0.008
Medical Product Use						
Mean number of filled prescriptions	40.3	28.8	39.5	28.6	0.866	0.030
Mean number of generics dispensed	12.1	5.7	11.5	5.6	0.577	0.102
Mean number of unique drug classes dispensed	11.2	5.1	10.4	4.9	0.844	0.168
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	8.6	9.3	8.2	10.4	0.402	0.041
Mean number of inpatient hospital encounters	0.4	0.7	0.4	0.8	-0.023	-0.030
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	0.038	0.032

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1ec. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	82,723	100.0%	58,552	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	50.7	15.8	-5.348	-0.362
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	7.798	0.185
35-44 years	*****	*****	*****	*****	5.036	0.124
45-54 years	19,292	23.3%	13,809	23.6%	-0.263	-0.006
55-64 years	14,218	17.2%	11,251	19.2%	-2.028	-0.053
65-74 years	5,846	7.1%	7,099	12.1%	-5.057	-0.172
75-84 years	1,138	1.4%	2,745	4.7%	-3.312	-0.194
≥ 85 years	213	0.3%	1,423	2.4%	-2.173	-0.190
Sex						
Female	33,461	40.4%	24,083	41.1%	-0.682	-0.014
Male	49,262	59.6%	34,469	58.9%	0.682	0.014
Race[2]						
American Indian or Alaska Native	1,001	1.2%	518	0.9%	0.325	0.032
Asian	1,885	2.3%	1,202	2.1%	0.226	0.016
Black or African American	21,339	25.8%	21,702	37.1%	-11.269	-0.245
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,924	8.4%	4,347	7.4%	0.946	0.035
White	51,574	62.3%	30,783	52.6%	9.772	0.199
Hispanic origin						
Yes	4,311	5.2%	2,955	5.0%	0.165	0.007
No	75,799	91.6%	54,205	92.6%	-0.946	-0.035
Unknown	2,613	3.2%	1,392	2.4%	0.781	0.048

Table 1ec. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,427	2.9%	5,050	8.6%	-5.691	-0.246
2011	6,044	7.3%	9,136	15.6%	-8.297	-0.263
2012	7,221	8.7%	7,322	12.5%	-3.776	-0.123
2013	7,434	9.0%	6,407	10.9%	-1.956	-0.065
2014	7,131	8.6%	5,290	9.0%	-0.414	-0.015
2015	7,635	9.2%	4,695	8.0%	1.211	0.043
2016	7,881	9.5%	4,279	7.3%	2.219	0.080
2017	8,039	9.7%	3,857	6.6%	3.131	0.115
2018	8,040	9.7%	3,386	5.8%	3.936	0.148
2019	7,412	9.0%	3,147	5.4%	3.585	0.139
2020	5,717	6.9%	2,508	4.3%	2.628	0.114
2021	5,288	6.4%	2,373	4.1%	2.340	0.105
2022	2,454	3.0%	1,102	1.9%	1.084	0.071
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.3	2.3	-0.253	-0.118
Substance abuse	29,275	35.4%	16,327	27.9%	7.505	0.162
Atrial fibrilation/flutter	1,424	1.7%	1,854	3.2%	-1.445	-0.094
Ischemic heart disease	5,891	7.1%	6,372	10.9%	-3.761	-0.132
Heart failure	3,171	3.8%	4,050	6.9%	-3.084	-0.137
Stroke	1,877	2.3%	2,306	3.9%	-1.669	-0.096
Diabetes	19,611	23.7%	16,781	28.7%	-4.953	-0.113
Hypertension	36,728	44.4%	30,367	51.9%	-7.465	-0.150
Rheumatic disease	409	0.5%	349	0.6%	-0.102	-0.014
Chronic kidney disease	8,997	10.9%	7,238	12.4%	-1.486	-0.046
Seizure disorder	9,170	11.1%	7,088	12.1%	-1.020	-0.032

Table 1ec. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	622	0.8%	559	1.0%	-0.203	-0.022
Dementia Diagnosis	6,002	7.3%	8,287	14.2%	-6.898	-0.225
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,262	1.5%	1,408	2.4%	-0.879	-0.063
COPD	12,764	15.4%	10,169	17.4%	-1.938	-0.052
Malignancy	2,603	3.1%	2,178	3.7%	-0.573	-0.031
Asthma	11,295	13.7%	6,811	11.6%	2.022	0.061
Hyperlipidemia	27,826	33.6%	20,810	35.5%	-1.903	-0.040
Depression	37,504	45.3%	22,555	38.5%	6.816	0.138
Schizophrenia	66,587	80.5%	47,252	80.7%	-0.207	-0.005
Bipolar disorder	38,633	46.7%	21,733	37.1%	9.584	0.195
ACE inhibitor use	13,498	16.3%	11,462	19.6%	-3.259	-0.085
ARB use	3,505	4.2%	3,121	5.3%	-1.093	-0.051
Beta-blocker use	15,754	19.0%	12,442	21.2%	-2.205	-0.055
Oral anticoagulant use	1,631	2.0%	1,528	2.6%	-0.638	-0.043
Antiplatelet agent use	1,145	1.4%	1,434	2.4%	-1.065	-0.078
Opioid use	15,752	19.0%	10,135	17.3%	1.732	0.045
Statin use	17,882	21.6%	14,085	24.1%	-2.439	-0.058
Wheelchair or walker use	207	0.3%	436	0.7%	-0.494	-0.070
Anti-arrhythmic use	281	0.3%	287	0.5%	-0.150	-0.023
Antidiabetic use	13,670	16.5%	10,958	18.7%	-2.190	-0.058
Calcium channel blocker use	8,637	10.4%	8,674	14.8%	-4.373	-0.132
Diuretic use	11,760	14.2%	10,628	18.2%	-3.935	-0.107
Antidepressant use	47,917	57.9%	28,524	48.7%	9.209	0.185
Gastric acid suppressant use	21,984	26.6%	15,204	26.0%	0.609	0.014
NSAIDs	18,024	21.8%	10,843	18.5%	3.270	0.082

Table 1ec. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,300	33.0%	16,377	28.0%	5.032	0.109
Chronic liver disease	5,218	6.3%	3,248	5.5%	0.761	0.032
Pneumonia	3,385	4.1%	3,340	5.7%	-1.612	-0.075
Cardiac arrhythmia	11,248	13.6%	7,281	12.4%	1.162	0.035
Paliperidone palmitate	82,723	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	68	0.1%	-0.094	-0.036
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	8,255	10.0%	6,389	10.9%	-0.933	-0.030
Medical Product Use						
Mean number of filled prescriptions	28.6	26.7	28.8	26.9	-0.240	-0.009
Mean number of generics dispensed	9.4	6.3	9.1	6.0	0.253	0.041
Mean number of unique drug classes dispensed	8.4	5.5	8.0	5.2	0.423	0.079
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.4	18.7	14.9	19.1	1.474	0.078
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.048	-0.051
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.029	-0.024

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ed. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	82,721	100.0%	58,551	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.4	13.6	50.7	15.8	-5.349	-0.362
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	7.799	0.186
35-44 years	*****	*****	*****	*****	5.036	0.124
45-54 years	19,292	23.3%	13,809	23.6%	-0.263	-0.006
55-64 years	14,218	17.2%	11,251	19.2%	-2.028	-0.053
65-74 years	5,846	7.1%	7,099	12.1%	-5.057	-0.172
75-84 years	1,137	1.4%	2,745	4.7%	-3.314	-0.194
≥ 85 years	213	0.3%	1,423	2.4%	-2.173	-0.190
Sex						
Female	33,459	40.4%	24,082	41.1%	-0.682	-0.014
Male	49,262	59.6%	34,469	58.9%	0.682	0.014
Race[2]						
American Indian or Alaska Native	1,001	1.2%	518	0.9%	0.325	0.032
Asian	1,885	2.3%	1,202	2.1%	0.226	0.016
Black or African American	21,339	25.8%	21,702	37.1%	-11.269	-0.245
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,924	8.4%	4,347	7.4%	0.946	0.035
White	51,572	62.3%	30,782	52.6%	9.772	0.199
Hispanic origin						
Yes	4,311	5.2%	2,955	5.0%	0.165	0.007
No	75,797	91.6%	54,204	92.6%	-0.946	-0.035
Unknown	2,613	3.2%	1,392	2.4%	0.781	0.048

Table 1ed. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,427	2.9%	5,050	8.6%	-5.691	-0.246
2011	6,044	7.3%	9,136	15.6%	-8.297	-0.263
2012	7,221	8.7%	7,322	12.5%	-3.776	-0.123
2013	7,434	9.0%	6,407	10.9%	-1.956	-0.065
2014	7,131	8.6%	5,290	9.0%	-0.414	-0.015
2015	7,635	9.2%	4,694	8.0%	1.213	0.043
2016	7,881	9.5%	4,279	7.3%	2.219	0.080
2017	8,039	9.7%	3,857	6.6%	3.131	0.115
2018	8,039	9.7%	3,386	5.8%	3.935	0.148
2019	7,411	9.0%	3,147	5.4%	3.584	0.139
2020	5,717	6.9%	2,508	4.3%	2.628	0.115
2021	5,288	6.4%	2,373	4.1%	2.340	0.105
2022	2,454	3.0%	1,102	1.9%	1.084	0.071
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.3	2.3	-0.253	-0.119
Substance abuse	29,274	35.4%	16,326	27.9%	7.505	0.162
Atrial fibrilation/flutter	1,423	1.7%	1,854	3.2%	-1.446	-0.094
Ischemic heart disease	5,891	7.1%	6,372	10.9%	-3.761	-0.132
Heart failure	3,170	3.8%	4,050	6.9%	-3.085	-0.137
Stroke	1,876	2.3%	2,306	3.9%	-1.671	-0.096
Diabetes	19,609	23.7%	16,781	28.7%	-4.955	-0.113
Hypertension	36,727	44.4%	30,366	51.9%	-7.464	-0.150
Rheumatic disease	408	0.5%	349	0.6%	-0.103	-0.014
Chronic kidney disease	8,995	10.9%	7,237	12.4%	-1.486	-0.046
Seizure disorder	9,170	11.1%	7,088	12.1%	-1.020	-0.032

Table 1ed. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	622	0.8%	559	1.0%	-0.203	-0.022
Dementia Diagnosis	6,001	7.3%	8,287	14.2%	-6.899	-0.225
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,262	1.5%	1,408	2.4%	-0.879	-0.063
COPD	12,763	15.4%	10,169	17.4%	-1.939	-0.052
Malignancy	2,603	3.1%	2,178	3.7%	-0.573	-0.031
Asthma	11,294	13.7%	6,810	11.6%	2.022	0.061
Hyperlipidemia	27,825	33.6%	20,810	35.5%	-1.904	-0.040
Depression	37,503	45.3%	22,554	38.5%	6.816	0.138
Schizophrenia	66,586	80.5%	47,251	80.7%	-0.206	-0.005
Bipolar disorder	38,632	46.7%	21,732	37.1%	9.585	0.195
ACE inhibitor use	13,498	16.3%	11,462	19.6%	-3.259	-0.085
ARB use	3,505	4.2%	3,121	5.3%	-1.093	-0.051
Beta-blocker use	15,752	19.0%	12,441	21.2%	-2.206	-0.055
Oral anticoagulant use	1,630	2.0%	1,528	2.6%	-0.639	-0.043
Antiplatelet agent use	1,145	1.4%	1,434	2.4%	-1.065	-0.078
Opioid use	15,751	19.0%	10,134	17.3%	1.733	0.045
Statin use	17,881	21.6%	14,085	24.1%	-2.440	-0.058
Wheelchair or walker use	206	0.2%	436	0.7%	-0.496	-0.071
Anti-arrhythmic use	281	0.3%	287	0.5%	-0.150	-0.023
Antidiabetic use	13,669	16.5%	10,958	18.7%	-2.191	-0.058
Calcium channel blocker use	8,637	10.4%	8,674	14.8%	-4.373	-0.132
Diuretic use	11,759	14.2%	10,628	18.2%	-3.936	-0.107
Antidepressant use	47,916	57.9%	28,523	48.7%	9.210	0.185
Gastric acid suppressant use	21,982	26.6%	15,203	26.0%	0.608	0.014
NSAIDs	18,023	21.8%	10,842	18.5%	3.271	0.082

Table 1ed. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	27,299	33.0%	16,376	28.0%	5.033	0.109
Chronic liver disease	5,217	6.3%	3,248	5.5%	0.759	0.032
Pneumonia	3,385	4.1%	3,340	5.7%	-1.612	-0.075
Cardiac arrhythmia	11,247	13.6%	7,281	12.4%	1.161	0.035
Paliperidone palmitate	82,721	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	68	0.1%	-0.094	-0.036
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	8,255	10.0%	6,389	10.9%	-0.933	-0.030
Medical Product Use						
Mean number of filled prescriptions	28.6	26.7	28.8	26.9	-0.239	-0.009
Mean number of generics dispensed	9.4	6.3	9.1	6.0	0.253	0.041
Mean number of unique drug classes dispensed	8.4	5.5	8.0	5.2	0.423	0.079
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	16.4	18.7	14.9	19.1	1.475	0.078
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.048	-0.052
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.029	-0.024

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ee. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	82,540	N/A	58,757	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	47.4	14.2	47.3	15.1	0.033	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	*****	*****	*****	*****	-1.788	-0.042
35-44 years	*****	*****	*****	*****	0.433	0.011
45-54 years	19,249	23.3%	13,718	23.3%	-0.026	-0.001
55-64 years	15,895	19.3%	9,712	16.5%	2.728	0.071
65-74 years	7,724	9.4%	5,298	9.0%	0.340	0.012
75-84 years	1,864	2.3%	1,781	3.0%	-0.773	-0.048
≥ 85 years	420	0.5%	836	1.4%	-0.914	-0.094
Sex						
Female	33,533	40.6%	23,883	40.6%	-0.021	-0.000
Male	49,007	59.4%	34,874	59.4%	0.021	0.000
Race[3]						
American Indian or Alaska Native	966	1.2%	571	1.0%	0.199	0.019
Asian	1,909	2.3%	1,223	2.1%	0.231	0.016
Black or African American	22,039	26.7%	21,088	35.9%	-9.189	-0.199
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,541	7.9%	4,760	8.1%	-0.178	-0.007
White	51,085	61.9%	31,115	53.0%	8.936	0.181
Hispanic origin						
Yes	4,130	5.0%	3,211	5.5%	-0.462	-0.021
No	75,999	92.1%	53,996	91.9%	0.178	0.007
Unknown	2,411	2.9%	1,549	2.6%	0.284	0.017

Table 1ee. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Year						
2010	2,441	3.0%	4,888	8.3%	-5.361	-0.234
2011	6,041	7.3%	8,858	15.1%	-7.757	-0.248
2012	7,256	8.8%	7,184	12.2%	-3.435	-0.112
2013	7,338	8.9%	6,534	11.1%	-2.230	-0.074
2014	7,025	8.5%	5,460	9.3%	-0.782	-0.027
2015	7,534	9.1%	4,824	8.2%	0.917	0.033
2016	7,823	9.5%	4,398	7.5%	1.992	0.072
2017	8,033	9.7%	3,906	6.6%	3.086	0.113
2018	7,968	9.7%	3,455	5.9%	3.773	0.141
2019	7,439	9.0%	3,204	5.5%	3.561	0.138
2020	5,783	7.0%	2,555	4.3%	2.658	0.115
2021	5,340	6.5%	2,402	4.1%	2.382	0.107
2022	2,517	3.0%	1,088	1.9%	1.197	0.077
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.2	2.1	2.2	2.1	-0.007	-0.003
Substance abuse	26,904	32.6%	19,322	32.9%	-0.289	-0.006
Atrial fibrilation/flutter	1,855	2.2%	1,344	2.3%	-0.040	-0.003
Ischemic heart disease	7,103	8.6%	5,072	8.6%	-0.026	-0.001
Heart failure	4,181	5.1%	2,993	5.1%	-0.029	-0.001
Stroke	2,395	2.9%	1,717	2.9%	-0.020	-0.001
Diabetes	21,287	25.8%	15,134	25.8%	0.033	0.001
Hypertension	39,196	47.5%	27,925	47.5%	-0.038	-0.001
Rheumatic disease	430	0.5%	313	0.5%	-0.012	-0.002
Chronic kidney disease	9,489	11.5%	6,765	11.5%	-0.018	-0.001
Seizure disorder	9,510	11.5%	6,784	11.5%	-0.024	-0.001

Table 1ee. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	683	0.8%	488	0.8%	-0.003	-0.000
Dementia Diagnosis	8,177	9.9%	5,865	10.0%	-0.075	-0.003
Dementia Diagnosis and Treatment	0	0.0%	0	0.0%	NaN	NaN
Parkinsons disease	1,563	1.9%	1,115	1.9%	-0.004	-0.000
COPD	13,424	16.3%	9,550	16.3%	0.010	0.000
Malignancy	2,776	3.4%	1,984	3.4%	-0.013	-0.001
Asthma	10,618	12.9%	7,618	13.0%	-0.101	-0.003
Hyperlipidemia	28,518	34.6%	20,309	34.6%	-0.014	-0.000
Depression	35,241	42.7%	25,149	42.8%	-0.106	-0.002
Schizophrenia	67,099	81.3%	47,860	81.5%	-0.161	-0.004
Bipolar disorder	35,541	43.1%	25,412	43.3%	-0.191	-0.004
ACE inhibitor use	14,549	17.6%	10,333	17.6%	0.041	0.001
ARB use	3,848	4.7%	2,729	4.6%	0.017	0.001
Beta-blocker use	16,387	19.9%	11,676	19.9%	-0.017	-0.000
Oral anticoagulant use	1,807	2.2%	1,304	2.2%	-0.030	-0.002
Antiplatelet agent use	1,475	1.8%	1,059	1.8%	-0.015	-0.001
Opioid use	15,015	18.2%	10,690	18.2%	-0.003	-0.000
Statin use	18,677	22.6%	13,253	22.6%	0.073	0.002
Wheelchair or walker use	394	0.5%	270	0.5%	0.018	0.003
Anti-arrhythmic use	319	0.4%	228	0.4%	-0.001	-0.000
Antidiabetic use	14,341	17.4%	10,190	17.3%	0.032	0.001
Calcium channel blocker use	10,096	12.2%	7,168	12.2%	0.032	0.001
Diuretic use	12,990	15.7%	9,218	15.7%	0.049	0.001
Antidepressant use	44,623	54.1%	31,849	54.2%	-0.143	-0.003
Gastric acid suppressant use	21,678	26.3%	15,445	26.3%	-0.023	-0.001
NSAIDs	16,893	20.5%	12,034	20.5%	-0.014	-0.000

Table 1ee. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	25,508	30.9%	18,236	31.0%	-0.132	-0.003
Chronic liver disease	4,985	6.0%	3,584	6.1%	-0.060	-0.003
Pneumonia	3,914	4.7%	2,783	4.7%	0.006	0.000
Cardiac arrhythmia	10,912	13.2%	7,878	13.4%	-0.188	-0.006
Paliperidone palmitate	82,540	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	18	0.0%	73	0.1%	-0.102	-0.038
Haloperidol decanoate	0	0.0%	*****	*****	NaN	NaN
IS Stay	8,707	10.5%	6,205	10.6%	-0.012	-0.000
Medical Product Use						
Mean number of filled prescriptions	28.3	26.8	29.0	26.8	-0.750	-0.028
Mean number of generics dispensed	9.2	6.3	9.3	6.1	-0.086	-0.014
Mean number of unique drug classes dispensed	8.3	5.5	8.1	5.3	0.141	0.026
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.4	16.0	20.0	-0.084	-0.004
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.9	1.2	0.9	1.2	-0.006	-0.005

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1ef. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,675	100.0%	3,932	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.3	10.9	76.4	10.6	-6.167	-0.575
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.410	0.071
35-44 years	*****	*****	*****	*****	0.762	0.085
45-54 years	94	5.6%	85	2.2%	3.450	0.179
55-64 years	356	21.3%	419	10.7%	10.598	0.292
65-74 years	666	39.8%	1,145	29.1%	10.641	0.225
75-84 years	371	22.1%	1,393	35.4%	-13.278	-0.296
≥ 85 years	159	9.5%	868	22.1%	-12.583	-0.350
Sex						
Female	973	58.1%	2,305	58.6%	-0.532	-0.011
Male	702	41.9%	1,627	41.4%	0.532	0.011
Race[2]						
American Indian or Alaska Native	16	1.0%	12	0.3%	0.650	0.082
Asian	29	1.7%	49	1.2%	0.485	0.040
Black or African American	329	19.6%	902	22.9%	-3.298	-0.081
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	88	5.3%	159	4.0%	1.210	0.057
White	1,213	72.4%	2,810	71.5%	0.953	0.021
Hispanic origin						
Yes	67	4.0%	119	3.0%	0.974	0.053
No	1,587	94.7%	3,773	96.0%	-1.210	-0.057
Unknown	21	1.3%	40	1.0%	0.236	0.022

Table 1ef. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	219	5.6%	-3.182	-0.163
2011	69	4.1%	456	11.6%	-7.478	-0.281
2012	126	7.5%	403	10.2%	-2.727	-0.096
2013	138	8.2%	414	10.5%	-2.290	-0.079
2014	153	9.1%	394	10.0%	-0.886	-0.030
2015	172	10.3%	338	8.6%	1.673	0.057
2016	163	9.7%	349	8.9%	0.855	0.029
2017	185	11.0%	316	8.0%	3.008	0.103
2018	153	9.1%	286	7.3%	1.861	0.068
2019	168	10.0%	263	6.7%	3.341	0.121
2020	130	7.8%	189	4.8%	2.954	0.122
2021	123	7.3%	214	5.4%	1.901	0.078
2022	55	3.3%	91	2.3%	0.969	0.059
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.6	5.2	2.9	-0.037	-0.013
Substance abuse	264	15.8%	401	10.2%	5.563	0.166
Atrial fibrilation/flutter	187	11.2%	540	13.7%	-2.569	-0.078
Ischemic heart disease	441	26.3%	1,272	32.3%	-6.022	-0.133
Heart failure	315	18.8%	881	22.4%	-3.600	-0.089
Stroke	224	13.4%	631	16.0%	-2.675	-0.076
Diabetes	740	44.2%	1,650	42.0%	2.216	0.045
Hypertension	1,412	84.3%	3,336	84.8%	-0.544	-0.015
Rheumatic disease	17	1.0%	65	1.7%	-0.638	-0.056
Chronic kidney disease	517	30.9%	1,176	29.9%	0.957	0.021
Seizure disorder	361	21.6%	753	19.2%	2.402	0.060

Table 1ef. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,675	100.0%	3,932	100.0%	0.000	NaN
Dementia Diagnosis	1,675	100.0%	3,932	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,675	100.0%	3,932	100.0%	0.000	NaN
Parkinsons disease	213	12.7%	392	10.0%	2.747	0.087
COPD	496	29.6%	1,088	27.7%	1.942	0.043
Malignancy	86	5.1%	230	5.8%	-0.715	-0.031
Asthma	154	9.2%	265	6.7%	2.454	0.091
Hyperlipidemia	1,017	60.7%	2,177	55.4%	5.350	0.109
Depression	1,129	67.4%	2,306	58.6%	8.756	0.182
Schizophrenia	1,119	66.8%	1,549	39.4%	27.411	0.571
Bipolar disorder	766	45.7%	1,208	30.7%	15.009	0.313
ACE inhibitor use	511	30.5%	1,187	30.2%	0.319	0.007
ARB use	181	10.8%	454	11.5%	-0.740	-0.023
Beta-blocker use	619	37.0%	1,496	38.0%	-1.092	-0.023
Oral anticoagulant use	134	8.0%	336	8.5%	-0.545	-0.020
Antiplatelet agent use	150	9.0%	397	10.1%	-1.141	-0.039
Opioid use	403	24.1%	1,068	27.2%	-3.102	-0.071
Statin use	757	45.2%	1,642	41.8%	3.434	0.069
Wheelchair or walker use	48	2.9%	163	4.1%	-1.280	-0.070
Anti-arrhythmic use	28	1.7%	98	2.5%	-0.821	-0.058
Antidiabetic use	448	26.7%	971	24.7%	2.051	0.047
Calcium channel blocker use	466	27.8%	1,170	29.8%	-1.935	-0.043
Diuretic use	585	34.9%	1,348	34.3%	0.643	0.014
Antidepressant use	1,272	75.9%	2,848	72.4%	3.509	0.080
Gastric acid suppressant use	657	39.2%	1,543	39.2%	-0.018	-0.000
NSAIDs	345	20.6%	607	15.4%	5.160	0.135

Table 1ef. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	779	46.5%	1,626	41.4%	5.154	0.104
Chronic liver disease	112	6.7%	233	5.9%	0.761	0.031
Pneumonia	233	13.9%	563	14.3%	-0.408	-0.012
Cardiac arrhythmia	326	19.5%	674	17.1%	2.321	0.060
Paliperidone palmitate	1,675	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	3,932	100.0%	NaN	NaN
IS Stay	303	18.1%	573	14.6%	3.517	0.095
Medical Product Use						
Mean number of filled prescriptions	51.2	35.4	48.5	32.3	2.643	0.078
Mean number of generics dispensed	14.7	6.2	13.9	5.7	0.805	0.135
Mean number of unique drug classes dispensed	13.3	5.4	12.4	4.9	0.940	0.182
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	18.0	19.0	12.2	15.4	5.725	0.331
Mean number of inpatient hospital encounters	0.5	0.9	0.6	1.0	-0.084	-0.090
Mean number of non-acute institutional encounters	1.4	1.5	1.2	1.5	0.278	0.190

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1eg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	1,670	99.7%	3,929	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	70.3	10.9	76.4	10.5	-6.131	-0.572
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	*****	*****	*****	*****	0.412	0.071
35-44 years	*****	*****	*****	*****	0.765	0.085
45-54 years	91	5.4%	85	2.2%	3.286	0.172
55-64 years	355	21.3%	419	10.7%	10.593	0.292
65-74 years	666	39.9%	1,144	29.1%	10.763	0.228
75-84 years	370	22.2%	1,392	35.4%	-13.273	-0.296
≥ 85 years	159	9.5%	867	22.1%	-12.546	-0.349
Sex						
Female	972	58.2%	2,303	58.6%	-0.412	-0.008
Male	698	41.8%	1,626	41.4%	0.412	0.008
Race[2]						
American Indian or Alaska Native	16	1.0%	12	0.3%	0.653	0.082
Asian	29	1.7%	49	1.2%	0.489	0.040
Black or African American	327	19.6%	900	22.9%	-3.326	-0.081
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	88	5.3%	159	4.0%	1.223	0.058
White	1,210	72.5%	2,809	71.5%	0.961	0.021
Hispanic origin						
Yes	67	4.0%	119	3.0%	0.983	0.053
No	1,582	94.7%	3,770	96.0%	-1.223	-0.058
Unknown	21	1.3%	40	1.0%	0.239	0.023

Table 1eg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	40	2.4%	219	5.6%	-3.179	-0.163
2011	69	4.1%	456	11.6%	-7.474	-0.280
2012	126	7.5%	403	10.3%	-2.712	-0.095
2013	138	8.3%	414	10.5%	-2.274	-0.078
2014	152	9.1%	391	10.0%	-0.850	-0.029
2015	172	10.3%	338	8.6%	1.697	0.058
2016	162	9.7%	349	8.9%	0.818	0.028
2017	184	11.0%	316	8.0%	2.975	0.101
2018	153	9.2%	286	7.3%	1.882	0.069
2019	167	10.0%	263	6.7%	3.306	0.120
2020	130	7.8%	189	4.8%	2.974	0.123
2021	123	7.4%	214	5.4%	1.919	0.078
2022	54	3.2%	91	2.3%	0.917	0.056
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	5.2	2.6	5.2	2.9	-0.033	-0.012
Substance abuse	262	15.7%	400	10.2%	5.508	0.165
Atrial fibrilation/flutter	186	11.1%	540	13.7%	-2.606	-0.079
Ischemic heart disease	440	26.3%	1,270	32.3%	-5.976	-0.132
Heart failure	314	18.8%	880	22.4%	-3.595	-0.089
Stroke	222	13.3%	629	16.0%	-2.716	-0.077
Diabetes	737	44.1%	1,649	42.0%	2.162	0.044
Hypertension	1,408	84.3%	3,333	84.8%	-0.519	-0.014
Rheumatic disease	16	1.0%	64	1.6%	-0.671	-0.059
Chronic kidney disease	514	30.8%	1,173	29.9%	0.924	0.020
Seizure disorder	361	21.6%	752	19.1%	2.477	0.062

Table 1eg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,670	100.0%	3,929	100.0%	0.000	NaN
Dementia Diagnosis	1,670	100.0%	3,929	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,670	100.0%	3,929	100.0%	0.000	NaN
Parkinsons disease	213	12.8%	392	10.0%	2.777	0.088
COPD	494	29.6%	1,086	27.6%	1.940	0.043
Malignancy	86	5.1%	230	5.9%	-0.704	-0.031
Asthma	153	9.2%	265	6.7%	2.417	0.089
Hyperlipidemia	1,012	60.6%	2,175	55.4%	5.241	0.106
Depression	1,126	67.4%	2,305	58.7%	8.759	0.182
Schizophrenia	1,115	66.8%	1,548	39.4%	27.367	0.570
Bipolar disorder	762	45.6%	1,207	30.7%	14.908	0.311
ACE inhibitor use	508	30.4%	1,185	30.2%	0.259	0.006
ARB use	180	10.8%	454	11.6%	-0.777	-0.025
Beta-blocker use	616	36.9%	1,494	38.0%	-1.139	-0.024
Oral anticoagulant use	133	8.0%	335	8.5%	-0.562	-0.020
Antiplatelet agent use	150	9.0%	397	10.1%	-1.122	-0.038
Opioid use	403	24.1%	1,067	27.2%	-3.025	-0.069
Statin use	754	45.1%	1,642	41.8%	3.358	0.068
Wheelchair or walker use	48	2.9%	163	4.1%	-1.274	-0.069
Anti-arrhythmic use	28	1.7%	98	2.5%	-0.818	-0.057
Antidiabetic use	446	26.7%	971	24.7%	1.993	0.046
Calcium channel blocker use	464	27.8%	1,169	29.8%	-1.969	-0.043
Diuretic use	583	34.9%	1,348	34.3%	0.601	0.013
Antidepressant use	1,268	75.9%	2,846	72.4%	3.492	0.080
Gastric acid suppressant use	655	39.2%	1,541	39.2%	0.000	0.000
NSAIDs	341	20.4%	607	15.4%	4.970	0.130

Table 1eg. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	776	46.5%	1,624	41.3%	5.133	0.104
Chronic liver disease	110	6.6%	232	5.9%	0.682	0.028
Pneumonia	232	13.9%	561	14.3%	-0.386	-0.011
Cardiac arrhythmia	323	19.3%	672	17.1%	2.238	0.058
Paliperidone palmitate	1,670	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	3,929	100.0%	NaN	NaN
IS Stay	301	18.0%	572	14.6%	3.466	0.094
Medical Product Use						
Mean number of filled prescriptions	51.1	35.4	48.5	32.3	2.564	0.076
Mean number of generics dispensed	14.7	6.2	13.9	5.7	0.794	0.133
Mean number of unique drug classes dispensed	13.3	5.4	12.4	4.9	0.935	0.181
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	17.7	18.5	12.2	15.4	5.527	0.325
Mean number of inpatient hospital encounters	0.5	0.9	0.6	1.0	-0.080	-0.087
Mean number of non-acute institutional encounters	1.4	1.5	1.2	1.5	0.279	0.190

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1eh. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	1,662	N/A	3,947	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	74.5	11.0	74.5	11.2	0.027	0.002
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	*****	*****	16	0.4%	-0.186	-0.033
35-44 years	*****	*****	29	0.7%	-0.157	-0.019
45-54 years	54	3.3%	125	3.2%	0.093	0.005
55-64 years	231	13.9%	560	14.2%	-0.277	-0.008
65-74 years	560	33.7%	1,235	31.3%	2.438	0.052
75-84 years	487	29.3%	1,271	32.2%	-2.871	-0.062
≥ 85 years	316	19.0%	712	18.0%	0.961	0.025
Sex						
Female	950	57.2%	2,303	58.4%	-1.208	-0.024
Male	712	42.8%	1,644	41.6%	1.208	0.024
Race[3]						
American Indian or Alaska Native	16	1.0%	12	0.3%	0.667	0.084
Asian	21	1.2%	48	1.2%	0.018	0.002
Black or African American	310	18.6%	956	24.2%	-5.588	-0.136
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	86	5.2%	163	4.1%	1.062	0.050
White	1,229	74.0%	2,768	70.1%	3.841	0.086
Hispanic origin						
Yes	63	3.8%	121	3.1%	0.744	0.041
No	1,575	94.8%	3,784	95.9%	-1.062	-0.050
Unknown	23	1.4%	43	1.1%	0.318	0.029

Table 1eh. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	44	2.6%	212	5.4%	-2.725	-0.139
2011	75	4.5%	454	11.5%	-7.010	-0.261
2012	119	7.2%	395	10.0%	-2.846	-0.102
2013	160	9.6%	412	10.4%	-0.809	-0.027
2014	152	9.1%	385	9.8%	-0.601	-0.021
2015	184	11.1%	340	8.6%	2.480	0.083
2016	148	8.9%	358	9.1%	-0.136	-0.005
2017	191	11.5%	325	8.2%	3.262	0.110
2018	146	8.8%	290	7.4%	1.459	0.054
2019	155	9.3%	274	6.9%	2.365	0.087
2020	123	7.4%	188	4.8%	2.656	0.111
2021	112	6.8%	219	5.6%	1.207	0.050
2022	52	3.1%	97	2.4%	0.696	0.042
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	5.3	2.7	5.2	2.8	0.059	0.021
Substance abuse	206	12.4%	472	12.0%	0.445	0.014
Atrial fibrilation/flutter	223	13.4%	515	13.0%	0.349	0.010
Ischemic heart disease	523	31.4%	1,205	30.5%	0.919	0.020
Heart failure	371	22.4%	853	21.6%	0.744	0.018
Stroke	267	16.1%	604	15.3%	0.788	0.022
Diabetes	705	42.4%	1,685	42.7%	-0.288	-0.006
Hypertension	1,420	85.4%	3,352	84.9%	0.510	0.014
Rheumatic disease	22	1.3%	57	1.4%	-0.098	-0.008
Chronic kidney disease	500	30.1%	1,185	30.0%	0.070	0.002
Seizure disorder	358	21.5%	797	20.2%	1.348	0.033

Table 1eh. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	1,662	100.0%	3,947	100.0%	0.000	NaN
Dementia Diagnosis	1,662	100.0%	3,947	100.0%	0.000	NaN
Dementia Diagnosis and Treatment	1,662	100.0%	3,947	100.0%	0.000	NaN
Parkinsons disease	178	10.7%	431	10.9%	-0.212	-0.007
COPD	475	28.6%	1,117	28.3%	0.303	0.007
Malignancy	94	5.7%	223	5.6%	0.014	0.001
Asthma	140	8.4%	304	7.7%	0.706	0.026
Hyperlipidemia	939	56.5%	2,247	56.9%	-0.420	-0.008
Depression	1,030	62.0%	2,434	61.7%	0.307	0.006
Schizophrenia	795	47.9%	1,888	47.8%	0.026	0.001
Bipolar disorder	606	36.4%	1,410	35.7%	0.706	0.015
ACE inhibitor use	516	31.1%	1,189	30.1%	0.947	0.021
ARB use	180	10.8%	446	11.3%	-0.452	-0.014
Beta-blocker use	645	38.8%	1,494	37.8%	0.971	0.020
Oral anticoagulant use	148	8.9%	334	8.5%	0.448	0.016
Antiplatelet agent use	179	10.8%	387	9.8%	0.997	0.033
Opioid use	432	26.0%	1,038	26.3%	-0.316	-0.007
Statin use	721	43.4%	1,697	43.0%	0.415	0.008
Wheelchair or walker use	62	3.7%	148	3.8%	-0.029	-0.002
Anti-arrhythmic use	41	2.5%	91	2.3%	0.170	0.011
Antidiabetic use	414	24.9%	998	25.3%	-0.354	-0.008
Calcium channel blocker use	499	30.1%	1,158	29.3%	0.719	0.016
Diuretic use	563	33.9%	1,363	34.5%	-0.676	-0.014
Antidepressant use	1,218	73.3%	2,898	73.4%	-0.134	-0.003
Gastric acid suppressant use	658	39.6%	1,557	39.5%	0.116	0.002
NSAIDs	272	16.4%	674	17.1%	-0.681	-0.018

Table 1eh. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	705	42.4%	1,690	42.8%	-0.369	-0.007
Chronic liver disease	98	5.9%	248	6.3%	-0.363	-0.015
Pneumonia	238	14.3%	559	14.2%	0.159	0.005
Cardiac arrhythmia	301	18.1%	711	18.0%	0.122	0.003
Paliperidone palmitate	1,662	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	0	0.0%	*****	*****	NaN	NaN
Haloperidol decanoate	0	0.0%	3,947	100.0%	NaN	NaN
IS Stay	293	17.6%	637	16.1%	1.473	0.039
Medical Product Use						
Mean number of filled prescriptions	49.1	34.3	49.4	32.8	-0.245	-0.007
Mean number of generics dispensed	14.2	6.1	14.1	5.8	0.089	0.015
Mean number of unique drug classes dispensed	12.9	5.3	12.6	5.0	0.393	0.077
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	14.4	15.4	14.4	19.0	0.005	0.000
Mean number of inpatient hospital encounters	0.6	1.0	0.6	0.9	0.030	0.031
Mean number of non-acute institutional encounters	1.3	1.5	1.3	1.5	0.085	0.057

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1ei. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	75,840	100.0%	55,522	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.9	52.2	16.8	-6.623	-0.431
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	20,407	26.9%	10,071	18.1%	8.769	0.211
35-44 years	17,823	23.5%	9,817	17.7%	5.820	0.144
45-54 years	17,577	23.2%	12,479	22.5%	0.701	0.017
55-64 years	12,898	17.0%	10,298	18.5%	-1.541	-0.040
65-74 years	5,572	7.3%	7,156	12.9%	-5.542	-0.185
75-84 years	1,251	1.6%	3,644	6.6%	-4.914	-0.250
≥ 85 years	312	0.4%	2,057	3.7%	-3.293	-0.234
Sex						
Female	30,706	40.5%	23,389	42.1%	-1.638	-0.033
Male	45,134	59.5%	32,133	57.9%	1.638	0.033
Race[2]						
American Indian or Alaska Native	913	1.2%	475	0.9%	0.348	0.035
Asian	1,736	2.3%	1,104	2.0%	0.301	0.021
Black or African American	19,575	25.8%	20,465	36.9%	-11.048	-0.240
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,390	8.4%	4,003	7.2%	1.216	0.045
White	47,226	62.3%	29,475	53.1%	9.184	0.187
Hispanic origin						
Yes	3,991	5.3%	2,748	4.9%	0.313	0.014
No	69,450	91.6%	51,519	92.8%	-1.216	-0.045
Unknown	2,399	3.2%	1,255	2.3%	0.903	0.056

Table 1ei. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	2,266	3.0%	4,855	8.7%	-5.756	-0.247
2011	5,627	7.4%	8,648	15.6%	-8.156	-0.258
2012	6,646	8.8%	6,893	12.4%	-3.652	-0.119
2013	6,800	9.0%	6,072	10.9%	-1.970	-0.066
2014	6,510	8.6%	4,971	9.0%	-0.369	-0.013
2015	7,025	9.3%	4,426	8.0%	1.291	0.046
2016	7,255	9.6%	4,069	7.3%	2.238	0.081
2017	7,385	9.7%	3,671	6.6%	3.126	0.114
2018	7,320	9.7%	3,215	5.8%	3.861	0.145
2019	6,797	9.0%	3,000	5.4%	3.559	0.138
2020	5,177	6.8%	2,362	4.3%	2.572	0.113
2021	4,781	6.3%	2,282	4.1%	2.194	0.099
2022	2,251	3.0%	1,058	1.9%	1.063	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.4	2.4	-0.361	-0.164
Substance abuse	25,769	34.0%	14,286	25.7%	8.248	0.181
Atrial fibrilation/flutter	1,358	1.8%	2,061	3.7%	-1.921	-0.118
Ischemic heart disease	5,374	7.1%	6,484	11.7%	-4.592	-0.158
Heart failure	2,937	3.9%	4,214	7.6%	-3.717	-0.160
Stroke	1,791	2.4%	2,529	4.6%	-2.193	-0.120
Diabetes	17,973	23.7%	16,123	29.0%	-5.340	-0.121
Hypertension	33,218	43.8%	29,321	52.8%	-9.010	-0.181
Rheumatic disease	360	0.5%	350	0.6%	-0.156	-0.021
Chronic kidney disease	8,198	10.8%	7,137	12.9%	-2.045	-0.063
Seizure disorder	8,218	10.8%	6,702	12.1%	-1.235	-0.039

Table 1ei. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,920	2.5%	3,861	7.0%	-4.422	-0.209
Dementia Diagnosis	6,283	8.3%	10,344	18.6%	-10.346	-0.307
Dementia Diagnosis and Treatment	1,372	1.8%	3,359	6.0%	-4.241	-0.220
Parkinsons disease	1,213	1.6%	1,516	2.7%	-1.131	-0.078
COPD	11,501	15.2%	9,657	17.4%	-2.228	-0.060
Malignancy	2,350	3.1%	2,074	3.7%	-0.637	-0.035
Asthma	9,983	13.2%	6,061	10.9%	2.247	0.069
Hyperlipidemia	25,337	33.4%	19,976	36.0%	-2.570	-0.054
Depression	33,757	44.5%	21,348	38.4%	6.061	0.123
Schizophrenia	60,133	79.3%	42,820	77.1%	2.167	0.053
Bipolar disorder	34,418	45.4%	19,556	35.2%	10.160	0.208
ACE inhibitor use	12,395	16.3%	11,149	20.1%	-3.737	-0.097
ARB use	3,287	4.3%	3,141	5.7%	-1.323	-0.061
Beta-blocker use	14,374	19.0%	12,119	21.8%	-2.874	-0.071
Oral anticoagulant use	1,544	2.0%	1,645	3.0%	-0.927	-0.059
Antiplatelet agent use	1,126	1.5%	1,603	2.9%	-1.402	-0.096
Opioid use	14,547	19.2%	10,009	18.0%	1.154	0.030
Statin use	16,568	21.8%	13,769	24.8%	-2.953	-0.070
Wheelchair or walker use	215	0.3%	540	1.0%	-0.689	-0.087
Anti-arrhythmic use	272	0.4%	345	0.6%	-0.263	-0.038
Antidiabetic use	12,633	16.7%	10,460	18.8%	-2.182	-0.057
Calcium channel blocker use	7,971	10.5%	8,664	15.6%	-5.094	-0.152
Diuretic use	10,941	14.4%	10,514	18.9%	-4.510	-0.121
Antidepressant use	44,122	58.2%	27,615	49.7%	8.441	0.170
Gastric acid suppressant use	20,095	26.5%	14,606	26.3%	0.190	0.004
NSAIDs	16,438	21.7%	10,132	18.2%	3.426	0.086

Table 1ei. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,778	32.7%	15,513	27.9%	4.731	0.103
Chronic liver disease	4,678	6.2%	3,016	5.4%	0.736	0.031
Pneumonia	3,084	4.1%	3,306	6.0%	-1.888	-0.087
Cardiac arrhythmia	9,763	12.9%	6,693	12.1%	0.818	0.025
Paliperidone palmitate	75,840	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	62	0.1%	-0.089	-0.034
Haloperidol decanoate	0	0.0%	55,522	100.0%	NaN	NaN
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.8	27.0	29.8	27.7	-0.922	-0.034
Mean number of generics dispensed	9.4	6.3	9.2	6.1	0.141	0.023
Mean number of unique drug classes dispensed	8.4	5.5	8.1	5.3	0.288	0.054
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.2	14.2	18.3	1.743	0.096
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.047	-0.051
Mean number of non-acute institutional encounters	0.7	1.1	0.8	1.2	-0.021	-0.018

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ej. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	75,837	100.0%	55,521	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	45.6	13.9	52.2	16.8	-6.622	-0.431
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	20,405	26.9%	10,071	18.1%	8.767	0.211
35-44 years	17,823	23.5%	9,817	17.7%	5.820	0.144
45-54 years	17,577	23.2%	12,479	22.5%	0.701	0.017
55-64 years	12,898	17.0%	10,298	18.5%	-1.540	-0.040
65-74 years	5,572	7.3%	7,155	12.9%	-5.540	-0.184
75-84 years	1,250	1.6%	3,644	6.6%	-4.915	-0.250
≥ 85 years	312	0.4%	2,057	3.7%	-3.293	-0.234
Sex						
Female	30,704	40.5%	23,389	42.1%	-1.640	-0.033
Male	45,133	59.5%	32,132	57.9%	1.640	0.033
Race[2]						
American Indian or Alaska Native	913	1.2%	475	0.9%	0.348	0.035
Asian	1,736	2.3%	1,104	2.0%	0.301	0.021
Black or African American	19,575	25.8%	20,464	36.9%	-11.046	-0.240
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	6,390	8.4%	4,003	7.2%	1.216	0.045
White	47,223	62.3%	29,475	53.1%	9.181	0.187
Hispanic origin						
Yes	3,991	5.3%	2,748	4.9%	0.313	0.014
No	69,447	91.6%	51,518	92.8%	-1.216	-0.045
Unknown	2,399	3.2%	1,255	2.3%	0.903	0.056

Table 1ej. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,266	3.0%	4,855	8.7%	-5.756	-0.247
2011	5,627	7.4%	8,648	15.6%	-8.156	-0.258
2012	6,646	8.8%	6,893	12.4%	-3.652	-0.119
2013	6,799	9.0%	6,071	10.9%	-1.969	-0.066
2014	6,510	8.6%	4,971	9.0%	-0.369	-0.013
2015	7,024	9.3%	4,426	8.0%	1.290	0.046
2016	7,255	9.6%	4,069	7.3%	2.238	0.081
2017	7,385	9.7%	3,671	6.6%	3.126	0.114
2018	7,320	9.7%	3,215	5.8%	3.862	0.145
2019	6,796	9.0%	3,000	5.4%	3.558	0.138
2020	5,177	6.8%	2,362	4.3%	2.572	0.113
2021	4,781	6.3%	2,282	4.1%	2.194	0.099
2022	2,251	3.0%	1,058	1.9%	1.063	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.1	1.9	2.4	2.4	-0.361	-0.164
Substance abuse	25,767	34.0%	14,286	25.7%	8.246	0.181
Atrial fibrilation/flutter	1,358	1.8%	2,060	3.7%	-1.920	-0.118
Ischemic heart disease	5,373	7.1%	6,483	11.7%	-4.592	-0.158
Heart failure	2,936	3.9%	4,213	7.6%	-3.717	-0.160
Stroke	1,791	2.4%	2,529	4.6%	-2.193	-0.120
Diabetes	17,971	23.7%	16,122	29.0%	-5.341	-0.121
Hypertension	33,217	43.8%	29,320	52.8%	-9.008	-0.181
Rheumatic disease	360	0.5%	350	0.6%	-0.156	-0.021
Chronic kidney disease	8,196	10.8%	7,137	12.9%	-2.047	-0.063
Seizure disorder	8,217	10.8%	6,701	12.1%	-1.234	-0.039

Table 1ej. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	1,919	2.5%	3,860	7.0%	-4.422	-0.209
Dementia Diagnosis	6,282	8.3%	10,343	18.6%	-10.345	-0.307
Dementia Diagnosis and Treatment	1,371	1.8%	3,358	6.0%	-4.240	-0.220
Parkinsons disease	1,213	1.6%	1,516	2.7%	-1.131	-0.078
COPD	11,499	15.2%	9,656	17.4%	-2.229	-0.060
Malignancy	2,350	3.1%	2,074	3.7%	-0.637	-0.035
Asthma	9,982	13.2%	6,060	10.9%	2.248	0.069
Hyperlipidemia	25,335	33.4%	19,976	36.0%	-2.572	-0.054
Depression	33,754	44.5%	21,348	38.5%	6.058	0.123
Schizophrenia	60,131	79.3%	42,819	77.1%	2.168	0.053
Bipolar disorder	34,416	45.4%	19,556	35.2%	10.159	0.208
ACE inhibitor use	12,395	16.3%	11,149	20.1%	-3.736	-0.097
ARB use	3,287	4.3%	3,141	5.7%	-1.323	-0.061
Beta-blocker use	14,373	19.0%	12,118	21.8%	-2.873	-0.071
Oral anticoagulant use	1,544	2.0%	1,645	3.0%	-0.927	-0.059
Antiplatelet agent use	1,125	1.5%	1,603	2.9%	-1.404	-0.096
Opioid use	14,546	19.2%	10,009	18.0%	1.153	0.030
Statin use	16,566	21.8%	13,769	24.8%	-2.955	-0.070
Wheelchair or walker use	214	0.3%	540	1.0%	-0.690	-0.088
Anti-arrhythmic use	272	0.4%	344	0.6%	-0.261	-0.037
Antidiabetic use	12,630	16.7%	10,459	18.8%	-2.184	-0.057
Calcium channel blocker use	7,971	10.5%	8,663	15.6%	-5.092	-0.152
Diuretic use	10,939	14.4%	10,513	18.9%	-4.511	-0.121
Antidepressant use	44,120	58.2%	27,615	49.7%	8.439	0.170
Gastric acid suppressant use	20,092	26.5%	14,606	26.3%	0.187	0.004
NSAIDs	16,437	21.7%	10,132	18.2%	3.425	0.086

Table 1ej. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	24,776	32.7%	15,513	27.9%	4.729	0.103
Chronic liver disease	4,676	6.2%	3,016	5.4%	0.734	0.031
Pneumonia	3,082	4.1%	3,305	6.0%	-1.889	-0.087
Cardiac arrhythmia	9,762	12.9%	6,692	12.1%	0.819	0.025
Paliperidone palmitate	75,837	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	62	0.1%	-0.089	-0.034
Haloperidol decanoate	0	0.0%	55,521	100.0%	NaN	NaN
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.8	27.0	29.8	27.7	-0.924	-0.034
Mean number of generics dispensed	9.4	6.3	9.2	6.1	0.141	0.023
Mean number of unique drug classes dispensed	8.4	5.5	8.1	5.3	0.288	0.053
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.9	18.2	14.2	18.3	1.742	0.096
Mean number of inpatient hospital encounters	0.4	0.9	0.4	1.0	-0.047	-0.050
Mean number of non-acute institutional encounters	0.7	1.1	0.8	1.2	-0.021	-0.018

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1ek. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	75,556	N/A	55,806	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.1	14.8	48.1	15.9	-0.000	-0.000
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	17,235	22.8%	13,824	24.8%	-1.961	-0.046
35-44 years	16,054	21.2%	11,669	20.9%	0.339	0.008
45-54 years	17,280	22.9%	12,667	22.7%	0.172	0.004
55-64 years	14,375	19.0%	8,963	16.1%	2.964	0.078
65-74 years	7,608	10.1%	5,250	9.4%	0.662	0.022
75-84 years	2,264	3.0%	2,266	4.1%	-1.064	-0.058
≥ 85 years	739	1.0%	1,167	2.1%	-1.113	-0.091
Sex						
Female	30,997	41.0%	22,925	41.1%	-0.055	-0.001
Male	44,559	59.0%	32,881	58.9%	0.055	0.001
Race[3]						
American Indian or Alaska Native	874	1.2%	538	1.0%	0.194	0.019
Asian	1,750	2.3%	1,138	2.0%	0.277	0.019
Black or African American	20,127	26.6%	20,121	36.1%	-9.416	-0.204
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	5,980	7.9%	4,459	8.0%	-0.075	-0.003
White	46,824	62.0%	29,551	53.0%	9.020	0.183
Hispanic origin						
Yes	3,796	5.0%	3,030	5.4%	-0.405	-0.018
No	69,576	92.1%	51,347	92.0%	0.075	0.003
Unknown	2,184	2.9%	1,429	2.6%	0.330	0.020

Table 1ek. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	2,275	3.0%	4,737	8.5%	-5.478	-0.237
2011	5,579	7.4%	8,449	15.1%	-7.756	-0.247
2012	6,640	8.8%	6,817	12.2%	-3.427	-0.112
2013	6,724	8.9%	6,213	11.1%	-2.234	-0.074
2014	6,404	8.5%	5,140	9.2%	-0.733	-0.026
2015	6,918	9.2%	4,552	8.2%	1.000	0.036
2016	7,164	9.5%	4,171	7.5%	2.009	0.072
2017	7,395	9.8%	3,700	6.6%	3.157	0.115
2018	7,247	9.6%	3,281	5.9%	3.713	0.139
2019	6,824	9.0%	3,030	5.4%	3.602	0.139
2020	5,239	6.9%	2,391	4.3%	2.651	0.115
2021	4,836	6.4%	2,286	4.1%	2.305	0.103
2022	2,310	3.1%	1,041	1.9%	1.193	0.077
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.2	2.2	2.2	2.2	-0.008	-0.004
Substance abuse	23,328	30.9%	17,404	31.2%	-0.311	-0.007
Atrial fibrilation/flutter	1,923	2.5%	1,433	2.6%	-0.023	-0.001
Ischemic heart disease	6,733	8.9%	4,997	9.0%	-0.042	-0.001
Heart failure	4,079	5.4%	3,023	5.4%	-0.020	-0.001
Stroke	2,443	3.2%	1,815	3.3%	-0.019	-0.001
Diabetes	19,632	26.0%	14,485	26.0%	0.027	0.001
Hypertension	35,950	47.6%	26,585	47.6%	-0.058	-0.001
Rheumatic disease	399	0.5%	294	0.5%	0.001	0.000
Chronic kidney disease	8,799	11.6%	6,519	11.7%	-0.035	-0.001
Seizure disorder	8,615	11.4%	6,361	11.4%	0.004	0.000

Table 1ek. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	3,241	4.3%	2,429	4.4%	-0.063	-0.003
Dementia Diagnosis	9,302	12.3%	6,958	12.5%	-0.157	-0.005
Dementia Diagnosis and Treatment	2,644	3.5%	1,986	3.6%	-0.059	-0.003
Parkinsons disease	1,568	2.1%	1,162	2.1%	-0.007	-0.001
COPD	12,209	16.2%	9,014	16.2%	0.007	0.000
Malignancy	2,522	3.3%	1,873	3.4%	-0.018	-0.001
Asthma	9,312	12.3%	6,931	12.4%	-0.096	-0.003
Hyperlipidemia	26,159	34.6%	19,323	34.6%	-0.003	-0.000
Depression	31,854	42.2%	23,599	42.3%	-0.127	-0.003
Schizophrenia	60,024	79.4%	44,343	79.5%	-0.015	-0.000
Bipolar disorder	31,385	41.5%	23,290	41.7%	-0.196	-0.004
ACE inhibitor use	13,530	17.9%	9,963	17.9%	0.053	0.001
ARB use	3,662	4.8%	2,699	4.8%	0.011	0.000
Beta-blocker use	15,142	20.0%	11,195	20.1%	-0.020	-0.001
Oral anticoagulant use	1,806	2.4%	1,339	2.4%	-0.010	-0.001
Antiplatelet agent use	1,537	2.0%	1,145	2.1%	-0.019	-0.001
Opioid use	13,981	18.5%	10,348	18.5%	-0.038	-0.001
Statin use	17,460	23.1%	12,845	23.0%	0.091	0.002
Wheelchair or walker use	442	0.6%	321	0.6%	0.010	0.001
Anti-arrhythmic use	336	0.4%	252	0.5%	-0.007	-0.001
Antidiabetic use	13,245	17.5%	9,763	17.5%	0.035	0.001
Calcium channel blocker use	9,558	12.7%	7,037	12.6%	0.041	0.001
Diuretic use	12,263	16.2%	9,034	16.2%	0.042	0.001
Antidepressant use	41,180	54.5%	30,542	54.7%	-0.226	-0.005
Gastric acid suppressant use	19,906	26.3%	14,728	26.4%	-0.045	-0.001
NSAIDs	15,347	20.3%	11,339	20.3%	-0.007	-0.000

Table 1ek. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	23,140	30.6%	17,192	30.8%	-0.180	-0.004
Chronic liver disease	4,460	5.9%	3,327	6.0%	-0.058	-0.002
Pneumonia	3,640	4.8%	2,702	4.8%	-0.023	-0.001
Cardiac arrhythmia	9,561	12.7%	7,159	12.8%	-0.175	-0.005
Paliperidone palmitate	75,556	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	68	0.1%	-0.099	-0.037
Haloperidol decanoate	0	0.0%	55,806	100.0%	NaN	NaN
IS Stay	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Mean number of filled prescriptions	28.8	27.3	29.5	27.3	-0.734	-0.027
Mean number of generics dispensed	9.3	6.3	9.3	6.1	-0.038	-0.006
Mean number of unique drug classes dispensed	8.3	5.5	8.2	5.3	0.163	0.030
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	15.4	17.7	15.5	19.4	-0.089	-0.005
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	-0.001	-0.001
Mean number of non-acute institutional encounters	0.8	1.2	0.8	1.2	-0.004	-0.003

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 1el. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,558	100.0%	6,962	100.0%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.1	14.9	53.2	16.7	-5.042	-0.318
Age	**Number**	**Percent[1]**	**Number**	**Percent[1]**		
18-34 years	2,030	23.7%	1,243	17.9%	5.866	0.145
35-44 years	1,785	20.9%	1,116	16.0%	4.828	0.125
45-54 years	1,809	21.1%	1,415	20.3%	0.813	0.020
55-64 years	1,676	19.6%	1,372	19.7%	-0.123	-0.003
65-74 years	940	11.0%	1,088	15.6%	-4.644	-0.137
75-84 years	258	3.0%	494	7.1%	-4.081	-0.187
≥ 85 years	60	0.7%	234	3.4%	-2.660	-0.189
Sex						
Female	3,728	43.6%	2,999	43.1%	0.485	0.010
Male	4,830	56.4%	3,963	56.9%	-0.485	-0.010
Race[2]						
American Indian or Alaska Native	104	1.2%	55	0.8%	0.425	0.043
Asian	178	2.1%	147	2.1%	-0.032	-0.002
Black or African American	2,093	24.5%	2,139	30.7%	-6.267	-0.141
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	622	7.3%	503	7.2%	0.043	0.002
White	5,561	65.0%	4,118	59.1%	5.830	0.120
Hispanic origin						
Yes	387	4.5%	326	4.7%	-0.160	-0.008
No	7,936	92.7%	6,459	92.8%	-0.043	-0.002
Unknown	235	2.7%	177	2.5%	0.204	0.013

Table 1el. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Year						
2010	201	2.3%	414	5.9%	-3.598	-0.181
2011	486	5.7%	944	13.6%	-7.880	-0.270
2012	701	8.2%	832	12.0%	-3.759	-0.125
2013	772	9.0%	749	10.8%	-1.738	-0.058
2014	774	9.0%	713	10.2%	-1.197	-0.041
2015	782	9.1%	607	8.7%	0.419	0.015
2016	789	9.2%	559	8.0%	1.190	0.042
2017	839	9.8%	502	7.2%	2.593	0.093
2018	873	10.2%	457	6.6%	3.637	0.132
2019	783	9.1%	410	5.9%	3.260	0.124
2020	670	7.8%	335	4.8%	3.017	0.124
2021	630	7.4%	305	4.4%	2.981	0.127
2022	258	3.0%	135	1.9%	1.076	0.069
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.2	2.7	-0.411	-0.166
Substance abuse	3,770	44.1%	2,442	35.1%	8.976	0.184
Atrial fibrilation/flutter	253	3.0%	333	4.8%	-1.827	-0.095
Ischemic heart disease	958	11.2%	1,160	16.7%	-5.468	-0.158
Heart failure	549	6.4%	717	10.3%	-3.884	-0.141
Stroke	310	3.6%	408	5.9%	-2.238	-0.105
Diabetes	2,378	27.8%	2,308	33.2%	-5.365	-0.117
Hypertension	4,922	57.5%	4,382	62.9%	-5.428	-0.111
Rheumatic disease	66	0.8%	64	0.9%	-0.148	-0.016
Chronic kidney disease	1,316	15.4%	1,277	18.3%	-2.965	-0.079
Seizure disorder	1,313	15.3%	1,139	16.4%	-1.018	-0.028

Table 1el. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	377	4.4%	630	9.0%	-4.644	-0.186
Dementia Diagnosis	1,394	16.3%	1,875	26.9%	-10.643	-0.261
Dementia Diagnosis and Treatment	303	3.5%	573	8.2%	-4.690	-0.200
Parkinsons disease	262	3.1%	284	4.1%	-1.018	-0.055
COPD	1,759	20.6%	1,600	23.0%	-2.428	-0.059
Malignancy	339	4.0%	334	4.8%	-0.836	-0.041
Asthma	1,466	17.1%	1,015	14.6%	2.551	0.070
Hyperlipidemia	3,506	41.0%	3,011	43.2%	-2.282	-0.046
Depression	4,876	57.0%	3,513	50.5%	6.516	0.131
Schizophrenia	7,573	88.5%	5,981	85.9%	2.581	0.077
Bipolar disorder	4,981	58.2%	3,385	48.6%	9.582	0.193
ACE inhibitor use	1,614	18.9%	1,500	21.5%	-2.686	-0.067
ARB use	399	4.7%	434	6.2%	-1.572	-0.069
Beta-blocker use	1,999	23.4%	1,819	26.1%	-2.769	-0.064
Oral anticoagulant use	221	2.6%	219	3.1%	-0.563	-0.034
Antiplatelet agent use	169	2.0%	228	3.3%	-1.300	-0.081
Opioid use	1,608	18.8%	1,194	17.2%	1.639	0.043
Statin use	2,071	24.2%	1,958	28.1%	-3.925	-0.089
Wheelchair or walker use	40	0.5%	59	0.8%	-0.380	-0.047
Anti-arrhythmic use	37	0.4%	40	0.6%	-0.142	-0.020
Antidiabetic use	1,485	17.4%	1,469	21.1%	-3.748	-0.095
Calcium channel blocker use	1,132	13.2%	1,180	16.9%	-3.722	-0.104
Diuretic use	1,404	16.4%	1,462	21.0%	-4.594	-0.118
Antidepressant use	5,067	59.2%	3,757	54.0%	5.243	0.106
Gastric acid suppressant use	2,546	29.7%	2,141	30.8%	-1.003	-0.022
NSAIDs	1,931	22.6%	1,318	18.9%	3.632	0.090

Table 1el. Unadjusted Characteristics of Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,301	38.6%	2,490	35.8%	2.807	0.058
Chronic liver disease	652	7.6%	465	6.7%	0.939	0.036
Pneumonia	534	6.2%	597	8.6%	-2.335	-0.089
Cardiac arrhythmia	1,811	21.2%	1,262	18.1%	3.035	0.076
Paliperidone palmitate	8,558	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.2%	-0.175	-0.056
Haloperidol decanoate	0	0.0%	6,962	100.0%	NaN	NaN
IS Stay	8,558	100.0%	6,962	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.6	27.5	32.3	27.7	-1.759	-0.064
Mean number of generics dispensed	10.4	6.6	10.9	6.2	-0.496	-0.077
Mean number of unique drug classes dispensed	9.3	5.7	9.3	5.4	-0.035	-0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.3	22.3	19.6	23.1	1.618	0.071
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.117	-0.123
Mean number of non-acute institutional encounters	1.9	1.4	2.0	1.4	-0.041	-0.029

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1em. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Unique patients	8,556	100.0%	6,955	99.9%	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	48.1	14.9	53.1	16.7	-5.024	-0.317
Age	**Number**	**Percent**[1]	**Number**	**Percent**[1]		
18-34 years	2,029	23.7%	1,242	17.9%	5.857	0.145
35-44 years	1,784	20.9%	1,116	16.0%	4.805	0.124
45-54 years	1,809	21.1%	1,414	20.3%	0.812	0.020
55-64 years	1,676	19.6%	1,372	19.7%	-0.138	-0.003
65-74 years	940	11.0%	1,087	15.6%	-4.643	-0.137
75-84 years	258	3.0%	490	7.0%	-4.030	-0.185
≥ 85 years	60	0.7%	234	3.4%	-2.663	-0.190
Sex						
Female	3,726	43.5%	2,995	43.1%	0.486	0.010
Male	4,830	56.5%	3,960	56.9%	-0.486	-0.010
Race[2]						
American Indian or Alaska Native	104	1.2%	54	0.8%	0.439	0.044
Asian	178	2.1%	147	2.1%	-0.033	-0.002
Black or African American	2,093	24.5%	2,136	30.7%	-6.249	-0.140
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	622	7.3%	503	7.2%	0.038	0.001
White	5,559	65.0%	4,115	59.2%	5.806	0.120
Hispanic origin						
Yes	387	4.5%	326	4.7%	-0.164	-0.008
No	7,934	92.7%	6,452	92.8%	-0.038	-0.001
Unknown	235	2.7%	177	2.5%	0.202	0.013

Table 1em. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	201	2.3%	413	5.9%	-3.589	-0.181
2011	486	5.7%	944	13.6%	-7.893	-0.270
2012	701	8.2%	831	11.9%	-3.755	-0.125
2013	772	9.0%	749	10.8%	-1.746	-0.059
2014	774	9.0%	712	10.2%	-1.191	-0.040
2015	781	9.1%	606	8.7%	0.415	0.015
2016	789	9.2%	559	8.0%	1.184	0.042
2017	839	9.8%	502	7.2%	2.588	0.093
2018	873	10.2%	457	6.6%	3.633	0.131
2019	783	9.2%	408	5.9%	3.285	0.125
2020	670	7.8%	335	4.8%	3.014	0.124
2021	630	7.4%	304	4.4%	2.992	0.128
2022	257	3.0%	135	1.9%	1.063	0.068
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[3]	2.8	2.3	3.2	2.7	-0.404	-0.163
Substance abuse	3,768	44.0%	2,439	35.1%	8.971	0.184
Atrial fibrilation/flutter	253	3.0%	331	4.8%	-1.802	-0.094
Ischemic heart disease	958	11.2%	1,155	16.6%	-5.410	-0.157
Heart failure	549	6.4%	713	10.3%	-3.835	-0.139
Stroke	310	3.6%	406	5.8%	-2.214	-0.104
Diabetes	2,378	27.8%	2,302	33.1%	-5.305	-0.115
Hypertension	4,921	57.5%	4,375	62.9%	-5.389	-0.110
Rheumatic disease	66	0.8%	64	0.9%	-0.149	-0.016
Chronic kidney disease	1,316	15.4%	1,270	18.3%	-2.879	-0.077
Seizure disorder	1,313	15.3%	1,137	16.3%	-1.002	-0.027

Table 1em. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[1]	Number	Percent[1]	Absolute Difference	Standardized Difference
Antidementia treatment	377	4.4%	626	9.0%	-4.594	-0.184
Dementia Diagnosis	1,394	16.3%	1,869	26.9%	-10.580	-0.259
Dementia Diagnosis and Treatment	303	3.5%	569	8.2%	-4.640	-0.198
Parkinsons disease	262	3.1%	284	4.1%	-1.021	-0.055
COPD	1,759	20.6%	1,594	22.9%	-2.360	-0.057
Malignancy	338	4.0%	332	4.8%	-0.823	-0.040
Asthma	1,465	17.1%	1,013	14.6%	2.557	0.070
Hyperlipidemia	3,506	41.0%	3,005	43.2%	-2.229	-0.045
Depression	4,874	57.0%	3,509	50.5%	6.513	0.131
Schizophrenia	7,571	88.5%	5,978	86.0%	2.535	0.076
Bipolar disorder	4,979	58.2%	3,382	48.6%	9.566	0.193
ACE inhibitor use	1,614	18.9%	1,497	21.5%	-2.660	-0.066
ARB use	399	4.7%	434	6.2%	-1.577	-0.069
Beta-blocker use	1,998	23.4%	1,815	26.1%	-2.744	-0.064
Oral anticoagulant use	221	2.6%	217	3.1%	-0.537	-0.032
Antiplatelet agent use	169	2.0%	226	3.2%	-1.274	-0.080
Opioid use	1,606	18.8%	1,189	17.1%	1.675	0.044
Statin use	2,071	24.2%	1,955	28.1%	-3.904	-0.089
Wheelchair or walker use	40	0.5%	59	0.8%	-0.381	-0.047
Anti-arrhythmic use	37	0.4%	40	0.6%	-0.143	-0.020
Antidiabetic use	1,485	17.4%	1,465	21.1%	-3.708	-0.094
Calcium channel blocker use	1,132	13.2%	1,177	16.9%	-3.693	-0.103
Diuretic use	1,404	16.4%	1,458	21.0%	-4.554	-0.117
Antidepressant use	5,065	59.2%	3,752	53.9%	5.251	0.106
Gastric acid suppressant use	2,545	29.7%	2,136	30.7%	-0.967	-0.021
NSAIDs	1,929	22.5%	1,317	18.9%	3.610	0.089

Table 1em. Unweighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[1]**	**Number**	**Percent[1]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,299	38.6%	2,487	35.8%	2.799	0.058
Chronic liver disease	651	7.6%	463	6.7%	0.952	0.037
Pneumonia	534	6.2%	592	8.5%	-2.271	-0.087
Cardiac arrhythmia	1,809	21.1%	1,258	18.1%	3.055	0.077
Paliperidone palmitate	8,556	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	13	0.2%	-0.175	-0.056
Haloperidol decanoate	0	0.0%	6,955	100.0%	NaN	NaN
IS Stay	8,556	100.0%	6,955	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.6	27.5	32.3	27.6	-1.746	-0.063
Mean number of generics dispensed	10.4	6.6	10.9	6.2	-0.490	-0.077
Mean number of unique drug classes dispensed	9.3	5.7	9.3	5.4	-0.030	-0.005
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	21.2	22.3	19.6	23.1	1.635	0.072
Mean number of inpatient hospital encounters	0.4	0.8	0.5	1.0	-0.110	-0.119
Mean number of non-acute institutional encounters	1.9	1.4	2.0	1.4	-0.037	-0.027

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1en. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Patient Characteristics[1]	**Number**	**Percent**	**Number**	**Percent**	**Absolute Difference**	**Standardized Difference**
Weighted patients	8,550	N/A	6,964	N/A	N/A	N/A
Demographic Characteristics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**		
Age (years)	50.2	15.5	50.2	16.3	0.024	0.001
Age	**Number**	**Percent[2]**	**Number**	**Percent[2]**		
18-34 years	1,762	20.6%	1,547	22.2%	-1.600	-0.039
35-44 years	1,620	18.9%	1,281	18.4%	0.554	0.014
45-54 years	1,752	20.5%	1,462	21.0%	-0.497	-0.012
55-64 years	1,777	20.8%	1,271	18.3%	2.530	0.064
65-74 years	1,151	13.5%	894	12.8%	0.631	0.019
75-84 years	389	4.5%	355	5.1%	-0.556	-0.026
≥ 85 years	99	1.2%	155	2.2%	-1.062	-0.082
Sex						
Female	3,703	43.3%	3,018	43.3%	-0.026	-0.001
Male	4,847	56.7%	3,946	56.7%	0.026	0.001
Race[3]						
American Indian or Alaska Native	101	1.2%	56	0.8%	0.378	0.038
Asian	176	2.1%	151	2.2%	-0.109	-0.008
Black or African American	2,133	24.9%	2,112	30.3%	-5.384	-0.121
Multi-racial	0	0.0%	0	0.0%	NaN	NaN
Unknown	589	6.9%	542	7.8%	-0.886	-0.034
White	5,551	64.9%	4,103	58.9%	6.001	0.124
Hispanic origin						
Yes	371	4.3%	347	5.0%	-0.640	-0.030
No	7,961	93.1%	6,423	92.2%	0.886	0.034
Unknown	218	2.6%	195	2.8%	-0.247	-0.015

Table 1en. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Demographic Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Year						
2010	203	2.4%	405	5.8%	-3.448	-0.175
2011	489	5.7%	920	13.2%	-7.495	-0.258
2012	707	8.3%	812	11.7%	-3.386	-0.113
2013	760	8.9%	756	10.9%	-1.962	-0.066
2014	775	9.1%	717	10.3%	-1.233	-0.042
2015	785	9.2%	615	8.8%	0.341	0.012
2016	797	9.3%	570	8.2%	1.136	0.040
2017	839	9.8%	503	7.2%	2.582	0.093
2018	859	10.1%	447	6.4%	3.628	0.132
2019	781	9.1%	427	6.1%	3.008	0.113
2020	674	7.9%	345	5.0%	2.919	0.119
2021	619	7.2%	312	4.5%	2.763	0.118
2022	262	3.1%	134	1.9%	1.146	0.074
Health Characteristics						
Charlson/Elixhauser combined comorbidity score[4]	2.9	2.5	2.9	2.5	0.007	0.003
Substance abuse	3,433	40.2%	2,799	40.2%	-0.045	-0.001
Atrial fibrilation/flutter	313	3.7%	258	3.7%	-0.046	-0.002
Ischemic heart disease	1,154	13.5%	941	13.5%	-0.016	-0.000
Heart failure	699	8.2%	565	8.1%	0.057	0.002
Stroke	391	4.6%	314	4.5%	0.068	0.003
Diabetes	2,585	30.2%	2,101	30.2%	0.072	0.002
Hypertension	5,117	59.9%	4,164	59.8%	0.061	0.001
Rheumatic disease	69	0.8%	59	0.8%	-0.035	-0.004
Chronic kidney disease	1,425	16.7%	1,155	16.6%	0.073	0.002
Seizure disorder	1,350	15.8%	1,101	15.8%	-0.015	-0.000

Table 1en. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	Number	Percent[2]	Number	Percent[2]	Absolute Difference	Standardized Difference
Antidementia treatment	555	6.5%	449	6.4%	0.050	0.002
Dementia Diagnosis	1,789	20.9%	1,453	20.9%	0.050	0.001
Dementia Diagnosis and Treatment	484	5.7%	390	5.6%	0.050	0.002
Parkinsons disease	306	3.6%	249	3.6%	0.003	0.000
COPD	1,839	21.5%	1,490	21.4%	0.106	0.003
Malignancy	373	4.4%	301	4.3%	0.043	0.002
Asthma	1,356	15.9%	1,102	15.8%	0.040	0.001
Hyperlipidemia	3,598	42.1%	2,932	42.1%	-0.018	-0.000
Depression	4,625	54.1%	3,768	54.1%	-0.008	-0.000
Schizophrenia	7,502	87.7%	6,111	87.7%	-0.005	-0.000
Bipolar disorder	4,611	53.9%	3,759	54.0%	-0.059	-0.001
ACE inhibitor use	1,707	20.0%	1,386	19.9%	0.060	0.002
ARB use	461	5.4%	375	5.4%	0.004	0.000
Beta-blocker use	2,102	24.6%	1,715	24.6%	-0.044	-0.001
Oral anticoagulant use	237	2.8%	194	2.8%	-0.012	-0.001
Antiplatelet agent use	221	2.6%	177	2.5%	0.045	0.003
Opioid use	1,531	17.9%	1,244	17.9%	0.043	0.001
Statin use	2,208	25.8%	1,798	25.8%	0.009	0.000
Wheelchair or walker use	60	0.7%	46	0.7%	0.039	0.005
Anti-arrhythmic use	40	0.5%	34	0.5%	-0.009	-0.001
Antidiabetic use	1,626	19.0%	1,323	19.0%	0.018	0.000
Calcium channel blocker use	1,269	14.8%	1,031	14.8%	0.042	0.001
Diuretic use	1,580	18.5%	1,276	18.3%	0.156	0.004
Antidepressant use	4,865	56.9%	3,953	56.8%	0.134	0.003
Gastric acid suppressant use	2,561	29.9%	2,085	29.9%	0.015	0.000
NSAIDs	1,788	20.9%	1,454	20.9%	0.035	0.001

Table 1en. Weighted Characteristics of Paliperidone vs. Haloperidol - 28 Day (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

	Medical Product				Covariate Balance	
	Paliperidone Users - 28 Day		Haloperidol Users - 28 Day			
Health Characteristics	**Number**	**Percent[2]**	**Number**	**Percent[2]**	**Absolute Difference**	**Standardized Difference**
Benzodiazepine-Hypnotics use	3,185	37.2%	2,588	37.2%	0.080	0.002
Chronic liver disease	612	7.2%	503	7.2%	-0.067	-0.003
Pneumonia	620	7.3%	500	7.2%	0.066	0.003
Cardiac arrhythmia	1,689	19.8%	1,380	19.8%	-0.066	-0.002
Paliperidone palmitate	8,550	100.0%	0	0.0%	NaN	NaN
Risperidone microspheres	*****	*****	12	0.2%	-0.159	-0.053
Haloperidol decanoate	0	0.0%	6,964	100.0%	NaN	NaN
IS Stay	8,550	100.0%	6,964	100.0%	0.000	NaN
Medical Product Use						
Mean number of filled prescriptions	30.9	27.9	31.7	27.0	-0.884	-0.032
Mean number of generics dispensed	10.4	6.6	10.9	6.2	-0.449	-0.070
Mean number of unique drug classes dispensed	9.3	5.7	9.3	5.3	0.018	0.003
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	20.7	21.9	20.7	23.9	-0.019	-0.001
Mean number of inpatient hospital encounters	0.4	0.9	0.4	0.9	0.002	0.002
Mean number of non-acute institutional encounters	1.9	1.4	1.9	1.4	-0.000	-0.000

[1]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Data represented by NaN (Not a Number) is due to their inability to be calculated

Table 2a. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,865	3,232.27	13.91	0.04	79	24.44	0.93	0.52 (0.39, 0.69)	<0.001
Risperidone Users - 14 Day	44,674	1,694.27	13.85	0.04	243	143.42	5.44		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,864	3,232.24	13.91	0.04	79	24.44	0.93	N/A	N/A
Risperidone Users - 14 Day	44,665	1,693.92	13.85	0.04	243	143.45	5.44		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	83,961	3,196.26	13.90	0.04	144	45.16	1.72	0.83 (0.65, 1.06)	0.133
Risperidone Users - 14 Day	45,384	1,720.66	13.85	0.04	127	74.06	2.81		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,865	3,232.27	13.91	0.04	79	24.44	0.93	0.52 (0.39, 0.69)	<0.001
Risperidone Users - 14 Day	44,674	1,694.27	13.85	0.04	243	143.42	5.44		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,864	3,232.24	13.91	0.04	79	24.44	0.93	N/A	N/A
Risperidone Users - 14 Day	44,665	1,693.92	13.85	0.04	243	143.45	5.44		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	83,961	3,196.26	13.90	0.04	144	45.16	1.72	0.83 (0.65, 1.06)	0.133
Risperidone Users - 14 Day	45,384	1,720.66	13.85	0.04	127	74.06	2.81		

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Age Group: 18-34 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	22,516	857.94	13.92	0.04	*****	*****	*****	3.39 (0.43,	0.244
Risperidone Users - 14 Day	7,599	288.14	13.85	0.04	*****	*****	*****	26.45)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	22,514	857.86	13.92	0.04	*****	*****	*****	N/A	N/A
Risperidone Users - 14 Day	7,594	287.95	13.85	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	22,516	857.93	13.92	0.04	*****	*****	*****	3.14 (0.41,	0.268
Risperidone Users - 14 Day	7,596	288.04	13.85	0.04	*****	*****	*****	23.88)	

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Age Group: 35-44 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	19,747	752.41	13.92	0.04	*****	*****	*****	0.51 (0.14, 1.82)	0.303
Risperidone Users - 14 Day	6,755	255.60	13.82	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	19,742	752.22	13.92	0.04	*****	*****	*****	N/A	N/A
Risperidone Users - 14 Day	6,754	255.56	13.82	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	19,740	752.12	13.92	0.04	*****	*****	*****	0.64 (0.17, 2.43)	0.509
Risperidone Users - 14 Day	6,759	255.80	13.82	0.04	*****	*****	*****		

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Age Group: 45-54 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	19,449	740.74	13.91	0.04	16	21.60	0.82	0.66 (0.30, 1.45)	0.297
Risperidone Users - 14 Day	8,005	303.20	13.83	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	19,433	740.13	13.91	0.04	16	21.62	0.82	N/A	N/A
Risperidone Users - 14 Day	8,004	303.16	13.83	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	19,428	739.89	13.91	0.04	17	22.82	0.87	0.80 (0.35, 1.82)	0.6
Risperidone Users - 14 Day	8,011	303.37	13.83	0.04	*****	*****	*****		

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Age Group: 55-64 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	14,759	561.84	13.90	0.04	14	24.92	0.95	0.30 (0.15, 0.58)	<0.001
Risperidone Users - 14 Day	7,196	273.05	13.86	0.04	24	87.90	3.34		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	14,756	561.72	13.90	0.04	14	24.92	0.95	N/A	N/A
Risperidone Users - 14 Day	7,194	272.97	13.86	0.04	24	87.92	3.34		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	14,746	561.42	13.91	0.04	15	25.94	0.99	0.39 (0.19, 0.77)	0.007
Risperidone Users - 14 Day	7,208	273.48	13.86	0.04	18	67.14	2.55		

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Age Group: 65-74 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	6,525	248.30	13.90	0.04	14	56.38	2.15	0.42 (0.23, 0.77)	0.005
Risperidone Users - 14 Day	6,779	257.95	13.90	0.04	39	151.19	5.75		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	6,521	248.15	13.90	0.04	14	56.42	2.15	N/A	N/A
Risperidone Users - 14 Day	6,768	257.54	13.90	0.04	38	147.55	5.61		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	6,483	246.18	13.87	0.04	24	99.02	3.76	0.87 (0.51, 1.50)	0.623
Risperidone Users - 14 Day	6,797	258.61	13.90	0.04	29	113.32	4.31		

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Age Group: 75-84 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	1,496	56.96	13.91	0.04	*****	*****	*****	0.43 (0.20, 0.89)	0.024
Risperidone Users - 14 Day	4,969	188.67	13.87	0.04	69	365.72	13.89		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	1,495	56.92	13.91	0.04	*****	*****	*****	N/A	N/A
Risperidone Users - 14 Day	4,955	188.14	13.87	0.04	69	366.75	13.93		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	1,474	55.93	13.86	0.04	18	326.44	12.39	0.98 (0.58, 1.65)	0.943
Risperidone Users - 14 Day	4,965	188.60	13.87	0.04	63	333.59	12.67		

Table 2b. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Age Group: ≥ 85 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	372	14.04	13.78	0.04	11	783.48	29.57	1.19 (0.63, 2.23)	0.587
Risperidone Users - 14 Day	3,362	127.31	13.83	0.04	96	754.06	28.55		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	371	14.00	13.78	0.04	11	785.71	29.65	N/A	N/A
Risperidone Users - 14 Day	3,338	126.42	13.83	0.04	96	759.37	28.76		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	379	14.04	13.54	0.04	23	1,642.60	60.88	2.19 (1.39, 3.46)	0.001
Risperidone Users - 14 Day	3,340	126.54	13.84	0.04	93	738.81	27.99		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 2c. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,865	3,232.27	13.91	0.04	79	24.44	0.93	0.52 (0.39, 0.69)	<0.001
Risperidone Users - 14 Day	44,674	1,694.27	13.85	0.04	243	143.42	5.44		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,864	3,232.24	13.91	0.04	79	24.44	0.93	N/A	N/A
Risperidone Users - 14 Day	44,665	1,693.92	13.85	0.04	243	143.45	5.44		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	83,961	3,196.26	13.90	0.04	144	45.16	1.72	0.83 (0.65, 1.06)	0.133
Risperidone Users - 14 Day	45,384	1,720.66	13.85	0.04	127	74.06	2.81		

Table 2c. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, No Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	83,187	3,168.47	13.91	0.04	*****	*****	*****	0.55 (0.40, 0.75)	<0.001
Risperidone Users - 14 Day	39,076	1,481.62	13.85	0.04	156	105.29	3.99		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	83,186	3,168.44	13.91	0.04	*****	*****	*****	N/A	N/A
Risperidone Users - 14 Day	39,066	1,481.26	13.85	0.04	155	104.64	3.97		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	82,633	3,146.31	13.91	0.04	113	35.90	1.37	0.91 (0.68, 1.21)	0.517
Risperidone Users - 14 Day	39,555	1,499.51	13.85	0.04	84	56.26	2.13		

Table 2c. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	1,677	63.76	13.89	0.04	*****	*****	*****	0.50 (0.25, 1.01)	0.054
Risperidone Users - 14 Day	5,589	212.30	13.87	0.04	87	409.80	15.57		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	1,675	63.69	13.89	0.04	*****	*****	*****	N/A	N/A
Risperidone Users - 14 Day	5,570	211.60	13.88	0.04	86	406.43	15.44		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	1,668	63.22	13.84	0.04	16	255.79	9.69	0.70 (0.41, 1.19)	0.188
Risperidone Users - 14 Day	5,585	212.10	13.87	0.04	77	363.95	13.82		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 2d. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,865	3,232.27	13.91	0.04	79	24.44	0.93	0.52 (0.39, 0.69)	<0.001
Risperidone Users - 14 Day	44,674	1,694.27	13.85	0.04	243	143.42	5.44		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,864	3,232.24	13.91	0.04	79	24.44	0.93	N/A	N/A
Risperidone Users - 14 Day	44,665	1,693.92	13.85	0.04	243	143.45	5.44		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	83,961	3,196.26	13.90	0.04	144	45.16	1.72	0.83 (0.65, 1.06)	0.133
Risperidone Users - 14 Day	45,384	1,720.66	13.85	0.04	127	74.06	2.81		

Table 2d. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, No IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	76,162	2,901.54	13.91	0.04	67	23.09	0.88	0.53 (0.39, 0.72)	<0.001
Risperidone Users - 14 Day	38,653	1,465.86	13.85	0.04	203	138.49	5.25		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	76,160	2,901.47	13.91	0.04	67	23.09	0.88	N/A	N/A
Risperidone Users - 14 Day	38,652	1,465.82	13.85	0.04	203	138.49	5.25		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	75,254	2,866.08	13.91	0.04	114	39.76	1.51	0.81 (0.62, 1.07)	0.135
Risperidone Users - 14 Day	39,332	1,491.17	13.85	0.04	102	68.28	2.59		

Table 2d. Effect Estimates for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 14 Day, IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	8,702	330.69	13.88	0.04	12	36.29	1.38	0.51 (0.25, 1.02)	0.057
Risperidone Users - 14 Day	6,012	228.06	13.86	0.04	40	175.39	6.65		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	8,697	330.50	13.88	0.04	12	36.31	1.38	N/A	N/A
Risperidone Users - 14 Day	6,011	228.02	13.86	0.04	40	175.42	6.65		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	8,607	326.62	13.86	0.04	26	78.75	2.99	0.83 (0.48, 1.44)	0.51
Risperidone Users - 14 Day	6,065	230.04	13.85	0.04	27	116.15	4.41		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 3a. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	0.46 (0.35, 0.60)	<0.001
Haloperidol Users - 14 Day	62,488	2,374.96	13.88	0.04	289	121.69	4.62		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	N/A	N/A
Haloperidol Users - 14 Day	62,484	2,374.80	13.88	0.04	289	121.69	4.63		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 14 Day	84,146	3,206.26	13.92	0.04	108	33.84	1.29	0.50 (0.39, 0.63)	<0.001
Haloperidol Users - 14 Day	62,754	2,385.67	13.89	0.04	197	82.75	3.15		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	0.46 (0.35,	<0.001
Haloperidol Users - 14 Day	62,488	2,374.96	13.88	0.04	289	121.69	4.62	0.60)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	N/A	N/A
Haloperidol Users - 14 Day	62,484	2,374.80	13.88	0.04	289	121.69	4.63		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	84,146	3,206.26	13.92	0.04	108	33.84	1.29	0.50 (0.39,	<0.001
Haloperidol Users - 14 Day	62,754	2,385.67	13.89	0.04	197	82.75	3.15	0.63)	

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Age Group: 18-34 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	22,437	855.49	13.93	0.04	*****	*****	*****	0.58 (0.21,	0.291
Haloperidol Users - 14 Day	11,314	430.03	13.88	0.04	*****	*****	*****	1.60)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	22,429	855.19	13.93	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	11,314	430.03	13.88	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	22,430	855.19	13.93	0.04	*****	*****	*****	0.55 (0.20,	0.238
Haloperidol Users - 14 Day	11,309	429.90	13.88	0.04	*****	*****	*****	1.49)	

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Age Group: 35-44 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	19,608	747.52	13.92	0.04	*****	*****	*****	0.33 (0.12,	0.033
Haloperidol Users - 14 Day	10,933	415.91	13.89	0.04	*****	*****	*****	0.92)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	19,607	747.48	13.92	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	10,931	415.84	13.89	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	19,611	747.54	13.92	0.04	*****	*****	*****	0.28 (0.11,	0.011
Haloperidol Users - 14 Day	10,927	415.54	13.89	0.04	12	28.79	1.09	0.75)	

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Age Group: 45-54 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	19,386	739.09	13.93	0.04	16	21.65	0.83	2.31 (0.84, 6.30)	0.103
Haloperidol Users - 14 Day	13,894	529.11	13.91	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	19,376	738.70	13.93	0.04	16	21.66	0.83	N/A	N/A
Haloperidol Users - 14 Day	13,892	529.03	13.91	0.04	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	19,380	738.80	13.92	0.04	18	24.85	0.95	2.26 (0.89, 5.76)	0.086
Haloperidol Users - 14 Day	13,893	528.87	13.90	0.04	*****	*****	*****		

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Age Group: 55-64 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	14,574	555.32	13.92	0.04	14	25.21	0.96	0.38 (0.20,	0.003
Haloperidol Users - 14 Day	11,670	444.22	13.90	0.04	30	67.53	2.57	0.71)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	14,569	555.13	13.92	0.04	14	25.22	0.96	N/A	N/A
Haloperidol Users - 14 Day	11,665	444.03	13.90	0.04	30	67.56	2.57		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	14,582	555.70	13.92	0.04	13	23.52	0.90	0.38 (0.20,	0.005
Haloperidol Users - 14 Day	11,657	443.69	13.90	0.04	27	61.16	2.33	0.74)	

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Age Group: 65-74 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	6,512	247.81	13.90	0.04	14	56.49	2.15	0.34 (0.19, 0.62)	<0.001
Haloperidol Users - 14 Day	8,244	313.22	13.88	0.04	55	175.60	6.67		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	6,510	247.77	13.90	0.04	14	56.50	2.15	N/A	N/A
Haloperidol Users - 14 Day	8,241	313.13	13.88	0.04	55	175.65	6.67		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	6,490	246.86	13.89	0.04	18	74.69	2.84	0.48 (0.28, 0.83)	0.008
Haloperidol Users - 14 Day	8,256	313.80	13.88	0.04	49	154.62	5.88		

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Age Group: 75-84 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	1,509	57.43	13.90	0.04	*****	*****	*****	0.31 (0.15,	0.002
Haloperidol Users - 14 Day	4,138	156.47	13.81	0.04	77	492.11	18.61	0.64)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	1,506	57.31	13.90	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	4,132	156.26	13.81	0.04	76	486.37	18.39		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	1,479	56.22	13.88	0.04	13	229.30	8.71	0.54 (0.30,	0.042
Haloperidol Users - 14 Day	4,144	156.85	13.83	0.04	67	429.26	16.25	0.98)	

Table 3b. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Age Group: ≥ 85 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	372	14.00	13.75	0.04	*****	*****	*****	0.71 (0.38, 1.33)	0.291
Haloperidol Users - 14 Day	2,291	85.84	13.68	0.04	105	1,223.21	45.83		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	371	13.96	13.75	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	2,275	85.26	13.69	0.04	103	1,208.07	45.27		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	365	13.55	13.54	0.04	18	1,345.75	49.89	1.16 (0.71, 1.92)	0.551
Haloperidol Users - 14 Day	2,279	85.47	13.70	0.04	100	1,170.70	43.91		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 3c. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	0.46 (0.35, 0.60)	<0.001
Haloperidol Users - 14 Day	62,488	2,374.96	13.88	0.04	289	121.69	4.62		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	N/A	N/A
Haloperidol Users - 14 Day	62,484	2,374.80	13.88	0.04	289	121.69	4.63		
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	84,146	3,206.26	13.92	0.04	108	33.84	1.29	0.50 (0.39, 0.63)	<0.001
Haloperidol Users - 14 Day	62,754	2,385.67	13.89	0.04	197	82.75	3.15		

Table 3c. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, No Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	82,723	3,152.94	13.92	0.04	*****	*****	*****	0.48 (0.36, 0.64)	<0.001
Haloperidol Users - 14 Day	58,552	2,226.36	13.89	0.04	209	93.88	3.57		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	82,721	3,152.86	13.92	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	58,551	2,226.32	13.89	0.04	209	93.88	3.57		
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	82,540	3,145.29	13.92	0.04	90	28.76	1.10	0.52 (0.40, 0.68)	<0.001
Haloperidol Users - 14 Day	58,757	2,234.28	13.89	0.04	150	67.08	2.55		

Table 3c. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	1,675	63.72	13.89	0.04	*****	*****	*****	0.39 (0.20, 0.79)	0.009
Haloperidol Users - 14 Day	3,932	148.45	13.79	0.04	80	538.90	20.35		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	1,670	63.53	13.89	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	3,929	148.33	13.79	0.04	80	539.34	20.36		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	1,662	63.05	13.86	0.04	14	214.36	8.13	0.47 (0.26, 0.83)	0.01
Haloperidol Users - 14 Day	3,947	149.05	13.79	0.04	69	463.06	17.49		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 3d. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	0.46 (0.35, 0.60)	<0.001
Haloperidol Users - 14 Day	62,488	2,374.96	13.88	0.04	289	121.69	4.62		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	84,398	3,216.66	13.92	0.04	77	23.94	0.91	N/A	N/A
Haloperidol Users - 14 Day	62,484	2,374.80	13.88	0.04	289	121.69	4.63		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	84,146	3,206.26	13.92	0.04	108	33.84	1.29	0.50 (0.39, 0.63)	<0.001
Haloperidol Users - 14 Day	62,754	2,385.67	13.89	0.04	197	82.75	3.15		

Table 3d. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, No IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	75,840	2,890.92	13.92	0.04	*****	*****	*****	0.44 (0.33, 0.59)	<0.001
Haloperidol Users - 14 Day	55,522	2,110.46	13.88	0.04	264	125.09	4.75		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	75,837	2,890.80	13.92	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	55,521	2,110.43	13.88	0.04	264	125.09	4.75		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	75,556	2,879.45	13.92	0.04	94	32.57	1.24	0.47 (0.37, 0.61)	<0.001
Haloperidol Users - 14 Day	55,806	2,121.80	13.89	0.04	179	84.43	3.21		

Table 3d. Effect Estimates for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 14 Day, IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 14 Day	8,558	325.74	13.90	0.04	*****	*****	*****	0.63 (0.29, 1.35)	0.234
Haloperidol Users - 14 Day	6,962	264.34	13.87	0.04	25	94.58	3.59		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 14 Day	8,556	325.66	13.90	0.04	*****	*****	*****	N/A	N/A
Haloperidol Users - 14 Day	6,955	264.10	13.87	0.04	24	90.87	3.45		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 14 Day	8,550	325.33	13.90	0.04	15	44.67	1.70	0.83 (0.41, 1.67)	0.597
Haloperidol Users - 14 Day	6,964	264.49	13.87	0.04	17	64.89	2.46		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 4a. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,865	6,427.17	27.66	0.08	187	29.10	2.20	0.56 (0.46,	<0.001
Risperidone Users - 28 Day	44,674	3,356.05	27.44	0.08	561	167.16	12.56	0.67)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,864	6,427.09	27.66	0.08	187	29.10	2.20	N/A	N/A
Risperidone Users - 28 Day	44,665	3,355.36	27.44	0.08	561	167.20	12.56		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	83,961	6,352.05	27.63	0.08	348	54.83	4.15	0.88 (0.75,	0.125
Risperidone Users - 28 Day	45,384	3,411.33	27.45	0.08	290	85.12	6.40	1.04)	

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,865	6,427.17	27.66	0.08	187	29.10	2.20	0.56 (0.46, 0.67)	<0.001
Risperidone Users - 28 Day	44,674	3,356.05	27.44	0.08	561	167.16	12.56		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,864	6,427.09	27.66	0.08	187	29.10	2.20	N/A	N/A
Risperidone Users - 28 Day	44,665	3,355.36	27.44	0.08	561	167.20	12.56		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	83,961	6,352.05	27.63	0.08	348	54.83	4.15	0.88 (0.75, 1.04)	0.125
Risperidone Users - 28 Day	45,384	3,411.33	27.45	0.08	290	85.12	6.40		

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Age Group: 18-34 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	22,516	1,706.87	27.69	0.08	14	8.20	0.62	2.36 (0.54, 10.39)	0.256
Risperidone Users - 28 Day	7,599	571.64	27.48	0.08	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	22,514	1,706.73	27.69	0.08	14	8.20	0.62	N/A	N/A
Risperidone Users - 28 Day	7,594	571.26	27.48	0.08	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	22,516	1,706.81	27.69	0.08	14	8.05	0.61	2.05 (0.50, 8.42)	0.318
Risperidone Users - 28 Day	7,596	571.39	27.47	0.08	*****	*****	*****		

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Age Group: 35-44 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	19,747	1,496.06	27.67	0.08	13	8.69	0.66	0.49 (0.21, 1.15)	0.102
Risperidone Users - 28 Day	6,755	507.08	27.42	0.08	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	19,742	1,495.67	27.67	0.08	13	8.69	0.66	N/A	N/A
Risperidone Users - 28 Day	6,754	507.01	27.42	0.08	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	19,740	1,495.54	27.67	0.08	13	8.88	0.67	0.58 (0.24, 1.39)	0.221
Risperidone Users - 28 Day	6,759	507.43	27.42	0.08	*****	*****	*****		

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Age Group: 45-54 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	19,449	1,473.83	27.68	0.08	37	25.10	1.90	0.79 (0.46, 1.38)	0.415
Risperidone Users - 28 Day	8,005	602.08	27.47	0.08	19	31.56	2.37		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	19,433	1,472.63	27.68	0.08	36	24.45	1.85	N/A	N/A
Risperidone Users - 28 Day	8,004	602.00	27.47	0.08	19	31.56	2.37		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	19,428	1,472.08	27.68	0.08	37	25.07	1.90	0.82 (0.47, 1.43)	0.483
Risperidone Users - 28 Day	8,011	602.43	27.47	0.08	18	30.60	2.30		

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Age Group: 55-64 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	14,759	1,116.82	27.64	0.08	39	34.92	2.64	0.46 (0.30, 0.71)	<0.001
Risperidone Users - 28 Day	7,196	541.25	27.47	0.08	43	79.45	5.98		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	14,756	1,116.59	27.64	0.08	39	34.93	2.64	N/A	N/A
Risperidone Users - 28 Day	7,194	541.10	27.47	0.08	43	79.47	5.98		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	14,746	1,115.92	27.64	0.08	41	36.85	2.79	0.60 (0.38, 0.95)	0.03
Risperidone Users - 28 Day	7,208	542.20	27.48	0.08	33	61.19	4.60		

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Age Group: 65-74 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	6,525	493.12	27.60	0.08	37	75.03	5.67	0.45 (0.31, 0.66)	<0.001
Risperidone Users - 28 Day	6,779	511.62	27.57	0.08	91	177.87	13.42		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	6,521	492.82	27.60	0.08	36	73.05	5.52	N/A	N/A
Risperidone Users - 28 Day	6,768	510.83	27.57	0.08	90	176.18	13.30		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	6,483	488.45	27.52	0.08	53	108.41	8.17	0.80 (0.56, 1.15)	0.226
Risperidone Users - 28 Day	6,797	512.84	27.56	0.08	69	135.33	10.21		

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Age Group: 75-84 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	1,496	112.92	27.57	0.08	24	212.54	16.04	0.47 (0.31, 0.73)	0.001
Risperidone Users - 28 Day	4,969	372.47	27.38	0.07	177	475.21	35.62		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	1,495	112.85	27.57	0.08	24	212.67	16.05	N/A	N/A
Risperidone Users - 28 Day	4,955	371.39	27.38	0.07	177	476.59	35.72		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	1,474	110.64	27.42	0.08	34	303.76	22.80	0.70 (0.48, 1.01)	0.055
Risperidone Users - 28 Day	4,965	372.60	27.41	0.08	163	437.06	32.80		

Table 4b. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Age Group: ≥ 85 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	372	27.46	26.97	0.07	23	837.58	61.83	1.03 (0.67, 1.59)	0.88
Risperidone Users - 28 Day	3,362	249.22	27.08	0.07	220	882.75	65.44		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	371	27.39	26.96	0.07	23	839.72	61.99	N/A	N/A
Risperidone Users - 28 Day	3,338	247.56	27.09	0.07	218	880.59	65.31		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	379	27.15	26.18	0.07	39	1,453.44	104.17	1.70 (1.21, 2.39)	0.002
Risperidone Users - 28 Day	3,340	247.87	27.10	0.07	213	858.20	63.68		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 4c. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,865	6,427.17	27.66	0.08	187	29.10	2.20	0.56 (0.46, 0.67)	<0.001
Risperidone Users - 28 Day	44,674	3,356.05	27.44	0.08	561	167.16	12.56		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,864	6,427.09	27.66	0.08	187	29.10	2.20	N/A	N/A
Risperidone Users - 28 Day	44,665	3,355.36	27.44	0.08	561	167.20	12.56		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	83,961	6,352.05	27.63	0.08	348	54.83	4.15	0.88 (0.75, 1.04)	0.125
Risperidone Users - 28 Day	45,384	3,411.33	27.45	0.08	290	85.12	6.40		

Table 4c. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, No Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	83,187	6,300.79	27.66	0.08	159	25.23	1.91	0.58 (0.47, 0.72)	<0.001
Risperidone Users - 28 Day	39,076	2,936.64	27.45	0.08	336	114.42	8.60		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	83,186	6,300.71	27.66	0.08	159	25.24	1.91	N/A	N/A
Risperidone Users - 28 Day	39,066	2,935.97	27.45	0.08	335	114.10	8.58		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	82,633	6,254.91	27.65	0.08	237	37.93	2.87	0.85 (0.69, 1.03)	0.097
Risperidone Users - 28 Day	39,555	2,973.75	27.46	0.08	183	61.48	4.62		

Table 4c. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	1,677	126.31	27.51	0.08	28	221.68	16.70	0.62 (0.41, 0.93)	0.02
Risperidone Users - 28 Day	5,589	418.72	27.36	0.07	225	537.35	40.26		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	1,675	126.15	27.51	0.08	28	221.96	16.72	N/A	N/A
Risperidone Users - 28 Day	5,570	417.36	27.37	0.07	223	534.31	40.04		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	1,668	124.80	27.32	0.07	50	404.10	30.23	0.84 (0.62, 1.14)	0.27
Risperidone Users - 28 Day	5,585	418.74	27.38	0.07	199	475.87	35.68		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 4d. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,865	6,427.17	27.66	0.08	187	29.10	2.20	0.56 (0.46,	<0.001
Risperidone Users - 28 Day	44,674	3,356.05	27.44	0.08	561	167.16	12.56	0.67)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,864	6,427.09	27.66	0.08	187	29.10	2.20	N/A	N/A
Risperidone Users - 28 Day	44,665	3,355.36	27.44	0.08	561	167.20	12.56		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	83,961	6,352.05	27.63	0.08	348	54.83	4.15	0.88 (0.75,	0.125
Risperidone Users - 28 Day	45,384	3,411.33	27.45	0.08	290	85.12	6.40	1.04)	

Table 4d. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, No IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	76,162	5,770.44	27.67	0.08	152	26.34	2.00	0.54 (0.44,	<0.001
Risperidone Users - 28 Day	38,653	2,904.65	27.45	0.08	468	161.12	12.11	0.66)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	76,160	5,770.29	27.67	0.08	152	26.34	2.00	N/A	N/A
Risperidone Users - 28 Day	38,652	2,904.57	27.45	0.08	468	161.13	12.11		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	75,254	5,696.84	27.65	0.08	276	48.38	3.66	0.85 (0.71,	0.068
Risperidone Users - 28 Day	39,332	2,957.54	27.46	0.08	235	79.59	5.98	1.01)	

Table 4d. Effect Estimates for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Risperidone - 28 Day, IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	8,702	656.65	27.56	0.08	35	53.30	4.02	0.67 (0.44,	0.066
Risperidone Users - 28 Day	6,012	450.71	27.38	0.07	93	206.34	15.47	1.03)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	8,697	656.27	27.56	0.08	35	53.33	4.02	N/A	N/A
Risperidone Users - 28 Day	6,011	450.63	27.38	0.07	93	206.38	15.47		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	8,607	648.28	27.51	0.08	63	97.33	7.33	0.96 (0.67,	0.816
Risperidone Users - 28 Day	6,065	454.69	27.38	0.07	58	127.57	9.56	1.38)	

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 5a. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	0.54 (0.45, 0.64)	<0.001
Haloperidol Users - 28 Day	62,488	4,711.39	27.54	0.08	594	126.08	9.51		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	N/A	N/A
Haloperidol Users - 28 Day	62,484	4,711.09	27.54	0.08	594	126.09	9.51		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	84,146	6,373.82	27.67	0.08	270	42.42	3.21	0.61 (0.52, 0.72)	<0.001
Haloperidol Users - 28 Day	62,754	4,734.96	27.56	0.08	402	85.00	6.41		

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	0.54 (0.45,	<0.001
Haloperidol Users - 28 Day	62,488	4,711.39	27.54	0.08	594	126.08	9.51	0.64)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	N/A	N/A
Haloperidol Users - 28 Day	62,484	4,711.09	27.54	0.08	594	126.09	9.51		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	84,146	6,373.82	27.67	0.08	270	42.42	3.21	0.61 (0.52,	<0.001
Haloperidol Users - 28 Day	62,754	4,734.96	27.56	0.08	402	85.00	6.41	0.72)	

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Age Group: 18-34 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	22,437	1,702.29	27.71	0.08	12	7.05	0.53	0.76 (0.31, 1.85)	0.542
Haloperidol Users - 28 Day	11,314	853.76	27.56	0.08	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	22,429	1,701.67	27.71	0.08	12	7.05	0.54	N/A	N/A
Haloperidol Users - 28 Day	11,314	853.76	27.56	0.08	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	22,430	1,701.60	27.71	0.08	12	7.04	0.53	0.71 (0.29, 1.71)	0.447
Haloperidol Users - 28 Day	11,309	853.49	27.56	0.08	*****	*****	*****		

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Age Group: 35-44 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	19,608	1,486.47	27.69	0.08	12	8.07	0.61	0.61 (0.27,	0.235
Haloperidol Users - 28 Day	10,933	826.58	27.61	0.08	*****	*****	*****	1.38)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	19,607	1,486.39	27.69	0.08	12	8.07	0.61	N/A	N/A
Haloperidol Users - 28 Day	10,931	826.42	27.61	0.08	*****	*****	*****		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	19,611	1,486.53	27.69	0.08	12	8.24	0.62	0.54 (0.25,	0.127
Haloperidol Users - 28 Day	10,927	825.82	27.60	0.08	13	15.21	1.15	1.19)	

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Age Group: 45-54 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	19,386	1,470.67	27.71	0.08	38	25.84	1.96	1.10 (0.66,	0.711
Haloperidol Users - 28 Day	13,894	1,051.77	27.65	0.08	25	23.77	1.80	1.82)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	19,376	1,469.91	27.71	0.08	38	25.85	1.96	N/A	N/A
Haloperidol Users - 28 Day	13,892	1,051.62	27.65	0.08	25	23.77	1.80		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	19,380	1,469.93	27.70	0.08	43	29.40	2.23	1.15 (0.71,	0.569
Haloperidol Users - 28 Day	13,893	1,051.05	27.63	0.08	27	25.55	1.93	1.86)	

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Age Group: 55-64 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	14,574	1,103.85	27.66	0.08	42	38.05	2.88	0.58 (0.39,	0.007
Haloperidol Users - 28 Day	11,670	882.47	27.62	0.08	59	66.86	5.06	0.86)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	14,569	1,103.47	27.66	0.08	42	38.06	2.88	N/A	N/A
Haloperidol Users - 28 Day	11,665	882.09	27.62	0.08	59	66.89	5.06		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	14,582	1,104.57	27.67	0.08	43	38.71	2.93	0.60 (0.40,	0.012
Haloperidol Users - 28 Day	11,657	881.32	27.61	0.08	57	64.44	4.87	0.89)	

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Age Group: 65-74 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	6,512	492.08	27.60	0.08	35	71.13	5.37	0.35 (0.24,	<0.001
Haloperidol Users - 28 Day	8,244	620.96	27.51	0.08	133	214.18	16.13	0.51)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	6,510	492.00	27.60	0.08	35	71.14	5.38	N/A	N/A
Haloperidol Users - 28 Day	8,241	620.79	27.51	0.08	133	214.24	16.14		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	6,490	489.88	27.57	0.08	43	87.49	6.60	0.46 (0.33,	<0.001
Haloperidol Users - 28 Day	8,256	622.34	27.53	0.08	118	190.03	14.32	0.65)	

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Age Group: 75-84 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	1,509	113.92	27.57	0.08	23	201.90	15.24	0.41 (0.27,	<0.001
Haloperidol Users - 28 Day	4,138	308.44	27.22	0.07	162	525.22	39.15	0.64)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	1,506	113.69	27.57	0.08	23	202.30	15.27	N/A	N/A
Haloperidol Users - 28 Day	4,132	308.04	27.23	0.07	160	519.41	38.72		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	1,479	111.29	27.48	0.08	27	245.72	18.49	0.53 (0.35,	0.002
Haloperidol Users - 28 Day	4,144	309.50	27.28	0.07	144	464.87	34.72	0.80)	

Table 5b. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Age Group: ≥ 85 years									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	372	27.39	26.89	0.07	23	839.72	61.83	0.77 (0.50,	0.229
Haloperidol Users - 28 Day	2,291	167.11	26.64	0.07	196	1,172.88	85.55	1.18)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	371	27.31	26.89	0.07	23	842.18	61.99	N/A	N/A
Haloperidol Users - 28 Day	2,275	166.03	26.66	0.07	193	1,162.44	84.84		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	365	26.27	26.26	0.07	34	1,287.94	92.58	1.13 (0.79,	0.506
Haloperidol Users - 28 Day	2,279	166.44	26.68	0.07	191	1,150.30	84.02	1.63)	

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 5c. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	0.54 (0.45, 0.64)	<0.001
Haloperidol Users - 28 Day	62,488	4,711.39	27.54	0.08	594	126.08	9.51		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	N/A	N/A
Haloperidol Users - 28 Day	62,484	4,711.09	27.54	0.08	594	126.09	9.51		
Inverse Probability of Treatment Weighted Analysis[1] ; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	84,146	6,373.82	27.67	0.08	270	42.42	3.21	0.61 (0.52, 0.72)	<0.001
Haloperidol Users - 28 Day	62,754	4,734.96	27.56	0.08	402	85.00	6.41		

Table 5c. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, No Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	82,723	6,270.41	27.69	0.08	157	25.04	1.90	0.56 (0.46, 0.68)	<0.001
Haloperidol Users - 28 Day	58,552	4,419.33	27.57	0.08	414	93.68	7.07		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	82,721	6,270.25	27.69	0.08	157	25.04	1.90	N/A	N/A
Haloperidol Users - 28 Day	58,551	4,419.26	27.57	0.08	414	93.68	7.07		
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]									
Paliperidone Users - 28 Day	82,540	6,253.78	27.67	0.08	206	33.00	2.50	0.60 (0.50, 0.72)	<0.001
Haloperidol Users - 28 Day	58,757	4,436.08	27.58	0.08	295	66.55	5.02		

Table 5c. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and Dementia Diagnosis and Treatment

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, Dementia Diagnosis and Treatment									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	1,675	126.26	27.53	0.08	28	221.76	16.72	0.49 (0.33, 0.74)	0.001
Haloperidol Users - 28 Day	3,932	291.76	27.10	0.07	180	616.95	45.78		
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	1,670	125.88	27.53	0.08	28	222.43	16.77	N/A	N/A
Haloperidol Users - 28 Day	3,929	291.53	27.10	0.07	180	617.43	45.81		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	1,662	124.58	27.38	0.07	41	326.01	24.44	0.60 (0.43, 0.85)	0.004
Haloperidol Users - 28 Day	3,947	293.23	27.13	0.07	158	540.36	40.14		

[1] All values in this section are weighted.

[2] ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 5d. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	0.54 (0.45,	<0.001
Haloperidol Users - 28 Day	62,488	4,711.39	27.54	0.08	594	126.08	9.51	0.64)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	84,398	6,396.67	27.68	0.08	185	28.92	2.19	N/A	N/A
Haloperidol Users - 28 Day	62,484	4,711.09	27.54	0.08	594	126.09	9.51		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	84,146	6,373.82	27.67	0.08	270	42.42	3.21	0.61 (0.52,	<0.001
Haloperidol Users - 28 Day	62,754	4,734.96	27.56	0.08	402	85.00	6.41	0.72)	

Table 5d. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, No IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	75,840	5,749.59	27.69	0.08	153	26.61	2.02	0.51 (0.42,	<0.001
Haloperidol Users - 28 Day	55,522	4,186.98	27.54	0.08	529	126.34	9.53	0.61)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	75,837	5,749.36	27.69	0.08	153	26.61	2.02	N/A	N/A
Haloperidol Users - 28 Day	55,521	4,186.90	27.54	0.08	529	126.35	9.53		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	75,556	5,724.72	27.67	0.08	225	39.35	2.98	0.57 (0.48,	<0.001
Haloperidol Users - 28 Day	55,806	4,211.58	27.56	0.08	356	84.64	6.39	0.68)	

Table 5d. Effect Estimates for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Analysis Type and IS Stay

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Paliperidone vs. Haloperidol - 28 Day, IS Stay									
Site-Adjusted Analysis, Unweighted									
Paliperidone Users - 28 Day	8,558	647.08	27.62	0.08	32	49.45	3.74	0.74 (0.48,	0.184
Haloperidol Users - 28 Day	6,962	524.11	27.50	0.08	65	124.02	9.34	1.15)	
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed									
Paliperidone Users - 28 Day	8,556	646.93	27.62	0.08	32	49.46	3.74	N/A	N/A
Haloperidol Users - 28 Day	6,955	523.64	27.50	0.08	64	122.22	9.20		
Inverse Probability of Treatment Weighted Analysis [1] ; Weight = ATES, Trimmed [2]									
Paliperidone Users - 28 Day	8,550	646.12	27.60	0.08	43	65.94	4.98	0.91 (0.60,	0.664
Haloperidol Users - 28 Day	6,964	524.60	27.51	0.08	45	85.16	6.42	1.39)	

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A: Not applicable

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2010 to July 1, 2022

	Paliperidone vs. Risperidone - 14 Day				Paliperidone vs. Haloperidol - 14 Day			
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day		Paliperidone Users - 14 Day		Haloperidol Users - 14 Day	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	74,313,461	N/A	74,313,461	N/A	74,313,461	N/A	74,313,461	N/A
Had required coverage type (medical and/or drug coverage)	48,708,751	25,604,710	48,708,751	25,604,710	48,708,751	25,604,710	48,708,751	25,604,710
Enrolled during specified age range	48,706,347	2,404	48,706,347	2,404	48,706,347	2,404	48,706,347	2,404
Had requestable medical charts	48,706,347	0	48,706,347	0	48,706,347	0	48,706,347	0
Met demographic requirements (sex, race, and Hispanic origin)	48,706,347	0	48,706,347	0	48,706,347	0	48,706,347	0
Members with a valid index event								
Had any cohort-defining claim during the query period	153,369	48,552,978	92,227	48,614,120	153,369	48,552,978	113,639	48,592,708
Claim recorded during specified age range	153,369	0	92,227	0	153,369	0	113,639	0
Episode defining index claim recorded during the query period	153,369	0	*****	*****	153,369	0	113,639	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	117,129	36,240	*****	*****	117,129	36,240	77,492	36,147
Met inclusion and exclusion criteria[1]	*****	*****	45,973	8,382	*****	*****	65,503	11,989
Evidence of washout	N/A	*****	N/A	8,382	N/A	*****	N/A	11,989
Met event incidence criteria	*****	0	45,973	0	*****	0	65,503	0

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2010 to July 1, 2022

	Paliperidone vs. Risperidone - 14 Day				Paliperidone vs. Haloperidol - 14 Day			
	Paliperidone Users - 14 Day		Risperidone Users - 14 Day		Paliperidone Users - 14 Day		Haloperidol Users - 14 Day	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	*****	*****	45,973	0	*****	*****	65,503	0
Had index episode of at least required length	88,845	0	45,973	0	88,845	0	65,503	0
Had index episode longer than blackout period	88,845	0	45,973	0	88,845	0	65,503	0
Did not have an event during blackout period	88,845	0	45,973	0	88,845	0	65,503	0
Final cohort								
Number of members	88,845	N/A	45,973	N/A	88,845	N/A	65,503	N/A
Number of episodes	88,845	N/A	45,973	N/A	88,845	N/A	65,503	N/A
Members meeting comparative cohort eligibility requirements								
Excluded due to same-day initition of both exposure groups	88,828	18	45,955	18	88,766	80	65,423	80
Excluded due to prior initiation of other exposure group	*****	*****	*****	*****	84,398	4,368	*****	*****
Excluded due to propensity score trimming	*****	*****	*****	*****	84,398	0	*****	*****
Included in comparative analysis	84,864	0	44,665	0	84,398	0	62,484	0
Additional information								
Number of events in comparative analysis	79	N/A	243	N/A	77	N/A	289	N/A

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2010 to July 1, 2022

	Paliperidone vs. Risperidone - 28 Day				Paliperidone vs. Haloperidol - 28 Day			
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day		Paliperidone Users - 28 Day		Haloperidol Users - 28 Day	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	74,313,461	N/A	74,313,461	N/A	74,313,461	N/A	74,313,461	N/A
Had required coverage type (medical and/or drug coverage)	48,708,751	25,604,710	48,708,751	25,604,710	48,708,751	25,604,710	48,708,751	25,604,710
Enrolled during specified age range	48,706,347	2,404	48,706,347	2,404	48,706,347	2,404	48,706,347	2,404
Had requestable medical charts	48,706,347	0	48,706,347	0	48,706,347	0	48,706,347	0
Met demographic requirements (sex, race, and Hispanic origin)	48,706,347	0	48,706,347	0	48,706,347	0	48,706,347	0
Members with a valid index event								
Had any cohort-defining claim during the query period	153,369	48,552,978	92,227	48,614,120	153,369	48,552,978	113,639	48,592,708
Claim recorded during specified age range	153,369	0	92,227	0	153,369	0	113,639	0
Episode defining index claim recorded during the query period	153,369	0	*****	*****	153,369	0	113,639	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	117,129	36,240	*****	*****	117,129	36,240	77,492	36,147
Met inclusion and exclusion criteria[1]	*****	*****	45,973	8,382	*****	*****	*****	*****
Evidence of washout	N/A	*****	N/A	8,382	N/A	*****	N/A	*****
Met event incidence criteria	*****	0	45,973	0	*****	0	*****	0

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2010 to July 1, 2022

	Paliperidone vs. Risperidone - 28 Day				Paliperidone vs. Haloperidol - 28 Day			
	Paliperidone Users - 28 Day		Risperidone Users - 28 Day		Paliperidone Users - 28 Day		Haloperidol Users - 28 Day	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	*****	*****	45,973	0	*****	*****	*****	*****
Had index episode of at least required length	88,845	0	45,973	0	88,845	0	65,502	0
Had index episode longer than blackout period	88,845	0	45,973	0	88,845	0	65,502	0
Did not have an event during blackout period	88,845	0	45,973	0	88,845	0	65,502	0
Final cohort								
Number of members	88,845	N/A	45,973	N/A	88,845	N/A	65,502	N/A
Number of episodes	88,845	N/A	45,973	N/A	88,845	N/A	65,502	N/A
Members meeting comparative cohort eligibility requirements								
Excluded due to same-day initition of both exposure groups	88,828	18	45,955	18	88,766	80	65,423	80
Excluded due to prior initiation of other exposure group	*****	*****	*****	*****	84,398	4,368	*****	*****
Excluded due to propensity score trimming	*****	*****	*****	*****	84,398	0	*****	*****
Included in comparative analysis	84,864	0	44,665	0	84,398	0	62,484	0
Additional information								
Number of events in comparative analysis	187	N/A	561	N/A	185	N/A	594	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution Before Trimming



Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution After Trimming



Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution Before Trimming



Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution After Trimming



Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Unweighted Propensity Score Distribution Before Trimming



Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Unweighted Propensity Score Distribution After Trimming



Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Unweighted Propensity Score Distribution After Trimming



Figure 1d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Unweighted Propensity Score Distribution Before Trimming



Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Unweighted Propensity Score Distribution After Trimming



Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution Before Trimming



Figure 1f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution After Trimming



Figure 1f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution Before Trimming



Figure 1g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution After Trimming



Figure 1g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution Before Trimming



Figure 1h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution After Trimming



Figure 1h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 1i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 1i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 1j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 1j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 1k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 1k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 1l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 1l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution Before Trimming



Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution After Trimming



Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution Before Trimming



Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution After Trimming



Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Unweighted Propensity Score Distribution Before Trimming



Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Unweighted Propensity Score Distribution After Trimming



Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Unweighted Propensity Score Distribution Before Trimming



Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Unweighted Propensity Score Distribution After Trimming



Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Unweighted Propensity Score Distribution Before Trimming



Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Unweighted Propensity Score Distribution After Trimming



Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution Before Trimming



Figure 2f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution After Trimming



Figure 2f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution Before Trimming



Figure 2g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution After Trimming



Figure 2g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution Before Trimming



Figure 2h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution After Trimming



Figure 2h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 2i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 2i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 2j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 2j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 2k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 2k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 2l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 2l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution Before Trimming



Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution After Trimming



Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution Before Trimming



Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution After Trimming



Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Unweighted Propensity Score Distribution Before Trimming



Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Unweighted Propensity Score Distribution After Trimming



Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Unweighted Propensity Score Distribution Before Trimming



Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Unweighted Propensity Score Distribution After Trimming



Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Unweighted Propensity Score Distribution Before Trimming



Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Unweighted Propensity Score Distribution After Trimming



Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution Before Trimming



Figure 3f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution After Trimming



Figure 3f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution Before Trimming



Figure 3g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution After Trimming



Figure 3g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution Before Trimming



Figure 3h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution After Trimming



Figure 3h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 3i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 3i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 3j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 3j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 3k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 3k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 3l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 3l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution Before Trimming



Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Unweighted Propensity Score Distribution After Trimming



Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution Before Trimming



Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Unweighted Propensity Score Distribution After Trimming



Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Unweighted Propensity Score Distribution After Trimming



Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Unweighted Propensity Score Distribution Before Trimming



Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Unweighted Propensity Score Distribution After Trimming



Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Unweighted Propensity Score Distribution After Trimming



Figure 4e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution Before Trimming



Figure 4f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Unweighted Propensity Score Distribution After Trimming



Figure 4f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution Before Trimming



Figure 4g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Unweighted Propensity Score Distribution After Trimming



Figure 4g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution Before Trimming



Figure 4h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Unweighted Propensity Score Distribution After Trimming



Figure 4h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 4i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 4i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution Before Trimming



Figure 4j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Unweighted Propensity Score Distribution After Trimming



Figure 4j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 4k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 4k. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution Before Trimming



Figure 4l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Unweighted Propensity Score Distribution After Trimming



Figure 4l. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 5a. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 5a. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 5b. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 5b. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



[1]Weighted using Average Treatment Effect, Stabilized, (ATES)

Figure 6a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 6b. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 6c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years



Figure 6d. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years



Figure 6e. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 6f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 6g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 6h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 6i. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 6j. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 6k. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 6l. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 6m. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 6n. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 6o. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 6p. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 6q. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 6r. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 6s. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 6t. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 6u. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay



Figure 6w. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Figure 6x. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 14 Day from the Weighted Population after Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Figure 7a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 7c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years



Figure 7e. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 7f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 7g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 7h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 7i. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 7j. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 7k. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 7l. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 7m. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 7n. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 7o. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 7p. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) fromJanuary 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 7q. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 7r. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 7s. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 7t. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 7u. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay



Figure 7v. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay



Figure 7w. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Figure 7x. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 14 Day from the Weighted Population after Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Figure 8a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 8b. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 8c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years



Figure 8d. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years



Figure 8e. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 8f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 8g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 8h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 8i. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 8j. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 8k. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 8l. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 8m. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 8n. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 8o. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 8p. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 8q. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 8r. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 8s. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 8t. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 8u. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay



Figure 8v. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay



Figure 8w. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Figure 8x. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Risperidone - 28 Day from the Weighted Population after Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Figure 9a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 9b. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022



Figure 9c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years



Figure 9d. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 18-34 years



Figure 9e. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 9f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 35-44 years



Figure 9g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 9h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 45-54 years



Figure 9i. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 9j. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 55-64 years



Figure 9k. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 9l. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 65-74 years



Figure 9m. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs.Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 9n. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: 75-84 years



Figure 9o. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 9p. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Age Group: ≥ 85 years



Figure 9q. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 9r. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No Dementia Diagnosis and Treatment



Figure 9s. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 9t. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, Dementia Diagnosis and Treatment



Figure 9u. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay



Figure 9v. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, No IS Stay



Figure 9w. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Whole Population in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Figure 9x. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Paliperidone vs. Haloperidol - 28 Day from the Weighted Population after Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, IS Stay



Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 7, 2023)

Masked DP ID[1]	DP Start Date	DP End Date[2]
DP01	01/01/2010	07/01/2022

[1]Participating Data Partner(s) include(s) Center for Medicare and Medicaid Services - Medicare Data.

[2]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418

Appendix C. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418
Age Group: 18-34 years					
Aggregated	30,108	0.402	3.015	1.000	0.129
DP01	30,108	0.402	3.015	1.000	0.129
Age Group: 35-44 years					
Aggregated	26,496	0.399	2.528	1.000	0.126
DP01	26,496	0.399	2.528	1.000	0.126
Age Group: 45-54 years					
Aggregated	27,437	0.379	2.787	1.000	0.144
DP01	27,437	0.379	2.787	1.000	0.144
Age Group: 55-64 years					
Aggregated	21,950	0.385	4.681	1.000	0.220
DP01	21,950	0.385	4.681	1.000	0.220
Age Group: 65-74 years					
Aggregated	13,289	0.545	5.991	0.999	0.397
DP01	13,289	0.545	5.991	0.999	0.397
Age Group: 75-84 years					
Aggregated	6,450	0.294	5.516	0.998	0.410
DP01	6,450	0.294	5.516	0.998	0.410
Age Group: ≥ 85 years					
Aggregated	3,709	0.173	8.757	1.003	0.340
DP01	3,709	0.173	8.757	1.003	0.340

Appendix D. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418
No Dementia Diagnosis and Treatment					
Aggregated	122,252	0.343	10.341	0.999	0.304
DP01	122,252	0.343	10.341	0.999	0.304
Dementia Diagnosis and Treatment					
Aggregated	7,245	0.250	13.799	1.001	0.546
DP01	7,245	0.250	13.799	1.001	0.546

Appendix E. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418
No IS Stay					
Aggregated	114,812	0.350	14.457	0.998	0.410
DP01	114,812	0.350	14.457	0.998	0.410
IS Stay					
Aggregated	14,708	0.438	6.794	0.998	0.405
DP01	14,708	0.438	6.794	0.998	0.405

Appendix F. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301

Appendix G. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301
Age Group: 18-34 years					
Aggregated	33,743	0.449	2.497	1.000	0.144
DP01	33,743	0.449	2.497	1.000	0.144
Age Group: 35-44 years					
Aggregated	30,538	0.431	3.785	1.000	0.174
DP01	30,538	0.431	3.785	1.000	0.174
Age Group: 45-54 years					
Aggregated	33,268	0.495	3.794	1.000	0.219
DP01	33,268	0.495	3.794	1.000	0.219
Age Group: 55-64 years					
Aggregated	26,234	0.544	3.174	1.000	0.233
DP01	26,234	0.544	3.174	1.000	0.233
Age Group: 65-74 years					
Aggregated	14,751	0.554	3.242	1.000	0.258
DP01	14,751	0.554	3.242	1.000	0.258
Age Group: 75-84 years					
Aggregated	5,638	0.348	4.382	0.997	0.325
DP01	5,638	0.348	4.382	0.997	0.325
Age Group: ≥ 85 years					
Aggregated	2,646	0.201	7.857	0.999	0.331
DP01	2,646	0.201	7.857	0.999	0.331

Appendix H. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301
No Dementia Diagnosis and Treatment					
Aggregated	141,272	0.452	5.046	1.000	0.269
DP01	141,272	0.452	5.046	1.000	0.269
Dementia Diagnosis and Treatment					
Aggregated	5,599	0.349	6.128	1.002	0.437
DP01	5,599	0.349	6.128	1.002	0.437

Appendix I. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 14 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301
No IS Stay					
Aggregated	131,358	0.459	7.539	1.000	0.307
DP01	131,358	0.459	7.539	1.000	0.307
IS Stay					
Aggregated	15,511	0.519	4.264	1.000	0.258
DP01	15,511	0.519	4.264	1.000	0.258

Appendix J. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418

Appendix K. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418
Age Group: 18-34 years					
Aggregated	30,108	0.402	3.015	1.000	0.129
DP01	30,108	0.402	3.015	1.000	0.129
Age Group: 35-44 years					
Aggregated	26,496	0.399	2.528	1.000	0.126
DP01	26,496	0.399	2.528	1.000	0.126
Age Group: 45-54 years					
Aggregated	27,437	0.379	2.787	1.000	0.144
DP01	27,437	0.379	2.787	1.000	0.144
Age Group: 55-64 years					
Aggregated	21,950	0.385	4.681	1.000	0.220
DP01	21,950	0.385	4.681	1.000	0.220
Age Group: 65-74 years					
Aggregated	13,289	0.545	5.991	0.999	0.397
DP01	13,289	0.545	5.991	0.999	0.397
Age Group: 75-84 years					
Aggregated	6,450	0.294	5.516	0.998	0.410
DP01	6,450	0.294	5.516	0.998	0.410
Age Group: ≥ 85 years					
Aggregated	3,709	0.173	8.757	1.003	0.340
DP01	3,709	0.173	8.757	1.003	0.340

Appendix L. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418
No Dementia Diagnosis and Treatment					
Aggregated	122,252	0.343	10.341	0.999	0.304
DP01	122,252	0.343	10.341	0.999	0.304
Dementia Diagnosis and Treatment					
Aggregated	7,245	0.250	13.799	1.001	0.546
DP01	7,245	0.250	13.799	1.001	0.546

Appendix M. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Risperidone - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	129,529	0.359	16.943	0.999	0.418
DP01	129,529	0.359	16.943	0.999	0.418
No IS Stay					
Aggregated	114,812	0.350	14.457	0.998	0.410
DP01	114,812	0.350	14.457	0.998	0.410
IS Stay					
Aggregated	14,708	0.438	6.794	0.998	0.405
DP01	14,708	0.438	6.794	0.998	0.405

Appendix N. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301

Appendix O. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301
Age Group: 18-34 years					
Aggregated	33,743	0.449	2.497	1.000	0.144
DP01	33,743	0.449	2.497	1.000	0.144
Age Group: 35-44 years					
Aggregated	30,538	0.431	3.785	1.000	0.174
DP01	30,538	0.431	3.785	1.000	0.174
Age Group: 45-54 years					
Aggregated	33,268	0.495	3.794	1.000	0.219
DP01	33,268	0.495	3.794	1.000	0.219
Age Group: 55-64 years					
Aggregated	26,234	0.544	3.174	1.000	0.233
DP01	26,234	0.544	3.174	1.000	0.233
Age Group: 65-74 years					
Aggregated	14,751	0.554	3.242	1.000	0.258
DP01	14,751	0.554	3.242	1.000	0.258
Age Group: 75-84 years					
Aggregated	5,638	0.348	4.382	0.997	0.325
DP01	5,638	0.348	4.382	0.997	0.325
Age Group: ≥ 85 years					
Aggregated	2,646	0.201	7.857	0.999	0.331
DP01	2,646	0.201	7.857	0.999	0.331

Appendix P. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), Dementia Diagnosis and Treatment, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301
No Dementia Diagnosis and Treatment					
Aggregated	141,272	0.452	5.046	1.000	0.269
DP01	141,272	0.452	5.046	1.000	0.269
Dementia Diagnosis and Treatment					
Aggregated	5,599	0.349	6.128	1.002	0.437
DP01	5,599	0.349	6.128	1.002	0.437

Appendix Q. Distribution of Inverse Probability of Treatment Weights After Trimming for Paliperidone vs. Haloperidol - 28 Day in the Sentinel Distributed Database (SDD) from January 1, 2010 to July 1, 2022, by Data Partner (DP), IS Stay, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	146,882	0.461	9.135	1.000	0.301
DP01	146,882	0.461	9.135	1.000	0.301
No IS Stay					
Aggregated	131,358	0.459	7.539	1.000	0.307
DP01	131,358	0.459	7.539	1.000	0.307
IS Stay					
Aggregated	15,511	0.519	4.264	1.000	0.258
DP01	15,511	0.519	4.264	1.000	0.258

Appendix R. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Haloperidol	
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
Paliperidone	
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
Risperidone	
risperidone microspheres	Risperdal Consta

Appendix S. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
	Haloperidol		
J1631	Injection, haloperidol decanoate, per 50 mg	Procedure	HCPCS
	Paliperidone		
C9255	Injection, paliperidone palmitate, 1 mg	Procedure	HCPCS
J2426	Injection, paliperidone palmitate extended release, 1 mg	Procedure	HCPCS
	Risperidone		
C9037	Injection, risperidone (Perseris), 0.5 mg	Procedure	HCPCS
J2794	Injection, risperidone (RISPERDAL CONSTA), 0.5 mg	Procedure	HCPCS
J2798	Injection, risperidone, (Perseris), 0.5 mg	Procedure	HCPCS

Appendix T. List of Generic and Brand Names of Medical Products Used to Define Exposure Incidence Criteria in this Request

Generic Name	Brand Name
Haloperidol	
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
Paliperidone	
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
Risperidone	
risperidone microspheres	Risperdal Consta
Other Long-Acting Injectable Antipsychotics (LAIA)	
aripiprazole	Abilify Maintena
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
fluphenazine decanoate	fluphenazine decanoate
olanzapine pamoate	Zyprexa Relprevv

Appendix U. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposure Incidence Criteria in this Request

Code	Description	Code Category	Code Type
	Haloperidol		
J1631	Injection, haloperidol decanoate, per 50 mg	Procedure	HCPCS
	Paliperidone		
C9255	Injection, paliperidone palmitate, 1 mg	Procedure	HCPCS
J2426	Injection, paliperidone palmitate extended release, 1 mg	Procedure	HCPCS
	Risperidone		
C9037	Injection, risperidone (Perseris), 0.5 mg	Procedure	HCPCS
J2794	Injection, risperidone (RISPERDAL CONSTA), 0.5 mg	Procedure	HCPCS
J2798	Injection, risperidone, (Perseris), 0.5 mg	Procedure	HCPCS
	Other Long-Acting Injectable Antipsychotics (LAIA)		
C9035	Injection, aripiprazole lauroxil (Aristada Initio), 1 mg	Procedure	HCPCS
C9470	Injection, aripiprazole lauroxil, 1 mg	Procedure	HCPCS
J0401	Injection, aripiprazole, extended release, 1 mg	Procedure	HCPCS
J1942	Injection, aripiprazole lauroxil, 1 mg	Procedure	HCPCS
J1943	Injection, aripiprazole lauroxil, (Aristada Initio), 1 mg	Procedure	HCPCS
J1944	Injection, aripiprazole lauroxil, (Aristada), 1 mg	Procedure	HCPCS
J2358	Injection, olanzapine, long-acting, 1 mg	Procedure	HCPCS
J2680	Injection, fluphenazine decanoate, up to 25 mg	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
	Substance Abuse		
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence,	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder,	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal,	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal,	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication,	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication,	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal,	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F55.0	Abuse of antacids	Diagnosis	ICD-10-CM
F55.1	Abuse of herbal or folk remedies	Diagnosis	ICD-10-CM
F55.2	Abuse of laxatives	Diagnosis	ICD-10-CM
F55.3	Abuse of steroids or hormones	Diagnosis	ICD-10-CM
F55.4	Abuse of vitamins	Diagnosis	ICD-10-CM
F55.8	Abuse of other non-psychoactive substances	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
O99.320	Drug use complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.321	Drug use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.322	Drug use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.323	Drug use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99.325	Drug use complicating the puerperium	Diagnosis	ICD-10-CM
P04.3	Newborn affected by maternal use of alcohol	Diagnosis	ICD-10-CM
P04.41	Newborn affected by maternal use of cocaine	Diagnosis	ICD-10-CM
P04.49	Newborn affected by maternal use of other drugs of addiction	Diagnosis	ICD-10-CM
P96.1	Neonatal withdrawal symptoms from maternal use of drugs of addiction	Diagnosis	ICD-10-CM
P96.2	Withdrawal symptoms from therapeutic use of drugs in newborn	Diagnosis	ICD-10-CM
Q86.0	Fetal alcohol syndrome (dysmorphic)	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Z71.42	Counseling for family member of alcoholic	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Z71.52	Counseling for family member of drug abuser	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
	Atrial Fibrillation		
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
	Ischemic Heart Disease		
410.00	Acute myocardial infarction of anterolateral wall, episode of care	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
	Heart Failure		
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
	Stroke		
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
	Diabetes		
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type,	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type],	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Hypertension		
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
	Rheumatic Disease		
393	Chronic rheumatic pericarditis	Diagnosis	ICD-9-CM
397	Diseases of other endocardial structures	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
397.0	Diseases of tricuspid valve	Diagnosis	ICD-9-CM
397.1	Rheumatic diseases of pulmonary valve	Diagnosis	ICD-9-CM
397.9	Rheumatic diseases of endocardium, valve unspecified	Diagnosis	ICD-9-CM
398	Other rheumatic heart disease	Diagnosis	ICD-9-CM
398.0	Rheumatic myocarditis	Diagnosis	ICD-9-CM
398.9	Other and unspecified rheumatic heart diseases	Diagnosis	ICD-9-CM
398.90	Unspecified rheumatic heart disease	Diagnosis	ICD-9-CM
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
398.99	Other and unspecified rheumatic heart diseases	Diagnosis	ICD-9-CM
I07.0	Rheumatic tricuspid stenosis	Diagnosis	ICD-10-CM
I07.1	Rheumatic tricuspid insufficiency	Diagnosis	ICD-10-CM
I07.2	Rheumatic tricuspid stenosis and insufficiency	Diagnosis	ICD-10-CM
I07.8	Other rheumatic tricuspid valve diseases	Diagnosis	ICD-10-CM
I07.9	Rheumatic tricuspid valve disease, unspecified	Diagnosis	ICD-10-CM
I08.1	Rheumatic disorders of both mitral and tricuspid valves	Diagnosis	ICD-10-CM
I08.2	Rheumatic disorders of both aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.3	Combined rheumatic disorders of mitral, aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.8	Other rheumatic multiple valve diseases	Diagnosis	ICD-10-CM
I08.9	Rheumatic multiple valve disease, unspecified	Diagnosis	ICD-10-CM
I09	Other rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.0	Rheumatic myocarditis	Diagnosis	ICD-10-CM
I09.1	Rheumatic diseases of endocardium, valve unspecified	Diagnosis	ICD-10-CM
I09.2	Chronic rheumatic pericarditis	Diagnosis	ICD-10-CM
I09.8	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I09.89	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.9	Rheumatic heart disease, unspecified	Diagnosis	ICD-10-CM
	Chronic Kidney Disease		
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type,	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
	Seizure		
333.2	Myoclonus	Diagnosis	ICD-9-CM
345	Epilepsy and recurrent seizures	Diagnosis	ICD-9-CM
345.0	Generalized nonconvulsive epilepsy	Diagnosis	ICD-9-CM
345.00	Generalized nonconvulsive epilepsy without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.01	Generalized nonconvulsive epilepsy with intractable epilepsy	Diagnosis	ICD-9-CM
345.1	Generalized convulsive epilepsy	Diagnosis	ICD-9-CM
345.10	Generalized convulsive epilepsy without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.11	Generalized convulsive epilepsy with intractable epilepsy	Diagnosis	ICD-9-CM
345.2	Epileptic petit mal status	Diagnosis	ICD-9-CM
345.3	Epileptic grand mal status	Diagnosis	ICD-9-CM
345.4	Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures	Diagnosis	ICD-9-CM
345.40	Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures, without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.41	Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures, with intractable epilepsy	Diagnosis	ICD-9-CM
345.5	Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
345.50	Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures, without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.51	Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures, with intractable epilepsy	Diagnosis	ICD-9-CM
345.6	Infantile spasms	Diagnosis	ICD-9-CM
345.60	Infantile spasms without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.61	Infantile spasms with intractable epilepsy	Diagnosis	ICD-9-CM
345.7	Epilepsia partialis continua	Diagnosis	ICD-9-CM
345.70	Epilepsia partialis continua without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.71	Epilepsia partialis continua with intractable epilepsy	Diagnosis	ICD-9-CM
345.8	Other forms of epilepsy and recurrent seizures	Diagnosis	ICD-9-CM
345.80	Other forms of epilepsy and recurrent seizures, without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.81	Other forms of epilepsy and recurrent seizures, with intractable epilepsy	Diagnosis	ICD-9-CM
345.9	Unspecified epilepsy	Diagnosis	ICD-9-CM
345.90	Unspecified epilepsy without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.91	Unspecified epilepsy with intractable epilepsy	Diagnosis	ICD-9-CM
780.3	Convulsions	Diagnosis	ICD-9-CM
780.31	Febrile convulsions (simple), unspecified	Diagnosis	ICD-9-CM
780.32	Complex febrile convulsions	Diagnosis	ICD-9-CM
780.33	Post traumatic seizures	Diagnosis	ICD-9-CM
780.39	Other convulsions	Diagnosis	ICD-9-CM
G25.3	Myoclonus	Diagnosis	ICD-10-CM
G40.001	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.009	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.011	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.019	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.101	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.109	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.111	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G40.119	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.201	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.209	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status	Diagnosis	ICD-10-CM
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.301	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.309	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.311	Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.319	Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.401	Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.409	Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.411	Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.419	Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.501	Epileptic seizures related to external causes, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.509	Epileptic seizures related to external causes, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.801	Other epilepsy, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.802	Other epilepsy, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.803	Other epilepsy, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.804	Other epilepsy, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.811	Lennox-Gastaut syndrome, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.812	Lennox-Gastaut syndrome, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.813	Lennox-Gastaut syndrome, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.814	Lennox-Gastaut syndrome, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.821	Epileptic spasms, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.822	Epileptic spasms, not intractable, without status epilepticus	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G40.823	Epileptic spasms, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.824	Epileptic spasms, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.89	Other seizures	Diagnosis	ICD-10-CM
G40.901	Epilepsy, unspecified, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.909	Epilepsy, unspecified, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.911	Epilepsy, unspecified, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.919	Epilepsy, unspecified, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.A01	Absence epileptic syndrome, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.A09	Absence epileptic syndrome, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.A11	Absence epileptic syndrome, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.A19	Absence epileptic syndrome, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.B01	Juvenile myoclonic epilepsy, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.B09	Juvenile myoclonic epilepsy, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.B11	Juvenile myoclonic epilepsy, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.B19	Juvenile myoclonic epilepsy, intractable, without status epilepticus	Diagnosis	ICD-10-CM
R56.00	Simple febrile convulsions	Diagnosis	ICD-10-CM
R56.01	Complex febrile convulsions	Diagnosis	ICD-10-CM
R56.1	Post traumatic seizures	Diagnosis	ICD-10-CM
R56.9	Unspecified convulsions	Diagnosis	ICD-10-CM
	Alzheimer's/Dementia		
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
	Parkinson's Disease		
332.0	Paralysis agitans	Diagnosis	ICD-9-CM
332.1	Secondary Parkinsonism	Diagnosis	ICD-9-CM
G20	Parkinson's disease	Diagnosis	ICD-10-CM
G21.11	Neuroleptic induced parkinsonism	Diagnosis	ICD-10-CM
G21.19	Other drug induced secondary parkinsonism	Diagnosis	ICD-10-CM
G21.2	Secondary parkinsonism due to other external agents	Diagnosis	ICD-10-CM
G21.3	Postencephalitic parkinsonism	Diagnosis	ICD-10-CM
G21.4	Vascular parkinsonism	Diagnosis	ICD-10-CM
G21.8	Other secondary parkinsonism	Diagnosis	ICD-10-CM
G21.9	Secondary parkinsonism, unspecified	Diagnosis	ICD-10-CM
	Chronic Obstructive Pulmonary Disease (COPD)		
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
	Malignancy		
0073T	Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session	Procedure	CPT-3
0182T	High dose rate electronic brachytherapy, per fraction	Procedure	CPT-3
0190T	Placement of intraocular radiation source applicator (List separately in addition to primary procedure)	Procedure	CPT-3
0347T	Placement of interstitial device(s) in bone for radiostereometric analysis (RSA)	Procedure	CPT-3
150	Malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
150.0	Malignant neoplasm of cervical esophagus	Diagnosis	ICD-9-CM
150.1	Malignant neoplasm of thoracic esophagus	Diagnosis	ICD-9-CM
150.2	Malignant neoplasm of abdominal esophagus	Diagnosis	ICD-9-CM
150.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-9-CM
150.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-9-CM
150.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-9-CM
150.8	Malignant neoplasm of other specified part of esophagus	Diagnosis	ICD-9-CM
150.9	Malignant neoplasm of esophagus, unspecified site	Diagnosis	ICD-9-CM
153	Malignant neoplasm of colon	Diagnosis	ICD-9-CM
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
154.2	Malignant neoplasm of anal canal	Diagnosis	ICD-9-CM
154.3	Malignant neoplasm of anus, unspecified site	Diagnosis	ICD-9-CM
154.8	Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
155	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.0	Malignant neoplasm of liver, primary	Diagnosis	ICD-9-CM
155.1	Malignant neoplasm of intrahepatic bile ducts	Diagnosis	ICD-9-CM
157	Malignant neoplasm of pancreas	Diagnosis	ICD-9-CM
157.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-9-CM
157.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-9-CM
157.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-9-CM
157.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-9-CM
157.4	Malignant neoplasm of islets of Langerhans	Diagnosis	ICD-9-CM
157.8	Malignant neoplasm of other specified sites of pancreas	Diagnosis	ICD-9-CM
157.9	Malignant neoplasm of pancreas, part unspecified	Diagnosis	ICD-9-CM
162	Malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
172	Malignant melanoma of skin	Diagnosis	ICD-9-CM
172.0	Malignant melanoma of skin of lip	Diagnosis	ICD-9-CM
172.1	Malignant melanoma of skin of eyelid, including canthus	Diagnosis	ICD-9-CM
172.2	Malignant melanoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
172.3	Malignant melanoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
172.4	Malignant melanoma of skin of scalp and neck	Diagnosis	ICD-9-CM
172.5	Malignant melanoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
172.6	Malignant melanoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
172.7	Malignant melanoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
172.8	Malignant melanoma of other specified sites of skin	Diagnosis	ICD-9-CM
172.9	Melanoma of skin, site unspecified	Diagnosis	ICD-9-CM
174	Malignant neoplasm of female breast	Diagnosis	ICD-9-CM
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175	Malignant neoplasm of male breast	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
179	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-9-CM
180	Malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
180.0	Malignant neoplasm of endocervix	Diagnosis	ICD-9-CM
180.1	Malignant neoplasm of exocervix	Diagnosis	ICD-9-CM
180.8	Malignant neoplasm of other specified sites of cervix	Diagnosis	ICD-9-CM
180.9	Malignant neoplasm of cervix uteri, unspecified site	Diagnosis	ICD-9-CM
182	Malignant neoplasm of body of uterus	Diagnosis	ICD-9-CM
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
182.1	Malignant neoplasm of isthmus	Diagnosis	ICD-9-CM
182.8	Malignant neoplasm of other specified sites of body of uterus	Diagnosis	ICD-9-CM
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
188	Malignant neoplasm of bladder	Diagnosis	ICD-9-CM
188.0	Malignant neoplasm of trigone of urinary bladder	Diagnosis	ICD-9-CM
188.1	Malignant neoplasm of dome of urinary bladder	Diagnosis	ICD-9-CM
188.2	Malignant neoplasm of lateral wall of urinary bladder	Diagnosis	ICD-9-CM
188.3	Malignant neoplasm of anterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.4	Malignant neoplasm of posterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-9-CM
188.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-9-CM
188.7	Malignant neoplasm of urachus	Diagnosis	ICD-9-CM
188.8	Malignant neoplasm of other specified sites of bladder	Diagnosis	ICD-9-CM
188.9	Malignant neoplasm of bladder, part unspecified	Diagnosis	ICD-9-CM
189	Malignant neoplasm of kidney and other and unspecified urinary organs	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.1	Malignant neoplasm of renal pelvis	Diagnosis	ICD-9-CM
19296	Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; on date separate from partial mastectomy	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
19297	Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; concurrent with partial mastectomy (List separately in addition to code for primary procedure)	Procedure	CPT-4
19298	Placement of radiotherapy after loading brachytherapy catheters (multiple tube and button type) into the breast for interstitial radioelement application following (at the time of or subsequent to) partial mastectomy, includes imaging guidance	Procedure	CPT-4
193	Malignant neoplasm of thyroid gland	Diagnosis	ICD-9-CM
194	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.0	Malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
194.1	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-9-CM
194.3	Malignant neoplasm of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
194.4	Malignant neoplasm of pineal gland	Diagnosis	ICD-9-CM
194.5	Malignant neoplasm of carotid body	Diagnosis	ICD-9-CM
194.6	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-9-CM
194.8	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.9	Malignant neoplasm of endocrine gland, site unspecified	Diagnosis	ICD-9-CM
200	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue	Diagnosis	ICD-9-CM
200.0	Reticulosarcoma	Diagnosis	ICD-9-CM
200.00	Reticulosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.01	Reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.02	Reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.03	Reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.04	Reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.05	Reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.06	Reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.07	Reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.08	Reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.1	Lymphosarcoma	Diagnosis	ICD-9-CM
200.10	Lymphosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.11	Lymphosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.12	Lymphosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.13	Lymphosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.14	Lymphosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.15	Lymphosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.16	Lymphosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.17	Lymphosarcoma of spleen	Diagnosis	ICD-9-CM
200.18	Lymphosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.2	Burkitt's tumor or lymphoma	Diagnosis	ICD-9-CM
200.20	Burkitt's tumor or lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
200.21	Burkitt's tumor or lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.22	Burkitt's tumor or lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.23	Burkitt's tumor or lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.24	Burkitt's tumor or lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.25	Burkitt's tumor or lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.26	Burkitt's tumor or lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.27	Burkitt's tumor or lymphoma of spleen	Diagnosis	ICD-9-CM
200.28	Burkitt's tumor or lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.3	Marginal zone lymphoma	Diagnosis	ICD-9-CM
200.30	Marginal zone lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.31	Marginal zone lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.32	Marginal zone lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.33	Marginal zone lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.34	Marginal zone lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.35	Marginal zone lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.36	Marginal zone lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.37	Marginal zone lymphoma, spleen	Diagnosis	ICD-9-CM
200.38	Marginal zone lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.4	Mantle cell lymphoma	Diagnosis	ICD-9-CM
200.40	Mantle cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.41	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.42	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.43	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.44	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.45	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.46	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.47	Mantle cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.48	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.5	Primary central nervous system lymphoma	Diagnosis	ICD-9-CM
200.50	Primary central nervous system lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.51	Primary central nervous system lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.52	Primary central nervous system lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.53	Primary central nervous system lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.54	Primary central nervous system lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.55	Primary central nervous system lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.56	Primary central nervous system lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.57	Primary central nervous system lymphoma, spleen	Diagnosis	ICD-9-CM
200.58	Primary central nervous system lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.6	Anaplastic large cell lymphoma	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
200.60	Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.61	Anaplastic large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.62	Anaplastic large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.63	Anaplastic large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.64	Anaplastic large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.65	Anaplastic large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.66	Anaplastic large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.67	Anaplastic large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.68	Anaplastic large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.7	Large cell lymphoma	Diagnosis	ICD-9-CM
200.70	Large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.71	Large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.72	Large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.73	Large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.74	Large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.75	Large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.76	Large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.77	Large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.78	Large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.8	Other named variants of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
200.80	Other named variants, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.81	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.82	Other named variants of lymphosarcoma and reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.83	Other named variants of lymphosarcoma and reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.84	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.85	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.86	Other named variants of lymphosarcoma and reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.87	Other named variants of lymphosarcoma and reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.88	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.0	Nodular lymphoma	Diagnosis	ICD-9-CM
202.00	Nodular lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.01	Nodular lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.02	Nodular lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.03	Nodular lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.04	Nodular lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
202.05	Nodular lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.06	Nodular lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.07	Nodular lymphoma of spleen	Diagnosis	ICD-9-CM
202.08	Nodular lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.1	Mycosis fungoides	Diagnosis	ICD-9-CM
202.10	Mycosis fungoides, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.11	Mycosis fungoides of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.12	Mycosis fungoides of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.13	Mycosis fungoides of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.14	Mycosis fungoides of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.15	Mycosis fungoides of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.16	Mycosis fungoides of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.17	Mycosis fungoides of spleen	Diagnosis	ICD-9-CM
202.18	Mycosis fungoides of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.2	Sezary's disease	Diagnosis	ICD-9-CM
202.20	Sezary's disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.21	Sezary's disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.22	Sezary's disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.23	Sezary's disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.24	Sezary's disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.25	Sezary's disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.26	Sezary's disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.27	Sezary's disease of spleen	Diagnosis	ICD-9-CM
202.28	Sezary's disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.4	Leukemic reticuloendotheliosis	Diagnosis	ICD-9-CM
202.40	Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.41	Leukemic reticuloendotheliosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.42	Leukemic reticuloendotheliosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.43	Leukemic reticuloendotheliosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.44	Leukemic reticuloendotheliosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.45	Leukemic reticuloendotheliosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.46	Leukemic reticuloendotheliosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.47	Leukemic reticuloendotheliosis of spleen	Diagnosis	ICD-9-CM
202.48	Leukemic reticuloendotheliosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.8	Other malignant lymphomas	Diagnosis	ICD-9-CM
202.80	Other malignant lymphomas, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.81	Other malignant lymphomas of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.82	Other malignant lymphomas of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.83	Other malignant lymphomas of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.84	Other malignant lymphomas of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
202.85	Other malignant lymphomas of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.86	Other malignant lymphomas of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.87	Other malignant lymphomas of spleen	Diagnosis	ICD-9-CM
202.88	Other malignant lymphomas of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.9	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.90	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.91	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.92	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.93	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.94	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.95	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.96	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.97	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of spleen	Diagnosis	ICD-9-CM
202.98	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
203.1	Plasma cell leukemia	Diagnosis	ICD-9-CM
203.10	Plasma cell leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.11	Plasma cell leukemia in remission	Diagnosis	ICD-9-CM
204.0	Acute lymphoid leukemia	Diagnosis	ICD-9-CM
204.00	Acute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.01	Acute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.1	Chronic lymphoid leukemia	Diagnosis	ICD-9-CM
204.10	Chronic lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.11	Chronic lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.2	Subacute lymphoid leukemia	Diagnosis	ICD-9-CM
204.20	Subacute lymphoid leukemia, without mention of having achieved	Diagnosis	ICD-9-CM
204.21	Subacute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.8	Other lymphoid leukemia	Diagnosis	ICD-9-CM
204.80	Other lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.81	Other lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.9	Unspecified lymphoid leukemia	Diagnosis	ICD-9-CM
204.90	Unspecified lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.91	Unspecified lymphoid leukemia in remission	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
205	Myeloid leukemia	Diagnosis	ICD-9-CM
205.0	Acute myeloid leukemia	Diagnosis	ICD-9-CM
205.00	Acute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.01	Acute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.1	Chronic myeloid leukemia	Diagnosis	ICD-9-CM
205.10	Chronic myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.11	Chronic myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.2	Subacute myeloid leukemia	Diagnosis	ICD-9-CM
205.20	Subacute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.21	Subacute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.3	Myeloid sarcoma	Diagnosis	ICD-9-CM
205.30	Myeloid sarcoma, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.31	Myeloid sarcoma in remission	Diagnosis	ICD-9-CM
205.8	Other myeloid leukemia	Diagnosis	ICD-9-CM
205.80	Other myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.81	Other myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.9	Unspecified myeloid leukemia	Diagnosis	ICD-9-CM
205.90	Unspecified myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.91	Unspecified myeloid leukemia in remission	Diagnosis	ICD-9-CM
20555	Placement of needles or catheters into muscle and/or soft tissue for subsequent interstitial radioelement application (at the time of or subsequent to the procedure)	Procedure	CPT-4
206	Monocytic leukemia	Diagnosis	ICD-9-CM
206.0	Acute monocytic leukemia	Diagnosis	ICD-9-CM
206.00	Acute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.01	Acute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.1	Chronic monocytic leukemia	Diagnosis	ICD-9-CM
206.10	Chronic monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.11	Chronic monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.2	Subacute monocytic leukemia	Diagnosis	ICD-9-CM
206.20	Subacute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.21	Subacute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.8	Other monocytic leukemia	Diagnosis	ICD-9-CM
206.80	Other monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.81	Other monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.9	Unspecified monocytic leukemia	Diagnosis	ICD-9-CM
206.90	Unspecified monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.91	Unspecified monocytic leukemia in remission	Diagnosis	ICD-9-CM
207	Other specified leukemia	Diagnosis	ICD-9-CM
207.0	Acute erythremia and erythroleukemia	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
207.00	Acute erythremia and erythroleukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.01	Acute erythremia and erythroleukemia in remission	Diagnosis	ICD-9-CM
207.1	Chronic erythremia	Diagnosis	ICD-9-CM
207.10	Chronic erythremia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.11	Chronic erythremia in remission	Diagnosis	ICD-9-CM
207.2	Megakaryocytic leukemia	Diagnosis	ICD-9-CM
207.20	Megakaryocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.21	Megakaryocytic leukemia in remission	Diagnosis	ICD-9-CM
207.8	Other specified leukemia	Diagnosis	ICD-9-CM
207.80	Other specified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.81	Other specified leukemia in remission	Diagnosis	ICD-9-CM
208.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.00	Acute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.01	Acute leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.10	Chronic leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.11	Chronic leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.2	Subacute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.20	Subacute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.21	Subactue leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.8	Other leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.80	Other leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.81	Other leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.9	Unspecified leukemia	Diagnosis	ICD-9-CM
208.90	Unspecified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.91	Unspecified leukemia in remission	Diagnosis	ICD-9-CM
32553	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), percutaneous, intra-thoracic, single or	Procedure	CPT-4
32701	Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or particle beam), entire course of treatment	Procedure	CPT-4
49327	Laparoscopy, surgical; with placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), intra-abdominal, intrapelvic, and/or retroperitoneum, including imaging guidance, if performed, single or multiple (List separately in addition to code for primary procedure)	Procedure	CPT-4
49411	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), percutaneous, intra-abdominal, intra-pelvic (except prostate), and/or retroperitoneum, single or multiple	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
49412	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), open, intra-abdominal, intrapelvic, and/or retroperitoneum, including image guidance, if performed, single or multiple (List separately in addition to code for primary procedure)	Procedure	CPT-4
51720	Bladder instillation of anticarcinogenic agent (including retention time)	Procedure	CPT-4
53220	Excision or fulguration of carcinoma of urethra	Procedure	CPT-4
55860	Exposure of prostate, any approach, for insertion of radioactive substance;	Procedure	CPT-4
55862	EXPOS PROSTATE-INSRT RADIOACT; W/LYMPH NODE BX	Procedure	CPT-4
55865	EXPOSURE PROSTATE-INSRT RADIOACT; W/BILAT LYMPH	Procedure	CPT-4
55875	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4
55876	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), prostate (via needle, any approach), single or	Procedure	CPT-4
55920	Placement of needles or catheters into pelvic organs and/or genitalia (except prostate) for subsequent interstitial radioelement application	Procedure	CPT-4
57155	Insertion of uterine tandem and/or vaginal ovoids for clinical brachytherapy	Procedure	CPT-4
58240	Pelvic exenteration for gynecologic malignancy, with total abdominal hysterectomy or cervicectomy, with or without removal of tube(s), with or without removal of ovary(s), with removal of bladder and ureteral transplantations, and/or abdominoperineal resection of rectum and colon and colstomy, or any combination thereof	Procedure	CPT-4
58346	Insertion of Heyman capsules for clinical brachytherapy	Procedure	CPT-4
58943	Oophorectomy, partial or total, unilateral or bilateral; for ovarian, tubal or primary peritoneal malignancy, with para-aortic and pelvic lymph node biopsies, peritoneal washings, peritoneal biopsies, diaphragmatic assessments, with or without salpingectomy(s), with or without omentectomy	Procedure	CPT-4
58950	Resection of ovarian, tubal or primary peritoneal malignancy with bilateral salpingo-oophorectomy and omentectomy;	Procedure	CPT-4
58951	Resection (initial) of ovarian, tubal or primary peritoneal malignancy with bilateral salpingo-oophorectomy and omentectomy; with total abdominal hysterectomy, pelvic and limited para-aortic lymphadenectomy	Procedure	CPT-4
58952	Resection (initial) of ovarian, tubal or primary peritoneal malignancy with bilateral salpingo-oophorectomy and omentectomy; with radical dissection for debulking (ie, radical excision or destruction, intra-abdominal or retroperitoneal tumors)	Procedure	CPT-4
58956	Bilateral salpingo-oophorectomy with total omentectomy, total abdominal hysterectomy for malignancy	Procedure	CPT-4
58957	Resection (tumor debulking) of recurrent ovarian, tubal, primary peritoneal, uterine malignancy (intra-abdominal, retroperitoneal tumors), with omentectomy, if performed;	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
58958	Resection (tumor debulking) of recurrent ovarian, tubal, primary peritoneal, uterine malignancy (intra-abdominal, retroperitoneal tumors), with omentectomy, if performed; with pelvic lymphadenectomy and limited para-aortic lymphadenectomy	Procedure	CPT-4
58960	Laparotomy, for staging or restaging of overian, tubal or primary peritoneal malignancy (second look), with or with omenectomy, peritoneal washing, biopsy of abdominal and pelvic peritoneam, diaphragmatic assessment with pelvic and limited para-aortic lymphadenectomy	Procedure	CPT-4
60252	THYROIDECTOMY TOT/SUBTL-MALIG; W/LTD NECK DISSEC	Procedure	CPT-4
60254	Thyroidectomy, total or subtotal for malignancy; with radical neck	Procedure	CPT-4
61517	Implantation of brain intracavitary chemotherapy agent (List separately in addition to code for primary procedure)	Procedure	CPT-4
61770	Stereotactic localization, including burr hole(s), with insertion of catheter(s) or probe(s) for placement of radiation source	Procedure	CPT-4
61793	Stereotactic radiosurgery (particle beam, gamma ray or linear accelerator), one or more sessions	Procedure	CPT-4
67218	Destruction of localized lesion of retina (eg, macular edema, tumors), 1 or more sessions; radiation by implantation of source (includes removal of source)	Procedure	CPT-4
76873	Ultrasound, transrectal; prostate volume study for brachytherapy treatment planning (separate procedure)	Procedure	CPT-4
76950	Ultrasonic guidance for placement of radiation therapy fields	Procedure	CPT-4
76960	Ultrasonic guidance for placement of radiation therapy fields, except for B-scan echography	Procedure	CPT-4
76965	Ultrasonic guidance for interstitial radioelement application	Procedure	CPT-4
77014	Computed tomography guidance for placement of radiation therapy fields	Procedure	CPT-4
77261	Therapeutic radiology treatment planning; simple	Procedure	CPT-4
77262	Therapeutic radiology treatment planning; intermediate	Procedure	CPT-4
77263	Therapeutic radiology treatment planning; complex	Procedure	CPT-4
77280	Therapeutic radiology simulation-aided field setting; simple	Procedure	CPT-4
77285	Therapeutic radiology simulation-aided field setting; intermediate	Procedure	CPT-4
77290	Therapeutic radiology simulation-aided field setting; complex	Procedure	CPT-4
77295	THERAP RAD SIMULATION-AIDED FIELD SETTING; 3-D	Procedure	CPT-4
77299	Unlisted procedure, therapeutic radiology clinical treatment planning	Procedure	CPT-4
77300	Basic radiation dosimetry calculation, central axis depth dose, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, as required during course of treatment, only when prescribed by the treating physician	Procedure	CPT-4
77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications	Procedure	CPT-4
77305	Teletherapy, isodose plan (whether hand or computer calculated); simple (1 or 2 parallel opposed unmodified ports directed to a single area of	Procedure	CPT-4
77306	Teletherapy isodose plan; simple (1 or 2 unmodified ports directed to a single area of interest), includes basic dosimetry calculation(s)	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
77307	Teletherapy isodose plan; complex (multiple treatment areas, tangential ports, the use of wedges, blocking, rotational beam, or special beam considerations), includes basic dosimetry calculation(s)	Procedure	CPT-4
77310	Teletherapy, isodose plan (whether hand or computer calculated); intermediate (3 or more treatment ports directed to a single area of	Procedure	CPT-4
77315	Teletherapy, isodose plan (whether hand or computer calculated); complex (mantle or inverted Y, tangential ports, the use of wedges, compensators, complex blocking, rotational beam, or special beam considerations)	Procedure	CPT-4
77316	Brachytherapy isodose plan; simple (calculation[s] made from 1 to 4 sources, or remote afterloading brachytherapy, 1 channel), includes basic dosimetry calculation(s)	Procedure	CPT-4
77317	Brachytherapy isodose plan; intermediate (calculation[s] made from 5 to 10 sources, or remote afterloading brachytherapy, 2-12 channels), includes basic dosimetry calculation(s)	Procedure	CPT-4
77318	Brachytherapy isodose plan; complex (calculation[s] made from over 10 sources, or remote afterloading brachytherapy, over 12 channels), includes basic dosimetry calculation(s)	Procedure	CPT-4
77321	Special teletherapy port plan, particles, hemibody, total body	Procedure	CPT-4
77326	Brachytherapy isodose calculation; simple (calculation made from single plane, one to four sources/ ribbon application, remote afterloading brachytherapy, 1 to 8 sources)	Procedure	CPT-4
77327	Brachytherapy isodose calculation; intermediate (multiplane dosage calculations, application involving 5 to 10 sources/ribbons, remote afterloading brachytherapy, 9 to 12 sources)	Procedure	CPT-4
77328	Brachytherapy isodose calculation; complex (multiplane isodose plan, volume implant calculations, over 10 sources/ribbons used, special spatial reconstruction, remote afterloading brachytherapy, over 12 sources)	Procedure	CPT-4
77331	Special dosimetry (eg, TLD, microdosimetry) (specify), only when prescribed by the treating physician	Procedure	CPT-4
77332	Treatment devices, design and construction; simple (simple block, simple bolus)	Procedure	CPT-4
77333	Treatment devices, design and construction; intermediate (multiple blocks, stents, bite blocks, special bolus)	Procedure	CPT-4
77334	Treatment devices, design and construction; complex (irregular blocks, special shields, compensators, wedges, molds or casts)	Procedure	CPT-4
77336	Continuing medical physics consultation, including assessment of treatment parameters, quality assurance of dose delivery, and review of patient treatment documentation in support of the radiation oncologist, reported per week of therapy	Procedure	CPT-4
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan	Procedure	CPT-4
77370	Special medical radiation physics consultation	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
77371	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based	Procedure	CPT-4
77372	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based	Procedure	CPT-4
77373	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions	Procedure	CPT-4
77380	Proton beam delivery to a single treatment area, single port, custom block, with or without compensation, with treatment set-up and verification images	Procedure	CPT-4
77381	Proton beam treatment to one or two treatment areas, two or more ports, two or more custom blocks, and two or more compensators, with treatment set-up and verification images	Procedure	CPT-4
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple	Procedure	CPT-4
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex	Procedure	CPT-4
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed	Procedure	CPT-4
77399	Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services	Procedure	CPT-4
77401	Radiation treatment delivery, superficial and/or ortho voltage	Procedure	CPT-4
77402	Radiation treatment delivery, => 1 MeV; simple	Procedure	CPT-4
77403	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 6-10 MeV	Procedure	CPT-4
77404	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 11-19 MeV	Procedure	CPT-4
77406	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 20 MeV or greater	Procedure	CPT-4
77407	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; up to 5 MeV	Procedure	CPT-4
77408	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 6-10 MeV	Procedure	CPT-4
77409	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 11-19 MeV	Procedure	CPT-4
77411	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 20 MeV or greater	Procedure	CPT-4
77412	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, special particle beam (eg, electron or neutrons); up to 5 MeV	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
77413	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, special particle beam (eg, electron or neutrons); 6-10 MeV	Procedure	CPT-4
77414	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV	Procedure	CPT-4
77416	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, special particle beam (eg, electron or neutrons); 20 MeV or greater	Procedure	CPT-4
77417	Therapeutic radiology port film(s)	Procedure	CPT-4
77418	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session	Procedure	CPT-4
77419	Weekly radiation therapy management; conformal	Procedure	CPT-4
77420	WK RAD THERAP MGMT; SIMPL	Procedure	CPT-4
77421	Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy	Procedure	CPT-4
77422	High energy neutron radiation treatment delivery; single treatment area using a single port or parallel-opposed ports with no blocks or simple blocking	Procedure	CPT-4
77423	High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s)	Procedure	CPT-4
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session	Procedure	CPT-4
77425	Intraoperative radiation treatment delivery, electrons, single treatment session	Procedure	CPT-4
77427	Radiation treatment management, 5 treatments	Procedure	CPT-4
77430	WK RAD THERAP MGMT; COMPLX	Procedure	CPT-4
77431	Radiation therapy management with complete course of therapy consisting of 1 or 2 fractions only	Procedure	CPT-4
77432	Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)	Procedure	CPT-4
77435	Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions	Procedure	CPT-4
77469	Intraoperative radiation treatment management	Procedure	CPT-4
77470	Special treatment procedure (eg, total body irradiation, hemibody irradiation, per oral, vaginal cone irradiation)	Procedure	CPT-4
77499	Unlisted procedure, therapeutic radiology treatment management	Procedure	CPT-4
77520	Proton treatment delivery; simple, without compensation	Procedure	CPT-4
77522	Proton treatment delivery; simple, with compensation	Procedure	CPT-4
77523	Proton treatment delivery; intermediate	Procedure	CPT-4
77525	Proton treatment delivery; complex	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
77600	Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less)	Procedure	CPT-4
77605	Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm)	Procedure	CPT-4
77610	Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators	Procedure	CPT-4
77615	Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators	Procedure	CPT-4
77620	Hyperthermia generated by intracavitary probe(s)	Procedure	CPT-4
77750	Infusion or instillation of radioelement solution	Procedure	CPT-4
77761	Intracavitary radioelement application; simple	Procedure	CPT-4
77762	Intracavitary radiation source application; intermediate	Procedure	CPT-4
77763	Intracavitary radioelement application; complex	Procedure	CPT-4
77776	Interstitial radiation source application; simple	Procedure	CPT-4
77777	Interstitial radioelement application; intermediate	Procedure	CPT-4
77778	Interstitial radioelement application; complex	Procedure	CPT-4
77781	Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters	Procedure	CPT-4
77782	Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters	Procedure	CPT-4
77783	Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters	Procedure	CPT-4
77784	Remote afterloading high intensity brachytherapy; over 12 source positions or catheters	Procedure	CPT-4
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1 channel	Procedure	CPT-4
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels	Procedure	CPT-4
77787	Remote afterloading high dose rate radionuclide brachytherapy; over 12 channels	Procedure	CPT-4
77789	Surface application of radioelement	Procedure	CPT-4
77790	Supervision, handling, loading of radioelement	Procedure	CPT-4
77799	Unlisted procedure, clinical brachytherapy	Procedure	CPT-4
78015	Thyroid carcinoma metastases imaging; limited area (eg, neck and chest only)	Procedure	CPT-4
78016	Thyroid carcinoma metastases imaging; with additional studies (eg, urinary recovery)	Procedure	CPT-4
78018	Thyroid carcinoma metastases imaging; whole body	Procedure	CPT-4
78020	Thyroid carcinoma metastases uptake (List separately in addition to code for primary procedure)	Procedure	CPT-4
79200	Intracavitary radioactive colloid therapy	Procedure	CPT-4
79300	Radiopharmaceutical therapy, by interstitial radioactive colloid administration	Procedure	CPT-4
79440	INTRA-ARTICULAR RADIOPHARM THERAP	Procedure	CPT-4
79999	Radiopharmaceutical therapy, unlisted procedure	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
90586	Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use	Procedure	CPT-4
92974	Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy (List separately in addition to code for primary procedure)	Procedure	CPT-4
96400	Chemotherapy administration, subcutaneous or intramuscular, with or without local anesthesia	Procedure	CPT-4
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Procedure	CPT-4
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	Procedure	CPT-4
96405	Chemotherapy administration, intralesional; up to and including 7 lesions	Procedure	CPT-4
96406	Chemotherapy administration, intralesional; more than 7 lesions	Procedure	CPT-4
96408	Chemotherapy administration, intravenous; push technique	Procedure	CPT-4
96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug	Procedure	CPT-4
96410	Chemotherapy administration, intravenous; infusion technique, up to one hour	Procedure	CPT-4
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary	Procedure	CPT-4
96412	Chemotherapy administration, intravenous; infusion technique, one to 8 hours, each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Procedure	CPT-4
96414	Chemotherapy administration, intravenous; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump	Procedure	CPT-4
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	Procedure	CPT-4
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96420	CHEMOTX ADMIN INTRA-ART; PUSH TECH	Procedure	CPT-4
96422	CHEMOTX ADMIN INTRA-ART; INFUSION TECH TO 1 HR	Procedure	CPT-4
96423	Chemotherapy administration, intra-arterial; infusion technique, each additional hour up to 8 hours (List separately in addition to code for primary procedure)	Procedure	CPT-4
96425	Chemotherapy administration, intra-arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump	Procedure	CPT-4

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
96440	CHEMOTX-PLEURAL CAVITY-REQ & INCL THORACENTESIS	Procedure	CPT-4
96445	Chemotherapy administration into peritoneal cavity, requiring and including peritoneocentesis	Procedure	CPT-4
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter	Procedure	CPT-4
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture	Procedure	CPT-4
96520	Refilling and maintenance of portable pump	Procedure	CPT-4
96521	Refilling and maintenance of portable pump	Procedure	CPT-4
96522	Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic (eg, intravenous, intra-arterial)	Procedure	CPT-4
96523	Irrigation of implanted venous access device for drug delivery systems	Procedure	CPT-4
96530	Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic (eg, intravenous, intra-arterial)	Procedure	CPT-4
96542	CHEMOTX INJ SUBARACH/INTRAVENTRIC-1/MX AGENTS	Procedure	CPT-4
96545	Provision of chemotherapy agent	Procedure	CPT-4
96549	UNLISTED CHEMOTX PROC	Procedure	CPT-4
99555	Home infusion for chemotherapy, per visit	Procedure	CPT-4
A4555	Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only	Procedure	HCPCS
A4650	Implantable radiation dosimeter, each	Procedure	HCPCS
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C21.0	Malignant neoplasm of anus, unspecified	Diagnosis	ICD-10-CM
C21.1	Malignant neoplasm of anal canal	Diagnosis	ICD-10-CM
C21.2	Malignant neoplasm of cloacogenic zone	Diagnosis	ICD-10-CM
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
C25.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-10-CM
C25.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-10-CM
C25.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-10-CM
C25.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-10-CM
C25.4	Malignant neoplasm of endocrine pancreas	Diagnosis	ICD-10-CM
C25.7	Malignant neoplasm of other parts of pancreas	Diagnosis	ICD-10-CM
C25.8	Malignant neoplasm of overlapping sites of pancreas	Diagnosis	ICD-10-CM
C25.9	Malignant neoplasm of pancreas, unspecified	Diagnosis	ICD-10-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
C43.0	Malignant melanoma of lip	Diagnosis	ICD-10-CM
C43.10	Malignant melanoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C43.11	Malignant melanoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C43.12	Malignant melanoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C43.20	Malignant melanoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C43.21	Malignant melanoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C43.22	Malignant melanoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C43.30	Malignant melanoma of unspecified part of face	Diagnosis	ICD-10-CM
C43.31	Malignant melanoma of nose	Diagnosis	ICD-10-CM
C43.39	Malignant melanoma of other parts of face	Diagnosis	ICD-10-CM
C43.4	Malignant melanoma of scalp and neck	Diagnosis	ICD-10-CM
C43.51	Malignant melanoma of anal skin	Diagnosis	ICD-10-CM
C43.52	Malignant melanoma of skin of breast	Diagnosis	ICD-10-CM
C43.59	Malignant melanoma of other part of trunk	Diagnosis	ICD-10-CM
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.61	Malignant melanoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.62	Malignant melanoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.70	Malignant melanoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C43.71	Malignant melanoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C43.72	Malignant melanoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C43.8	Malignant melanoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C43.9	Malignant melanoma of skin, unspecified	Diagnosis	ICD-10-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
C53.0	Malignant neoplasm of endocervix	Diagnosis	ICD-10-CM
C53.1	Malignant neoplasm of exocervix	Diagnosis	ICD-10-CM
C53.8	Malignant neoplasm of overlapping sites of cervix uteri	Diagnosis	ICD-10-CM
C53.9	Malignant neoplasm of cervix uteri, unspecified	Diagnosis	ICD-10-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
C55	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-10-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
C73	Malignant neoplasm of thyroid gland	Diagnosis	ICD-10-CM
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C74.01	Malignant neoplasm of cortex of right adrenal gland	Diagnosis	ICD-10-CM
C74.02	Malignant neoplasm of cortex of left adrenal gland	Diagnosis	ICD-10-CM
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.11	Malignant neoplasm of medulla of right adrenal gland	Diagnosis	ICD-10-CM
C74.12	Malignant neoplasm of medulla of left adrenal gland	Diagnosis	ICD-10-CM
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.91	Malignant neoplasm of unspecified part of right adrenal gland	Diagnosis	ICD-10-CM
C74.92	Malignant neoplasm of unspecified part of left adrenal gland	Diagnosis	ICD-10-CM
C75.0	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-10-CM
C75.1	Malignant neoplasm of pituitary gland	Diagnosis	ICD-10-CM
C75.2	Malignant neoplasm of craniopharyngeal duct	Diagnosis	ICD-10-CM
C75.3	Malignant neoplasm of pineal gland	Diagnosis	ICD-10-CM
C75.4	Malignant neoplasm of carotid body	Diagnosis	ICD-10-CM
C75.5	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-10-CM
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified	Diagnosis	ICD-10-CM
C75.9	Malignant neoplasm of endocrine gland, unspecified	Diagnosis	ICD-10-CM
C82.00	Follicular lymphoma grade I, unspecified site	Diagnosis	ICD-10-CM
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.07	Follicular lymphoma grade I, spleen	Diagnosis	ICD-10-CM
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.10	Follicular lymphoma grade II, unspecified site	Diagnosis	ICD-10-CM
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.17	Follicular lymphoma grade II, spleen	Diagnosis	ICD-10-CM
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.20	Follicular lymphoma grade III, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.27	Follicular lymphoma grade III, unspecified, spleen	Diagnosis	ICD-10-CM
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.30	Follicular lymphoma grade IIIa, unspecified site	Diagnosis	ICD-10-CM
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.37	Follicular lymphoma grade IIIa, spleen	Diagnosis	ICD-10-CM
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.40	Follicular lymphoma grade IIIb, unspecified site	Diagnosis	ICD-10-CM
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.47	Follicular lymphoma grade IIIb, spleen	Diagnosis	ICD-10-CM
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.50	Diffuse follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.57	Diffuse follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.60	Cutaneous follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.67	Cutaneous follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.80	Other types of follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.87	Other types of follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.90	Follicular lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.97	Follicular lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.00	Small cell B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.07	Small cell B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.10	Mantle cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.17	Mantle cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.19	Mantle cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.30	Diffuse large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.37	Diffuse large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.57	Lymphoblastic (diffuse) lymphoma, spleen	Diagnosis	ICD-10-CM
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.70	Burkitt lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.72	Burkitt lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.76	Burkitt lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.77	Burkitt lymphoma, spleen	Diagnosis	ICD-10-CM
C83.78	Burkitt lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.79	Burkitt lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.80	Other non-follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C83.87	Other non-follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph	Diagnosis	ICD-10-CM
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple	Diagnosis	ICD-10-CM
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.00	Mycosis fungoides, unspecified site	Diagnosis	ICD-10-CM
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.02	Mycosis fungoides, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.03	Mycosis fungoides, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.06	Mycosis fungoides, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.07	Mycosis fungoides, spleen	Diagnosis	ICD-10-CM
C84.08	Mycosis fungoides, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.09	Mycosis fungoides, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.10	Sezary disease, unspecified site	Diagnosis	ICD-10-CM
C84.11	Sezary disease, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.12	Sezary disease, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.13	Sezary disease, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.14	Sezary disease, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.16	Sezary disease, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.17	Sezary disease, spleen	Diagnosis	ICD-10-CM
C84.18	Sezary disease, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.19	Sezary disease, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site	Diagnosis	ICD-10-CM
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen	Diagnosis	ICD-10-CM
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site	Diagnosis	ICD-10-CM
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen	Diagnosis	ICD-10-CM
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen	Diagnosis	ICD-10-CM
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and	Diagnosis	ICD-10-CM
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site	Diagnosis	ICD-10-CM
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.Z7	Other mature T/NK-cell lymphomas, spleen	Diagnosis	ICD-10-CM
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.10	Unspecified B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower	Diagnosis	ICD-10-CM
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.17	Unspecified B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ	Diagnosis	ICD-10-CM
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.87	Other specified types of non-Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.97	Non-Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C86.0	Extranodal NK/T-cell lymphoma, nasal type	Diagnosis	ICD-10-CM
C86.1	Hepatosplenic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.2	Enteropathy-type (intestinal) T-cell lymphoma	Diagnosis	ICD-10-CM
C86.3	Subcutaneous panniculitis-like T-cell lymphoma	Diagnosis	ICD-10-CM
C86.4	Blastic NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.5	Angioimmunoblastic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.6	Primary cutaneous CD30-positive T-cell proliferations	Diagnosis	ICD-10-CM
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	Diagnosis	ICD-10-CM
C8953	Chemotherapy administration, intravenous; push technique	Procedure	HCPCS
C8954	Chemotherapy administration, intravenous; infusion technique, up to one hour	Procedure	HCPCS
C8955	Chemotherapy administration, intravenous; infusion technique, each additional hour (List separately in addition to C8954)	Procedure	HCPCS
C90.10	Plasma cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C90.11	Plasma cell leukemia in remission	Diagnosis	ICD-10-CM
C9021	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
C9025	Injection, ramucirumab, 5 mg	Procedure	HCPCS
C91.00	Acute lymphoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.01	Acute lymphoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.11	Chronic lymphocytic leukemia of B-cell type in remission	Diagnosis	ICD-10-CM
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.31	Prolymphocytic leukemia of B-cell type, in remission	Diagnosis	ICD-10-CM
C91.40	Hairy cell leukemia not having achieved remission	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C91.41	Hairy cell leukemia, in remission	Diagnosis	ICD-10-CM
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission	Diagnosis	ICD-10-CM
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission	Diagnosis	ICD-10-CM
C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.61	Prolymphocytic leukemia of T-cell type, in remission	Diagnosis	ICD-10-CM
C91.90	Lymphoid leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C91.91	Lymphoid leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission	Diagnosis	ICD-10-CM
C91.A1	Mature B-cell leukemia Burkitt-type, in remission	Diagnosis	ICD-10-CM
C91.Z0	Other lymphoid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.Z1	Other lymphoid leukemia, in remission	Diagnosis	ICD-10-CM
C9131	Injection, ado-trastuzumab emtansine, 1 mg	Procedure	HCPCS
C92.00	Acute myeloblastic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.01	Acute myeloblastic leukemia, in remission	Diagnosis	ICD-10-CM
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	Diagnosis	ICD-10-CM
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission	Diagnosis	ICD-10-CM
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	Diagnosis	ICD-10-CM
C92.21	Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission	Diagnosis	ICD-10-CM
C92.30	Myeloid sarcoma, not having achieved remission	Diagnosis	ICD-10-CM
C92.31	Myeloid sarcoma, in remission	Diagnosis	ICD-10-CM
C92.40	Acute promyelocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.41	Acute promyelocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.50	Acute myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.51	Acute myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission	Diagnosis	ICD-10-CM
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission	Diagnosis	ICD-10-CM
C92.90	Myeloid leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C92.91	Myeloid leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission	Diagnosis	ICD-10-CM
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission	Diagnosis	ICD-10-CM
C92.Z0	Other myeloid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C92.Z1	Other myeloid leukemia, in remission	Diagnosis	ICD-10-CM
C9259	Injection, pralatrexate, 1 mg	Procedure	HCPCS
C9260	Injection, ofatumumab, 10 mg	Procedure	HCPCS
C9262	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
C9265	Injection, romidepsin, 1 mg	Procedure	HCPCS
C9273	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
C9276	Injection, cabazitaxel, 1 mg	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C9280	Injection, eribulin mesylate, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9287	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
C9289	Injection, asparaginase Erwinia chrysanthemi, 1,000 IU	Procedure	HCPCS
C9292	Injection, pertuzumab, 10 mg	Procedure	HCPCS
C9295	Injection, carfilzomib, 1 mg	Procedure	HCPCS
C9296	Injection, ziv-aflibercept, 1 mg	Procedure	HCPCS
C9297	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.01	Acute monoblastic/monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.11	Chronic myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.31	Juvenile myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.91	Monocytic leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z1	Other monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.01	Acute erythroid leukemia, in remission	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.21	Acute megakaryoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.31	Mast cell leukemia, in remission	Diagnosis	ICD-10-CM
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.81	Other specified leukemias, in remission	Diagnosis	ICD-10-CM
C9414	Etoposide; oral, 50 mg, brand name	Procedure	HCPCS
C9415	Doxorubicin HCl, 10 mg, brand name	Procedure	HCPCS
C9416	BCG (intravesical) per instillation, brand name	Procedure	HCPCS
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
C9418	Cisplatin, powder or solution, per 10 mg, brand name	Procedure	HCPCS
C9419	Injection, cladribine, per 1 mg, brand name	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
C9422	Cytarabine, 100 mg, brand name	Procedure	HCPCS
C9423	Dacarbazine, 100 mg, brand name	Procedure	HCPCS
C9424	Daunorubicin, 10 mg	Procedure	HCPCS
C9425	Etoposide, 10 mg, brand name	Procedure	HCPCS
C9426	Floxuridine, 500 mg, brand name	Procedure	HCPCS
C9427	Ifosfamide, 1 gm, brand name	Procedure	HCPCS
C9428	Mesna, 200 mg, brand name	Procedure	HCPCS
C9429	Idarubicin HCl, 5 mg, brand name	Procedure	HCPCS
C9430	Leuprolide acetate, per 1 mg, brand name	Procedure	HCPCS
C9431	Paclitaxel, 30 mg, brand name	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
C9432	Mitomycin, 5 mg, brand name	Procedure	HCPCS
C9433	Thiotepa, 15 mg, brand name	Procedure	HCPCS
C9434	Supply of radiopharmaceutical diagnostic imaging agent, Gallium Ga 67, per mci, brand name	Procedure	HCPCS
C9435	Injection, gonadorelin HCl, brand name, per 100 mcg	Procedure	HCPCS
C9436	Azathioprine, parenteral, brand name, per 100 mg	Procedure	HCPCS
C9437	Carmustine, brand name, 100 mg	Procedure	HCPCS
C9442	Injection, belinostat, 10 mg	Procedure	HCPCS
C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.01	Acute leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.11	Chronic leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.91	Leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
C9725	Placement of endorectal intracavitary applicator for high intensity brachytherapy	Procedure	HCPCS
C9726	Placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedure	Procedure	HCPCS
C9728	Placement of interstitial device(s) for radiation therapy/surgery guidance (e.g., fiducial markers, dosimeter), for other than the following sites (any approach): abdomen, pelvis, prostate, retroperitoneum, thorax, single or multiple	Procedure	HCPCS
D03.0	Melanoma in situ of lip	Diagnosis	ICD-10-CM
D03.10	Melanoma in situ of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D03.11	Melanoma in situ of right eyelid, including canthus	Diagnosis	ICD-10-CM
D03.12	Melanoma in situ of left eyelid, including canthus	Diagnosis	ICD-10-CM
D03.20	Melanoma in situ of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D03.21	Melanoma in situ of right ear and external auricular canal	Diagnosis	ICD-10-CM
D03.22	Melanoma in situ of left ear and external auricular canal	Diagnosis	ICD-10-CM
D03.30	Melanoma in situ of unspecified part of face	Diagnosis	ICD-10-CM
D03.39	Melanoma in situ of other parts of face	Diagnosis	ICD-10-CM
D03.4	Melanoma in situ of scalp and neck	Diagnosis	ICD-10-CM
D03.51	Melanoma in situ of anal skin	Diagnosis	ICD-10-CM
D03.52	Melanoma in situ of breast (skin) (soft tissue)	Diagnosis	ICD-10-CM
D03.59	Melanoma in situ of other part of trunk	Diagnosis	ICD-10-CM
D03.60	Melanoma in situ of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.61	Melanoma in situ of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.62	Melanoma in situ of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.70	Melanoma in situ of unspecified lower limb, including hip	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
D03.71	Melanoma in situ of right lower limb, including hip	Diagnosis	ICD-10-CM
D03.72	Melanoma in situ of left lower limb, including hip	Diagnosis	ICD-10-CM
D03.8	Melanoma in situ of other sites	Diagnosis	ICD-10-CM
D03.9	Melanoma in situ, unspecified	Diagnosis	ICD-10-CM
D4381	localized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue, per tooth	Procedure	HCPCS
D5983	radiation carrier	Procedure	HCPCS
D5984	radiation shield	Procedure	HCPCS
D5985	radiation cone locator	Procedure	HCPCS
E0766	Electrical stimulation device used for cancer treatment, includes all accessories, any type	Procedure	HCPCS
G0210	PET imaging whole body; diagnosis; lung cancer, nonsmall cell	Procedure	HCPCS
G0211	PET imaging whole body; initial staging; lung cancer; nonsmall cell	Procedure	HCPCS
G0212	PET imaging whole body; restaging; lung cancer; nonsmall	Procedure	HCPCS
G0215	PET imaging whole body; restaging; colorectal cancer	Procedure	HCPCS
G0223	PET imaging whole body or regional; diagnosis; head and neck cancer; excluding thyroid and CNS cancers	Procedure	HCPCS
G0224	PET imaging whole body or regional; initial staging; head and neck cancer; excluding thyroid and CNS cancers	Procedure	HCPCS
G0225	PET imaging whole body or regional; restaging; head and neck cancer, excluding thyroid and CNS cancers	Procedure	HCPCS
G0226	PET imaging whole body; diagnosis; esophageal cancer	Procedure	HCPCS
G0227	PET imaging whole body; initial staging; esophageal cancer	Procedure	HCPCS
G0228	PET imaging whole body; restaging; esophageal cancer	Procedure	HCPCS
G0231	PET, whole body, for recurrence of colorectal or colorectal metastatic cancer; gamma cameras only	Procedure	HCPCS
G0233	PET, whole body, for recurrence of melanoma; gamma cameras only	Procedure	HCPCS
G0234	PET, regional or whole body, for solitary pulmonary nodule following CT or for initial staging of pathologically diagnosed nonsmall cell lung cancer; gamma cameras only	Procedure	HCPCS
G0252	PET imaging, full and partial-ring PET scanners only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (e.g., initial staging of axillary lymph nodes)	Procedure	HCPCS
G0253	PET imaging for breast cancer, full and partial-ring PET scanners only, staging/restaging of local regional recurrence or distant metastases (i.e., staging/restaging after or prior to course of treatment)	Procedure	HCPCS
G0254	PET imaging for breast cancer, full and partial ring PET scanners only, evaluation of response to treatment, performed during course of treatment	Procedure	HCPCS
G0292	Administration(s) of experimental drug(s) only in a medicare qualifying clinical trial (includes administration for chemotherapy and other types of therapy via infusion and/or other than infusion), per day	Procedure	HCPCS
G0296	Counseling visit to discuss need for lung cancer screening using low dose CT scan (LDCT) (service is for eligibility determination and shared decision making)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G0355	Chemotherapy administration, subcutaneous or intramuscular nonhormonal antineoplastic	Procedure	HCPCS
G0359	Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug	Procedure	HCPCS
G0361	Initiation of prolonged chemotherapy infusion (more than eight hours), requiring use of a portable or implantable pump	Procedure	HCPCS
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate	Procedure	HCPCS
G0464	Colorectal cancer screening; stool-based DNA and fecal occult hemoglobin (e.g., KRAS, NDRG4 and BMP3)	Procedure	HCPCS
G6001	Ultrasonic guidance for placement of radiation therapy fields	Procedure	HCPCS
G6002	Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy	Procedure	HCPCS
G6003	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5 mev	Procedure	HCPCS
G6004	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10 mev	Procedure	HCPCS
G6005	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19 mev	Procedure	HCPCS
G6006	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20 mev or greater	Procedure	HCPCS
G6007	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: up to 5 mev	Procedure	HCPCS
G6008	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 6-10 mev	Procedure	HCPCS
G6009	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 11-19 mev	Procedure	HCPCS
G6010	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 20 mev or greater	Procedure	HCPCS
G6011	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 mev	Procedure	HCPCS
G6012	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev	Procedure	HCPCS
G6013	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev	Procedure	HCPCS
G6014	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 mev or greater	Procedure	HCPCS
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session	Procedure	HCPCS
G6017	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment	Procedure	HCPCS
G8371	Chemotherapy documented as not received or prescribed for Stage III colon cancer patients	Procedure	HCPCS
G8372	Chemotherapy documented as received or prescribed for Stage III colon cancer patients	Procedure	HCPCS
G8373	Chemotherapy plan documented prior to chemotherapy administration	Procedure	HCPCS
G8374	Chemotherapy plan not documented prior to chemotherapy administration	Procedure	HCPCS
G8376	Clinician documentation that breast cancer patient was not eligible for tamoxifen or aromatase inhibitor therapy measure	Procedure	HCPCS
G8377	Clinician documentation that colon cancer patient is not eligible for chemotherapy measure	Procedure	HCPCS
G8379	Documentation of radiation therapy recommended within 12 months of first office visit	Procedure	HCPCS
G8380	For patients with ER or PR positive, Stage IC-III breast cancer, clinician did not document that the patient received or was prescribed tamoxifen or aromatase inhibitor	Procedure	HCPCS
G8381	For patients with ER or PR positive, Stage IC-III breast cancer, clinician documented or prescribed that the patient is receiving tamoxifen or aromatase inhibitor	Procedure	HCPCS
G8389	Myelodysplastic syndrome (MDS) patients with no documentation of iron stores prior to receiving erythropoietin therapy	Procedure	HCPCS
G8464	Clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined	Procedure	HCPCS
G8465	High or very high risk of recurrence of prostate cancer	Procedure	HCPCS
G8518	Clinical stage prior to surgery for lung cancer and esophageal cancer resection was recorded	Procedure	HCPCS
G8519	Clinician documented that patient was not eligible for clinical stage prior to surgery for lung cancer and esophageal cancer resection measure	Procedure	HCPCS
G8520	Clinician stage prior to surgery for lung cancer and esophageal cancer resection was not recorded, reason not specified	Procedure	HCPCS
G8875	Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method	Procedure	HCPCS
G8881	Stage of breast cancer is greater than T1N0M0 or T2N0M0	Procedure	HCPCS
G8927	Adjuvant chemotherapy referred, prescribed or previously received for AJCC stage III, colon cancer	Procedure	HCPCS
G8944	AJCC melanoma cancer stage 0 through IIC melanoma	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9021	Chemotherapy assessment for nausea and/or vomiting, patient reported, performed at the time of chemotherapy administration; assessment Level 1: not at all (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9022	Chemotherapy assessment for nausea and/or vomiting, patient reported, performed at the time of chemotherapy administration; assessment Level 2: a little (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9023	Chemotherapy assessment for nausea and/or vomiting, patient reported, performed at the time of chemotherapy administration; assessment Level 3: quite a bit (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9024	Chemotherapy assessment for nausea and/or vomiting, patient reported, performed at the time of chemotherapy administration; assessment Level 4: very much (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9025	Chemotherapy assessment for pain, patient reported, performed at the time of chemotherapy administration; assessment Level 1: not at all (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9026	Chemotherapy assessment for pain, patient reported, performed at the time of chemotherapy administration; assessment Level 2: a little (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9027	Chemotherapy assessment for pain, patient reported, performed at the time of chemotherapy administration; assessment Level 3: quite a bit (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9028	Chemotherapy assessment for pain, patient reported, performed at the time of chemotherapy administration; assessment Level 4: very much (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9029	Chemotherapy assessment for lack of energy (fatigue), patient reported, performed at the time of chemotherapy administration; assessment Level 1: not at all (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9030	Chemotherapy assessment for lack of energy (fatigue), patient reported, performed at the time of chemotherapy administration; assessment Level 2: a little (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9031	Chemotherapy assessment for lack of energy (fatigue), patient reported, performed at the time of chemotherapy administration, assessment Level 3: quite a bit (for use in a Medicare approved demonstration project)	Procedure	HCPCS
G9032	Chemotherapy assessment for lack of energy (fatigue), patient reported, performed at the time of chemotherapy administration, assessment Level 4: very much (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9050	Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9051	Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer-directed therapy or managing consequences of cancer-directed therapy (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9052	Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer-directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9053	Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer-directed therapy is being administered or arranged at present; cancer-directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9054	Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative therapies (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9055	Oncology; primary focus of visit; other, unspecified service not otherwise listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9056	Oncology; practice guidelines; management adheres to guidelines (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9057	Oncology; practice guidelines; management differs from guidelines as a result of patient enrollment in an institutional review board-approved clinical trial (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9058	Oncology; practice guidelines; management differs from guidelines because the treating physician disagrees with guideline recommendations (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9059	Oncology; practice guidelines; management differs from guidelines because the patient, after being offered treatment consistent with guidelines, has opted for alternative treatment or management, including no treatment (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9060	Oncology; practice guidelines; management differs from guidelines for reason(s) associated with patient comorbid illness or performance status not factored into guidelines (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9061	Oncology; practice guidelines; patient's condition not addressed by available guidelines (for use in a Medicare-approved demonstration	Procedure	HCPCS
G9062	Oncology; practice guidelines; management differs from guidelines for other reason(s) not listed (for use in a Medicare-approved demonstration	Procedure	HCPCS
G9063	Oncology; disease status; limited to nonsmall cell lung cancer; extent of disease initially established as Stage I (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9064	Oncology; disease status; limited to nonsmall cell lung cancer; extent of disease initially established as Stage II (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9065	Oncology; disease status; limited to nonsmall cell lung cancer; extent of disease initially established as Stage III a (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9066	Oncology; disease status; limited to nonsmall cell lung cancer; Stage III B-IV at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9067	Oncology; disease status; limited to nonsmall cell lung cancer; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9069	Oncology; disease status; small cell lung cancer, limited to small cell and combined small cell/nonsmall cell; extensive Stage at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9070	Oncology; disease status; small cell lung cancer, limited to small cell and combined small cell/nonsmall; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9071	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage I or Stage IIA-IIB; or T3, N1, M0; and ER and/or PR positive; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9072	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage I, or Stage IIA-IIB; or T3, N1, M0; and ER and PR negative; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9073	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage IIIA-IIIB; and not T3, N1, M0; and ER and/or PR positive; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9074	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; Stage IIIA-IIIB; and not T3, N1, M0; and ER and PR negative; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9075	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9076	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; extent of disease unknown, under evaluation, presurgical or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9077	Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; T1-T2c and Gleason 2-7 and PSA < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9078	Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; T2 or T3a Gleason 8-10 or PSA > 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9079	Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; T3b-T4, any N; any T, N1 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9080	Oncology; disease status; prostate cancer, limited to adenocarcinoma; after initial treatment with rising PSA or failure of PSA decline (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9081	Oncology; disease status; prostate cancer, limited to adenocarcinoma, non-castrate, incompetely castrate; clinical metastases or M1 at diagnosis (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9082	Oncology; disease status; prostate cancer, limited to adenocarcinoma; castrate; clinical metastases or M1 at diagnosis (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9083	Oncology; disease status; prostate cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9084	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-3, N0, M0 with no evidence of disease progression, recurrence or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9085	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T4, N0, M0 with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9086	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-4, N1-2, M0 with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9087	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive with current clinical, radiologic, or biochemical evidence of disease (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9088	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive without current clinical, radiologic, or biochemical evidence of disease (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9089	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9090	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-2, N0, M0 (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9091	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T3, N0, M0 (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9092	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-3, N1-2, M0 (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9093	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T4, any N, M0 (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9094	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9095	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9096	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as T1-T3, N0-N1 or NX (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9097	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as T4, any N, M0 (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9098	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9099	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9100	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post R0 resection (with or without neoadjuvant therapy) with no evidence of disease recurrence, progression, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9101	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post R1 or R2 resection (with or without neoadjuvant therapy) with no evidence of disease progression, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9102	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic M0, unresectable with no evidence of disease progression, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9103	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9104	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9105	Oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post R0 resection without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9106	Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; post R1 or R2 resection with no evidence of disease progression, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9107	Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; unresectable at diagnosis, M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9108	Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9109	Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as T1-T2 and N0, M0 (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9110	Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as T3-4 and/or N1-3, M0 (prior to neoadjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9111	Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9112	Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9113	Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic Stage IA-B (Grade 1) without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9114	Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic Stage IA-B (Grade 2-3); or Stage IC (all grades); or Stage II; without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9115	Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic Stage III-IV; without evidence of progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9116	Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9117	Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9123	Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9124	Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and /or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9125	Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; blast phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9128	Oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, Stage I (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9129	Oncology; disease status; limited to multiple myeloma, systemic disease; Stage II or higher (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9130	Oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9131	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9132	Oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-refractory/androgen-independent (e.g., rising PSA on antiandrogen therapy or postorchiectomy); clinical metastases (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9133	Oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-responsive; clinical metastases or M1 at diagnosis (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9134	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; Stage I, II at diagnosis, not relapsed, not refractory (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9135	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; Stage III, IV, not relapsed, not refractory (for use in a Medicare-approved demonstration project)	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
G9136	Oncology; disease status; non-Hodgkin's lymphoma, transformed from original cellular diagnosis to a second cellular classification (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9137	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; relapsed/refractory (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9138	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; diagnostic evaluation, stage not determined, evaluation of possible relapse or nonresponse to therapy, or not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
G9139	Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; extent of disease unknown, staging in progress, not listed (for use in a Medicare-approved demonstration project)	Procedure	HCPCS
J0207	Injection, amifostine, 500 mg	Procedure	HCPCS
J1260	Injection, dolasetron mesylate, 10 mg	Procedure	HCPCS
J8498	Antiemetic drug, rectal/suppository, not otherwise specified	Procedure	HCPCS
J8510	Busulfan; oral, 2 mg	Procedure	HCPCS
J8520	Capecitabine, oral, 150 mg	Procedure	HCPCS
J8521	Capecitabine, oral, 500 mg	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J8560	Etoposide, oral, 50 mg	Procedure	HCPCS
J8562	Fludarabine phosphate, oral, 10 mg	Procedure	HCPCS
J8597	Antiemetic drug, oral, not otherwise specified	Procedure	HCPCS
J8600	Melphalan, oral 2 mg	Procedure	HCPCS
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J8700	Temozolomide, oral, 5 mg	Procedure	HCPCS
J8705	Topotecan, oral, 0.25 mg	Procedure	HCPCS
J8999	Prescription drug, oral, chemotherapeutic, nos	Procedure	HCPCS
J9000	Injection, doxorubicin HCl, 10 mg	Procedure	HCPCS
J9002	Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg	Procedure	HCPCS
J9015	Injection, aldesleukin, per single use vial	Procedure	HCPCS
J9017	Injection, arsenic trioxide, 1 mg	Procedure	HCPCS
J9019	Injection, asparaginase (Erwinaze), 1,000 IU	Procedure	HCPCS
J9020	Injection, asparaginase, not otherwise specified, 10,000 units	Procedure	HCPCS
J9025	Injection, azacitidine, 1 mg	Procedure	HCPCS
J9031	BCG (intravesical) per instillation	Procedure	HCPCS
J9033	Injection, bendamustine HCl (Treanda), 1 mg	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
J9042	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
J9043	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
J9045	Injection, carboplatin, 50 mg	Procedure	HCPCS
J9047	Injection, carfilzomib, 1 mg	Procedure	HCPCS
J9050	Injection, carmustine, 100 mg	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
J9060	Injection, cisplatin, powder or solution, 10 mg	Procedure	HCPCS
J9062	Cisplatin, 50 mg	Procedure	HCPCS
J9065	Injection, cladribine, per 1 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS
J9100	Cytarabine, 100 mg	Procedure	HCPCS
J9110	Injection, cytarabine, 500 mg	Procedure	HCPCS
J9120	Injection, dactinomycin, 0.5 mg	Procedure	HCPCS
J9130	Dacarbazine, 100 mg	Procedure	HCPCS
J9140	Dacarbazine, 200 mg	Procedure	HCPCS
J9150	Injection, daunorubicin, 10 mg	Procedure	HCPCS
J9151	Injection, daunorubicin citrate, liposomal formulation, 10 mg	Procedure	HCPCS
J9165	Injection, diethylstilbestrol diphosphate, 250 mg	Procedure	HCPCS
J9179	Injection, eribulin mesylate, 0.1 mg	Procedure	HCPCS
J9181	Injection, etoposide, 10 mg	Procedure	HCPCS
J9185	Injection, fludarabine phosphate, 50 mg	Procedure	HCPCS
J9190	Injection, fluorouracil, 500 mg	Procedure	HCPCS
J9200	Floxuridine, 500 mg	Procedure	HCPCS
J9201	Injection, gemcitabine HCl, not otherwise specified, 200 mg	Procedure	HCPCS
J9202	Goserelin acetate implant, per 3.6 mg	Procedure	HCPCS
J9206	Injection, irinotecan, 20 mg	Procedure	HCPCS
J9207	Injection, ixabepilone, 1 mg	Procedure	HCPCS
J9208	Injection, ifosfamide, 1 g	Procedure	HCPCS
J9209	Injection, mesna, 200 mg	Procedure	HCPCS
J9211	Idarubicin HCl, 5 mg	Procedure	HCPCS
J9213	Injection, interferon, alfa-2a, recombinant, 3 million units	Procedure	HCPCS
J9214	Injection, interferon, alfa-2b, recombinant, 1 million units	Procedure	HCPCS
J9215	Injection, interferon, alfa-N3, (human leukocyte derived), 250,000 IU	Procedure	HCPCS
J9216	Injection, interferon, gamma 1-b, 3 million units	Procedure	HCPCS
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	Procedure	HCPCS
J9218	Leuprolide acetate, per 1 mg	Procedure	HCPCS
J9219	Leuprolide acetate implant, 65 mg	Procedure	HCPCS
J9225	Histrelin implant (Vantas), 50 mg	Procedure	HCPCS
J9226	Histrelin implant (Supprelin LA), 50 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9230	Injection, mechlorethamine HCl, (nitrogen mustard), 10 mg	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
J9245	Injection, melphalan hydrochloride, not otherwise specified, 50 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
J9263	Injection, oxaliplatin, 0.5 mg	Procedure	HCPCS
J9265	Injection, paclitaxel, 30 mg	Procedure	HCPCS
J9266	Injection, pegaspargase, per single dose vial	Procedure	HCPCS
J9267	Injection, paclitaxel, 1 mg	Procedure	HCPCS
J9268	Pentostatin, per 10 mg	Procedure	HCPCS
J9270	Plicamycin, 2.5 mg	Procedure	HCPCS
J9280	Mitomycin, 5 mg	Procedure	HCPCS
J9290	Mitomycin, 20 mg	Procedure	HCPCS
J9291	Mitomycin, 40 mg	Procedure	HCPCS
J9293	Injection, mitoxantrone HCl, per 5 mg	Procedure	HCPCS
J9300	Injection, gemtuzumab ozogamicin, 5 mg	Procedure	HCPCS
J9301	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
J9302	Injection, ofatumumab, 10 mg	Procedure	HCPCS
J9303	Injection, panitumumab, 10 mg	Procedure	HCPCS
J9306	Injection, pertuzumab, 1 mg	Procedure	HCPCS
J9310	Injection, rituximab, 100 mg	Procedure	HCPCS
J9315	Injection, romidepsin, 1 mg	Procedure	HCPCS
J9320	Streptozocin, 1 g	Procedure	HCPCS
J9328	Injection, temozolomide, 1 mg	Procedure	HCPCS
J9330	Injection, temsirolimus, 1 mg	Procedure	HCPCS
J9340	Thiotepa, 15 mg	Procedure	HCPCS
J9350	Injection, topotecan, 4 mg	Procedure	HCPCS
J9351	Injection, topotecan, 0.1 mg	Procedure	HCPCS
J9354	Injection, ado-trastuzumab emtansine, 1 mg	Procedure	HCPCS
J9360	Injection, vinblastine sulfate, 1 mg	Procedure	HCPCS
J9370	Vincristine sulfate, 1 mg	Procedure	HCPCS
J9371	Injection, vincristine sulfate liposome, 1 mg	Procedure	HCPCS
J9375	Vincristine sulfate, 2 mg	Procedure	HCPCS
J9380	Vincristine sulfate, 5 mg	Procedure	HCPCS
J9390	Vinorelbine tartrate, per 10 mg	Procedure	HCPCS
J9600	Porfimer sodium, 75 mg	Procedure	HCPCS
J9999	Not otherwise classified, antineoplastic drugs	Procedure	HCPCS
Q0083	Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit	Procedure	HCPCS
Q0084	Chemotherapy administration by infusion technique only, per visit	Procedure	HCPCS
Q0085	Chemotherapy administration by both infusion technique and other technique(s) (e.g. subcutaneous, intramuscular, push), per visit	Procedure	HCPCS
Q0161	Chlorpromazine HCl, 5 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
Q0162	Ondansetron 1 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0163	Diphenhydramine HCl, 50 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at time of chemotherapy treatment not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0164	Prochlorperazine maleate, 5 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0165	Prochlorperazine maleate, 10 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0166	Granisetron HCl, 1 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen	Procedure	HCPCS
Q0167	Dronabinol, 2.5 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0168	Dronabinol, 5 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0169	Promethazine HCl, 12.5 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0170	Promethazine HCl, 25 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0171	Chlorpromazine HCl, 10 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0172	Chlorpromazine HCl, 25 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0173	Trimethobenzamide HCl, 250 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0174	Thiethylperazine maleate, 10 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
Q0175	Perphenazine, 4 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0176	Perphenazine, 8 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Procedure	HCPCS
Q0177	Hydroxyzine pamoate, 25 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0178	Hydroxyzine pamoate, 50 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0179	Ondansetron HCl 8 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0180	Dolasetron mesylate, 100 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen	Procedure	HCPCS
Q0181	Unspecified oral dosage form, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0511	Pharmacy supply fee for oral anticancer, oral antiemetic, or immunosuppressive drug(s); for the first prescription in a 30-day period	Procedure	HCPCS
Q0512	Pharmacy supply fee for oral anticancer, oral antiemetic, or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	Procedure	HCPCS
Q2017	Injection, teniposide, 50 mg	Procedure	HCPCS
Q2025	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
Q2048	Injection, doxorubicin hydrochloride, liposomal, DOXIL, 10 mg	Procedure	HCPCS
Q2049	Injection, doxorubicin HCl, liposomal, imported Lipodox, 10 mg	Procedure	HCPCS
Q2050	Injection, doxorubicin HCl, liposomal, not otherwise specified, 10 mg	Procedure	HCPCS
Q3001	Radioelements for brachytherapy, any type, each	Procedure	HCPCS
	Asthma		
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
	Hyperlipidemia		
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
	Depression		
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
	Schizophrenia		
295.00	Simple schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.01	Simple schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.02	Simple schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.03	Simple schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.04	Simple schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.05	Simple schizophrenia, in remission	Diagnosis	ICD-9-CM
295.10	Disorganized schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.11	Disorganized schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.12	Disorganized schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
295.15	Disorganized schizophrenia, in remission	Diagnosis	ICD-9-CM
295.20	Catatonic schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.21	Catatonic schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.22	Catatonic schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.25	Catatonic schizophrenia, in remission	Diagnosis	ICD-9-CM
295.30	Paranoid schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.31	Paranoid schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.32	Paranoid schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.35	Paranoid schizophrenia, in remission	Diagnosis	ICD-9-CM
295.40	Schizophreniform disorder, unspecified	Diagnosis	ICD-9-CM
295.41	Schizophreniform disorder, subchronic	Diagnosis	ICD-9-CM
295.42	Schizophreniform disorder, chronic	Diagnosis	ICD-9-CM
295.43	Schizophreniform disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.44	Schizophreniform disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.45	Schizophreniform disorder, in remission	Diagnosis	ICD-9-CM
295.50	Latent schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.51	Latent schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.52	Latent schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.53	Latent schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.54	Latent schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.55	Latent schizophrenia, in remission	Diagnosis	ICD-9-CM
295.60	Schizophrenic disorders, residual type, unspecified	Diagnosis	ICD-9-CM
295.61	Schizophrenic disorders, residual type, subchronic	Diagnosis	ICD-9-CM
295.62	Schizophrenic disorders, residual type, chronic	Diagnosis	ICD-9-CM
295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.65	Schizophrenic disorders, residual type, in remission	Diagnosis	ICD-9-CM
295.70	Schizoaffective disorder, unspecified	Diagnosis	ICD-9-CM
295.71	Schizoaffective disorder, subchronic	Diagnosis	ICD-9-CM
295.72	Schizoaffective disorder, chronic	Diagnosis	ICD-9-CM
295.73	Schizoaffective disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.74	Schizoaffective disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.75	Schizoaffective disorder, in remission	Diagnosis	ICD-9-CM
295.80	Other specified types of schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.81	Other specified types of schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.82	Other specified types of schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
295.85	Other specified types of schizophrenia, in remission	Diagnosis	ICD-9-CM
295.90	Unspecified schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.91	Unspecified schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.92	Unspecified schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.95	Unspecified schizophrenia, in remission	Diagnosis	ICD-9-CM
F20.0	Paranoid schizophrenia	Diagnosis	ICD-10-CM
F20.1	Disorganized schizophrenia	Diagnosis	ICD-10-CM
F20.2	Catatonic schizophrenia	Diagnosis	ICD-10-CM
F20.3	Undifferentiated schizophrenia	Diagnosis	ICD-10-CM
F20.5	Residual schizophrenia	Diagnosis	ICD-10-CM
F20.81	Schizophreniform disorder	Diagnosis	ICD-10-CM
F20.89	Other schizophrenia	Diagnosis	ICD-10-CM
F20.9	Schizophrenia, unspecified	Diagnosis	ICD-10-CM
F25.0	Schizoaffective disorder, bipolar type	Diagnosis	ICD-10-CM
F25.1	Schizoaffective disorder, depressive type	Diagnosis	ICD-10-CM
F25.8	Other schizoaffective disorders	Diagnosis	ICD-10-CM
F25.9	Schizoaffective disorder, unspecified	Diagnosis	ICD-10-CM
	Bipolar Disorder		
296.00	Bipolar I disorder, single manic episode, unspecified	Diagnosis	ICD-9-CM
296.01	Bipolar I disorder, single manic episode, mild	Diagnosis	ICD-9-CM
296.02	Bipolar I disorder, single manic episode, moderate	Diagnosis	ICD-9-CM
296.03	Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.04	Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.05	Bipolar I disorder, single manic episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.06	Bipolar I disorder, single manic episode, in full remission	Diagnosis	ICD-9-CM
296.10	Manic disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.11	Manic disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.12	Manic disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.13	Manic disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.14	Manic disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.15	Manic disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.16	Manic disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.40	Bipolar I disorder, most recent episode (or current) manic, unspecified	Diagnosis	ICD-9-CM
296.41	Bipolar I disorder, most recent episode (or current) manic, mild	Diagnosis	ICD-9-CM
296.42	Bipolar I disorder, most recent episode (or current) manic, moderate	Diagnosis	ICD-9-CM
296.43	Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
296.44	Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.45	Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.46	Bipolar I disorder, most recent episode (or current) manic, in full remission	Diagnosis	ICD-9-CM
296.50	Bipolar I disorder, most recent episode (or current) depressed, unspecified	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.7	Bipolar I disorder, most recent episode (or current) unspecified	Diagnosis	ICD-9-CM
296.80	Bipolar disorder, unspecified	Diagnosis	ICD-9-CM
296.81	Atypical manic disorder	Diagnosis	ICD-9-CM
296.82	Atypical depressive disorder	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
296.90	Unspecified episodic mood disorder	Diagnosis	ICD-9-CM
296.99	Other specified episodic mood disorder	Diagnosis	ICD-9-CM
F30.10	Manic episode without psychotic symptoms, unspecified	Diagnosis	ICD-10-CM
F30.11	Manic episode without psychotic symptoms, mild	Diagnosis	ICD-10-CM
F30.12	Manic episode without psychotic symptoms, moderate	Diagnosis	ICD-10-CM
F30.13	Manic episode, severe, without psychotic symptoms	Diagnosis	ICD-10-CM
F30.2	Manic episode, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F30.3	Manic episode in partial remission	Diagnosis	ICD-10-CM
F30.4	Manic episode in full remission	Diagnosis	ICD-10-CM
F30.8	Other manic episodes	Diagnosis	ICD-10-CM
F30.9	Manic episode, unspecified	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.74	Bipolar disorder, in full remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F34.81	Disruptive mood dysregulation disorder	Diagnosis	ICD-10-CM
F34.89	Other specified persistent mood disorders	Diagnosis	ICD-10-CM
F34.9	Persistent mood [affective] disorder, unspecified	Diagnosis	ICD-10-CM
F39	Unspecified mood [affective] disorder	Diagnosis	ICD-10-CM
	Chronic Liver Disease		
070.22	Viral hepatitis B with hepatic coma, chronic, without mention of hepatitis delta	Diagnosis	ICD-9-CM
070.23	Viral hepatitis B with hepatic coma, chronic, with hepatitis delta	Diagnosis	ICD-9-CM
070.32	Viral hepatitis B without mention of hepatic coma, chronic, without mention of hepatitis delta	Diagnosis	ICD-9-CM
070.33	Viral hepatitis B without mention of hepatic coma, chronic, with hepatitis delta	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
070.44	Chronic hepatitis C with hepatic coma	Diagnosis	ICD-9-CM
070.54	Chronic hepatitis C without mention of hepatic coma	Diagnosis	ICD-9-CM
070.59	Other specified viral hepatitis without mention of hepatic coma	Diagnosis	ICD-9-CM
273.4	Alpha-1-antitrypsin deficiency	Diagnosis	ICD-9-CM
275.01	Hereditary hemochromatosis	Diagnosis	ICD-9-CM
275.1	Disorders of copper metabolism	Diagnosis	ICD-9-CM
456.0	Esophageal varices with bleeding	Diagnosis	ICD-9-CM
456.1	Esophageal varices without mention of bleeding	Diagnosis	ICD-9-CM
456.20	Esophageal varices with bleeding in diseases classified elsewhere	Diagnosis	ICD-9-CM
456.21	Esophageal varices without mention of bleeding in diseases classified elsewhere	Diagnosis	ICD-9-CM
456.8	Varices of other sites	Diagnosis	ICD-9-CM
567.23	Spontaneous bacterial peritonitis	Diagnosis	ICD-9-CM
568.82	Peritoneal effusion (chronic)	Diagnosis	ICD-9-CM
570	Acute and subacute necrosis of liver	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
571.40	Unspecified chronic hepatitis	Diagnosis	ICD-9-CM
571.41	Chronic persistent hepatitis	Diagnosis	ICD-9-CM
571.42	Autoimmune hepatitis	Diagnosis	ICD-9-CM
571.49	Other chronic hepatitis	Diagnosis	ICD-9-CM
571.5	Cirrhosis of liver without mention of alcohol	Diagnosis	ICD-9-CM
571.6	Biliary cirrhosis	Diagnosis	ICD-9-CM
571.8	Other chronic nonalcoholic liver disease	Diagnosis	ICD-9-CM
571.9	Unspecified chronic liver disease without mention of alcohol	Diagnosis	ICD-9-CM
572.0	Abscess of liver	Diagnosis	ICD-9-CM
572.1	Portal pyemia	Diagnosis	ICD-9-CM
572.2	Hepatic encephalopathy	Diagnosis	ICD-9-CM
572.3	Portal hypertension	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
572.8	Other sequelae of chronic liver disease	Diagnosis	ICD-9-CM
573.0	Chronic passive congestion of liver	Diagnosis	ICD-9-CM
573.3	Unspecified hepatitis	Diagnosis	ICD-9-CM
573.4	Hepatic infarction	Diagnosis	ICD-9-CM
573.5	Hepatopulmonary syndrome	Diagnosis	ICD-9-CM
573.8	Other specified disorders of liver	Diagnosis	ICD-9-CM
573.9	Unspecified disorder of liver	Diagnosis	ICD-9-CM
789.59	Other ascites	Diagnosis	ICD-9-CM
997.49	Other digestive system complications	Diagnosis	ICD-9-CM
B18	Chronic viral hepatitis	Diagnosis	ICD-10-CM
B18.0	Chronic viral hepatitis B with delta-agent	Diagnosis	ICD-10-CM
B18.1	Chronic viral hepatitis B without delta-agent	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
B18.2	Chronic viral hepatitis C	Diagnosis	ICD-10-CM
B18.8	Other chronic viral hepatitis	Diagnosis	ICD-10-CM
B18.9	Chronic viral hepatitis, unspecified	Diagnosis	ICD-10-CM
E83.01	Wilson's disease	Diagnosis	ICD-10-CM
E83.110	Hereditary hemochromatosis	Diagnosis	ICD-10-CM
E88.01	Alpha-1-antitrypsin deficiency	Diagnosis	ICD-10-CM
I85	Esophageal varices	Diagnosis	ICD-10-CM
I85.0	Esophageal varices	Diagnosis	ICD-10-CM
I85.00	Esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.01	Esophageal varices with bleeding	Diagnosis	ICD-10-CM
I85.1	Secondary esophageal varices	Diagnosis	ICD-10-CM
I85.10	Secondary esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.11	Secondary esophageal varices with bleeding	Diagnosis	ICD-10-CM
I86.4	Gastric varices	Diagnosis	ICD-10-CM
K65.2	Spontaneous bacterial peritonitis	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K83.01	Primary sclerosing cholangitis	Diagnosis	ICD-10-CM
K91.83	Postprocedural hepatorenal syndrome	Diagnosis	ICD-10-CM
R18	Ascites	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
R18.8	Other ascites	Diagnosis	ICD-10-CM
V42.7	Liver replaced by transplant	Diagnosis	ICD-9-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
	Pneumonia		
480	Viral pneumonia	Diagnosis	ICD-9-CM
480.0	Pneumonia due to adenovirus	Diagnosis	ICD-9-CM
480.1	Pneumonia due to respiratory syncytial virus	Diagnosis	ICD-9-CM
480.2	Pneumonia due to parainfluenza virus	Diagnosis	ICD-9-CM
480.3	Pneumonia due to SARS-associated coronavirus	Diagnosis	ICD-9-CM
480.8	Pneumonia due to other virus not elsewhere classified	Diagnosis	ICD-9-CM
480.9	Unspecified viral pneumonia	Diagnosis	ICD-9-CM
481	Pneumococcal pneumonia (streptococcus pneumoniae pneumonia)	Diagnosis	ICD-9-CM
482	Other bacterial pneumonia	Diagnosis	ICD-9-CM
482.0	Pneumonia due to Klebsiella pneumoniae	Diagnosis	ICD-9-CM
482.1	Pneumonia due to Pseudomonas	Diagnosis	ICD-9-CM
482.2	Pneumonia due to Hemophilus influenzae (H. influenzae)	Diagnosis	ICD-9-CM
482.3	Pneumonia due to Streptococcus	Diagnosis	ICD-9-CM
482.30	Pneumonia due to unspecified Streptococcus	Diagnosis	ICD-9-CM
482.31	Pneumonia due to Streptococcus, group A	Diagnosis	ICD-9-CM
482.32	Pneumonia due to Streptococcus, group B	Diagnosis	ICD-9-CM
482.39	Pneumonia due to other Streptococcus	Diagnosis	ICD-9-CM
482.4	Pneumonia due to Staphylococcus	Diagnosis	ICD-9-CM
482.40	Pneumonia due to Staphylococcus, unspecified	Diagnosis	ICD-9-CM
482.41	Methicillin susceptible pneumonia due to Staphylococcus aureus	Diagnosis	ICD-9-CM
482.42	Methicillin resistant pneumonia due to Staphylococcus aureus	Diagnosis	ICD-9-CM
482.49	Other Staphylococcus pneumonia	Diagnosis	ICD-9-CM
482.8	Pneumonia due to other specified bacteria	Diagnosis	ICD-9-CM
482.81	Pneumonia due to anaerobes	Diagnosis	ICD-9-CM
482.82	Pneumonia due to Escherichia coli (E. coli)	Diagnosis	ICD-9-CM
482.83	Pneumonia due to other gram-negative bacteria	Diagnosis	ICD-9-CM
482.84	Legionnaires' disease	Diagnosis	ICD-9-CM
482.89	Pneumonia due to other specified bacteria	Diagnosis	ICD-9-CM
482.9	Unspecified bacterial pneumonia	Diagnosis	ICD-9-CM
483	Pneumonia due to other specified organism	Diagnosis	ICD-9-CM
483.0	Pneumonia due to Mycoplasma pneumoniae	Diagnosis	ICD-9-CM
483.1	Pneumonia due to Chlamydia	Diagnosis	ICD-9-CM
483.8	Pneumonia due to other specified organism	Diagnosis	ICD-9-CM
484	Pneumonia in infectious diseases classified elsewhere	Diagnosis	ICD-9-CM
484.1	Pneumonia in cytomegalic inclusion disease	Diagnosis	ICD-9-CM
484.3	Pneumonia in whooping cough	Diagnosis	ICD-9-CM
484.5	Pneumonia in anthrax	Diagnosis	ICD-9-CM
484.6	Pneumonia in aspergillosis	Diagnosis	ICD-9-CM
484.7	Pneumonia in other systemic mycoses	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
484.8	Pneumonia in other infectious diseases classified elsewhere	Diagnosis	ICD-9-CM
485	Bronchopneumonia, organism unspecified	Diagnosis	ICD-9-CM
486	Pneumonia, organism unspecified	Diagnosis	ICD-9-CM
487.0	Influenza with pneumonia	Diagnosis	ICD-9-CM
488.01	Influenza due to identified avian influenza virus with pneumonia	Diagnosis	ICD-9-CM
488.11	Influenza due to identified 2009 H1N1 influenza virus with pneumonia	Diagnosis	ICD-9-CM
488.81	Influenza due to identified novel influenza A virus with pneumonia	Diagnosis	ICD-9-CM
507	Pneumonitis due to solids and liquids	Diagnosis	ICD-9-CM
507.0	Pneumonitis due to inhalation of food or vomitus	Diagnosis	ICD-9-CM
507.1	Pneumonitis due to inhalation of oils and essences	Diagnosis	ICD-9-CM
507.8	Pneumonitis due to other solids and liquids	Diagnosis	ICD-9-CM
997.3	Respiratory complications	Diagnosis	ICD-9-CM
997.31	Ventilator associated pneumonia	Diagnosis	ICD-9-CM
997.32	Postprocedural aspiration pneumonia	Diagnosis	ICD-9-CM
997.39	Other respiratory complications	Diagnosis	ICD-9-CM
A22.1	Pulmonary anthrax	Diagnosis	ICD-10-CM
A37.01	Whooping cough due to Bordetella pertussis with pneumonia	Diagnosis	ICD-10-CM
A37.11	Whooping cough due to Bordetella parapertussis with pneumonia	Diagnosis	ICD-10-CM
A37.81	Whooping cough due to other Bordetella species with pneumonia	Diagnosis	ICD-10-CM
A37.91	Whooping cough, unspecified species with pneumonia	Diagnosis	ICD-10-CM
A48.1	Legionnaires' disease	Diagnosis	ICD-10-CM
B25.0	Cytomegaloviral pneumonitis	Diagnosis	ICD-10-CM
B44.0	Invasive pulmonary aspergillosis	Diagnosis	ICD-10-CM
B77.81	Ascariasis pneumonia	Diagnosis	ICD-10-CM
J09.X1	Influenza due to identified novel influenza A virus with pneumonia	Diagnosis	ICD-10-CM
J10.00	Influenza due to other identified influenza virus with unspecified type of pneumonia	Diagnosis	ICD-10-CM
J10.01	Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia	Diagnosis	ICD-10-CM
J10.08	Influenza due to other identified influenza virus with other specified pneumonia	Diagnosis	ICD-10-CM
J11.00	Influenza due to unidentified influenza virus with unspecified type of pneumonia	Diagnosis	ICD-10-CM
J11.08	Influenza due to unidentified influenza virus with specified pneumonia	Diagnosis	ICD-10-CM
J12.0	Adenoviral pneumonia	Diagnosis	ICD-10-CM
J12.1	Respiratory syncytial virus pneumonia	Diagnosis	ICD-10-CM
J12.2	Parainfluenza virus pneumonia	Diagnosis	ICD-10-CM
J12.3	Human metapneumovirus pneumonia	Diagnosis	ICD-10-CM
J12.81	Pneumonia due to SARS-associated coronavirus	Diagnosis	ICD-10-CM
J12.82	Pneumonia due to coronavirus disease 2019	Diagnosis	ICD-10-CM
J12.89	Other viral pneumonia	Diagnosis	ICD-10-CM
J12.9	Viral pneumonia, unspecified	Diagnosis	ICD-10-CM
J13	Pneumonia due to Streptococcus pneumoniae	Diagnosis	ICD-10-CM
J14	Pneumonia due to Hemophilus influenzae	Diagnosis	ICD-10-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
J15.0	Pneumonia due to Klebsiella pneumoniae	Diagnosis	ICD-10-CM
J15.1	Pneumonia due to Pseudomonas	Diagnosis	ICD-10-CM
J15.20	Pneumonia due to staphylococcus, unspecified	Diagnosis	ICD-10-CM
J15.211	Pneumonia due to Methicillin susceptible Staphylococcus aureus	Diagnosis	ICD-10-CM
J15.212	Pneumonia due to Methicillin resistant Staphylococcus aureus	Diagnosis	ICD-10-CM
J15.29	Pneumonia due to other staphylococcus	Diagnosis	ICD-10-CM
J15.3	Pneumonia due to streptococcus, group B	Diagnosis	ICD-10-CM
J15.4	Pneumonia due to other streptococci	Diagnosis	ICD-10-CM
J15.5	Pneumonia due to Escherichia coli	Diagnosis	ICD-10-CM
J15.6	Pneumonia due to other Gram-negative bacteria	Diagnosis	ICD-10-CM
J15.7	Pneumonia due to Mycoplasma pneumoniae	Diagnosis	ICD-10-CM
J15.8	Pneumonia due to other specified bacteria	Diagnosis	ICD-10-CM
J15.9	Unspecified bacterial pneumonia	Diagnosis	ICD-10-CM
J16.0	Chlamydial pneumonia	Diagnosis	ICD-10-CM
J16.8	Pneumonia due to other specified infectious organisms	Diagnosis	ICD-10-CM
J17	Pneumonia in diseases classified elsewhere	Diagnosis	ICD-10-CM
J18.0	Bronchopneumonia, unspecified organism	Diagnosis	ICD-10-CM
J18.1	Lobar pneumonia, unspecified organism	Diagnosis	ICD-10-CM
J18.8	Other pneumonia, unspecified organism	Diagnosis	ICD-10-CM
J18.9	Pneumonia, unspecified organism	Diagnosis	ICD-10-CM
J69.0	Pneumonitis due to inhalation of food and vomit	Diagnosis	ICD-10-CM
J69.1	Pneumonitis due to inhalation of oils and essences	Diagnosis	ICD-10-CM
J69.8	Pneumonitis due to inhalation of other solids and liquids	Diagnosis	ICD-10-CM
J95.4	Chemical pneumonitis due to anesthesia	Diagnosis	ICD-10-CM
J95.5	Postprocedural subglottic stenosis	Diagnosis	ICD-10-CM
J95.851	Ventilator associated pneumonia	Diagnosis	ICD-10-CM
J95.859	Other complication of respirator [ventilator]	Diagnosis	ICD-10-CM
J95.88	Other intraoperative complications of respiratory system, not elsewhere classified	Diagnosis	ICD-10-CM
J95.89	Other postprocedural complications and disorders of respiratory system, not elsewhere classified	Diagnosis	ICD-10-CM
	Cardiac Arrhythmia		
426.0	Atrioventricular block, complete	Diagnosis	ICD-9-CM
426.1	Atrioventricular block, other and unspecified	Diagnosis	ICD-9-CM
426.10	Unspecified atrioventricular block	Diagnosis	ICD-9-CM
426.11	First degree atrioventricular block	Diagnosis	ICD-9-CM
426.12	Mobitz (type) II atrioventricular block	Diagnosis	ICD-9-CM
426.13	Other second degree atrioventricular block	Diagnosis	ICD-9-CM
426.6	Other heart block	Diagnosis	ICD-9-CM
426.7	Anomalous atrioventricular excitation	Diagnosis	ICD-9-CM
426.81	Lown-Ganong-Levine syndrome	Diagnosis	ICD-9-CM
426.82	Long QT syndrome	Diagnosis	ICD-9-CM
427	Cardiac dysrhythmias	Diagnosis	ICD-9-CM
427.0	Paroxysmal supraventricular tachycardia	Diagnosis	ICD-9-CM

Appendix V. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in This Request

Code	Description	Code Category	Code Type
427.1	Paroxysmal ventricular tachycardia	Diagnosis	ICD-9-CM
427.2	Unspecified paroxysmal tachycardia	Diagnosis	ICD-9-CM
427.3	Atrial fibrillation and flutter	Diagnosis	ICD-9-CM
427.32	Atrial flutter	Diagnosis	ICD-9-CM
427.4	Ventricular fibrillation and flutter	Diagnosis	ICD-9-CM
427.41	Ventricular fibrillation	Diagnosis	ICD-9-CM
427.42	Ventricular flutter	Diagnosis	ICD-9-CM
427.5	Cardiac arrest	Diagnosis	ICD-9-CM
427.81	Sinoatrial node dysfunction	Diagnosis	ICD-9-CM
785.0	Unspecified tachycardia	Diagnosis	ICD-9-CM
I44.0	Atrioventricular block, first degree	Diagnosis	ICD-10-CM
I44.1	Atrioventricular block, second degree	Diagnosis	ICD-10-CM
I44.2	Atrioventricular block, complete	Diagnosis	ICD-10-CM
I44.3	Other and unspecified atrioventricular block	Diagnosis	ICD-10-CM
I44.30	Unspecified atrioventricular block	Diagnosis	ICD-10-CM
I45.5	Other specified heart block	Diagnosis	ICD-10-CM
I45.6	Pre-excitation syndrome	Diagnosis	ICD-10-CM
I45.81	Long QT syndrome	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I48	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
I49.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.5	Sick sinus syndrome	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
R00.1	Bradycardia, unspecified	Diagnosis	ICD-10-CM

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
	Antidementia Use		
S0014	Tacrine HCl, 10 mg	Procedure	HCPCS
	Wheelchair or walker use		
E0148	Walker, heavy-duty, without wheels, rigid or folding, any type, each	Procedure	HCPCS
E0149	Walker, heavy-duty, wheeled, rigid or folding, any type	Procedure	HCPCS
E0154	Platform attachment, walker, each	Procedure	HCPCS
E0155	Wheel attachment, rigid pick-up walker, per pair	Procedure	HCPCS
E0156	Seat attachment, walker	Procedure	HCPCS
E0157	Crutch attachment, walker, each	Procedure	HCPCS
E0158	Leg extensions for walker, per set of four	Procedure	HCPCS
E0159	Brake attachment for wheeled walker, replacement, each	Procedure	HCPCS
K0458	Heavy duty walker, without wheels, each	Procedure	HCPCS
K0459	Heavy duty wheeled walker, each	Procedure	HCPCS
L1520	Thoracic-hip-knee-ankle orthotic (THKAO), swivel walker	Procedure	HCPCS
97542	Wheelchair management/propulsion training, each 15 minutes	Procedure	CPT-4
E0192	Low pressure and positioning equalization pad, for wheelchair	Procedure	HCPCS
E0950	Wheelchair accessory, tray, each	Procedure	HCPCS
E0951	Heel loop/holder, any type, with or without ankle strap, each	Procedure	HCPCS
E0952	Toe loop/holder, any type, each	Procedure	HCPCS
E0953	Wheelchair accessory, lateral thigh or knee support, any type including fixed mounting hardware, each	Procedure	HCPCS
E0954	Wheelchair accessory, foot box, any type, includes attachment and mounting hardware, each foot	Procedure	HCPCS
E0955	Wheelchair accessory, headrest, cushioned, any type, including fixed mounting hardware, each	Procedure	HCPCS
E0956	Wheelchair accessory, lateral trunk or hip support, any type, including fixed mounting hardware, each	Procedure	HCPCS
E0957	Wheelchair accessory, medial thigh support, any type, including fixed mounting hardware, each	Procedure	HCPCS
E0958	Manual wheelchair accessory, one-arm drive attachment, each	Procedure	HCPCS
E0959	Manual wheelchair accessory, adapter for amputee, each	Procedure	HCPCS
E0960	Wheelchair accessory, shoulder harness/straps or chest strap, including any type mounting hardware	Procedure	HCPCS
E0961	Manual wheelchair accessory, wheel lock brake extension (handle), each	Procedure	HCPCS
E0962	One-inch cushion, for wheelchair	Procedure	HCPCS
E0963	Two-inch cushion, for wheelchair	Procedure	HCPCS
E0964	Three-inch cushion, for wheelchair	Procedure	HCPCS
E0965	Four-inch cushion, for wheelchair	Procedure	HCPCS
E0966	Manual wheelchair accessory, headrest extension, each	Procedure	HCPCS
E0967	Manual wheelchair accessory, hand rim with projections, any type, replacement only, each	Procedure	HCPCS
E0968	Commode seat, wheelchair	Procedure	HCPCS
E0969	Narrowing device, wheelchair	Procedure	HCPCS
E0970	No. 2 footplates, except for elevating legrest	Procedure	HCPCS
E0971	Manual wheelchair accessory, antitipping device, each	Procedure	HCPCS
E0972	Wheelchair accessory, transfer board or device, each	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E0973	Wheelchair accessory, adjustable height, detachable armrest, complete assembly, each	Procedure	HCPCS
E0974	Manual wheelchair accessory, antirollback device, each	Procedure	HCPCS
E0977	Wedge cushion, wheelchair	Procedure	HCPCS
E0978	Wheelchair accessory, positioning belt/safety belt/pelvic strap, each	Procedure	HCPCS
E0980	Safety vest, wheelchair	Procedure	HCPCS
E0981	Wheelchair accessory, seat upholstery, replacement only, each	Procedure	HCPCS
E0982	Wheelchair accessory, back upholstery, replacement only, each	Procedure	HCPCS
E0983	Manual wheelchair accessory, power add-on to convert manual wheelchair to motorized wheelchair, joystick control	Procedure	HCPCS
E0984	Manual wheelchair accessory, power add-on to convert manual wheelchair to motorized wheelchair, tiller control	Procedure	HCPCS
E0985	Wheelchair accessory, seat lift mechanism	Procedure	HCPCS
E0986	Manual wheelchair accessory, push-rim activated power assist system	Procedure	HCPCS
E0988	Manual wheelchair accessory, lever-activated, wheel drive, pair	Procedure	HCPCS
E0990	Wheelchair accessory, elevating legrest, complete assembly, each	Procedure	HCPCS
E0992	Manual wheelchair accessory, solid seat insert	Procedure	HCPCS
E0994	Armrest, each	Procedure	HCPCS
E0995	Wheelchair accessory, calf rest/pad, replacement only, each	Procedure	HCPCS
E1002	Wheelchair accessory, power seating system, tilt only	Procedure	HCPCS
E1003	Wheelchair accessory, power seating system, recline only, without shear reduction	Procedure	HCPCS
E1004	Wheelchair accessory, power seating system, recline only, with mechanical shear reduction	Procedure	HCPCS
E1005	Wheelchair accessory, power seating system, recline only, with power shear reduction	Procedure	HCPCS
E1006	Wheelchair accessory, power seating system, combination tilt and recline, without shear reduction	Procedure	HCPCS
E1007	Wheelchair accessory, power seating system, combination tilt and recline, with mechanical shear reduction	Procedure	HCPCS
E1008	Wheelchair accessory, power seating system, combination tilt and recline, with power shear reduction	Procedure	HCPCS
E1009	Wheelchair accessory, addition to power seating system, mechanically linked leg elevation system, including pushrod and legrest, each	Procedure	HCPCS
E1010	Wheelchair accessory, addition to power seating system, power leg elevation system, including legrest, pair	Procedure	HCPCS
E1015	Shock absorber for manual wheelchair, each	Procedure	HCPCS
E1016	Shock absorber for power wheelchair, each	Procedure	HCPCS
E1017	Heavy-duty shock absorber for heavy-duty or extra heavy-duty manual wheelchair, each	Procedure	HCPCS
E1018	Heavy-duty shock absorber for heavy-duty or extra heavy-duty power wheelchair, each	Procedure	HCPCS
E1019	Wheelchair accessory, power seating system, heavy duty feature, patient weight capacity greater than 250 pounds and less than or equal to 400 pounds	Procedure	HCPCS
E1020	Residual limb support system for wheelchair, any type	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E1021	Wheelchair accessory, power seating system, extra heavy duty feature, weight capacity greater than 400 pounds	Procedure	HCPCS
E1028	Wheelchair accessory, manual swingaway, retractable or removable mounting hardware for joystick, other control interface or positioning accessory	Procedure	HCPCS
E1029	Wheelchair accessory, ventilator tray, fixed	Procedure	HCPCS
E1030	Wheelchair accessory, ventilator tray, gimbaled	Procedure	HCPCS
E1038	Transport chair, adult size, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
E1039	Transport chair, adult size, heavy-duty, patient weight capacity greater than 300 pounds	Procedure	HCPCS
E1050	Fully-reclining wheelchair, fixed full-length arms, swing-away detachable elevating legrests	Procedure	HCPCS
E1060	Fully-reclining wheelchair, detachable arms, desk or full-length, swing-away detachable elevating legrests	Procedure	HCPCS
E1070	Fully-reclining wheelchair, detachable arms (desk or full-length) swing-away detachable footrest	Procedure	HCPCS
E1083	Hemi-wheelchair, fixed full-length arms, swing-away detachable elevating legrest	Procedure	HCPCS
E1084	Hemi-wheelchair, detachable arms desk or full-length arms, swing-away detachable elevating legrests	Procedure	HCPCS
E1085	Hemi-wheelchair, fixed full-length arms, swing-away detachable footrests	Procedure	HCPCS
E1086	Hemi-wheelchair, detachable arms, desk or full-length, swing-away detachable footrests	Procedure	HCPCS
E1087	High strength lightweight wheelchair, fixed full-length arms, swing-away detachable elevating legrests	Procedure	HCPCS
E1088	High strength lightweight wheelchair, detachable arms desk or full-length, swing-away detachable elevating legrests	Procedure	HCPCS
E1089	High-strength lightweight wheelchair, fixed-length arms, swing-away detachable footrest	Procedure	HCPCS
E1090	High-strength lightweight wheelchair, detachable arms, desk or full-length, swing-away detachable footrests	Procedure	HCPCS
E1092	Wide heavy-duty wheel chair, detachable arms (desk or full-length), swing-away detachable elevating legrests	Procedure	HCPCS
E1093	Wide heavy-duty wheelchair, detachable arms, desk or full-length arms, swing-away detachable footrests	Procedure	HCPCS
E1100	Semi-reclining wheelchair, fixed full-length arms, swing-away detachable elevating legrests	Procedure	HCPCS
E1110	Semi-reclining wheelchair, detachable arms (desk or full-length) elevating legrest	Procedure	HCPCS
E1130	Standard wheelchair, fixed full-length arms, fixed or swing-away detachable footrests	Procedure	HCPCS
E1140	Wheelchair, detachable arms, desk or full-length, swing-away detachable footrests	Procedure	HCPCS
E1150	Wheelchair, detachable arms, desk or full-length swing-away detachable elevating legrests	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E1160	Wheelchair, fixed full-length arms, swing-away detachable elevating	Procedure	HCPCS
E1161	Manual adult size wheelchair, includes tilt in space	Procedure	HCPCS
E1170	Amputee wheelchair, fixed full-length arms, swing-away detachable elevating legrests	Procedure	HCPCS
E1171	Amputee wheelchair, fixed full-length arms, without footrests or legrest	Procedure	HCPCS
E1172	Amputee wheelchair, detachable arms (desk or full-length) without footrests or legrest	Procedure	HCPCS
E1180	Amputee wheelchair, detachable arms (desk or full-length) swing-away detachable footrests	Procedure	HCPCS
E1190	Amputee wheelchair, detachable arms (desk or full-length) swing-away detachable elevating legrests	Procedure	HCPCS
E1195	Heavy-duty wheelchair, fixed full-length arms, swing-away detachable elevating legrests	Procedure	HCPCS
E1200	Amputee wheelchair, fixed full-length arms, swing-away detachable	Procedure	HCPCS
E1210	Motorized wheelchair; fixed full-length arms, swing-away, detachable, elevating legrests	Procedure	HCPCS
E1211	Motorized wheelchair; detachable arms, desk or full-length, swing-away, detachable, elevating legrests	Procedure	HCPCS
E1212	Motorized wheelchair; fixed full-length arms, swing-away, detachable footrests	Procedure	HCPCS
E1213	Motorized wheelchair; detachable arms, desk or full-length, swing-away, detachable footrests	Procedure	HCPCS
E1220	Wheelchair; specially sized or constructed, (indicate brand name, model number, if any) and justification	Procedure	HCPCS
E1221	Wheelchair with fixed arm, footrests	Procedure	HCPCS
E1222	Wheelchair with fixed arm, elevating legrests	Procedure	HCPCS
E1223	Wheelchair with detachable arms, footrests	Procedure	HCPCS
E1224	Wheelchair with detachable arms, elevating legrests	Procedure	HCPCS
E1225	Wheelchair accessory, manual semi-reclining back, (recline greater than 15 degrees, but less than 80 degrees), each	Procedure	HCPCS
E1226	Wheelchair accessory, manual fully reclining back, (recline greater than 80 degrees), each	Procedure	HCPCS
E1227	Special height arms for wheelchair	Procedure	HCPCS
E1228	Special back height for wheelchair	Procedure	HCPCS
E1230	Power operated vehicle (three- or four-wheel nonhighway), specify brand name and model number	Procedure	HCPCS
E1240	Lightweight wheelchair, detachable arms, (desk or full-length) swing-away detachable, elevating legrest	Procedure	HCPCS
E1250	Lightweight wheelchair, fixed full-length arms, swing-away detachable footrest	Procedure	HCPCS
E1260	Lightweight wheelchair, detachable arms (desk or full-length) swing-away detachable footrest	Procedure	HCPCS
E1270	Lightweight wheelchair, fixed full-length arms, swing-away detachable elevating legrests	Procedure	HCPCS
E1280	Heavy-duty wheelchair, detachable arms (desk or full-length) elevating legrests	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E1285	Heavy-duty wheelchair, fixed full-length arms, swing-away detachable footrest	Procedure	HCPCS
E1290	Heavy-duty wheelchair, detachable arms (desk or full-length) swing-away detachable footrest	Procedure	HCPCS
E1295	Heavy-duty wheelchair, fixed full-length arms, elevating legrest	Procedure	HCPCS
E1296	Special wheelchair seat height from floor	Procedure	HCPCS
E1297	Special wheelchair seat depth, by upholstery	Procedure	HCPCS
E1298	Special wheelchair seat depth and/or width, by construction	Procedure	HCPCS
E2201	Manual wheelchair accessory, nonstandard seat frame, width greater than or equal to 20 in and less than 24 in	Procedure	HCPCS
E2202	Manual wheelchair accessory, nonstandard seat frame width, 24-27 in	Procedure	HCPCS
E2203	Manual wheelchair accessory, nonstandard seat frame depth, 20 to less than 22 in	Procedure	HCPCS
E2204	Manual wheelchair accessory, nonstandard seat frame depth, 22 to 25 in	Procedure	HCPCS
E2205	Manual wheelchair accessory, handrim without projections (includes ergonomic or contoured), any type, replacement only, each	Procedure	HCPCS
E2206	Manual wheelchair accessory, wheel lock assembly, complete, replacement only, each	Procedure	HCPCS
E2207	Wheelchair accessory, crutch and cane holder, each	Procedure	HCPCS
E2208	Wheelchair accessory, cylinder tank carrier, each	Procedure	HCPCS
E2209	Accessory, arm trough, with or without hand support, each	Procedure	HCPCS
E2210	Wheelchair accessory, bearings, any type, replacement only, each	Procedure	HCPCS
E2211	Manual wheelchair accessory, pneumatic propulsion tire, any size, each	Procedure	HCPCS
E2212	Manual wheelchair accessory, tube for pneumatic propulsion tire, any size, each	Procedure	HCPCS
E2213	Manual wheelchair accessory, insert for pneumatic propulsion tire (removable), any type, any size, each	Procedure	HCPCS
E2214	Manual wheelchair accessory, pneumatic caster tire, any size, each	Procedure	HCPCS
E2215	Manual wheelchair accessory, tube for pneumatic caster tire, any size,	Procedure	HCPCS
E2216	Manual wheelchair accessory, foam filled propulsion tire, any size, each	Procedure	HCPCS
E2217	Manual wheelchair accessory, foam filled caster tire, any size, each	Procedure	HCPCS
E2218	Manual wheelchair accessory, foam propulsion tire, any size, each	Procedure	HCPCS
E2219	Manual wheelchair accessory, foam caster tire, any size, each	Procedure	HCPCS
E2220	Manual wheelchair accessory, solid (rubber/plastic) propulsion tire, any size, replacement only, each	Procedure	HCPCS
E2221	Manual wheelchair accessory, solid (rubber/plastic) caster tire (removable), any size, replacement only, each	Procedure	HCPCS
E2222	Manual wheelchair accessory, solid (rubber/plastic) caster tire with integrated wheel, any size, replacement only, each	Procedure	HCPCS
E2224	Manual wheelchair accessory, propulsion wheel excludes tire, any size, replacement only, each	Procedure	HCPCS
E2225	Manual wheelchair accessory, caster wheel excludes tire, any size, replacement only, each	Procedure	HCPCS
E2226	Manual wheelchair accessory, caster fork, any size, replacement only, each	Procedure	HCPCS
E2227	Manual wheelchair accessory, gear reduction drive wheel, each	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E2228	Manual wheelchair accessory, wheel braking system and lock, complete, each	Procedure	HCPCS
E2230	Manual wheelchair accessory, manual standing system	Procedure	HCPCS
E2231	Manual wheelchair accessory, solid seat support base (replaces sling seat), includes any type mounting hardware	Procedure	HCPCS
E2300	Wheelchair accessory, power seat elevation system, any type	Procedure	HCPCS
E2301	Wheelchair accessory, power standing system, any type	Procedure	HCPCS
E2310	Power wheelchair accessory, electronic connection between wheelchair controller and one power seating system motor, including all related electronics, indicator feature, mechanical function selection switch, and fixed mounting hardware	Procedure	HCPCS
E2311	Power wheelchair accessory, electronic connection between wheelchair controller and 2 or more power seating system motors, including all related electronics, indicator feature, mechanical function selection switch, and fixed mounting hardware	Procedure	HCPCS
E2312	Power wheelchair accessory, hand or chin control interface, mini-proportional remote joystick, proportional, including fixed mounting hardware	Procedure	HCPCS
E2313	Power wheelchair accessory, harness for upgrade to expandable controller, including all fasteners, connectors and mounting hardware,	Procedure	HCPCS
E2321	Power wheelchair accessory, hand control interface, remote joystick, nonproportional, including all related electronics, mechanical stop switch, and fixed mounting hardware	Procedure	HCPCS
E2322	Power wheelchair accessory, hand control interface, multiple mechanical switches, nonproportional, including all related electronics, mechanical stop switch, and fixed mounting hardware	Procedure	HCPCS
E2323	Power wheelchair accessory, specialty joystick handle for hand control interface, prefabricated	Procedure	HCPCS
E2324	Power wheelchair accessory, chin cup for chin control interface	Procedure	HCPCS
E2325	Power wheelchair accessory, sip and puff interface, nonproportional, including all related electronics, mechanical stop switch, and manual swingaway mounting hardware	Procedure	HCPCS
E2326	Power wheelchair accessory, breath tube kit for sip and puff interface	Procedure	HCPCS
E2327	Power wheelchair accessory, head control interface, mechanical, proportional, including all related electronics, mechanical direction change switch, and fixed mounting hardware	Procedure	HCPCS
E2328	Power wheelchair accessory, head control or extremity control interface, electronic, proportional, including all related electronics and fixed mounting hardware	Procedure	HCPCS
E2329	Power wheelchair accessory, head control interface, contact switch mechanism, nonproportional, including all related electronics, mechanical stop switch, mechanical direction change switch, head array, and fixed mounting hardware	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E2330	Power wheelchair accessory, head control interface, proximity switch mechanism, nonproportional, including all related electronics, mechanical stop switch, mechanical direction change switch, head array, and fixed mounting hardware	Procedure	HCPCS
E2331	Power wheelchair accessory, attendant control, proportional, including all related electronics and fixed mounting hardware	Procedure	HCPCS
E2340	Power wheelchair accessory, nonstandard seat frame width, 20-23 in	Procedure	HCPCS
E2341	Power wheelchair accessory, nonstandard seat frame width, 24-27 in	Procedure	HCPCS
E2342	Power wheelchair accessory, nonstandard seat frame depth, 20 or 21 in	Procedure	HCPCS
E2343	Power wheelchair accessory, nonstandard seat frame depth, 22-25 in	Procedure	HCPCS
E2351	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface	Procedure	HCPCS
E2358	Power wheelchair accessory, group 34 nonsealed lead acid battery, each	Procedure	HCPCS
E2359	Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)	Procedure	HCPCS
E2360	Power wheelchair accessory, 22 NF nonsealed lead acid battery, each	Procedure	HCPCS
E2361	Power wheelchair accessory, 22 NF sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)	Procedure	HCPCS
E2362	Power wheelchair accessory, group 24 nonsealed lead acid battery, each	Procedure	HCPCS
E2363	Power wheelchair accessory, group 24 sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)	Procedure	HCPCS
E2364	Power wheelchair accessory, U-1 nonsealed lead acid battery, each	Procedure	HCPCS
E2365	Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)	Procedure	HCPCS
E2366	Power wheelchair accessory, battery charger, single mode, for use with only one battery type, sealed or nonsealed, each	Procedure	HCPCS
E2367	Power wheelchair accessory, battery charger, dual mode, for use with either battery type, sealed or nonsealed, each	Procedure	HCPCS
E2368	Power wheelchair component, drive wheel motor, replacement only	Procedure	HCPCS
E2369	Power wheelchair component, drive wheel gear box, replacement only	Procedure	HCPCS
E2370	Power wheelchair component, integrated drive wheel motor and gear box combination, replacement only	Procedure	HCPCS
E2371	Power wheelchair accessory, group 27 sealed lead acid battery, (e.g., gel cell, absorbed glassmat), each	Procedure	HCPCS
E2372	Power wheelchair accessory, group 27 nonsealed lead acid battery, each	Procedure	HCPCS
E2373	Power wheelchair accessory, hand or chin control interface, compact remote joystick, proportional, including fixed mounting hardware	Procedure	HCPCS
E2374	Power wheelchair accessory, hand or chin control interface, standard remote joystick (not including controller), proportional, including all related electronics and fixed mounting hardware, replacement only	Procedure	HCPCS
E2375	Power wheelchair accessory, nonexpandable controller, including all related electronics and mounting hardware, replacement only	Procedure	HCPCS
E2376	Power wheelchair accessory, expandable controller, including all related electronics and mounting hardware, replacement only	Procedure	HCPCS
E2377	Power wheelchair accessory, expandable controller, including all related electronics and mounting hardware, upgrade provided at initial issue	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E2378	Power wheelchair component, actuator, replacement only	Procedure	HCPCS
E2381	Power wheelchair accessory, pneumatic drive wheel tire, any size, replacement only, each	Procedure	HCPCS
E2382	Power wheelchair accessory, tube for pneumatic drive wheel tire, any size, replacement only, each	Procedure	HCPCS
E2383	Power wheelchair accessory, insert for pneumatic drive wheel tire (removable), any type, any size, replacement only, each	Procedure	HCPCS
E2384	Power wheelchair accessory, pneumatic caster tire, any size, replacement only, each	Procedure	HCPCS
E2385	Power wheelchair accessory, tube for pneumatic caster tire, any size, replacement only, each	Procedure	HCPCS
E2386	Power wheelchair accessory, foam filled drive wheel tire, any size, replacement only, each	Procedure	HCPCS
E2387	Power wheelchair accessory, foam filled caster tire, any size, replacement only, each	Procedure	HCPCS
E2388	Power wheelchair accessory, foam drive wheel tire, any size, replacement only, each	Procedure	HCPCS
E2389	Power wheelchair accessory, foam caster tire, any size, replacement only, each	Procedure	HCPCS
E2390	Power wheelchair accessory, solid (rubber/plastic) drive wheel tire, any size, replacement only, each	Procedure	HCPCS
E2391	Power wheelchair accessory, solid (rubber/plastic) caster tire (removable), any size, replacement only, each	Procedure	HCPCS
E2392	Power wheelchair accessory, solid (rubber/plastic) caster tire with integrated wheel, any size, replacement only, each	Procedure	HCPCS
E2394	Power wheelchair accessory, drive wheel excludes tire, any size, replacement only, each	Procedure	HCPCS
E2395	Power wheelchair accessory, caster wheel excludes tire, any size, replacement only, each	Procedure	HCPCS
E2396	Power wheelchair accessory, caster fork, any size, replacement only, each	Procedure	HCPCS
E2397	Power wheelchair accessory, lithium-based battery, each	Procedure	HCPCS
E2601	General use wheelchair seat cushion, width less than 22 in, any depth	Procedure	HCPCS
E2602	General use wheelchair seat cushion, width 22 in or greater, any depth	Procedure	HCPCS
E2603	Skin protection wheelchair seat cushion, width less than 22 in, any depth	Procedure	HCPCS
E2604	Skin protection wheelchair seat cushion, width 22 in or greater, any depth	Procedure	HCPCS
E2605	Positioning wheelchair seat cushion, width less than 22 in, any depth	Procedure	HCPCS
E2606	Positioning wheelchair seat cushion, width 22 in or greater, any depth	Procedure	HCPCS
E2607	Skin protection and positioning wheelchair seat cushion, width less than 22 in, any depth	Procedure	HCPCS
E2608	Skin protection and positioning wheelchair seat cushion, width 22 in or greater, any depth	Procedure	HCPCS
E2609	Custom fabricated wheelchair seat cushion, any size	Procedure	HCPCS
E2610	Wheelchair seat cushion, powered	Procedure	HCPCS
E2611	General use wheelchair back cushion, width less than 22 in, any height, including any type mounting hardware	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E2612	General use wheelchair back cushion, width 22 in or greater, any height, including any type mounting hardware	Procedure	HCPCS
E2613	Positioning wheelchair back cushion, posterior, width less than 22 in, any height, including any type mounting hardware	Procedure	HCPCS
E2614	Positioning wheelchair back cushion, posterior, width 22 in or greater, any height, including any type mounting hardware	Procedure	HCPCS
E2615	Positioning wheelchair back cushion, posterior-lateral, width less than 22 in, any height, including any type mounting hardware	Procedure	HCPCS
E2616	Positioning wheelchair back cushion, posterior-lateral, width 22 in or greater, any height, including any type mounting hardware	Procedure	HCPCS
E2617	Custom fabricated wheelchair back cushion, any size, including any type mounting hardware	Procedure	HCPCS
E2619	Replacement cover for wheelchair seat cushion or back cushion, each	Procedure	HCPCS
E2620	Positioning wheelchair back cushion, planar back with lateral supports, width less than 22 in, any height, including any type mounting hardware	Procedure	HCPCS
E2621	Positioning wheelchair back cushion, planar back with lateral supports, width 22 in or greater, any height, including any type mounting hardware	Procedure	HCPCS
E2622	Skin protection wheelchair seat cushion, adjustable, width less than 22 in, any depth	Procedure	HCPCS
E2623	Skin protection wheelchair seat cushion, adjustable, width 22 in or greater, any depth	Procedure	HCPCS
E2624	Skin protection and positioning wheelchair seat cushion, adjustable, width less than 22 in, any depth	Procedure	HCPCS
E2625	Skin protection and positioning wheelchair seat cushion, adjustable, width 22 in or greater, any depth	Procedure	HCPCS
E2626	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, adjustable	Procedure	HCPCS
E2627	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, adjustable Rancho type	Procedure	HCPCS
E2628	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, reclining	Procedure	HCPCS
E2629	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, friction arm support (friction dampening to proximal and distal joints)	Procedure	HCPCS
E2630	Wheelchair accessory, shoulder elbow, mobile arm support, monosuspension arm and hand support, overhead elbow forearm hand sling support, yoke type suspension support	Procedure	HCPCS
E2631	Wheelchair accessory, addition to mobile arm support, elevating proximal arm	Procedure	HCPCS
E2632	Wheelchair accessory, addition to mobile arm support, offset or lateral rocker arm with elastic balance control	Procedure	HCPCS
E2633	Wheelchair accessory, addition to mobile arm support, supinator	Procedure	HCPCS
G9156	Evaluation for wheelchair requiring face-to-face visit with physician	Procedure	HCPCS
K0001	Standard wheelchair	Procedure	HCPCS
K0002	Standard hemi (low seat) wheelchair	Procedure	HCPCS
K0003	Lightweight wheelchair	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K0004	High strength, lightweight wheelchair	Procedure	HCPCS
K0005	Ultralightweight wheelchair	Procedure	HCPCS
K0006	Heavy-duty wheelchair	Procedure	HCPCS
K0007	Extra heavy-duty wheelchair	Procedure	HCPCS
K0008	Custom manual wheelchair/base	Procedure	HCPCS
K0009	Other manual wheelchair/base	Procedure	HCPCS
K0010	Standard-weight frame motorized/power wheelchair	Procedure	HCPCS
K0011	Standard-weight frame motorized/power wheelchair with programmable control parameters for speed adjustment, tremor dampening, acceleration control and braking	Procedure	HCPCS
K0012	Lightweight portable motorized/power wheelchair	Procedure	HCPCS
K0013	Custom motorized/power wheelchair base	Procedure	HCPCS
K0014	Other motorized/power wheelchair base	Procedure	HCPCS
K0015	Detachable, nonadjustable height armrest, each	Procedure	HCPCS
K0017	Detachable, adjustable height armrest, base, each	Procedure	HCPCS
K0018	Detachable, adjustable height armrest, upper portion, replacement only, each	Procedure	HCPCS
K0019	Arm pad, each	Procedure	HCPCS
K0020	Fixed, adjustable height armrest, pair	Procedure	HCPCS
K0037	High mount flip-up footrest, each	Procedure	HCPCS
K0038	Leg strap, each	Procedure	HCPCS
K0039	Leg strap, H style, each	Procedure	HCPCS
K0040	Adjustable angle footplate, each	Procedure	HCPCS
K0041	Large size footplate, each	Procedure	HCPCS
K0042	Standard size footplate, each	Procedure	HCPCS
K0043	Footrest, lower extension tube, replacement only, each	Procedure	HCPCS
K0044	Footrest, upper hanger bracket, each	Procedure	HCPCS
K0045	Footrest, complete assembly, replacement only, each	Procedure	HCPCS
K0046	Elevating legrest, lower extension tube, replacement only, each	Procedure	HCPCS
K0047	Elevating legrest, upper hanger bracket, replacement only, each	Procedure	HCPCS
K0050	Ratchet assembly, replacement only	Procedure	HCPCS
K0051	Cam release assembly, footrest or legrest, replacement only, each	Procedure	HCPCS
K0052	Swingaway, detachable footrests, replacement only, each	Procedure	HCPCS
K0053	Elevating footrests, articulating (telescoping), each	Procedure	HCPCS
K0056	Seat height less than 17 in or equal to or greater than 21 in for a high-strength, lightweight, or ultralightweight wheelchair	Procedure	HCPCS
K0065	Spoke protectors, each	Procedure	HCPCS
K0069	Rear wheel assembly, complete, with solid tire, spokes or molded, replacement only, each	Procedure	HCPCS
K0070	Rear wheel assembly, complete, with pneumatic tire, spokes or molded, replacement only, each	Procedure	HCPCS
K0071	Front caster assembly, complete, with pneumatic tire, replacement only, each	Procedure	HCPCS
K0072	Front caster assembly, complete, with semipneumatic tire, each	Procedure	HCPCS
K0073	Caster pin lock, each	Procedure	HCPCS
K0077	Front caster assembly, complete, with solid tire, each	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K0098	Drive belt for power wheelchair, replacement only	Procedure	HCPCS
K0105	IV hanger, each	Procedure	HCPCS
K0108	Wheelchair component or accessory, not otherwise specified	Procedure	HCPCS
K0195	Elevating legrests, pair (for use with capped rental wheelchair base)	Procedure	HCPCS
K0669	Wheelchair accessory, wheelchair seat or back cushion, does not meet specific code criteria or no written coding verification from DME PDAC	Procedure	HCPCS
K0733	Power wheelchair accessory, 12 to 24 amp hour sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)	Procedure	HCPCS
K0734	Skin protection wheelchair seat cushion, adjustable, width less than 22 in, any depth	Procedure	HCPCS
K0735	Skin protection wheelchair seat cushion, adjustable, width 22 in or greater, any depth	Procedure	HCPCS
K0736	Skin protection and positioning wheelchair seat cushion, adjustable, width less than 22 in, any depth	Procedure	HCPCS
K0737	Skin protection and positioning wheelchair seat cushion, adjustable, width 22 in or greater, any depth	Procedure	HCPCS
K0800	Power operated vehicle, group 1 standard, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0801	Power operated vehicle, group 1 heavy-duty, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0802	Power operated vehicle, group 1 very heavy-duty, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0806	Power operated vehicle, group 2 standard, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0807	Power operated vehicle, group 2 heavy-duty, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0808	Power operated vehicle, group 2 very heavy-duty, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0812	Power operated vehicle, not otherwise classified	Procedure	HCPCS
K0813	Power wheelchair, group 1 standard, portable, sling/solid seat and back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0814	Power wheelchair, group 1 standard, portable, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0815	Power wheelchair, group 1 standard, sling/solid seat and back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0816	Power wheelchair, group 1 standard, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0820	Power wheelchair, group 2 standard, portable, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0821	Power wheelchair, group 2 standard, portable, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0822	Power wheelchair, group 2 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0823	Power wheelchair, group 2 standard, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K0824	Power wheelchair, group 2 heavy-duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0825	Power wheelchair, group 2 heavy-duty, captain's chair, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0826	Power wheelchair, group 2 very heavy-duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0827	Power wheelchair, group 2 very heavy-duty, captain's chair, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0828	Power wheelchair, group 2 extra heavy-duty, sling/solid seat/back, patient weight capacity 601 pounds or more	Procedure	HCPCS
K0829	Power wheelchair, group 2 extra heavy-duty, captain's chair, patient weight 601 pounds or more	Procedure	HCPCS
K0830	Power wheelchair, group 2 standard, seat elevator, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0831	Power wheelchair, group 2 standard, seat elevator, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0835	Power wheelchair, group 2 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0836	Power wheelchair, group 2 standard, single power option, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0837	Power wheelchair, group 2 heavy-duty, single power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0838	Power wheelchair, group 2 heavy-duty, single power option, captain's chair, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0839	Power wheelchair, group 2 very heavy-duty, single power option sling/solid seat/back, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0840	Power wheelchair, group 2 extra heavy-duty, single power option, sling/solid seat/back, patient weight capacity 601 pounds or more	Procedure	HCPCS
K0841	Power wheelchair, group 2 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0842	Power wheelchair, group 2 standard, multiple power option, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0843	Power wheelchair, group 2 heavy-duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0848	Power wheelchair, group 3 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0849	Power wheelchair, group 3 standard, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0850	Power wheelchair, group 3 heavy-duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0851	Power wheelchair, group 3 heavy-duty, captain's chair, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0852	Power wheelchair, group 3 very heavy-duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0853	Power wheelchair, group 3 very heavy-duty, captain's chair, patient weight capacity 451 to 600 pounds	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K0854	Power wheelchair, group 3 extra heavy-duty, sling/solid seat/back, patient weight capacity 601 pounds or more	Procedure	HCPCS
K0855	Power wheelchair, group 3 extra heavy-duty, captain's chair, patient weight capacity 601 pounds or more	Procedure	HCPCS
K0856	Power wheelchair, group 3 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0857	Power wheelchair, group 3 standard, single power option, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0858	Power wheelchair, group 3 heavy-duty, single power option, sling/solid seat/back, patient weight 301 to 450 pounds	Procedure	HCPCS
K0859	Power wheelchair, group 3 heavy-duty, single power option, captain's chair, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0860	Power wheelchair, group 3 very heavy-duty, single power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0861	Power wheelchair, group 3 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0862	Power wheelchair, group 3 heavy-duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0863	Power wheelchair, group 3 very heavy-duty, multiple power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0864	Power wheelchair, group 3 extra heavy-duty, multiple power option, sling/solid seat/back, patient weight capacity 601 pounds or more	Procedure	HCPCS
K0868	Power wheelchair, group 4 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0869	Power wheelchair, group 4 standard, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0870	Power wheelchair, group 4 heavy-duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0871	Power wheelchair, group 4 very heavy-duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds	Procedure	HCPCS
K0877	Power wheelchair, group 4 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0878	Power wheelchair, group 4 standard, single power option, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0879	Power wheelchair, group 4 heavy-duty, single power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0880	Power wheelchair, group 4 very heavy-duty, single power option, sling/solid seat/back, patient weight 451 to 600 pounds	Procedure	HCPCS
K0884	Power wheelchair, group 4 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0885	Power wheelchair, group 4 standard, multiple power option, captain's chair, patient weight capacity up to and including 300 pounds	Procedure	HCPCS
K0886	Power wheelchair, group 4 heavy-duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds	Procedure	HCPCS
K0898	Power wheelchair, not otherwise classified	Procedure	HCPCS
K0899	Power mobility device, not coded by DME PDAC or does not meet criteria	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L3964	Shoulder-elbow orthotic (SEO), mobile arm support attached to wheelchair, balanced, adjustable, prefabricated, includes fitting and	Procedure	HCPCS
L3965	Shoulder-elbow orthotic (SEO), mobile arm support attached to wheelchair, balanced, adjustable Rancho type, prefabricated, includes fitting and adjustment	Procedure	HCPCS
L3966	Shoulder-elbow orthotic (SEO), mobile arm support attached to wheelchair, balanced, reclining, prefabricated, includes fitting and	Procedure	HCPCS
L3968	Shoulder-elbow orthotic (SEO), mobile arm support attached to wheelchair, balanced, friction arm support (friction dampening to proximal and distal joints), prefabricated, includes fitting and adjustment	Procedure	HCPCS
L3969	Shoulder-elbow orthotic (SEO), mobile arm support, monosuspension arm and hand support, overhead elbow forearm hand sling support, yoke type suspension support, prefabricated, includes fitting and adjustment	Procedure	HCPCS
L3970	Shoulder-elbow orthotic (SEO), addition to mobile arm support, elevating proximal arm	Procedure	HCPCS
L3972	Shoulder-elbow orthotic (SEO), addition to mobile arm support, offset or lateral rocker arm with elastic balance control	Procedure	HCPCS
L3974	Shoulder-elbow orthotic (SEO), addition to mobile arm support, supinator	Procedure	HCPCS
	Diuretic Use		
4190F	Appropriate diuretic therapeutic monitoring test ordered or performed (AM)	Procedure	CPT-2
4221F	Diuretic medication therapy for 6 months or more (MM)	Procedure	CPT-2
78708	Kidney imaging morphology; with vascular flow and function, single study, with pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic)	Procedure	CPT-4
78709	Kidney imaging morphology; with vascular flow and function, multiple studies, with and without pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic)	Procedure	CPT-4
84588	Vasopressin (antidiuretic hormone, ADH)	Procedure	CPT-4
S9361	Home infusion therapy, diuretic intravenous therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	Procedure	HCPCS
	Antidepressant Use		
4064F	Antidepressant pharmacotherapy prescribed (MDD, MDD ADOL)	Procedure	CPT-2
80332	Antidepressants, serotonergic class; 1 or 2	Procedure	CPT-4
80333	Antidepressants, serotonergic class; 3-5	Procedure	CPT-4
80334	Antidepressants, serotonergic class; 6 or more	Procedure	CPT-4
80335	Antidepressants, tricyclic and other cyclicals; 1 or 2	Procedure	CPT-4
80336	Antidepressants, tricyclic and other cyclicals; 3-5	Procedure	CPT-4
80337	Antidepressants, tricyclic and other cyclicals; 6 or more	Procedure	CPT-4
80338	Antidepressants, not otherwise specified	Procedure	CPT-4
G8126	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase	Procedure	HCPCS

Appendix W. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
G8129	Patient documented as being treated with antidepressant medication for at least 6 months continuous treatment phase	Procedure	HCPCS
G9194	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase	Procedure	HCPCS
	Gastric Acid Suppressant Use		
4185F	Continuous (12-months) therapy with proton pump inhibitor (PPI) or histamine H2 receptor antagonist (H2RA) received (GERD)	Procedure	CPT-2
	Benzodiazepine Use		
80154	Benzodiazepines	Procedure	CPT-4
80346	Benzodiazepines; 1-12	Procedure	CPT-4
80347	Benzodiazepines; 13 or more	Procedure	CPT-4
80368	Sedative hypnotics (non-benzodiazepines)	Procedure	CPT-4
G0033	Two or more benzodiazepine prescriptions ordered for patients who had a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between January 1 of the year prior to the measurement period and the IPSD for benzodiazepines	Procedure	HCPCS
G6031	Assay of benzodiazepines	Procedure	HCPCS

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Antidementia Use	
donepezil HCl	Aricept
donepezil HCl	Aricept ODT
donepezil HCl	donepezil
galantamine HBr	Razadyne
galantamine HBr	Razadyne ER
galantamine HBr	galantamine
memantine HCl	Namenda
memantine HCl	Namenda Titration Pak
memantine HCl	Namenda XR
memantine HCl	memantine
memantine HCl/donepezil HCl	Namzaric
rivastigmine	Exelon Patch
rivastigmine	rivastigmine
rivastigmine tartrate	Exelon
rivastigmine tartrate	rivastigmine tartrate
tacrine HCl	Cognex
Angiotensin-Converting Enzyme (ACE) Inhibitor Use	
amlodipine besylate/benazepril HCl	Lotrel
amlodipine besylate/benazepril HCl	amlodipine-benazepril
benazepril HCl	Lotensin
benazepril HCl	benazepril
benazepril HCl/hydrochlorothiazide	Lotensin HCT
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
captopril	Capoten
captopril	captopril
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
enalapril maleate	Epaned
enalapril maleate	Vasotec
enalapril maleate	enalapril maleate
enalapril maleate/hydrochlorothiazide	Vaseretic
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
enalaprilat dihydrate	enalaprilat
fosinopril sodium	Monopril
fosinopril sodium	fosinopril
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
lisinopril	Prinivil
lisinopril	Qbrelis
lisinopril	Zestril
lisinopril	lisinopril
lisinopril/dietary supplement,comb.10	Lytensopril
lisinopril/dietary supplement,comb.10	Lytensopril-90
lisinopril/hydrochlorothiazide	Prinzide
lisinopril/hydrochlorothiazide	Zestoretic
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
moexipril HCl	Univasc
moexipril HCl	moexipril
moexipril HCl/hydrochlorothiazide	Uniretic

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
moexipril HCl/hydrochlorothiazide	moexipril-hydrochlorothiazide
perindopril arginine/amlodipine besylate	Prestalia
perindopril erbumine	Aceon
perindopril erbumine	perindopril erbumine
quinapril HCl	Accupril
quinapril HCl	quinapril
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	Quinaretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
ramipril	Altace
ramipril	ramipril
trandolapril	Mavik
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil
Angiotensin II Receptor Blocker (ARB) Use	
amlodipine besylate/olmesartan medoxomil	Azor
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
azilsartan medoxomil	Edarbi
azilsartan medoxomil/chlorthalidone	Edarbyclor
candesartan cilexetil	Atacand
candesartan cilexetil	candesartan
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
eprosartan mesylate	Teveten
eprosartan mesylate	eprosartan
eprosartan mesylate/hydrochlorothiazide	Teveten HCT
irbesartan	Avapro
irbesartan	irbesartan
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
losartan potassium	Cozaar
losartan potassium	losartan
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
nebivolol HCl/valsartan	Byvalson
olmesartan medoxomil	Benicar
olmesartan medoxomil	olmesartan
olmesartan medoxomil/amlodipine	Tribenzor
olmesartan medoxomil/amlodipine	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
sacubitril/valsartan	Entresto
telmisartan	Micardis

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
telmisartan	telmisartan
telmisartan/amlodipine besylate	Twynsta
telmisartan/amlodipine besylate	telmisartan-amlodipine
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
valsartan	Diovan
valsartan	valsartan
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
Beta Blocker Use	
acebutolol HCl	Sectral
acebutolol HCl	acebutolol
atenolol	Tenormin
atenolol	atenolol
betaxolol HCl	Betoptic S
betaxolol HCl	Kerlone
betaxolol HCl	betaxolol
bisoprolol fumarate	Zebeta
bisoprolol fumarate	bisoprolol fumarate
canakinumab/PF	Ilaris (PF)
carteolol HCl	carteolol
carvedilol	Coreg
carvedilol	carvedilol
carvedilol phosphate	Coreg CR
carvedilol phosphate	carvedilol phosphate
esmolol HCl	Brevibloc
esmolol HCl	esmolol
esmolol HCl in sodium chloride, iso-osmotic	Brevibloc in NaCl (iso-osm)
esmolol HCl in sodium chloride, iso-osmotic	esmolol in NaCl (iso-osm)
esmolol HCl in sterile water	esmolol in sterile water
labetalol HCl	Trandate
labetalol HCl	labetalol
labetalol HCl in dextrose, iso-osmotic	labetalol in dextrose,iso-osm
labetalol HCl in sodium chloride, iso-osmotic	labetalol in NaCl (iso-osmot)
labetalol in dextrose 5 % in water	labetalol in dextrose 5 %
levobunolol HCl	Betagan
levobunolol HCl	levobunolol
metipranolol	Optipranolol
metipranolol	metipranolol
metoprolol succinate	Kapspargo Sprinkle
metoprolol succinate	Toprol XL
metoprolol succinate	metoprolol succinate
metoprolol tartrate	Lopressor
metoprolol tartrate	metoprolol tartrate
metoprolol tartrate/dietary supplement,comb.10	Hypertensolol
nadolol	Corgard
nadolol	nadolol
nebivolol HCl	Bystolic

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
nebivolol HCl	nebivolol
penbutolol sulfate	Levatol
pindolol	pindolol
propranolol HCl	Hemangeol
propranolol HCl	Inderal
propranolol HCl	Inderal LA
propranolol HCl	Inderal XL
propranolol HCl	InnoPran XL
propranolol HCl	propranolol
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
sotalol HCl	sotalol
timolol	Betimol
timolol maleate	Istalol
timolol maleate	Timoptic
timolol maleate	Timoptic-XE
timolol maleate	timolol maleate
timolol maleate/PF	Timoptic Ocudose (PF)
timolol maleate/PF	timolol maleate (PF)
Oral Anticoagulant Use	
apixaban	Eliquis
apixaban	Eliquis DVT-PE Treat 30D Start
betrixaban maleate	Bevyxxa
dabigatran etexilate mesylate	Pradaxa
edoxaban tosylate	Savaysa
rivaroxaban	Xarelto
rivaroxaban	Xarelto DVT-PE Treat 30d Start
warfarin sodium	Coumadin
warfarin sodium	Jantoven
warfarin sodium	warfarin
Antiplatelet Agent Use	
abciximab	Reopro
anagrelide HCl	Agrylin
anagrelide HCl	anagrelide
aspirin	Adult Aspirin EC Low Strength
aspirin	Adult Aspirin Regimen
aspirin	Adult Low Dose Aspirin
aspirin	Analgesic
aspirin	AsperDrink
aspirin	Aspir-81
aspirin	Aspir-Low
aspirin	Aspir-Trin
aspirin	Aspirin Childrens
aspirin	Aspirin Extra Strength
aspirin	Aspirin Low Dose

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
aspirin	Aspirin Low-Strength
aspirin	Aspirina
aspirin	Baby Aspirin
aspirin	Bayer Advanced
aspirin	Bayer Aspirin
aspirin	Bayer Chewable Aspirin
aspirin	Child Aspirin
aspirin	Children's Aspirin
aspirin	Durlaza
aspirin	E.C. Prin
aspirin	EC Aspirin
aspirin	Ecotrin
aspirin	Ecotrin Low Strength
aspirin	Ecotrin Maximum Strength
aspirin	Enteric Coated Aspirin
aspirin	Extra Strength Bayer
aspirin	Genacote
aspirin	Halfprin
aspirin	Lite Coat Aspirin
aspirin	Lo-Dose Aspirin
aspirin	Miniprin
aspirin	St Joseph Aspirin
aspirin	St. Joseph Aspirin
aspirin	St. Joseph Low-Dose Aspirin
aspirin	Stanback Headache Powder
aspirin	Vazalore
aspirin	aspirin
aspirin/calcium carbonate	Women's Aspirin with Calcium
aspirin/dipyridamole	Aggrenox
aspirin/dipyridamole	aspirin-dipyridamole
aspirin/omeprazole	Yosprala
aspirin/omeprazole	aspirin-omeprazole
cangrelor tetrasodium	Kengreal
cilostazol	Pletal
cilostazol	cilostazol
clopidogrel bisulfate	Plavix
clopidogrel bisulfate	clopidogrel
dipyridamole	Persantine
dipyridamole	dipyridamole
eptifibatide	Integrilin
eptifibatide	eptifibatide
prasugrel HCl	Effient
prasugrel HCl	prasugrel
ticagrelor	Brilinta
ticlopidine HCl	ticlopidine
tirofiban HCl monohydrate	Aggrastat Concentrate
tirofiban HCl monohydrate in 0.9 % sodium chloride	Aggrastat in sodium chloride
vorapaxar sulfate	Zontivity

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Opioid Use	
acetaminophen with codeine phosphate	Capital with Codeine
acetaminophen with codeine phosphate	Cocet
acetaminophen with codeine phosphate	Cocet Plus
acetaminophen with codeine phosphate	Tylenol-Codeine #3
acetaminophen with codeine phosphate	Tylenol-Codeine #4
acetaminophen with codeine phosphate	Vopac
acetaminophen with codeine phosphate	acetaminophen-codeine
acetaminophen/caffeine/dihydrocodeine bitartrate	Dvorah
acetaminophen/caffeine/dihydrocodeine bitartrate	Panlor(acetam-caff-dihydrocod)
acetaminophen/caffeine/dihydrocodeine bitartrate	Trezix
acetaminophen/caffeine/dihydrocodeine bitartrate	acetaminophen-caff-dihydrocod
alfentanil HCl	Alfenta
alfentanil HCl	alfentanil
benzhydrocodone HCl/acetaminophen	Apadaz
benzhydrocodone HCl/acetaminophen	benzhydrocodone-acetaminophen
buprenorphine	Butrans
buprenorphine	buprenorphine
buprenorphine HCl	Belbuca
buprenorphine HCl	Buprenex
buprenorphine HCl	buprenorphine HCl
butalbital/acetaminophen/caffeine/codeine phosphate	Fioricet with Codeine
butalbital/acetaminophen/caffeine/codeine phosphate	butalbital-acetaminop-caf-cod
butorphanol tartrate	Stadol
butorphanol tartrate	butorphanol
codeine phosphate	codeine phosphate
codeine phosphate/butalbital/aspirin/caffeine	Ascomp with Codeine
codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound W/Codeine
codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound-Codeine
codeine phosphate/butalbital/aspirin/caffeine	Fiorinal-Codeine #3
codeine phosphate/butalbital/aspirin/caffeine	codeine-butalbital-ASA-caff
codeine sulfate	codeine sulfate
difelikefalin acetate	Korsuva
fentanyl	Duragesic
fentanyl	Subsys
fentanyl	fentanyl
fentanyl HCl	Ionsys
fentanyl citrate	Abstral
fentanyl citrate	Actiq
fentanyl citrate	Fentora
fentanyl citrate	Lazanda
fentanyl citrate	Onsolis
fentanyl citrate	fentanyl citrate
fentanyl citrate in 0.9 % sodium chloride/PF	fentanyl citrate (PF)-0.9%NaCl
fentanyl citrate in dextrose 5% in water/PF	fentanyl citrate in D5W (PF)
fentanyl citrate/PF	fentanyl citrate (PF)
fentanyl citrate/bupivacaine HCl in 0.9 % sodium chloride/PF	fentanyl (PF)-bupivacaine-NaCl
fentanyl citrate/ropivacaine HCl/sodium chloride 0.9%/PF	fentanyl-ropivacaine-NaCl (PF)

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
hydrocodone bitartrate	Hysingla ER
hydrocodone bitartrate	Zohydro ER
hydrocodone bitartrate	hydrocodone bitartrate
hydrocodone bitartrate/acetaminophen	Anexsia
hydrocodone bitartrate/acetaminophen	Co-Gesic
hydrocodone bitartrate/acetaminophen	Dolorex Forte
hydrocodone bitartrate/acetaminophen	Hycet
hydrocodone bitartrate/acetaminophen	Hydrogesic
hydrocodone bitartrate/acetaminophen	Lorcet (hydrocodone)
hydrocodone bitartrate/acetaminophen	Lorcet 10/650
hydrocodone bitartrate/acetaminophen	Lorcet HD
hydrocodone bitartrate/acetaminophen	Lorcet Plus
hydrocodone bitartrate/acetaminophen	Lortab
hydrocodone bitartrate/acetaminophen	Lortab 10-325
hydrocodone bitartrate/acetaminophen	Lortab 5-325
hydrocodone bitartrate/acetaminophen	Lortab 7.5-325
hydrocodone bitartrate/acetaminophen	Lortab Elixir
hydrocodone bitartrate/acetaminophen	Margesic-H
hydrocodone bitartrate/acetaminophen	Maxidone
hydrocodone bitartrate/acetaminophen	Norco
hydrocodone bitartrate/acetaminophen	Polygesic
hydrocodone bitartrate/acetaminophen	Stagesic
hydrocodone bitartrate/acetaminophen	Verdrocet
hydrocodone bitartrate/acetaminophen	Vicodin
hydrocodone bitartrate/acetaminophen	Vicodin ES
hydrocodone bitartrate/acetaminophen	Vicodin HP
hydrocodone bitartrate/acetaminophen	Xodol 10/300
hydrocodone bitartrate/acetaminophen	Xodol 5/300
hydrocodone bitartrate/acetaminophen	Xodol 7.5/300
hydrocodone bitartrate/acetaminophen	Zamicet
hydrocodone bitartrate/acetaminophen	Zolvit
hydrocodone bitartrate/acetaminophen	Zydone
hydrocodone bitartrate/acetaminophen	hydrocodone-acetaminophen
hydrocodone bitartrate/acetaminophen/dietary supplement	Theracodophen-325
hydrocodone bitartrate/acetaminophen/dietary supplement	Theracodophen-650
hydrocodone bitartrate/acetaminophen/dietary supplement	Theracodophen-Low-90
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	Reprexain
hydrocodone/ibuprofen	Vicoprofen
hydrocodone/ibuprofen	Xylon 10
hydrocodone/ibuprofen	hydrocodone-ibuprofen
hydromorphone HCl	Dilaudid
hydromorphone HCl	Exalgo ER
hydromorphone HCl	hydromorphone
hydromorphone HCl in 0.9 % sodium chloride	hydromorphone in 0.9 % NaCl
hydromorphone HCl in 0.9 % sodium chloride/PF	hydromorphone (PF)-0.9 % NaCl
hydromorphone HCl in dextrose 5 %-water/PF	hydromorphone in D5W (PF)
hydromorphone HCl in sodium chloride, iso-osmotic/PF	hydromorphone(PF)-NaCl,iso-osm

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
hydromorphone HCl in sterile water/PF	hydromorphone (PF) in water
hydromorphone HCl/PF	Dilaudid (PF)
hydromorphone HCl/PF	Dilaudid-HP (PF)
hydromorphone HCl/PF	hydromorphone (PF)
hydromorphone HCl/bupivacaine HCl in 0.9% sodium	hydromorphone-bupiv (PF)-NaCl
hydromorphone HCl/ropivacaine in 0.9 % sodium chloride/PF	hydromorph(PF)-ropiv-0.9% NaCl
ibuprofen/oxycodone HCl	Combunox
ibuprofen/oxycodone HCl	ibuprofen-oxycodone
levorphanol tartrate	levorphanol tartrate
meperidine HCl	Demerol
meperidine HCl	Meperitab
meperidine HCl	meperidine
meperidine HCl in 0.9 % sodium chloride	meperidine in 0.9 % NaCl
meperidine HCl in 0.9 % sodium chloride/PF	meperidine (PF) in 0.9 % NaCl
meperidine HCl/PF	Demerol (PF)
meperidine HCl/PF	meperidine (PF)
methadone HCl	Diskets
methadone HCl	Dolophine
methadone HCl	Methadone Intensol
methadone HCl	Methadose
methadone HCl	methadone
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
morphine sulfate	Arymo ER
morphine sulfate	Avinza
morphine sulfate	Kadian
morphine sulfate	MS Contin
morphine sulfate	MorphaBond ER
morphine sulfate	Oramorph SR
morphine sulfate	Roxanol Concentrate
morphine sulfate	morphine
morphine sulfate	morphine concentrate
morphine sulfate in 0.9 % sodium chloride	morphine in 0.9 % sodium chlor
morphine sulfate in 0.9 % sodium chloride/PF	morphine (PF) in 0.9 % sod chl
morphine sulfate in sodium chloride, iso-osmotic/PF	morphine(PF)in iso sod chlorid
morphine sulfate liposomal/PF	DepoDur (PF)
morphine sulfate/PF	Astramorph-PF
morphine sulfate/PF	Duramorph (PF)
morphine sulfate/PF	Infumorph P/F
morphine sulfate/PF	Mitigo (PF)
morphine sulfate/PF	morphine (PF)
morphine sulfate/dextrose 5 % in water	morphine in dextrose 5 %
morphine sulfate/dextrose 5%-water/PF	morphine (PF) in dextrose 5 %
morphine sulfate/naltrexone HCl	Embeda
nalbuphine HCl	nalbuphine
oliceridine fumarate	Olinvyk
oxycodone HCl	Dazidox
oxycodone HCl	ETH-Oxydose
oxycodone HCl	Oxaydo

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
oxycodone HCl	Oxecta
oxycodone HCl	OxyContin
oxycodone HCl	OxyIR
oxycodone HCl	Roxicodone
oxycodone HCl	Roxicodone Intensol
oxycodone HCl	RoxyBond
oxycodone HCl	oxycodone
oxycodone HCl/acetaminophen	ALCET
oxycodone HCl/acetaminophen	Endocet
oxycodone HCl/acetaminophen	Magnacet
oxycodone HCl/acetaminophen	Nalocet
oxycodone HCl/acetaminophen	Percocet
oxycodone HCl/acetaminophen	Primalev
oxycodone HCl/acetaminophen	Primlev
oxycodone HCl/acetaminophen	Prolate
oxycodone HCl/acetaminophen	Roxicet
oxycodone HCl/acetaminophen	Tylox
oxycodone HCl/acetaminophen	Xartemis XR
oxycodone HCl/acetaminophen	Xolox
oxycodone HCl/acetaminophen	oxycodone-acetaminophen
oxycodone HCl/aspirin	Endodan
oxycodone HCl/aspirin	Percodan
oxycodone HCl/aspirin	oxycodone-aspirin
oxycodone HCl/oxycodone terephthalate/aspirin	oxycodone HCl-oxycodone-ASA
oxycodone myristate	Xtampza ER
oxymorphone HCl	Numorphan
oxymorphone HCl	Opana
oxymorphone HCl	Opana ER
oxymorphone HCl	oxymorphone
pentazocine HCl/acetaminophen	Talacen
pentazocine HCl/acetaminophen	pentazocine-acetaminophen
pentazocine HCl/naloxone HCl	Talwin NX
pentazocine HCl/naloxone HCl	pentazocine-naloxone
pentazocine lactate	Talwin
propoxyphene HCl	Darvon
propoxyphene HCl	propoxyphene
propoxyphene HCl/acetaminophen	propoxyphene-acetaminophen
propoxyphene napsylate	Darvon-N
propoxyphene napsylate/acetaminophen	Balacet 325
propoxyphene napsylate/acetaminophen	Darvocet A500
propoxyphene napsylate/acetaminophen	Darvocet-N 100
propoxyphene napsylate/acetaminophen	Darvocet-N 50
propoxyphene napsylate/acetaminophen	Propoxacet-N 100
propoxyphene napsylate/acetaminophen	propoxyphene N-acetaminophen
sufentanil citrate	Dsuvia
sufentanil citrate/bupivacaine HCl/0.9 % sodium chloride/PF	sufentanil-bupivacain-NaCl(PF)
tapentadol HCl	Nucynta
tapentadol HCl	Nucynta ER

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
tramadol HCl	ConZip
tramadol HCl	Qdolo
tramadol HCl	Rybix ODT
tramadol HCl	Ryzolt
tramadol HCl	Ultram
tramadol HCl	Ultram ER
tramadol HCl	tramadol
tramadol HCl/acetaminophen	Ultracet
tramadol HCl/acetaminophen	tramadol-acetaminophen
tramadol HCl/celecoxib	Seglentis
tramadol HCl/dietary supplement,misc. cb.11	Theratramadol-60
tramadol HCl/dietary supplement,misc. cb.11	Theratramadol-90
Statin Use	
amlodipine besylate/atorvastatin calcium	Caduet
amlodipine besylate/atorvastatin calcium	amlodipine-atorvastatin
atorvastatin calcium	Lipitor
atorvastatin calcium	atorvastatin
ezetimibe/atorvastatin calcium	Liptruzet
ezetimibe/rosuvastatin calcium	Roszet
ezetimibe/rosuvastatin calcium	ezetimibe-rosuvastatin
ezetimibe/simvastatin	Vytorin 10-10
ezetimibe/simvastatin	Vytorin 10-20
ezetimibe/simvastatin	Vytorin 10-40
ezetimibe/simvastatin	Vytorin 10-80
ezetimibe/simvastatin	ezetimibe-simvastatin
fluvastatin sodium	Lescol
fluvastatin sodium	Lescol XL
fluvastatin sodium	fluvastatin
lovastatin	Altoprev
lovastatin	Mevacor
lovastatin	lovastatin
niacin/lovastatin	Advicor
niacin/simvastatin	Simcor
pitavastatin calcium	Livalo
pitavastatin magnesium	Zypitamag
pravastatin sodium	Pravachol
pravastatin sodium	pravastatin
rosuvastatin calcium	Crestor
rosuvastatin calcium	Ezallor Sprinkle
rosuvastatin calcium	rosuvastatin
simvastatin	FloLipid
simvastatin	Zocor
simvastatin	simvastatin
sitagliptin phosphate/simvastatin	Juvisync
Antiarrhythmic Use	
adenosine	Adenocard
adenosine	adenosine
adenosine in 0.9 % sodium chloride	adenosine in 0.9 % sod chlor

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
amiodarone HCl	Cordarone
amiodarone HCl	Pacerone
amiodarone HCl	amiodarone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
bretylium tosylate	bretylium tosylate
diltiazem HCl	diltiazem HCl
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
disopyramide phosphate	disopyramide phosphate
dofetilide	Tikosyn
dofetilide	dofetilide
dronedarone HCl	Multaq
esmolol HCl	Brevibloc
esmolol HCl	esmolol
esmolol HCl in sodium chloride, iso-osmotic	Brevibloc in NaCl (iso-osm)
esmolol HCl in sodium chloride, iso-osmotic	esmolol in NaCl (iso-osm)
esmolol HCl in sterile water	esmolol in sterile water
flecainide acetate	Tambocor
flecainide acetate	flecainide
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
lidocaine HCl in dextrose 5% in water/PF	lidocaine in 5 % dextrose (PF)
lidocaine HCl in sodium chloride, iso-osmotic/PF	lidocaine in NaCl,iso-osmo(PF)
lidocaine HCl/PF	Xylocaine (Cardiac) (PF)
lidocaine HCl/PF	lidocaine (PF)
mexiletine HCl	Mexitil
mexiletine HCl	mexiletine
phenytoin sodium	phenytoin sodium
procainamide HCl	procainamide
propafenone HCl	Rythmol
propafenone HCl	Rythmol SR
propafenone HCl	propafenone
quinidine gluconate	quinidine gluconate
quinidine sulfate	Quinidex Extentabs
quinidine sulfate	quinidine sulfate
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
sotalol HCl	sotalol
verapamil HCl	Calan
verapamil HCl	verapamil
Antidiabetic Use	
acarbose	Precose
acarbose	acarbose
albiglutide	Tanzeum

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
alogliptin benzoate	Nesina
alogliptin benzoate	alogliptin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/pioglitazone HCl	Oseni
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
bromocriptine mesylate	Cycloset
bromocriptine mesylate	Parlodel
bromocriptine mesylate	bromocriptine
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
chlorpropamide	chlorpropamide
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
dapagliflozin propanediol/saxagliptin HCl	Qtern
diluent,insulin aspart combination no.1	Diluting Medium for Novolog
dulaglutide	Trulicity
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
glimepiride	Amaryl
glimepiride	glimepiride
glipizide/metformin HCl	Metaglip
glipizide/metformin HCl	glipizide-metformin
glyburide	Diabeta
glyburide	glyburide
glyburide,micronized	Glynase
glyburide,micronized	glyburide micronized
glyburide/metformin HCl	Glucovance
glyburide/metformin HCl	glyburide-metformin
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin
insulin NPH human isophane	Humulin N Pen
insulin NPH human isophane	Novolin N Flexpen
insulin NPH human isophane	Novolin N InnoLet
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane	Novolin N PenFill
insulin NPH human isophane/insulin regular, human	Humulin 50/50
insulin NPH human isophane/insulin regular, human	Humulin 70/30 Insulin Pen

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin NPH human isophane/insulin regular, human	Novolin 70/30 InnoLet Insulin
insulin NPH human isophane/insulin regular, human	Novolin 70/30 PenFill
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin aspart	Novolog Flexpen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart	insulin aspart U-100
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insuln
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin degludec/liraglutide	Xultophy 100/3.6
insulin detemir	Levemir FlexTouch U-100 Insuln
insulin detemir	Levemir Flexpen
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin
insulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine,human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Pen
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev U-100 Insulin

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insuln
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R Flexpen
insulin regular, human	Novolin R InnoLet
insulin regular, human	Novolin R PenFill
insulin regular, human	Novolin R Regular U-100 Insuln
insulin regular, human in 0.9 % sodium chloride	Myxredlin
linagliptin	Tradjenta
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lixisenatide	Adlyxin
metformin HCl	Fortamet
metformin HCl	Glucophage
metformin HCl	Glucophage XR
metformin HCl	Glumetza
metformin HCl	Riomet
metformin HCl	Riomet ER
metformin HCl	metformin
miglitol	Glyset
miglitol	miglitol
nateglinide	Starlix
nateglinide	nateglinide
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	Actoplus Met XR
pioglitazone HCl/metformin HCl	pioglitazone-metformin
pramlintide acetate	Symlin
pramlintide acetate	SymlinPen 120
pramlintide acetate	SymlinPen 60
repaglinide	Prandin
repaglinide	repaglinide
repaglinide/metformin HCl	Prandimet
repaglinide/metformin HCl	repaglinide-metformin
rosiglitazone maleate	Avandia
rosiglitazone maleate/metformin HCl	Avandamet
saxagliptin HCl	Onglyza
saxagliptin HCl/metformin HCl	Kombiglyze XR
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
sitagliptin phosphate	Januvia
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
tolazamide	tolazamide
tolbutamide	tolbutamide
Calcium Channel Blocker Use	
aliskiren hemifumarate/amlodipine besylate	Tekamlo
aliskiren hemifumarate/amlodipine/hydrochlorothiazide	Amturnide
amlodipine benzoate	Katerzia
amlodipine besylate	Norliqva
amlodipine besylate	Norvasc
amlodipine besylate	amlodipine
amlodipine besylate	amlodipine besylate (bulk)
amlodipine besylate/atorvastatin calcium	Caduet
amlodipine besylate/atorvastatin calcium	amlodipine-atorvastatin
amlodipine besylate/benazepril HCl	Lotrel
amlodipine besylate/benazepril HCl	amlodipine-benazepril
amlodipine besylate/celecoxib	Consensi
amlodipine besylate/olmesartan medoxomil	Azor
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
clevidipine butyrate	Cleviprex
diltiazem HCl	Cardizem
diltiazem HCl	Cardizem CD
diltiazem HCl	Cardizem LA
diltiazem HCl	Cardizem SR
diltiazem HCl	Cartia XT
diltiazem HCl	DILT-CD
diltiazem HCl	DILT-XR
diltiazem HCl	Dilacor XR
diltiazem HCl	Diltia XT
diltiazem HCl	Diltzac ER
diltiazem HCl	Matzim LA
diltiazem HCl	Taztia XT
diltiazem HCl	Tiadylt ER
diltiazem HCl	Tiazac
diltiazem HCl	diltiazem HCl
diltiazem HCl	diltiazem HCl (bulk)
diltiazem HCl in 0.9 % sodium chloride	diltiazem HCl in 0.9% NaCl
diltiazem HCl/dextrose 5 % in water	diltiazem in dextrose 5 %
enalapril maleate/felodipine	Lexxel
felodipine	Plendil
felodipine	felodipine
isradipine	DynaCirc
isradipine	DynaCirc CR

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
isradipine	isradipine
levamlodipine maleate	Conjupri
nicardipine HCl	Cardene IV
nicardipine HCl	Cardene SR
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in 5 % dextrose in water	nicardipine in 5 % dextrose
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nifedipine	Adalat CC
nifedipine	Afeditab CR
nifedipine	Nifediac CC
nifedipine	Nifedical XL
nifedipine	Procardia
nifedipine	Procardia XL
nifedipine	nifedipine
nifedipine	nifedipine (bulk)
nifedipine, micronized	nifedipine, micronized (bulk)
nimodipine	Nymalize
nimodipine	nimodipine
nimodipine	nimodipine (bulk)
nisoldipine	Sular
nisoldipine	nisoldipine
olmesartan medoxomil/amlodipine	Tribenzor
olmesartan medoxomil/amlodipine	olmesartan-amlodipin-hcthiazid
perindopril arginine/amlodipine besylate	Prestalia
telmisartan/amlodipine besylate	Twynsta
telmisartan/amlodipine besylate	telmisartan-amlodipine
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil
verapamil HCl	Calan
verapamil HCl	Calan SR
verapamil HCl	Covera-HS
verapamil HCl	Isoptin SR
verapamil HCl	Verelan
verapamil HCl	Verelan PM
verapamil HCl	verapamil
verapamil HCl	verapamil (bulk)
Diuretic Use	
acetazolamide	Diamox Sequels
acetazolamide	acetazolamide
acetazolamide sodium	acetazolamide sodium
aliskiren hemifumarate/hydrochlorothiazide	Tekturna HCT
amiloride HCl	Midamor
amiloride HCl	amiloride
amiloride HCl/hydrochlorothiazide	amiloride-hydrochlorothiazide
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
ammonium chloride	ammonium chloride
atenolol/chlorthalidone	Tenoretic 100
atenolol/chlorthalidone	Tenoretic 50
atenolol/chlorthalidone	atenolol-chlorthalidone
azilsartan medoxomil/chlorthalidone	Edarbyclor
benazepril HCl/hydrochlorothiazide	Lotensin HCT
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bumetanide	bumetanide
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
chlorothiazide	Diuril
chlorothiazide	chlorothiazide
chlorothiazide sodium	Diuril IV
chlorothiazide sodium	chlorothiazide sodium
chlorthalidone	Thalitone
chlorthalidone	chlorthalidone
clonidine HCl/chlorthalidone	Clorpres
conivaptan HCl	Vaprisol
conivaptan HCl/dextrose 5 % in water	Vaprisol in 5 % dextrose
enalapril maleate/hydrochlorothiazide	Vaseretic
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
eplerenone	Inspra
eplerenone	eplerenone
eprosartan mesylate/hydrochlorothiazide	Teveten HCT
ethacrynate sodium	Sodium Edecrin
ethacrynate sodium	ethacrynate sodium
ethacrynic acid	Edecrin
ethacrynic acid	ethacrynic acid
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
furosemide	Lasix
furosemide	furosemide
furosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl
furosemide/dextrose 5 % in water	furosemide in dextrose 5 %
glycerin	Introl
hydralazine HCl/hydrochlorothiazide	Hydra-Zide
hydrochlorothiazide	Microzide
hydrochlorothiazide	hydrochlorothiazide
indapamide	indapamide
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
lisinopril/hydrochlorothiazide	Prinzide
lisinopril/hydrochlorothiazide	Zestoretic
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
losartan potassium/hydrochlorothiazide	Hyzaar

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
mannitol	Osmitrol 10 %
mannitol	Osmitrol 15 %
mannitol	Osmitrol 20 %
mannitol	Osmitrol 5 %
mannitol	mannitol 10 %
mannitol	mannitol 15 %
mannitol	mannitol 20 %
mannitol	mannitol 25 %
mannitol	mannitol 5 %
mannitol/sorbitol	Lollipop Base
methazolamide	Neptazane
methazolamide	methazolamide
methyclothiazide	Enduron
methyclothiazide	methyclothiazide
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide
metolazone	Zaroxolyn
metolazone	metolazone
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol succinate/hydrochlorothiazide	metoprolol su-hydrochlorothiaz
metoprolol tartrate/hydrochlorothiazide	Lopressor HCT
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
moexipril HCl/hydrochlorothiazide	Uniretic
moexipril HCl/hydrochlorothiazide	moexipril-hydrochlorothiazide
nadolol/bendroflumethiazide	Corzide
nadolol/bendroflumethiazide	nadolol-bendroflumethiazide
olmesartan medoxomil/amlodipine	Tribenzor
olmesartan medoxomil/amlodipine	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
pamabrom	Diuretic Softgels
pamabrom	Diurex Max
potassium sulfate/corn/buchu/couch grass/hydrangea	Natural Herbal Diuretic
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	Quinaretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
spironolactone	Aldactone
spironolactone	CaroSpir
spironolactone	spironolactone
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
tolvaptan	Samsca
tolvaptan	tolvaptan
torsemide	Demadex
torsemide	Soaanz

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
torsemide	torsemide
triamterene	Dyrenium
triamterene	triamterene
triamterene/hydrochlorothiazide	Dyazide
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid
urea	Ure-Na
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
Antidepressant Use	
amitriptyline HCl	amitriptyline
amitriptyline HCl/chlordiazepoxide	Limbitrol
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amoxapine	amoxapine
brexanolone	Zulresso
bupropion HBr	Aplenzin
bupropion HCl	Budeprion SR
bupropion HCl	Budeprion XL
bupropion HCl	Forfivo XL
bupropion HCl	Wellbutrin
bupropion HCl	Wellbutrin SR
bupropion HCl	Wellbutrin XL
bupropion HCl	bupropion HCl
bupropion HCl/dietary supplement combination no.15	Appbutamone-D
bupropion HCl/dietary supplement combination no.16	Appbutamone
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clomipramine HCl	Anafranil
clomipramine HCl	clomipramine
desipramine HCl	Norpramin
desipramine HCl	desipramine
desvenlafaxine	Khedezla
desvenlafaxine	desvenlafaxine
desvenlafaxine fumarate	desvenlafaxine fumarate
desvenlafaxine succinate	Pristiq
desvenlafaxine succinate	desvenlafaxine succinate
doxepin HCl	Silenor
doxepin HCl	doxepin
duloxetine HCl	Cymbalta
duloxetine HCl	Drizalma Sprinkle
duloxetine HCl	Irenka
duloxetine HCl	duloxetine
escitalopram oxalate	Lexapro
escitalopram oxalate	escitalopram oxalate
esketamine HCl	Spravato
fluoxetine HCl	Prozac
fluoxetine HCl	Prozac Weekly

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
fluoxetine HCl	Rapiflux
fluoxetine HCl	Sarafem
fluoxetine HCl	Selfemra
fluoxetine HCl	fluoxetine
fluoxetine HCl/dietary supplement no.17	Gaboxetine
fluoxetine HCl/dietary supplement no.8	Sentroxatine
fluvoxamine maleate	Luvox CR
fluvoxamine maleate	fluvoxamine
imipramine HCl	Tofranil
imipramine HCl	imipramine HCl
imipramine pamoate	Tofranil-PM
imipramine pamoate	imipramine pamoate
isocarboxazid	Marplan
levomilnacipran HCl	Fetzima
maprotiline HCl	maprotiline
milnacipran HCl	Savella
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mirtazapine	mirtazapine
nefazodone HCl	nefazodone
nortriptyline HCl	Pamelor
nortriptyline HCl	nortriptyline
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine HCl	paroxetine HCl
paroxetine mesylate	Brisdelle
paroxetine mesylate	Pexeva
paroxetine mesylate	paroxetine mesylate(menop.sym)
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenelzine sulfate	Nardil
phenelzine sulfate	phenelzine
protriptyline HCl	Vivactil
protriptyline HCl	protriptyline
selegiline	Emsam
sertraline HCl	Zoloft
sertraline HCl	sertraline
tranylcypromine sulfate	Parnate
tranylcypromine sulfate	tranylcypromine
trazodone HCl	Desyrel
trazodone HCl	Oleptro ER
trazodone HCl	trazodone
trazodone HCl/dietary supplement no.8	Trazamine
trimipramine maleate	Surmontil
trimipramine maleate	trimipramine

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
venlafaxine HCl	Effexor
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
vilazodone HCl	Viibryd
vortioxetine hydrobromide	Brintellix
vortioxetine hydrobromide	Trintellix
Gastric Acid Suppressant Use	
LANSOPRAZOLE	FIRST-Lansoprazole
OMEPRAZOLE	FIRST-Omeprazole
OMEPRAZOLE	Omeprazole+SyrSpend SF Alka
RANITIDINE HCL	Deprizine
aspirin/omeprazole	Yosprala
aspirin/omeprazole	aspirin-omeprazole
cimetidine	Acid Reducer (cimetidine)
cimetidine	Acid Relief (cimetidine)
cimetidine	Heartburn 200
cimetidine	Heartburn Relief (cimetidine)
cimetidine	Tagamet
cimetidine	Tagamet HB
cimetidine	cimetidine
cimetidine HCl	cimetidine HCl
cimetidine HCl in 0.9 % sodium chloride	cimetidine in 0.9 % NaCl
dexlansoprazole	Dexilant
dexlansoprazole	Kapidex
dexlansoprazole	dexlansoprazole
esomeprazole magnesium	Heartburn Treatment
esomeprazole magnesium	Nexium
esomeprazole magnesium	Nexium 24HR
esomeprazole magnesium	Nexium Packet
esomeprazole magnesium	esomeprazole magnesium
esomeprazole magnesium/glycerin	Esomep-EZS
esomeprazole sodium	Nexium IV
esomeprazole sodium	esomeprazole sodium
esomeprazole strontium	esomeprazole strontium
famotidine	Acid Controller
famotidine	Acid Reducer (famotidine)
famotidine	Acid-Pep
famotidine	Heartburn Prevention
famotidine	Heartburn Relief (famotidine)
famotidine	Pepcid
famotidine	Pepcid AC
famotidine	Pepcid AC Maximum Strength
famotidine	Zantac-360 (famotidine)
famotidine	famotidine
famotidine in 0.9 % sodium chloride	famotidine in 0.9 % NaCl
famotidine in sodium chloride, iso-osmotic/PF	famotidine (PF)-NaCl (iso-os)
famotidine/PF	famotidine (PF)
famotidine/calcium carbonate/magnesium hydroxide	Acid Controller Complete

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
famotidine/calcium carbonate/magnesium hydroxide	Acid Reducer Complete (famot)
famotidine/calcium carbonate/magnesium hydroxide	Complete
famotidine/calcium carbonate/magnesium hydroxide	Dual Action Complete
famotidine/calcium carbonate/magnesium hydroxide	Duo Fusion
famotidine/calcium carbonate/magnesium hydroxide	Pepcid Complete
famotidine/calcium carbonate/magnesium hydroxide	Tums Dual Action (famotidine)
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
lansoprazole	Heartburn Relief 24 Hour
lansoprazole	Heartburn Treatment 24 Hour
lansoprazole	Prevacid
lansoprazole	Prevacid 24Hr
lansoprazole	Prevacid IV
lansoprazole	Prevacid SoluTab
lansoprazole	lansoprazole
lansoprazole/amoxicillin trihydrate/clarithromycin	Prevpac
lansoprazole/amoxicillin trihydrate/clarithromycin	amoxicil-clarithromy-lansopraz
nizatidine	Axid
nizatidine	Axid AR
nizatidine	nizatidine
omeprazole	Prilosec
omeprazole	omeprazole
omeprazole magnesium	Acid Reducer (omeprazole)
omeprazole magnesium	Prilosec
omeprazole magnesium	Prilosec OTC
omeprazole magnesium	omeprazole magnesium
omeprazole magnesium/amoxicillin trihydrate/rifabutin	Talicia
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
omeprazole/sodium bicarbonate	OmePPi
omeprazole/sodium bicarbonate	Zegerid
omeprazole/sodium bicarbonate	Zegerid OTC
omeprazole/sodium bicarbonate	omeprazole-sodium bicarbonate
pantoprazole sodium	Protonix
pantoprazole sodium	pantoprazole
rabeprazole sodium	AcipHex
rabeprazole sodium	AcipHex Sprinkle
rabeprazole sodium	rabeprazole
ranitidine HCl	Acid Control (ranitidine)
ranitidine HCl	Acid Reducer (ranitidine)
ranitidine HCl	Heartburn Relief (ranitidine)
ranitidine HCl	Taladine
ranitidine HCl	Wal-Zan 150
ranitidine HCl	Wal-Zan 75
ranitidine HCl	Zantac
ranitidine HCl	Zantac 25 EFFERdose
ranitidine HCl	Zantac 75
ranitidine HCl	Zantac Maximum Strength
ranitidine HCl	ranitidine HCl

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ranitidine HCl in 0.45 % sodium chloride	Zantac in 0.45 % sod. chloride
ranitidine HCl/dietary supplement no.17	Gabitidine
ranitidine HCl/dietary supplement no.8	Sentradine
Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	
Ibuprofen/Caffeine/Vitamins B1, B2, B6, & B12	IC400
Ibuprofen/Caffeine/Vitamins B1, B2, B6, & B12	IC800
NAPROXEN	Napro
NAPROXEN	Naproderm
amlodipine besylate/celecoxib	Consensi
bromfenac sodium	BromSite
bromfenac sodium	Bromday
bromfenac sodium	Bromday TwinPack
bromfenac sodium	Prolensa
bromfenac sodium	XIBROM
bromfenac sodium	bromfenac
bromfenac sodium	bromfenac sodium (bulk)
bupivacaine/ketorolac/ketamine	bupivacaine-ketorolac-ketamine
bupivacaine/meloxicam	Zynrelef
celecoxib	Celebrex
celecoxib	Elyxyb
celecoxib	celecoxib
celecoxib	celecoxib (bulk)
celecoxib/capsaicin/menthol	CapXib
celecoxib/capsaicin/methyl salicylate/menthol	NuDroxiPAK
celecoxib/lidocaine/menthol	LidoXib
chlorpheniramine maleate/phenylephrine HCl/ibuprofen	Advil Allergy-Congestion Rlf
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Allergy Sinus
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Multi-Symptom Cold
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Children's Advil Allergy Sinus
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
diclofenac epolamine	Flector
diclofenac epolamine	Licart
diclofenac epolamine	diclofenac epolamine
diclofenac potassium	Cambia
diclofenac potassium	Cataflam
diclofenac potassium	Lofena
diclofenac potassium	Zipsor
diclofenac potassium	diclofenac potassium
diclofenac sodium	Arthritis Pain (diclofenac)
diclofenac sodium	Diclo Gel
diclofenac sodium	Diclofono
diclofenac sodium	Dicloprep-100
diclofenac sodium	Diclozor
diclofenac sodium	Dyloject
diclofenac sodium	Klofensaid II
diclofenac sodium	Pennsaid
diclofenac sodium	Solaraze
diclofenac sodium	VennGel One

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
diclofenac sodium	Voltaren
diclofenac sodium	Voltaren Arthritis Pain
diclofenac sodium	Voltaren-XR
diclofenac sodium	Vopac MDS
diclofenac sodium	diclofenac sodium
diclofenac sodium	diclofenac sodium (bulk)
diclofenac sodium, micronized	diclofenac sod, micro (bulk)
diclofenac sodium/benzalkonium chloride	DS Prep Pak
diclofenac sodium/capsaicin	CapsFenac Pak
diclofenac sodium/capsaicin	Dicloheal-60
diclofenac sodium/capsaicin	Diclopak
diclofenac sodium/capsaicin	Flexipak
diclofenac sodium/capsaicin	Inavix
diclofenac sodium/capsaicin	NuDiclo SoluPAK
diclofenac sodium/capsaicin	NuDiclo TabPAK
diclofenac sodium/capsaicin	Pennsaicin
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-50
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-75
diclofenac sodium/capsicum oleoresin	Capsinac
diclofenac sodium/capsicum oleoresin	DermaSilkRx DicloPak
diclofenac sodium/capsicum oleoresin	DermacinRx Lexitral
diclofenac sodium/capsicum oleoresin	Diclofex DC
diclofenac sodium/capsicum oleoresin	Diclosaicin
diclofenac sodium/capsicum oleoresin	Diclotral
diclofenac sodium/capsicum oleoresin	Iclofenac CP
diclofenac sodium/capsicum oleoresin	Inflammacin
diclofenac sodium/capsicum oleoresin	Kapzin DC
diclofenac sodium/capsicum oleoresin	Lexitral PharmaPak II
diclofenac sodium/capsicum oleoresin	PrevidolRx Plus Analgesic Pak
diclofenac sodium/capsicum oleoresin	Sure Result DSS Premium Pack
diclofenac sodium/capsicum oleoresin	Xelitral
diclofenac sodium/capsicum oleoresin	Xenaflamm
diclofenac sodium/capsicum oleoresin	Ziclopro
diclofenac sodium/hyaluronate sodium/niacinamide	Roaoxia
diclofenac sodium/hyaluronate sodium/niacinamide	diclofenac-hyaluronate-niacin
diclofenac sodium/kinesiology tape	Clofenax
diclofenac sodium/kinesiology tape	Diclo Gel-Xrylix Sheet
diclofenac sodium/kinesiology tape	Lexixryl
diclofenac sodium/kinesiology tape	Profinac
diclofenac sodium/kinesiology tape	Xrylix (diclofenac-kines tape)
diclofenac sodium/kinesiology tape	Xrylix II
diclofenac sodium/lidocaine	Lidovix
diclofenac sodium/lidocaine HCl/kinesiology tape	TriXylitral
diclofenac sodium/lidocaine/methyl salicylate/camphor	Diclovix
diclofenac sodium/menthol	DiThol
diclofenac sodium/menthol/camphor	Diclotrex
diclofenac sodium/menthol/camphor	Diclotrex II
diclofenac sodium/menthol/camphor	Inflatherm(diclofenac-menthol)

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
diclofenac sodium/menthol/kinesiology tape	DiMentho
diclofenac sodium/menthol/kinesiology tape	Diclovix M
diclofenac sodium/methyl salicylate/menthol	DicloPR
diclofenac sodium/methyl salicylate/menthol	Varophen (diclofenac)
diclofenac sodium/methyl salicylate/menthol/camphor	Inflamma-K
diclofenac sodium/misoprostol	Arthrotec 50
diclofenac sodium/misoprostol	Arthrotec 75
diclofenac sodium/misoprostol	diclofenac-misoprostol
diclofenac sodium/silicone, adhesive	Solaravix
diclofenac sodium/trolamine salicylate	Inflatherm (diclofenac-trolam)
diclofenac submicronized	Zorvolex
diclofenac submicronized	diclofenac submicronized
etodolac	Lodine
etodolac	Lodine XL
etodolac	etodolac
etodolac	etodolac (bulk)
etodolac/capsaicin/methyl salicylate/menthol	NuDroxiPAK E-400
fenoprofen calcium	Fenortho
fenoprofen calcium	Nalfon
fenoprofen calcium	ProFeno
fenoprofen calcium	fenoprofen
fenoprofen calcium, dihydrate	fenoprofen calcium dihyd(bulk)
flurbiprofen	Ansaid
flurbiprofen	flurbiprofen
flurbiprofen	flurbiprofen (bulk)
flurbiprofen sodium	Ocufen
flurbiprofen sodium	flurbiprofen sodium
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	Reprexain
hydrocodone/ibuprofen	Vicoprofen
hydrocodone/ibuprofen	Xylon 10
hydrocodone/ibuprofen	hydrocodone-ibuprofen
ibuprofen	A-G Profen
ibuprofen	Addaprin
ibuprofen	Advanced Pain Relief
ibuprofen	Advil
ibuprofen	Advil Junior Strength
ibuprofen	Advil Liqui-Gel
ibuprofen	Advil Migraine
ibuprofen	Bupranol FP
ibuprofen	Caldolor
ibuprofen	Cap-Profen
ibuprofen	Child Ibuprofen
ibuprofen	Children's Advil
ibuprofen	Children's Ibu-Drops
ibuprofen	Children's Ibuprofen
ibuprofen	Children's Medi-Profen
ibuprofen	Children's Motrin

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ibuprofen	Children's Motrin Jr Strength
ibuprofen	Children's Profen IB
ibuprofen	Childs Ibuprofen
ibuprofen	ElixSure IB Suspension
ibuprofen	I-Prin
ibuprofen	IBU
ibuprofen	IBU-200
ibuprofen	IBU-Tab
ibuprofen	Ibu-Drops
ibuprofen	Ibuprofen IB
ibuprofen	Ibuprofen Jr Strength
ibuprofen	Ibuprofen M
ibuprofen	Ibutab
ibuprofen	Infant's Advil
ibuprofen	Infant's Ibuprofen
ibuprofen	Infant's Medi-Profen
ibuprofen	Infant's Motrin
ibuprofen	Infants Ibu-Drops
ibuprofen	Infants ProfenIB
ibuprofen	Medi-Profen
ibuprofen	Menadol
ibuprofen	Motrin
ibuprofen	Motrin IB
ibuprofen	Motrin Junior Strength
ibuprofen	Motrin Migraine
ibuprofen	Nuprin
ibuprofen	Nuprin Menstrual Relief
ibuprofen	Profen IB
ibuprofen	Provil
ibuprofen	Tab-Profen
ibuprofen	Wal-Profen
ibuprofen	Yaprofen
ibuprofen	ibuprofen
ibuprofen	ibuprofen (bulk)
ibuprofen lysine/PF	NeoProfen (ibuprofen lysn)(PF)
ibuprofen lysine/PF	ibuprofen lysine (PF)
ibuprofen/acetaminophen	Advil Dual Action
ibuprofen/capsaicin/methyl salicylate/menthol	NuDroxiPAK I-800
ibuprofen/dietary supplement,misc. cb.11	Theraprofen-60
ibuprofen/dietary supplement,misc. cb.11	Theraprofen-90
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen/diphenhydramine HCl	Ibuprofen PM
ibuprofen/diphenhydramine HCl	ibuprofen-diphenhydramine HCl
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Motrin PM
ibuprofen/diphenhydramine citrate	ibuprofen-diphenhydramine cit
ibuprofen/famotidine	Duexis

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ibuprofen/famotidine	ibuprofen-famotidine
ibuprofen/glycerin	Ibupak
ibuprofen/irritants counter-irritants combination no.2	Comfort Pac-Ibuprofen
ibuprofen/oxycodone HCl	Combunox
ibuprofen/oxycodone HCl	ibuprofen-oxycodone
ibuprofen/phenylephrine HCl	Advil Congestion Relief
ibuprofen/phenylephrine HCl	Advil Sinus Congestion-Pain
ibuprofen/phenylephrine HCl	Congestion Relief (ibuprof-PE)
ibuprofen/phenylephrine HCl	Sudafed PE Head Congestn-Pain
ibuprofen/pseudoephedrine HCl	Advil Cold and Sinus
ibuprofen/pseudoephedrine HCl	Advil Flu and Body Ache
ibuprofen/pseudoephedrine HCl	Children's Advil Cold
ibuprofen/pseudoephedrine HCl	Children's Dimetapp Cold,Fever
ibuprofen/pseudoephedrine HCl	Children's Ibuprofen Cold
ibuprofen/pseudoephedrine HCl	Children's Motrin Cold
ibuprofen/pseudoephedrine HCl	Cold and Sinus Pain Relief
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief (ibuprofen)
ibuprofen/pseudoephedrine HCl	DayQuil Sinus Pressure/Pain
ibuprofen/pseudoephedrine HCl	Dristan Sinus
ibuprofen/pseudoephedrine HCl	Ibup Sinus
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold-Sinus(with PSE)
ibuprofen/pseudoephedrine HCl	Iprin Cold and Sinus
ibuprofen/pseudoephedrine HCl	Medi-Profen
ibuprofen/pseudoephedrine HCl	Motrin Cold
ibuprofen/pseudoephedrine HCl	Motrin Cold and Sinus
ibuprofen/pseudoephedrine HCl	Motrin IB Sinus
ibuprofen/pseudoephedrine HCl	Nuprin Cold Relief
ibuprofen/pseudoephedrine HCl	Nuprin Flu Relief
ibuprofen/pseudoephedrine HCl	Profen IB Cold And Sinus
ibuprofen/pseudoephedrine HCl	Vicks DayQuil (pseudoeph-ibup)
ibuprofen/pseudoephedrine HCl	Wal-Profen Cold-Sinus
ibuprofen/pseudoephedrine HCl	Wal-Profen D Cold and Sinus
ibuprofen/pseudoephedrine HCl	pseudoephedrine-ibuprofen
indomethacin	Indocin
indomethacin	Indocin SR
indomethacin	indomethacin
indomethacin	indomethacin (bulk)
indomethacin sodium	Indocin I.V.
indomethacin sodium	indomethacin sodium
indomethacin, submicronized	Tivorbex
indomethacin, submicronized	indomethacin submicronized
ketoprofen	Actron
ketoprofen	Frotek
ketoprofen	Orudis
ketoprofen	Orudis KT
ketoprofen	Oruvail

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ketoprofen	ketoprofen
ketoprofen	ketoprofen (bulk)
ketoprofen, micronized	Frotek
ketoprofen, micronized	ketoprofen, micronized (bulk)
ketorolac tromethamine	Acular
ketorolac tromethamine	Acular LS
ketorolac tromethamine	Acular PF
ketorolac tromethamine	ReadySharp ketorolac
ketorolac tromethamine	Sprix
ketorolac tromethamine	Toradol
ketorolac tromethamine	ketorolac
ketorolac tromethamine	ketorolac (bulk)
ketorolac tromethamine/PF	Acuvail (PF)
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova II SUIK
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova SUIK
lansoprazole/naproxen	PREVACID NapraPAC
meclofenamate sodium	meclofenamate
mefenamic acid	Ponstel
mefenamic acid	mefenamic acid
mefenamic acid	mefenamic acid (bulk)
meloxicam	Anjeso
meloxicam	Mobic
meloxicam	Qmiiz ODT
meloxicam	meloxicam
meloxicam	meloxicam (bulk)
meloxicam, submicronized	Vivlodex
meloxicam, submicronized	meloxicam submicronized
meloxicam/irritants counter-irritants combination no.2	Comfort Pac-Meloxicam
nabumetone	Relafen
nabumetone	Relafen DS
nabumetone	nabumetone
nabumetone	nabumetone (bulk)
nabumetone, micronized	nabumetone, micronized (bulk)
nabumetone/capsaicin/methyl salicylate/menthol	NuDroxiPAK N-500
naproxen	EC-Naprosyn
naproxen	EC-Naproxen
naproxen	Naprosyn
naproxen	Romixen 500
naproxen	naproxen
naproxen	naproxen (bulk)
naproxen sodium	Aleve
naproxen sodium	All Day Pain Relief
naproxen sodium	All Day Relief
naproxen sodium	Anaprox
naproxen sodium	Anaprox DS
naproxen sodium	Flanax (naproxen)
naproxen sodium	Mediproxen
naproxen sodium	Midol (naproxen)

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
naproxen sodium	Naprelan
naproxen sodium	Naprelan CR
naproxen sodium	Naprelan CR Dose Card
naproxen sodium	Wal-Proxen
naproxen sodium	naproxen sodium
naproxen sodium	naproxen sodium (bulk)
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen sodium/diphenhydramine HCl	Naproxen PM
naproxen sodium/menthol	NaproPak Cool
naproxen sodium/pseudoephedrine HCl	Aleve Cold and Sinus
naproxen sodium/pseudoephedrine HCl	Aleve Sinus and Headache
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Cold
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Headache
naproxen sodium/pseudoephedrine HCl	All Day Cold and Sinus
naproxen sodium/pseudoephedrine HCl	All Day Pain Relief Sinus,Cold
naproxen sodium/pseudoephedrine HCl	Cold and Sinus
naproxen sodium/pseudoephedrine HCl	Cold-Sinus Relief
naproxen sodium/pseudoephedrine HCl	Sinus and Cold-D
naproxen sodium/pseudoephedrine HCl	Sudafed 12 Hr Pressure-Pain
naproxen sodium/pseudoephedrine HCl	Sudafed 12 Hr Sinus-Pain
naproxen sodium/pseudoephedrine HCl	Sudafed Sinus 12Hr Pressr-Pain
naproxen/capsaicin/menthol	NaproPax
naproxen/capsaicin/menthol	NaproxenPax
naproxen/capsaicin/menthol/methyl salicylate	Pain Relief Collection
naproxen/dietary supplement,misc. cb.11	Theraproxen
naproxen/dietary supplement,misc. cb.11	Theraproxen-90
naproxen/esomeprazole magnesium	Vimovo
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/irritant counter-irritant combination no.2	Comfort Pac-Naproxen
nepafenac	Ilevro
nepafenac	Nevanac
oxaprozin	Daypro
oxaprozin	oxaprozin
phenylbutazone	phenylbutazone (bulk)
phenylephrine HCl/ketorolac tromethamine	Omidria
piroxicam	Feldene
piroxicam	piroxicam
piroxicam	piroxicam (bulk)
piroxicam/dietary supplement,misc. cb.11	Therafeldamine
prednisolone acetate/bromfenac sodium	prednisolone acetate-bromfenac
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/gatifloxacin/nepafenac	prednisolone-gatiflox-nepafen
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone acetate/nepafenac	prednisolone acetate-nepafenac
prednisolone sodium phosphate/bromfenac sodium	prednisolone sod ph-bromfenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
rofecoxib	Vioxx
ropivacaine HCl/clonidine HCl/ketorolac tromethamine	ropivacaine-clonidin-ketorolac
ropivacaine HCl/epinephrine/clonidine HCl/ketorolac trometh	ropivacaine-epi-clonid-ketorol
ropivacaine/ketorolac/ketamine	ropivacaine-ketorolac-ketamine
sulindac	Clinoril
sulindac	sulindac
sulindac	sulindac (bulk)
sumatriptan succinate/naproxen sodium	Treximet
sumatriptan succinate/naproxen sodium	sumatriptan-naproxen
suprofen	Profenal
tolmetin sodium	Tolectin DS
tolmetin sodium	tolmetin
tramadol HCl/celecoxib	Seglentis
tropicamide/proparacaine/phenylephrine/ketorolac in water	Mydriatic4(trop-prop-PE-ktrlc)
tropicamide/proparacaine/phenylephrine/ketorolac in water	tropic-proparacai-pe-ketor-wat
valdecoxib	Bextra
Benzodiazepine Use	
alprazolam	Alprazolam Intensol
alprazolam	Niravam
alprazolam	Xanax
alprazolam	Xanax XR
alprazolam	alprazolam
alprazolam/dietary supplement,misc combo no.17	Gabazolamine
amitriptyline HCl/chlordiazepoxide	Limbitrol
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amobarbital sodium	Amytal
bromelains/melatonin/herbal complex no.233	MidNite PM
butabarbital sodium	Butisol
calcium carb,hydroxide/soy isoflavone/black cohosh/melatonin	Estroven Nighttime (cal-meltn)
calcium phosphate/melatonin	calcium-melatonin
chloral hydrate	Somnote
chloral hydrate	chloral hydrate
chlordiazepoxide HCl	Librium
chlordiazepoxide HCl	chlordiazepoxide HCl
clobazam	Onfi
clobazam	Sympazan
clobazam	clobazam
clonazepam	Klonopin
clonazepam	clonazepam
clorazepate dipotassium	Tranxene T-Tab
clorazepate dipotassium	Tranxene-SD
clorazepate dipotassium	clorazepate dipotassium
daridorexant HCl	Quviviq
dexmedetomidine HCl	Precedex
dexmedetomidine HCl	dexmedetomidine
dexmedetomidine HCl in 0.9 % sodium chloride	Precedex in 0.9 % sodium chlor

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
dexmedetomidine HCl in 0.9 % sodium chloride	dexmedetomidine in 0.9 % NaCl
dexmedetomidine in 5 % dextrose in water	dexmedetomidine in dextrose 5%
diazepam	Diastat
diazepam	Diastat AcuDial
diazepam	Diazepam Intensol
diazepam	Valium
diazepam	Valtoco
diazepam	diazepam
diphenhydramine HCl	diphenhydramine HCl
doxepin HCl	Silenor
doxepin HCl	doxepin
estazolam	Prosom
estazolam	estazolam
eszopiclone	Lunesta
eszopiclone	eszopiclone
ethyl alcohol/herbal drugs	Lydia Pinkham Herbal
flurazepam HCl	flurazepam
lemborexant	Dayvigo
lorazepam	Ativan
lorazepam	Lorazepam Intensol
lorazepam	Loreev XR
lorazepam	lorazepam
lorazepam in 0.9 % sodium chloride	lorazepam in 0.9% sod chloride
lorazepam in 5 % dextrose and water	lorazepam in dextrose 5 %
melatonin	Children's Sleep (melatonin)
melatonin	Meladox
melatonin	Melatin
melatonin	VitaJoy Melatonin
melatonin	melatonin
melatonin/5-HTP/valerian/folic acid/dietary combination 28	Hypnosom
melatonin/5-Hydroxytryptophan/tryptophan/B6/magnesium oxide	Somnicin
melatonin/GABA/5-HTP/theanine/magnesium citrate,oxide/herbs	Sopordren
melatonin/chamomile flower	melatonin-chamomile flower
melatonin/gamma-aminobutyric acid/herbal complex no.183	Sintralyne-PM
melatonin/gamma-aminobutyric acid/valerian	Medi-Doze
melatonin/genistein/herbal complex no.233	Midnite for Menopause
melatonin/herbal complex no.184	Sleep Caps
melatonin/herbal complex no.184	melatonin-herbal complex #184
melatonin/herbal complex no.233	MidNite
melatonin/lemon balm leaf extract	melatonin-lemon balm leaf extr
melatonin/pyridoxal phosphate	Melatonin-B6 (pyridoxal phos)
melatonin/pyridoxal phosphate	melatonin-pyridoxal phos (B6)
melatonin/pyridoxine	Melatonin (with B6)
melatonin/pyridoxine	melatonin-pyridoxine (vit B6)
melatonin/pyridoxine HCl (vit B6)	Melatonex
melatonin/pyridoxine HCl (vit B6)	melatonin-pyridoxine HCl (B6)

Appendix X. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
melatonin/theanine	melatonin-theanine
melatonin/tryptophan	Restone
melatonin/tryptophan	Wrestone
melatonin/tryptophan/valerian/chamomile/niacin/inositol/B6	Toprophan
mephobarbital	Mebaral
mephobarbital	mephobarbital
midazolam	Nayzilam
midazolam HCl	midazolam
midazolam HCl in 0.9 % sodium chloride	midazolam in 0.9 % sod chlorid
midazolam HCl in 0.9 % sodium chloride/PF	midazolam (PF) in 0.9 % NaCl
midazolam HCl in 5 % dextrose and water/PF	midazolam in dextrose 5 % (PF)
midazolam HCl in dextrose 5% in water	midazolam in dextrose 5 %
midazolam HCl/PF	midazolam (PF)
midazolam in sodium chloride, iso-osmotic	midazolam in NaCl, iso-osmotic
midazolam in sodium chloride, iso-osmotic/PF	midazolam in NaCl,iso-osmo(PF)
oxazepam	oxazepam
pentobarbital sodium	Nembutal Sodium
pentobarbital sodium	pentobarbital sodium
phenobarbital	phenobarbital
phenobarbital sodium	Luminal
phenobarbital sodium	phenobarbital sodium
phenobarbital sodium in 0.9 % sodium chloride	phenobarbital in 0.9 % sod chl
quazepam	Doral
quazepam	quazepam
ramelteon	Rozerem
ramelteon	ramelteon
remimazolam besylate	Byfavo
secobarbital sodium	Seconal Sodium
suvorexant	Belsomra
tasimelteon	Hetlioz
tasimelteon	Hetlioz LQ
temazepam	Restoril
temazepam	temazepam
temazepam/dietary supplement no.8	Strazepam
triazolam	Halcion
triazolam	triazolam
tryptophan	tryptophan
valerian root extract	valerian root extract
valerian root extract/hops	valerian root extract-hops
zaleplon	Sonata
zaleplon	zaleplon
zolpidem tartrate	Ambien
zolpidem tartrate	Ambien CR
zolpidem tartrate	Edluar
zolpidem tartrate	Intermezzo
zolpidem tartrate	Zolpimist
zolpidem tartrate	zolpidem

Appendix Y.1. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.1.0, to assess all-cause mortality among users of long-acting injectable antipsychotics (LAIA) in the Sentinel Distributed Database (SDD).

Query period: January 1, 2010 - July 1, 2022
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: N/A
Post-episode enrollment requirement for Type 2 analyses: Days specified; optional
Enrollment gap: 45 days
Age groups: 18-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+ years
Censor output categorization: Range of follow-up time specified
Restrictions: None
Envelope macro: No reclassification
Distribution of index-defining codes: No
Freeze data: Yes

		14-Day Episode Duration Paliperidone palmitate vs. Risperidone microspheres Paliperidone palmitate vs. Haloperidol decanoate	
Group names	**Descriptive Cohort**	**Comparison 1**	**Comparison 2**
Drug/Exposure			
Exposure/Comparator	All LAIA	Paliperidone palmitate | Risperidone microspheres	Paliperidone palmitate | Haloperidol decanoate
Incident w/ Respect to:	All LAIA	All LAIA	All LAIA
Washout (days)	-183	-183	-183
Exposure Care Setting	Any care setting	Any care setting	Any care setting
Incidence Assessment	Dispensing date	Dispensing date	Dispensing date
Cohort Definition	First valid index date during query period	First valid index date during query period	First valid index date during query period
Stockpile Overlapping Claims	No stockpiling - each injection will constitute a new event, provided it meets incidence criteria	No stockpiling - each injection will constitute a new event, provided it meets incidence criteria	No stockpiling - each injection will constitute a new event, provided it meets incidence criteria

Appendix Y.1. Specifications Defining Parameters for this Request			
		14-Day Episode Duration Paliperidone palmitate vs. Risperidone microspheres Paliperidone palmitate vs. Haloperidol decanoate	
Group names	**Descriptive Cohort**	**Comparison 1**	**Comparison 2**
Point Exposure	Y	Y Y	Y Y
Episode Gap	0	0	0
Episode Extension Period	0	0	0
Maximum Episode Duration	N/A	14	14
Censor Criteria	Data Partner End Date; Query Period End Date; Initation of a different LAIA	Data Partner End Date; Query Period End Date; Initation of a different LAIA	Data Partner End Date; Query Period End Date; Initation of a different LAIA
Inclusion/Exclusion			
Pre-Existing Condition	N/A	N/A	N/A
Include/Exclude	N/A	N/A	N/A
Lookback Period	N/A	N/A	N/A
Care Setting	N/A	N/A	N/A
Event/Outcome			
Event/Outcome Definition	N/A	Death (within 2 weeks)	Death (within 2 weeks)
Care Setting	N/A	N/A	N/A
Washout (days)	0	0	0
Blackout Period	0	0	0
Risk Window Interval Start	0	0	0
Propensity Score Analysis			
Covariates	N/A	See Appendix Y.3	See Appendix Y.3
Subgroups	N/A	1. Age group (18-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+) at time of LAIA initiation, 2. Dementia, 3. Institutional Stay (Adate to Ddate)	1. Age group (18-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+) at time of LAIA initiation, 2. Dementia, 3. Institutional Stay (Adate to Ddate)

Appendix Y.1. Specifications Defining Parameters for this Request

	28-day Episode Duration Paliperidone palmitate vs. Risperidone microspheres Paliperidone palmitate vs. Haloperidol decanoate	
Group names	**Comparison 3**	**Comparison 4**
Drug/Exposure		
Exposure/Comparator	Paliperidone palmitate | Risperidone microspheres	Paliperidone palmitate | Haloperidol decanoate
Incident w/ Respect to:	All LAIA	All LAIA
Washout (days)	-183	-183
Exposure Care Setting	Any care setting	Any care setting
Incidence Assessment	Dispensing date	Dispensing date
Cohort Definition	First valid index date during query period	First valid index date during query period
Stockpile overlapping claims	No stockpiling - each injection will constitute a new event, provided it meets incidence criteria	No stockpiling - each injection will constitute a new event, provided it meets incidence criteria
Point Exposure	Y | Y	Y | Y
Episode Gap	0	0
Episode Extension Period	0	0
Maximum Episode Duration	28	28
Censor Criteria	Data Partner End Date; Query Period End Date; Initation of a different LAIA	Data Partner End Date; Query Period End Date; Initation of a different LAIA
Inclusion/Exclusion		
Pre-Existing Condition	N/A	N/A
Include/Exclude	N/A	N/A
Lookback Period	N/A	N/A
Care Setting	N/A	N/A

Appendix Y.1. Specifications Defining Parameters for this Request

	28-day Episode Duration Paliperidone palmitate vs. Risperidone microspheres Paliperidone palmitate vs. Haloperidol decanoate	
Group names	**Comparison 3**	**Comparison 4**
Event/Outcome		
Event/Outcome Definition	Death (within 4 weeks)	Death (within 4 weeks)
Care Setting	N/A	N/A
Washout (days)	0	0
Blackout Period	0	0
Risk Window Interval Start	0	0
Propensity Score Analysis		
Covariates	See Appendix Y.3	See Appendix Y.3
Subgroups	1. Age group (18-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+) at time of LAIA initiation, 2. Dementia, 3. Institutional Stay (Adate to Ddate)	1. Age group (18-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+) at time of LAIA initiation, 2. Dementia, 3. Institutional Stay (Adate to Ddate)

International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360. National Drug Codes (NDC) are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."
N/A: Not applicable

Appendix Y.2. Specifications for Propensity Score (PS) Models for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.1.0, to assess all-cause mortality among users of long-acting injectable antipsychotics (LAIA) in the Sentinel Distributed Database (SDD).

	PS Models	Comparison				Analyses		
	Model	**Comparison**	**EOI**	**REF**	**PS Model Label**	**Analysis name 1**	**Analysis name 2**	**Analysis name 3**
1	Overall	Paliperidone vs. Risperidone, 14 day mortality	Paliperidone	Risperidone	pal_ris_14	pal_ris_14_0	pal_ris_14_1	pal_ris_14_2.5
2	Overall	Paliperidone vs. Haloperidol, 14 day mortality	Paliperidone	Haloperidol	pal_hal_14	pal_hal_14_0	pal_hal_14_1	pal_hal_14_2.5
3	Overall	Paliperidone vs. Risperidone, 28 day mortality	Paliperidone	Risperidone	pal_ris_28	pal_ris_28_0	pal_ris_28_1	pal_ris_28_2.5
4	Overall	Paliperidone vs. Haloperidol, 28 day mortality	Paliperidone	Haloperidol	pal_hal_28	pal_hal_28_0	pal_hal_28_1	pal_hal_28_2.5

Appendix Y.2. Specifications for Propensity Score (PS) Models for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.1.0, to assess all-cause mortality among users of long-acting injectable antipsychotics (LAIA) in the Sentinel Distributed Database (SDD).

Propensity Score Estimation Parameters

Covariates	See Covariates tab
Firth Logistic Intercept Corrected Method	No
High-dimensional Propensity Score	No

Propensity Score Analysis (IPTW)

	Analysis Group
Analysis name	All listed above
IP weight calculation	Average treatment effect (ATE) stabilized
Weight truncation?	- No truncation - 1st percentile truncation - 2.5 percentile truncation

Subgroups

	Analysis Group		
Analysis name	All listed above		
Subgroups	Age Group (years)	Dementia	Institutional Stays
Sugroup Categories	18-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+	dementia, no dementia	institutional stay (Adate to Ddate), No institutional stay
Firth Logistic Intercept Corrected Method	No	No	No
Re-estimate	Yes: the propensity score will be re-estimated		

Appendix Y.3. Specifications Defining Baseline Characteristics for this Request						
Characteristics						
Run	Characteristic Number	Covariate in Propensity Score (PS) Model (y/n)?	Covariate in Regression Model (y/n)?	Characteristic	Operationalization	Care Setting
						*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting
r01	45	y	y	Age	Continuous	N/A
r00	46	y	y	Sex	Dichotomous	N/A
r01	0	y	n	Charlson Comorbidity Index	Continuous	Any
r01	1	y	n	Substance abuse	Dichotomous	Any
r01	2	y	n	Atrial fibrillation/flutter	Dichotomous	Any
r01	3	y	n	Ischemic heart disease	Dichotomous	Any
r01	4	y	n	Heart failure	Dichotomous	Any
r01	5	y	n	Stroke	Dichotomous	Any
r01	6	y	n	Diabetes	Dichotomous	Any
r01	7	y	n	Hypertension	Dichotomous	Any
r01	8	y	n	Rheumatic disease	Dichotomous	Any
r01	9	y	n	Chronic kidney disease	Dichotomous	Any
r01	10	y	n	Seizure disorder	Dichotomous	Any
r01	42	y	n	Dementia Diagnosis	Dichotomous	Any
r01	11	y	n	Anti-Dementia drug (memantine, galantamine, rivastigmine, donepezil, tacrine)	Dichotomous	Any
r01	43	y	n	Dementia Diagnosis and Treatment	Dichotomous	Any
r01	12	y	n	Parkinson’s disease	Dichotomous	Any
r01	13	y	n	Chronic obstructive pulmonary disease (COPD)	Dichotomous	Any
r01	14	y	n	Malignancy	Dichotomous	Any
r01	15	y	n	Asthma	Dichotomous	Any
r01	16	y	n	Hyperlipidemia	Dichotomous	Any

Appendix Y.3. Specifications Defining Baseline Characteristics for this Request						
Characteristics						
Run	Characteristic Number	Covariate in Propensity Score (PS) Model (y/n)?	Covariate in Regression Model (y/n)?	Characteristic	Operationalization	Care Setting
r01	17	y	n	Depression	Dichotomous	Any
r01	18	y	n	Schizophrenia	Dichotomous	Any
r01	19	y	n	Bipolar disorder	Dichotomous	Any
r01	20	y	n	Angiotension-converting enzyme (ACE) inhibitor use	Dichotomous	Any
r01	21	y	n	Angiotensin II receptor blocker (ARB) use	Dichotomous	Any
r01	22	y	n	β-Blocker use	Dichotomous	Any
r01	23	y	n	Oral anticoagulant use	Dichotomous	Any
r01	24	y	n	Antiplatelet agent use	Dichotomous	Any
r01	25	y	n	Opioid use	Dichotomous	Any
r01	26	y	n	Statin use	Dichotomous	Any
r01	27	y	n	Wheelchair or walker use	Dichotomous	Any
r01	28	y	n	Anti-arrhythmic use	Dichotomous	Any
r01	29	y	n	Antidiabetic use	Dichotomous	Any
r01	30	y	n	Calcium channel blocker use	Dichotomous	Any
r01	31	y	n	Diuretic use	Dichotomous	Any
r01	32	y	n	Antidepressant use	Dichotomous	Any
r01	33	y	n	Gastric acid suppressant use	Dichotomous	Any
r01	34	y	n	Nonsteroidal anti-inflammatory drugs (NSAIDs)	Dichotomous	Any
r01	35	y	n	Benzodiazepine-Hypnotics use	Dichotomous	Any
r01	36	y	n	Chronic liver disease	Dichotomous	Any
r01	37	y	n	Pnuemonia	Dichotomous	Any
r01	38	y	n	Cardiac arrhythmia	Dichotomous	Any
r01	39	y	n	Paliperidone palmitate	Dichotomous	Any
r01	40	y	n	Risperidone microspheres	Dichotomous	Any
r01	41	y	n	Haloperidol decanoate	Dichotomous	Any
r01	44	y	n	IS Stay	Dichotomous	Any
r01		y	n	No. of ambulatory encounters	Continuous	Any
r01		y	n	No. of institutional stays	Continuous	Any
r01		y	n	No. of inpatient encounters	Continuous	Any

Appendix Y.3. Specifications Defining Baseline Characteristics for this Request						
Characteristics						
Run	Characteristic Number	Characteristic	Principal Diagnosis Position	Number of Instances the Covariate Should Be Found in Evaluation Period	Evaluation Period Start	Evaluation Period End
			Only applicable for Inpatient and Institutional stays: *Any; *Principal; *Secondary; *Unknown			
r01	45	Age	N/A	N/A	0	0
r00	46	Sex	N/A	N/A	0	0
r01	0	Charlson Comorbidity Index	Any	1	-183	0
r01	1	Substance abuse	Any	1	-183	0
r01	2	Atrial fibrillation/flutter	Any	1	-183	0
r01	3	Ischemic heart disease	Any	1	-183	0
r01	4	Heart failure	Any	1	-183	0
r01	5	Stroke	Any	1	-183	0
r01	6	Diabetes	Any	1	-183	0
r01	7	Hypertension	Any	1	-183	0
r01	8	Rheumatic disease	Any	1	-183	0
r01	9	Chronic kidney disease	Any	1	-183	0
r01	10	Seizure disorder	Any	1	-183	0
r01	42	Dementia Diagnosis	Any	1	-183	0
r01	11	Anti-Dementia drug (memantine, galantamine, rivastigmine, donepezil, tacrine)	Any	1	-183	0
r01	43	Dementia Diagnosis and Treatment	Any	1	-183	0
r01	12	Parkinson's disease	Any	1	-183	0
r01	13	Chronic obstructive pulmonary disease (COPD)	Any	1	-183	0
r01	14	Malignancy	Any	1	-183	0
r01	15	Asthma	Any	1	-183	0
r01	16	Hyperlipidemia	Any	1	-183	0

Appendix Y.3. Specifications Defining Baseline Characteristics for this Request						
Characteristics						
Run	Characteristic Number	Characteristic	Principal Diagnosis Position	Number of Instances the Covariate Should Be Found in Evaluation Period	Evaluation Period Start	Evaluation Period End
r01	17	Depression	Any	1	-183	0
r01	18	Schizophrenia	Any	1	-183	0
r01	19	Bipolar disorder	Any	1	-183	0
r01	20	Angiotension-converting enzyme (ACE) inhibitor use	Any	1	-183	0
r01	21	Angiotensin II receptor blocker (ARB) use	Any	1	-183	0
r01	22	β-Blocker use	Any	1	-183	0
r01	23	Oral anticoagulant use	Any	1	-183	0
r01	24	Antiplatelet agent use	Any	1	-183	0
r01	25	Opioid use	Any	1	-183	0
r01	26	Statin use	Any	1	-183	0
r01	27	Wheelchair or walker use	Any	1	-183	0
r01	28	Anti-arrhythmic use	Any	1	-183	0
r01	29	Antidiabetic use	Any	1	-183	0
r01	30	Calcium channel blocker use	Any	1	-183	0
r01	31	Diuretic use	Any	1	-183	0
r01	32	Antidepressant use	Any	1	-183	0
r01	33	Gastric acid suppressant use	Any	1	-183	0
r01	34	Nonsteroidal anti-inflammatory drugs (NSAIDs)	Any	1	-183	0
r01	35	Benzodiazepine-Hypnotics use	Any	1	-183	0
r01	36	Chronic liver disease	Any	1	-183	0
r01	37	Pnuemonia	Any	1	-183	0
r01	38	Cardiac arrhythmia	Any	1	-183	0
r01	39	Paliperidone palmitate	Any	1	-183	0
r01	40	Risperidone microspheres	Any	1	-183	0
r01	41	Haloperidol decanoate	Any	1	-183	0
r01	44	IS Stay	Any	1	-183	0
r01		No. of ambulatory encounters	Any	1	-183	0
r01		No. of institutional stays	Any	1	-183	0
r01		No. of inpatient encounters	Any	1	-183	0

N/A: Not applicable

Appendix Y.4. Design Diagram for this Request



*None
**None

***Covariates:

Window I: Age, sex

Window II: Charlson Comorbidity Index, mean (SD); Substance abuse; Atrial fibrillation/flutter; Ischemic heart disease; Heart failure; Stroke; Diabetes; Hypertension; Rheumatic disease; Chronic kidney disease; Seizure disorder; Dementia; Parkinson's disease; COPD; Malignancy; Asthma; Hyperlipidemia; Depression; Schizophrenia; Bipolar disorder; ACE inhibitor use; ARB use; β-Blocker use; Oral anticoagulant use; Antiplatelet agent use; Opioid use; Statin use; Wheelchair or walker use; No. of ambulatory encounters, mean (SD); No. of inpatient encounters, mean (SD)